1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	O
7	-	O
8	<UNK>	O
9	.	O
1	<UNK>	O
2	<UNK>	O
3	should	O
4	be	O
5	removed	O
6	<UNK>	O
7	<UNK>	O
8	possible	O
9	.	O
1	<UNK>	B
2	-	O
3	<UNK>	O
4	action	O
5	of	O
6	<UNK>	O
7	after	O
8	intra	O
9	-	O
10	<UNK>	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O
1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	O
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	<UNK>	O
11	with	O
12	<UNK>	O
13	<UNK>	O
14	H	O
15	.	O
1	A	O
2	mixture	O
3	of	O
4	human	O
5	albumin	B
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	<UNK>	O
12	-	O
13	<UNK>	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O
1	In	O
2	the	O
3	matched	O
4	control	O
5	group	O
6	the	O
7	<UNK>	O
8	-	O
9	rate	O
10	of	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	<UNK>	O
16	was	O
17	over	O
18	12	O
19	%,	O
20	a	O
21	<UNK>	O
22	similar	O
23	to	O
24	the	O
25	percentage	O
26	of	O
27	women	O
28	present	O
29	in	O
30	the	O
31	practice	O
32	population	O
33	during	O
34	one	O
35	year	O
36	with	O
37	transient	O
38	,	O
39	symptomatic	O
40	,	O
41	and	O
42	persistent	O
43	A	O
44	.	O
45	B	O
46	.	O
1	<UNK>	O
2	.	O
1	<UNK>	O
2	alone	O
3	was	O
4	effective	O
5	in	O
6	volume	O
7	responsive	O
8	patients	O
9	at	O
10	a	O
11	dose	O
12	of	O
13	5	O
14	+/-	O
15	1	O
16	.	O
17	0	O
18	mg	O
19	daily	O
20	.	O
1	59	O
2	cases	O
3	of	O
4	<UNK>	O
5	<UNK>	O
6	cancers	O
7	(	O
8	T1	O
9	,	O
10	T2	O
11	,	O
12	T3	O
13	,	O
14	<UNK>	O
15	,	O
16	N1	O
17	)	O
18	had	O
19	a	O
20	minimum	O
21	<UNK>	O
22	of	O
23	two	O
24	years	O
25	(	O
26	average	O
27	4	O
28	years	O
29	+/-	O
30	3	O
31	months	O
32	).	O
1	<UNK>	O
2	disease	O
3	of	O
4	<UNK>	O
5	newborn	O
6	.	O
1	VII	O
2	.	O
1	These	O
2	observations	O
3	have	O
4	led	O
5	us	O
6	to	O
7	conclude	O
8	that	O
9	an	O
10	elevated	O
11	VIII	O
12	-	O
13	ratio	O
14	is	O
15	a	O
16	very	O
17	sensitive	O
18	<UNK>	O
19	of	O
20	<UNK>	O
21	coagulation	O
22	.	O
1	<UNK>	O
2	of	O
3	the	O
4	times	O
5	of	O
6	<UNK>	O
7	development	O
1	<UNK>	O
2	human	O
3	fibrinogen	B
4	was	O
5	<UNK>	O
6	to	O
7	coagulation	O
8	by	O
9	<UNK>	O
10	thrombin	B
11	.	O
1	The	O
2	inner	O
3	<UNK>	O
4	were	O
5	exposed	O
6	by	O
7	<UNK>	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	<UNK>	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	<UNK>	O
33	technique	O
34	.	O
1	<UNK>	O
2	did	O
3	not	O
4	affect	O
5	the	O
6	percentage	O
7	of	O
8	<UNK>	O
9	-	O
10	treated	O
11	animals	O
12	with	O
13	abnormal	O
14	urinary	O
15	excretion	O
16	patterns	O
17	,	O
18	but	O
19	did	O
20	increase	O
21	the	O
22	magnitude	O
23	of	O
24	the	O
25	<UNK>	O
26	in	O
27	elimination	O
28	of	O
29	<UNK>	O
30	and	O
31	<UNK>	O
32	acids	O
33	.	O
1	<UNK>	O
2	-	O
3	99m	O
4	<UNK>	O
5	<UNK>	O
6	myocardial	O
7	<UNK>	O
8	were	O
9	obtained	O
10	in	O
11	<UNK>	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	<UNK>	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O
1	<UNK>	O
2	with	O
3	""""	O
4	sensitivity	O
5	""""	O
6	to	O
7	<UNK>	O
8	<UNK>	O
9	(	O
10	<UNK>	O
11	)	O
12	studied	O
13	in	O
14	<UNK>	O
15	in	O
16	an	O
17	<UNK>	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	<UNK>	O
24	.	O
1	In	O
2	both	O
3	these	O
4	<UNK>	O
5	,	O
6	however	O
7	,	O
8	the	O
9	<UNK>	O
10	mRNA	O
11	<UNK>	O
12	the	O
13	late	O
14	<UNK>	O
15	of	O
16	SV40	O
17	and	O
18	<UNK>	O
19	viruses	O
20	.	O
1	Serum	O
2	ACTH	B
3	did	O
4	not	O
5	respond	O
6	to	O
7	insulin	B
8	and	O
9	<UNK>	O
10	.	O
1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	O
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	<UNK>	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	<UNK>	O
19	<UNK>	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	<UNK>	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	<UNK>	O
34	women	O
35	.	O
1	High	O
2	levels	O
3	of	O
4	serum	O
5	<UNK>	B
6	were	O
7	found	O
8	in	O
9	patients	O
10	with	O
11	chronic	O
12	renal	O
13	failure	O
14	.	O
1	<UNK>	O
2	of	O
3	anti	O
4	-	O
5	lymphocyte	O
6	antibodies	O
7	using	O
8	the	O
9	<UNK>	B
10	<UNK>	I
11	<UNK>	O
12	.	O
1	<UNK>	O
2	,	O
3	2	O
4	<UNK>	O
5	<UNK>	O
6	.	O
1	<UNK>	O
2	-	O
3	61	O
4	.	O
1	<UNK>	O
2	-	O
3	8	O
4	.	O
1	<UNK>	O
2	marrow	O
3	transplantation	O
4	-	O
5	<UNK>	O
6	.	O
1	In	O
2	this	O
3	article	O
4	,	O
5	the	O
6	clinical	O
7	<UNK>	O
8	of	O
9	the	O
10	principal	O
11	dopamine	O
12	receptor	O
13	stimulating	O
14	agents	O
15	(	O
16	<UNK>	O
17	and	O
18	its	O
19	derivatives	O
20	;	O
21	<UNK>	O
22	,	O
23	<UNK>	O
24	-	O
25	<UNK>	O
26	derivatives	O
27	)	O
28	are	O
29	discussed	O
30	on	O
31	the	O
32	basis	O
33	of	O
34	their	O
35	biochemical	O
36	and	O
37	<UNK>	O
38	properties	O
39	.	O
1	The	O
2	<UNK>	O
3	standard	O
4	method	O
5	for	O
6	the	O
7	detection	O
8	of	O
9	<UNK>	O
10	in	O
11	milk	O
12	is	O
13	not	O
14	suitable	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	<UNK>	O
20	residues	O
21	in	O
22	milk	O
23	.	O
1	<UNK>	O
2	antigens	O
3	of	O
4	Staphylococcus	O
5	aureus	O
1	The	O
2	course	O
3	of	O
4	<UNK>	O
5	fever	O
6	remained	O
7	<UNK>	O
8	by	O
9	<UNK>	O
10	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	patients	O
6	who	O
7	are	O
8	potentially	O
9	<UNK>	O
10	with	O
11	radiotherapy	O
12	.	O
1	It	O
2	was	O
3	concluded	O
4	,	O
5	that	O
6	on	O
7	a	O
8	given	O
9	<UNK>	O
10	,	O
11	75	O
12	,	O
13	7	O
14	per	O
15	cent	O
16	of	O
17	the	O
18	<UNK>	O
19	were	O
20	in	O
21	contact	O
22	with	O
23	vascular	O
24	<UNK>	O
25	.	O
1	Isolation	O
2	of	O
3	T	O
4	.	O
5	<UNK>	O
6	strains	O
7	in	O
8	<UNK>	O
9	and	O
10	their	O
11	adaptation	O
12	to	O
13	laboratory	O
14	animals	O
1	<UNK>	O
2	adaptation	O
3	(	O
4	first	O
5	of	O
6	two	O
7	parts	O
8	).	O
1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	<UNK>	O
9	for	O
10	many	O
11	years	O
12	and	O
13	no	O
14	<UNK>	O
15	is	O
16	being	O
17	made	O
18	for	O
19	any	O
20	<UNK>	O
21	in	O
22	this	O
23	regard	O
24	.	O
1	A	O
2	prospective	O
3	<UNK>	O
4	comparing	O
5	<UNK>	O
6	,	O
7	<UNK>	O
8	plus	O
9	<UNK>	O
10	<UNK>	O
11	,	O
12	and	O
13	uterine	O
14	<UNK>	O
15	plus	O
16	<UNK>	O
17	in	O
18	stage	O
19	I	O
20	endometrial	O
21	carcinoma	O
22	.	O
1	<UNK>	O
2	were	O
3	processed	O
4	with	O
5	a	O
6	<UNK>	O
7	-	O
8	<UNK>	O
9	computer	O
10	program	O
11	which	O
12	<UNK>	O
13	an	O
14	<UNK>	O
15	-	O
16	volume	O
17	curve	O
18	from	O
19	an	O
20	assigned	O
21	LV	O
22	region	O
23	-	O
24	of	O
25	-	O
26	interest	O
27	.	O
1	Effects	O
2	of	O
3	<UNK>	O
4	chloride	O
5	,	O
6	<UNK>	O
7	,	O
8	<UNK>	O
9	,	O
10	<UNK>	O
11	and	O
12	<UNK>	O
13	on	O
14	the	O
15	development	O
16	of	O
17	<UNK>	O
18	embryos	O
19	.	O
1	The	O
2	<UNK>	O
3	of	O
4	<UNK>	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O
1	This	O
2	expression	O
3	<UNK>	O
4	:	O
5	(	O
6	1	O
7	)	O
8	a	O
9	<UNK>	O
10	flow	O
11	regimen	O
12	during	O
13	<UNK>	O
14	,	O
15	and	O
16	(	O
17	2	O
18	)	O
19	a	O
20	constant	O
21	CT	O
22	value	O
23	over	O
24	the	O
25	range	O
26	of	O
27	VT	O
28	.	O
1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	<UNK>	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	<UNK>	O
17	tissue	O
18	.	O
1	On	O
2	the	O
3	role	O
4	of	O
5	transferrin	B
6	in	O
7	the	O
8	uptake	O
9	of	O
10	<UNK>	O
11	by	O
12	tumor	O
13	cells	O
14	.	O
1	<UNK>	O
2	of	O
3	human	O
4	blood	O
5	<UNK>	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	<UNK>	O
13	their	O
14	ability	O
15	to	O
16	<UNK>	O
17	after	O
18	challenge	O
19	with	O
20	collagen	B
21	.	O
1	Although	O
2	<UNK>	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	<UNK>	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	<UNK>	O
28	<UNK>	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	<UNK>	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	""""	O
42	classical	O
43	""""	O
44	<UNK>	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	<UNK>	O
51	.	O
1	Of	O
2	the	O
3	compounds	O
4	tested	O
5	,	O
6	alpha	O
7	-(	O
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	O
13	-	O
14	<UNK>	O
15	)-	O
16	N	O
17	-	O
18	<UNK>	O
19	1	O
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	O
39	and	O
40	the	O
41	gram	O
42	-	O
43	positive	O
44	organisms	O
45	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	<UNK>	O
6	can	O
7	be	O
8	evoked	O
9	also	O
10	in	O
11	the	O
12	case	O
13	when	O
14	the	O
15	<UNK>	O
16	<UNK>	O
17	tone	O
18	is	O
19	normal	O
20	or	O
21	even	O
22	below	O
23	normal	O
24	:	O
25	it	O
26	is	O
27	the	O
28	equilibrium	O
29	of	O
30	the	O
31	<UNK>	O
32	<UNK>	O
33	-	O
34	<UNK>	O
35	systems	O
36	which	O
37	must	O
38	be	O
39	<UNK>	O
40	towards	O
41	dopamine	O
42	,	O
43	which	O
44	is	O
45	necessary	O
46	for	O
47	the	O
48	development	O
49	of	O
50	this	O
51	behavioral	O
52	<UNK>	O
53	.	O
1	In	O
2	the	O
3	<UNK>	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	<UNK>	O
15	-	O
16	alpha	O
17	-	O
18	<UNK>	O
19	.	O
1	<UNK>	O
2	of	O
3	patients	O
4	with	O
5	<UNK>	O
6	diseases	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	human	O
5	.	O
1	In	O
2	one	O
3	patient	O
4	with	O
5	severe	O
6	<UNK>	O
7	the	O
8	<UNK>	O
9	concentration	O
10	in	O
11	serum	O
12	was	O
13	low	O
14	until	O
15	the	O
16	intestinal	O
17	function	O
18	<UNK>	O
19	and	O
20	the	O
21	<UNK>	O
22	concentration	O
23	<UNK>	O
24	up	O
25	<UNK>	O
26	when	O
27	the	O
28	<UNK>	O
29	<UNK>	O
30	.	O
1	Serum	O
2	levels	O
3	of	O
4	IgG	B
5	and	O
6	IgM	B
7	were	O
8	also	O
9	raised	O
10	,	O
11	but	O
12	<UNK>	O
13	to	O
14	the	O
15	findings	O
16	of	O
17	other	O
18	<UNK>	O
19	IgA	B
20	levels	O
21	were	O
22	normal	O
23	.	O
1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	<UNK>	O
14	(	O
15	one	O
16	<UNK>	O
17	,	O
18	containing	O
19	<UNK>	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	<UNK>	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	<UNK>	O
32	negative	O
33	variation	O
34	(	O
35	<UNK>	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	<UNK>	O
49	<UNK>	O
50	for	O
51	<UNK>	O
52	,	O
53	<UNK>	O
54	,	O
55	tension	O
56	,	O
57	<UNK>	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	<UNK>	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O
1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	<UNK>	O
25	is	O
26	<UNK>	O
27	by	O
28	<UNK>	O
29	blockade	O
30	of	O
31	alpha	O
32	-	O
33	and	O
34	beta	O
35	-	O
36	<UNK>	B
37	.	O
1	Three	O
2	patients	O
3	with	O
4	four	O
5	<UNK>	O
6	units	O
7	have	O
8	<UNK>	O
9	single	O
10	-	O
11	stage	O
12	<UNK>	O
13	involving	O
14	<UNK>	O
15	and	O
16	<UNK>	O
17	<UNK>	O
18	following	O
19	<UNK>	O
20	loop	O
21	cutaneous	O
22	<UNK>	O
23	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	-	O
5	90	O
6	and	O
7	<UNK>	O
8	on	O
9	<UNK>	O
10	<UNK>	O
1	<UNK>	O
2	and	O
3	differential	O
4	diagnosis	O
1	<UNK>	O
2	induced	O
3	bone	O
4	changes	O
5	and	O
6	its	O
7	response	O
8	to	O
9	lipid	O
10	<UNK>	O
11	agents	O
12	.	O
1	2	O
2	)	O
3	The	O
4	time	O
5	-	O
6	<UNK>	O
7	<UNK>	O
8	was	O
9	applied	O
10	to	O
11	gain	O
12	high	O
13	stability	O
14	.	O
1	<UNK>	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O
1	<UNK>	O
2	findings	O
3	in	O
4	the	O
5	<UNK>	O
6	and	O
7	in	O
8	the	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	units	O
14	.	O
1	These	O
2	consisted	O
3	of	O
4	<UNK>	O
5	and	O
6	<UNK>	O
7	mainly	O
8	of	O
9	the	O
10	<UNK>	O
11	biliary	O
12	<UNK>	O
13	(	O
14	<UNK>	O
15	).	O
1	<UNK>	O
2	.	O
1	<UNK>	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O
1	Serum	O
2	<UNK>	B
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	<UNK>	O
9	.	O
1	Effect	O
2	of	O
3	<UNK>	O
4	in	O
5	small	O
6	doses	O
7	on	O
8	the	O
9	central	O
10	<UNK>	O
11	loci	O
12	has	O
13	been	O
14	studied	O
15	in	O
16	<UNK>	O
17	anesthetized	O
18	cats	O
19	by	O
20	<UNK>	O
21	it	O
22	to	O
23	the	O
24	central	O
25	sites	O
26	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	in	O
6	<UNK>	O
7	and	O
8	the	O
9	<UNK>	O
10	<UNK>	O
1	Significant	O
2	increases	O
3	in	O
4	mean	O
5	serum	O
6	E2	O
7	concentration	O
8	(	O
9	100	O
10	to	O
11	150	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	were	O
17	noted	O
18	at	O
19	6	O
20	and	O
21	8	O
22	hours	O
23	after	O
24	administration	O
25	on	O
26	day	O
27	1	O
28	and	O
29	at	O
30	8	O
31	hours	O
32	on	O
33	day	O
34	4	O
35	.	O
1	Patients	O
2	were	O
3	<UNK>	O
4	into	O
5	age	O
6	-	O
7	matched	O
8	groups	O
9	of	O
10	primary	O
11	untreated	O
12	cancer	O
13	(	O
14	21	O
15	),	O
16	recurrent	O
17	cancer	O
18	(	O
19	18	O
20	),	O
21	and	O
22	""""	O
23	<UNK>	O
24	""""	O
25	patients	O
26	who	O
27	had	O
28	been	O
29	free	O
30	of	O
31	disease	O
32	for	O
33	at	O
34	least	O
35	9	O
36	months	O
37	(	O
38	16	O
39	).	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	<UNK>	O
10	in	O
11	vitro	O
1	<UNK>	O
2	transfer	O
3	factor	O
4	.	O
1	<UNK>	B
2	factor	O
3	and	O
4	<UNK>	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	<UNK>	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O
1	This	O
2	report	O
3	<UNK>	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	<UNK>	O
9	<UNK>	O
10	of	O
11	<UNK>	O
12	monkeys	O
13	(	O
14	<UNK>	O
15	<UNK>	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	<UNK>	O
24	<UNK>	O
25	.	O
1	<UNK>	O
2	(	O
3	<UNK>	O
4	),	O
5	one	O
6	of	O
7	the	O
8	few	O
9	<UNK>	O
10	tested	O
11	thus	O
12	far	O
13	that	O
14	has	O
15	not	O
16	induced	O
17	<UNK>	O
18	in	O
19	rats	O
20	,	O
21	caused	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	respiratory	O
27	tract	O
28	tumors	O
29	in	O
30	<UNK>	O
31	<UNK>	O
32	hamsters	O
33	treated	O
34	<UNK>	O
35	with	O
36	single	O
37	or	O
38	weekly	O
39	doses	O
40	of	O
41	the	O
42	compound	O
43	.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	is	O
5	the	O
6	end	O
7	result	O
8	of	O
9	an	O
10	unusual	O
11	<UNK>	O
12	disorder	O
13	,	O
14	which	O
15	initially	O
16	requires	O
17	surgical	O
18	treatment	O
19	.	O
1	<UNK>	O
2	of	O
3	both	O
4	<UNK>	O
5	and	O
6	<UNK>	O
7	were	O
8	significantly	O
9	higher	O
10	during	O
11	early	O
12	spontaneous	O
13	<UNK>	O
14	,	O
15	at	O
16	a	O
17	cervical	O
18	<UNK>	O
19	of	O
20	less	O
21	than	O
22	4	O
23	cm	O
24	,	O
25	than	O
26	before	O
27	the	O
28	onset	O
29	of	O
30	<UNK>	O
31	.	O
1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	<UNK>	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	<UNK>	O
13	patient	O
14	is	O
15	<UNK>	O
16	<UNK>	O
17	<UNK>	O
18	.	O
1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	<UNK>	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	<UNK>	O
18	of	O
19	<UNK>	O
20	materials	O
21	.	O
1	The	O
2	<UNK>	O
3	to	O
4	<UNK>	O
5	<UNK>	O
6	(	O
7	<UNK>	O
8	)	O
9	by	O
10	gas	O
11	-	O
12	liquid	O
13	chromatography	O
14	are	O
15	mainly	O
16	due	O
17	to	O
18	the	O
19	lack	O
20	of	O
21	sensitivity	O
22	of	O
23	the	O
24	gas	O
25	-	O
26	<UNK>	O
27	itself	O
28	(	O
29	higher	O
30	than	O
31	200	O
32	ng	O
33	)	O
34	and	O
35	to	O
36	the	O
37	poor	O
38	resolution	O
39	of	O
40	the	O
41	<UNK>	O
42	<UNK>	O
43	.	O
1	After	O
2	giving	O
3	a	O
4	survey	O
5	on	O
6	the	O
7	<UNK>	O
8	of	O
9	antibiotic	O
10	resistance	O
11	in	O
12	the	O
13	region	O
14	of	O
15	Northern	O
16	<UNK>	O
17	during	O
18	<UNK>	O
19	/	O
20	74	O
21	and	O
22	comparing	O
23	the	O
24	activity	O
25	of	O
26	a	O
27	<UNK>	O
28	(	O
29	<UNK>	O
30	)	O
31	<UNK>	O
32	(	O
33	<UNK>	O
34	)	O
35	combination	O
36	to	O
37	other	O
38	commonly	O
39	used	O
40	<UNK>	O
41	and	O
42	<UNK>	O
43	agents	O
44	,	O
45	the	O
46	results	O
47	of	O
48	tests	O
49	with	O
50	the	O
51	new	O
52	combination	O
53	of	O
54	N1	O
55	-(	O
56	4	O
57	,	O
58	5	O
59	-	O
60	<UNK>	O
61	-	O
62	2	O
63	-	O
64	<UNK>	O
65	)-	O
66	<UNK>	O
67	)	O
68	(	O
69	<UNK>	O
70	)	O
71	and	O
72	2	O
73	,	O
74	4	O
75	-	O
76	<UNK>	O
77	-	O
78	5	O
79	-(	O
80	3	O
81	,	O
82	4	O
83	,	O
84	5	O
85	-	O
86	<UNK>	O
87	-	O
88	<UNK>	O
89	)-	O
90	<UNK>	O
91	(	O
92	<UNK>	O
93	)	O
94	at	O
95	a	O
96	ratio	O
97	of	O
98	5	O
99	:	O
100	1	O
101	(	O
102	<UNK>	O
103	<UNK>	O
104	;	O
105	<UNK>	O
106	,	O
107	<UNK>	O
108	)	O
109	are	O
110	compared	O
111	to	O
112	those	O
113	of	O
114	tests	O
115	with	O
116	<UNK>	O
117	/	O
118	<UNK>	O
119	.	O
1	<UNK>	O
2	:	O
3	<UNK>	O
4	<UNK>	O
5	(	O
6	<UNK>	O
7	)	O
8	damage	O
9	the	O
10	<UNK>	O
11	cause	O
12	of	O
13	'	O
14	post	O
15	-	O
16	inflammatory	O
17	<UNK>	O
18	and	O
19	<UNK>	O
20	<UNK>	O
21	(	O
22	<UNK>	O
23	<UNK>	O
1	<UNK>	O
2	cultures	O
3	of	O
4	S	O
5	.	O
6	<UNK>	O
7	<UNK>	O
8	a	O
9	demonstrated	O
10	no	O
11	growth	O
12	on	O
13	<UNK>	O
14	agar	O
15	.	O
1	<UNK>	O
2	women	O
3	at	O
4	term	O
5	had	O
6	the	O
7	<UNK>	O
8	levels	O
9	of	O
10	antithrombin	B
11	III	O
12	.	O
1	The	O
2	performance	O
3	of	O
4	three	O
5	commonly	O
6	used	O
7	chemical	O
8	<UNK>	O
9	<UNK>	O
10	for	O
11	<UNK>	O
12	was	O
13	measured	O
14	under	O
15	<UNK>	O
16	conditions	O
17	in	O
18	a	O
19	copper	O
20	<UNK>	O
21	.	O
1	<UNK>	O
2	of	O
3	macrophage	O
4	function	O
5	by	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	cells	O
10	did	O
11	not	O
12	show	O
13	any	O
14	<UNK>	O
15	effect	O
16	as	O
17	an	O
18	increased	O
19	susceptibility	O
20	became	O
21	apparent	O
22	.	O
1	All	O
2	<UNK>	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	<UNK>	O
17	<UNK>	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	<UNK>	O
30	found	O
31	in	O
32	the	O
33	<UNK>	O
34	that	O
35	were	O
36	<UNK>	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O
1	Since	O
2	<UNK>	B
3	is	O
4	co	O
5	-	O
6	<UNK>	O
7	with	O
8	the	O
9	hemoglobin	B
10	,	O
11	the	O
12	2	O
13	<UNK>	O
14	<UNK>	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	<UNK>	O
25	the	O
26	hemoglobin	B
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	<UNK>	O
33	)	O
34	<UNK>	O
35	solution	O
36	.	O
1	I	O
2	.	O
1	<UNK>	O
2	measurements	O
3	of	O
4	temperature	O
5	changes	O
6	and	O
7	estimates	O
8	of	O
9	the	O
10	<UNK>	O
11	produced	O
12	at	O
13	the	O
14	<UNK>	O
15	.	O
1	<UNK>	O
2	of	O
3	""""	O
4	<UNK>	O
5	Effects	O
6	of	O
7	<UNK>	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	/	O
12	No	O
13	<UNK>	O
14	or	O
15	A	O
16	-	O
17	F	O
18	<UNK>	O
19	<UNK>	O
20	upon	O
21	<UNK>	O
22	-	O
23	term	O
24	and	O
25	<UNK>	O
26	-	O
27	term	O
28	<UNK>	O
29	of	O
30	<UNK>	O
31	<UNK>	O
32	.	O
1	After	O
2	90	O
3	d	O
4	a	O
5	<UNK>	O
6	,	O
7	<UNK>	O
8	<UNK>	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O
1	As	O
2	<UNK>	O
3	<UNK>	O
4	in	O
5	<UNK>	O
6	from	O
7	<UNK>	O
8	to	O
9	<UNK>	O
10	with	O
11	age	O
12	,	O
13	<UNK>	O
14	<UNK>	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	<UNK>	O
25	<UNK>	O
26	until	O
27	<UNK>	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O
1	<UNK>	O
2	<UNK>	O
3	,	O
4	serum	O
5	IgE	B
6	and	O
7	total	O
8	<UNK>	O
9	counts	O
10	in	O
11	patients	O
12	with	O
13	bronchial	O
14	asthma	O
15	.	O
1	<UNK>	O
2	for	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	with	O
7	<UNK>	O
8	mass	O
1	The	O
2	<UNK>	O
3	action	O
4	of	O
5	<UNK>	O
6	<UNK>	O
7	upon	O
8	the	O
9	<UNK>	O
10	effects	O
11	induced	O
12	by	O
13	<UNK>	O
14	has	O
15	been	O
16	studied	O
17	in	O
18	32	O
19	acute	O
20	<UNK>	O
21	states	O
22	.	O
1	The	O
2	<UNK>	O
3	from	O
4	<UNK>	O
5	through	O
6	<UNK>	O
7	of	O
8	<UNK>	O
9	previously	O
10	untreated	O
11	patients	O
12	with	O
13	<UNK>	O
14	cell	O
15	carcinoma	O
16	of	O
17	the	O
18	oral	O
19	cavity	O
20	,	O
21	<UNK>	O
22	,	O
23	<UNK>	O
24	<UNK>	O
25	and	O
26	<UNK>	O
27	who	O
28	had	O
29	clinically	O
30	positive	O
31	cervical	O
32	lymph	O
33	node	O
34	<UNK>	O
35	<UNK>	O
36	N1	O
37	,	O
38	<UNK>	O
39	,	O
40	or	O
41	<UNK>	O
42	,	O
43	and	O
44	whose	O
45	initial	O
46	neck	O
47	treatment	O
48	consisted	O
49	of	O
50	external	O
51	radiation	O
52	therapy	O
53	alone	O
54	were	O
55	reviewed	O
56	.	O
1	Effect	O
2	of	O
3	ingestion	O
4	of	O
5	<UNK>	O
6	during	O
7	the	O
8	<UNK>	O
9	period	O
10	of	O
11	the	O
12	genital	O
13	organs	O
1	<UNK>	O
2	of	O
3	infection	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	<UNK>	O
1	<UNK>	O
2	<UNK>	O
3	of	O
4	the	O
5	<UNK>	O
6	showed	O
7	smaller	O
8	than	O
9	8	O
10	%	O
11	of	O
12	the	O
13	<UNK>	O
14	<UNK>	B
15	activity	O
16	and	O
17	smaller	O
18	than	O
19	14	O
20	%	O
21	of	O
22	the	O
23	<UNK>	O
24	capacity	O
25	of	O
26	liver	O
27	<UNK>	O
28	from	O
29	the	O
30	rat	O
31	.	O
1	A	O
2	clinical	O
3	,	O
4	<UNK>	O
5	and	O
6	prognostic	O
7	study	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	:	O
7	a	O
8	<UNK>	O
9	report	O
10	.	O
1	This	O
2	sequence	O
3	is	O
4	almost	O
5	identical	O
6	with	O
7	that	O
8	of	O
9	human	O
10	<UNK>	B
11	hormone	O
12	(	O
13	<UNK>	O
14	,	O
15	M	O
16	.	O
1	<UNK>	O
2	-	O
3	6	O
4	-	O
5	phosphate	O
6	dehydrogenase	B
7	(	O
8	G	O
9	-	O
10	6	O
11	-	O
12	<UNK>	O
13	)	O
14	deficiency	O
15	in	O
16	the	O
17	newborn	O
18	.	O
1	<UNK>	O
2	F	O
3	(	O
4	<UNK>	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	<UNK>	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	<UNK>	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O
1	<UNK>	O
2	of	O
3	ten	O
4	dependent	O
5	and	O
6	ten	O
7	saline	O
8	mice	O
9	were	O
10	<UNK>	O
11	tested	O
12	in	O
13	both	O
14	light	O
15	and	O
16	dark	O
17	conditions	O
18	in	O
19	each	O
20	of	O
21	five	O
22	<UNK>	O
23	<UNK>	O
24	(	O
25	2	O
26	-	O
27	23	O
28	in	O
29	high	O
30	).	O
1	D	O
2	.	O
1	<UNK>	O
2	ion	O
3	action	O
4	on	O
5	bacteria	O
6	.	O
1	Following	O
2	<UNK>	O
3	,	O
4	the	O
5	affected	O
6	epithelial	O
7	<UNK>	O
8	appeared	O
9	greatly	O
10	<UNK>	O
11	over	O
12	the	O
13	<UNK>	O
14	<UNK>	O
15	<UNK>	O
16	,	O
17	with	O
18	almost	O
19	complete	O
20	loss	O
21	of	O
22	structural	O
23	<UNK>	O
24	.	O
1	2	O
2	-	O
3	<UNK>	O
4	occlusion	O
5	of	O
6	<UNK>	O
7	is	O
8	<UNK>	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	<UNK>	O
17	<UNK>	O
18	of	O
19	dogs	O
20	.	O
1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	4	O
7	groups	O
8	receiving	O
9	<UNK>	O
10	II	O
11	with	O
12	or	O
13	without	O
14	<UNK>	O
15	,	O
16	morphine	O
17	or	O
18	<UNK>	O
19	.	O
1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	<UNK>	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	<UNK>	O
26	'	O
27	s	O
28	<UNK>	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	<UNK>	O
37	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	<UNK>	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	<UNK>	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O
1	The	O
2	authors	O
3	found	O
4	that	O
5	except	O
6	for	O
7	<UNK>	O
8	and	O
9	<UNK>	O
10	all	O
11	<UNK>	O
12	-	O
13	<UNK>	O
14	<UNK>	O
15	correlations	O
16	were	O
17	positive	O
18	,	O
19	in	O
20	contrast	O
21	to	O
22	<UNK>	O
23	'	O
24	s	O
25	<UNK>	O
26	of	O
27	type	O
28	I	O
29	<UNK>	O
30	.	O
1	A	O
2	<UNK>	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	<UNK>	O
8	technique	O
9	<UNK>	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O
1	<UNK>	O
2	factor	O
3	VIII	O
4	inhibitor	O
5	in	O
6	non	O
7	-	O
8	<UNK>	O
9	patients	O
1	The	O
2	authors	O
3	report	O
4	the	O
5	results	O
6	of	O
7	a	O
8	series	O
9	of	O
10	<UNK>	O
11	tests	O
12	conducted	O
13	on	O
14	<UNK>	O
15	materials	O
16	(	O
17	<UNK>	O
18	)	O
19	activated	O
20	with	O
21	<UNK>	O
22	(	O
23	<UNK>	O
24	)	O
25	an	O
26	<UNK>	O
27	recently	O
28	proposed	O
29	as	O
30	a	O
31	<UNK>	O
32	capable	O
33	of	O
34	<UNK>	O
35	<UNK>	O
36	materials	O
37	.	O
1	Nuclear	O
2	extracts	O
3	prepared	O
4	from	O
5	both	O
6	neural	O
7	and	O
8	non	O
9	-	O
10	neural	O
11	cell	O
12	lines	O
13	,	O
14	mouse	O
15	brain	O
16	,	O
17	and	O
18	mouse	O
19	liver	O
20	contain	O
21	proteins	O
22	that	O
23	recognize	O
24	and	O
25	bind	O
26	to	O
27	the	O
28	<UNK>	O
29	and	O
30	<UNK>	O
31	sequences	O
32	indicating	O
33	that	O
34	proteins	O
35	which	O
36	bind	O
37	to	O
38	these	O
39	target	O
40	sequences	O
41	are	O
42	<UNK>	O
43	.	O
1	<UNK>	O
2	skeletal	O
3	muscle	O
4	<UNK>	B
5	.	O
1	A	O
2	statistically	O
3	significant	O
4	improvement	O
5	due	O
6	to	O
7	the	O
8	administration	O
9	of	O
10	<UNK>	O
11	was	O
12	observed	O
13	in	O
14	symptoms	O
15	associated	O
16	with	O
17	<UNK>	O
18	to	O
19	normal	O
20	prolactin	B
21	levels	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	abdominal	O
28	tension	O
29	,	O
30	<UNK>	O
31	,	O
32	weight	O
33	gain	O
34	and	O
35	breast	O
36	<UNK>	O
37	.	O
1	This	O
2	analysis	O
3	,	O
4	together	O
5	with	O
6	a	O
7	<UNK>	O
8	of	O
9	the	O
10	<UNK>	O
11	found	O
12	upstream	O
13	of	O
14	known	O
15	<UNK>	B
16	,	O
17	6	O
18	-	O
19	dependent	O
20	genes	O
21	,	O
22	leads	O
23	to	O
24	the	O
25	<UNK>	O
26	of	O
27	a	O
28	<UNK>	O
29	consensus	O
30	sequence	O
31	for	O
32	this	O
33	important	O
34	regulatory	O
35	element	O
36	.	O
1	These	O
2	studies	O
3	show	O
4	that	O
5	<UNK>	B
6	binds	O
7	to	O
8	various	O
9	target	O
10	motifs	O
11	that	O
12	are	O
13	distinct	O
14	from	O
15	the	O
16	<UNK>	O
17	motif	O
18	:	O
19	the	O
20	<UNK>	B
21	-	O
22	associated	O
23	virus	O
24	<UNK>	B
25	promoter	O
26	and	O
27	elements	O
28	in	O
29	the	O
30	immunoglobulin	B
31	light	O
32	-	O
33	and	O
34	heavy	O
35	-	O
36	chain	O
37	genes	O
38	,	O
39	as	O
40	well	O
41	as	O
42	elements	O
43	in	O
44	ribosomal	O
45	protein	O
46	genes	O
47	.	O
1	Both	O
2	<UNK>	B
3	and	O
4	<UNK>	B
5	cut	O
6	the	O
7	terminal	O
8	<UNK>	O
9	sequence	O
10	at	O
11	the	O
12	same	O
13	site	O
14	(	O
15	nucleotide	O
16	<UNK>	O
17	).	O
1	The	O
2	<UNK>	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	determine	O
10	the	O
11	<UNK>	O
12	of	O
13	retrovirus	O
14	mediated	O
15	expression	O
16	of	O
17	<UNK>	B
18	in	O
19	the	O
20	<UNK>	O
21	and	O
22	<UNK>	O
23	human	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	,	O
28	and	O
29	in	O
30	an	O
31	Epstein	O
32	-	O
33	Barr	O
34	virus	O
35	transformed	O
36	B	O
37	-	O
38	lymphocyte	O
39	cell	O
40	line	O
41	(	O
42	EBV	O
43	-	O
44	<UNK>	B
45	)	O
46	derived	O
47	from	O
48	a	O
49	<UNK>	B
50	-	O
51	deficient	O
52	<UNK>	O
53	patient	O
54	.	O
1	Comparison	O
2	with	O
3	the	O
4	sequence	O
5	<UNK>	O
6	show	O
7	that	O
8	<UNK>	B
9	is	O
10	a	O
11	member	O
12	of	O
13	the	O
14	immunoglobulin	B
15	gene	O
16	superfamily	O
17	,	O
18	with	O
19	similarity	O
20	to	O
21	Drosophila	O
22	<UNK>	O
23	,	O
24	the	O
25	melanoma	O
26	Ag	O
27	<UNK>	B
28	-	O
29	18	O
30	,	O
31	members	O
32	of	O
33	the	O
34	<UNK>	B
35	Ag	O
36	family	O
37	,	O
38	the	O
39	<UNK>	O
40	receptor	O
41	,	O
42	and	O
43	the	O
44	neural	O
45	cell	O
46	adhesion	O
47	molecule	O
48	.	O
1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	<UNK>	B
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	virus	O
18	and	O
19	<UNK>	O
20	in	O
21	that	O
22	the	O
23	more	O
24	<UNK>	B
25	-	O
26	coding	O
27	sequence	O
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	O
38	type	O
39	-	O
40	like	O
41	was	O
42	its	O
43	phenotype	O
44	.	O
1	After	O
2	the	O
3	first	O
4	28	O
5	patients	O
6	<UNK>	O
7	was	O
8	replaced	O
9	by	O
10	<UNK>	O
11	(	O
12	<UNK>	O
13	-	O
14	26	O
15	)	O
16	due	O
17	to	O
18	<UNK>	O
19	.	O
1	METHODS	O
2	:	O
3	IgG	B
4	antibodies	O
5	vs	O
6	<UNK>	O
7	-	O
8	6	O
9	(	O
10	anti	O
11	-	O
12	<UNK>	O
13	-	O
14	6	O
15	-	O
16	IgG	B
17	)	O
18	were	O
19	determined	O
20	by	O
21	indirect	O
22	immunofluorescence	O
23	in	O
24	100	O
25	<UNK>	O
26	(	O
27	29	O
28	<UNK>	O
29	and	O
30	71	O
31	<UNK>	O
32	for	O
33	HIV	O
34	-	O
35	1	O
36	of	O
37	which	O
38	45	O
39	were	O
40	in	O
41	stage	O
42	II	O
43	and	O
44	26	O
45	in	O
46	IV	O
47	-	O
48	C1	O
49	of	O
50	<UNK>	O
51	)	O
52	as	O
53	well	O
54	as	O
55	in	O
56	100	O
57	healthy	O
58	subjects	O
59	of	O
60	a	O
61	similar	O
62	age	O
63	(	O
64	control	O
65	group	O
66	).	O
1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	B
23	-	O
24	3	O
25	beta	O
26	protein	O
27	(	O
28	amino	O
29	acids	O
30	<UNK>	O
31	to	O
32	<UNK>	O
33	).	O
1	<UNK>	B
2	-	O
3	1	O
4	is	O
5	expressed	O
6	in	O
7	a	O
8	larger	O
9	number	O
10	of	O
11	these	O
12	cell	O
13	lines	O
14	.	O
1	A	O
2	single	O
3	<UNK>	B
4	-	O
5	2	O
6	site	O
7	is	O
8	a	O
9	major	O
10	positive	O
11	regulatory	O
12	element	O
13	required	O
14	for	O
15	transcription	O
16	of	O
17	the	O
18	muscle	O
19	-	O
20	specific	O
21	subunit	O
22	of	O
23	the	O
24	human	O
25	<UNK>	B
26	<UNK>	I
27	gene	O
28	in	O
29	skeletal	O
30	and	O
31	cardiac	O
32	muscle	O
33	cells	O
34	.	O
1	Although	O
2	the	O
3	E	O
4	-	O
5	box	O
6	consensus	O
7	is	O
8	<UNK>	O
9	defined	O
10	as	O
11	<UNK>	O
12	,	O
13	the	O
14	adjacent	O
15	nucleotides	O
16	of	O
17	functional	O
18	E	O
19	-	O
20	boxes	O
21	are	O
22	variable	O
23	for	O
24	genes	O
25	regulated	O
26	by	O
27	the	O
28	bHLH	O
29	proteins	O
30	.	O
1	<UNK>	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	<UNK>	B
10	<UNK>	O
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	<UNK>	B
19	left	O
20	E	O
21	-	O
22	box	O
23	site	O
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	O
30	E	O
31	-	O
32	box	O
33	.	O
1	<UNK>	O
2	,	O
3	there	O
4	are	O
5	multiple	O
6	<UNK>	O
7	in	O
8	which	O
9	short	O
10	oligonucleotide	O
11	direct	O
12	repeats	O
13	<UNK>	O
14	a	O
15	region	O
16	absent	O
17	from	O
18	either	O
19	<UNK>	O
20	or	O
21	vaccinia	O
22	virus	O
23	.	O
1	This	O
2	soluble	O
3	form	O
4	of	O
5	the	O
6	<UNK>	B
7	(	O
8	<UNK>	B
9	)	O
10	bound	O
11	<UNK>	B
12	with	O
13	an	O
14	affinity	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	<UNK>	O
21	,	O
22	membrane	O
23	-	O
24	associated	O
25	receptor	O
26	.	O
1	Also	O
2	,	O
3	the	O
4	human	O
5	glycoprotein	O
6	alpha	O
7	-	O
8	subunit	O
9	promoter	O
10	was	O
11	induced	O
12	10	O
13	-	O
14	fold	O
15	by	O
16	<UNK>	B
17	in	O
18	<UNK>	O
19	rat	O
20	pituitary	O
21	cells	O
22	.(	O
23	ABSTRACT	O
24	TRUNCATED	O
25	AT	O
26	400	O
27	WORDS	O
28	)	O
1	<UNK>	O
2	studies	O
3	using	O
4	<UNK>	O
5	labeled	O
6	<UNK>	O
7	and	O
8	<UNK>	O
9	<UNK>	O
10	<UNK>	O
11	confirmed	O
12	that	O
13	the	O
14	<UNK>	O
15	did	O
16	not	O
17	<UNK>	O
18	<UNK>	O
19	or	O
20	<UNK>	O
21	<UNK>	O
22	.	O
1	We	O
2	have	O
3	cloned	O
4	and	O
5	characterized	O
6	a	O
7	55	O
8	-	O
9	kb	O
10	region	O
11	of	O
12	DNA	O
13	surrounding	O
14	<UNK>	B
15	.	O
1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	B
9	binding	O
10	site	O
11	II	O
12	sequence	O
13	that	O
14	was	O
15	required	O
16	for	O
17	this	O
18	regulation	O
19	.	O
1	<UNK>	O
2	of	O
3	H	O
4	-	O
5	<UNK>	B
6	with	O
7	an	O
8	<UNK>	B
9	<UNK>	O
10	in	O
11	the	O
12	<UNK>	O
13	/	O
14	<UNK>	O
15	B	O
16	cell	O
17	lymphoma	O
18	.	O
1	Finally	O
2	,	O
3	we	O
4	determined	O
5	that	O
6	the	O
7	<UNK>	B
8	amino	O
9	terminus	O
10	was	O
11	both	O
12	necessary	O
13	and	O
14	sufficient	O
15	for	O
16	binding	O
17	<UNK>	O
18	as	O
19	we	O
20	were	O
21	able	O
22	to	O
23	transfer	O
24	<UNK>	O
25	-	O
26	binding	O
27	properties	O
28	to	O
29	a	O
30	reporter	O
31	gene	O
32	product	O
33	previously	O
34	unable	O
35	to	O
36	bind	O
37	RNA	O
38	.	O
1	<UNK>	O
2	<UNK>	O
3	may	O
4	be	O
5	decreased	O
6	by	O
7	transient	O
8	changes	O
9	in	O
10	<UNK>	O
11	error	O
12	caused	O
13	by	O
14	<UNK>	O
15	,	O
16	the	O
17	<UNK>	O
18	agent	O
19	<UNK>	O
20	,	O
21	<UNK>	O
22	<UNK>	O
23	,	O
24	and	O
25	<UNK>	B
26	<UNK>	I
27	inhibitors	O
28	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	21	O
6	-	O
7	<UNK>	O
8	<UNK>	O
9	structure	O
10	is	O
11	also	O
12	present	O
13	in	O
14	each	O
15	unit	O
16	.	O
1	We	O
2	have	O
3	isolated	O
4	and	O
5	<UNK>	O
6	a	O
7	differentially	O
8	-	O
9	regulated	O
10	gene	O
11	family	O
12	in	O
13	the	O
14	<UNK>	O
15	<UNK>	O
16	<UNK>	O
17	major	O
18	.	O
1	At	O
2	some	O
3	sites	O
4	,	O
5	%	O
6	T	O
7	is	O
8	greatly	O
9	increased	O
10	by	O
11	<UNK>	O
12	-	O
13	concentrations	O
14	up	O
15	to	O
16	1	O
17	M	O
18	,	O
19	while	O
20	at	O
21	other	O
22	sites	O
23	%	O
24	T	O
25	is	O
26	reduced	O
27	or	O
28	unaffected	O
29	by	O
30	these	O
31	conditions	O
32	.	O
1	The	O
2	initial	O
3	translation	O
4	protein	O
5	encoded	O
6	by	O
7	the	O
8	cDNA	O
9	is	O
10	53	O
11	,	O
12	<UNK>	O
13	kDa	O
14	and	O
15	possesses	O
16	a	O
17	<UNK>	O
18	amino	O
19	acid	O
20	composition	O
21	with	O
22	<UNK>	O
23	acid	O
24	<UNK>	O
25	22	O
26	%	O
27	of	O
28	the	O
29	total	O
30	amino	O
31	acid	O
32	residues	O
33	.	O
1	Genetic	O
2	and	O
3	biochemical	O
4	evidence	O
5	suggests	O
6	that	O
7	v	O
8	-	O
9	Crk	B
10	can	O
11	induce	O
12	transformation	O
13	of	O
14	chicken	O
15	embryo	O
16	fibroblasts	O
17	by	O
18	<UNK>	O
19	the	O
20	activity	O
21	of	O
22	cellular	O
23	proteins	O
24	involved	O
25	in	O
26	growth	O
27	regulation	O
28	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	-	O
5	associated	O
6	surface	O
7	glycoprotein	O
8	<UNK>	B
9	is	O
10	implicated	O
11	in	O
12	<UNK>	O
13	growth	O
14	and	O
15	<UNK>	O
16	as	O
17	revealed	O
18	by	O
19	antibody	O
20	<UNK>	O
21	experiments	O
22	.	O
1	Surprisingly	O
2	,	O
3	the	O
4	full	O
5	-	O
6	deletion	O
7	mutant	O
8	showed	O
9	a	O
10	strong	O
11	block	O
12	in	O
13	virus	O
14	release	O
15	,	O
16	suggesting	O
17	that	O
18	<UNK>	O
19	is	O
20	involved	O
21	in	O
22	virus	O
23	assembly	O
24	.	O
1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	<UNK>	O
7	plasma	O
8	levels	O
9	were	O
10	<UNK>	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O
1	Thirty	O
2	percent	O
3	of	O
4	patients	O
5	were	O
6	<UNK>	O
7	off	O
8	all	O
9	steroids	O
10	,	O
11	and	O
12	the	O
13	average	O
14	steroid	O
15	dose	O
16	in	O
17	the	O
18	group	O
19	who	O
20	received	O
21	steroids	O
22	was	O
23	8	O
24	.	O
25	6	O
26	mg	O
27	of	O
28	<UNK>	O
29	per	O
30	day	O
31	.	O
1	The	O
2	<UNK>	O
3	tissues	O
4	of	O
5	the	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	were	O
10	<UNK>	O
11	and	O
12	then	O
13	<UNK>	O
14	with	O
15	calcium	O
16	<UNK>	O
17	.	O
1	If	O
2	no	O
3	<UNK>	O
4	was	O
5	received	O
6	,	O
7	<UNK>	O
8	contact	O
9	or	O
10	home	O
11	<UNK>	O
12	were	O
13	made	O
14	.	O
1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O
1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	<UNK>	O
9	of	O
10	the	O
11	<UNK>	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	<UNK>	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	<UNK>	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O
1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	O
6	<UNK>	B
7	variants	O
8	,	O
9	termed	O
10	M	O
11	(	O
12	muscle	O
13	),	O
14	L	O
15	(	O
16	liver	O
17	),	O
18	E1	O
19	,	O
20	and	O
21	E2	O
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	<UNK>	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	<UNK>	O
35	criteria	O
36	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	endogenous	O
6	N	O
7	-	O
8	methylation	O
9	of	O
10	<UNK>	O
11	into	O
12	N	O
13	-	O
14	<UNK>	O
15	occurs	O
16	in	O
17	the	O
18	brain	O
19	in	O
20	vivo	O
21	.	O
1	<UNK>	O
2	of	O
3	the	O
4	selected	O
5	sequences	O
6	allowed	O
7	us	O
8	to	O
9	<UNK>	O
10	a	O
11	consensus	O
12	sequence	O
13	for	O
14	binding	O
15	of	O
16	the	O
17	individual	O
18	<UNK>	O
19	Rel	B
20	-	O
21	related	O
22	proteins	O
23	,	O
24	and	O
25	DNA	O
26	-	O
27	protein	O
28	binding	O
29	analysis	O
30	of	O
31	the	O
32	selected	O
33	DNA	O
34	sequences	O
35	revealed	O
36	sequence	O
37	specificity	O
38	of	O
39	the	O
40	proteins	O
41	.	O
1	Using	O
2	either	O
3	a	O
4	p50	B
5	-	O
6	or	O
7	p65	B
8	-	O
9	selected	O
10	kappa	B
11	B	O
12	motif	O
13	,	O
14	which	O
15	displayed	O
16	differential	O
17	binding	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	other	O
23	protein	O
24	,	O
25	little	O
26	to	O
27	no	O
28	binding	O
29	was	O
30	observed	O
31	with	O
32	the	O
33	heterodimeric	O
34	NF	B
35	-	O
36	kappa	B
37	B	O
38	complex	O
39	.	O
1	By	O
2	screening	O
3	a	O
4	<UNK>	O
5	cell	O
6	cDNA	O
7	library	O
8	with	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	region	O
14	of	O
15	the	O
16	H	O
17	-	O
18	<UNK>	B
19	nuclear	O
20	hormone	O
21	receptor	O
22	cDNA	O
23	,	O
24	we	O
25	isolated	O
26	a	O
27	cDNA	O
28	that	O
29	is	O
30	selectively	O
31	expressed	O
32	in	O
33	<UNK>	O
34	cells	O
35	.	O
1	<UNK>	O
2	threshold	O
3	was	O
4	determined	O
5	through	O
6	an	O
7	<UNK>	O
8	O2	O
9	<UNK>	O
10	catheter	O
11	.	O
1	Thus	O
2	,	O
3	chronic	O
4	<UNK>	O
5	decrease	O
6	induced	O
7	by	O
8	H	O
9	or	O
10	P	O
11	resulted	O
12	in	O
13	a	O
14	significant	O
15	fall	O
16	in	O
17	blood	O
18	pressure	O
19	compared	O
20	to	O
21	control	O
22	(	O
23	201	O
24	+/-	O
25	3	O
26	v	O
27	<UNK>	O
28	+/-	O
29	4	O
30	,	O
31	<UNK>	O
32	+/-	O
33	4	O
34	mm	O
35	Hg	O
36	,	O
37	respectively	O
38	;	O
39	P	O
40	<	O
41	.	O
42	05	O
43	).	O
1	The	O
2	effects	O
3	of	O
4	diltiazem	O
5	were	O
6	<UNK>	O
7	,	O
8	thus	O
9	the	O
10	<UNK>	O
11	induced	O
12	by	O
13	d	O
14	-	O
15	cis	O
16	diltiazem	O
17	was	O
18	significantly	O
19	greater	O
20	in	O
21	all	O
22	cases	O
23	than	O
24	that	O
25	induced	O
26	by	O
27	l	O
28	-	O
29	cis	O
30	diltiazem	O
31	,	O
32	which	O
33	suggests	O
34	that	O
35	calcium	O
36	channel	O
37	blockade	O
38	plays	O
39	a	O
40	role	O
41	in	O
42	these	O
43	interactions	O
44	.	O
1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	<UNK>	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	<UNK>	O
43	).	O
1	It	O
2	corresponds	O
3	to	O
4	the	O
5	complete	O
6	mitochondrial	O
7	<UNK>	O
8	and	O
9	the	O
10	<UNK>	O
11	-	O
12	bearing	O
13	domain	O
14	that	O
15	are	O
16	encoded	O
17	by	O
18	exons	O
19	I	O
20	through	O
21	IV	O
22	of	O
23	the	O
24	functional	O
25	E2	O
26	gene	O
27	.	O
1	The	O
2	second	O
3	method	O
4	,	O
5	the	O
6	""""	O
7	<UNK>	O
8	""""	O
9	assay	O
10	,	O
11	has	O
12	a	O
13	sensitivity	O
14	range	O
15	of	O
16	0	O
17	.	O
18	03	O
19	-	O
20	5	O
21	.	O
22	0	O
23	micrograms	O
24	<UNK>	O
25	with	O
26	100	O
27	-	O
28	500	O
29	<UNK>	O
30	<UNK>	O
31	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	<UNK>	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O
1	A	O
2	second	O
3	domain	O
4	,	O
5	located	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	<UNK>	O
12	amino	O
13	acids	O
14	of	O
15	<UNK>	B
16	,	O
17	is	O
18	required	O
19	for	O
20	inhibitory	O
21	and	O
22	DNA	O
23	-	O
24	binding	O
25	activities	O
26	.	O
1	In	O
2	order	O
3	to	O
4	investigate	O
5	the	O
6	blood	O
7	<UNK>	O
8	of	O
9	<UNK>	O
10	vein	O
11	graft	O
12	(	O
13	<UNK>	O
14	),	O
15	changes	O
16	in	O
17	<UNK>	O
18	(	O
19	<UNK>	O
20	)	O
21	production	O
22	following	O
23	<UNK>	O
24	and	O
25	arterial	O
26	<UNK>	O
27	were	O
28	studied	O
29	<UNK>	O
30	.	O
1	<UNK>	B
2	-	O
3	<UNK>	B
4	antibodies	O
5	detect	O
6	a	O
7	<UNK>	O
8	protein	O
9	in	O
10	extracts	O
11	of	O
12	C	O
13	.	O
14	<UNK>	O
15	in	O
16	agreement	O
17	with	O
18	the	O
19	size	O
20	predicted	O
21	from	O
22	the	O
23	nucleotide	O
24	sequence	O
25	of	O
26	the	O
27	cloned	O
28	gene	O
29	.	O
1	<UNK>	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	<UNK>	O
8	with	O
9	<UNK>	O
10	.	O
1	For	O
2	pressure	O
3	greater	O
4	than	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	,	O
9	an	O
10	increased	O
11	<UNK>	O
12	of	O
13	the	O
14	<UNK>	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	<UNK>	O
20	the	O
21	<UNK>	O
22	reflex	O
23	from	O
24	<UNK>	O
25	<UNK>	O
26	.	O
1	One	O
2	air	O
3	<UNK>	O
4	occurred	O
5	;	O
6	this	O
7	was	O
8	the	O
9	only	O
10	filter	O
11	-	O
12	or	O
13	<UNK>	O
14	-	O
15	related	O
16	<UNK>	O
17	.	O
1	<UNK>	O
2	studies	O
3	showed	O
4	that	O
5	the	O
6	direct	O
7	fluorescent	O
8	-	O
9	antibody	O
10	<UNK>	O
11	were	O
12	the	O
13	least	O
14	sensitive	O
15	in	O
16	this	O
17	case	O
18	and	O
19	did	O
20	not	O
21	detect	O
22	<UNK>	O
23	than	O
24	10	O
25	(	O
26	4	O
27	)	O
28	<UNK>	O
29	bodies	O
30	per	O
31	ml	O
32	,	O
33	while	O
34	most	O
35	ELISA	O
36	<UNK>	O
37	detected	O
38	between	O
39	130	O
40	and	O
41	<UNK>	O
42	<UNK>	O
43	bodies	O
44	per	O
45	ml	O
46	.	O
1	For	O
2	this	O
3	<UNK>	O
4	,	O
5	the	O
6	particle	O
7	forming	O
8	capacity	O
9	of	O
10	derivatives	O
11	of	O
12	the	O
13	HIV	O
14	-	O
15	1	O
16	group	O
17	specific	O
18	core	O
19	antigen	O
20	<UNK>	B
21	gag	I
22	was	O
23	assayed	O
24	and	O
25	compared	O
26	dependent	O
27	on	O
28	various	O
29	expression	O
30	systems	O
31	:	O
32	recombinant	O
33	bacteria	O
34	,	O
35	vaccinia	O
36	-	O
37	and	O
38	<UNK>	O
39	were	O
40	established	O
41	encoding	O
42	the	O
43	entire	O
44	core	O
45	protein	O
46	<UNK>	B
47	either	O
48	in	O
49	its	O
50	<UNK>	O
51	sequence	O
52	or	O
53	lacking	O
54	the	O
55	<UNK>	O
56	consensus	O
57	signal	O
58	.	O
1	This	O
2	may	O
3	result	O
4	in	O
5	more	O
6	<UNK>	O
7	and	O
8	<UNK>	O
9	reduced	O
10	renal	O
11	clearance	O
12	.	O
1	The	O
2	major	O
3	pathological	O
4	findings	O
5	of	O
6	the	O
7	placenta	O
8	were	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	.	O
1	We	O
2	investigated	O
3	the	O
4	diagnostic	O
5	value	O
6	of	O
7	a	O
8	new	O
9	in	O
10	vitro	O
11	test	O
12	,	O
13	<UNK>	O
14	CAP	O
15	<UNK>	O
16	(	O
17	<UNK>	O
18	<UNK>	O
19	<UNK>	O
20	,	O
21	<UNK>	O
22	,	O
23	<UNK>	O
24	),	O
25	for	O
26	the	O
27	quantitative	O
28	measurement	O
29	of	O
30	allergen	O
31	-	O
32	specific	O
33	IgE	B
34	antibodies	O
35	by	O
36	comparison	O
37	with	O
38	<UNK>	O
39	in	O
40	2	O
41	groups	O
42	of	O
43	patients	O
44	,	O
45	71	O
46	<UNK>	O
47	and	O
48	48	O
49	non	O
50	-	O
51	<UNK>	O
52	.	O
1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	<UNK>	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	<UNK>	O
14	death	O
15	.	O
1	A	O
2	second	O
3	large	O
4	group	O
5	of	O
6	disorders	O
7	in	O
8	pregnancy	O
9	is	O
10	caused	O
11	by	O
12	effects	O
13	of	O
14	infections	O
15	of	O
16	the	O
17	<UNK>	O
18	without	O
19	<UNK>	O
20	being	O
21	transmitted	O
22	to	O
23	the	O
24	embryo	O
25	or	O
26	the	O
27	placenta	O
28	.	O
1	Four	O
2	short	O
3	nucleotide	O
4	sequences	O
5	(	O
6	boxes	O
7	I	O
8	to	O
9	IV	O
10	)	O
11	contribute	O
12	to	O
13	the	O
14	light	O
15	responsiveness	O
16	of	O
17	the	O
18	<UNK>	B
19	<UNK>	I
20	synthase	I
21	promoter	O
22	.	O
1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	<UNK>	O
8	<UNK>	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	O
23	to	O
24	150	O
25	-	O
26	200	O
27	%	O
28	after	O
29	the	O
30	induction	O
31	of	O
32	anesthesia	O
33	,	O
34	and	O
35	then	O
36	decreased	O
37	to	O
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	<UNK>	O
46	<UNK>	O
47	<UNK>	O
48	flap	O
49	.	O
1	<UNK>	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	<UNK>	B
7	,	O
8	<UNK>	B
9	,	O
10	and	O
11	<UNK>	B
12	function	O
13	<UNK>	O
14	in	O
15	transcriptional	O
16	activation	O
17	,	O
18	possibly	O
19	forming	O
20	a	O
21	<UNK>	O
22	complex	O
23	.	O
1	Mutations	O
2	in	O
3	either	O
4	gene	O
5	block	O
6	some	O
7	crucial	O
8	late	O
9	step	O
10	in	O
11	assembly	O
12	of	O
13	F1	O
14	,	O
15	causing	O
16	the	O
17	alpha	O
18	and	O
19	beta	O
20	subunits	O
21	to	O
22	accumulate	O
23	in	O
24	mitochondria	O
25	as	O
26	inactive	O
27	<UNK>	O
28	(	O
29	<UNK>	O
30	,	O
31	S	O
32	.	O
1	There	O
2	was	O
3	however	O
4	,	O
5	no	O
6	significant	O
7	difference	O
8	in	O
9	the	O
10	prevalence	O
11	of	O
12	chronic	O
13	respiratory	O
14	symptoms	O
15	between	O
16	animal	O
17	food	O
18	workers	O
19	with	O
20	positive	O
21	and	O
22	negative	O
23	skin	O
24	tests	O
25	to	O
26	<UNK>	O
27	<UNK>	O
28	or	O
29	to	O
30	<UNK>	O
31	<UNK>	O
32	or	O
33	among	O
34	those	O
35	with	O
36	increased	O
37	or	O
38	normal	O
39	IgE	B
40	(	O
41	except	O
42	for	O
43	<UNK>	O
44	).	O
1	A	O
2	comparison	O
3	of	O
4	the	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	the	O
10	T	O
11	.	O
12	<UNK>	O
13	enzyme	O
14	with	O
15	that	O
16	of	O
17	the	O
18	Escherichia	O
19	coli	O
20	enzyme	O
21	showed	O
22	(	O
23	i	O
24	)	O
25	a	O
26	37	O
27	%	O
28	overall	O
29	similarity	O
30	;	O
31	(	O
32	ii	O
33	)	O
34	the	O
35	conservation	O
36	of	O
37	the	O
38	Ser	O
39	residue	O
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	phosphorylated	O
47	in	O
48	the	O
49	E	O
50	.	O
51	coli	O
52	enzyme	O
53	,	O
54	and	O
55	of	O
56	the	O
57	surrounding	O
58	sequence	O
59	;	O
60	and	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	presence	O
66	of	O
67	<UNK>	O
68	<UNK>	O
69	residues	O
70	at	O
71	the	O
72	C	O
73	terminus	O
74	of	O
75	the	O
76	T	O
77	.	O
78	<UNK>	O
79	enzyme	O
80	.	O
1	<UNK>	O
2	tobacco	O
3	<UNK>	O
4	protein	O
5	has	O
6	44	O
7	%	O
8	amino	O
9	acid	O
10	identity	O
11	with	O
12	ribosomal	O
13	protein	O
14	<UNK>	B
15	/	O
16	<UNK>	O
17	of	O
18	Escherichia	O
19	coli	O
20	.	O
1	Characterization	O
2	of	O
3	these	O
4	R	O
5	subunits	O
6	by	O
7	their	O
8	8	O
9	-	O
10	<UNK>	O
11	-	O
12	cAMP	O
13	<UNK>	O
14	labeling	O
15	and	O
16	<UNK>	O
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	phosphorylation	O
24	-	O
25	dependent	O
26	mobility	O
27	shift	O
28	on	O
29	sodium	O
30	<UNK>	O
31	sulfate	O
32	-	O
33	polyacrylamide	O
34	gel	O
35	electrophoresis	O
36	(	O
37	SDS	O
38	-	O
39	<UNK>	O
40	),	O
41	indicated	O
42	subunit	O
43	sizes	O
44	of	O
45	<UNK>	B
46	beta	O
47	(	O
48	53	O
49	kDa	O
50	)	O
51	greater	O
52	than	O
53	<UNK>	B
54	alpha	O
55	<UNK>	O
56	(	O
57	51	O
58	kDa	O
59	)	O
60	greater	O
61	than	O
62	<UNK>	B
63	alpha	O
64	(	O
65	49	O
66	kDa	O
67	).	O
1	<UNK>	O
2	processing	O
3	occurs	O
4	<UNK>	O
5	.	O
1	<UNK>	O
2	hybridization	O
3	of	O
4	<UNK>	B
5	-	O
6	1	O
7	back	O
8	to	O
9	<UNK>	O
10	genomic	O
11	DNA	O
12	indicates	O
13	two	O
14	distinct	O
15	<UNK>	B
16	-	O
17	1	O
18	loci	O
19	in	O
20	normal	O
21	human	O
22	DNA	O
23	,	O
24	an	O
25	identical	O
26	band	O
27	pattern	O
28	in	O
29	<UNK>	O
30	DNA	O
31	,	O
32	and	O
33	a	O
34	single	O
35	locus	O
36	in	O
37	<UNK>	O
38	monkey	O
39	DNA	O
40	.	O
1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	<UNK>	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	<UNK>	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O
1	This	O
2	DNA	O
3	motif	O
4	represents	O
5	a	O
6	novel	O
7	protein	O
8	-	O
9	binding	O
10	sequence	O
11	.	O
1	<UNK>	O
2	temperature	O
3	and	O
4	<UNK>	B
5	are	O
6	both	O
7	required	O
8	for	O
9	the	O
10	induction	O
11	of	O
12	the	O
13	<UNK>	B
14	<UNK>	O
15	.	O
1	The	O
2	recently	O
3	developed	O
4	gamma	O
5	-	O
6	interferon	B
7	(	O
8	IFN	B
9	-	O
10	gamma	O
11	)	O
12	assay	O
13	system	O
14	for	O
15	the	O
16	diagnosis	O
17	of	O
18	bovine	O
19	tuberculosis	O
20	in	O
21	cattle	O
22	has	O
23	been	O
24	<UNK>	O
25	by	O
26	the	O
27	<UNK>	O
28	<UNK>	O
29	on	O
30	<UNK>	O
31	for	O
32	use	O
33	in	O
34	<UNK>	O
35	.	O
1	The	O
2	Klebsiella	O
3	<UNK>	B
4	gene	O
5	<UNK>	B
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	synthesis	O
13	of	O
14	monoamine	B
15	oxidase	I
16	,	O
17	was	O
18	induced	O
19	by	O
20	<UNK>	O
21	and	O
22	the	O
23	related	O
24	compounds	O
25	,	O
26	subjected	O
27	to	O
28	<UNK>	O
29	and	O
30	<UNK>	O
31	ion	O
32	repression	O
33	,	O
34	and	O
35	cloned	O
36	.	O
1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	O
14	<UNK>	B
15	variants	O
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	O
23	gene	O
24	.	O
1	Protein	O
2	tyrosine	O
3	kinases	O
4	(	O
5	<UNK>	B
6	)	O
7	are	O
8	implicated	O
9	in	O
10	the	O
11	control	O
12	of	O
13	cell	O
14	growth	O
15	by	O
16	<UNK>	O
17	of	O
18	their	O
19	frequent	O
20	appearance	O
21	as	O
22	products	O
23	of	O
24	retroviral	O
25	oncogenes	O
26	,	O
27	as	O
28	intracellular	O
29	signal	O
30	<UNK>	O
31	,	O
32	and	O
33	as	O
34	growth	O
35	factor	O
36	receptors	O
37	or	O
38	components	O
39	<UNK>	O
40	.	O
1	Unlike	O
2	the	O
3	typical	O
4	enhancer	O
5	element	O
6	,	O
7	this	O
8	region	O
9	functions	O
10	in	O
11	an	O
12	orientation	O
13	-	O
14	dependent	O
15	manner	O
16	.	O
1	<UNK>	O
2	was	O
3	recorded	O
4	with	O
5	<UNK>	O
6	<UNK>	O
7	at	O
8	25	O
9	-	O
10	250	O
11	<UNK>	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	<UNK>	O
19	method	O
20	.	O
1	<UNK>	O
2	-	O
3	drug	O
4	interactions	O
5	are	O
6	most	O
7	likely	O
8	to	O
9	occur	O
10	in	O
11	patients	O
12	receiving	O
13	multiple	O
14	<UNK>	O
15	and	O
16	with	O
17	drugs	O
18	that	O
19	have	O
20	a	O
21	<UNK>	O
22	therapeutic	O
23	<UNK>	O
24	.	O
1	A	O
2	<UNK>	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	<UNK>	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	<UNK>	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	<UNK>	O
38	<UNK>	O
39	<UNK>	O
40	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	baculovirus	O
6	-	O
7	expressed	O
8	TR	B
9	mediates	O
10	transcriptional	O
11	activation	O
12	and	O
13	repression	O
14	in	O
15	a	O
16	promoter	O
17	-	O
18	specific	O
19	manner	O
20	in	O
21	vitro	O
22	.	O
1	<UNK>	O
2	the	O
3	natural	O
4	<UNK>	O
5	?	O
1	The	O
2	serum	O
3	erythropoietin	B
4	(	O
5	EPO	B
6	)	O
7	concentrations	O
8	of	O
9	15	O
10	male	O
11	<UNK>	O
12	(	O
13	26	O
14	.	O
15	3	O
16	U	O
17	.	O
18	ml	O
19	-	O
20	1	O
21	)	O
22	were	O
23	significantly	O
24	lower	O
25	than	O
26	those	O
27	of	O
28	45	O
29	male	O
30	distance	O
31	<UNK>	O
32	(	O
33	31	O
34	.	O
35	6	O
36	U	O
37	.	O
38	ml	O
39	-	O
40	1	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	).	O
1	His	O
2	<UNK>	B
3	II	O
4	activity	O
5	and	O
6	antigen	O
7	levels	O
8	were	O
9	49	O
10	%	O
11	and	O
12	50	O
13	%,	O
14	respectively	O
15	,	O
16	and	O
17	his	O
18	<UNK>	O
19	also	O
20	showed	O
21	similar	O
22	low	O
23	levels	O
24	.	O
1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	<UNK>	O
7	of	O
8	<UNK>	O
9	in	O
10	CP	O
11	/	O
12	<UNK>	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	<UNK>	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	<UNK>	O
33	disorder	O
34	presentation	O
35	.	O
1	Furthermore	O
2	,	O
3	no	O
4	transcripts	O
5	of	O
6	the	O
7	same	O
8	size	O
9	and	O
10	having	O
11	the	O
12	same	O
13	developmental	O
14	profile	O
15	as	O
16	those	O
17	generated	O
18	by	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	<UNK>	B
24	fragment	O
25	were	O
26	identified	O
27	by	O
28	probes	O
29	<UNK>	O
30	the	O
31	<UNK>	O
32	of	O
33	the	O
34	cloned	O
35	region	O
36	.	O
1	In	O
2	an	O
3	<UNK>	O
4	study	O
5	the	O
6	performance	O
7	of	O
8	the	O
9	<UNK>	O
10	is	O
11	being	O
12	compared	O
13	with	O
14	that	O
15	of	O
16	the	O
17	<UNK>	O
18	<UNK>	O
19	<UNK>	O
20	(	O
21	<UNK>	O
22	).	O
1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	<UNK>	O
9	inhibit	O
10	kappa	B
11	B	O
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	O
19	immunodeficiency	O
20	virus	O
21	long	O
22	terminal	O
23	repeat	O
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	<UNK>	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O
1	Therefore	O
2	,	O
3	with	O
4	a	O
5	biopsy	O
6	from	O
7	the	O
8	<UNK>	O
9	site	O
10	there	O
11	is	O
12	a	O
13	risk	O
14	of	O
15	missing	O
16	early	O
17	rejection	O
18	.	O
1	<UNK>	O
2	the	O
3	application	O
4	solutions	O
5	of	O
6	<UNK>	O
7	<UNK>	O
8	should	O
9	not	O
10	be	O
11	used	O
12	longer	O
13	than	O
14	one	O
15	day	O
16	.	O
1	Two	O
2	cDNAs	O
3	encoding	O
4	casein	B
5	kinase	I
6	-	O
7	1	O
8	have	O
9	been	O
10	isolated	O
11	from	O
12	a	O
13	yeast	O
14	cDNA	O
15	library	O
16	and	O
17	termed	O
18	<UNK>	B
19	and	O
20	<UNK>	B
21	.	O
1	However	O
2	,	O
3	<UNK>	O
4	was	O
5	at	O
6	least	O
7	2	O
8	-	O
9	fold	O
10	more	O
11	effective	O
12	in	O
13	stimulating	O
14	CAT	B
15	activity	O
16	of	O
17	fusion	O
18	genes	O
19	containing	O
20	upstream	O
21	sequences	O
22	(-	O
23	<UNK>	O
24	to	O
25	-	O
26	<UNK>	O
27	)	O
28	than	O
29	those	O
30	containing	O
31	proximal	O
32	sequences	O
33	(-	O
34	<UNK>	O
35	to	O
36	-	O
37	<UNK>	O
38	),	O
39	suggesting	O
40	two	O
41	regions	O
42	in	O
43	the	O
44	<UNK>	B
45	-	O
46	I	O
47	gene	O
48	that	O
49	mediate	O
50	the	O
51	<UNK>	O
52	response	O
53	.	O
1	An	O
2	examination	O
3	of	O
4	the	O
5	role	O
6	of	O
7	the	O
8	carboxyl	O
9	terminus	O
10	in	O
11	regulating	O
12	<UNK>	B
13	-	O
14	B	O
15	transcriptional	O
16	activity	O
17	revealed	O
18	that	O
19	,	O
20	in	O
21	<UNK>	O
22	with	O
23	other	O
24	nuclear	O
25	receptors	O
26	,	O
27	mutants	O
28	lacking	O
29	portions	O
30	of	O
31	the	O
32	carboxyl	O
33	terminus	O
34	had	O
35	greatly	O
36	decreased	O
37	activity	O
38	.	O
1	The	O
2	<UNK>	O
3	that	O
4	<UNK>	O
5	oxide	O
6	does	O
7	not	O
8	produce	O
9	<UNK>	O
10	<UNK>	O
11	readily	O
12	might	O
13	be	O
14	that	O
15	the	O
16	one	O
17	-	O
18	electron	O
19	reduction	O
20	<UNK>	O
21	through	O
22	an	O
23	<UNK>	O
24	-	O
25	intermediate	O
26	which	O
27	is	O
28	<UNK>	O
29	very	O
30	<UNK>	O
31	:	O
32	<UNK>	O
33	(	O
34	<UNK>	O
35	/	O
36	<UNK>	O
37	<UNK>	O
38	=	O
39	-	O
40	1	O
41	.	O
42	1	O
43	V	O
44	.	O
1	All	O
2	mutant	O
3	<UNK>	O
4	T	O
5	antigens	O
6	bound	O
7	to	O
8	<UNK>	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O
1	The	O
2	relation	O
3	between	O
4	myocardial	O
5	beta	O
6	-	O
7	adrenergic	O
8	receptor	O
9	and	O
10	left	O
11	ventricular	O
12	(	O
13	LV	O
14	)	O
15	function	O
16	was	O
17	studied	O
18	in	O
19	10	O
20	patients	O
21	,	O
22	aged	O
23	41	O
24	to	O
25	61	O
26	years	O
27	(	O
28	average	O
29	51	O
30	),	O
31	with	O
32	LV	O
33	volume	O
34	<UNK>	O
35	mainly	O
36	due	O
37	to	O
38	chronic	O
39	<UNK>	O
40	<UNK>	O
41	.	O
1	In	O
2	addition	O
3	to	O
4	the	O
5	previously	O
6	identified	O
7	and	O
8	characterized	O
9	<UNK>	O
10	1	O
11	<UNK>	O
12	93	O
13	nucleotides	O
14	downstream	O
15	from	O
16	the	O
17	major	O
18	late	O
19	transcription	O
20	start	O
21	site	O
22	,	O
23	a	O
24	second	O
25	<UNK>	O
26	,	O
27	<UNK>	O
28	2	O
29	,	O
30	<UNK>	O
31	55	O
32	nucleotides	O
33	downstream	O
34	from	O
35	it	O
36	,	O
37	has	O
38	been	O
39	identified	O
40	.	O
1	<UNK>	O
2	results	O
3	with	O
4	a	O
5	<UNK>	O
6	<UNK>	O
7	test	O
8	in	O
9	the	O
10	assessment	O
11	of	O
12	<UNK>	O
13	antibody	O
14	status	O
15	of	O
16	cardiac	O
17	transplant	O
18	donors	O
19	.	O
1	We	O
2	have	O
3	identified	O
4	<UNK>	B
5	'	O
6	s	O
7	nuclear	O
8	localization	O
9	signal	O
10	(	O
11	<UNK>	O
12	)	O
13	and	O
14	show	O
15	that	O
16	it	O
17	can	O
18	confer	O
19	cell	O
20	cycle	O
21	-	O
22	dependent	O
23	nuclear	O
24	entry	O
25	to	O
26	a	O
27	heterologous	O
28	protein	O
29	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	B
4	.	O
5	2	O
6	is	O
7	not	O
8	found	O
9	in	O
10	S	O
11	.	O
12	cerevisiae	O
13	and	O
14	appears	O
15	at	O
16	an	O
17	unique	O
18	location	O
19	in	O
20	K	O
21	.	O
22	<UNK>	O
23	.	O
1	<UNK>	O
2	400	O
3	mg	O
4	b	O
5	.	O
6	i	O
7	.	O
8	d	O
9	.	O
10	administered	O
11	orally	O
12	for	O
13	28	O
14	days	O
15	represents	O
16	a	O
17	safe	O
18	and	O
19	effective	O
20	treatment	O
21	for	O
22	chronic	O
23	bacterial	O
24	<UNK>	O
25	.	O
1	During	O
2	coronary	O
3	stenosis	O
4	,	O
5	on	O
6	the	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	<UNK>	O
11	at	O
12	the	O
13	same	O
14	dose	O
15	significantly	O
16	<UNK>	O
17	regional	O
18	myocardial	O
19	dysfunction	O
20	without	O
21	changing	O
22	<UNK>	O
23	flow	O
24	,	O
25	global	O
26	<UNK>	O
27	and	O
28	cardiac	O
29	lactate	O
30	metabolism	O
31	.	O
1	This	O
2	exon	O
3	,	O
4	here	O
5	named	O
6	exon	O
7	0	O
8	,	O
9	contained	O
10	the	O
11	entire	O
12	5	O
13	'	O
14	untranslated	O
15	region	O
16	and	O
17	the	O
18	N	O
19	-	O
20	terminal	O
21	signal	O
22	sequence	O
23	of	O
24	the	O
25	polypeptide	O
26	.	O
1	Induction	O
2	of	O
3	Jurkat	O
4	<UNK>	O
5	T	O
6	cells	O
7	with	O
8	phorbol	O
9	12	O
10	-	O
11	myristate	O
12	13	O
13	-	O
14	acetate	O
15	and	O
16	<UNK>	O
17	did	O
18	not	O
19	affect	O
20	the	O
21	level	O
22	of	O
23	<UNK>	B
24	mRNA	O
25	.	O
1	Recently	O
2	,	O
3	studies	O
4	of	O
5	agents	O
6	that	O
7	<UNK>	O
8	collagen	B
9	synthesis	O
10	and	O
11	<UNK>	O
12	have	O
13	yielded	O
14	several	O
15	new	O
16	<UNK>	O
17	inhibitors	O
18	.	O
1	<UNK>	O
2	cDNA	O
3	hybridization	O
4	to	O
5	genomic	O
6	DNA	O
7	<UNK>	O
8	indicated	O
9	a	O
10	small	O
11	subfamily	O
12	of	O
13	<UNK>	B
14	genes	O
15	,	O
16	simple	O
17	patterns	O
18	of	O
19	<UNK>	O
20	indicated	O
21	that	O
22	most	O
23	cDNAs	O
24	,	O
25	including	O
26	<UNK>	B
27	cDNA	O
28	,	O
29	<UNK>	O
30	to	O
31	single	O
32	-	O
33	copy	O
34	genes	O
35	.	O
1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	O
20	5	O
21	.	O
22	4	O
23	,	O
24	and	O
25	to	O
26	the	O
27	<UNK>	O
28	gene	O
29	,	O
30	<UNK>	B
31	.	O
1	The	O
2	SH2	B
3	and	O
4	SH3	B
5	domains	O
6	of	O
7	<UNK>	B
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	B
16	and	O
17	<UNK>	B
18	.	O
1	<UNK>	O
2	.	O
1	This	O
2	report	O
3	<UNK>	O
4	that	O
5	at	O
6	least	O
7	two	O
8	of	O
9	the	O
10	18	O
11	kDa	O
12	<UNK>	B
13	in	O
14	maize	O
15	are	O
16	products	O
17	of	O
18	different	O
19	but	O
20	related	O
21	genes	O
22	.	O
1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	O
9	matrix	O
10	glycoprotein	O
11	<UNK>	B
12	.	O
1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	<UNK>	B
9	-	O
10	related	O
11	kinase	B
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	O
17	yeast	O
18	<UNK>	B
19	mutation	O
20	.	O
1	In	O
2	patients	O
3	with	O
4	<UNK>	O
5	and	O
6	joint	O
7	<UNK>	O
8	(	O
9	n	O
10	=	O
11	48	O
12	)	O
13	<UNK>	O
14	<UNK>	B
15	had	O
16	a	O
17	sensitivity	O
18	of	O
19	77	O
20	%,	O
21	which	O
22	was	O
23	only	O
24	<UNK>	O
25	by	O
26	that	O
27	of	O
28	the	O
29	<UNK>	O
30	erythrocyte	O
31	<UNK>	O
32	rate	O
33	(	O
34	sensitivity	O
35	89	O
36	%).	O
1	E	O
2	.,	O
3	<UNK>	O
4	,	O
5	C	O
6	.,	O
7	<UNK>	O
8	,	O
9	D	O
10	.,	O
11	<UNK>	O
12	,	O
13	B	O
14	.,	O
15	<UNK>	O
16	,	O
17	R	O
18	.,	O
19	<UNK>	O
20	,	O
21	B	O
22	.,	O
23	<UNK>	O
24	-	O
25	<UNK>	O
26	,	O
27	G	O
28	.,	O
29	and	O
30	<UNK>	O
31	,	O
32	R	O
33	.,	O
34	(	O
35	1990	O
36	)	O
37	<UNK>	O
38	63	O
39	,	O
40	<UNK>	O
41	-	O
42	<UNK>	O
43	).	O
1	An	O
2	approximately	O
3	2	O
4	-	O
5	kilobase	O
6	<UNK>	O
7	transcript	O
8	was	O
9	expressed	O
10	in	O
11	all	O
12	<UNK>	O
13	organs	O
14	tested	O
15	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	<UNK>	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	O
12	enzyme	O
13	inhibitors	O
14	can	O
15	<UNK>	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	<UNK>	O
22	<UNK>	B
23	.	O
1	Analysis	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequence	O
8	suggests	O
9	that	O
10	<UNK>	B
11	protein	O
12	contains	O
13	six	O
14	<UNK>	O
15	-	O
16	spanning	O
17	domains	O
18	,	O
19	two	O
20	<UNK>	O
21	potential	O
22	N	O
23	-	O
24	glycosylation	O
25	sites	O
26	,	O
27	and	O
28	intracellular	O
29	N	O
30	and	O
31	C	O
32	termini	O
33	.	O
1	The	O
2	<UNK>	O
3	concentrations	O
4	of	O
5	<UNK>	B
6	had	O
7	a	O
8	sensitivity	O
9	of	O
10	37	O
11	.	O
12	5	O
13	%	O
14	and	O
15	a	O
16	specificity	O
17	of	O
18	100	O
19	%.	O
1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	<UNK>	O
9	to	O
10	32	O
11	<UNK>	O
12	/	O
13	l	O
14	(	O
15	<UNK>	O
16	11	O
17	).	O
1	Zn	O
2	(	O
3	II	O
4	)	O
5	<UNK>	O
6	domain	O
7	mutants	O
8	of	O
9	T4	O
10	gene	O
11	32	O
12	protein	O
13	.	O
1	In	O
2	some	O
3	early	O
4	B	O
5	cells	O
6	and	O
7	<UNK>	O
8	murine	O
9	leukemia	O
10	virus	O
11	-	O
12	transformed	O
13	pre	O
14	-	O
15	B	O
16	-	O
17	cell	O
18	lines	O
19	,	O
20	<UNK>	O
21	mRNA	O
22	is	O
23	constitutively	O
24	expressed	O
25	.	O
1	The	O
2	genome	O
3	of	O
4	<UNK>	O
5	virus	O
6	<UNK>	O
7	six	O
8	segments	O
9	of	O
10	single	O
11	-	O
12	stranded	O
13	,	O
14	negative	O
15	sense	O
16	RNA	O
17	.	O
1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	<UNK>	B
7	protein	O
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	<UNK>	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O
1	The	O
2	primary	O
3	pancreatic	O
4	<UNK>	O
5	<UNK>	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	O
19	lipase	B
20	nor	O
21	the	O
22	development	O
23	of	O
24	<UNK>	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O
1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	<UNK>	O
11	)	O
12	in	O
13	<UNK>	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	<UNK>	O
19	little	O
20	systematic	O
21	study	O
22	.	O
1	Patients	O
2	with	O
3	moderate	O
4	<UNK>	O
5	were	O
6	impaired	O
7	on	O
8	all	O
9	serial	O
10	positions	O
11	for	O
12	both	O
13	spatial	O
14	order	O
15	and	O
16	spatial	O
17	recognition	O
18	memory	O
19	.	O
1	One	O
2	patients	O
3	had	O
4	plasma	O
5	C	O
6	-	O
7	peptide	O
8	greater	O
9	than	O
10	3	O
11	<UNK>	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O
1	To	O
2	<UNK>	O
3	this	O
4	problem	O
5	,	O
6	we	O
7	have	O
8	overexpressed	O
9	<UNK>	B
10	using	O
11	the	O
12	baculovirus	O
13	/	O
14	insect	O
15	cell	O
16	expression	O
17	system	O
18	.	O
1	This	O
2	study	O
3	<UNK>	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	<UNK>	O
10	different	O
11	,	O
12	<UNK>	O
13	as	O
14	a	O
15	potent	O
16	<UNK>	O
17	for	O
18	<UNK>	O
19	dogs	O
20	.	O
1	<UNK>	O
2	factor	O
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	O
13	Myc	B
14	transcriptional	O
15	activation	O
16	domain	O
17	at	O
18	<UNK>	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	O
35	(	O
36	<UNK>	O
37	,	O
38	E	O
39	.,	O
40	<UNK>	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	<UNK>	O
47	,	O
48	F	O
49	.	O
1	<UNK>	O
2	acid	O
3	residues	O
4	<UNK>	O
5	-	O
6	<UNK>	O
7	of	O
8	the	O
9	previously	O
10	reported	O
11	sequence	O
12	are	O
13	replaced	O
14	by	O
15	new	O
16	residues	O
17	<UNK>	O
18	to	O
19	150	O
20	.	O
1	<UNK>	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	<UNK>	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O
1	12	O
2	-	O
3	O	O
4	-	O
5	<UNK>	O
6	13	O
7	-	O
8	acetate	O
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	rapidly	O
14	and	O
15	<UNK>	O
16	the	O
17	expression	O
18	of	O
19	mRNAs	O
20	coding	O
21	for	O
22	the	O
23	myogenic	O
24	regulators	O
25	<UNK>	B
26	and	O
27	<UNK>	B
28	.	O
1	These	O
2	introns	O
3	<UNK>	O
4	to	O
5	the	O
6	class	O
7	of	O
8	nuclear	O
9	pre	O
10	-	O
11	mRNA	O
12	introns	O
13	and	O
14	contain	O
15	typical	O
16	5	O
17	'-	O
18	and	O
19	3	O
20	'-	O
21	consensus	O
22	sequences	O
23	,	O
24	as	O
25	well	O
26	as	O
27	unique	O
28	features	O
29	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	almost	O
6	6	O
7	kb	O
8	of	O
9	DNA	O
10	sequence	O
11	is	O
12	presented	O
13	,	O
14	including	O
15	<UNK>	O
16	bp	O
17	5	O
18	'	O
19	to	O
20	the	O
21	gene	O
22	,	O
23	over	O
24	4	O
25	kb	O
26	of	O
27	exon	O
28	and	O
29	exon	O
30	-	O
31	intron	O
32	<UNK>	O
33	,	O
34	and	O
35	<UNK>	O
36	bp	O
37	3	O
38	'	O
39	to	O
40	the	O
41	gene	O
42	.	O
1	A	O
2	method	O
3	is	O
4	described	O
5	for	O
6	detecting	O
7	targeted	O
8	events	O
9	at	O
10	the	O
11	mu	O
12	heavy	O
13	chain	O
14	gene	O
15	which	O
16	<UNK>	O
17	on	O
18	co	O
19	-	O
20	conversion	O
21	(	O
22	or	O
23	co	O
24	-	O
25	exchange	O
26	)	O
27	of	O
28	a	O
29	point	O
30	mutation	O
31	with	O
32	a	O
33	<UNK>	O
34	marker	O
35	contained	O
36	on	O
37	a	O
38	replacement	O
39	vector	O
40	.	O
1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	<UNK>	B
22	/	O
23	<UNK>	B
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	<UNK>	O
31	and	O
32	a	O
33	<UNK>	B
34	consensus	O
35	recognition	O
36	sequence	O
37	at	O
38	nucleotide	O
39	-	O
40	<UNK>	O
41	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	combined	O
7	treatment	O
8	with	O
9	a	O
10	<UNK>	O
11	synthetase	B
12	inhibitor	O
13	and	O
14	a	O
15	<UNK>	O
16	receptor	O
17	antagonist	O
18	provides	O
19	a	O
20	better	O
21	protection	O
22	against	O
23	<UNK>	O
24	<UNK>	O
25	than	O
26	with	O
27	either	O
28	agent	O
29	alone	O
30	.	O
1	<UNK>	O
2	<UNK>	O
3	analysis	O
4	using	O
5	<UNK>	O
6	derived	O
7	from	O
8	<UNK>	O
9	of	O
10	(	O
11	<UNK>	O
12	/	O
13	<UNK>	O
14	x	O
15	<UNK>	O
16	<UNK>	O
17	)	O
18	F1	O
19	x	O
20	<UNK>	O
21	/	O
22	<UNK>	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	<UNK>	B
28	gene	O
29	is	O
30	<UNK>	O
31	linked	O
32	to	O
33	the	O
34	<UNK>	B
35	,	O
36	<UNK>	B
37	,	O
38	<UNK>	B
39	,	O
40	and	O
41	<UNK>	B
42	loci	O
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O
1	Using	O
2	an	O
3	image	O
4	-	O
5	processing	O
6	computer	O
7	,	O
8	regional	O
9	LV	O
10	time	O
11	-	O
12	density	O
13	curves	O
14	were	O
15	constructed	O
16	for	O
17	one	O
18	cardiac	O
19	cycle	O
20	.	O
1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	<UNK>	O
9	.	O
1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	<UNK>	O
9	after	O
10	addition	O
11	of	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	little	O
3	is	O
4	known	O
5	<UNK>	O
6	the	O
7	role	O
8	of	O
9	5	O
10	-	O
11	<UNK>	B
12	receptor	O
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	native	O
5	copper	O
1	In	O
2	ten	O
3	other	O
4	experiments	O
5	(	O
6	5	O
7	experimental	O
8	and	O
9	5	O
10	control	O
11	rats	O
12	)	O
13	99mTc	O
14	-	O
15	<UNK>	O
16	<UNK>	O
17	was	O
18	injected	O
19	<UNK>	O
20	.	O
1	These	O
2	results	O
3	were	O
4	superior	O
5	to	O
6	those	O
7	in	O
8	24	O
9	patients	O
10	with	O
11	conventional	O
12	end	O
13	-	O
14	to	O
15	-	O
16	end	O
17	<UNK>	O
18	on	O
19	clinical	O
20	testing	O
21	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	<UNK>	O
5	in	O
6	combination	O
7	have	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	effective	O
13	in	O
14	early	O
15	termination	O
16	of	O
17	pregnancy	O
18	.	O
1	<UNK>	O
2	are	O
3	using	O
4	more	O
5	subjects	O
6	or	O
7	an	O
8	improved	O
9	research	O
10	<UNK>	O
11	,	O
12	developing	O
13	consensus	O
14	<UNK>	O
15	or	O
16	using	O
17	<UNK>	O
18	-	O
19	analysis	O
20	.	O
1	A	O
2	two	O
3	phase	O
4	<UNK>	O
5	flow	O
6	tubular	O
7	heat	O
8	<UNK>	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	<UNK>	O
17	<UNK>	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	<UNK>	O
25	.	O
1	<UNK>	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	<UNK>	O
9	alpha	O
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	<UNK>	O
23	and	O
24	<UNK>	O
25	in	O
26	7	O
27	<UNK>	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	<UNK>	O
39	cycle	O
40	.	O
1	After	O
2	treatment	O
3	with	O
4	<UNK>	O
5	,	O
6	the	O
7	<UNK>	O
8	secreted	O
9	<UNK>	O
10	18	O
11	-	O
12	kDa	O
13	polypeptides	O
14	which	O
15	could	O
16	also	O
17	bind	O
18	IgE	B
19	.	O
1	The	O
2	<UNK>	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	<UNK>	B
13	-	O
14	1	O
15	mutant	O
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	<UNK>	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	<UNK>	B
33	gene	O
34	,	O
35	<UNK>	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O
1	The	O
2	RNA	O
3	genome	O
4	of	O
5	rabbit	O
6	<UNK>	O
7	disease	O
8	virus	O
9	(	O
10	<UNK>	O
11	)	O
12	was	O
13	<UNK>	O
14	cloned	O
15	.	O
1	Therefore	O
2	,	O
3	we	O
4	have	O
5	developed	O
6	a	O
7	system	O
8	to	O
9	study	O
10	nuclear	O
11	targeting	O
12	in	O
13	plants	O
14	and	O
15	have	O
16	established	O
17	that	O
18	the	O
19	nuclear	O
20	transport	O
21	machinery	O
22	is	O
23	similar	O
24	in	O
25	<UNK>	O
26	and	O
27	<UNK>	O
28	.	O
1	<UNK>	O
2	'	O
3	disease	O
4	,	O
5	<UNK>	O
6	<UNK>	O
7	,	O
8	anti	O
9	-	O
10	nuclear	O
11	factor	O
12	,	O
13	<UNK>	O
14	,	O
15	rheumatoid	O
16	factor	O
17	and	O
18	normal	O
19	controls	O
20	.	O
1	<UNK>	O
2	evidence	O
3	was	O
4	obtained	O
5	that	O
6	<UNK>	B
7	is	O
8	involved	O
9	in	O
10	peptide	O
11	utilization	O
12	.	O
1	The	O
2	effects	O
3	of	O
4	c	B
5	-	O
6	myc	B
7	were	O
8	further	O
9	<UNK>	O
10	by	O
11	showing	O
12	that	O
13	c	B
14	-	O
15	myc	B
16	can	O
17	inhibit	O
18	differentiation	O
19	independently	O
20	of	O
21	<UNK>	B
22	,	O
23	a	O
24	negative	O
25	regulator	O
26	of	O
27	muscle	O
28	differentiation	O
29	.	O
1	The	O
2	<UNK>	B
3	.	O
4	<UNK>	O
5	DNA	O
6	repair	O
7	mutant	O
8	from	O
9	the	O
10	fission	O
11	yeast	O
12	,	O
13	Schizosaccharomyces	O
14	pombe	O
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	<UNK>	O
23	radiation	O
24	.	O
1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	<UNK>	O
16	the	O
17	diagnosis	O
18	of	O
19	<UNK>	O
20	.	O
1	<UNK>	O
2	<UNK>	O
3	,	O
4	a	O
5	technique	O
6	that	O
7	<UNK>	O
8	<UNK>	O
9	(	O
10	<UNK>	O
11	)	O
12	<UNK>	O
13	between	O
14	the	O
15	<UNK>	O
16	and	O
17	the	O
18	bone	O
19	,	O
20	as	O
21	well	O
22	as	O
23	between	O
24	the	O
25	<UNK>	O
26	<UNK>	O
27	and	O
28	the	O
29	<UNK>	O
30	,	O
31	to	O
32	improve	O
33	the	O
34	stability	O
35	of	O
36	internal	O
37	<UNK>	O
38	was	O
39	tested	O
40	in	O
41	vitro	O
42	using	O
43	20	O
44	paired	O
45	<UNK>	O
46	third	O
47	<UNK>	O
48	<UNK>	O
49	with	O
50	mid	O
51	-	O
52	<UNK>	O
53	<UNK>	O
54	<UNK>	O
55	with	O
56	six	O
57	-	O
58	<UNK>	O
59	broad	O
60	<UNK>	O
61	<UNK>	O
62	<UNK>	O
63	.	O
1	<UNK>	O
2	CD	O
3	-	O
4	1	O
5	mice	O
6	,	O
7	4	O
8	days	O
9	old	O
10	,	O
11	exposed	O
12	to	O
13	0	O
14	.	O
15	1	O
16	%	O
17	<UNK>	O
18	sulfate	O
19	on	O
20	<UNK>	O
21	days	O
22	6	O
23	-	O
24	20	O
25	were	O
26	compared	O
27	with	O
28	untreated	O
29	<UNK>	O
30	of	O
31	the	O
32	same	O
33	age	O
34	to	O
35	determine	O
36	its	O
37	effect	O
38	on	O
39	the	O
40	development	O
41	of	O
42	<UNK>	O
43	first	O
44	<UNK>	O
45	.	O
1	<UNK>	O
2	<UNK>	O
3	and	O
4	<UNK>	O
5	<UNK>	O
6	were	O
7	not	O
8	affected	O
9	by	O
10	<UNK>	O
11	<UNK>	O
12	.	O
1	<UNK>	O
2	of	O
3	40	O
4	patients	O
5	,	O
6	who	O
7	initially	O
8	did	O
9	not	O
10	show	O
11	eye	O
12	complications	O
13	due	O
14	to	O
15	<UNK>	O
16	,	O
17	37	O
18	patients	O
19	were	O
20	essentially	O
21	the	O
22	same	O
23	10	O
24	years	O
25	later	O
26	.	O
1	Thus	O
2	,	O
3	two	O
4	very	O
5	different	O
6	regulatory	O
7	elements	O
8	are	O
9	used	O
10	to	O
11	mediate	O
12	estrogen	O
13	induction	O
14	of	O
15	related	O
16	genes	O
17	in	O
18	chickens	O
19	and	O
20	<UNK>	O
21	.	O
1	The	O
2	<UNK>	B
3	gene	O
4	product	O
5	also	O
6	<UNK>	O
7	the	O
8	<UNK>	B
9	promoter	O
10	but	O
11	did	O
12	not	O
13	affect	O
14	expression	O
15	from	O
16	its	O
17	own	O
18	promoter	O
19	.	O
1	<UNK>	O
2	in	O
3	the	O
4	<UNK>	O
5	PCO2	O
6	but	O
7	not	O
8	in	O
9	the	O
10	<UNK>	O
11	H	O
12	+	O
13	were	O
14	highly	O
15	correlated	O
16	with	O
17	decreases	O
18	in	O
19	both	O
20	myocardial	O
21	<UNK>	O
22	and	O
23	oxygen	O
24	consumption	O
25	(	O
26	<UNK>	O
27	=	O
28	.	O
29	88	O
30	).	O
1	Analysis	O
2	of	O
3	mRNA	O
4	expression	O
5	shows	O
6	that	O
7	AT	O
8	-	O
9	<UNK>	B
10	and	O
11	AT	O
12	-	O
13	<UNK>	B
14	are	O
15	expressed	O
16	in	O
17	all	O
18	the	O
19	tissues	O
20	examined	O
21	.	O
1	Sequence	O
2	requirements	O
3	for	O
4	premature	O
5	transcription	O
6	arrest	O
7	within	O
8	the	O
9	first	O
10	intron	O
11	of	O
12	the	O
13	mouse	O
14	c	B
15	-	O
16	fos	B
17	gene	O
18	.	O
1	Disruption	O
2	of	O
3	the	O
4	chromosomal	O
5	<UNK>	B
6	gene	O
7	in	O
8	alpha	O
9	and	O
10	a	O
11	/	O
12	alpha	O
13	cells	O
14	conferred	O
15	the	O
16	<UNK>	O
17	phenotype	O
18	,	O
19	and	O
20	the	O
21	a	O
22	/	O
23	alpha	O
24	<UNK>	O
25	could	O
26	not	O
27	<UNK>	O
28	.	O
1	<UNK>	O
2	and	O
3	repeated	O
4	<UNK>	O
5	were	O
6	required	O
7	to	O
8	lower	O
9	<UNK>	O
10	to	O
11	<UNK>	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	mucosa	O
3	<UNK>	O
4	in	O
5	persons	O
6	exposed	O
7	to	O
8	different	O
9	<UNK>	O
10	<UNK>	O
11	did	O
12	not	O
13	<UNK>	O
14	on	O
15	the	O
16	forms	O
17	of	O
18	PC	O
19	,	O
20	<UNK>	O
21	and	O
22	the	O
23	diseases	O
24	'	O
25	stages	O
26	.	O
1	<UNK>	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	<UNK>	O
9	<UNK>	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O
1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	<UNK>	O
7	<UNK>	O
8	a	O
9	number	O
10	of	O
11	<UNK>	O
12	in	O
13	the	O
14	negative	O
15	and	O
16	positive	O
17	<UNK>	O
18	with	O
19	a	O
20	gradually	O
21	decreasing	O
22	amplitude	O
23	in	O
24	the	O
25	course	O
26	of	O
27	5	O
28	-	O
29	25	O
30	days	O
31	following	O
32	the	O
33	operation	O
34	,	O
35	after	O
36	which	O
37	relatively	O
38	stable	O
39	negative	O
40	values	O
41	of	O
42	the	O
43	<UNK>	O
44	are	O
45	established	O
46	on	O
47	the	O
48	average	O
49	in	O
50	electrodes	O
51	<UNK>	O
52	to	O
53	the	O
54	level	O
55	of	O
56	the	O
57	<UNK>	O
58	<UNK>	O
59	,	O
60	and	O
61	positive	O
62	values	O
63	in	O
64	electrodes	O
65	<UNK>	O
66	to	O
67	the	O
68	level	O
69	of	O
70	the	O
71	<UNK>	O
72	<UNK>	O
73	.	O
1	In	O
2	group	O
3	III	O
4	,	O
5	patients	O
6	also	O
7	received	O
8	their	O
9	own	O
10	<UNK>	O
11	<UNK>	O
12	blood	O
13	,	O
14	<UNK>	O
15	for	O
16	6	O
17	hours	O
18	after	O
19	operation	O
20	,	O
21	after	O
22	concentration	O
23	and	O
24	<UNK>	O
25	in	O
26	a	O
27	<UNK>	O
28	.	O
1	Both	O
2	groups	O
3	then	O
4	underwent	O
5	<UNK>	O
6	induction	O
7	,	O
8	and	O
9	completed	O
10	the	O
11	test	O
12	again	O
13	(	O
14	R2	O
15	).	O
1	<UNK>	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	analysis	O
7	to	O
8	the	O
9	auditory	O
10	<UNK>	O
11	.	O
1	Recombinant	O
2	human	O
3	TFIID	B
4	supported	O
5	weak	O
6	basal	O
7	transcription	O
8	in	O
9	heat	O
10	-	O
11	treated	O
12	nuclear	O
13	extracts	O
14	whereas	O
15	a	O
16	partially	O
17	purified	O
18	TFIID	B
19	fraction	O
20	from	O
21	HeLa	O
22	cells	O
23	<UNK>	O
24	a	O
25	maximal	O
26	level	O
27	of	O
28	transcription	O
29	.	O
1	Only	O
2	after	O
3	a	O
4	pretreatment	O
5	<UNK>	O
6	at	O
7	increasing	O
8	its	O
9	oxide	O
10	surface	O
11	layer	O
12	was	O
13	<UNK>	O
14	<UNK>	O
15	found	O
16	to	O
17	<UNK>	O
18	the	O
19	<UNK>	O
20	from	O
21	solutions	O
22	containing	O
23	2	O
24	mmol	O
25	/	O
26	L	O
27	<UNK>	O
28	,	O
29	2	O
30	mmol	O
31	/	O
32	L	O
33	<UNK>	O
34	,	O
35	50	O
36	mmol	O
37	/	O
38	L	O
39	<UNK>	O
40	,	O
41	pH	O
42	7	O
43	.	O
44	2	O
45	,	O
46	and	O
47	to	O
48	induce	O
49	<UNK>	O
50	from	O
51	<UNK>	O
52	solutions	O
53	containing	O
54	1	O
55	.	O
56	2	O
57	mmol	O
58	/	O
59	L	O
60	<UNK>	O
61	,	O
62	1	O
63	.	O
64	2	O
65	mmol	O
66	/	O
67	L	O
68	<UNK>	O
69	,	O
70	50	O
71	mmol	O
72	/	O
73	L	O
74	<UNK>	O
75	,	O
76	pH	O
77	7	O
78	.	O
79	2	O
80	,	O
81	at	O
82	37	O
83	degrees	O
84	C	O
85	.	O
1	(	O
2	2	O
3	)	O
4	<UNK>	O
5	<UNK>	O
6	in	O
7	the	O
8	<UNK>	O
9	model	O
10	sets	O
11	in	O
12	at	O
13	a	O
14	lower	O
15	O2	O
16	requirement	O
17	value	O
18	,	O
19	and	O
20	increases	O
21	more	O
22	gradually	O
23	with	O
24	increasing	O
25	O2	O
26	requirement	O
27	,	O
28	than	O
29	in	O
30	the	O
31	corresponding	O
32	<UNK>	O
33	models	O
34	with	O
35	the	O
36	same	O
37	average	O
38	<UNK>	O
39	diameter	O
40	.	O
1	The	O
2	antihypertensive	O
3	effect	O
4	of	O
5	<UNK>	O
6	has	O
7	been	O
8	examined	O
9	over	O
10	a	O
11	12	O
12	-	O
13	month	O
14	period	O
15	in	O
16	<UNK>	O
17	hypertensive	O
18	patients	O
19	.	O
1	<UNK>	O
2	<UNK>	O
3	microscopy	O
4	in	O
5	<UNK>	O
6	cell	O
7	<UNK>	O
8	.	O
1	<UNK>	O
2	H	O
3	,	O
4	but	O
5	not	O
6	R	O
7	,	O
8	<UNK>	O
9	the	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	<UNK>	O
14	the	O
15	<UNK>	O
16	.	O
1	Four	O
2	putative	O
3	positive	O
4	cDNA	O
5	clones	O
6	were	O
7	isolated	O
8	,	O
9	and	O
10	the	O
11	largest	O
12	insert	O
13	(	O
14	<UNK>	B
15	-	O
16	1	O
17	)	O
18	was	O
19	sequenced	O
20	in	O
21	both	O
22	<UNK>	O
23	.	O
1	DNA	O
2	sequence	O
3	and	O
4	evolution	O
5	of	O
6	the	O
7	<UNK>	B
8	domain	O
9	of	O
10	the	O
11	<UNK>	O
12	hamster	O
13	<UNK>	O
14	protein	O
15	<UNK>	O
16	.	O
1	A	O
2	high	O
3	-	O
4	frequency	O
5	restriction	O
6	fragment	O
7	length	O
8	<UNK>	O
9	was	O
10	evident	O
11	in	O
12	the	O
13	DNA	O
14	from	O
15	29	O
16	unrelated	O
17	individuals	O
18	using	O
19	the	O
20	enzyme	O
21	<UNK>	B
22	.	O
1	Although	O
2	heart	O
3	rate	O
4	and	O
5	diastolic	O
6	pressure	O
7	rose	O
8	in	O
9	some	O
10	degree	O
11	1	O
12	min	O
13	after	O
14	<UNK>	O
15	,	O
16	free	O
17	and	O
18	total	O
19	CA	O
20	concentrations	O
21	did	O
22	not	O
23	increase	O
24	during	O
25	study	O
26	period	O
27	.	O
1	Induction	O
2	requires	O
3	the	O
4	<UNK>	B
5	gene	O
6	product	O
7	,	O
8	which	O
9	binds	O
10	to	O
11	specific	O
12	sites	O
13	in	O
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	<UNK>	B
20	gene	O
21	.	O
1	<UNK>	B
2	synthetase	I
3	(	O
4	<UNK>	O
5	:	O
6	L	O
7	-	O
8	aspartate	O
9	<UNK>	B
10	(	O
11	GDP	O
12	),	O
13	EC	O
14	6	O
15	.	O
16	3	O
17	.	O
18	4	O
19	.	O
20	4	O
21	)	O
22	plays	O
23	an	O
24	important	O
25	role	O
26	in	O
27	<UNK>	O
28	biosynthesis	O
29	<UNK>	O
30	the	O
31	GTP	O
32	-	O
33	dependent	O
34	conversion	O
35	of	O
36	<UNK>	O
37	to	O
38	AMP	O
39	.	O
1	DNA	O
2	-	O
3	protein	O
4	UV	O
5	cross	O
6	-	O
7	linking	O
8	studies	O
9	indicated	O
10	that	O
11	<UNK>	B
12	-	O
13	1	O
14	has	O
15	an	O
16	electrophoretic	O
17	mobility	O
18	on	O
19	sodium	O
20	<UNK>	O
21	sulfate	O
22	-	O
23	<UNK>	O
24	<UNK>	O
25	of	O
26	approximately	O
27	85	O
28	kDa	O
29	and	O
30	suggested	O
31	that	O
32	additional	O
33	proteins	O
34	,	O
35	specific	O
36	to	O
37	each	O
38	promoter	O
39	,	O
40	bind	O
41	to	O
42	each	O
43	site	O
44	.	O
1	The	O
2	results	O
3	<UNK>	O
4	the	O
5	conclusion	O
6	that	O
7	predominantly	O
8	dynamic	O
9	activity	O
10	increases	O
11	the	O
12	<UNK>	B
13	content	O
14	of	O
15	mature	O
16	<UNK>	O
17	<UNK>	O
18	muscles	O
19	.	O
1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	O
7	<UNK>	O
8	<UNK>	B
9	<UNK>	I
10	hydroxylase	I
11	gene	O
12	(	O
13	<UNK>	B
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O
1	The	O
2	first	O
3	follow	O
4	-	O
5	up	O
6	was	O
7	at	O
8	a	O
9	nearly	O
10	constant	O
11	interval	O
12	of	O
13	5	O
14	.	O
15	1	O
16	years	O
17	in	O
18	<UNK>	O
19	and	O
20	3	O
21	.	O
22	2	O
23	years	O
24	in	O
25	<UNK>	O
26	;	O
27	<UNK>	O
28	major	O
29	<UNK>	O
30	events	O
31	had	O
32	occurred	O
33	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	<UNK>	B
20	binding	O
21	sites	O
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	<UNK>	B
29	and	O
30	<UNK>	B
31	promoters	O
32	.	O
1	After	O
2	6	O
3	months	O
4	,	O
5	<UNK>	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	<UNK>	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	<UNK>	O
21	of	O
22	7	O
23	controls	O
24	.	O
1	A	O
2	dose	O
3	of	O
4	3	O
5	and	O
6	6	O
7	micrograms	O
8	/	O
9	kg	O
10	/	O
11	day	O
12	GM	B
13	-	O
14	CSF	B
15	reduces	O
16	the	O
17	severity	O
18	of	O
19	<UNK>	O
20	and	O
21	<UNK>	O
22	after	O
23	<UNK>	O
24	-	O
25	cyclophosphamide	O
26	chemotherapy	O
27	,	O
28	which	O
29	may	O
30	lead	O
31	to	O
32	more	O
33	effective	O
34	chemotherapy	O
35	for	O
36	ovarian	O
37	cancer	O
38	in	O
39	the	O
40	future	O
41	.	O
1	The	O
2	<UNK>	B
3	alpha	O
4	gene	O
5	is	O
6	<UNK>	O
7	as	O
8	follows	O
9	:	O
10	the	O
11	first	O
12	exon	O
13	<UNK>	O
14	for	O
15	the	O
16	first	O
17	<UNK>	O
18	nucleotides	O
19	of	O
20	the	O
21	5	O
22	'	O
23	UTR	O
24	.	O
1	Using	O
2	an	O
3	ELISA	O
4	,	O
5	we	O
6	found	O
7	that	O
8	<UNK>	O
9	protein	O
10	A	O
11	(	O
12	SP	O
13	-	O
14	A	O
15	)	O
16	was	O
17	markedly	O
18	elevated	O
19	in	O
20	the	O
21	<UNK>	O
22	patients	O
23	.	O
1	We	O
2	purified	O
3	a	O
4	Ca2	O
5	+/	O
6	calmodulin	B
7	(	O
8	CaM	B
9	)-	O
10	dependent	O
11	protein	O
12	kinase	B
13	(	O
14	CaM	B
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	O
27	type	O
28	II	O
29	CaM	B
30	kinases	O
31	.	O
1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	O
6	<UNK>	B
7	gene	O
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O
1	Most	O
2	of	O
3	the	O
4	expressed	O
5	human	O
6	<UNK>	O
7	polypeptides	O
8	(	O
9	five	O
10	<UNK>	O
11	)	O
12	were	O
13	found	O
14	in	O
15	the	O
16	<UNK>	O
17	<UNK>	O
18	while	O
19	primarily	O
20	full	O
21	-	O
22	length	O
23	mature	O
24	<UNK>	O
25	was	O
26	found	O
27	in	O
28	the	O
29	soluble	O
30	fraction	O
31	.	O
1	The	O
2	alpha	O
3	4	O
4	gene	O
5	5	O
6	'	O
7	flanking	O
8	region	O
9	<UNK>	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O
1	To	O
2	facilitate	O
3	the	O
4	availability	O
5	of	O
6	important	O
7	new	O
8	therapeutic	O
9	agents	O
10	,	O
11	the	O
12	<UNK>	O
13	and	O
14	<UNK>	O
15	<UNK>	O
16	(	O
17	<UNK>	O
18	)	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	<UNK>	O
24	<UNK>	O
25	<UNK>	O
26	therapeutic	O
27	<UNK>	O
28	to	O
29	<UNK>	O
30	new	O
31	drugs	O
32	and	O
33	<UNK>	O
34	end	O
35	-	O
36	of	O
37	-	O
38	phase	O
39	II	O
40	<UNK>	O
41	with	O
42	drug	O
43	<UNK>	O
44	.	O
1	3	O
2	.	O
1	Furthermore	O
2	,	O
3	the	O
4	DNA	O
5	polymerase	O
6	II	O
7	complex	O
8	was	O
9	difficult	O
10	to	O
11	<UNK>	O
12	from	O
13	<UNK>	B
14	-	O
15	1	O
16	mutant	O
17	cells	O
18	,	O
19	suggesting	O
20	that	O
21	a	O
22	stable	O
23	DNA	O
24	polymerase	O
25	II	O
26	complex	O
27	requires	O
28	<UNK>	B
29	and	O
30	is	O
31	essential	O
32	for	O
33	chromosomal	O
34	replication	O
35	.	O
1	To	O
2	determine	O
3	whether	O
4	<UNK>	O
5	cell	O
6	secretory	O
7	products	O
8	contribute	O
9	to	O
10	the	O
11	changes	O
12	in	O
13	bone	O
14	turnover	O
15	that	O
16	characterize	O
17	the	O
18	development	O
19	of	O
20	<UNK>	O
21	<UNK>	O
22	,	O
23	we	O
24	evaluated	O
25	the	O
26	effects	O
27	of	O
28	<UNK>	O
29	and	O
30	subsequent	O
31	estrogen	O
32	replacement	O
33	on	O
34	the	O
35	spontaneous	O
36	secretion	O
37	of	O
38	interleukin	B
39	1	O
40	(	O
41	IL	B
42	-	O
43	1	O
44	)	O
45	and	O
46	tumor	O
47	necrosis	O
48	factor	O
49	alpha	O
50	(	O
51	TNF	B
52	-	O
53	alpha	O
54	)	O
55	and	O
56	on	O
57	the	O
58	<UNK>	B
59	A	O
60	-	O
61	induced	O
62	secretion	O
63	of	O
64	granulocyte	B
65	-	O
66	macrophage	O
67	colony	O
68	-	O
69	stimulating	O
70	factor	O
71	(	O
72	GM	B
73	-	O
74	CSF	B
75	)	O
76	from	O
77	peripheral	O
78	blood	O
79	<UNK>	O
80	cells	O
81	.	O
1	<UNK>	O
2	shock	O
3	and	O
4	bacterial	O
5	translocation	O
6	in	O
7	a	O
8	<UNK>	O
9	model	O
10	.	O
1	<UNK>	O
2	small	O
3	deletions	O
4	within	O
5	the	O
6	conserved	O
7	region	O
8	completely	O
9	abolished	O
10	transforming	O
11	activity	O
12	of	O
13	<UNK>	B
14	,	O
15	while	O
16	extensive	O
17	deletion	O
18	outside	O
19	of	O
20	this	O
21	region	O
22	had	O
23	no	O
24	effect	O
25	.	O
1	The	O
2	stimulus	O
3	threshold	O
4	for	O
5	<UNK>	O
6	showed	O
7	a	O
8	less	O
9	individual	O
10	variation	O
11	than	O
12	amplitude	O
13	.	O
1	An	O
2	<UNK>	B
3	-	O
4	independent	O
5	pathway	O
6	for	O
7	<UNK>	O
8	control	O
9	in	O
10	Saccharomyces	O
11	cerevisiae	O
12	acts	O
13	through	O
14	<UNK>	B
15	transcript	O
16	accumulation	O
17	.	O
1	In	O
2	all	O
3	cases	O
4	,	O
5	high	O
6	-	O
7	level	O
8	expression	O
9	of	O
10	the	O
11	truncated	O
12	avian	O
13	<UNK>	B
14	was	O
15	obtained	O
16	.	O
1	In	O
2	<UNK>	O
3	these	O
4	rats	O
5	were	O
6	<UNK>	O
7	and	O
8	<UNK>	O
9	the	O
10	active	O
11	<UNK>	O
12	response	O
13	later	O
14	than	O
15	the	O
16	controls	O
17	.	O
1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	<UNK>	O
13	<UNK>	O
14	amino	O
15	acid	O
16	residue	O
17	domain	O
18	with	O
19	8	O
20	N	O
21	-	O
22	glycosylation	O
23	sites	O
24	,	O
25	a	O
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O
1	A	O
2	new	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	method	O
7	for	O
8	<UNK>	O
9	regional	O
10	cerebral	O
11	uptake	O
12	of	O
13	99m	O
14	<UNK>	O
15	-	O
16	<UNK>	O
17	<UNK>	O
18	<UNK>	O
19	(	O
20	99mTc	O
21	-	O
22	<UNK>	O
23	)	O
24	was	O
25	used	O
26	to	O
27	assess	O
28	single	O
29	<UNK>	O
30	emission	O
31	<UNK>	O
32	from	O
33	5	O
34	normal	O
35	subjects	O
36	,	O
37	14	O
38	patients	O
39	with	O
40	<UNK>	O
41	'	O
42	s	O
43	disease	O
44	,	O
45	14	O
46	patients	O
47	with	O
48	<UNK>	O
49	of	O
50	frontal	O
51	lobe	O
52	type	O
53	and	O
54	4	O
55	patients	O
56	with	O
57	<UNK>	O
58	with	O
59	motor	O
60	<UNK>	O
61	disease	O
62	.	O
1	Effect	O
2	of	O
3	separate	O
4	and	O
5	combined	O
6	effects	O
7	of	O
8	<UNK>	O
9	-	O
10	<UNK>	O
11	,	O
12	<UNK>	O
13	and	O
14	<UNK>	O
15	phosphate	O
16	on	O
17	the	O
18	<UNK>	O
19	gland	O
20	of	O
21	rats	O
1	<UNK>	O
2	<UNK>	O
3	was	O
4	made	O
5	with	O
6	a	O
7	<UNK>	O
8	<UNK>	O
9	,	O
10	and	O
11	data	O
12	analysis	O
13	performed	O
14	with	O
15	an	O
16	<UNK>	O
17	knowledge	O
18	-	O
19	based	O
20	statistical	O
21	<UNK>	O
22	,	O
23	<UNK>	O
24	,	O
25	employing	O
26	a	O
27	<UNK>	O
28	<UNK>	O
29	analysis	O
30	technique	O
31	.	O
1	<UNK>	O
2	was	O
3	induced	O
4	by	O
5	<UNK>	O
6	drinking	O
7	of	O
8	<UNK>	O
9	(	O
10	150	O
11	ml	O
12	/	O
13	h	O
14	).	O
1	The	O
2	5	O
3	'	O
4	regions	O
5	of	O
6	these	O
7	two	O
8	<UNK>	O
9	actin	B
10	genes	O
11	contain	O
12	many	O
13	unusual	O
14	features	O
15	including	O
16	(	O
17	CT	O
18	)	O
19	repeats	O
20	and	O
21	long	O
22	<UNK>	O
23	of	O
24	<UNK>	O
25	-	O
26	rich	O
27	DNA	O
28	.	O
1	All	O
2	8	O
3	(	O
4	100	O
5	%)	O
6	patients	O
7	with	O
8	<UNK>	O
9	hepatic	O
10	failure	O
11	who	O
12	received	O
13	grafts	O
14	<UNK>	O
15	,	O
16	including	O
17	3	O
18	who	O
19	received	O
20	<UNK>	O
21	-	O
22	<UNK>	O
23	grafts	O
24	,	O
25	though	O
26	2	O
27	of	O
28	these	O
29	subsequently	O
30	required	O
31	<UNK>	O
32	.	O
1	However	O
2	,	O
3	overexpression	O
4	of	O
5	both	O
6	the	O
7	<UNK>	B
8	and	O
9	<UNK>	B
10	proteins	O
11	did	O
12	not	O
13	generate	O
14	a	O
15	<UNK>	O
16	<UNK>	O
17	response	O
18	than	O
19	overexpression	O
20	of	O
21	<UNK>	B
22	in	O
23	the	O
24	presence	O
25	of	O
26	wild	O
27	-	O
28	type	O
29	levels	O
30	of	O
31	<UNK>	B
32	.	O
1	This	O
2	Mr	O
3	is	O
4	similar	O
5	to	O
6	those	O
7	of	O
8	the	O
9	purified	O
10	<UNK>	B
11	<UNK>	I
12	<UNK>	I
13	estimated	O
14	by	O
15	sodium	O
16	<UNK>	O
17	sulfate	O
18	-	O
19	polyacrylamide	O
20	gel	O
21	electrophoresis	O
22	and	O
23	<UNK>	O
24	density	O
25	gradient	O
26	<UNK>	O
27	,	O
28	which	O
29	are	O
30	about	O
31	54	O
32	,	O
33	000	O
34	and	O
35	65	O
36	,	O
37	000	O
38	,	O
39	respectively	O
40	.	O
1	<UNK>	O
2	mutants	O
3	assigned	O
4	to	O
5	the	O
6	<UNK>	O
7	complementation	O
8	group	O
9	<UNK>	O
10	were	O
11	found	O
12	to	O
13	lack	O
14	alpha	O
15	-	O
16	<UNK>	B
17	dehydrogenase	I
18	activity	O
19	as	O
20	a	O
21	result	O
22	of	O
23	mutations	O
24	in	O
25	the	O
26	<UNK>	B
27	<UNK>	I
28	(	O
29	<UNK>	B
30	)	O
31	component	O
32	of	O
33	the	O
34	complex	O
35	.	O
1	We	O
2	also	O
3	discovered	O
4	a	O
5	V	O
6	lambda	O
7	pseudogene	O
8	,	O
9	called	O
10	<UNK>	B
11	V	O
12	lambda	O
13	1	O
14	,	O
15	3	O
16	kb	O
17	upstream	O
18	of	O
19	the	O
20	<UNK>	B
21	lambda	O
22	gene	O
23	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	a	O
5	chronic	O
6	care	O
7	<UNK>	O
8	:	O
9	an	O
10	introduction	O
11	.	O
1	Furthermore	O
2	,	O
3	expression	O
4	of	O
5	the	O
6	promoter	O
7	in	O
8	embryonic	O
9	Drosophila	O
10	melanogaster	O
11	cells	O
12	that	O
13	lack	O
14	<UNK>	B
15	and	O
16	Sp1	B
17	is	O
18	<UNK>	O
19	dependent	O
20	on	O
21	all	O
22	three	O
23	sites	O
24	remaining	O
25	intact	O
26	and	O
27	on	O
28	the	O
29	presence	O
30	of	O
31	<UNK>	O
32	<UNK>	O
33	Sp1	B
34	and	O
35	<UNK>	B
36	.	O
1	Additionally	O
2	,	O
3	although	O
4	c	B
5	-	O
6	fos	B
7	and	O
8	<UNK>	B
9	-	O
10	1	O
11	mRNAs	O
12	are	O
13	expressed	O
14	at	O
15	elevated	O
16	levels	O
17	in	O
18	stimulated	O
19	liver	O
20	cells	O
21	,	O
22	fos	B
23	-	O
24	B	O
25	,	O
26	<UNK>	B
27	-	O
28	1	O
29	,	O
30	and	O
31	<UNK>	B
32	-	O
33	2	O
34	are	O
35	not	O
36	,	O
37	which	O
38	suggests	O
39	that	O
40	factors	O
41	in	O
42	addition	O
43	to	O
44	the	O
45	serum	O
46	response	O
47	factor	O
48	participate	O
49	in	O
50	the	O
51	regulation	O
52	of	O
53	immediate	O
54	-	O
55	early	O
56	gene	O
57	induction	O
58	.	O
1	Of	O
2	<UNK>	O
3	patients	O
4	,	O
5	<UNK>	O
6	cases	O
7	with	O
8	complete	O
9	<UNK>	O
10	of	O
11	patient	O
12	'	O
13	s	O
14	background	O
15	were	O
16	<UNK>	O
17	:	O
18	Group	O
19	A	O
20	(	O
21	surgery	O
22	+	O
23	<UNK>	O
24	+	O
25	5	O
26	-	O
27	<UNK>	O
28	:	O
29	chemotherapy	O
30	)	O
31	<UNK>	O
32	cases	O
33	,	O
34	group	O
35	B	O
36	(	O
37	surgery	O
38	+	O
39	<UNK>	O
40	+	O
41	5	O
42	-	O
43	<UNK>	O
44	+	O
45	<UNK>	O
46	-	O
47	<UNK>	O
48	or	O
49	<UNK>	O
50	:	O
51	<UNK>	O
52	)	O
53	<UNK>	O
54	and	O
55	group	O
56	C	O
57	(	O
58	surgery	O
59	alone	O
60	)	O
61	<UNK>	O
62	.	O
1	A	O
2	<UNK>	O
3	relapse	O
4	requiring	O
5	treatment	O
6	occurred	O
7	by	O
8	5	O
9	years	O
10	in	O
11	16	O
12	.	O
13	8	O
14	%	O
15	of	O
16	<UNK>	O
17	<UNK>	O
18	,	O
19	5	O
20	.	O
21	2	O
22	%	O
23	of	O
24	97	O
25	<UNK>	O
26	,	O
27	and	O
28	20	O
29	.	O
30	0	O
31	%	O
32	of	O
33	115	O
34	<UNK>	O
35	patients	O
36	with	O
37	organisms	O
38	sensitive	O
39	to	O
40	<UNK>	O
41	and	O
42	<UNK>	O
43	initially	O
44	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	has	O
7	the	O
8	<UNK>	O
9	homology	O
10	(	O
11	61	O
12	%)	O
13	to	O
14	the	O
15	<UNK>	O
16	<UNK>	B
17	<UNK>	I
18	<UNK>	I
19	<UNK>	I
20	.	O
1	The	O
2	experimental	O
3	group	O
4	consisted	O
5	of	O
6	61	O
7	<UNK>	O
8	class	O
9	II	O
10	/	O
11	2	O
12	<UNK>	O
13	<UNK>	O
14	.	O
1	In	O
2	that	O
3	case	O
4	,	O
5	the	O
6	ratio	O
7	of	O
8	<UNK>	O
9	<UNK>	O
10	was	O
11	0	O
12	.	O
13	<UNK>	O
14	,	O
15	<UNK>	O
16	and	O
17	<UNK>	O
18	strength	O
19	,	O
20	<UNK>	O
21	.	O
22	3	O
23	and	O
24	86	O
25	.	O
26	3	O
27	<UNK>	O
28	respectively	O
29	,	O
30	<UNK>	O
31	,	O
32	43	O
33	.	O
34	2	O
35	<UNK>	O
36	,	O
37	water	O
38	absorption	O
39	14	O
40	.	O
41	2	O
42	micrograms	O
43	/	O
44	<UNK>	O
45	and	O
46	thermal	O
47	<UNK>	O
48	coefficient	O
49	,	O
50	47	O
51	.	O
52	4	O
53	x	O
54	10	O
55	(-	O
56	6	O
57	)/	O
58	degrees	O
59	C	O
60	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	tube	O
5	in	O
6	the	O
7	abdominal	O
8	wall	O
9	.	O
1	TCR	B
2	alpha	O
3	and	O
4	beta	O
5	gene	O
6	expression	O
7	may	O
8	be	O
9	regulated	O
10	by	O
11	a	O
12	common	O
13	set	O
14	of	O
15	T	O
16	-	O
17	cell	O
18	nuclear	O
19	proteins	O
20	in	O
21	that	O
22	the	O
23	T	O
24	beta	O
25	2	O
26	element	O
27	binding	O
28	a	O
29	set	O
30	of	O
31	cyclic	O
32	AMP	O
33	response	O
34	element	O
35	-	O
36	binding	O
37	proteins	O
38	that	O
39	are	O
40	also	O
41	bound	O
42	by	O
43	the	O
44	T	O
45	alpha	O
46	1	O
47	element	O
48	of	O
49	the	O
50	human	O
51	TCR	B
52	alpha	O
53	enhancer	O
54	and	O
55	the	O
56	<UNK>	O
57	element	O
58	present	O
59	in	O
60	a	O
61	large	O
62	number	O
63	of	O
64	human	O
65	and	O
66	murine	O
67	TCR	B
68	beta	O
69	promoters	O
70	.	O
1	The	O
2	deleted	O
3	nucleotide	O
4	sequence	O
5	<UNK>	O
6	to	O
7	sequences	O
8	that	O
9	,	O
10	by	O
11	<UNK>	O
12	to	O
13	the	O
14	organization	O
15	of	O
16	the	O
17	type	O
18	I	O
19	collagen	B
20	genes	O
21	,	O
22	should	O
23	be	O
24	<UNK>	O
25	encoded	O
26	by	O
27	exon	O
28	41	O
29	of	O
30	the	O
31	<UNK>	B
32	gene	O
33	.	O
1	<UNK>	O
2	(	O
3	<UNK>	O
4	)	O
5	31	O
6	.	O
1	<UNK>	O
2	study	O
1	<UNK>	O
2	or	O
3	not	O
4	there	O
5	are	O
6	sequences	O
7	<UNK>	O
8	cAMP	O
9	responsiveness	O
10	which	O
11	are	O
12	common	O
13	both	O
14	to	O
15	P	O
16	-	O
17	<UNK>	B
18	and	O
19	the	O
20	other	O
21	<UNK>	O
22	P	O
23	-	O
24	<UNK>	O
25	genes	O
26	remains	O
27	to	O
28	be	O
29	established	O
30	.	O
1	It	O
2	is	O
3	the	O
4	human	O
5	homolog	O
6	of	O
7	the	O
8	mouse	O
9	<UNK>	B
10	protein	O
11	involved	O
12	in	O
13	resistance	O
14	to	O
15	influenza	O
16	virus	O
17	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	<UNK>	B
8	is	O
9	<UNK>	O
10	residues	O
11	long	O
12	and	O
13	is	O
14	very	O
15	similar	O
16	(	O
17	71	O
18	%	O
19	identical	O
20	)	O
21	to	O
22	that	O
23	of	O
24	<UNK>	B
25	,	O
26	a	O
27	widely	O
28	distributed	O
29	,	O
30	pH	O
31	-	O
32	sensitive	O
33	actin	B
34	-	O
35	<UNK>	O
36	protein	O
37	.	O
1	We	O
2	have	O
3	determined	O
4	the	O
5	nucleotide	O
6	(	O
7	nt	O
8	)	O
9	sequence	O
10	of	O
11	the	O
12	7	O
13	.	O
14	5	O
15	-	O
16	kb	O
17	<UNK>	B
18	segment	O
19	that	O
20	<UNK>	O
21	a	O
22	cluster	O
23	of	O
24	six	O
25	genes	O
26	(	O
27	<UNK>	B
28	,	O
29	<UNK>	O
30	,	O
31	<UNK>	B
32	,	O
33	<UNK>	B
34	,	O
35	tRNA	O
36	(	O
37	Gly	O
38	)	O
39	and	O
40	<UNK>	B
41	)	O
42	located	O
43	on	O
44	chromosome	O
45	X	O
46	of	O
47	the	O
48	yeast	O
49	Saccharomyces	O
50	cerevisiae	O
51	.	O
1	No	O
2	recombination	O
3	signal	O
4	sequences	O
5	have	O
6	been	O
7	found	O
8	contiguous	O
9	to	O
10	the	O
11	recombination	O
12	point	O
13	.	O
1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	the	O
7	deduced	O
8	amino	O
9	acid	O
10	sequence	O
11	of	O
12	the	O
13	3T3	O
14	-	O
15	L1	O
16	<UNK>	O
17	insulin	B
18	receptor	O
19	of	O
20	the	O
21	mouse	O
22	was	O
23	determined	O
24	.	O
1	The	O
2	cDNA	O
3	sequence	O
4	has	O
5	an	O
6	<UNK>	O
7	-	O
8	bp	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	whose	O
16	predicted	O
17	amino	O
18	acid	O
19	sequence	O
20	is	O
21	97	O
22	.	O
23	6	O
24	%	O
25	identical	O
26	to	O
27	the	O
28	<UNK>	O
29	carboxy	O
30	-	O
31	terminal	O
32	amino	O
33	acids	O
34	of	O
35	the	O
36	human	O
37	ets	B
38	-	O
39	1	O
40	protein	O
41	.	O
1	The	O
2	protein	O
3	product	O
4	of	O
5	<UNK>	B
6	,	O
7	which	O
8	is	O
9	probably	O
10	a	O
11	new	O
12	<UNK>	B
13	gene	O
14	(	O
15	named	O
16	<UNK>	B
17	),	O
18	contains	O
19	65	O
20	%	O
21	hydrophobic	O
22	amino	O
23	acids	O
24	,	O
25	especially	O
26	rich	O
27	in	O
28	alanine	O
29	and	O
30	leucine	O
31	.	O
1	The	O
2	diagnosis	O
3	of	O
4	<UNK>	O
5	tuberculosis	O
6	should	O
7	be	O
8	<UNK>	O
9	considered	O
10	in	O
11	<UNK>	O
12	of	O
13	unknown	O
14	origin	O
15	.	O
1	The	O
2	<UNK>	B
3	rRNA	O
4	binding	O
5	ribosomal	O
6	protein	O
7	equivalent	O
8	to	O
9	bacterial	O
10	protein	O
11	<UNK>	B
12	is	O
13	encoded	O
14	by	O
15	<UNK>	O
16	<UNK>	O
17	genes	O
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O
1	Significant	O
2	correlations	O
3	were	O
4	obtained	O
5	between	O
6	changes	O
7	in	O
8	<UNK>	O
9	in	O
10	response	O
11	to	O
12	<UNK>	O
13	and	O
14	the	O
15	presence	O
16	of	O
17	not	O
18	deep	O
19	residual	O
20	-	O
21	organic	O
22	<UNK>	O
23	,	O
24	so	O
25	-	O
26	called	O
27	""""	O
28	<UNK>	O
29	""""	O
30	in	O
31	<UNK>	O
32	disorders	O
33	.	O
1	The	O
2	E6	B
3	/	O
4	E7	B
5	promoter	O
6	of	O
7	all	O
8	genital	O
9	human	O
10	<UNK>	O
11	is	O
12	responsible	O
13	for	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	transforming	O
19	genes	O
20	.	O
1	The	O
2	characterized	O
3	Y	O
4	'	O
5	repeated	O
6	sequence	O
7	families	O
8	provide	O
9	an	O
10	experimental	O
11	system	O
12	in	O
13	which	O
14	repeated	O
15	sequence	O
16	interactions	O
17	and	O
18	subsequent	O
19	evolution	O
20	can	O
21	be	O
22	studied	O
23	.	O
1	The	O
2	<UNK>	O
3	induced	O
4	<UNK>	O
5	responses	O
6	were	O
7	not	O
8	suppressed	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	<UNK>	O
14	or	O
15	<UNK>	O
16	B	O
17	.	O
1	This	O
2	<UNK>	O
3	of	O
4	the	O
5	ability	O
6	to	O
7	<UNK>	O
8	from	O
9	hormonal	O
10	influence	O
11	<UNK>	O
12	female	O
13	sexual	O
14	<UNK>	O
15	the	O
16	primary	O
17	regulator	O
18	of	O
19	mating	O
20	in	O
21	<UNK>	O
22	.	O
1	No	O
2	therapy	O
3	<UNK>	O
4	for	O
5	<UNK>	O
6	the	O
7	progression	O
8	of	O
9	the	O
10	disease	O
11	with	O
12	the	O
13	possible	O
14	exception	O
15	of	O
16	laser	O
17	<UNK>	O
18	treatment	O
19	used	O
20	to	O
21	<UNK>	O
22	<UNK>	O
23	<UNK>	O
24	membranes	O
25	in	O
26	an	O
27	<UNK>	O
28	to	O
29	<UNK>	O
30	complications	O
31	of	O
32	<UNK>	O
33	<UNK>	O
34	.	O
1	<UNK>	O
2	<UNK>	B
3	protein	O
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	<UNK>	O
13	factors	O
14	,	O
15	<UNK>	B
16	and	O
17	general	O
18	regulatory	O
19	factor	O
20	I	O
21	/	O
22	repressor	O
23	/	O
24	activator	O
25	site	O
26	binding	O
27	protein	O
28	1	O
29	/	O
30	translation	O
31	upstream	O
32	factor	O
33	.	O
1	Among	O
2	known	O
3	<UNK>	O
4	larvae	O
5	,	O
6	the	O
7	<UNK>	O
8	<UNK>	O
9	(	O
10	<UNK>	O
11	,	O
12	<UNK>	O
13	)	O
14	is	O
15	as	O
16	<UNK>	O
17	in	O
18	<UNK>	O
19	form	O
20	as	O
21	are	O
22	the	O
23	adults	O
24	.	O
1	Clinical	O
2	<UNK>	O
3	of	O
4	adult	O
5	<UNK>	O
6	.	O
1	The	O
2	3	O
3	'	O
4	region	O
5	,	O
6	<UNK>	B
7	,	O
8	is	O
9	necessary	O
10	for	O
11	maximal	O
12	expression	O
13	.	O
1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	<UNK>	O
9	<UNK>	O
10	preparation	O
11	based	O
12	on	O
13	<UNK>	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	<UNK>	O
20	clinical	O
21	environment	O
22	.	O
1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	O
6	albumin	B
7	,	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O
1	Within	O
2	this	O
3	sequence	O
4	the	O
5	<UNK>	B
6	gene	O
7	was	O
8	identified	O
9	as	O
10	a	O
11	<UNK>	O
12	-	O
13	bp	O
14	-	O
15	long	O
16	open	O
17	reading	O
18	frame	O
19	coding	O
20	for	O
21	a	O
22	protein	O
23	of	O
24	<UNK>	O
25	amino	O
26	acids	O
27	and	O
28	<UNK>	O
29	,	O
30	<UNK>	O
31	<UNK>	O
32	molecular	O
33	mass	O
34	.	O
1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	<UNK>	O
9	<UNK>	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	<UNK>	O
16	<UNK>	O
1	<UNK>	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	O
15	<UNK>	B
16	mRNA	O
17	is	O
18	located	O
19	<UNK>	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O
1	For	O
2	<UNK>	O
3	,	O
4	larger	O
5	-	O
6	than	O
7	-	O
8	expected	O
9	distribution	O
10	coefficients	O
11	were	O
12	obtained	O
13	in	O
14	the	O
15	<UNK>	O
16	experiments	O
17	,	O
18	an	O
19	<UNK>	O
20	of	O
21	the	O
22	<UNK>	O
23	formation	O
24	of	O
25	metal	O
26	-	O
27	<UNK>	O
28	during	O
29	a	O
30	slow	O
31	reaction	O
32	.	O
1	This	O
2	growth	O
3	arrest	O
4	is	O
5	partly	O
6	suppressed	O
7	on	O
8	minimal	O
9	medium	O
10	or	O
11	under	O
12	conditions	O
13	in	O
14	which	O
15	the	O
16	cells	O
17	are	O
18	less	O
19	dependent	O
20	on	O
21	mitochondrial	O
22	metabolism	O
23	.	O
1	<UNK>	O
2	-	O
3	induced	O
4	<UNK>	O
5	symptoms	O
6	in	O
7	an	O
8	<UNK>	O
9	following	O
10	<UNK>	O
11	surgery	O
12	.	O
1	As	O
2	in	O
3	mammals	O
4	,	O
5	considerable	O
6	nucleotide	O
7	<UNK>	O
8	was	O
9	observed	O
10	at	O
11	the	O
12	<UNK>	O
13	of	O
14	the	O
15	variable	O
16	,	O
17	<UNK>	O
18	,	O
19	and	O
20	joining	O
21	elements	O
22	in	O
23	chicken	O
24	TCR	B
25	beta	O
26	cDNAs	O
27	.	O
1	The	O
2	<UNK>	B
3	suppressor	O
4	mutation	O
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	<UNK>	O
25	<UNK>	B
26	mutations	O
27	.	O
1	This	O
2	interaction	O
3	occurs	O
4	over	O
5	a	O
6	wide	O
7	range	O
8	of	O
9	both	O
10	parameters	O
11	;	O
12	for	O
13	<UNK>	O
14	density	O
15	from	O
16	at	O
17	least	O
18	10	O
19	to	O
20	<UNK>	O
21	<UNK>	O
22	/	O
23	cm2	O
24	and	O
25	,	O
26	for	O
27	<UNK>	O
28	per	O
29	phase	O
30	,	O
31	from	O
32	at	O
33	least	O
34	0	O
35	.	O
36	05	O
37	to	O
38	5	O
39	.	O
40	0	O
41	<UNK>	O
42	per	O
43	phase	O
44	.	O
1	Sequence	O
2	and	O
3	genetic	O
4	organization	O
5	of	O
6	a	O
7	<UNK>	O
8	<UNK>	O
9	gene	O
10	cluster	O
11	that	O
12	encodes	O
13	several	O
14	enzymes	O
15	of	O
16	glucose	O
17	metabolism	O
18	.	O
1	Plasma	O
2	<UNK>	O
3	was	O
4	obtained	O
5	during	O
6	each	O
7	baseline	O
8	and	O
9	drug	O
10	course	O
11	.	O
1	Effects	O
2	of	O
3	<UNK>	O
4	on	O
5	upper	O
6	-	O
7	gastrointestinal	O
8	motility	O
9	and	O
10	<UNK>	O
11	hormones	O
1	<UNK>	O
2	<UNK>	O
3	:	O
4	blood	O
5	levels	O
6	and	O
7	metabolic	O
8	<UNK>	O
9	.	O
1	In	O
2	26	O
3	patients	O
4	with	O
5	angina	O
6	<UNK>	O
7	,	O
8	the	O
9	changes	O
10	of	O
11	<UNK>	O
12	,	O
13	<UNK>	O
14	and	O
15	<UNK>	O
16	/	O
17	<UNK>	O
18	were	O
19	more	O
20	sensitive	O
21	for	O
22	the	O
23	detection	O
24	of	O
25	exercise	O
26	-	O
27	induced	O
28	ischemia	O
29	than	O
30	the	O
31	appearance	O
32	of	O
33	chest	O
34	pain	O
35	and	O
36	the	O
37	changes	O
38	of	O
39	ECG	O
40	.	O
1	The	O
2	<UNK>	O
3	oxygen	O
4	concentration	O
5	needed	O
6	(	O
7	<UNK>	O
8	)	O
9	and	O
10	the	O
11	<UNK>	O
12	<UNK>	O
13	differed	O
14	in	O
15	a	O
16	highly	O
17	significant	O
18	manner	O
19	beginning	O
20	on	O
21	the	O
22	<UNK>	O
23	day	O
24	after	O
25	trauma	O
26	.	O
1	The	O
2	<UNK>	O
3	and	O
4	mineral	O
5	oil	O
6	<UNK>	O
7	were	O
8	almost	O
9	as	O
10	effective	O
11	as	O
12	milk	O
13	but	O
14	less	O
15	effective	O
16	than	O
17	<UNK>	O
18	(	O
19	0	O
20	.	O
21	<UNK>	O
22	)	O
23	in	O
24	stimulating	O
25	ingestion	O
26	.	O
1	Effect	O
2	of	O
3	biliary	O
4	<UNK>	O
5	and	O
6	<UNK>	O
7	on	O
8	serum	O
9	<UNK>	B
10	-	O
11	1	O
12	level	O
1	By	O
2	<UNK>	O
3	a	O
4	series	O
5	of	O
6	deletions	O
7	in	O
8	the	O
9	<UNK>	B
10	promoter	O
11	,	O
12	we	O
13	further	O
14	<UNK>	O
15	these	O
16	sequences	O
17	to	O
18	30	O
19	base	O
20	pairs	O
21	,	O
22	located	O
23	between	O
24	<UNK>	O
25	and	O
26	<UNK>	O
27	base	O
28	pairs	O
29	upstream	O
30	of	O
31	the	O
32	mRNA	O
33	cap	O
34	site	O
35	.	O
1	<UNK>	B
2	-	O
3	induced	O
4	expression	O
5	of	O
6	a	O
7	gene	O
8	for	O
9	a	O
10	ribosomal	O
11	protein	O
12	related	O
13	to	O
14	the	O
15	<UNK>	B
16	oncogene	I
17	.	O
1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	<UNK>	O
13	and	O
14	resulting	O
15	c	B
16	-	O
17	myc	B
18	<UNK>	O
19	in	O
20	<UNK>	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	<UNK>	O
35	'	O
36	s	O
37	lymphoma	O
38	c	B
39	-	O
40	myc	B
41	alleles	O
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	<UNK>	O
49	<UNK>	O
50	.	O
1	<UNK>	O
2	<UNK>	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	<UNK>	O
41	of	O
42	the	O
43	study	O
44	.	O
1	The	O
2	coding	O
3	sequences	O
4	of	O
5	the	O
6	<UNK>	B
7	gene	O
8	<UNK>	O
9	over	O
10	25	O
11	kb	O
12	of	O
13	DNA	O
14	,	O
15	whereas	O
16	the	O
17	<UNK>	B
18	-	O
19	<UNK>	O
20	sequences	O
21	are	O
22	included	O
23	within	O
24	a	O
25	single	O
26	5	O
27	.	O
28	6	O
29	-	O
30	kb	O
31	<UNK>	B
32	-	O
33	R1	O
34	fragment	O
35	.	O
1	<UNK>	O
2	systems	O
3	--	O
4	45	O
5	;	O
6	<UNK>	O
7	health	O
8	and	O
9	illness	O
10	in	O
11	old	O
12	age	O
13	--	O
14	3	O
15	.	O
1	Comparison	O
2	of	O
3	transmembrane	O
4	and	O
5	cytoplasmic	O
6	domains	O
7	to	O
8	a	O
9	third	O
10	cell	O
11	-	O
12	surface	O
13	proteoglycan	O
14	,	O
15	<UNK>	B
16	from	O
17	human	O
18	lung	O
19	fibroblasts	O
20	(	O
21	<UNK>	O
22	,	O
23	P	O
24	.,	O
25	<UNK>	O
26	,	O
27	J	O
28	.,	O
29	<UNK>	O
30	,	O
31	J	O
32	.,	O
33	<UNK>	O
34	<UNK>	O
35	,	O
36	H	O
37	.,	O
38	and	O
39	<UNK>	O
40	,	O
41	C	O
42	.	O
1	A	O
2	second	O
3	,	O
4	novel	O
5	C	O
6	subunit	O
7	(	O
8	<UNK>	O
9	alpha	O
10	',	O
11	<UNK>	O
12	residues	O
13	)	O
14	has	O
15	a	O
16	unique	O
17	56	O
18	-	O
19	residue	O
20	carboxyl	O
21	-	O
22	terminal	O
23	region	O
24	that	O
25	is	O
26	generated	O
27	by	O
28	the	O
29	alternative	O
30	splicing	O
31	of	O
32	the	O
33	C	O
34	pre	O
35	-	O
36	mRNA	O
37	.	O
1	<UNK>	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	<UNK>	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O
1	<UNK>	O
2	renal	O
3	<UNK>	O
4	with	O
5	recombinant	O
6	human	O
7	erythropoietin	B
8	.	O
1	<UNK>	O
2	factors	O
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	<UNK>	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	<UNK>	O
17	).	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	costs	O
5	were	O
6	reduced	O
7	when	O
8	<UNK>	O
9	<UNK>	O
10	with	O
11	40	O
12	-	O
13	mL	O
14	<UNK>	O
15	<UNK>	O
16	was	O
17	compared	O
18	with	O
19	<UNK>	O
20	<UNK>	O
21	with	O
22	unit	O
23	-	O
24	dose	O
25	<UNK>	O
26	.	O
1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	<UNK>	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	<UNK>	O
13	cause	O
14	of	O
15	<UNK>	O
16	among	O
17	<UNK>	O
18	of	O
19	the	O
20	<UNK>	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	<UNK>	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	<UNK>	O
38	factor	O
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O
1	<UNK>	O
2	-	O
3	administration	O
4	of	O
5	<UNK>	O
6	,	O
7	angiotensin	B
8	II	O
9	and	O
10	<UNK>	O
11	via	O
12	the	O
13	hepatic	O
14	artery	O
15	may	O
16	reduce	O
17	drug	O
18	exposure	O
19	in	O
20	the	O
21	systemic	O
22	<UNK>	O
23	and	O
24	therefore	O
25	may	O
26	increase	O
27	the	O
28	therapeutic	O
29	ratio	O
30	of	O
31	<UNK>	O
32	administration	O
33	via	O
34	the	O
35	hepatic	O
36	artery	O
37	.	O
1	Transient	O
2	expression	O
3	of	O
4	human	O
5	and	O
6	chicken	O
7	progesterone	O
8	receptors	O
9	does	O
10	not	O
11	support	O
12	alternative	O
13	translational	O
14	initiation	O
15	from	O
16	a	O
17	single	O
18	mRNA	O
19	as	O
20	the	O
21	mechanism	O
22	generating	O
23	two	O
24	receptor	O
25	isoforms	O
26	.	O
1	On	O
2	<UNK>	O
3	examination	O
4	the	O
5	<UNK>	O
6	epithelium	O
7	of	O
8	the	O
9	<UNK>	O
10	membrane	O
11	was	O
12	found	O
13	to	O
14	be	O
15	changed	O
16	into	O
17	<UNK>	O
18	epithelium	O
19	,	O
20	with	O
21	<UNK>	O
22	distribution	O
23	of	O
24	<UNK>	O
25	nuclei	O
26	in	O
27	the	O
28	<UNK>	O
29	cytoplasm	O
30	.	O
1	These	O
2	results	O
3	suggest	O
4	an	O
5	increased	O
6	risk	O
7	of	O
8	developing	O
9	cancer	O
10	among	O
11	<UNK>	O
12	patients	O
13	and	O
14	the	O
15	possibility	O
16	of	O
17	<UNK>	O
18	effect	O
19	of	O
20	<UNK>	O
21	against	O
22	subsequent	O
23	cancer	O
24	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	a	O
5	patient	O
6	with	O
7	chronic	O
8	graft	O
9	-	O
10	versus	O
11	-	O
12	host	O
13	disease	O
14	.	O
1	The	O
2	pattern	O
3	for	O
4	catalytic	O
5	zinc	O
6	sites	O
7	included	O
8	two	O
9	ligands	O
10	close	O
11	in	O
12	sequence	O
13	,	O
14	a	O
15	sequence	O
16	-	O
17	<UNK>	O
18	ligand	O
19	,	O
20	and	O
21	a	O
22	main	O
23	-	O
24	chain	O
25	<UNK>	O
26	bond	O
27	joining	O
28	two	O
29	ligands	O
30	.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	newborn	O
5	rats	O
6	(	O
7	n	O
8	=	O
9	85	O
10	)	O
11	<UNK>	O
12	100	O
13	%	O
14	oxygen	O
15	(	O
16	O2	O
17	)	O
18	or	O
19	<UNK>	O
20	air	O
21	(	O
22	RA	O
23	)	O
24	during	O
25	the	O
26	first	O
27	8	O
28	days	O
29	of	O
30	life	O
31	,	O
32	and	O
33	then	O
34	RA	O
35	.	O
1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	<UNK>	O
6	produced	O
7	beta	O
8	<UNK>	B
9	-	O
10	<UNK>	B
11	receptor	O
12	kinase	B
13	fusion	O
14	protein	O
15	recognized	O
16	a	O
17	44	O
18	<UNK>	O
19	phosphoprotein	O
20	phosphorylated	O
21	on	O
22	serine	O
23	,	O
24	threonine	O
25	and	O
26	tyrosine	O
27	in	O
28	extracts	O
29	of	O
30	<UNK>	B
31	-	O
32	<UNK>	O
33	transformed	O
34	<UNK>	O
35	cells	O
36	.	O
1	The	O
2	cDNAs	O
3	cross	O
4	-	O
5	<UNK>	O
6	with	O
7	genomic	O
8	sequences	O
9	in	O
10	rat	O
11	,	O
12	human	O
13	,	O
14	and	O
15	chicken	O
16	DNA	O
17	,	O
18	but	O
19	not	O
20	with	O
21	DNA	O
22	from	O
23	<UNK>	O
24	,	O
25	Drosophila	O
26	,	O
27	or	O
28	sea	O
29	<UNK>	O
30	.	O
1	ATP	O
2	gamma	O
3	S	O
4	inhibition	O
5	can	O
6	be	O
7	<UNK>	O
8	by	O
9	high	O
10	concentrations	O
11	of	O
12	ATP	O
13	,	O
14	<UNK>	O
15	,	O
16	<UNK>	O
17	,	O
18	or	O
19	<UNK>	O
20	.	O
1	The	O
2	4	O
3	-	O
4	AP	B
5	(	O
6	4	O
7	-	O
8	20	O
9	mM	O
10	)	O
11	effect	O
12	resulted	O
13	in	O
14	a	O
15	decrease	O
16	of	O
17	the	O
18	sensory	O
19	activity	O
20	,	O
21	which	O
22	was	O
23	fully	O
24	restored	O
25	by	O
26	<UNK>	O
27	or	O
28	<UNK>	O
29	<UNK>	O
1	A	O
2	new	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	sleep	O
10	<UNK>	O
11	during	O
12	continuous	O
13	<UNK>	O
14	EEG	O
15	<UNK>	O
16	.	O
1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	O
16	X	O
17	collagen	B
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O
1	<UNK>	O
2	flap	O
3	areas	O
4	were	O
5	established	O
6	following	O
7	vascular	O
8	<UNK>	O
9	ligation	O
10	(	O
11	both	O
12	vessels	O
13	or	O
14	only	O
15	artery	O
16	or	O
17	vein	O
18	),	O
19	on	O
20	the	O
21	third	O
22	day	O
23	after	O
24	flap	O
25	<UNK>	O
26	in	O
27	both	O
28	<UNK>	O
29	and	O
30	free	O
31	<UNK>	O
32	.	O
1	<UNK>	O
2	caused	O
3	a	O
4	<UNK>	O
5	potassium	O
6	<UNK>	O
7	measured	O
8	as	O
9	<UNK>	O
10	+	O
11	<UNK>	O
12	from	O
13	control	O
14	<UNK>	O
15	,	O
16	but	O
17	was	O
18	without	O
19	effect	O
20	in	O
21	<UNK>	O
22	<UNK>	O
23	.	O
1	Their	O
2	<UNK>	O
3	<UNK>	O
4	are	O
5	very	O
6	similar	O
7	and	O
8	both	O
9	possess	O
10	three	O
11	hydrophobic	O
12	segments	O
13	that	O
14	are	O
15	likely	O
16	alpha	O
17	-	O
18	helical	O
19	transmembrane	O
20	segments	O
21	.	O
1	In	O
2	TNF	B
3	-	O
4	resistant	O
5	<UNK>	O
6	bladder	O
7	carcinoma	O
8	cells	O
9	,	O
10	TNF	B
11	failed	O
12	to	O
13	alter	O
14	EGF	B
15	-	O
16	R	O
17	tyrosine	O
18	protein	O
19	kinase	B
20	activity	O
21	although	O
22	both	O
23	EGF	B
24	and	O
25	phorbol	O
26	ester	O
27	were	O
28	shown	O
29	to	O
30	modulate	O
31	the	O
32	enzymatic	O
33	activity	O
34	of	O
35	the	O
36	receptor	O
37	in	O
38	these	O
39	cells	O
40	.	O
1	Structural	O
2	organization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	mouse	O
8	estrogen	O
9	receptor	O
10	.	O
1	The	O
2	results	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	1	O
8	)	O
9	Total	O
10	integrated	O
11	<UNK>	O
12	activity	O
13	of	O
14	<UNK>	O
15	group	O
16	was	O
17	approximately	O
18	equal	O
19	in	O
20	any	O
21	<UNK>	O
22	position	O
23	,	O
24	whereas	O
25	that	O
26	of	O
27	<UNK>	O
28	and	O
29	<UNK>	O
30	group	O
31	varied	O
32	from	O
33	position	O
34	to	O
35	position	O
36	.	O
1	In	O
2	76	O
3	%	O
4	of	O
5	59	O
6	lead	O
7	-	O
8	toxic	O
9	children	O
10	,	O
11	bone	O
12	lead	O
13	values	O
14	measured	O
15	by	O
16	<UNK>	O
17	were	O
18	equal	O
19	to	O
20	or	O
21	greater	O
22	than	O
23	those	O
24	measured	O
25	in	O
26	normal	O
27	and	O
28	<UNK>	O
29	exposed	O
30	adults	O
31	.	O
1	In	O
2	resting	O
3	3T3	O
4	cells	O
5	,	O
6	jun	B
7	-	O
8	D	O
9	is	O
10	expressed	O
11	at	O
12	a	O
13	higher	O
14	level	O
15	compared	O
16	to	O
17	c	B
18	-	O
19	jun	B
20	and	O
21	jun	B
22	-	O
23	B	O
24	,	O
25	and	O
26	its	O
27	transcription	O
28	is	O
29	stimulated	O
30	only	O
31	slightly	O
32	by	O
33	serum	O
34	growth	O
35	factors	O
36	.	O
1	<UNK>	O
2	of	O
3	the	O
4	renal	O
5	blood	O
6	flow	O
7	<UNK>	O
8	the	O
9	<UNK>	O
10	and	O
11	tubular	O
12	excretion	O
13	processes	O
14	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	<UNK>	O
5	in	O
6	growing	O
7	animals	O
1	In	O
2	all	O
3	<UNK>	O
4	under	O
5	IFN	B
6	,	O
7	the	O
8	latency	O
9	of	O
10	the	O
11	<UNK>	O
12	component	O
13	of	O
14	the	O
15	<UNK>	O
16	was	O
17	<UNK>	O
18	as	O
19	compared	O
20	to	O
21	baseline	O
22	conditions	O
23	.	O
1	<UNK>	O
2	status	O
3	and	O
4	future	O
5	<UNK>	O
1	The	O
2	<UNK>	O
3	measurement	O
4	during	O
5	<UNK>	O
6	<UNK>	O
7	predicted	O
8	the	O
9	<UNK>	O
10	of	O
11	<UNK>	O
12	with	O
13	<UNK>	O
14	of	O
15	spontaneous	O
16	circulation	O
17	.	O
1	The	O
2	other	O
3	patients	O
4	continued	O
5	the	O
6	trial	O
7	with	O
8	single	O
9	daily	O
10	doses	O
11	of	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	<UNK>	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O
1	<UNK>	O
2	patients	O
3	,	O
4	divided	O
5	according	O
6	to	O
7	their	O
8	initial	O
9	total	O
10	gastrointestinal	O
11	transit	O
12	times	O
13	and	O
14	presenting	O
15	symptoms	O
16	,	O
17	were	O
18	treated	O
19	with	O
20	<UNK>	O
21	<UNK>	O
22	50	O
23	mg	O
24	t	O
25	.	O
26	d	O
27	.	O
28	s	O
29	.	O
30	or	O
31	placebo	O
32	for	O
33	1	O
34	month	O
35	according	O
36	to	O
37	a	O
38	double	O
39	-	O
40	blind	O
41	,	O
42	parallel	O
43	group	O
44	<UNK>	O
45	.	O
1	Moreover	O
2	,	O
3	exons	O
4	<UNK>	O
5	and	O
6	2b	O
7	share	O
8	the	O
9	same	O
10	5	O
11	'	O
12	sequence	O
13	but	O
14	differ	O
15	from	O
16	each	O
17	other	O
18	by	O
19	the	O
20	use	O
21	of	O
22	two	O
23	distinct	O
24	donor	O
25	splice	O
26	sites	O
27	<UNK>	O
28	bp	O
29	<UNK>	O
30	in	O
31	the	O
32	gene	O
33	.	O
1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	HBV	O
6	markers	O
7	was	O
8	higher	O
9	among	O
10	<UNK>	O
11	members	O
12	than	O
13	in	O
14	the	O
15	blood	O
16	donors	O
17	of	O
18	our	O
19	area	O
20	.	O
1	<UNK>	O
2	<UNK>	O
3	are	O
4	confirmed	O
5	for	O
6	the	O
7	positive	O
8	responses	O
9	,	O
10	but	O
11	not	O
12	for	O
13	the	O
14	<UNK>	O
15	,	O
16	suggesting	O
17	that	O
18	the	O
19	<UNK>	O
20	model	O
21	is	O
22	<UNK>	O
23	.	O
1	The	O
2	adenovirus	O
3	E1A	B
4	gene	O
5	encodes	O
6	a	O
7	protein	O
8	that	O
9	transcriptionally	O
10	activates	O
11	viral	O
12	early	O
13	genes	O
14	.	O
1	In	O
2	the	O
3	<UNK>	O
4	test	O
5	,	O
6	however	O
7	,	O
8	<UNK>	O
9	attenuated	O
10	morphine	O
11	analgesia	O
12	at	O
13	the	O
14	lower	O
15	doses	O
16	(	O
17	0	O
18	.	O
19	1	O
20	and	O
21	0	O
22	.	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	)	O
28	and	O
29	<UNK>	O
30	morphine	O
31	analgesia	O
32	at	O
33	the	O
34	highest	O
35	dose	O
36	(	O
37	10	O
38	mg	O
39	/	O
40	kg	O
41	).	O
1	We	O
2	have	O
3	isolated	O
4	cDNA	O
5	clones	O
6	from	O
7	rat	O
8	brain	O
9	and	O
10	human	O
11	liver	O
12	encoding	O
13	a	O
14	putative	O
15	isoform	O
16	of	O
17	the	O
18	Na	O
19	,	O
20	K	O
21	-	O
22	ATPase	B
23	beta	O
24	subunit	O
25	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	patients	O
6	who	O
7	undergo	O
8	postoperative	O
9	irradiation	O
10	for	O
11	low	O
12	grade	O
13	spinal	O
14	<UNK>	O
15	and	O
16	localized	O
17	spinal	O
18	<UNK>	O
19	achieve	O
20	excellent	O
21	survival	O
22	.	O
1	Effects	O
2	of	O
3	nitrogen	O
4	(	O
5	<UNK>	O
6	:	O
7	5	O
8	and	O
9	14	O
10	<UNK>	O
11	)	O
12	and	O
13	<UNK>	O
14	(	O
15	<UNK>	O
16	:	O
17	13	O
18	and	O
19	14	O
20	<UNK>	O
21	)	O
22	were	O
23	also	O
24	tested	O
25	.	O
1	The	O
2	application	O
3	of	O
4	<UNK>	O
5	and	O
6	<UNK>	O
7	did	O
8	not	O
9	change	O
10	significantly	O
11	the	O
12	routine	O
13	<UNK>	O
14	classification	O
15	of	O
16	<UNK>	O
17	into	O
18	CMV	O
19	-	O
20	<UNK>	O
21	and	O
22	<UNK>	O
23	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	in	O
9	the	O
10	differential	O
11	diagnosis	O
12	of	O
13	<UNK>	O
14	<UNK>	O
15	and	O
16	<UNK>	O
17	<UNK>	O
18	<UNK>	O
19	after	O
20	<UNK>	O
21	bone	O
22	marrow	O
23	transplantation	O
1	However	O
2	,	O
3	bilateral	O
4	<UNK>	O
5	pulmonary	O
6	<UNK>	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O
1	<UNK>	B
2	,	O
3	which	O
4	encodes	O
5	the	O
6	major	O
7	capsid	O
8	protein	O
9	,	O
10	each	O
11	fused	O
12	to	O
13	the	O
14	chloramphenicol	B
15	acetyltransferase	I
16	gene	O
17	.	O
1	<UNK>	O
2	,	O
3	a	O
4	<UNK>	B
5	<UNK>	O
6	<UNK>	B
7	<UNK>	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	<UNK>	B
19	introns	O
20	<UNK>	B
21	alpha	O
22	and	O
23	<UNK>	B
24	beta	O
25	is	O
26	defective	O
27	only	O
28	in	O
29	<UNK>	B
30	gene	O
31	expression	O
32	and	O
33	not	O
34	in	O
35	<UNK>	B
36	mRNA	O
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O
1	There	O
2	has	O
3	been	O
4	similar	O
5	improvement	O
6	in	O
7	<UNK>	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	cancer	O
12	,	O
13	<UNK>	O
14	cancer	O
15	,	O
16	or	O
17	<UNK>	O
18	bile	O
19	<UNK>	O
20	cancer	O
21	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	<UNK>	B
6	induced	O
7	a	O
8	beta	O
9	-	O
10	<UNK>	B
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	<UNK>	B
16	-	O
17	cortisol	O
18	release	O
19	.	O
1	<UNK>	O
2	<UNK>	O
3	tumor	O
4	with	O
5	metastasis	O
6	to	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	and	O
11	face	O
12	regions	O
1	<UNK>	O
2	cells	O
3	of	O
4	mating	O
5	type	O
6	A	O
7	of	O
8	the	O
9	<UNK>	O
10	yeast	O
11	<UNK>	O
12	<UNK>	O
13	<UNK>	O
14	a	O
15	mating	O
16	<UNK>	O
17	,	O
18	<UNK>	B
19	A	O
20	,	O
21	which	O
22	is	O
23	an	O
24	<UNK>	O
25	containing	O
26	S	O
27	-	O
28	<UNK>	O
29	cysteine	O
30	at	O
31	its	O
32	carboxy	O
33	terminus	O
34	.	O
1	No	O
2	significant	O
3	differences	O
4	were	O
5	found	O
6	in	O
7	relation	O
8	to	O
9	Type	O
10	A	O
11	behaviour	O
12	and	O
13	beta	O
14	-	O
15	<UNK>	B
16	blockade	O
17	.	O
1	<UNK>	O
2	in	O
3	asthma	O
4	.	O
1	We	O
2	have	O
3	therefore	O
4	evaluated	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	<UNK>	O
11	,	O
12	a	O
13	new	O
14	orally	O
15	active	O
16	selective	O
17	alpha	O
18	1	O
19	blocker	O
20	,	O
21	in	O
22	patients	O
23	with	O
24	systemic	O
25	hypertension	O
26	with	O
27	concomitant	O
28	<UNK>	O
29	<UNK>	O
30	.	O
1	High	O
2	ATP	O
3	/	O
4	GTP	O
5	ratios	O
6	<UNK>	O
7	initiation	O
8	of	O
9	RNA	O
10	primer	O
11	synthesis	O
12	at	O
13	3	O
14	'-	O
15	<UNK>	O
16	sites	O
17	,	O
18	whereas	O
19	low	O
20	ATP	O
21	/	O
22	GTP	O
23	ratios	O
24	<UNK>	O
25	initiation	O
26	at	O
27	3	O
28	'-	O
29	<UNK>	O
30	sites	O
31	.	O
1	The	O
2	<UNK>	O
3	-	O
4	<UNK>	O
5	<UNK>	O
6	had	O
7	increased	O
8	serum	O
9	IgG	B
10	,	O
11	<UNK>	O
12	IgG	B
13	and	O
14	IgA	B
15	and	O
16	increased	O
17	<UNK>	B
18	<UNK>	O
19	in	O
20	both	O
21	<UNK>	O
22	<UNK>	O
23	and	O
24	serum	O
25	following	O
26	the	O
27	SC	O
28	dose	O
29	of	O
30	<UNK>	O
31	bacteria	O
32	.	O
1	Recent	O
2	investigations	O
3	have	O
4	shown	O
5	that	O
6	<UNK>	O
7	<UNK>	O
8	can	O
9	suppress	O
10	the	O
11	<UNK>	O
12	contact	O
13	<UNK>	O
14	reaction	O
15	completely	O
16	and	O
17	that	O
18	<UNK>	O
19	cells	O
20	,	O
21	identified	O
22	by	O
23	<UNK>	B
24	antibodies	O
25	and	O
26	electron	O
27	microscopy	O
28	,	O
29	<UNK>	O
30	from	O
31	the	O
32	<UNK>	O
33	at	O
34	the	O
35	same	O
36	time	O
37	.	O
1	Four	O
2	full	O
3	-	O
4	thickness	O
5	skin	O
6	<UNK>	O
7	were	O
8	made	O
9	in	O
10	the	O
11	back	O
12	of	O
13	10	O
14	female	O
15	pigs	O
16	that	O
17	treated	O
18	twice	O
19	a	O
20	day	O
21	for	O
22	14	O
23	days	O
24	with	O
25	2	O
26	ml	O
27	of	O
28	epidermal	B
29	growth	O
30	factor	O
31	(	O
32	300	O
33	ng	O
34	/	O
35	ml	O
36	)	O
37	or	O
38	2	O
39	ml	O
40	of	O
41	<UNK>	O
42	'	O
43	s	O
44	lactate	O
45	solution	O
46	in	O
47	a	O
48	single	O
49	-	O
50	blind	O
51	,	O
52	randomized	O
53	fashion	O
54	.	O
1	<UNK>	O
2	experimental	O
3	and	O
4	clinical	O
5	<UNK>	O
6	of	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	and	O
11	spinal	O
12	<UNK>	O
13	replacement	O
14	<UNK>	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O
1	We	O
2	investigated	O
3	the	O
4	incidence	O
5	of	O
6	congenital	O
7	<UNK>	O
8	deficiency	O
9	among	O
10	<UNK>	O
11	by	O
12	the	O
13	use	O
14	of	O
15	H	O
16	-	O
17	R	O
18	-	O
19	R	O
20	<UNK>	O
21	<UNK>	O
22	.	O
1	<UNK>	O
2	patients	O
3	presenting	O
4	to	O
5	<UNK>	O
6	with	O
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	<UNK>	O
13	between	O
14	<UNK>	O
15	and	O
16	<UNK>	O
17	,	O
18	were	O
19	reviewed	O
20	.	O
1	<UNK>	O
2	filling	O
3	consists	O
4	in	O
5	<UNK>	O
6	<UNK>	O
7	system	O
8	directly	O
9	at	O
10	the	O
11	<UNK>	O
12	<UNK>	O
13	after	O
14	surgical	O
15	approach	O
16	.	O
1	<UNK>	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	O
14	<UNK>	O
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	<UNK>	O
29	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	47	O
6	-	O
7	<UNK>	O
8	major	O
9	<UNK>	O
10	membrane	O
11	<UNK>	O
12	of	O
13	<UNK>	B
14	<UNK>	I
15	.	O
1	<UNK>	O
2	studies	O
3	have	O
4	<UNK>	O
5	out	O
6	the	O
7	possibility	O
8	of	O
9	""""	O
10	<UNK>	O
11	""""	O
12	organic	O
13	factors	O
14	in	O
15	<UNK>	O
16	<UNK>	O
17	,	O
18	detectable	O
19	only	O
20	by	O
21	means	O
22	of	O
23	laboratory	O
24	investigations	O
25	:	O
26	mild	O
27	<UNK>	O
28	,	O
29	<UNK>	O
30	,	O
31	<UNK>	O
32	selectively	O
33	located	O
34	at	O
35	the	O
36	site	O
37	of	O
38	the	O
39	sexual	O
40	arteries	O
41	,	O
42	venous	O
43	<UNK>	O
44	,	O
45	<UNK>	O
46	<UNK>	O
47	.	O
1	Doppler	O
2	<UNK>	O
3	in	O
4	<UNK>	O
5	<UNK>	O
6	<UNK>	O
7	for	O
8	dialysis	O
1	Following	O
2	the	O
3	patients	O
4	during	O
5	a	O
6	course	O
7	of	O
8	therapy	O
9	with	O
10	a	O
11	selective	O
12	<UNK>	O
13	calcium	O
14	antagonist	O
15	,	O
16	the	O
17	beta	O
18	-	O
19	adrenergic	O
20	reflex	O
21	<UNK>	O
22	became	O
23	substantially	O
24	attenuated	O
25	but	O
26	was	O
27	<UNK>	O
28	during	O
29	a	O
30	placebo	O
31	course	O
32	of	O
33	therapy	O
34	.	O
1	The	O
2	calcium	O
3	requirement	O
4	for	O
5	<UNK>	O
6	storage	O
7	of	O
8	the	O
9	cardiac	O
10	<UNK>	O
11	.	O
1	The	O
2	<UNK>	B
3	.	O
4	8	O
5	gene	O
6	has	O
7	a	O
8	strong	O
9	codon	O
10	usage	O
11	<UNK>	O
12	which	O
13	is	O
14	<UNK>	O
15	different	O
16	from	O
17	that	O
18	of	O
19	the	O
20	<UNK>	B
21	gene	O
22	.	O
1	Four	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	showed	O
7	clinical	O
8	improvement	O
9	according	O
10	to	O
11	<UNK>	O
12	-	O
13	<UNK>	O
14	,	O
15	pain	O
16	score	O
17	,	O
18	<UNK>	O
19	and	O
20	CRP	B
21	.	O
1	<UNK>	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	complementation	O
7	group	O
8	identified	O
9	by	O
10	these	O
11	mutants	O
12	is	O
13	<UNK>	O
14	to	O
15	the	O
16	<UNK>	B
17	alpha	O
18	1	O
19	mutation	O
20	identified	O
21	previously	O
22	.	O
1	<UNK>	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	size	O
7	of	O
8	the	O
9	mRNA	O
10	is	O
11	about	O
12	1	O
13	.	O
14	4	O
15	kilobases	O
16	.	O
1	The	O
2	R	O
3	.	O
4	<UNK>	O
5	<UNK>	B
6	promoter	O
7	but	O
8	not	O
9	the	O
10	K	O
11	.	O
12	<UNK>	O
13	<UNK>	B
14	promoter	O
15	showed	O
16	sigma	B
17	54	O
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	O
43	-	O
44	dependent	O
45	promoters	O
46	.	O
1	<UNK>	O
2	clinical	O
3	symptoms	O
4	of	O
5	the	O
6	disease	O
7	were	O
8	defined	O
9	in	O
10	this	O
11	group	O
12	of	O
13	patients	O
14	.	O
1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	structural	O
7	and	O
8	functional	O
9	organization	O
10	of	O
11	the	O
12	eukaryotic	O
13	<UNK>	O
14	,	O
15	we	O
16	have	O
17	<UNK>	O
18	to	O
19	isolate	O
20	and	O
21	characterize	O
22	<UNK>	O
23	components	O
24	of	O
25	the	O
26	yeast	O
27	Saccharomyces	O
28	cerevisiae	O
29	.	O
1	A	O
2	transcription	O
3	factor	O
4	<UNK>	O
5	assay	O
6	was	O
7	used	O
8	to	O
9	show	O
10	that	O
11	the	O
12	<UNK>	B
13	mutation	O
14	affects	O
15	two	O
16	distinct	O
17	stages	O
18	in	O
19	transcription	O
20	:	O
21	one	O
22	prior	O
23	to	O
24	and	O
25	one	O
26	after	O
27	stable	O
28	complex	O
29	formation	O
30	;	O
31	and	O
32	that	O
33	these	O
34	effects	O
35	are	O
36	mediated	O
37	by	O
38	a	O
39	component	O
40	of	O
41	the	O
42	stable	O
43	complex	O
44	.	O
1	<UNK>	O
2	and	O
3	the	O
4	skin	O
5	.	O
1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	<UNK>	O
7	(	O
8	06	O
9	.	O
10	<UNK>	O
11	-	O
12	10	O
13	.	O
14	<UNK>	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	<UNK>	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	<UNK>	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O
1	The	O
2	present	O
3	data	O
4	also	O
5	suggest	O
6	that	O
7	when	O
8	compared	O
9	to	O
10	the	O
11	systemic	O
12	vascular	O
13	<UNK>	O
14	,	O
15	the	O
16	pulmonary	O
17	vascular	O
18	<UNK>	O
19	is	O
20	less	O
21	responsive	O
22	to	O
23	<UNK>	O
24	administration	O
25	of	O
26	<UNK>	O
27	-	O
28	1	O
29	.	O
1	The	O
2	encoded	O
3	protein	O
4	has	O
5	a	O
6	leader	O
7	sequence	O
8	of	O
9	27	O
10	amino	O
11	acids	O
12	.	O
1	The	O
2	<UNK>	O
3	of	O
4	drug	O
5	action	O
6	.	O
1	Chronic	O
2	dose	O
3	effects	O
4	of	O
5	methyl	O
6	<UNK>	O
7	on	O
8	<UNK>	O
9	:	O
10	<UNK>	B
11	and	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	weight	O
3	and	O
4	kidney	O
5	-	O
6	to	O
7	-	O
8	body	O
9	weight	O
10	ratio	O
11	were	O
12	significantly	O
13	elevated	O
14	at	O
15	the	O
16	highest	O
17	dose	O
18	level	O
19	after	O
20	10	O
21	weeks	O
22	and	O
23	at	O
24	the	O
25	two	O
26	higher	O
27	dose	O
28	levels	O
29	after	O
30	15	O
31	weeks	O
32	of	O
33	exposure	O
34	.	O
1	<UNK>	O
2	variation	O
3	in	O
4	HLA	B
5	-	O
6	B	O
7	and	O
8	HLA	B
9	-	O
10	C	O
11	sequences	O
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	B
18	-	O
19	B	O
20	alleles	O
21	.	O
1	<UNK>	O
2	clones	O
3	containing	O
4	both	O
5	<UNK>	O
6	sequences	O
7	were	O
8	identified	O
9	,	O
10	and	O
11	restriction	O
12	mapping	O
13	showed	O
14	them	O
15	to	O
16	be	O
17	less	O
18	than	O
19	15	O
20	kb	O
21	<UNK>	O
22	.	O
1	Among	O
2	<UNK>	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	<UNK>	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	<UNK>	O
21	<UNK>	O
22	.	O
1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	by	O
8	S1	B
9	nuclease	I
10	mapping	O
11	.	O
1	<UNK>	O
2	<UNK>	O
3	and	O
4	plasma	O
5	<UNK>	O
6	(	O
7	E2	O
8	)	O
9	and	O
10	progesterone	O
11	(	O
12	<UNK>	O
13	)	O
14	levels	O
15	in	O
16	23	O
17	patients	O
18	were	O
19	evaluated	O
20	during	O
21	26	O
22	replacement	O
23	therapy	O
24	cycles	O
25	for	O
26	premature	O
27	ovarian	O
28	failure	O
29	.	O
1	Each	O
2	individual	O
3	<UNK>	O
4	25	O
5	<UNK>	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	<UNK>	O
18	<UNK>	O
19	.	O
1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	NF	B
7	-	O
8	<UNK>	B
9	,	O
10	NF	B
11	-	O
12	<UNK>	B
13	,	O
14	and	O
15	AP	B
16	-	O
17	1	O
18	sequences	O
19	are	O
20	each	O
21	necessary	O
22	for	O
23	full	O
24	enhancer	O
25	activity	O
26	.	O
1	<UNK>	O
2	follows	O
3	<UNK>	O
4	'	O
5	s	O
6	<UNK>	O
7	to	O
8	<UNK>	O
9	out	O
10	appropriate	O
11	importance	O
12	to	O
13	the	O
14	<UNK>	O
15	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	an	O
5	account	O
6	of	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	,	O
11	<UNK>	O
12	and	O
13	<UNK>	O
14	effects	O
15	of	O
16	some	O
17	calcium	O
18	antagonists	O
19	,	O
20	and	O
21	their	O
22	clinical	O
23	application	O
24	is	O
25	discussed	O
26	.	O
1	It	O
2	was	O
3	possible	O
4	to	O
5	<UNK>	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	<UNK>	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	<UNK>	O
19	immune	O
20	response	O
21	.	O
1	1	O
2	-(	O
3	1	O
4	-	O
5	<UNK>	O
6	)	O
7	<UNK>	O
8	(	O
9	1	O
10	-	O
11	<UNK>	O
12	)	O
13	has	O
14	been	O
15	reported	O
16	to	O
17	have	O
18	serotonin	O
19	antagonist	O
20	properties	O
21	at	O
22	the	O
23	5	O
24	-	O
25	<UNK>	B
26	<UNK>	O
27	of	O
28	receptor	O
29	,	O
30	and	O
31	it	O
32	has	O
33	been	O
34	suggested	O
35	that	O
36	it	O
37	may	O
38	have	O
39	agonist	O
40	<UNK>	O
41	at	O
42	the	O
43	5	O
44	-	O
45	<UNK>	B
46	site	O
47	.	O
1	<UNK>	O
2	right	O
3	ventricular	O
4	hypertrophy	O
5	was	O
6	seen	O
7	in	O
8	4	O
9	,	O
10	and	O
11	<UNK>	O
12	hypertrophy	O
13	in	O
14	5	O
15	patients	O
16	.	O
1	<UNK>	O
2	on	O
3	23	O
4	white	O
5	rats	O
6	and	O
7	10	O
8	guinea	O
9	pigs	O
10	have	O
11	shown	O
12	that	O
13	<UNK>	O
14	<UNK>	O
15	-	O
16	induced	O
17	inhibition	O
18	of	O
19	<UNK>	O
20	synthesis	O
21	prevented	O
22	development	O
23	of	O
24	pulmonary	O
25	<UNK>	O
26	,	O
27	evoked	O
28	by	O
29	heterologous	O
30	serum	O
31	in	O
32	rats	O
33	and	O
34	by	O
35	<UNK>	O
36	in	O
37	guinea	O
38	pigs	O
39	.	O
1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	lack	O
7	of	O
8	conservation	O
9	of	O
10	the	O
11	membrane	O
12	attachment	O
13	sequence	O
14	arginine	O
15	-	O
16	<UNK>	O
17	-	O
18	<UNK>	O
19	acid	O
20	<UNK>	O
21	against	O
22	its	O
23	functional	O
24	importance	O
25	in	O
26	<UNK>	B
27	.	O
1	The	O
2	<UNK>	O
3	of	O
4	formed	O
5	cysts	O
6	and	O
7	growth	O
8	rates	O
9	were	O
10	<UNK>	O
11	estimated	O
12	and	O
13	analyzed	O
14	<UNK>	O
15	by	O
16	<UNK>	O
17	for	O
18	5	O
19	<UNK>	O
20	cultures	O
21	of	O
22	<UNK>	O
23	<UNK>	O
24	<UNK>	O
25	grown	O
26	for	O
27	2	O
28	years	O
29	under	O
30	laboratory	O
31	conditions	O
32	,	O
33	<UNK>	O
34	as	O
35	constant	O
36	as	O
37	possible	O
38	from	O
39	the	O
40	view	O
41	point	O
42	of	O
43	environmental	O
44	temperature	O
45	(	O
46	24	O
47	+/-	O
48	1	O
49	degree	O
50	C	O
51	),	O
52	<UNK>	O
53	(	O
54	25	O
55	<UNK>	O
56	m	O
57	-	O
58	2	O
59	s	O
60	-	O
61	1	O
62	),	O
63	and	O
64	artificial	O
65	<UNK>	O
66	.	O
1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	<UNK>	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	<UNK>	O
21	for	O
22	15	O
23	min	O
24	)	O
25	<UNK>	O
26	the	O
27	staining	O
28	of	O
29	<UNK>	O
30	areas	O
31	and	O
32	<UNK>	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O
1	<UNK>	O
2	limits	O
3	(	O
4	to	O
5	10	O
6	micrograms	O
7	/	O
8	kg	O
9	)	O
10	were	O
11	detectable	O
12	,	O
13	but	O
14	with	O
15	lower	O
16	<UNK>	O
17	(	O
18	60	O
19	%).	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	were	O
6	<UNK>	O
7	and	O
8	<UNK>	O
9	with	O
10	each	O
11	other	O
12	to	O
13	form	O
14	a	O
15	relatively	O
16	<UNK>	O
17	<UNK>	O
18	which	O
19	extended	O
20	over	O
21	the	O
22	entire	O
23	surface	O
24	of	O
25	both	O
26	<UNK>	O
27	.	O
1	During	O
2	<UNK>	O
3	-	O
4	maximal	O
5	exercise	O
6	,	O
7	<UNK>	O
8	in	O
9	the	O
10	<UNK>	O
11	dogs	O
12	decreased	O
13	from	O
14	a	O
15	resting	O
16	value	O
17	of	O
18	4	O
19	.	O
20	<UNK>	O
21	+/-	O
22	0	O
23	.	O
24	18	O
25	mm	O
26	Hg	O
27	X	O
28	ml	O
29	-	O
30	1	O
31	X	O
32	min	O
33	-	O
34	1	O
35	to	O
36	1	O
37	.	O
38	91	O
39	+/-	O
40	0	O
41	.	O
42	17	O
43	mm	O
44	Hg	O
45	X	O
46	ml	O
47	-	O
48	1	O
49	X	O
50	min	O
51	-	O
52	1	O
53	at	O
54	a	O
55	<UNK>	O
56	of	O
57	6	O
58	.	O
59	4	O
60	<UNK>	O
61	(	O
62	<UNK>	O
63	)/	O
64	16	O
65	%	O
66	(	O
67	grade	O
68	).	O
1	<UNK>	O
2	,	O
3	and	O
4	W	O
5	.	O
1	The	O
2	lack	O
3	of	O
4	change	O
5	in	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	two	O
11	spliced	O
12	products	O
13	expressed	O
14	from	O
15	either	O
16	the	O
17	normal	O
18	or	O
19	the	O
20	5	O
21	'-	O
22	<UNK>	O
23	myb	B
24	further	O
25	indicates	O
26	that	O
27	the	O
28	insertion	O
29	of	O
30	the	O
31	unique	O
32	<UNK>	O
33	amino	O
34	acids	O
35	in	O
36	the	O
37	larger	O
38	myb	B
39	transcripts	O
40	is	O
41	not	O
42	a	O
43	consequence	O
44	of	O
45	tumor	O
46	-	O
47	specific	O
48	activation	O
49	of	O
50	the	O
51	mouse	O
52	myb	B
53	oncogene	I
54	.	O
1	The	O
2	predicted	O
3	L	O
4	mRNA	O
5	was	O
6	<UNK>	O
7	nucleotides	O
8	long	O
9	and	O
10	contained	O
11	a	O
12	single	O
13	open	O
14	reading	O
15	frame	O
16	corresponding	O
17	to	O
18	an	O
19	L	O
20	protein	O
21	encompassing	O
22	<UNK>	B
23	amino	O
24	acids	O
25	with	O
26	a	O
27	<UNK>	O
28	of	O
29	<UNK>	O
30	,	O
31	<UNK>	O
32	.	O
1	<UNK>	O
2	+	O
3	<UNK>	O
4	M	O
5	-	O
6	MuLV	O
7	-	O
8	<UNK>	O
9	animals	O
10	became	O
11	<UNK>	O
12	at	O
13	3	O
14	to	O
15	13	O
16	months	O
17	<UNK>	O
18	,	O
19	whereas	O
20	delta	O
21	<UNK>	O
22	+	O
23	<UNK>	O
24	M	O
25	-	O
26	MuLV	O
27	-	O
28	<UNK>	O
29	animals	O
30	became	O
31	<UNK>	O
32	at	O
33	6	O
34	to	O
35	24	O
36	months	O
37	<UNK>	O
38	.	O
1	In	O
2	these	O
3	cells	O
4	,	O
5	E2	O
6	proteins	O
7	had	O
8	little	O
9	or	O
10	no	O
11	stimulatory	O
12	effect	O
13	on	O
14	the	O
15	transcriptional	O
16	activity	O
17	of	O
18	the	O
19	HPV	O
20	-	O
21	11	O
22	enhancer	O
23	-	O
24	SV40	O
25	promoter	O
26	.	O
1	Chronic	O
2	E	O
3	-	O
4	B	O
5	virus	O
6	infection	O
7	<UNK>	O
8	in	O
9	malignant	O
10	lymphoma	O
11	:	O
12	a	O
13	case	O
14	report	O
1	<UNK>	O
2	the	O
3	muscle	O
4	isoform	O
5	consists	O
6	of	O
7	<UNK>	O
8	amino	O
9	acids	O
10	and	O
11	<UNK>	O
12	with	O
13	the	O
14	sequence	O
15	Ala	O
16	-	O
17	<UNK>	O
18	-	O
19	Leu	O
20	-	O
21	<UNK>	O
22	,	O
23	the	O
24	second	O
25	isoform	O
26	is	O
27	<UNK>	O
28	amino	O
29	acids	O
30	in	O
31	length	O
32	due	O
33	to	O
34	the	O
35	replacement	O
36	of	O
37	these	O
38	last	O
39	4	O
40	amino	O
41	acids	O
42	with	O
43	a	O
44	50	O
45	-	O
46	amino	O
47	acid	O
48	sequence	O
49	that	O
50	contains	O
51	a	O
52	potential	O
53	transmembrane	O
54	domain	O
55	followed	O
56	by	O
57	a	O
58	consensus	O
59	sequence	O
60	for	O
61	an	O
62	N	O
63	-	O
64	linked	O
65	glycosylation	O
66	site	O
67	.	O
1	<UNK>	O
2	of	O
3	a	O
4	threonine	O
5	residue	O
6	by	O
7	an	O
8	alanine	O
9	residue	O
10	at	O
11	position	O
12	-	O
13	2	O
14	(	O
15	P2	O
16	)	O
17	of	O
18	this	O
19	cleavage	O
20	site	O
21	abolished	O
22	cleavage	O
23	,	O
24	whereas	O
25	substitution	O
26	of	O
27	a	O
28	tyrosine	O
29	residue	O
30	by	O
31	a	O
32	<UNK>	O
33	residue	O
34	at	O
35	amino	O
36	acid	O
37	position	O
38	-	O
39	1	O
40	(	O
41	P1	O
42	)	O
43	of	O
44	the	O
45	cleavage	O
46	site	O
47	did	O
48	not	O
49	influence	O
50	processing	O
51	.	O
1	A	O
2	highly	O
3	hydrophobic	O
4	sequence	O
5	located	O
6	near	O
7	the	O
8	carboxyl	O
9	-	O
10	terminal	O
11	<UNK>	O
12	of	O
13	the	O
14	molecule	O
15	most	O
16	likely	O
17	<UNK>	O
18	the	O
19	anchor	O
20	to	O
21	the	O
22	plasma	O
23	membrane	O
24	.	O
1	<UNK>	O
2	<UNK>	O
3	developed	O
4	in	O
5	35	O
6	patients	O
7	(	O
8	44	O
9	eyes	O
10	)	O
11	during	O
12	the	O
13	study	O
14	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	-	O
5	4	O
6	by	O
7	the	O
8	<UNK>	O
9	gland	O
10	closely	O
11	<UNK>	O
12	<UNK>	O
13	in	O
14	<UNK>	O
15	<UNK>	O
16	flow	O
17	rate	O
18	.	O
1	<UNK>	O
2	exposure	O
3	to	O
4	the	O
5	<UNK>	O
6	<UNK>	O
7	causes	O
8	behavioral	O
9	<UNK>	O
10	,	O
11	<UNK>	O
12	and	O
13	<UNK>	O
14	<UNK>	O
15	in	O
16	mice	O
17	,	O
18	but	O
19	not	O
20	rats	O
21	or	O
22	hamsters	O
23	.	O
1	Six	O
2	patients	O
3	with	O
4	human	O
5	T	O
6	-	O
7	cell	O
8	<UNK>	O
9	virus	O
10	type	O
11	I	O
12	(	O
13	HTLV	O
14	-	O
15	I	O
16	)-	O
17	associated	O
18	<UNK>	O
19	(	O
20	<UNK>	O
21	)	O
22	were	O
23	studied	O
24	by	O
25	<UNK>	O
26	methods	O
27	.	O
1	<UNK>	O
2	blood	O
3	donors	O
4	for	O
5	non	O
6	-	O
7	A	O
8	,	O
9	non	O
10	-	O
11	B	O
12	hepatitis	O
13	:	O
14	<UNK>	O
15	,	O
16	perhaps	O
17	,	O
18	but	O
19	<UNK>	O
20	.	O
1	In	O
2	a	O
3	<UNK>	O
4	double	O
5	-	O
6	blind	O
7	study	O
8	,	O
9	46	O
10	first	O
11	<UNK>	O
12	<UNK>	O
13	were	O
14	given	O
15	<UNK>	O
16	or	O
17	<UNK>	O
18	for	O
19	up	O
20	to	O
21	5	O
22	weeks	O
23	;	O
24	the	O
25	mean	O
26	daily	O
27	dose	O
28	at	O
29	the	O
30	end	O
31	was	O
32	18	O
33	.	O
34	8	O
35	mg	O
36	<UNK>	O
37	and	O
38	20	O
39	mg	O
40	<UNK>	O
41	.	O
1	<UNK>	O
2	and	O
3	inverted	O
4	repeat	O
5	elements	O
6	of	O
7	10	O
8	,	O
9	11	O
10	,	O
11	16	O
12	,	O
13	19	O
14	,	O
15	and	O
16	22	O
17	nucleotides	O
18	(	O
19	nt	O
20	)	O
21	<UNK>	O
22	the	O
23	promoter	O
24	site	O
25	.	O
1	<UNK>	O
2	bacterial	O
3	<UNK>	O
4	were	O
5	screened	O
6	for	O
7	recombinant	O
8	plasmids	O
9	containing	O
10	cDNA	O
11	coding	O
12	for	O
13	<UNK>	B
14	by	O
15	hybrid	O
16	-	O
17	selected	O
18	mRNA	O
19	translation	O
20	.	O
1	<UNK>	O
2	attenuated	O
3	the	O
4	increase	O
5	of	O
6	the	O
7	intensity	O
8	of	O
9	the	O
10	ischemic	O
11	and	O
12	pressure	O
13	pain	O
14	components	O
15	with	O
16	increasing	O
17	ischemia	O
18	duration	O
19	,	O
20	but	O
21	only	O
22	the	O
23	effect	O
24	on	O
25	the	O
26	pressure	O
27	pain	O
28	component	O
29	was	O
30	significant	O
31	.	O
1	This	O
2	loss	O
3	was	O
4	independent	O
5	of	O
6	drug	O
7	concentration	O
8	and	O
9	a	O
10	correction	O
11	factor	O
12	was	O
13	employed	O
14	to	O
15	<UNK>	O
16	the	O
17	true	O
18	free	O
19	<UNK>	O
20	concentration	O
21	.	O
1	<UNK>	O
2	studies	O
3	with	O
4	potassium	O
5	chloride	O
6	and	O
7	<UNK>	O
8	suggest	O
9	that	O
10	<UNK>	O
11	acts	O
12	as	O
13	a	O
14	calcium	O
15	antagonist	O
16	by	O
17	blocking	O
18	the	O
19	<UNK>	O
20	of	O
21	extracellular	O
22	calcium	O
23	.	O
1	On	O
2	<UNK>	O
3	to	O
4	the	O
5	<UNK>	O
6	,	O
7	<UNK>	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	<UNK>	O
15	(	O
16	serum	O
17	<UNK>	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	<UNK>	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	<UNK>	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	<UNK>	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	<UNK>	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	<UNK>	O
63	/	O
64	dl	O
65	).	O
1	<UNK>	O
2	assessment	O
3	was	O
4	obtained	O
5	before	O
6	and	O
7	following	O
8	administration	O
9	of	O
10	<UNK>	O
11	10	O
12	micrograms	O
13	/	O
14	kg	O
15	IV	O
16	or	O
17	dopamine	O
18	,	O
19	5	O
20	to	O
21	12	O
22	micrograms	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	IV	O
28	.	O
1	<UNK>	O
2	use	O
3	of	O
4	<UNK>	O
5	to	O
6	<UNK>	O
7	<UNK>	O
8	after	O
9	<UNK>	O
10	failure	O
11	.	O
1	The	O
2	data	O
3	indicates	O
4	the	O
5	presence	O
6	of	O
7	5	O
8	-	O
9	<UNK>	B
10	<UNK>	O
11	receptors	O
12	in	O
13	the	O
14	bronchial	O
15	artery	O
16	of	O
17	these	O
18	species	O
19	.	O
1	<UNK>	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	<UNK>	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	O
15	<UNK>	B
16	activity	O
17	.	O
1	Thus	O
2	,	O
3	quantitative	O
4	analysis	O
5	of	O
6	<UNK>	O
7	-	O
8	201	O
9	uptake	O
10	and	O
11	<UNK>	O
12	provided	O
13	objective	O
14	evidence	O
15	for	O
16	improved	O
17	myocardial	O
18	perfusion	O
19	after	O
20	coronary	O
21	<UNK>	O
22	.	O
1	<UNK>	O
2	2	O
3	,	O
4	in	O
5	which	O
6	2	O
7	.	O
8	4	O
9	mg	O
10	/	O
11	kg	O
12	c	B
13	-	O
14	<UNK>	O
15	was	O
16	administered	O
17	immediately	O
18	before	O
19	X	O
20	-	O
21	ray	O
22	on	O
23	5	O
24	consecutive	O
25	days	O
26	produced	O
27	the	O
28	highest	O
29	degree	O
30	of	O
31	enhancement	O
32	of	O
33	radiation	O
34	effect	O
35	(	O
36	expressed	O
37	as	O
38	dose	O
39	-	O
40	effect	O
41	factor	O
42	);	O
43	and	O
44	the	O
45	next	O
46	<UNK>	O
47	enhancement	O
48	was	O
49	produced	O
50	by	O
51	12	O
52	mg	O
53	/	O
54	kg	O
55	c	B
56	-	O
57	<UNK>	O
58	administered	O
59	24	O
60	h	O
61	before	O
62	the	O
63	start	O
64	of	O
65	<UNK>	O
66	daily	O
67	radiotherapy	O
68	.	O
1	The	O
2	<UNK>	B
3	-	O
4	1	O
5	-	O
6	encoded	O
7	transcript	O
8	contains	O
9	three	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	two	O
15	of	O
16	which	O
17	are	O
18	located	O
19	in	O
20	the	O
21	<UNK>	O
22	-	O
23	nucleotide	O
24	leader	O
25	segment	O
26	<UNK>	O
27	the	O
28	<UNK>	B
29	-	O
30	1	O
31	coding	O
32	region	O
33	.	O
1	<UNK>	O
2	absorption	O
3	<UNK>	O
4	applied	O
5	to	O
6	<UNK>	O
7	expressed	O
8	E1A	B
9	proteins	O
10	revealed	O
11	that	O
12	the	O
13	<UNK>	O
14	-	O
15	amino	O
16	acid	O
17	protein	O
18	binds	O
19	one	O
20	zinc	O
21	ion	O
22	,	O
23	whereas	O
24	the	O
25	<UNK>	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	binds	O
31	no	O
32	zinc	O
33	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	is	O
6	an	O
7	important	O
8	improvement	O
9	,	O
10	and	O
11	in	O
12	some	O
13	cases	O
14	it	O
15	may	O
16	<UNK>	O
17	other	O
18	techniques	O
19	for	O
20	<UNK>	O
21	<UNK>	O
22	bleeding	O
23	.	O
1	A	O
2	rare	O
3	chronic	O
4	course	O
5	of	O
6	<UNK>	O
7	-	O
8	<UNK>	O
9	syndrome	O
10	associated	O
11	with	O
12	thrombosis	O
13	of	O
14	the	O
15	portal	O
16	vein	O
17	was	O
18	observed	O
19	in	O
20	a	O
21	30	O
22	-	O
23	year	O
24	-	O
25	old	O
26	male	O
27	patient	O
28	suffering	O
29	from	O
30	<UNK>	O
31	<UNK>	O
32	.	O
1	After	O
2	one	O
3	<UNK>	O
4	<UNK>	O
5	,	O
6	sleep	O
7	EEG	O
8	<UNK>	O
9	were	O
10	performed	O
11	during	O
12	three	O
13	consecutive	O
14	<UNK>	O
15	in	O
16	ten	O
17	drug	O
18	-	O
19	free	O
20	<UNK>	O
21	presenting	O
22	generalized	O
23	<UNK>	O
24	disorder	O
25	(	O
26	<UNK>	O
27	)	O
28	with	O
29	significant	O
30	depression	O
31	,	O
32	compared	O
33	with	O
34	a	O
35	age	O
36	-	O
37	and	O
38	sex	O
39	-	O
40	matched	O
41	group	O
42	of	O
43	patients	O
44	with	O
45	<UNK>	O
46	and	O
47	a	O
48	group	O
49	of	O
50	primary	O
51	major	O
52	<UNK>	O
53	disorder	O
54	(	O
55	<UNK>	O
56	)	O
57	patients	O
58	.	O
1	Evidence	O
2	for	O
3	a	O
4	role	O
5	of	O
6	endogenous	O
7	<UNK>	B
8	-	O
9	releasing	B
10	factor	O
11	in	O
12	cold	O
13	,	O
14	<UNK>	O
15	,	O
16	<UNK>	O
17	,	O
18	and	O
19	<UNK>	O
20	stress	O
21	.	O
1	<UNK>	O
2	33	O
3	-	O
4	<UNK>	O
5	,	O
6	a	O
7	methionine	O
8	-	O
9	<UNK>	B
10	<UNK>	O
11	,	O
12	suppressed	O
13	plasma	O
14	ACTH	B
15	to	O
16	85	O
17	%	O
18	of	O
19	basal	O
20	level	O
21	,	O
22	while	O
23	<UNK>	O
24	(	O
25	<UNK>	O
26	-	O
27	<UNK>	O
28	)	O
29	caused	O
30	no	O
31	significant	O
32	change	O
33	.	O
1	Examination	O
2	of	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	<UNK>	O
8	<UNK>	O
9	M	O
10	gene	O
11	product	O
12	reveals	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	hydrophobic	O
18	sequences	O
19	including	O
20	a	O
21	19	O
22	-	O
23	amino	O
24	acid	O
25	,	O
26	carboxy	O
27	-	O
28	proximal	O
29	,	O
30	hydrophobic	O
31	region	O
32	(	O
33	G2	O
34	).	O
1	The	O
2	<UNK>	O
3	kDa	O
4	precursor	O
5	is	O
6	<UNK>	O
7	<UNK>	O
8	(	O
9	t	O
10	1	O
11	/	O
12	2	O
13	=	O
14	2	O
15	h	O
16	)	O
17	by	O
18	proteolytic	O
19	processing	O
20	into	O
21	a	O
22	125	O
23	kDa	O
24	(	O
25	alpha	O
26	<UNK>	O
27	and	O
28	83	O
29	kDa	O
30	(	O
31	beta	O
32	<UNK>	O
33	species	O
34	.	O
1	At	O
2	<UNK>	O
3	<UNK>	O
4	for	O
5	transformation	O
6	,	O
7	<UNK>	O
8	cells	O
9	contain	O
10	<UNK>	B
11	produced	O
12	from	O
13	the	O
14	4	O
15	.	O
16	0	O
17	-	O
18	kilobase	O
19	(	O
20	kb	O
21	)	O
22	viral	O
23	RNA	O
24	genome	O
25	and	O
26	<UNK>	B
27	-	O
28	<UNK>	B
29	translated	O
30	from	O
31	a	O
32	3	O
33	.	O
34	5	O
35	-	O
36	kb	O
37	spliced	O
38	mRNA	O
39	.	O
1	The	O
2	<UNK>	B
3	and	O
4	<UNK>	B
5	genes	O
6	are	O
7	transcribed	O
8	<UNK>	O
9	from	O
10	initiation	O
11	sites	O
12	that	O
13	are	O
14	separated	O
15	by	O
16	only	O
17	<UNK>	O
18	bp	O
19	.	O
1	Comparison	O
2	of	O
3	sequences	O
4	of	O
5	<UNK>	O
6	and	O
7	bovine	O
8	,	O
9	rat	O
10	and	O
11	guinea	O
12	-	O
13	pig	O
14	alpha	O
15	<UNK>	B
16	-	O
17	casein	B
18	mRNAs	O
19	has	O
20	revealed	O
21	a	O
22	greater	O
23	homology	O
24	in	O
25	the	O
26	3	O
27	'	O
28	and	O
29	especially	O
30	5	O
31	'	O
32	non	O
33	coding	O
34	regions	O
35	.	O
1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	<UNK>	O
6	bp	O
7	of	O
8	cloned	O
9	R	O
10	.	O
11	<UNK>	O
12	chromosomal	O
13	DNA	O
14	,	O
15	including	O
16	the	O
17	three	O
18	structural	O
19	genes	O
20	<UNK>	B
21	,	O
22	<UNK>	B
23	and	O
24	<UNK>	B
25	has	O
26	been	O
27	determined	O
28	.	O
1	Two	O
2	copies	O
3	of	O
4	the	O
5	72	O
6	-	O
7	bp	O
8	repeat	O
9	provided	O
10	efficient	O
11	activation	O
12	of	O
13	gene	O
14	expression	O
15	.	O
1	<UNK>	O
2	(	O
3	3	O
4	mg	O
5	/	O
6	kg	O
7	)	O
8	generalized	O
9	to	O
10	<UNK>	O
11	11	O
12	-	O
13	<UNK>	O
14	whereas	O
15	the	O
16	structurally	O
17	related	O
18	<UNK>	O
19	5	O
20	-	O
21	<UNK>	O
22	(	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	and	O
28	30	O
29	mg	O
30	/	O
31	kg	O
32	)	O
33	did	O
34	not	O
35	.	O
1	The	O
2	<UNK>	O
3	5	O
4	'-	O
5	<UNK>	O
6	-	O
7	3	O
8	',	O
9	thought	O
10	to	O
11	be	O
12	important	O
13	for	O
14	<UNK>	O
15	activity	O
16	,	O
17	not	O
18	only	O
19	was	O
20	found	O
21	in	O
22	this	O
23	sequence	O
24	and	O
25	in	O
26	the	O
27	5	O
28	'-	O
29	flanking	O
30	region	O
31	,	O
32	but	O
33	also	O
34	was	O
35	present	O
36	twice	O
37	in	O
38	the	O
39	3	O
40	'	O
41	end	O
42	of	O
43	the	O
44	gene	O
45	that	O
46	did	O
47	not	O
48	show	O
49	specific	O
50	receptor	O
51	binding	O
52	.	O
1	<UNK>	O
2	of	O
3	specific	O
4	cellular	O
5	genes	O
6	from	O
7	the	O
8	chimeric	O
9	viral	O
10	-	O
11	cellular	O
12	transcripts	O
13	seems	O
14	to	O
15	be	O
16	<UNK>	O
17	.	O
1	<UNK>	O
2	of	O
3	4	O
4	bp	O
5	reduced	O
6	SV40	O
7	early	O
8	promoter	O
9	-	O
10	dependent	O
11	chloramphenicol	B
12	acetyltransferase	I
13	(	O
14	CAT	B
15	)	O
16	expression	O
17	by	O
18	six	O
19	-	O
20	to	O
21	<UNK>	O
22	.	O
1	Two	O
2	mutants	O
3	,	O
4	each	O
5	<UNK>	O
6	of	O
7	a	O
8	separate	O
9	<UNK>	O
10	complementation	O
11	group	O
12	,	O
13	have	O
14	been	O
15	analyzed	O
16	.	O
1	<UNK>	O
2	function	O
3	of	O
4	a	O
5	positively	O
6	regulated	O
7	promoter	O
8	reveals	O
9	new	O
10	sequences	O
11	essential	O
12	for	O
13	activity	O
14	.	O
1	ACTH	B
2	release	O
3	is	O
4	transiently	O
5	suppressed	O
6	in	O
7	some	O
8	children	O
9	after	O
10	exogenous	O
11	ACTH	B
12	treatment	O
13	.	O
1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	upstream	O
7	promoter	O
8	element	O
9	of	O
10	the	O
11	yeast	O
12	<UNK>	B
13	gene	O
14	consists	O
15	of	O
16	these	O
17	identical	O
18	sequence	O
19	motifs	O
20	.	O
1	One	O
2	group	O
3	of	O
4	six	O
5	cDNA	O
6	clones	O
7	was	O
8	derived	O
9	from	O
10	a	O
11	2	O
12	.	O
13	9	O
14	-	O
15	kilobase	O
16	early	O
17	transcript	O
18	encoded	O
19	by	O
20	the	O
21	<UNK>	O
22	repeat	O
23	element	O
24	and	O
25	showed	O
26	restriction	O
27	site	O
28	<UNK>	O
29	for	O
30	the	O
31	enzyme	O
32	<UNK>	B
33	.	O
1	<UNK>	O
2	produced	O
3	a	O
4	dose	O
5	-	O
6	dependent	O
7	<UNK>	O
8	followed	O
9	by	O
10	<UNK>	O
11	.	O
1	The	O
2	presence	O
3	of	O
4	circulating	O
5	platelet	O
6	<UNK>	O
7	and	O
8	elevated	O
9	levels	O
10	of	O
11	<UNK>	B
12	A	O
13	(	O
14	a	O
15	cleavage	O
16	product	O
17	of	O
18	fibrin	B
19	)	O
20	suggests	O
21	that	O
22	platelet	O
23	activation	O
24	and	O
25	fibrin	B
26	<UNK>	O
27	may	O
28	play	O
29	a	O
30	role	O
31	in	O
32	the	O
33	pathogenesis	O
34	of	O
35	this	O
36	disorder	O
37	.	O
1	This	O
2	<UNK>	O
3	these	O
4	compounds	O
5	<UNK>	O
6	as	O
7	<UNK>	O
8	for	O
9	these	O
10	and	O
11	other	O
12	<UNK>	O
13	in	O
14	-	O
15	vivo	O
16	and	O
17	in	O
18	-	O
19	vitro	O
20	.	O
1	The	O
2	relationship	O
3	between	O
4	primary	O
5	malignant	O
6	lymphoma	O
7	of	O
8	the	O
9	thyroid	O
10	and	O
11	chronic	O
12	<UNK>	O
13	is	O
14	discussed	O
15	.	O
1	However	O
2	,	O
3	excretion	O
4	of	O
5	6	O
6	-	O
7	<UNK>	O
8	-	O
9	prostaglandin	O
10	F1	O
11	alpha	O
12	was	O
13	further	O
14	reduced	O
15	in	O
16	the	O
17	<UNK>	O
18	who	O
19	used	O
20	oral	O
21	<UNK>	O
22	(	O
23	<UNK>	O
24	+/-	O
25	20	O
26	to	O
27	86	O
28	+/-	O
29	9	O
30	ng	O
31	/	O
32	<UNK>	O
33	of	O
34	creatinine	O
35	,	O
36	p	O
37	less	O
38	than	O
39	0	O
40	.	O
41	05	O
42	).	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	<UNK>	O
5	in	O
6	a	O
7	renal	O
8	transplant	O
9	during	O
10	<UNK>	O
11	A	O
12	therapy	O
13	.	O
1	<UNK>	O
2	of	O
3	the	O
4	<UNK>	O
5	<UNK>	O
6	in	O
7	<UNK>	O
8	<UNK>	O
9	.	O
1	During	O
2	<UNK>	O
3	the	O
4	<UNK>	O
5	was	O
6	<UNK>	O
7	and	O
8	a	O
9	<UNK>	O
10	flow	O
11	of	O
12	50	O
13	%	O
14	O2	O
15	at	O
16	4	O
17	-	O
18	5	O
19	l	O
20	/	O
21	min	O
22	was	O
23	<UNK>	O
24	through	O
25	the	O
26	side	O
27	<UNK>	O
28	of	O
29	a	O
30	small	O
31	catheter	O
32	whose	O
33	tip	O
34	was	O
35	positioned	O
36	1	O
37	cm	O
38	<UNK>	O
39	of	O
40	the	O
41	<UNK>	O
42	.	O
1	Significant	O
2	treatment	O
3	-	O
4	related	O
5	problems	O
6	appeared	O
7	during	O
8	the	O
9	second	O
10	<UNK>	O
11	in	O
12	5	O
13	patients	O
14	,	O
15	including	O
16	one	O
17	chest	O
18	wall	O
19	sarcoma	O
20	;	O
21	all	O
22	of	O
23	these	O
24	patients	O
25	had	O
26	received	O
27	at	O
28	least	O
29	60	O
30	Gy	O
31	to	O
32	breast	O
33	and	O
34	regional	O
35	nodal	O
36	areas	O
37	.	O
1	Clinical	O
2	and	O
3	biological	O
4	correlates	O
5	of	O
6	<UNK>	O
7	states	O
8	.	O
1	Effects	O
2	of	O
3	long	O
4	-	O
5	term	O
6	<UNK>	O
7	<UNK>	O
8	on	O
9	<UNK>	B
10	release	O
11	in	O
12	dogs	O
13	.	O
1	Of	O
2	7	O
3	patients	O
4	treated	O
5	with	O
6	cyclophosphamide	O
7	,	O
8	<UNK>	O
9	,	O
10	<UNK>	O
11	and	O
12	cisplatin	O
13	(	O
14	<UNK>	O
15	-	O
16	5	O
17	),	O
18	6	O
19	had	O
20	<UNK>	O
21	disease	O
22	,	O
23	of	O
24	whom	O
25	5	O
26	yielded	O
27	a	O
28	response	O
29	(	O
30	2	O
31	complete	O
32	responses	O
33	for	O
34	19	O
35	+	O
36	and	O
37	40	O
38	months	O
39	and	O
40	3	O
41	partial	O
42	responses	O
43	for	O
44	4	O
45	,	O
46	7	O
47	and	O
48	8	O
49	months	O
50	).	O
1	The	O
2	genetic	O
3	basis	O
4	for	O
5	the	O
6	expression	O
7	of	O
8	a	O
9	latent	O
10	<UNK>	O
11	<UNK>	O
12	in	O
13	the	O
14	rabbit	O
15	was	O
16	investigated	O
17	.	O
1	HDL	B
2	-	O
3	cholesterol	O
4	(+	O
5	6	O
6	%,	O
7	P	O
8	less	O
9	than	O
10	.	O
11	01	O
12	)	O
13	and	O
14	<UNK>	B
15	A	O
16	-	O
17	I	O
18	(+	O
19	6	O
20	%,	O
21	P	O
22	less	O
23	than	O
24	.	O
25	01	O
26	)	O
27	concentrations	O
28	increased	O
29	significantly	O
30	only	O
31	in	O
32	the	O
33	young	O
34	.	O
1	Of	O
2	49	O
3	receptors	O
4	which	O
5	<UNK>	O
6	in	O
7	phase	O
8	with	O
9	ventilation	O
10	,	O
11	13	O
12	<UNK>	O
13	like	O
14	mammalian	O
15	rapidly	O
16	<UNK>	O
17	pulmonary	O
18	stretch	O
19	receptors	O
20	,	O
21	19	O
22	like	O
23	mammalian	O
24	<UNK>	O
25	<UNK>	O
26	pulmonary	O
27	stretch	O
28	receptors	O
29	(	O
30	<UNK>	O
31	),	O
32	and	O
33	17	O
34	like	O
35	avian	O
36	<UNK>	O
37	CO2	O
38	-	O
39	sensitive	O
40	<UNK>	O
41	(	O
42	<UNK>	O
43	).	O
1	<UNK>	O
2	<UNK>	O
3	had	O
4	a	O
5	larger	O
6	number	O
7	of	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	wide	O
12	<UNK>	O
13	in	O
14	baseline	O
15	for	O
16	<UNK>	O
17	time	O
18	,	O
19	<UNK>	O
20	time	O
21	,	O
22	and	O
23	<UNK>	O
24	.	O
1	<UNK>	O
2	.	O
1	The	O
2	platelet	O
3	adhesion	O
4	rate	O
5	on	O
6	these	O
7	<UNK>	O
8	were	O
9	tested	O
10	<UNK>	O
11	the	O
12	<UNK>	O
13	of	O
14	the	O
15	<UNK>	O
16	of	O
17	the	O
18	basic	O
19	-	O
20	<UNK>	O
21	<UNK>	O
22	(	O
23	<UNK>	O
24	),	O
25	<UNK>	O
26	(	O
27	<UNK>	O
28	),	O
29	and	O
30	<UNK>	O
31	(	O
32	<UNK>	O
33	)	O
34	in	O
35	two	O
36	different	O
37	<UNK>	O
38	test	O
39	<UNK>	O
40	.	O
1	<UNK>	O
2	treatment	O
3	of	O
4	bladder	O
5	carcinoma	O
6	by	O
7	partial	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	of	O
5	solutions	O
6	of	O
7	the	O
8	appropriate	O
9	boundary	O
10	value	O
11	problems	O
12	are	O
13	established	O
14	,	O
15	in	O
16	the	O
17	case	O
18	of	O
19	small	O
20	<UNK>	O
21	coefficients	O
22	and	O
23	transport	O
24	rates	O
25	,	O
26	or	O
27	large	O
28	diffusion	O
29	coefficients	O
30	and	O
31	small	O
32	resistance	O
33	to	O
34	flow	O
35	constants	O
36	.	O
1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	O
7	-	O
8	kDa	O
9	nuclear	O
10	pore	O
11	glycoprotein	O
12	shows	O
13	little	O
14	similarity	O
15	to	O
16	other	O
17	characterized	O
18	proteins	O
19	and	O
20	<UNK>	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	O
31	pore	O
32	<UNK>	O
33	.	O
1	The	O
2	pathogenesis	O
3	of	O
4	<UNK>	O
5	'	O
6	s	O
7	<UNK>	O
1	The	O
2	median	O
3	survival	O
4	is	O
5	not	O
6	reached	O
7	with	O
8	a	O
9	median	O
10	follow	O
11	-	O
12	up	O
13	time	O
14	of	O
15	9	O
16	.	O
17	6	O
18	years	O
19	.	O
1	<UNK>	O
2	evaluation	O
3	of	O
4	various	O
5	methods	O
6	of	O
7	determining	O
8	markers	O
9	of	O
10	fetal	O
11	<UNK>	O
12	in	O
13	<UNK>	O
14	fluid	O
1	<UNK>	O
2	was	O
3	characterized	O
4	by	O
5	rapid	O
6	improvement	O
7	such	O
8	that	O
9	all	O
10	measured	O
11	parameters	O
12	<UNK>	O
13	by	O
14	1	O
15	week	O
16	,	O
17	except	O
18	for	O
19	cross	O
20	-	O
21	<UNK>	O
22	cardiac	O
23	area	O
24	which	O
25	remained	O
26	<UNK>	O
27	up	O
28	to	O
29	4	O
30	weeks	O
31	(	O
32	14	O
33	+/-	O
34	3	O
35	cm2	O
36	,	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	05	O
43	versus	O
44	control	O
45	<UNK>	O
46	ABSTRACT	O
47	TRUNCATED	O
48	AT	O
49	250	O
50	WORDS	O
51	)	O
1	<UNK>	O
2	of	O
3	0	O
4	.	O
5	1	O
6	or	O
7	0	O
8	.	O
9	2	O
10	M	O
11	sodium	O
12	<UNK>	O
13	phosphate	O
14	in	O
15	the	O
16	<UNK>	O
17	solutions	O
18	resulted	O
19	in	O
20	a	O
21	decrease	O
22	in	O
23	the	O
24	<UNK>	O
25	-	O
26	life	O
27	of	O
28	diltiazem	O
29	.	O
1	<UNK>	O
2	had	O
3	a	O
4	past	O
5	history	O
6	of	O
7	<UNK>	O
8	infections	O
9	;	O
10	neither	O
11	did	O
12	any	O
13	have	O
14	<UNK>	O
15	.	O
1	<UNK>	O
2	patients	O
3	were	O
4	in	O
5	the	O
6	<UNK>	O
7	disease	O
8	group	O
9	;	O
10	13	O
11	were	O
12	detected	O
13	by	O
14	SPECT	O
15	and	O
16	10	O
17	by	O
18	<UNK>	O
19	.	O
1	In	O
2	one	O
3	of	O
4	these	O
5	tumors	O
6	the	O
7	observed	O
8	<UNK>	O
9	was	O
10	not	O
11	due	O
12	to	O
13	the	O
14	insertion	O
15	of	O
16	an	O
17	intact	O
18	<UNK>	O
19	<UNK>	O
20	.	O
1	Finally	O
2	,	O
3	over	O
4	a	O
5	similar	O
6	range	O
7	of	O
8	<UNK>	O
9	,	O
10	oxygen	O
11	extraction	O
12	was	O
13	greater	O
14	in	O
15	patients	O
16	with	O
17	<UNK>	O
18	compared	O
19	to	O
20	patients	O
21	with	O
22	non	O
23	-	O
24	<UNK>	O
25	respiratory	O
26	failure	O
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	67	O
34	and	O
35	<UNK>	O
36	=	O
37	-	O
38	0	O
39	.	O
40	62	O
41	vs	O
42	r	O
43	=	O
44	-	O
45	0	O
46	.	O
47	45	O
48	and	O
49	<UNK>	O
50	=	O
51	-	O
52	0	O
53	.	O
54	35	O
55	;	O
56	p	O
57	less	O
58	than	O
59	0	O
60	.	O
61	05	O
62	).	O
1	<UNK>	O
2	,	O
3	moderate	O
4	<UNK>	O
5	,	O
6	<UNK>	O
7	<UNK>	O
8	,	O
9	arterial	O
10	<UNK>	O
11	and	O
12	moderate	O
13	venous	O
14	<UNK>	O
15	<UNK>	O
16	to	O
17	play	O
18	a	O
19	partial	O
20	role	O
21	of	O
22	organic	O
23	<UNK>	O
24	or	O
25	cofactor	O
26	,	O
27	the	O
28	sexual	O
29	consequences	O
30	of	O
31	which	O
32	are	O
33	amplified	O
34	by	O
35	<UNK>	O
36	factors	O
37	,	O
38	partly	O
39	secondary	O
40	to	O
41	the	O
42	initial	O
43	sexual	O
44	<UNK>	O
45	.	O
1	<UNK>	O
2	and	O
3	H	O
4	.	O
1	In	O
2	contrast	O
3	,	O
4	we	O
5	observed	O
6	high	O
7	concentrations	O
8	in	O
9	29	O
10	of	O
11	75	O
12	patients	O
13	with	O
14	tumors	O
15	of	O
16	the	O
17	central	O
18	nervous	O
19	system	O
20	,	O
21	especially	O
22	in	O
23	<UNK>	O
24	(	O
25	6	O
26	/	O
27	9	O
28	),	O
29	<UNK>	O
30	(	O
31	9	O
32	/	O
33	23	O
34	),	O
35	and	O
36	<UNK>	O
37	(	O
38	5	O
39	/	O
40	5	O
41	).	O
1	<UNK>	O
2	after	O
3	anterior	O
4	<UNK>	O
5	and	O
6	<UNK>	O
7	<UNK>	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	of	O
5	<UNK>	O
6	<UNK>	O
7	in	O
8	<UNK>	O
9	initiated	O
10	the	O
11	<UNK>	O
12	<UNK>	O
13	'	O
14	s	O
15	<UNK>	O
16	Study	O
17	(	O
18	<UNK>	O
19	81	O
20	)	O
21	using	O
22	a	O
23	four	O
24	-	O
25	drug	O
26	combination	O
27	of	O
28	chemotherapy	O
29	prior	O
30	to	O
31	<UNK>	O
32	local	O
33	control	O
34	with	O
35	surgery	O
36	and	O
37	/	O
38	or	O
39	radiation	O
40	.	O
1	Since	O
2	high	O
3	levels	O
4	of	O
5	immunoglobulin	B
6	G	O
7	were	O
8	demonstrated	O
9	against	O
10	the	O
11	surface	O
12	of	O
13	the	O
14	<UNK>	O
15	after	O
16	immunization	O
17	,	O
18	<UNK>	O
19	transfer	O
20	experiments	O
21	were	O
22	initiated	O
23	.	O
1	Fifty	O
2	-	O
3	four	O
4	patients	O
5	were	O
6	divided	O
7	into	O
8	groups	O
9	according	O
10	to	O
11	their	O
12	clinical	O
13	presentation	O
14	;	O
15	seven	O
16	asymptomatic	O
17	volunteers	O
18	,	O
19	20	O
20	patients	O
21	with	O
22	duodenal	O
23	-	O
24	gastric	O
25	<UNK>	O
26	<UNK>	O
27	(	O
28	<UNK>	O
29	),	O
30	16	O
31	patients	O
32	with	O
33	recurrent	O
34	ulcers	O
35	of	O
36	the	O
37	duodenal	O
38	<UNK>	O
39	(	O
40	<UNK>	O
41	),	O
42	and	O
43	11	O
44	patients	O
45	with	O
46	<UNK>	O
47	'	O
48	s	O
49	disease	O
50	.	O
1	No	O
2	previous	O
3	studies	O
4	have	O
5	determined	O
6	the	O
7	<UNK>	O
8	-	O
9	dynamics	O
10	of	O
11	intravenous	O
12	<UNK>	O
13	when	O
14	administered	O
15	in	O
16	a	O
17	dose	O
18	of	O
19	15	O
20	mg	O
21	/	O
22	kg	O
23	and	O
24	at	O
25	a	O
26	rate	O
27	of	O
28	50	O
29	mg	O
30	/	O
31	min	O
32	,	O
33	as	O
34	is	O
35	common	O
36	practice	O
37	during	O
38	<UNK>	O
39	testing	O
40	.	O
1	High	O
2	concentrations	O
3	of	O
4	tumor	O
5	-	O
6	associated	O
7	<UNK>	B
8	inhibitor	O
9	in	O
10	<UNK>	O
11	patients	O
12	.	O
1	In	O
2	the	O
3	chicken	O
4	liver	O
5	,	O
6	levels	O
7	of	O
8	chicken	O
9	<UNK>	O
10	mRNA	O
11	were	O
12	rapidly	O
13	induced	O
14	by	O
15	<UNK>	O
16	(	O
17	<UNK>	O
18	+,	O
19	<UNK>	O
20	+,	O
21	<UNK>	O
22	<UNK>	O
23	<UNK>	O
24	and	O
25	<UNK>	O
26	.	O
1	<UNK>	O
2	estimates	O
3	for	O
4	these	O
5	organs	O
6	were	O
7	2	O
8	.	O
9	3	O
10	+/-	O
11	1	O
12	.	O
13	1	O
14	and	O
15	2	O
16	.	O
17	3	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	<UNK>	O
23	<UNK>	O
24	02	O
25	+/-	O
26	.	O
27	01	O
28	Gy	O
29	),	O
30	respectively	O
31	,	O
32	with	O
33	a	O
34	whole	O
35	-	O
36	body	O
37	<UNK>	O
38	of	O
39	0	O
40	.	O
41	28	O
42	<UNK>	O
43	<UNK>	O
44	<UNK>	O
45	Gy	O
46	).	O
1	Nucleotide	O
2	sequencing	O
3	indicates	O
4	that	O
5	this	O
6	E1	O
7	alpha	O
8	cDNA	O
9	clone	O
10	is	O
11	<UNK>	O
12	base	O
13	pairs	O
14	(	O
15	bp	O
16	)	O
17	in	O
18	length	O
19	with	O
20	an	O
21	open	O
22	reading	O
23	frame	O
24	of	O
25	<UNK>	O
26	bp	O
27	and	O
28	a	O
29	3	O
30	'-	O
31	untranslated	O
32	region	O
33	of	O
34	<UNK>	O
35	bp	O
36	.	O
1	<UNK>	O
2	interest	O
3	of	O
4	such	O
5	studies	O
6	is	O
7	limited	O
8	since	O
9	the	O
10	pharmacokinetic	O
11	parameters	O
12	are	O
13	<UNK>	O
14	evaluated	O
15	in	O
16	man	O
17	during	O
18	phase	O
19	I	O
20	trials	O
21	.	O
1	<UNK>	O
2	on	O
3	the	O
4	location	O
5	and	O
6	size	O
7	of	O
8	the	O
9	mass	O
10	,	O
11	a	O
12	wide	O
13	range	O
14	of	O
15	clinical	O
16	<UNK>	O
17	is	O
18	associated	O
19	with	O
20	the	O
21	lesion	O
22	.	O
1	<UNK>	O
2	analysis	O
3	of	O
4	the	O
5	degrees	O
6	of	O
7	secondary	O
8	spinal	O
9	cord	O
10	<UNK>	O
11	was	O
12	performed	O
13	in	O
14	group	O
15	-	O
16	1	O
17	dogs	O
18	by	O
19	measuring	O
20	and	O
21	comparing	O
22	ratios	O
23	of	O
24	the	O
25	<UNK>	O
26	to	O
27	the	O
28	<UNK>	O
29	<UNK>	O
30	of	O
31	the	O
32	<UNK>	O
33	spinal	O
34	cord	O
35	<UNK>	O
36	from	O
37	<UNK>	O
38	within	O
39	(	O
40	<UNK>	O
41	to	O
42	L1	O
43	)	O
44	and	O
45	out	O
46	of	O
47	(	O
48	<UNK>	O
49	,	O
50	<UNK>	O
51	-	O
52	12	O
53	,	O
54	L1	O
55	-	O
56	2	O
57	,	O
58	and	O
59	L2	O
60	)	O
61	the	O
62	region	O
63	of	O
64	surgical	O
65	<UNK>	O
66	.	O
1	The	O
2	state	O
3	of	O
4	the	O
5	liver	O
6	in	O
7	generalized	O
8	forms	O
9	of	O
10	<UNK>	O
11	infection	O
1	<UNK>	O
2	<UNK>	O
3	can	O
4	<UNK>	O
5	and	O
6	be	O
7	lethal	O
8	.	O
1	<UNK>	O
2	<UNK>	O
3	induced	O
4	a	O
5	significant	O
6	change	O
7	in	O
8	the	O
9	<UNK>	O
10	<UNK>	O
11	of	O
12	the	O
13	<UNK>	O
14	<UNK>	O
15	by	O
16	increasing	O
17	the	O
18	minimum	O
19	diameter	O
20	(	O
21	12	O
22	%)	O
23	without	O
24	any	O
25	significant	O
26	alterations	O
27	in	O
28	cortical	O
29	area	O
30	,	O
31	density	O
32	,	O
33	mineral	O
34	,	O
35	and	O
36	collagen	B
37	concentrations	O
38	.	O
1	<UNK>	O
2	function	O
3	tests	O
4	were	O
5	performed	O
6	on	O
7	300	O
8	<UNK>	O
9	,	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	of	O
3	the	O
4	<UNK>	O
5	for	O
6	Clinical	O
7	<UNK>	O
8	<UNK>	O
9	.	O
1	<UNK>	O
2	heart	O
3	disease	O
4	,	O
5	age	O
6	of	O
7	more	O
8	than	O
9	75	O
10	years	O
11	,	O
12	and	O
13	the	O
14	fact	O
15	that	O
16	the	O
17	patient	O
18	was	O
19	a	O
20	<UNK>	O
21	were	O
22	independent	O
23	predictors	O
24	of	O
25	poor	O
26	cardiac	O
27	function	O
28	.	O
1	Moreover	O
2	,	O
3	unlike	O
4	control	O
5	rats	O
6	<UNK>	O
7	animals	O
8	did	O
9	not	O
10	show	O
11	<UNK>	O
12	to	O
13	the	O
14	highest	O
15	concentrations	O
16	of	O
17	<UNK>	O
18	solutions	O
19	.	O
1	We	O
2	conclude	O
3	that	O
4	<UNK>	O
5	clearance	O
6	of	O
7	S	O
8	.	O
9	aureus	O
10	from	O
11	a	O
12	site	O
13	<UNK>	O
14	to	O
15	<UNK>	O
16	was	O
17	delayed	O
18	when	O
19	compared	O
20	to	O
21	a	O
22	<UNK>	O
23	-	O
24	<UNK>	O
25	site	O
26	.	O
1	<UNK>	O
2	,	O
3	c	B
4	and	O
5	CT	O
6	(	O
7	<UNK>	O
8	to	O
9	the	O
10	initial	O
11	lung	O
12	mass	O
13	)	O
14	decreased	O
15	<UNK>	O
16	with	O
17	<UNK>	O
18	in	O
19	lung	O
20	mass	O
21	%	O
22	delta	O
23	<UNK>	O
24	,	O
25	c	B
26	=	O
27	1	O
28	.	O
29	26	O
30	-	O
31	0	O
32	.	O
33	98	O
34	%	O
35	mass	O
36	removed	O
37	(	O
38	r	O
39	=	O
40	0	O
41	.	O
42	90	O
43	,	O
44	P	O
45	less	O
46	than	O
47	0	O
48	.	O
49	01	O
50	)	O
51	and	O
52	%	O
53	delta	O
54	CT	O
55	=	O
56	-	O
57	3	O
58	.	O
59	99	O
60	-	O
61	0	O
62	.	O
63	98	O
64	%	O
65	mass	O
66	removed	O
67	(	O
68	r	O
69	=	O
70	0	O
71	.	O
72	82	O
73	,	O
74	P	O
75	less	O
76	than	O
77	0	O
78	.	O
79	01	O
80	)	O
81	relationships	O
82	that	O
83	were	O
84	not	O
85	altered	O
86	by	O
87	blocker	O
88	pretreatment	O
89	.(	O
90	ABSTRACT	O
91	TRUNCATED	O
92	AT	O
93	250	O
94	WORDS	O
95	)	O
1	From	O
2	these	O
3	results	O
4	,	O
5	it	O
6	is	O
7	concluded	O
8	that	O
9	<UNK>	O
10	has	O
11	clear	O
12	<UNK>	O
13	properties	O
14	which	O
15	are	O
16	not	O
17	due	O
18	to	O
19	adrenergic	O
20	or	O
21	calcium	O
22	entry	O
23	mechanisms	O
24	and	O
25	that	O
26	there	O
27	are	O
28	differences	O
29	in	O
30	the	O
31	<UNK>	O
32	effects	O
33	of	O
34	<UNK>	O
35	with	O
36	respect	O
37	to	O
38	different	O
39	vascular	O
40	<UNK>	O
41	.	O
1	After	O
2	a	O
3	baseline	O
4	study	O
5	,	O
6	<UNK>	O
7	syndrome	O
8	was	O
9	<UNK>	O
10	by	O
11	stimulation	O
12	at	O
13	seven	O
14	different	O
15	sites	O
16	around	O
17	the	O
18	base	O
19	of	O
20	the	O
21	<UNK>	O
22	,	O
23	and	O
24	<UNK>	O
25	'	O
26	s	O
27	were	O
28	obtained	O
29	.	O
1	A	O
2	<UNK>	O
3	<UNK>	O
4	of	O
5	<UNK>	O
6	'	O
7	s	O
8	(	O
9	<UNK>	O
10	,	O
11	<UNK>	O
12	)	O
13	model	O
14	with	O
15	<UNK>	O
16	<UNK>	O
17	(	O
18	<UNK>	O
19	)	O
20	was	O
21	<UNK>	O
22	.	O
1	The	O
2	<UNK>	O
3	of	O
4	the	O
5	defects	O
6	in	O
7	<UNK>	O
8	or	O
9	<UNK>	O
10	region	O
11	was	O
12	80	O
13	%	O
14	in	O
15	single	O
16	-	O
17	position	O
18	scans	O
19	in	O
20	stress	O
21	studies	O
22	.	O
1	These	O
2	data	O
3	should	O
4	be	O
5	useful	O
6	in	O
7	developing	O
8	<UNK>	O
9	for	O
10	<UNK>	O
11	detection	O
12	and	O
13	<UNK>	O
14	diagnosis	O
15	of	O
16	11	O
17	beta	O
18	-	O
19	hydroxylase	B
20	deficiency	O
21	,	O
22	the	O
23	second	O
24	most	O
25	frequent	O
26	cause	O
27	of	O
28	congenital	O
29	adrenal	O
30	hyperplasia	O
31	.	O
1	<UNK>	O
2	is	O
3	the	O
4	<UNK>	O
5	<UNK>	O
6	and	O
7	<UNK>	O
8	<UNK>	O
9	<UNK>	O
10	for	O
11	a	O
12	<UNK>	O
13	<UNK>	O
14	synthesized	O
15	from	O
16	1	O
17	-	O
18	<UNK>	O
19	with	O
20	3	O
21	-	O
22	5	O
23	%	O
24	<UNK>	O
25	as	O
26	the	O
27	source	O
28	of	O
29	residual	O
30	double	O
31	<UNK>	O
32	for	O
33	<UNK>	O
34	.	O
1	<UNK>	O
2	phage	O
3	-	O
4	plasmid	O
5	expression	O
6	vectors	O
7	were	O
8	constructed	O
9	from	O
10	<UNK>	O
11	/	O
12	19	O
13	plasmids	O
14	by	O
15	cloning	O
16	a	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	(	O
22	<UNK>	O
23	)	O
24	origin	O
25	of	O
26	replication	O
27	from	O
28	bacteriophage	O
29	<UNK>	O
30	and	O
31	<UNK>	O
32	a	O
33	bacteriophage	O
34	T7	O
35	promoter	O
36	within	O
37	the	O
38	beta	O
39	-	O
40	galactosidase	B
41	gene	O
42	.	O
1	Neither	O
2	ethanol	O
3	nor	O
4	estrogen	O
5	has	O
6	been	O
7	shown	O
8	to	O
9	cause	O
10	<UNK>	B
11	-	O
12	deficiency	O
13	in	O
14	animals	O
15	.	O
1	Although	O
2	not	O
3	common	O
4	,	O
5	the	O
6	disorder	O
7	is	O
8	the	O
9	most	O
10	frequently	O
11	diagnosed	O
12	<UNK>	O
13	of	O
14	<UNK>	O
15	metabolism	O
16	in	O
17	many	O
18	<UNK>	O
19	,	O
20	and	O
21	further	O
22	<UNK>	O
23	into	O
24	its	O
25	unusual	O
26	pathogenesis	O
27	may	O
28	<UNK>	O
29	the	O
30	<UNK>	O
31	effects	O
32	of	O
33	the	O
34	4	O
35	<UNK>	O
36	agents	O
37	.	O
1	Five	O
2	out	O
3	of	O
4	eight	O
5	consecutive	O
6	cases	O
7	with	O
8	initial	O
9	symptoms	O
10	of	O
11	a	O
12	'	O
13	<UNK>	O
14	<UNK>	O
15	'	O
16	were	O
17	identified	O
18	as	O
19	malignant	O
20	<UNK>	O
21	(	O
22	<UNK>	O
23	sarcoma	O
24	)	O
25	which	O
26	within	O
27	5	O
28	months	O
29	to	O
30	4	O
31	years	O
32	led	O
33	to	O
34	<UNK>	O
35	and	O
36	death	O
37	.	O
1	In	O
2	a	O
3	<UNK>	O
4	system	O
5	a	O
6	protein	O
7	with	O
8	an	O
9	<UNK>	O
10	molecular	O
11	weight	O
12	of	O
13	36	O
14	,	O
15	000	O
16	was	O
17	synthesized	O
18	.	O
1	This	O
2	means	O
3	that	O
4	the	O
5	loss	O
6	of	O
7	<UNK>	O
8	must	O
9	be	O
10	calculated	O
11	by	O
12	using	O
13	a	O
14	<UNK>	O
15	and	O
16	not	O
17	a	O
18	<UNK>	O
19	model	O
20	as	O
21	<UNK>	O
22	did	O
23	.	O
1	In	O
2	vitro	O
3	translation	O
4	of	O
5	RNA	O
6	synthesized	O
7	from	O
8	the	O
9	cloned	O
10	cDNAs	O
11	<UNK>	O
12	that	O
13	<UNK>	O
14	transcripts	O
15	are	O
16	translated	O
17	into	O
18	a	O
19	novel	O
20	12	O
21	.	O
22	5	O
23	-	O
24	<UNK>	O
25	protein	O
26	corresponding	O
27	to	O
28	the	O
29	first	O
30	open	O
31	reading	O
32	frame	O
33	.	O
1	<UNK>	O
2	prolonged	O
3	<UNK>	O
4	after	O
5	<UNK>	O
6	,	O
7	and	O
8	sinus	O
9	arrest	O
10	developed	O
11	in	O
12	two	O
13	of	O
14	10	O
15	group	O
16	2	O
17	and	O
18	two	O
19	of	O
20	five	O
21	group	O
22	3	O
23	animals	O
24	.	O
1	The	O
2	latter	O
3	was	O
4	determined	O
5	as	O
6	follows	O
7	:	O
8	Type	O
9	I	O
10	-	O
11	solid	O
12	tumor	O
13	tissue	O
14	without	O
15	significant	O
16	peripheral	O
17	isolated	O
18	tumor	O
19	cells	O
20	;	O
21	Type	O
22	II	O
23	-	O
24	solid	O
25	tumor	O
26	tissue	O
27	associated	O
28	with	O
29	peripheral	O
30	isolated	O
31	tumor	O
32	cells	O
33	;	O
34	Type	O
35	III	O
36	-	O
37	isolated	O
38	tumor	O
39	cells	O
40	only	O
41	.	O
1	<UNK>	O
2	to	O
3	its	O
4	relatively	O
5	soluble	O
6	chemical	O
7	form	O
8	,	O
9	<UNK>	O
10	was	O
11	rapidly	O
12	<UNK>	O
13	from	O
14	lung	O
15	to	O
16	bone	O
17	where	O
18	a	O
19	substantial	O
20	portion	O
21	was	O
22	retained	O
23	for	O
24	a	O
25	long	O
26	period	O
27	of	O
28	time	O
29	.	O
1	<UNK>	O
2	that	O
3	are	O
4	transformed	O
5	via	O
6	phase	O
7	II	O
8	reactions	O
9	usually	O
10	do	O
11	not	O
12	require	O
13	dosage	O
14	<UNK>	O
15	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	with	O
5	increased	O
6	light	O
7	sensitivity	O
1	It	O
2	is	O
3	largely	O
4	predicted	O
5	by	O
6	<UNK>	O
7	<UNK>	O
8	(	O
9	estimated	O
10	by	O
11	activated	O
12	partial	O
13	<UNK>	B
14	time	O
15	)	O
16	and	O
17	/	O
18	or	O
19	antibody	O
20	to	O
21	<UNK>	O
22	.	O
1	The	O
2	presence	O
3	in	O
4	such	O
5	patients	O
6	of	O
7	antibodies	O
8	to	O
9	<UNK>	O
10	and	O
11	noradrenaline	O
12	is	O
13	<UNK>	O
14	of	O
15	considerable	O
16	disruption	O
17	of	O
18	<UNK>	O
19	<UNK>	O
20	.	O
1	In	O
2	addition	O
3	,	O
4	on	O
5	the	O
6	<UNK>	O
7	'	O
8	s	O
9	maternal	O
10	scale	O
11	,	O
12	<UNK>	O
13	mothers	O
14	were	O
15	found	O
16	to	O
17	view	O
18	their	O
19	infants	O
20	as	O
21	more	O
22	<UNK>	O
23	and	O
24	dependent	O
25	than	O
26	<UNK>	O
27	mothers	O
28	did	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	<UNK>	O
36	).	O
1	A	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	for	O
6	pediatric	O
7	patients	O
8	.	O
1	<UNK>	O
1	The	O
2	statistical	O
3	significance	O
4	of	O
5	the	O
6	prognosis	O
7	factors	O
8	was	O
9	studied	O
10	by	O
11	<UNK>	O
12	-	O
13	and	O
14	<UNK>	O
15	methods	O
16	,	O
17	according	O
18	to	O
19	the	O
20	model	O
21	of	O
22	<UNK>	O
23	,	O
24	with	O
25	the	O
26	help	O
27	of	O
28	an	O
29	<UNK>	O
30	computer	O
31	.	O
1	These	O
2	changes	O
3	at	O
4	the	O
5	site	O
6	of	O
7	injection	O
8	<UNK>	O
9	of	O
10	a	O
11	focal	O
12	<UNK>	O
13	characterized	O
14	by	O
15	a	O
16	<UNK>	O
17	increase	O
18	in	O
19	signal	O
20	intensity	O
21	on	O
22	T1	O
23	weighted	O
24	images	O
25	and	O
26	markedly	O
27	increased	O
28	signal	O
29	intensity	O
30	on	O
31	T2	O
32	weighted	O
33	images	O
34	.	O
1	<UNK>	O
2	of	O
3	the	O
4	<UNK>	O
5	muscle	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	stretch	O
11	receptors	O
12	in	O
13	the	O
14	<UNK>	O
1	Factors	O
2	that	O
3	showed	O
4	significant	O
5	correlation	O
6	to	O
7	elevated	O
8	<UNK>	O
9	'	O
10	s	O
11	in	O
12	the	O
13	highly	O
14	elevated	O
15	portion	O
16	of	O
17	our	O
18	<UNK>	O
19	population	O
20	were	O
21	poor	O
22	NIH	O
23	score	O
24	,	O
25	increased	O
26	patient	O
27	age	O
28	,	O
29	low	O
30	peak	O
31	<UNK>	O
32	flow	O
33	rate	O
34	,	O
35	and	O
36	elevated	O
37	total	O
38	serum	O
39	IgG	B
40	.	O
1	<UNK>	O
2	is	O
3	the	O
4	most	O
5	common	O
6	cause	O
7	of	O
8	<UNK>	O
9	contact	O
10	<UNK>	O
11	in	O
12	<UNK>	O
13	,	O
14	resulting	O
15	in	O
16	positive	O
17	reactions	O
18	in	O
19	<UNK>	O
20	tests	O
21	between	O
22	7	O
23	and	O
24	14	O
25	%.	O
1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	<UNK>	O
13	were	O
14	reported	O
15	.	O
1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	<UNK>	O
8	of	O
9	the	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	<UNK>	O
14	(	O
15	<UNK>	O
16	;	O
17	a	O
18	<UNK>	O
19	measure	O
20	of	O
21	Type	O
22	A	O
23	behavior	O
24	).	O
1	The	O
2	combination	O
3	of	O
4	F1	O
5	and	O
6	<UNK>	O
7	which	O
8	was	O
9	the	O
10	best	O
11	<UNK>	O
12	of	O
13	<UNK>	O
14	in	O
15	this	O
16	population	O
17	(	O
18	G1	O
19	)	O
20	might	O
21	be	O
22	<UNK>	O
23	as	O
24	<UNK>	O
25	<UNK>	O
26	<UNK>	O
27	mainly	O
28	abdominal	O
29	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	during	O
6	pregnancy	O
7	there	O
8	are	O
9	increases	O
10	in	O
11	bone	O
12	formation	O
13	rates	O
14	<UNK>	O
15	to	O
16	the	O
17	increases	O
18	in	O
19	skeletal	O
20	mass	O
21	.	O
1	There	O
2	were	O
3	18	O
4	patients	O
5	with	O
6	Group	O
7	II	O
8	(	O
9	a	O
10	)	O
11	tumors	O
12	;	O
13	although	O
14	tumor	O
15	biopsy	O
16	was	O
17	<UNK>	O
18	on	O
19	eight	O
20	of	O
21	these	O
22	,	O
23	pathological	O
24	diagnosis	O
25	at	O
26	the	O
27	time	O
28	of	O
29	surgery	O
30	was	O
31	made	O
32	in	O
33	only	O
34	one	O
35	case	O
36	.	O
1	<UNK>	O
2	of	O
3	them	O
4	were	O
5	on	O
6	treatment	O
7	with	O
8	systemic	O
9	steroids	O
10	.	O
1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	<UNK>	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	<UNK>	O
29	,	O
30	<UNK>	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O
1	From	O
2	life	O
3	-	O
4	<UNK>	O
5	analyses	O
6	of	O
7	these	O
8	patients	O
9	,	O
10	we	O
11	estimated	O
12	that	O
13	the	O
14	incidence	O
15	of	O
16	secondary	O
17	<UNK>	O
18	in	O
19	patients	O
20	who	O
21	have	O
22	<UNK>	O
23	disease	O
24	is	O
25	about	O
26	25	O
27	per	O
28	cent	O
29	at	O
30	the	O
31	age	O
32	of	O
33	<UNK>	O
34	years	O
35	,	O
36	and	O
37	that	O
38	malignant	O
39	<UNK>	O
40	is	O
41	almost	O
42	a	O
43	<UNK>	O
44	in	O
45	patients	O
46	who	O
47	have	O
48	<UNK>	O
49	syndrome	O
50	.	O
1	An	O
2	ion	O
3	chromatographic	O
4	method	O
5	was	O
6	used	O
7	to	O
8	determine	O
9	<UNK>	O
10	ion	O
11	in	O
12	the	O
13	urine	O
14	of	O
15	<UNK>	O
16	.	O
1	<UNK>	O
2	of	O
3	human	O
4	myocardial	O
5	<UNK>	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O
1	Inhibition	O
2	of	O
3	<UNK>	O
4	-	O
5	stimulated	O
6	gastric	O
7	secretion	O
8	by	O
9	40	O
10	<UNK>	O
11	<UNK>	O
12	,	O
13	a	O
14	new	O
15	long	O
16	-	O
17	acting	O
18	gastric	O
19	<UNK>	O
20	agent	O
21	.	O
1	<UNK>	O
2	<UNK>	O
3	who	O
4	has	O
5	<UNK>	O
6	as	O
7	a	O
8	<UNK>	O
9	<UNK>	O
10	in	O
11	<UNK>	O
12	for	O
13	the	O
14	past	O
15	20	O
16	years	O
1	<UNK>	O
2	<UNK>	O
3	emission	O
4	<UNK>	O
5	tomography	O
6	(	O
7	SPECT	O
8	),	O
9	by	O
10	<UNK>	O
11	three	O
12	-	O
13	dimensional	O
14	<UNK>	O
15	of	O
16	myocardial	O
17	<UNK>	O
18	-	O
19	201	O
20	,	O
21	<UNK>	O
22	<UNK>	O
23	for	O
24	improved	O
25	localization	O
26	of	O
27	<UNK>	O
28	.	O
1	In	O
2	19	O
3	patients	O
4	<UNK>	O
5	not	O
6	only	O
7	<UNK>	O
8	the	O
9	bleeding	O
10	but	O
11	provided	O
12	<UNK>	O
13	therapy	O
14	(	O
15	<UNK>	O
16	I	O
17	-	O
18	II	O
19	);	O
20	4	O
21	patients	O
22	died	O
23	(	O
24	mortality	O
25	rate	O
26	16	O
27	%).	O
1	The	O
2	results	O
3	obtained	O
4	are	O
5	similar	O
6	to	O
7	those	O
8	described	O
9	with	O
10	the	O
11	previous	O
12	<UNK>	O
13	<UNK>	O
14	although	O
15	greater	O
16	variability	O
17	in	O
18	induction	O
19	and	O
20	recovery	O
21	times	O
22	was	O
23	noted	O
24	with	O
25	the	O
26	<UNK>	O
27	<UNK>	O
28	.	O
1	The	O
2	H2	O
3	receptor	O
4	antagonists	O
5	and	O
6	<UNK>	O
7	cost	O
8	about	O
9	the	O
10	same	O
11	and	O
12	have	O
13	few	O
14	side	O
15	effects	O
16	.	O
1	The	O
2	Mean	O
3	was	O
4	74	O
5	,	O
6	3	O
7	+/-	O
8	53	O
9	,	O
10	6	O
11	micrograms	O
12	J	O
13	/	O
14	g	O
15	<UNK>	O
16	,	O
17	the	O
18	<UNK>	O
19	61	O
20	micrograms	O
21	J	O
22	/	O
23	g	O
24	<UNK>	O
25	.	O
1	In	O
2	the	O
3	region	O
4	<UNK>	O
5	with	O
6	mixed	O
7	<UNK>	O
8	-	O
9	<UNK>	O
10	population	O
11	an	O
12	<UNK>	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	<UNK>	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O
1	The	O
2	distribution	O
3	of	O
4	patients	O
5	was	O
6	as	O
7	follows	O
8	:	O
9	group	O
10	1	O
11	--	O
12	complex	O
13	gamma	O
14	-	O
15	therapy	O
16	(	O
17	55	O
18	cases	O
19	),	O
20	group	O
21	2	O
22	--	O
23	complex	O
24	gamma	O
25	-	O
26	therapy	O
27	plus	O
28	<UNK>	O
29	<UNK>	O
30	(	O
31	50	O
32	cases	O
33	)	O
34	and	O
35	group	O
36	3	O
37	--	O
38	complex	O
39	radiation	O
40	treatment	O
41	with	O
42	<UNK>	O
43	<UNK>	O
44	<UNK>	O
45	from	O
46	the	O
47	<UNK>	O
48	type	O
49	<UNK>	O
50	and	O
51	<UNK>	O
52	<UNK>	O
53	(	O
54	50	O
55	cases	O
56	).	O
1	The	O
2	availability	O
3	of	O
4	<UNK>	O
5	and	O
6	<UNK>	O
7	<UNK>	O
8	an	O
9	alternative	O
10	and	O
11	effective	O
12	treatment	O
13	for	O
14	the	O
15	<UNK>	O
16	reversal	O
17	of	O
18	<UNK>	O
19	bleeding	O
20	in	O
21	patients	O
22	who	O
23	require	O
24	<UNK>	O
25	invasive	O
26	procedures	O
27	.	O
1	<UNK>	O
2	and	O
3	pulmonary	O
4	<UNK>	O
5	in	O
6	congenital	O
7	factor	O
8	<UNK>	O
9	deficiency	O
1	A	O
2	significant	O
3	degree	O
4	of	O
5	homology	O
6	was	O
7	also	O
8	found	O
9	among	O
10	these	O
11	genes	O
12	and	O
13	the	O
14	<UNK>	B
15	gene	O
16	of	O
17	related	O
18	phage	O
19	<UNK>	O
20	,	O
21	which	O
22	<UNK>	O
23	for	O
24	an	O
25	enzyme	O
26	with	O
27	different	O
28	modification	O
29	specificity	O
30	.	O
1	<UNK>	B
2	-	O
3	releasing	B
4	hormone	O
5	-	O
6	induced	O
7	<UNK>	O
8	of	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	muscle	O
13	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O
1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	<UNK>	O
6	was	O
7	4	O
8	.	O
9	79	O
10	%	O
11	in	O
12	men	O
13	and	O
14	4	O
15	.	O
16	85	O
17	%	O
18	in	O
19	women	O
20	.	O
1	The	O
2	possible	O
3	origin	O
4	and	O
5	role	O
6	of	O
7	CSF	B
8	prolactin	I
9	are	O
10	discussed	O
11	.	O
1	In	O
2	each	O
3	<UNK>	O
4	O2	O
5	is	O
6	removed	O
7	by	O
8	the	O
9	tissues	O
10	as	O
11	a	O
12	chemical	O
13	reaction	O
14	<UNK>	O
15	place	O
16	between	O
17	O2	O
18	and	O
19	<UNK>	B
20	(	O
21	<UNK>	B
22	).	O
1	<UNK>	O
2	excretion	O
3	,	O
4	appeared	O
5	to	O
6	be	O
7	markedly	O
8	affected	O
9	by	O
10	the	O
11	<UNK>	O
12	although	O
13	other	O
14	factors	O
15	such	O
16	as	O
17	social	O
18	and	O
19	environmental	O
20	stress	O
21	cannot	O
22	be	O
23	<UNK>	O
24	.	O
1	<UNK>	O
1	The	O
2	<UNK>	O
3	and	O
4	<UNK>	O
5	of	O
6	the	O
7	<UNK>	O
8	fibers	O
9	of	O
10	the	O
11	superior	O
12	temporal	O
13	region	O
14	(	O
15	<UNK>	O
16	)	O
17	are	O
18	studied	O
19	using	O
20	the	O
21	<UNK>	O
22	technique	O
23	.	O
1	To	O
2	assess	O
3	the	O
4	effects	O
5	of	O
6	alveolar	O
7	hypoxia	O
8	and	O
9	angiotensin	B
10	II	O
11	infusion	O
12	on	O
13	distribution	O
14	of	O
15	blood	O
16	flow	O
17	to	O
18	the	O
19	lung	O
20	we	O
21	performed	O
22	perfusion	O
23	lung	O
24	scans	O
25	on	O
26	anesthetized	O
27	<UNK>	O
28	<UNK>	O
29	<UNK>	O
30	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	members	O
5	of	O
6	<UNK>	O
7	<UNK>	O
8	.	O
1	The	O
2	frequency	O
3	of	O
4	<UNK>	B
5	phenotypes	O
6	in	O
7	<UNK>	O
8	children	O
9	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	,	O
5	<UNK>	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	<UNK>	O
16	.	O
1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	simple	O
7	<UNK>	O
8	-	O
9	control	O
10	<UNK>	O
11	has	O
12	been	O
13	developed	O
14	that	O
15	<UNK>	O
16	the	O
17	patient	O
18	to	O
19	<UNK>	O
20	<UNK>	O
21	-	O
22	<UNK>	O
23	during	O
24	<UNK>	O
25	scans	O
26	.	O
1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	<UNK>	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	<UNK>	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O
1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	<UNK>	O
15	under	O
16	2	O
17	cm	O
18	<UNK>	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	<UNK>	O
35	in	O
36	lung	O
37	<UNK>	O
38	.	O
1	Two	O
2	<UNK>	O
3	with	O
4	<UNK>	O
5	<UNK>	O
6	caused	O
7	by	O
8	<UNK>	B
9	<UNK>	I
10	deficiency	O
11	developed	O
12	a	O
13	progressive	O
14	neurological	O
15	syndrome	O
16	<UNK>	O
17	<UNK>	O
18	<UNK>	O
19	,	O
20	<UNK>	O
21	,	O
22	<UNK>	O
23	tract	O
24	signs	O
25	,	O
26	and	O
27	evidence	O
28	of	O
29	spinal	O
30	motor	O
31	neuron	O
32	involvement	O
33	.	O
1	55	O
2	+/-	O
3	11	O
4	%),	O
5	all	O
6	other	O
7	parameters	O
8	showed	O
9	a	O
10	significant	O
11	increase	O
12	:	O
13	<UNK>	O
14	index	O
15	5	O
16	.	O
17	4	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	<UNK>	O
23	to	O
24	6	O
25	.	O
26	0	O
27	+/-	O
28	1	O
29	.	O
30	7	O
31	<UNK>	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	);	O
40	<UNK>	O
41	6	O
42	.	O
43	3	O
44	+/-	O
45	0	O
46	.	O
47	7	O
48	to	O
49	6	O
50	.	O
51	8	O
52	+/-	O
53	0	O
54	.	O
55	9	O
56	cm	O
57	(	O
58	p	O
59	less	O
60	than	O
61	0	O
62	.	O
63	001	O
64	);	O
65	<UNK>	O
66	<UNK>	O
67	+/-	O
68	<UNK>	O
69	ml	O
70	to	O
71	<UNK>	O
72	+/-	O
73	<UNK>	O
74	ml	O
75	(	O
76	p	O
77	less	O
78	than	O
79	0	O
80	.	O
81	01	O
82	);	O
83	<UNK>	O
84	<UNK>	O
85	+/-	O
86	131	O
87	ml	O
88	to	O
89	<UNK>	O
90	+/-	O
91	<UNK>	O
92	ml	O
93	(	O
94	p	O
95	less	O
96	than	O
97	0	O
98	.	O
99	001	O
100	);	O
101	<UNK>	O
102	<UNK>	O
103	+/-	O
104	57	O
105	ml	O
106	to	O
107	<UNK>	O
108	+/-	O
109	77	O
110	ml	O
111	(	O
112	p	O
113	less	O
114	than	O
115	0	O
116	.	O
117	001	O
118	).	O
1	35	O
2	patients	O
3	with	O
4	acute	O
5	arterial	O
6	<UNK>	O
7	[	O
8	27	O
9	]	O
10	and	O
11	graft	O
12	<UNK>	O
13	[	O
14	8	O
15	<UNK>	O
16	responsible	O
17	for	O
18	severe	O
19	and	O
20	recent	O
21	ischemia	O
22	,	O
23	were	O
24	treated	O
25	by	O
26	<UNK>	O
27	therapy	O
28	(	O
29	<UNK>	B
30	:	O
31	1	O
32	000	O
33	units	O
34	/	O
35	kg	O
36	/	O
37	hour	O
38	,	O
39	and	O
40	Lys	O
41	<UNK>	B
42	).	O
1	We	O
2	conclude	O
3	that	O
4	<UNK>	O
5	hormones	O
6	reduce	O
7	HDL	B
8	-	O
9	cholesterol	O
10	concentrations	O
11	and	O
12	the	O
13	<UNK>	B
14	-	O
15	cholesterol	O
16	<UNK>	O
17	,	O
18	possibly	O
19	by	O
20	<UNK>	O
21	hepatic	O
22	<UNK>	O
23	lipase	B
24	activity	O
25	.	O
1	Because	O
2	of	O
3	its	O
4	wide	O
5	spectrum	O
6	of	O
7	activity	O
8	particularly	O
9	against	O
10	<UNK>	O
11	resistant	O
12	strains	O
13	of	O
14	H	O
15	.	O
16	<UNK>	O
17	and	O
18	because	O
19	of	O
20	its	O
21	good	O
22	tolerance	O
23	<UNK>	O
24	is	O
25	very	O
26	useful	O
27	in	O
28	treatment	O
29	of	O
30	respiratory	O
31	tract	O
32	infections	O
33	in	O
34	children	O
35	.	O
1	<UNK>	O
2	<UNK>	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	<UNK>	O
8	conditions	O
9	in	O
10	independently	O
11	<UNK>	O
12	patients	O
13	with	O
14	<UNK>	O
15	.	O
1	Plasma	O
2	and	O
3	bladder	O
4	<UNK>	O
5	concentration	O
6	were	O
7	measured	O
8	following	O
9	<UNK>	O
10	<UNK>	O
11	,	O
12	and	O
13	also	O
14	<UNK>	O
15	examination	O
16	,	O
17	<UNK>	O
18	,	O
19	complete	O
20	blood	O
21	count	O
22	and	O
23	blood	O
24	<UNK>	O
25	were	O
26	performed	O
27	in	O
28	order	O
29	to	O
30	<UNK>	O
31	the	O
32	toxicity	O
33	of	O
34	<UNK>	O
35	<UNK>	O
36	.	O
1	<UNK>	O
2	I	O
3	is	O
4	<UNK>	O
5	for	O
6	storage	O
7	and	O
8	<UNK>	O
9	-	O
10	reading	O
11	.	O
1	<UNK>	O
2	of	O
3	remission	O
4	in	O
5	advanced	O
6	gastric	O
7	cancer	O
8	patients	O
9	responding	O
10	to	O
11	<UNK>	O
12	dose	O
13	of	O
14	<UNK>	O
15	and	O
16	5	O
17	-	O
18	<UNK>	O
1	National	O
2	<UNK>	O
3	of	O
4	Health	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	.	O
1	<UNK>	O
2	:	O
3	progressive	O
4	<UNK>	O
5	<UNK>	O
6	.	O
1	The	O
2	rates	O
3	of	O
4	total	O
5	energy	O
6	use	O
7	(	O
8	mean	O
9	+/-	O
10	SD	O
11	=	O
12	39	O
13	.	O
14	3	O
15	+/-	O
16	1	O
17	.	O
18	2	O
19	vs	O
20	35	O
21	.	O
22	7	O
23	+/-	O
24	1	O
25	.	O
26	3	O
27	<UNK>	O
28	X	O
29	min	O
30	-	O
31	1	O
32	;	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	)	O
40	were	O
41	significantly	O
42	higher	O
43	at	O
44	-	O
45	10	O
46	degrees	O
47	C	O
48	than	O
49	at	O
50	22	O
51	degrees	O
52	C	O
53	.	O
1	Blood	O
2	<UNK>	O
3	in	O
4	patients	O
5	with	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	.	O
1	The	O
2	<UNK>	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	<UNK>	O
8	-	O
9	groups	O
10	of	O
11	<UNK>	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	<UNK>	O
19	<UNK>	O
20	<UNK>	O
21	<UNK>	O
22	.	O
1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	<UNK>	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	<UNK>	O
13	measurements	O
14	,	O
15	<UNK>	O
16	and	O
17	serum	O
18	<UNK>	B
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	<UNK>	O
26	with	O
27	P	O
28	.	O
29	<UNK>	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O
1	<UNK>	O
2	<UNK>	O
3	development	O
4	of	O
5	the	O
6	<UNK>	O
7	cortex	O
8	in	O
9	the	O
10	rat	O
11	.	O
1	Treatment	O
2	of	O
3	<UNK>	O
4	'	O
5	s	O
6	disease	O
7	.	O
1	HL	O
2	-	O
3	A	O
4	antibodies	O
5	in	O
6	<UNK>	O
7	patients	O
1	<UNK>	O
2	resin	O
3	for	O
4	the	O
5	treatment	O
6	of	O
7	the	O
8	<UNK>	O
9	of	O
10	renal	O
11	failure	O
12	.	O
1	<UNK>	O
2	of	O
3	maternal	O
4	<UNK>	O
5	<UNK>	O
6	:	O
7	anti	O
8	-	O
9	<UNK>	O
10	immune	O
11	globulin	B
12	.	O
1	<UNK>	O
2	action	O
3	of	O
4	a	O
5	new	O
6	antibiotic	O
7	-	O
8	<UNK>	O
9	association	O
10	used	O
11	for	O
12	<UNK>	O
13	in	O
14	<UNK>	O
1	<UNK>	O
2	<UNK>	O
3	findings	O
4	in	O
5	the	O
6	<UNK>	O
7	body	O
8	of	O
9	the	O
10	<UNK>	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	cells	O
5	:	O
6	study	O
7	in	O
8	rats	O
9	after	O
10	administration	O
11	of	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	-	O
3	beta	O
4	-	O
5	1	O
6	lipoprotein	O
7	and	O
8	early	O
9	detection	O
10	of	O
11	risk	O
12	factors	O
13	for	O
14	coronary	O
15	heart	O
16	disease	O
17	.	O
1	Effect	O
2	of	O
3	<UNK>	O
4	on	O
5	<UNK>	O
6	-	O
7	induced	O
8	increases	O
9	of	O
10	<UNK>	O
11	and	O
12	<UNK>	B
13	activity	O
14	in	O
15	the	O
16	plasma	O
17	of	O
18	rats	O
1	<UNK>	O
2	between	O
3	cells	O
4	of	O
5	the	O
6	human	O
7	<UNK>	O
8	organ	O
9	.	O
1	Changes	O
2	following	O
3	<UNK>	O
4	surgery	O
5	.	O
1	<UNK>	O
2	pH	O
3	,	O
4	H	O
5	ion	O
6	<UNK>	O
7	and	O
8	H	O
9	ion	O
10	<UNK>	O
11	coefficient	O
12	in	O
13	<UNK>	O
14	<UNK>	O
15	muscle	O
16	.	O
1	<UNK>	O
2	studies	O
3	on	O
4	SF	O
5	-	O
6	<UNK>	O
7	.	O
1	<UNK>	O
2	<UNK>	O
3	medical	O
4	care	O
1	<UNK>	O
2	significant	O
3	<UNK>	O
4	changes	O
5	in	O
6	<UNK>	O
7	<UNK>	O
8	probably	O
9	associated	O
10	with	O
11	a	O
12	<UNK>	O
13	-	O
14	like	O
15	<UNK>	O
16	.	O
1	A	O
2	short	O
3	history	O
4	of	O
5	<UNK>	O
6	in	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	.	O
1	<UNK>	O
2	pattern	O
3	of	O
4	<UNK>	O
5	tuberculosis	O
6	(	O
7	H	O
8	37	O
9	<UNK>	O
10	)	O
11	to	O
12	a	O
13	new	O
14	antibiotic	O
15	,	O
16	<UNK>	O
1	<UNK>	O
2	processes	O
3	in	O
4	the	O
5	<UNK>	O
6	<UNK>	O
1	<UNK>	O
2	<UNK>	O
3	tumors	O
4	of	O
5	the	O
6	<UNK>	O
1	<UNK>	O
2	behavior	O
3	of	O
4	<UNK>	O
5	,	O
6	<UNK>	O
7	x	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	non	O
12	-	O
13	<UNK>	O
14	<UNK>	O
15	.	O
1	<UNK>	O
2	complicated	O
3	by	O
4	chronic	O
5	steroid	O
6	treatment	O
7	.	O
1	<UNK>	O
2	in	O
3	the	O
4	<UNK>	O
5	of	O
6	the	O
7	blood	O
8	following	O
9	a	O
10	short	O
11	-	O
12	term	O
13	local	O
14	action	O
15	of	O
16	a	O
17	<UNK>	O
18	magnetic	O
19	field	O
20	on	O
21	the	O
22	human	O
23	body	O
1	<UNK>	O
2	system	O
3	in	O
4	<UNK>	O
5	<UNK>	O
6	.	O
1	<UNK>	O
2	solution	O
3	of	O
4	<UNK>	O
5	joint	O
6	<UNK>	O
7	with	O
8	a	O
9	<UNK>	O
10	<UNK>	O
11	flap	O
1	Effects	O
2	of	O
3	<UNK>	O
4	radiation	O
5	in	O
6	the	O
7	human	O
8	oral	O
9	cavity	O
10	and	O
11	<UNK>	O
12	:	O
13	results	O
14	of	O
15	a	O
16	survey	O
17	.	O
1	<UNK>	O
2	pattern	O
3	of	O
4	<UNK>	O
5	<UNK>	O
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	O
12	between	O
13	<UNK>	B
14	and	O
15	<UNK>	B
16	antibodies	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	.	O
1	<UNK>	O
2	<UNK>	O
3	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	L	O
5	.	O
6	R	O
7	.	O
8	C	O
9	.	O
10	P	O
11	.	O
1	<UNK>	O
2	.	O
1	Analysis	O
2	of	O
3	<UNK>	O
4	.	O
1	Plasma	O
2	<UNK>	B
3	in	O
4	patients	O
5	of	O
6	bronchial	O
7	asthma	O
8	and	O
9	the	O
10	effect	O
11	of	O
12	<UNK>	O
13	administration	O
14	on	O
15	it	O
16	.	O
1	Factors	O
2	affecting	O
3	the	O
4	inhibition	O
5	of	O
6	<UNK>	O
7	by	O
8	<UNK>	O
9	.	O
1	<UNK>	O
2	<UNK>	O
3	sensitivity	O
4	determined	O
5	<UNK>	O
6	for	O
7	the	O
8	<UNK>	O
9	eye	O
10	.	O
1	Clinical	O
2	and	O
3	<UNK>	O
4	examinations	O
5	in	O
6	occlusion	O
7	disease	O
8	of	O
9	the	O
10	great	O
11	intestinal	O
12	arteries	O
1	<UNK>	O
2	treatment	O
3	of	O
4	<UNK>	O
5	with	O
6	transfer	O
7	factor	O
8	.	O
1	<UNK>	O
2	treatment	O
3	of	O
4	central	O
5	nervous	O
6	system	O
7	injuries	O
1	New	O
2	<UNK>	O
3	from	O
4	<UNK>	O
5	of	O
6	<UNK>	O
7	<UNK>	O
8	.	O
1	<UNK>	O
2	abdominal	O
3	<UNK>	O
4	with	O
5	131	O
6	-	O
7	I	O
8	-	O
9	tagged	O
10	<UNK>	O
11	--	O
12	<UNK>	O
13	of	O
14	the	O
15	thyroid	O
16	gland	O
17	,	O
18	kidney	O
19	and	O
20	spleen	O
21	(	O
22	comparison	O
23	with	O
24	131	O
25	-	O
26	I	O
27	-	O
28	RB	B
29	)	O
1	<UNK>	O
2	in	O
3	children	O
1	<UNK>	O
2	caused	O
3	by	O
4	3	O
5	,	O
6	4	O
7	-	O
8	<UNK>	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	smoking	O
5	on	O
6	some	O
7	blood	O
8	coagulation	O
9	tests	O
10	.	O
1	<UNK>	O
2	-	O
3	TR	B
4	-	O
5	68	O
6	-	O
7	54	O
8	.	O
1	<UNK>	O
2	<UNK>	O
3	(	O
4	L	O
5	.)	O
6	and	O
7	<UNK>	O
8	<UNK>	O
9	(	O
10	<UNK>	O
11	)	O
12	in	O
13	<UNK>	O
14	<UNK>	O
15	.	O
1	<UNK>	O
2	cord	O
3	<UNK>	O
4	of	O
5	the	O
6	<UNK>	O
7	reflex	O
8	.	O
1	<UNK>	O
2	-	O
3	and	O
4	<UNK>	O
5	of	O
6	the	O
7	<UNK>	O
1	IX	O
2	.	O
1	<UNK>	B
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	<UNK>	O
7	hypertension	O
8	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	capacity	O
6	produced	O
7	by	O
8	<UNK>	O
9	-	O
10	induced	O
11	salt	O
12	retention	O
13	in	O
14	man	O
15	.	O
1	<UNK>	O
2	<UNK>	O
3	and	O
4	the	O
5	<UNK>	O
6	<UNK>	O
7	.	O
1	V	O
2	.	O
1	3	O
2	.	O
1	<UNK>	O
2	venous	O
3	catheter	O
4	used	O
5	for	O
6	recording	O
7	<UNK>	O
8	<UNK>	O
9	.	O
1	<UNK>	O
2	shifts	O
3	of	O
4	basal	O
5	skin	O
6	potentials	O
7	during	O
8	human	O
9	sleep	O
10	.	O
1	<UNK>	O
2	on	O
3	the	O
4	exchange	O
5	of	O
6	<UNK>	O
7	in	O
8	intact	O
9	and	O
10	<UNK>	O
11	rats	O
12	by	O
13	the	O
14	<UNK>	O
15	analysis	O
16	method	O
1	<UNK>	O
2	applied	O
3	to	O
4	cattle	O
1	Evaluation	O
2	of	O
3	<UNK>	O
4	blood	O
5	cell	O
6	<UNK>	O
7	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	activity	O
5	against	O
6	<UNK>	O
7	larvae	O
1	<UNK>	O
2	changes	O
3	in	O
4	man	O
5	during	O
6	<UNK>	O
1	The	O
2	significance	O
3	of	O
4	the	O
5	<UNK>	B
6	<UNK>	I
7	test	O
8	for	O
9	the	O
10	differentiation	O
11	and	O
12	identification	O
13	of	O
14	<UNK>	O
15	species	O
16	.	O
1	<UNK>	O
2	of	O
3	mast	O
4	cells	O
5	to	O
6	<UNK>	O
7	<UNK>	O
8	of	O
9	the	O
10	skin	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	.	O
1	I	O
2	.	O
1	Functional	O
2	disorders	O
3	of	O
4	the	O
5	<UNK>	O
6	following	O
7	<UNK>	O
8	surgery	O
1	Clinical	O
2	trials	O
3	with	O
4	1	O
5	,	O
6	3	O
7	-	O
8	<UNK>	O
9	(	O
10	2	O
11	-	O
12	<UNK>	O
13	)-	O
14	1	O
15	-	O
16	<UNK>	O
17	,	O
18	<UNK>	O
19	-	O
20	<UNK>	O
21	.	O
1	Study	O
2	on	O
3	<UNK>	O
4	in	O
5	the	O
6	mouse	O
7	<UNK>	O
8	caused	O
9	by	O
10	x	O
11	-	O
12	radiation	O
13	,	O
14	hypoxia	O
15	,	O
16	<UNK>	O
17	blue	O
18	injection	O
19	of	O
20	<UNK>	O
21	-	O
22	A	O
23	upon	O
24	<UNK>	O
25	animals	O
26	during	O
27	pregnancy	O
28	.	O
1	<UNK>	O
2	of	O
3	a	O
4	hospital	O
5	that	O
6	<UNK>	O
7	its	O
8	<UNK>	O
9	orientation	O
10	program	O
11	.	O
1	On	O
2	the	O
3	amount	O
4	and	O
5	significance	O
6	of	O
7	the	O
8	effective	O
9	glucose	O
10	level	O
11	in	O
12	tumors	O
13	.	O
1	<UNK>	O
2	and	O
3	folate	O
4	deficiency	O
5	in	O
6	pregnancy	O
1	<UNK>	O
2	maternal	O
3	alpha	O
4	<UNK>	B
5	and	O
6	<UNK>	O
7	:	O
8	fetal	O
9	prognosis	O
1	Also	O
2	discussed	O
3	is	O
4	the	O
5	possibility	O
6	of	O
7	a	O
8	combined	O
9	genetic	O
10	and	O
11	environmental	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	mammary	O
3	tumors	O
4	induced	O
5	by	O
6	mouse	O
7	mammary	O
8	tumor	O
9	virus	O
10	(	O
11	<UNK>	O
12	)	O
13	contain	O
14	a	O
15	<UNK>	O
16	in	O
17	the	O
18	same	O
19	region	O
20	of	O
21	the	O
22	host	O
23	-	O
24	cell	O
25	genome	O
26	,	O
27	leading	O
28	to	O
29	expression	O
30	of	O
31	a	O
32	putative	O
33	cellular	O
34	oncogene	B
35	called	O
36	<UNK>	B
37	-	O
38	1	O
39	.	O
1	<UNK>	B
2	at	O
3	the	O
4	approach	O
5	of	O
6	death	O
7	.	O
1	<UNK>	O
2	<UNK>	O
3	levels	O
4	and	O
5	<UNK>	O
6	calcium	O
7	binding	O
8	activity	O
9	in	O
10	<UNK>	O
11	-	O
12	induced	O
13	<UNK>	O
14	.	O
1	Plasma	O
2	and	O
3	<UNK>	O
4	lipid	O
5	profile	O
6	and	O
7	lipoprotein	O
8	lipase	B
9	activity	O
10	in	O
11	<UNK>	O
12	plasma	O
13	on	O
14	<UNK>	O
15	rabbits	O
16	were	O
17	studied	O
18	and	O
19	also	O
20	the	O
21	incidence	O
22	of	O
23	<UNK>	O
24	in	O
25	different	O
26	arterial	O
27	<UNK>	O
28	.	O
1	<UNK>	O
2	-	O
3	selection	O
4	experiments	O
5	against	O
6	total	O
7	<UNK>	O
8	-	O
9	inducible	O
10	RNA	O
11	were	O
12	performed	O
13	with	O
14	plasmid	O
15	DNA	O
16	derived	O
17	from	O
18	clones	O
19	enriched	O
20	in	O
21	<UNK>	O
22	-	O
23	inducible	O
24	information	O
25	.	O
1	<UNK>	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	<UNK>	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	<UNK>	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	<UNK>	O
40	.	O
1	Serum	O
2	<UNK>	O
3	acid	O
4	had	O
5	an	O
6	<UNK>	O
7	and	O
8	the	O
9	<UNK>	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	<UNK>	O
27	,	O
28	gamma	O
29	-	O
30	GTP	O
31	and	O
32	<UNK>	O
33	.	O
1	In	O
2	several	O
3	cases	O
4	of	O
5	<UNK>	O
6	<UNK>	O
7	,	O
8	<UNK>	O
9	<UNK>	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	<UNK>	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	<UNK>	O
30	changes	O
31	were	O
32	investigated	O
33	.	O
1	A	O
2	polypeptide	O
3	chain	O
4	of	O
5	34	O
6	residues	O
7	of	O
8	the	O
9	deduced	O
10	yeast	O
11	amino	O
12	acid	O
13	sequence	O
14	closely	O
15	<UNK>	O
16	a	O
17	peptide	O
18	sequence	O
19	at	O
20	the	O
21	<UNK>	O
22	binding	O
23	site	O
24	of	O
25	bovine	O
26	muscle	O
27	<UNK>	O
28	kinase	B
29	.	O
1	Differential	O
2	<UNK>	O
3	size	O
4	associated	O
5	with	O
6	<UNK>	O
7	brain	O
8	damage	O
9	.	O
1	<UNK>	O
2	of	O
3	immune	O
4	cells	O
5	such	O
6	as	O
7	transfer	O
8	factor	O
9	and	O
10	<UNK>	O
11	form	O
12	the	O
13	third	O
14	and	O
15	possibly	O
16	most	O
17	important	O
18	group	O
19	of	O
20	immune	O
21	-	O
22	stimulating	O
23	agents	O
24	.	O
1	The	O
2	number	O
3	of	O
4	elements	O
5	and	O
6	their	O
7	sizes	O
8	relative	O
9	to	O
10	the	O
11	<UNK>	O
12	were	O
13	varied	O
14	in	O
15	a	O
16	series	O
17	of	O
18	five	O
19	experiments	O
20	.	O
1	<UNK>	B
2	<UNK>	O
3	and	O
4	their	O
5	possible	O
6	<UNK>	O
7	for	O
8	surface	O
9	<UNK>	O
10	in	O
11	health	O
12	and	O
13	disease	O
14	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	<UNK>	O
5	acid	O
6	<UNK>	O
7	<UNK>	O
1	Because	O
2	RNase	B
3	III	O
4	host	O
5	mutants	O
6	are	O
7	defective	O
8	in	O
9	<UNK>	B
10	regulation	O
11	,	O
12	processing	O
13	of	O
14	the	O
15	PL	O
16	mRNA	O
17	at	O
18	<UNK>	B
19	by	O
20	this	O
21	<UNK>	O
22	may	O
23	cause	O
24	<UNK>	B
25	mRNA	O
26	decay	O
27	and	O
28	decrease	O
29	<UNK>	B
30	synthesis	O
31	.	O
1	At	O
2	least	O
3	one	O
4	clone	O
5	,	O
6	lambda	O
7	<UNK>	O
8	41	O
9	,	O
10	contains	O
11	,	O
12	in	O
13	addition	O
14	to	O
15	the	O
16	histone	B
17	genes	O
18	,	O
19	a	O
20	region	O
21	that	O
22	<UNK>	O
23	with	O
24	a	O
25	cytoplasmic	O
26	RNA	O
27	approximately	O
28	<UNK>	O
29	nucleotides	O
30	in	O
31	length	O
32	.	O
1	The	O
2	frequency	O
3	of	O
4	previous	O
5	transfusion	O
6	in	O
7	chronic	O
8	hepatitis	O
9	,	O
10	cirrhosis	O
11	and	O
12	<UNK>	O
13	carcinoma	O
14	of	O
15	type	O
16	<UNK>	O
17	was	O
18	42	O
19	.	O
20	8	O
21	,	O
22	37	O
23	.	O
24	1	O
25	and	O
26	15	O
27	.	O
28	1	O
29	%,	O
30	respectively	O
31	,	O
32	whereas	O
33	the	O
34	incidence	O
35	of	O
36	early	O
37	<UNK>	O
38	hepatitis	O
39	was	O
40	8	O
41	.	O
42	5	O
43	,	O
44	8	O
45	.	O
46	6	O
47	and	O
48	7	O
49	.	O
50	5	O
51	%,	O
52	respectively	O
53	.	O
54	in	O
55	chronic	O
56	liver	O
57	diseases	O
58	with	O
59	a	O
60	history	O
61	of	O
62	<UNK>	O
63	and	O
64	/	O
65	or	O
66	hepatitis	O
67	,	O
68	previous	O
69	<UNK>	O
70	are	O
71	more	O
72	frequently	O
73	associated	O
74	with	O
75	type	O
76	<UNK>	O
77	than	O
78	with	O
79	type	O
80	B	O
81	disease	O
82	.	O
1	In	O
2	49	O
3	patients	O
4	in	O
5	whom	O
6	<UNK>	O
7	equilibrium	O
8	<UNK>	O
9	and	O
10	cardiac	O
11	<UNK>	O
12	were	O
13	performed	O
14	within	O
15	a	O
16	6	O
17	day	O
18	interval	O
19	,	O
20	total	O
21	and	O
22	<UNK>	O
23	portions	O
24	of	O
25	global	O
26	and	O
27	regional	O
28	right	O
29	ventricular	O
30	ejection	O
31	fraction	O
32	(	O
33	<UNK>	O
34	)	O
35	were	O
36	correlated	O
37	with	O
38	pulmonary	O
39	arterial	O
40	systolic	O
41	pressure	O
42	.	O
1	In	O
2	conclusion	O
3	,	O
4	these	O
5	studies	O
6	indicate	O
7	that	O
8	<UNK>	O
9	(	O
10	1	O
11	)	O
12	decreases	O
13	histamine	O
14	-	O
15	stimulated	O
16	gastric	O
17	acid	O
18	secretion	O
19	,	O
20	and	O
21	(	O
22	2	O
23	)	O
24	<UNK>	O
25	bile	O
26	-	O
27	induced	O
28	disruption	O
29	of	O
30	the	O
31	gastric	O
32	mucosal	O
33	<UNK>	O
34	in	O
35	the	O
36	canine	O
37	<UNK>	O
38	<UNK>	O
39	.	O
1	<UNK>	O
2	density	O
3	increased	O
4	in	O
5	<UNK>	O
6	-	O
7	exposed	O
8	,	O
9	but	O
10	not	O
11	in	O
12	<UNK>	O
13	-	O
14	<UNK>	O
15	-	O
16	exposed	O
17	animals	O
18	.	O
1	The	O
2	<UNK>	O
3	between	O
4	viral	O
5	and	O
6	cellular	O
7	sequences	O
8	were	O
9	determined	O
10	by	O
11	DNA	O
12	sequence	O
13	analysis	O
14	to	O
15	be	O
16	<UNK>	O
17	nucleotides	O
18	into	O
19	the	O
20	<UNK>	B
21	sequence	O
22	and	O
23	1	O
24	,	O
25	<UNK>	O
26	nucleotides	O
27	into	O
28	the	O
29	polymerase	O
30	sequence	O
31	.	O
1	Expression	O
2	of	O
3	herpes	O
4	simplex	O
5	virus	O
6	beta	O
7	and	O
8	gamma	O
9	genes	O
10	integrated	O
11	in	O
12	mammalian	O
13	cells	O
14	and	O
15	their	O
16	induction	O
17	by	O
18	an	O
19	alpha	O
20	gene	O
21	product	O
22	.	O
1	This	O
2	is	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	<UNK>	O
8	that	O
9	<UNK>	O
10	was	O
11	generated	O
12	by	O
13	recombination	O
14	between	O
15	<UNK>	O
16	DNA	O
17	of	O
18	a	O
19	simian	O
20	sarcoma	O
21	associated	O
22	virus	O
23	and	O
24	proto	O
25	-	O
26	<UNK>	B
27	and	O
28	that	O
29	introns	O
30	were	O
31	spliced	O
32	out	O
33	subsequently	O
34	from	O
35	a	O
36	fused	O
37	viral	O
38	-	O
39	<UNK>	B
40	messenger	O
41	RNA	O
42	.	O
1	Each	O
2	of	O
3	these	O
4	spliced	O
5	mRNAs	O
6	has	O
7	an	O
8	untranslated	O
9	leader	O
10	sequence	O
11	of	O
12	<UNK>	O
13	bases	O
14	and	O
15	a	O
16	single	O
17	intron	O
18	of	O
19	approximately	O
20	<UNK>	O
21	bases	O
22	which	O
23	are	O
24	contained	O
25	<UNK>	O
26	within	O
27	<UNK>	O
28	/	O
29	<UNK>	O
30	sequences	O
31	.	O
1	The	O
2	<UNK>	O
3	difference	O
4	between	O
5	the	O
6	<UNK>	O
7	and	O
8	<UNK>	O
9	<UNK>	B
10	is	O
11	the	O
12	absence	O
13	,	O
14	in	O
15	the	O
16	<UNK>	O
17	protein	O
18	,	O
19	of	O
20	12	O
21	amino	O
22	acids	O
23	located	O
24	between	O
25	the	O
26	two	O
27	functional	O
28	domains	O
29	in	O
30	the	O
31	<UNK>	O
32	protein	O
33	(	O
34	amino	O
35	acids	O
36	<UNK>	O
37	-	O
38	<UNK>	O
39	).	O
1	No	O
2	significant	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	<UNK>	O
8	or	O
9	wall	O
10	thickness	O
11	and	O
12	body	O
13	surface	O
14	area	O
15	,	O
16	age	O
17	,	O
18	blood	O
19	pressure	O
20	,	O
21	heart	O
22	rate	O
23	,	O
24	cardiac	O
25	output	O
26	,	O
27	total	O
28	peripheral	O
29	resistance	O
30	and	O
31	left	O
32	ventricular	O
33	systolic	O
34	wall	O
35	stress	O
36	,	O
37	whereas	O
38	<UNK>	O
39	was	O
40	correlated	O
41	with	O
42	urinary	O
43	<UNK>	O
44	only	O
45	in	O
46	hypertensive	O
47	patients	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	<UNK>	O
54	,	O
55	p	O
56	less	O
57	than	O
58	0	O
59	.	O
60	001	O
61	).	O
1	Here	O
2	we	O
3	have	O
4	determined	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	3	O
10	.	O
11	5	O
12	kb	O
13	from	O
14	the	O
15	3	O
16	'	O
17	end	O
18	of	O
19	delta	O
20	gag	B
21	to	O
22	the	O
23	3	O
24	'	O
25	end	O
26	of	O
27	<UNK>	O
28	cloned	O
29	<UNK>	O
30	<UNK>	O
31	DNA	O
32	,	O
33	in	O
34	order	O
35	to	O
36	elucidate	O
37	the	O
38	genetic	O
39	structure	O
40	of	O
41	the	O
42	virus	O
43	and	O
44	to	O
45	compare	O
46	it	O
47	with	O
48	other	O
49	<UNK>	B
50	-	O
51	and	O
52	myc	B
53	-	O
54	containing	O
55	oncogenic	O
56	viruses	O
57	as	O
58	well	O
59	as	O
60	with	O
61	the	O
62	chicken	O
63	proto	O
64	-	O
65	myc	B
66	gene	O
67	.	O
1	Thirty	O
2	isolates	O
3	of	O
4	<UNK>	O
5	<UNK>	O
6	type	O
7	b	O
8	were	O
9	obtained	O
10	during	O
11	an	O
12	<UNK>	O
13	of	O
14	invasive	O
15	H	O
16	.	O
17	<UNK>	O
18	type	O
19	b	O
20	disease	O
21	and	O
22	were	O
23	classified	O
24	by	O
25	the	O
26	electrophoretic	O
27	profile	O
28	of	O
29	their	O
30	<UNK>	O
31	(	O
32	LPS	O
33	).	O
1	<UNK>	O
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	<UNK>	O
8	action	O
9	of	O
10	vaccine	O
11	<UNK>	O
12	in	O
13	the	O
14	<UNK>	O
15	immunization	O
16	of	O
17	<UNK>	O
18	against	O
19	<UNK>	O
20	<UNK>	O
1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	<UNK>	O
10	.	O
1	<UNK>	O
2	plasma	O
3	norepinephrine	O
4	(	O
5	NE	O
6	)	O
7	and	O
8	<UNK>	O
9	(	O
10	E	O
11	)	O
12	levels	O
13	were	O
14	lower	O
15	during	O
16	active	O
17	therapy	O
18	than	O
19	2	O
20	<UNK>	O
21	after	O
22	withdrawal	O
23	(	O
24	<UNK>	O
25	and	O
26	control	O
27	:	O
28	plasma	O
29	NE	O
30	,	O
31	0	O
32	.	O
33	27	O
34	+/-	O
35	0	O
36	.	O
37	03	O
38	/	O
39	0	O
40	.	O
41	64	O
42	+/-	O
43	0	O
44	.	O
45	13	O
46	ng	O
47	/	O
48	ml	O
49	;	O
50	plasma	O
51	E	O
52	,	O
53	0	O
54	.	O
55	<UNK>	O
56	+/-	O
57	0	O
58	.	O
59	02	O
60	/	O
61	0	O
62	.	O
63	17	O
64	+/-	O
65	0	O
66	.	O
67	05	O
68	ng	O
69	/	O
70	ml	O
71	).	O
1	The	O
2	statistical	O
3	analysis	O
4	of	O
5	data	O
6	of	O
7	<UNK>	B
8	test	O
9	on	O
10	a	O
11	sample	O
12	of	O
13	57	O
14	healthy	O
15	volunteers	O
16	has	O
17	<UNK>	O
18	an	O
19	evaluation	O
20	of	O
21	the	O
22	upper	O
23	limits	O
24	of	O
25	the	O
26	normal	O
27	<UNK>	B
28	response	O
29	;	O
30	the	O
31	secretory	O
32	area	O
33	(	O
34	As	O
35	)	O
36	was	O
37	shown	O
38	to	O
39	be	O
40	more	O
41	<UNK>	O
42	.	O
1	These	O
2	children	O
3	were	O
4	<UNK>	O
5	into	O
6	four	O
7	diagnostic	O
8	<UNK>	O
9	:	O
10	1	O
11	)	O
12	<UNK>	O
13	GH	B
14	deficiency	O
15	(	O
16	n	O
17	=	O
18	10	O
19	);	O
20	2	O
21	)	O
22	organic	O
23	<UNK>	O
24	(	O
25	n	O
26	=	O
27	7	O
28	);	O
29	3	O
30	)	O
31	<UNK>	O
32	growth	O
33	retardation	O
34	(	O
35	n	O
36	=	O
37	5	O
38	);	O
39	and	O
40	4	O
41	)	O
42	<UNK>	O
43	<UNK>	O
44	of	O
45	growth	O
46	and	O
47	/	O
48	or	O
49	<UNK>	O
50	short	O
51	<UNK>	O
52	(	O
53	n	O
54	=	O
55	18	O
56	),	O
57	by	O
58	standard	O
59	clinical	O
60	criteria	O
61	and	O
62	physiological	O
63	and	O
64	<UNK>	O
65	tests	O
66	of	O
67	GH	B
68	<UNK>	O
69	.	O
1	<UNK>	O
2	<UNK>	O
3	mg	O
4	given	O
5	at	O
6	<UNK>	O
7	is	O
8	as	O
9	effective	O
10	as	O
11	400	O
12	mg	O
13	twice	O
14	daily	O
15	;	O
16	the	O
17	single	O
18	dose	O
19	regimen	O
20	may	O
21	improve	O
22	patient	O
23	<UNK>	O
24	,	O
25	thus	O
26	<UNK>	O
27	treatment	O
28	.	O
1	Our	O
2	results	O
3	indicate	O
4	that	O
5	serum	O
6	<UNK>	O
7	is	O
8	a	O
9	<UNK>	O
10	measurement	O
11	of	O
12	bone	O
13	metabolism	O
14	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	the	O
5	luteal	O
6	phase	O
7	was	O
8	7	O
9	.	O
10	8	O
11	%	O
12	greater	O
13	than	O
14	that	O
15	in	O
16	the	O
17	follicular	O
18	phase	O
19	.	O
1	This	O
2	experiment	O
3	was	O
4	conducted	O
5	to	O
6	determine	O
7	if	O
8	the	O
9	sex	O
10	or	O
11	<UNK>	O
12	<UNK>	O
13	production	O
14	was	O
15	the	O
16	important	O
17	factor	O
18	.(	O
19	ABSTRACT	O
20	TRUNCATED	O
21	AT	O
22	250	O
23	WORDS	O
24	)	O
1	In	O
2	two	O
3	experiments	O
4	,	O
5	neonatal	O
6	female	O
7	BALB	O
8	/	O
9	<UNK>	O
10	or	O
11	BALB	O
12	/	O
13	<UNK>	O
14	mice	O
15	were	O
16	given	O
17	subcutaneous	O
18	injections	O
19	of	O
20	5	O
21	micrograms	O
22	17	O
23	beta	O
24	-	O
25	estradiol	O
26	or	O
27	<UNK>	O
28	oil	O
29	for	O
30	the	O
31	first	O
32	3	O
33	days	O
34	of	O
35	life	O
36	and	O
37	were	O
38	<UNK>	O
39	at	O
40	60	O
41	days	O
42	of	O
43	age	O
44	,	O
45	at	O
46	which	O
47	time	O
48	<UNK>	O
49	<UNK>	O
50	(	O
51	<UNK>	O
52	I	O
53	and	O
54	II	O
55	)	O
56	or	O
57	<UNK>	O
58	(	O
59	<UNK>	O
60	II	O
61	)	O
62	were	O
63	<UNK>	O
64	<UNK>	O
65	.	O
1	Significant	O
2	alterations	O
3	in	O
4	the	O
5	<UNK>	O
6	rats	O
7	from	O
8	<UNK>	O
9	rats	O
10	included	O
11	:	O
12	<UNK>	O
13	and	O
14	<UNK>	O
15	hypertrophy	O
16	,	O
17	formation	O
18	of	O
19	<UNK>	O
20	<UNK>	O
21	<UNK>	O
22	<UNK>	O
23	,	O
24	decreased	O
25	total	O
26	serum	O
27	protein	O
28	,	O
29	<UNK>	O
30	alpha	O
31	-	O
32	globulin	B
33	levels	O
34	as	O
35	shown	O
36	by	O
37	serum	O
38	electrophoresis	O
39	,	O
40	and	O
41	increased	O
42	sperm	O
43	<UNK>	B
44	antibody	O
45	<UNK>	O
46	.	O
1	E2	O
2	treatments	O
3	elevated	O
4	<UNK>	O
5	plasma	O
6	TG	O
7	7	O
8	.	O
9	<UNK>	O
10	,	O
11	PL	O
12	5	O
13	.	O
14	<UNK>	O
15	,	O
16	and	O
17	C	O
18	7	O
19	.	O
20	<UNK>	O
21	;	O
22	and	O
23	<UNK>	O
24	plasma	O
25	TG	O
26	6	O
27	.	O
28	<UNK>	O
29	,	O
30	PL	O
31	3	O
32	.	O
33	<UNK>	O
34	,	O
35	and	O
36	C	O
37	2	O
38	.	O
39	<UNK>	O
40	.	O
1	By	O
2	contrast	O
3	,	O
4	<UNK>	O
5	from	O
6	rats	O
7	with	O
8	chronic	O
9	metabolic	O
10	<UNK>	O
11	produced	O
12	significantly	O
13	more	O
14	<UNK>	O
15	than	O
16	both	O
17	these	O
18	groups	O
19	(	O
20	2	O
21	.	O
22	73	O
23	+/-	O
24	0	O
25	.	O
26	29	O
27	<UNK>	O
28	X	O
29	min	O
30	-	O
31	1	O
32	X	O
33	g	O
34	-	O
35	1	O
36	).	O
1	<UNK>	B
2	cyclase	I
3	activity	O
4	of	O
5	gastric	O
6	mucosa	O
7	in	O
8	patients	O
9	with	O
10	duodenal	O
11	ulcer	O
12	before	O
13	and	O
14	after	O
15	treatment	O
1	<UNK>	O
2	from	O
3	all	O
4	3	O
5	species	O
6	yielded	O
7	maximum	O
8	responses	O
9	with	O
10	a	O
11	48	O
12	-	O
13	hour	O
14	<UNK>	O
15	and	O
16	12	O
17	-	O
18	to	O
19	-	O
20	16	O
21	hour	O
22	<UNK>	O
23	<UNK>	O
24	period	O
25	at	O
26	41	O
27	C	O
28	and	O
29	1	O
30	:	O
31	20	O
32	blood	O
33	dilution	O
34	.	O
1	The	O
2	<UNK>	O
3	and	O
4	regional	O
5	<UNK>	O
6	of	O
7	the	O
8	<UNK>	O
9	,	O
10	<UNK>	O
11	and	O
12	common	O
13	<UNK>	O
14	nerves	O
15	to	O
16	the	O
17	<UNK>	O
18	<UNK>	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	O
34	phosphatase	B
35	(	O
36	<UNK>	B
37	)	O
38	method	O
39	.	O
1	Human	O
2	thyroid	O
3	<UNK>	O
4	(	O
5	<UNK>	B
6	)	O
7	in	O
8	thyroid	O
9	diseases	O
1	An	O
2	experimental	O
3	long	O
4	-	O
5	term	O
6	study	O
7	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	<UNK>	O
7	the	O
8	venous	O
9	system	O
10	as	O
11	efficiently	O
12	as	O
13	the	O
14	double	O
15	<UNK>	O
16	<UNK>	O
17	.	O
1	During	O
2	a	O
3	single	O
4	<UNK>	O
5	occlusion	O
6	<UNK>	O
7	35	O
8	minutes	O
9	(	O
10	series	O
11	I	O
12	,	O
13	n	O
14	=	O
15	10	O
16	)	O
17	9	O
18	<UNK>	O
19	<UNK>	O
20	were	O
21	<UNK>	O
22	immediately	O
23	and	O
24	30	O
25	minutes	O
26	after	O
27	ligation	O
28	,	O
29	15	O
30	<UNK>	O
31	<UNK>	O
32	being	O
33	<UNK>	O
34	after	O
35	15	O
36	-	O
37	20	O
38	minutes	O
39	.	O
1	HL	O
2	02	O
3	type	O
4	<UNK>	O
5	<UNK>	O
6	.	O
1	<UNK>	O
2	of	O
3	a	O
4	<UNK>	O
5	syndrome	O
6	and	O
7	a	O
8	complex	O
9	granulocyte	B
10	function	O
11	disorder	O
12	in	O
13	a	O
14	<UNK>	O
1	The	O
2	subgroup	O
3	<UNK>	O
4	the	O
5	medial	O
6	<UNK>	O
7	lies	O
8	exclusively	O
9	along	O
10	the	O
11	medial	O
12	face	O
13	of	O
14	the	O
15	<UNK>	O
16	nucleus	O
17	,	O
18	with	O
19	no	O
20	aberrant	O
21	neurons	O
22	in	O
23	the	O
24	medial	O
25	<UNK>	O
26	<UNK>	O
27	,	O
28	as	O
29	have	O
30	been	O
31	found	O
32	in	O
33	other	O
34	mammals	O
35	.	O
1	The	O
2	authors	O
3	have	O
4	tested	O
5	the	O
6	interference	O
7	of	O
8	the	O
9	hemoglobin	B
10	by	O
11	two	O
12	routine	O
13	methods	O
14	(	O
15	<UNK>	O
16	<UNK>	O
17	and	O
18	<UNK>	O
19	modified	O
20	)	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	<UNK>	O
26	urea	O
27	.	O
1	<UNK>	O
2	N	O
3	-	O
4	<UNK>	B
5	activity	O
6	per	O
7	mg	O
8	creatinine	O
9	did	O
10	not	O
11	differ	O
12	significantly	O
13	between	O
14	groups	O
15	.	O
1	After	O
2	1	O
3	.	O
4	5	O
5	years	O
6	of	O
7	such	O
8	<UNK>	O
9	control	O
10	,	O
11	all	O
12	<UNK>	O
13	were	O
14	<UNK>	O
15	by	O
16	bilateral	O
17	<UNK>	O
18	<UNK>	O
19	.	O
1	The	O
2	range	O
3	of	O
4	serum	O
5	concentrations	O
6	,	O
7	mean	O
8	values	O
9	,	O
10	median	O
11	values	O
12	,	O
13	and	O
14	standard	O
15	<UNK>	O
16	for	O
17	each	O
18	<UNK>	O
19	are	O
20	reported	O
21	for	O
22	males	O
23	and	O
24	females	O
25	and	O
26	for	O
27	three	O
28	age	O
29	groups	O
30	(	O
31	25	O
32	-	O
33	44	O
34	,	O
35	45	O
36	-	O
37	59	O
38	,	O
39	60	O
40	-	O
41	70	O
42	).	O
1	The	O
2	<UNK>	B
3	levels	O
4	were	O
5	within	O
6	the	O
7	physiological	O
8	<UNK>	O
9	;	O
10	the	O
11	responses	O
12	to	O
13	<UNK>	B
14	were	O
15	normal	O
16	,	O
17	and	O
18	elevated	O
19	only	O
20	in	O
21	a	O
22	few	O
23	cases	O
24	.	O
1	<UNK>	B
2	III	O
3	in	O
4	hip	O
5	surgery	O
1	<UNK>	O
2	concentration	O
3	in	O
4	the	O
5	<UNK>	O
6	indicated	O
7	little	O
8	,	O
9	if	O
10	any	O
11	accumulation	O
12	.	O
1	No	O
2	patient	O
3	with	O
4	<UNK>	O
5	-	O
6	related	O
7	<UNK>	O
8	had	O
9	<UNK>	O
10	<UNK>	O
11	block	O
12	or	O
13	<UNK>	O
14	branch	O
15	block	O
16	.	O
1	The	O
2	maps	O
3	of	O
4	<UNK>	O
5	2	O
6	showed	O
7	that	O
8	a	O
9	maximum	O
10	first	O
11	appeared	O
12	on	O
13	the	O
14	upper	O
15	right	O
16	back	O
17	and	O
18	then	O
19	<UNK>	O
20	down	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	posterior	O
27	<UNK>	O
28	.	O
1	<UNK>	O
2	<UNK>	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	<UNK>	O
10	(	O
11	<UNK>	O
12	<UNK>	O
13	<UNK>	O
14	<UNK>	O
15	)	O
16	type	O
17	F	O
18	<UNK>	O
19	-	O
20	<UNK>	O
21	implant	O
1	1	O
2	.	O
1	The	O
2	alterations	O
3	in	O
4	differentiation	O
5	of	O
6	<UNK>	O
7	cells	O
8	,	O
9	together	O
10	with	O
11	the	O
12	failure	O
13	of	O
14	<UNK>	O
15	,	O
16	resulted	O
17	in	O
18	significantly	O
19	lower	O
20	rates	O
21	of	O
22	bone	O
23	formation	O
24	(	O
25	as	O
26	measured	O
27	by	O
28	<UNK>	O
29	labeling	O
30	)	O
31	in	O
32	the	O
33	magnesium	O
34	-	O
35	deficient	O
36	rats	O
37	.	O
1	<UNK>	O
2	of	O
3	C	O
4	mu	O
5	RNAs	O
6	,	O
7	unlike	O
8	mu	O
9	mRNAs	O
10	,	O
11	does	O
12	not	O
13	require	O
14	recombination	O
15	with	O
16	the	O
17	joining	O
18	region	O
19	(	O
20	<UNK>	B
21	)	O
22	locus	O
23	.	O
1	<UNK>	O
2	of	O
3	the	O
4	immunoglobulin	B
5	C	O
6	mu	O
7	gene	O
8	<UNK>	O
9	in	O
10	structure	O
11	and	O
12	splicing	O
13	during	O
14	lymphoid	O
15	development	O
16	.	O
1	The	O
2	role	O
3	of	O
4	DNA	O
5	<UNK>	O
6	and	O
7	alternative	O
8	RNA	O
9	processing	O
10	in	O
11	the	O
12	expression	O
13	of	O
14	immunoglobulin	B
15	delta	O
16	genes	O
17	.	O
1	Although	O
2	the	O
3	mechanism	O
4	of	O
5	action	O
6	of	O
7	<UNK>	O
8	-	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	has	O
13	not	O
14	been	O
15	clearly	O
16	defined	O
17	,	O
18	it	O
19	is	O
20	evident	O
21	from	O
22	both	O
23	<UNK>	O
24	and	O
25	early	O
26	clinical	O
27	studies	O
28	that	O
29	these	O
30	compounds	O
31	are	O
32	of	O
33	interest	O
34	.	O
1	The	O
2	sympathetic	O
3	<UNK>	O
4	influence	O
5	on	O
6	the	O
7	myocardium	O
8	with	O
9	<UNK>	O
10	depends	O
11	to	O
12	a	O
13	large	O
14	measure	O
15	on	O
16	the	O
17	intensity	O
18	of	O
19	the	O
20	<UNK>	O
21	biosynthesis	O
22	and	O
23	function	O
24	of	O
25	<UNK>	O
26	<UNK>	O
27	.	O
1	The	O
2	already	O
3	elevated	O
4	prolactin	B
5	levels	O
6	in	O
7	<UNK>	O
8	women	O
9	were	O
10	not	O
11	influenced	O
12	by	O
13	chronic	O
14	<UNK>	O
15	administration	O
16	.	O
1	Comparison	O
2	of	O
3	three	O
4	different	O
5	preparations	O
6	of	O
7	<UNK>	O
8	<UNK>	O
9	in	O
10	the	O
11	prevention	O
12	of	O
13	exercise	O
14	-	O
15	induced	O
16	<UNK>	O
17	:	O
18	a	O
19	double	O
20	-	O
21	blind	O
22	study	O
23	.	O
1	<UNK>	O
2	<UNK>	O
3	did	O
4	not	O
5	rise	O
6	within	O
7	12	O
8	h	O
9	after	O
10	<UNK>	O
11	infusion	O
12	a	O
13	finding	O
14	which	O
15	<UNK>	O
16	further	O
17	investigation	O
18	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	was	O
6	administered	O
7	to	O
8	21	O
9	patients	O
10	.	O
1	Of	O
2	<UNK>	O
3	patients	O
4	with	O
5	well	O
6	-	O
7	defined	O
8	drug	O
9	reactions	O
10	,	O
11	<UNK>	O
12	(	O
13	70	O
14	per	O
15	cent	O
16	)	O
17	gave	O
18	a	O
19	positive	O
20	response	O
21	to	O
22	the	O
23	mast	O
24	cell	O
25	test	O
26	.	O
1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	<UNK>	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	<UNK>	O
22	the	O
23	observed	O
24	CBF	O
25	fall	O
26	of	O
27	27	O
28	%.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	after	O
5	deep	O
6	<UNK>	O
7	(	O
8	20	O
9	degrees	O
10	C	O
11	)	O
12	causes	O
13	a	O
14	considerable	O
15	increase	O
16	in	O
17	the	O
18	brain	O
19	tissues	O
20	<UNK>	B
21	activity	O
22	at	O
23	all	O
24	studied	O
25	<UNK>	O
26	<UNK>	O
27	(	O
28	37	O
29	,	O
30	30	O
31	,	O
32	20	O
33	and	O
34	10	O
35	degrees	O
36	C	O
37	)	O
38	as	O
39	compared	O
40	to	O
41	control	O
42	rats	O
43	and	O
44	rats	O
45	under	O
46	<UNK>	O
47	.	O
1	Significant	O
2	<UNK>	O
3	<UNK>	O
4	occurred	O
5	in	O
6	early	O
7	shock	O
8	in	O
9	both	O
10	treatment	O
11	groups	O
12	.	O
1	<UNK>	O
2	of	O
3	exercise	O
4	-	O
5	induced	O
6	<UNK>	O
7	by	O
8	M	O
9	-	O
10	mode	O
11	<UNK>	O
12	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	significant	O
6	pulmonary	O
7	metabolism	O
8	of	O
9	5	O
10	-	O
11	HT	O
12	followed	O
13	by	O
14	<UNK>	O
15	of	O
16	5	O
17	-	O
18	<UNK>	O
19	into	O
20	venous	O
21	output	O
22	occurs	O
23	during	O
24	single	O
25	-	O
26	<UNK>	O
27	circulation	O
28	.	O
1	<UNK>	O
2	of	O
3	placental	O
4	maturation	O
5	,	O
6	2	O
7	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	<UNK>	O
6	findings	O
7	,	O
8	the	O
9	origin	O
10	of	O
11	<UNK>	O
12	appeared	O
13	to	O
14	be	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	fibroblasts	O
20	.	O
1	Both	O
2	groups	O
3	were	O
4	subjected	O
5	to	O
6	tests	O
7	of	O
8	delayed	O
9	hypersensitivity	O
10	with	O
11	<UNK>	B
12	,	O
13	<UNK>	B
14	and	O
15	<UNK>	B
16	.	O
1	<UNK>	O
2	<UNK>	O
3	to	O
4	improve	O
5	the	O
6	diagnosis	O
7	when	O
8	compared	O
9	with	O
10	classical	O
11	<UNK>	O
12	in	O
13	about	O
14	20	O
15	%	O
16	of	O
17	cases	O
18	.	O
1	Total	O
2	<UNK>	O
3	levels	O
4	in	O
5	<UNK>	O
6	fluid	O
7	remained	O
8	significantly	O
9	depressed	O
10	in	O
11	the	O
12	patient	O
13	group	O
14	for	O
15	24	O
16	hours	O
17	after	O
18	the	O
19	400	O
20	-	O
21	mg	O
22	test	O
23	dose	O
24	of	O
25	<UNK>	O
26	on	O
27	day	O
28	8	O
29	.	O
1	<UNK>	O
2	of	O
3	111	O
4	<UNK>	O
5	-	O
6	labelled	O
7	<UNK>	O
8	<UNK>	O
9	was	O
10	studied	O
11	in	O
12	2	O
13	patients	O
14	after	O
15	correction	O
16	of	O
17	platelet	O
18	count	O
19	and	O
20	was	O
21	still	O
22	found	O
23	<UNK>	O
24	.	O
1	When	O
2	O2	O
3	therapy	O
4	was	O
5	controlled	O
6	for	O
7	,	O
8	the	O
9	association	O
10	between	O
11	<UNK>	O
12	and	O
13	<UNK>	O
14	did	O
15	not	O
16	achieve	O
17	statistical	O
18	significance	O
19	(	O
20	P	O
21	=	O
22	.	O
23	07	O
24	).	O
1	<UNK>	O
2	for	O
3	<UNK>	O
4	<UNK>	O
5	--	O
6	3	O
7	.	O
1	Thus	O
2	it	O
3	appears	O
4	that	O
5	the	O
6	management	O
7	of	O
8	blood	O
9	,	O
10	including	O
11	<UNK>	O
12	is	O
13	of	O
14	great	O
15	importance	O
16	.	O
1	<UNK>	O
2	creatine	B
3	kinase	I
4	activity	O
5	<UNK>	O
6	<UNK>	O
7	from	O
8	a	O
9	single	O
10	peak	O
11	,	O
12	<UNK>	B
13	appeared	O
14	in	O
15	multiple	O
16	episodes	O
17	<UNK>	O
18	<UNK>	O
19	by	O
20	a	O
21	single	O
22	peak	O
23	value	O
24	and	O
25	having	O
26	no	O
27	clear	O
28	clinical	O
29	correlation	O
30	.	O
1	Specific	O
2	IgE	B
3	levels	O
4	decreased	O
5	slightly	O
6	,	O
7	but	O
8	always	O
9	remained	O
10	within	O
11	the	O
12	pathological	O
13	range	O
14	.	O
1	<UNK>	B
2	and	O
3	<UNK>	O
4	<UNK>	O
5	.	O
1	The	O
2	<UNK>	O
3	results	O
4	show	O
5	that	O
6	<UNK>	O
7	has	O
8	high	O
9	efficacy	O
10	and	O
11	safety	O
12	and	O
13	it	O
14	can	O
15	be	O
16	<UNK>	O
17	that	O
18	it	O
19	is	O
20	a	O
21	drug	O
22	required	O
23	in	O
24	the	O
25	pediatric	O
26	field	O
27	.	O
1	(	O
2	<UNK>	O
3	):	O
4	<UNK>	O
5	<UNK>	O
6	,	O
7	77	O
8	-	O
9	72	O
10	)	O
11	that	O
12	stimulating	O
13	the	O
14	<UNK>	O
15	<UNK>	O
16	<UNK>	O
17	(	O
18	<UNK>	O
19	)	O
20	can	O
21	change	O
22	the	O
23	magnitude	O
24	of	O
25	the	O
26	<UNK>	O
27	product	O
28	(	O
29	<UNK>	O
30	-	O
31	<UNK>	O
32	)	O
33	in	O
34	the	O
35	ear	O
36	-	O
37	<UNK>	O
38	<UNK>	O
39	pressure	O
40	.	O
1	We	O
2	compared	O
3	the	O
4	volume	O
5	of	O
6	the	O
7	pulmonary	O
8	<UNK>	O
9	,	O
10	extracellular	O
11	water	O
12	space	O
13	using	O
14	sodium	O
15	and	O
16	<UNK>	O
17	indicators	O
18	in	O
19	8	O
20	normal	O
21	and	O
22	11	O
23	<UNK>	O
24	rabbit	O
25	lungs	O
26	by	O
27	steady	O
28	-	O
29	state	O
30	techniques	O
31	.	O
1	<UNK>	O
2	to	O
3	<UNK>	O
4	with	O
5	these	O
6	and	O
7	related	O
8	<UNK>	O
9	are	O
10	presented	O
11	.	O
1	The	O
2	differential	O
3	investigation	O
4	of	O
5	<UNK>	O
6	,	O
7	however	O
8	,	O
9	showed	O
10	that	O
11	the	O
12	high	O
13	-	O
14	density	O
15	lipoprotein	O
16	(	O
17	HDL	B
18	)	O
19	fractions	O
20	are	O
21	<UNK>	O
22	or	O
23	relatively	O
24	decreased	O
25	with	O
26	respect	O
27	to	O
28	low	O
29	-	O
30	density	O
31	<UNK>	O
32	(	O
33	LDL	B
34	)	O
35	in	O
36	cerebral	O
37	<UNK>	O
38	and	O
39	in	O
40	transient	O
41	<UNK>	O
42	<UNK>	O
43	.	O
1	<UNK>	O
2	obtained	O
3	from	O
4	normal	O
5	volunteers	O
6	and	O
7	from	O
8	the	O
9	great	O
10	majority	O
11	of	O
12	the	O
13	patients	O
14	,	O
15	<UNK>	O
16	those	O
17	with	O
18	asthma	O
19	,	O
20	had	O
21	no	O
22	effect	O
23	on	O
24	<UNK>	O
25	<UNK>	O
26	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	<UNK>	O
5	acid	O
6	and	O
7	m	O
8	-	O
9	and	O
10	p	O
11	-	O
12	<UNK>	O
13	acid	O
14	have	O
15	been	O
16	determined	O
17	in	O
18	the	O
19	plasma	O
20	of	O
21	normal	O
22	,	O
23	healthy	O
24	subjects	O
25	after	O
26	<UNK>	O
27	,	O
28	consumption	O
29	of	O
30	a	O
31	<UNK>	O
32	and	O
33	ingestion	O
34	of	O
35	<UNK>	O
36	labelled	O
37	<UNK>	O
38	precursors	O
39	,	O
40	by	O
41	high	O
42	-	O
43	resolution	O
44	gas	O
45	chromatography	O
46	--	O
47	high	O
48	resolution	O
49	mass	O
50	<UNK>	O
51	with	O
52	selected	O
53	ion	O
54	monitoring	O
55	of	O
56	their	O
57	<UNK>	O
58	-	O
59	<UNK>	O
60	derivatives	O
61	.	O
1	CSF	B
2	adenosine	O
3	<UNK>	B
4	activity	O
5	(	O
6	<UNK>	O
7	)	O
8	was	O
9	measured	O
10	at	O
11	the	O
12	same	O
13	time	O
14	.	O
1	<UNK>	O
2	reactivity	O
3	had	O
4	<UNK>	O
5	to	O
6	normal	O
7	in	O
8	half	O
9	the	O
10	workers	O
11	who	O
12	had	O
13	left	O
14	their	O
15	original	O
16	<UNK>	O
17	,	O
18	but	O
19	in	O
20	only	O
21	one	O
22	<UNK>	O
23	who	O
24	had	O
25	<UNK>	O
26	within	O
27	<UNK>	O
28	original	O
29	<UNK>	O
30	.	O
1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	<UNK>	O
8	between	O
9	the	O
10	two	O
11	studies	O
12	,	O
13	both	O
14	at	O
15	rest	O
16	(	O
17	56	O
18	.	O
19	0	O
20	+/-	O
21	13	O
22	.	O
23	8	O
24	%	O
25	vs	O
26	58	O
27	.	O
28	2	O
29	+/-	O
30	11	O
31	.	O
32	7	O
33	%,	O
34	p	O
35	=	O
36	<UNK>	O
37	)	O
38	and	O
39	with	O
40	exercise	O
41	(	O
42	51	O
43	.	O
44	1	O
45	+/-	O
46	17	O
47	.	O
48	6	O
49	%	O
50	vs	O
51	54	O
52	.	O
53	3	O
54	+/-	O
55	17	O
56	.	O
57	6	O
58	%,	O
59	p	O
60	=	O
61	<UNK>	O
62	)	O
63	and	O
64	a	O
65	highly	O
66	significant	O
67	correlation	O
68	was	O
69	shown	O
70	between	O
71	the	O
72	two	O
73	groups	O
74	of	O
75	values	O
76	(	O
77	rest	O
78	r	O
79	=	O
80	0	O
81	.	O
82	90	O
83	,	O
84	exercise	O
85	r	O
86	=	O
87	0	O
88	.	O
89	93	O
90	,	O
91	p	O
92	less	O
93	than	O
94	0	O
95	.	O
96	001	O
97	).	O
1	After	O
2	<UNK>	O
3	therapy	O
4	,	O
5	complete	O
6	remission	O
7	of	O
8	Hodgkin	O
9	'	O
10	s	O
11	disease	O
12	was	O
13	accompanied	O
14	by	O
15	<UNK>	O
16	of	O
17	the	O
18	<UNK>	B
19	level	O
20	and	O
21	<UNK>	O
22	of	O
23	<UNK>	O
24	'	O
25	s	O
26	cells	O
27	.	O
1	<UNK>	O
2	:	O
3	A	O
4	modified	O
5	method	O
6	for	O
7	the	O
8	in	O
9	vivo	O
10	labeling	O
11	of	O
12	red	O
13	blood	O
14	cells	O
15	with	O
16	Tc	O
17	-	O
18	99m	O
19	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	at	O
5	the	O
6	site	O
7	of	O
8	the	O
9	entry	O
10	of	O
11	blood	O
12	vessels	O
13	into	O
14	the	O
15	central	O
16	nervous	O
17	system	O
18	.	O
1	<UNK>	O
2	<UNK>	O
3	and	O
4	<UNK>	O
1	In	O
2	vitro	O
3	<UNK>	O
4	tests	O
5	of	O
6	human	O
7	sperm	O
8	into	O
9	cervical	O
10	<UNK>	O
11	were	O
12	introduced	O
13	in	O
14	order	O
15	to	O
16	study	O
17	the	O
18	interaction	O
19	between	O
20	sperm	O
21	and	O
22	cervical	O
23	<UNK>	O
24	.	O
1	Serum	O
2	creatine	B
3	kinase	I
4	(	O
5	<UNK>	B
6	)	O
7	was	O
8	measured	O
9	in	O
10	ten	O
11	subjects	O
12	in	O
13	the	O
14	laboratory	O
15	before	O
16	and	O
17	after	O
18	the	O
19	performance	O
20	of	O
21	<UNK>	O
22	<UNK>	O
23	and	O
24	a	O
25	<UNK>	O
26	task	O
27	.	O
1	It	O
2	is	O
3	<UNK>	O
4	that	O
5	altered	O
6	blood	O
7	flow	O
8	,	O
9	mediated	O
10	through	O
11	the	O
12	well	O
13	-	O
14	known	O
15	prostaglandin	O
16	synthetase	B
17	inhibitory	O
18	effects	O
19	of	O
20	<UNK>	O
21	,	O
22	resulted	O
23	in	O
24	tubular	O
25	necrosis	O
26	.	O
1	<UNK>	O
2	20	O
3	mg	O
4	<UNK>	O
5	/	O
6	20	O
7	ml	O
8	<UNK>	O
9	water	O
10	or	O
11	40	O
12	mg	O
13	/	O
14	40	O
15	ml	O
16	<UNK>	O
17	water	O
18	was	O
19	<UNK>	O
20	<UNK>	O
21	into	O
22	the	O
23	bladder	O
24	with	O
25	a	O
26	catheter	O
27	after	O
28	emptying	O
29	it	O
30	and	O
31	was	O
32	left	O
33	for	O
34	about	O
35	25	O
36	-	O
37	<UNK>	O
38	min	O
39	.	O
1	<UNK>	O
2	secretion	O
3	in	O
4	<UNK>	O
1	At	O
2	an	O
3	<UNK>	O
4	temperature	O
5	of	O
6	25	O
7	degrees	O
8	C	O
9	,	O
10	the	O
11	responses	O
12	to	O
13	spinal	O
14	<UNK>	O
15	are	O
16	reduced	O
17	during	O
18	the	O
19	dark	O
20	phase	O
21	.	O
1	<UNK>	O
2	features	O
3	of	O
4	<UNK>	O
5	<UNK>	O
6	.	O
1	Following	O
2	extended	O
3	recovery	O
4	<UNK>	O
5	EEG	O
6	was	O
7	normal	O
8	despite	O
9	extensive	O
10	cellular	O
11	loss	O
12	in	O
13	areas	O
14	<UNK>	O
15	and	O
16	<UNK>	O
17	.	O
1	<UNK>	O
2	potential	O
3	and	O
4	single	O
5	unit	O
6	responses	O
7	to	O
8	olfactory	O
9	nerve	O
10	<UNK>	O
11	in	O
12	the	O
13	isolated	O
14	<UNK>	O
15	olfactory	O
16	<UNK>	O
17	.	O
1	<UNK>	O
2	reactivity	O
3	in	O
4	theophylline	O
5	<UNK>	O
6	kit	O
7	decreased	O
8	.	O
1	<UNK>	O
2	of	O
3	the	O
4	digital	O
5	<UNK>	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	<UNK>	O
11	with	O
12	the	O
13	<UNK>	O
14	and	O
15	strain	O
16	-	O
17	<UNK>	O
18	methods	O
19	.	O
1	The	O
2	oral	O
3	temperature	O
4	rose	O
5	and	O
6	the	O
7	serum	O
8	creatine	B
9	kinase	I
10	levels	O
11	fell	O
12	only	O
13	in	O
14	those	O
15	patients	O
16	who	O
17	were	O
18	<UNK>	O
19	<UNK>	O
20	.	O
1	<UNK>	O
2	of	O
3	aortic	O
4	<UNK>	O
5	and	O
6	its	O
7	variations	O
8	in	O
9	arterial	O
10	hypertension	O
11	.	O
1	Effects	O
2	of	O
3	early	O
4	<UNK>	O
5	<UNK>	O
6	on	O
7	development	O
8	of	O
9	<UNK>	O
10	-	O
11	<UNK>	O
12	<UNK>	O
13	in	O
14	the	O
15	cat	O
16	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	as	O
5	a	O
6	single	O
7	procedure	O
8	.	O
1	The	O
2	new	O
3	<UNK>	O
4	-	O
5	synthetic	O
6	oral	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	9	O
11	,	O
12	000	O
13	,	O
14	has	O
15	been	O
16	evaluated	O
17	in	O
18	a	O
19	large	O
20	number	O
21	of	O
22	<UNK>	O
23	patients	O
24	with	O
25	urinary	O
26	infections	O
27	.	O
1	33	O
2	out	O
3	of	O
4	90	O
5	neurons	O
6	of	O
7	the	O
8	cat	O
9	medial	O
10	<UNK>	O
11	body	O
12	revealed	O
13	the	O
14	<UNK>	O
15	of	O
16	their	O
17	<UNK>	O
18	to	O
19	movement	O
20	of	O
21	<UNK>	O
22	when	O
23	velocity	O
24	of	O
25	the	O
26	movement	O
27	changed	O
28	from	O
29	30	O
30	to	O
31	180	O
32	<UNK>	O
33	/	O
34	s	O
35	.	O
1	Based	O
2	on	O
3	<UNK>	O
4	<UNK>	O
5	analyses	O
6	,	O
7	the	O
8	<UNK>	O
9	of	O
10	<UNK>	O
11	were	O
12	found	O
13	to	O
14	be	O
15	linear	O
16	within	O
17	the	O
18	dose	O
19	<UNK>	O
20	studied	O
21	(	O
22	50	O
23	to	O
24	200	O
25	mg	O
26	for	O
27	i	O
28	.	O
29	v	O
30	.	O
31	injection	O
32	and	O
33	150	O
34	to	O
35	<UNK>	O
36	mg	O
37	for	O
38	oral	O
39	administration	O
40	).	O
1	<UNK>	B
2	secretion	O
3	during	O
4	food	O
5	stimulation	O
6	in	O
7	<UNK>	O
8	system	O
9	diseases	O
1	<UNK>	O
2	or	O
3	<UNK>	O
4	emptying	O
5	regions	O
6	of	O
7	the	O
8	left	O
9	ventricle	O
10	were	O
11	detected	O
12	by	O
13	a	O
14	relatively	O
15	new	O
16	nuclear	O
17	technique	O
18	--	O
19	phase	O
20	imaging	O
21	.	O
1	<UNK>	O
2	patients	O
3	with	O
4	non	O
5	-	O
6	<UNK>	O
7	<UNK>	O
8	with	O
9	<UNK>	O
10	subsequently	O
11	had	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	<UNK>	O
17	<UNK>	O
18	performed	O
19	.	O
1	<UNK>	O
2	microscopic	O
3	<UNK>	O
4	of	O
5	the	O
6	cerebral	O
7	cortex	O
8	in	O
9	rats	O
10	<UNK>	O
11	to	O
12	22	O
13	degrees	O
14	C	O
1	A	O
2	<UNK>	O
3	thin	O
4	-	O
5	layer	O
6	chromatographic	O
7	determination	O
8	of	O
9	<UNK>	O
10	acid	O
11	and	O
12	<UNK>	O
13	acids	O
14	.	O
1	The	O
2	<UNK>	O
3	mean	O
4	<UNK>	O
5	-	O
6	inhibition	O
7	antibody	O
8	<UNK>	O
9	(	O
10	<UNK>	O
11	)	O
12	of	O
13	non	O
14	-	O
15	<UNK>	O
16	,	O
17	once	O
18	-	O
19	<UNK>	O
20	,	O
21	and	O
22	twice	O
23	-	O
24	<UNK>	O
25	chickens	O
26	were	O
27	compared	O
28	at	O
29	2	O
30	-	O
31	week	O
32	intervals	O
33	following	O
34	primary	O
35	immunization	O
36	,	O
37	secondary	O
38	immunization	O
39	,	O
40	and	O
41	challenge	O
42	.	O
1	2	O
2	.	O
3	numerous	O
4	<UNK>	O
5	<UNK>	O
6	vessels	O
7	<UNK>	O
8	<UNK>	O
9	from	O
10	the	O
11	primary	O
12	arteries	O
13	to	O
14	feed	O
15	a	O
16	secondary	O
17	arterial	O
18	system	O
19	which	O
20	<UNK>	O
21	the	O
22	primary	O
23	one	O
24	.	O
1	The	O
2	authors	O
3	conclude	O
4	that	O
5	<UNK>	O
6	of	O
7	low	O
8	platelet	O
9	MAO	B
10	as	O
11	a	O
12	possible	O
13	correlate	O
14	of	O
15	<UNK>	O
16	<UNK>	O
17	disorder	O
18	,	O
19	as	O
20	well	O
21	as	O
22	<UNK>	O
23	,	O
24	increases	O
25	the	O
26	<UNK>	O
27	of	O
28	<UNK>	O
29	necessary	O
30	before	O
31	findings	O
32	of	O
33	low	O
34	platelet	O
35	MAO	B
36	can	O
37	be	O
38	<UNK>	O
39	as	O
40	primary	O
41	.	O
1	<UNK>	O
2	,	O
3	a	O
4	known	O
5	disease	O
6	,	O
7	of	O
8	which	O
9	little	O
10	is	O
11	known	O
1	However	O
2	,	O
3	at	O
4	lower	O
5	temperature	O
6	the	O
7	positive	O
8	<UNK>	O
9	was	O
10	not	O
11	clear	O
12	and	O
13	rather	O
14	negative	O
15	<UNK>	O
16	appeared	O
17	(	O
18	1	O
19	--	O
20	3	O
21	Hz	O
22	).	O
1	A	O
2	16	O
3	-	O
4	year	O
5	follow	O
6	-	O
7	up	O
8	study	O
9	of	O
10	69	O
11	<UNK>	O
12	with	O
13	complete	O
14	lesions	O
15	from	O
16	T1	O
17	-	O
18	<UNK>	O
19	is	O
20	presented	O
21	.	O
1	<UNK>	O
2	extraction	O
3	in	O
4	primary	O
5	<UNK>	O
1	We	O
2	report	O
3	a	O
4	case	O
5	of	O
6	<UNK>	O
7	<UNK>	O
8	during	O
9	the	O
10	third	O
11	<UNK>	O
12	of	O
13	pregnancy	O
14	.	O
1	<UNK>	O
2	plasma	O
3	and	O
4	lipoprotein	O
5	lipid	O
6	concentrations	O
7	,	O
8	<UNK>	O
9	tissue	O
10	lipoprotein	O
11	lipase	B
12	activity	O
13	,	O
14	<UNK>	O
15	data	O
16	,	O
17	alcohol	O
18	consumption	O
19	,	O
20	smoking	O
21	<UNK>	O
22	,	O
23	weekly	O
24	<UNK>	O
25	<UNK>	O
26	and	O
27	performance	O
28	on	O
29	a	O
30	<UNK>	O
31	<UNK>	O
32	were	O
33	recorded	O
34	before	O
35	and	O
36	after	O
37	the	O
38	training	O
39	period	O
40	.	O
1	Our	O
2	study	O
3	differs	O
4	from	O
5	previous	O
6	studies	O
7	in	O
8	that	O
9	it	O
10	is	O
11	limited	O
12	to	O
13	one	O
14	diagnostic	O
15	<UNK>	O
16	,	O
17	yet	O
18	at	O
19	the	O
20	same	O
21	time	O
22	<UNK>	O
23	a	O
24	broad	O
25	range	O
26	of	O
27	social	O
28	and	O
29	work	O
30	-	O
31	related	O
32	factors	O
33	in	O
34	<UNK>	O
35	.	O
1	In	O
2	a	O
3	control	O
4	group	O
5	both	O
6	common	O
7	carotid	O
8	arteries	O
9	(	O
10	<UNK>	O
11	)	O
12	were	O
13	<UNK>	O
14	.	O
1	At	O
2	pH	O
3	6	O
4	.	O
5	9	O
6	,	O
7	the	O
8	same	O
9	<UNK>	O
10	concentrations	O
11	significantly	O
12	reduced	O
13	resting	O
14	potential	O
15	(	O
16	3	O
17	-	O
18	10	O
19	%),	O
20	action	O
21	potential	O
22	amplitude	O
23	(	O
24	3	O
25	-	O
26	8	O
27	%)	O
28	and	O
29	<UNK>	O
30	(	O
31	14	O
32	-	O
33	22	O
34	%).	O
1	The	O
2	operation	O
3	recommended	O
4	is	O
5	excision	O
6	of	O
7	3	O
8	mm	O
9	of	O
10	central	O
11	<UNK>	O
12	followed	O
13	by	O
14	end	O
15	-	O
16	to	O
17	-	O
18	end	O
19	repair	O
20	of	O
21	the	O
22	<UNK>	O
23	.	O
1	In	O
2	the	O
3	<UNK>	O
4	group	O
5	arterial	O
6	pressure	O
7	decreased	O
8	50	O
9	mmHg	O
10	to	O
11	normal	O
12	by	O
13	24	O
14	h	O
15	and	O
16	was	O
17	associated	O
18	with	O
19	increased	O
20	<UNK>	O
21	and	O
22	a	O
23	small	O
24	decrease	O
25	in	O
26	blood	O
27	volume	O
28	(	O
29	9	O
30	.	O
31	8	O
32	%).	O
1	The	O
2	potentially	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	drugs	O
7	are	O
8	reviewed	O
9	.	O
1	<UNK>	O
2	different	O
3	species	O
4	(	O
5	eight	O
6	<UNK>	O
7	,	O
8	one	O
9	<UNK>	O
10	and	O
11	five	O
12	<UNK>	O
13	)	O
14	have	O
15	been	O
16	<UNK>	O
17	.	O
1	At	O
2	4	O
3	<UNK>	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	<UNK>	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	<UNK>	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O
1	<UNK>	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	<UNK>	O
18	.	O
1	Some	O
2	strains	O
3	of	O
4	A	O
5	.	O
6	<UNK>	O
7	produced	O
8	all	O
9	four	O
10	<UNK>	O
11	B1	O
12	<UNK>	O
13	G1	O
14	G2	O
15	,	O
16	while	O
17	the	O
18	other	O
19	ones	O
20	produced	O
21	AF	O
22	B1	O
23	+	O
24	G1	O
25	only	O
26	,	O
27	with	O
28	concentrations	O
29	of	O
30	<UNK>	O
31	from	O
32	0	O
33	.	O
34	1	O
35	to	O
36	<UNK>	O
37	mg	O
38	/	O
39	kg	O
40	.	O
1	Both	O
2	classes	O
3	of	O
4	<UNK>	B
5	proteins	O
6	were	O
7	found	O
8	to	O
9	form	O
10	dimers	O
11	;	O
12	an	O
13	which	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	the	O
19	dimerization	O
20	.	O
1	These	O
2	<UNK>	O
3	E6	B
4	/	O
5	E7	B
6	cDNAs	O
7	were	O
8	cloned	O
9	under	O
10	the	O
11	SV40	O
12	enhancer	O
13	/	O
14	promoter	O
15	and	O
16	the	O
17	<UNK>	O
18	LTR	O
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	B
25	-	O
26	<UNK>	O
27	transformation	O
28	and	O
29	induction	O
30	of	O
31	cellular	O
32	DNA	O
33	synthesis	O
34	,	O
35	both	O
36	of	O
37	which	O
38	<UNK>	O
39	on	O
40	the	O
41	E7	B
42	gene	O
43	product	O
44	.	O
1	<UNK>	O
2	coefficients	O
3	between	O
4	the	O
5	reference	O
6	methods	O
7	and	O
8	<UNK>	O
9	were	O
10	>	O
11	or	O
12	=	O
13	0	O
14	.	O
15	95	O
16	for	O
17	water	O
18	,	O
19	fat	O
20	,	O
21	crude	O
22	protein	O
23	and	O
24	connective	O
25	-	O
26	tissue	O
27	-	O
28	protein	O
29	<UNK>	O
30	<UNK>	O
31	protein	O
32	,	O
33	and	O
34	>	O
35	or	O
36	=	O
37	0	O
38	.	O
39	86	O
40	for	O
41	connective	O
42	-	O
43	tissue	O
44	-	O
45	protein	O
46	.	O
1	This	O
2	study	O
3	analyzed	O
4	whether	O
5	the	O
6	localization	O
7	of	O
8	an	O
9	accessory	O
10	pathway	O
11	could	O
12	be	O
13	predicted	O
14	by	O
15	using	O
16	the	O
17	polarity	O
18	of	O
19	the	O
20	<UNK>	O
21	complex	O
22	during	O
23	sinus	O
24	rhythm	O
25	on	O
26	the	O
27	surface	O
28	ECG	O
29	,	O
30	instead	O
31	of	O
32	the	O
33	delta	O
34	wave	O
35	polarity	O
36	as	O
37	used	O
38	in	O
39	many	O
40	reports	O
41	.	O
1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	<UNK>	B
8	mRNA	O
9	(	O
10	<UNK>	B
11	mRNA	O
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	<UNK>	B
27	mRNA	O
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	<UNK>	O
40	to	O
41	<UNK>	O
42	,	O
43	roots	O
44	and	O
45	<UNK>	O
46	.	O
1	However	O
2	,	O
3	the	O
4	requirement	O
5	of	O
6	<UNK>	B
7	for	O
8	the	O
9	production	O
10	of	O
11	G	O
12	.	O
13	C	O
14	-->	O
15	T	O
16	.	O
17	A	O
18	<UNK>	O
19	by	O
20	the	O
21	<UNK>	B
22	<UNK>	O
23	,	O
24	which	O
25	induces	O
26	only	O
27	these	O
28	substitutions	O
29	,	O
30	was	O
31	similar	O
32	to	O
33	that	O
34	for	O
35	<UNK>	B
36	-	O
37	mediated	O
38	G	O
39	.	O
40	C	O
41	-->	O
42	T	O
43	.	O
44	A	O
45	<UNK>	O
46	.	O
1	The	O
2	identity	O
3	between	O
4	<UNK>	B
5	H	O
6	and	O
7	H	O
8	'	O
9	is	O
10	96	O
11	%,	O
12	between	O
13	H	O
14	and	O
15	F	O
16	78	O
17	%,	O
18	and	O
19	between	O
20	H	O
21	'	O
22	and	O
23	F	O
24	75	O
25	%,	O
26	respectively	O
27	.	O
1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	13	O
7	<UNK>	O
8	<UNK>	O
9	,	O
10	age	O
11	ranged	O
12	from	O
13	three	O
14	days	O
15	to	O
16	13	O
17	.	O
18	1	O
19	years	O
20	(	O
21	mean	O
22	5	O
23	.	O
24	7	O
25	+/-	O
26	SD	O
27	4	O
28	.	O
29	8	O
30	years	O
31	).	O
1	The	O
2	effects	O
3	of	O
4	a	O
5	1	O
6	-	O
7	or	O
8	24	O
9	-	O
10	hour	O
11	pretreatment	O
12	regimen	O
13	with	O
14	<UNK>	O
15	lipid	O
16	A	O
17	(	O
18	<UNK>	O
19	,	O
20	35	O
21	micrograms	O
22	/	O
23	kg	O
24	i	O
25	.	O
26	v	O
27	.)	O
28	on	O
29	myocardial	O
30	<UNK>	O
31	produced	O
32	by	O
33	repetitive	O
34	coronary	O
35	<UNK>	O
36	were	O
37	studied	O
38	in	O
39	<UNK>	O
40	-	O
41	anesthetized	O
42	dogs	O
43	.	O
1	These	O
2	observations	O
3	<UNK>	O
4	actin	B
5	<UNK>	O
6	assembly	O
7	to	O
8	increased	O
9	cell	O
10	substrate	O
11	adhesion	O
12	.	O
1	The	O
2	highest	O
3	decrease	O
4	in	O
5	<UNK>	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	<UNK>	O
12	was	O
13	used	O
14	together	O
15	with	O
16	<UNK>	O
17	.	O
1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O
1	<UNK>	O
2	transplantation	O
3	in	O
4	one	O
5	patient	O
6	<UNK>	O
7	metabolic	O
8	complications	O
9	but	O
10	did	O
11	not	O
12	improve	O
13	<UNK>	O
14	count	O
15	or	O
16	the	O
17	infectious	O
18	status	O
19	,	O
20	while	O
21	<UNK>	O
22	was	O
23	<UNK>	O
24	by	O
25	G	O
26	-	O
27	CSF	B
28	.	O
1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	B
7	nuclease	I
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O
1	<UNK>	O
2	of	O
3	the	O
4	bovine	O
5	gene	O
6	encoding	O
7	the	O
8	endothelial	O
9	<UNK>	O
10	oxide	O
11	synthase	B
12	.	O
1	Effects	O
2	of	O
3	alterations	O
4	of	O
5	primer	O
6	-	O
7	binding	O
8	site	O
9	sequences	O
10	on	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	type	O
15	1	O
16	replication	O
17	.	O
1	A	O
2	particularly	O
3	striking	O
4	<UNK>	B
5	<UNK>	O
6	fragment	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	over	O
11	nearly	O
12	2	O
13	,	O
14	000	O
15	base	O
16	pairs	O
17	,	O
18	<UNK>	O
19	the	O
20	<UNK>	B
21	translation	O
22	initiation	O
23	site	O
24	.	O
1	A	O
2	chicken	O
3	<UNK>	B
4	cDNA	O
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	O
21	<UNK>	B
22	-	O
23	<UNK>	B
24	.	O
1	<UNK>	B
2	-	O
3	<UNK>	B
4	delta	O
5	-	O
6	mediated	O
7	DNA	O
8	-	O
9	RNA	O
10	helicase	B
11	activity	O
12	required	O
13	ATP	O
14	hydrolysis	O
15	and	O
16	the	O
17	presence	O
18	of	O
19	<UNK>	O
20	+	O
21	<UNK>	O
22	and	O
23	was	O
24	inhibited	O
25	by	O
26	high	O
27	<UNK>	O
28	strength	O
29	.	O
1	Both	O
2	mutations	O
3	completely	O
4	abolished	O
5	binding	O
6	of	O
7	the	O
8	<UNK>	B
9	SH3	I
10	domain	O
11	to	O
12	proline	O
13	-	O
14	rich	O
15	target	O
16	proteins	O
17	in	O
18	a	O
19	filter	O
20	-	O
21	binding	O
22	assay	O
23	.	O
1	<UNK>	O
2	variables	O
3	included	O
4	cancer	O
5	volume	O
6	,	O
7	<UNK>	O
8	grade	O
9	,	O
10	<UNK>	O
11	<UNK>	O
12	,	O
13	<UNK>	O
14	<UNK>	O
15	<UNK>	O
16	,	O
17	and	O
18	lymph	O
19	node	O
20	metastasis	O
21	.	O
1	The	O
2	fusion	O
3	proteins	O
4	were	O
5	tested	O
6	by	O
7	ELISA	O
8	for	O
9	reactivity	O
10	with	O
11	a	O
12	panel	O
13	of	O
14	human	O
15	anti	O
16	-	O
17	<UNK>	O
18	sera	O
19	in	O
20	order	O
21	to	O
22	define	O
23	the	O
24	nature	O
25	of	O
26	the	O
27	<UNK>	O
28	.	O
1	We	O
2	showed	O
3	previously	O
4	that	O
5	a	O
6	fusion	O
7	protein	O
8	(	O
9	GAL4	B
10	-	O
11	<UNK>	B
12	)	O
13	containing	O
14	the	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	of	O
20	GAL4	B
21	and	O
22	sequences	O
23	of	O
24	chicken	O
25	l	O
26	kappa	B
27	B	O
28	-	O
29	alpha	O
30	(	O
31	<UNK>	B
32	)	O
33	inhibits	O
34	growth	O
35	in	O
36	the	O
37	yeast	O
38	Saccharomyces	O
39	cerevisiae	O
40	.	O
1	Specific	O
2	requirements	O
3	for	O
4	<UNK>	O
5	-	O
6	chain	O
7	amino	O
8	acids	O
9	,	O
10	<UNK>	O
11	,	O
12	and	O
13	arginine	O
14	are	O
15	evaluated	O
16	.	O
1	The	O
2	<UNK>	B
3	operon	O
4	from	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	is	O
10	expressed	O
11	from	O
12	an	O
13	<UNK>	B
14	-	O
15	type	O
16	promoter	O
17	that	O
18	<UNK>	O
19	mutagenesis	O
20	of	O
21	the	O
22	<UNK>	B
23	gene	O
24	.	O
1	<UNK>	B
2	D1	I
3	promoter	O
4	activity	O
5	was	O
6	stimulated	O
7	by	O
8	overexpression	O
9	of	O
10	mitogen	B
11	-	O
12	activated	O
13	protein	O
14	kinase	B
15	(	O
16	<UNK>	B
17	)	O
18	or	O
19	c	B
20	-	O
21	Ets	B
22	-	O
23	2	O
24	through	O
25	the	O
26	proximal	O
27	22	O
28	base	O
29	pairs	O
30	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	<UNK>	B
6	<UNK>	I
7	substitution	O
8	exhibits	O
9	constitutive	O
10	transcriptional	O
11	activation	O
12	from	O
13	a	O
14	consensus	O
15	<UNK>	O
16	(	O
17	<UNK>	O
18	).	O
1	<UNK>	O
2	of	O
3	<UNK>	B
4	P1	O
5	-	O
6	lacZ	B
7	expression	O
8	at	O
9	different	O
10	<UNK>	O
11	levels	O
12	is	O
13	<UNK>	O
14	for	O
15	the	O
16	<UNK>	B
17	(	O
18	<UNK>	B
19	)	O
20	mutant	O
21	as	O
22	resulting	O
23	from	O
24	a	O
25	hypersensitivity	O
26	to	O
27	<UNK>	O
28	.	O
1	Characterization	O
2	of	O
3	the	O
4	3	O
5	'	O
6	ends	O
7	of	O
8	the	O
9	plus	O
10	-	O
11	strand	O
12	DNA	O
13	fragments	O
14	reveals	O
15	(	O
16	1	O
17	)	O
18	that	O
19	the	O
20	upstream	O
21	fragment	O
22	is	O
23	<UNK>	O
24	<UNK>	O
25	<UNK>	B
26	<UNK>	O
27	a	O
28	plus	O
29	-	O
30	strand	O
31	overlap	O
32	and	O
33	(	O
34	2	O
35	)	O
36	that	O
37	the	O
38	majority	O
39	of	O
40	plus	O
41	-	O
42	strand	O
43	strong	O
44	-	O
45	stop	O
46	DNA	O
47	fragments	O
48	<UNK>	O
49	a	O
50	copy	O
51	of	O
52	the	O
53	<UNK>	O
54	-	O
55	strand	O
56	primer	O
57	binding	O
58	site	O
59	in	O
60	agreement	O
61	with	O
62	the	O
63	<UNK>	O
64	model	O
65	of	O
66	retroviral	O
67	genomic	O
68	RNA	O
69	reverse	O
70	transcription	O
71	.	O
1	This	O
2	combined	O
3	intravenous	O
4	<UNK>	O
5	regimen	O
6	gave	O
7	good	O
8	<UNK>	O
9	and	O
10	analgesia	O
11	to	O
12	pigs	O
13	for	O
14	up	O
15	to	O
16	2	O
17	h	O
18	as	O
19	monitored	O
20	by	O
21	clinical	O
22	signs	O
23	.	O
1	A	O
2	general	O
3	model	O
4	for	O
5	<UNK>	O
6	-	O
7	mediated	O
8	mRNA	O
9	degradation	O
10	involving	O
11	a	O
12	potential	O
13	role	O
14	for	O
15	certain	O
16	<UNK>	O
17	nuclear	O
18	<UNK>	O
19	and	O
20	<UNK>	O
21	-	O
22	binding	O
23	proteins	O
24	is	O
25	proposed	O
26	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	G	O
6	beta	O
7	gamma	O
8	-	O
9	stimulated	O
10	Shc	B
11	phosphorylation	O
12	represents	O
13	an	O
14	early	O
15	step	O
16	in	O
17	the	O
18	pathway	O
19	leading	O
20	to	O
21	<UNK>	B
22	activation	O
23	,	O
24	similar	O
25	to	O
26	the	O
27	mechanism	O
28	utilized	O
29	by	O
30	growth	O
31	factor	O
32	tyrosine	O
33	kinase	B
34	receptors	O
35	.	O
1	All	O
2	<UNK>	O
3	resulted	O
4	in	O
5	<UNK>	O
6	with	O
7	<UNK>	O
8	<UNK>	O
9	bacteria	O
10	in	O
11	the	O
12	range	O
13	from	O
14	6	O
15	x	O
16	10	O
17	(	O
18	3	O
19	)	O
20	to	O
21	1	O
22	.	O
23	2	O
24	x	O
25	10	O
26	(	O
27	6	O
28	)	O
29	<UNK>	O
30	/	O
31	ml	O
32	liquid	O
33	<UNK>	O
34	,	O
35	and	O
36	94	O
37	%	O
38	them	O
39	with	O
40	<UNK>	O
41	bacteria	O
42	,	O
43	the	O
44	threshold	O
45	being	O
46	under	O
47	100	O
48	<UNK>	O
49	/	O
50	ml	O
51	(	O
52	<UNK>	O
53	1	O
54	).	O
1	As	O
2	for	O
3	31	O
4	stage	O
5	I	O
6	-	O
7	II	O
8	lung	O
9	cancer	O
10	patients	O
11	,	O
12	<UNK>	O
13	has	O
14	been	O
15	observed	O
16	in	O
17	82	O
18	.	O
19	8	O
20	%	O
21	of	O
22	them	O
23	and	O
24	PR	O
25	in	O
26	13	O
27	.	O
28	8	O
29	%;	O
30	the	O
31	response	O
32	was	O
33	always	O
34	assessed	O
35	with	O
36	chest	O
37	<UNK>	O
38	,	O
39	CT	O
40	,	O
41	<UNK>	O
42	,	O
43	<UNK>	O
44	and	O
45	/	O
46	or	O
47	<UNK>	O
48	.	O
1	<UNK>	O
2	(	O
3	<UNK>	O
4	40	O
5	-	O
6	<UNK>	O
7	)	O
8	is	O
9	a	O
10	novel	O
11	calcium	O
12	antagonist	O
13	from	O
14	a	O
15	new	O
16	chemical	O
17	class	O
18	and	O
19	is	O
20	the	O
21	first	O
22	that	O
23	selectively	O
24	blocks	O
25	the	O
26	T	O
27	-	O
28	type	O
29	calcium	O
30	channel	O
31	.	O
1	This	O
2	action	O
3	is	O
4	dependent	O
5	on	O
6	helix	O
7	-	O
8	loop	O
9	-	O
10	helix	O
11	factors	O
12	bound	O
13	to	O
14	the	O
15	E1	O
16	element	O
17	.	O
1	The	O
2	results	O
3	indicate	O
4	considerable	O
5	<UNK>	O
6	in	O
7	the	O
8	<UNK>	O
9	between	O
10	<UNK>	B
11	regulatory	O
12	sites	O
13	.	O
1	We	O
2	show	O
3	that	O
4	c	B
5	-	O
6	Fos	B
7	(	O
8	the	O
9	c	B
10	-	O
11	fos	B
12	<UNK>	I
13	product	O
14	),	O
15	which	O
16	is	O
17	an	O
18	<UNK>	O
19	<UNK>	O
20	nuclear	O
21	protein	O
22	,	O
23	is	O
24	<UNK>	O
25	highly	O
26	<UNK>	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	<UNK>	B
41	.	O
1	Cloning	O
2	,	O
3	sequencing	O
4	and	O
5	expression	O
6	of	O
7	the	O
8	3	O
9	-	O
10	<UNK>	B
11	kinase	I
12	gene	O
13	of	O
14	<UNK>	O
15	<UNK>	O
16	in	O
17	Escherichia	O
18	coli	O
19	and	O
20	characterization	O
21	of	O
22	the	O
23	protein	O
24	.	O
1	We	O
2	also	O
3	isolated	O
4	two	O
5	alternatively	O
6	spliced	O
7	forms	O
8	of	O
9	human	O
10	<UNK>	B
11	cDNA	O
12	lacking	O
13	sequences	O
14	encoding	O
15	membrane	O
16	-	O
17	proximal	O
18	regions	O
19	of	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	which	O
24	maintain	O
25	the	O
26	same	O
27	reading	O
28	frame	O
29	as	O
30	<UNK>	B
31	-	O
32	<UNK>	B
33	.	O
1	In	O
2	<UNK>	O
3	1	O
4	,	O
5	eight	O
6	<UNK>	O
7	were	O
8	allowed	O
9	to	O
10	<UNK>	O
11	naturally	O
12	(	O
13	d	O
14	<UNK>	O
15	,	O
16	NF	B
17	<UNK>	O
18	)	O
19	and	O
20	eight	O
21	<UNK>	O
22	were	O
23	induced	O
24	to	O
25	<UNK>	O
26	(	O
27	<UNK>	O
28	<UNK>	O
29	)	O
30	<UNK>	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	<UNK>	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O
1	These	O
2	results	O
3	suggested	O
4	that	O
5	<UNK>	B
6	negatively	O
7	<UNK>	O
8	the	O
9	expression	O
10	of	O
11	<UNK>	B
12	itself	O
13	.	O
1	If	O
2	<UNK>	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	<UNK>	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	<UNK>	B
38	delta	O
39	mutation	O
40	.	O
1	The	O
2	single	O
3	-	O
4	stranded	O
5	DNA	O
6	<UNK>	B
7	alpha	O
8	recognition	O
9	element	O
10	<UNK>	O
11	these	O
12	complexes	O
13	.	O
1	<UNK>	O
2	of	O
3	human	O
4	<UNK>	B
5	alpha	O
6	with	O
7	the	O
8	retinoblastoma	B
9	protein	O
10	,	O
11	Rb	B
12	,	O
13	regulates	O
14	binding	O
15	to	O
16	the	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	<UNK>	B
22	alpha	O
23	recognition	O
24	element	O
25	.	O
1	The	O
2	mouse	O
3	beta	O
4	2	O
5	-	O
6	<UNK>	B
7	gene	O
8	(	O
9	>	O
10	33	O
11	kilobases	O
12	)	O
13	contains	O
14	seven	O
15	exons	O
16	,	O
17	all	O
18	of	O
19	which	O
20	have	O
21	homologues	O
22	at	O
23	the	O
24	corresponding	O
25	position	O
26	in	O
27	the	O
28	alpha	O
29	1	O
30	-	O
31	<UNK>	B
32	gene	O
33	.	O
1	It	O
2	contains	O
3	three	O
4	putative	O
5	TATA	O
6	boxes	O
7	far	O
8	upstream	O
9	of	O
10	the	O
11	main	O
12	start	O
13	sites	O
14	region	O
15	,	O
16	one	O
17	AP	B
18	-	O
19	1	O
20	box	O
21	,	O
22	one	O
23	AP	B
24	-	O
25	2	O
26	box	O
27	,	O
28	one	O
29	<UNK>	B
30	box	O
31	,	O
32	one	O
33	<UNK>	O
34	box	O
35	,	O
36	one	O
37	half	O
38	serum	O
39	-	O
40	responsive	O
41	element	O
42	,	O
43	and	O
44	putative	O
45	binding	O
46	sites	O
47	for	O
48	Sp1	B
49	(	O
50	five	O
51	),	O
52	GC	O
53	-	O
54	rich	O
55	binding	O
56	factor	O
57	(	O
58	five	O
59	),	O
60	<UNK>	B
61	-	O
62	NF1	B
63	(	O
64	one	O
65	),	O
66	Myb	B
67	(	O
68	one	O
69	),	O
70	p53	B
71	(	O
72	two	O
73	),	O
74	Ets	B
75	-	O
76	1	O
77	(	O
78	one	O
79	),	O
80	NF	B
81	-	O
82	IL6	B
83	(	O
84	two	O
85	),	O
86	MyoD	B
87	(	O
88	two	O
89	),	O
90	<UNK>	B
91	(	O
92	one	O
93	),	O
94	and	O
95	hepatocyte	O
96	nuclear	O
97	factor	O
98	-	O
99	5	O
100	(	O
101	one	O
102	).	O
1	Deletion	O
2	of	O
3	the	O
4	NF	B
5	-	O
6	IL6	B
7	beta	O
8	leucine	O
9	zipper	O
10	domain	O
11	also	O
12	greatly	O
13	diminished	O
14	the	O
15	interaction	O
16	between	O
17	these	O
18	two	O
19	proteins	O
20	.	O
1	After	O
2	cells	O
3	were	O
4	stably	O
5	transfected	O
6	with	O
7	<UNK>	B
8	,	O
9	endogenous	O
10	MHC	B
11	class	O
12	II	O
13	genes	O
14	were	O
15	constitutively	O
16	expressed	O
17	,	O
18	and	O
19	MHC	B
20	class	O
21	II	O
22	promoters	O
23	,	O
24	<UNK>	O
25	by	O
26	transfection	O
27	,	O
28	were	O
29	<UNK>	O
30	transcribed	O
31	in	O
32	<UNK>	B
33	-	O
34	expressing	O
35	cells	O
36	.	O
1	However	O
2	,	O
3	the	O
4	few	O
5	studies	O
6	that	O
7	<UNK>	O
8	<UNK>	O
9	prophylaxis	O
10	in	O
11	bone	O
12	marrow	O
13	transplantation	O
14	have	O
15	not	O
16	always	O
17	shown	O
18	a	O
19	survival	O
20	<UNK>	O
21	.	O
1	<UNK>	O
2	adaptation	O
3	<UNK>	O
4	and	O
5	recovery	O
6	:	O
7	acute	O
8	stage	O
9	after	O
10	<UNK>	O
11	<UNK>	O
12	resection	O
13	.	O
1	A	O
2	cDNA	O
3	clone	O
4	corresponding	O
5	to	O
6	the	O
7	putative	O
8	<UNK>	O
9	20	O
10	-	O
11	oxidase	B
12	genomic	O
13	sequence	O
14	was	O
15	constructed	O
16	with	O
17	the	O
18	reverse	O
19	transcription	O
20	-	O
21	PCR	O
22	method	O
23	,	O
24	and	O
25	the	O
26	identity	O
27	of	O
28	the	O
29	cDNA	O
30	clone	O
31	was	O
32	confirmed	O
33	by	O
34	<UNK>	O
35	the	O
36	<UNK>	O
37	of	O
38	the	O
39	fusion	O
40	protein	O
41	expressed	O
42	in	O
43	Escherichia	O
44	coli	O
45	to	O
46	<UNK>	O
47	<UNK>	B
48	to	O
49	<UNK>	B
50	and	O
51	<UNK>	B
52	to	O
53	<UNK>	B
54	.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	can	O
5	be	O
6	used	O
7	for	O
8	the	O
9	treatment	O
10	of	O
11	infections	O
12	caused	O
13	by	O
14	gram	O
15	-	O
16	negative	O
17	,	O
18	gram	O
19	-	O
20	positive	O
21	,	O
22	<UNK>	O
23	,	O
24	and	O
25	<UNK>	O
26	bacteria	O
27	.	O
1	<UNK>	O
2	in	O
3	urinary	O
4	calcium	O
5	and	O
6	<UNK>	O
7	after	O
8	<UNK>	O
9	infusion	O
10	.	O
1	To	O
2	<UNK>	O
3	whether	O
4	these	O
5	disorders	O
6	of	O
7	GnRH	B
8	deficiency	O
9	are	O
10	associated	O
11	with	O
12	altered	O
13	<UNK>	O
14	secretion	O
15	profiles	O
16	,	O
17	we	O
18	compared	O
19	untreated	O
20	young	O
21	males	O
22	<UNK>	O
23	(	O
24	n	O
25	=	O
26	7	O
27	)	O
28	and	O
29	DP	B
30	(	O
31	n	O
32	=	O
33	7	O
34	)	O
35	to	O
36	normal	O
37	<UNK>	O
38	male	O
39	controls	O
40	(	O
41	n	O
42	=	O
43	6	O
44	).	O
1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	O
6	Oct	B
7	-	O
8	1	O
9	from	O
10	the	O
11	nuclear	O
12	extract	O
13	by	O
14	using	O
15	Oct	B
16	-	O
17	1	O
18	-	O
19	specific	O
20	antiserum	O
21	or	O
22	a	O
23	sequence	O
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	<UNK>	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	O
45	that	O
46	obtained	O
47	from	O
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	O
56	related	O
57	sequences	O
58	were	O
59	mutated	O
60	.	O
1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	complexes	O
7	similar	O
8	to	O
9	the	O
10	<UNK>	B
11	,	O
12	<UNK>	O
13	and	O
14	<UNK>	B
15	complexes	O
16	are	O
17	formed	O
18	by	O
19	rat	O
20	cortex	O
21	nuclear	O
22	extracts	O
23	and	O
24	the	O
25	<UNK>	O
26	element	O
27	in	O
28	EMSA	O
29	experiments	O
30	,	O
31	suggesting	O
32	the	O
33	<UNK>	O
34	of	O
35	our	O
36	in	O
37	vitro	O
38	observations	O
39	to	O
40	the	O
41	in	O
42	vivo	O
43	<UNK>	O
44	of	O
45	the	O
46	rat	O
47	<UNK>	B
48	promoter	O
49	.	O
1	<UNK>	O
2	,	O
3	clinical	O
4	and	O
5	<UNK>	O
6	aspects	O
7	are	O
8	evaluated	O
9	according	O
10	to	O
11	experience	O
12	<UNK>	O
13	in	O
14	recent	O
15	years	O
16	,	O
17	with	O
18	immediate	O
19	and	O
20	delayed	O
21	<UNK>	O
22	,	O
23	carried	O
24	out	O
25	in	O
26	the	O
27	most	O
28	<UNK>	O
29	<UNK>	O
30	<UNK>	O
31	.	O
1	In	O
2	human	O
3	<UNK>	O
4	cells	O
5	,	O
6	the	O
7	<UNK>	O
8	-	O
9	dependent	O
10	<UNK>	O
11	activity	O
12	is	O
13	poorly	O
14	expressed	O
15	and	O
16	<UNK>	O
17	inducible	O
18	by	O
19	thyroid	O
20	hormones	O
21	.	O
1	It	O
2	was	O
3	proposed	O
4	that	O
5	the	O
6	synthetase	B
7	-	O
8	related	O
9	sequences	O
10	of	O
11	<UNK>	B
12	stimulate	O
13	the	O
14	activity	O
15	of	O
16	the	O
17	kinase	B
18	by	O
19	interacting	O
20	directly	O
21	with	O
22	<UNK>	O
23	tRNA	O
24	that	O
25	<UNK>	O
26	during	O
27	amino	O
28	acid	O
29	<UNK>	O
30	.	O
1	To	O
2	compare	O
3	the	O
4	<UNK>	B
5	and	O
6	putative	O
7	<UNK>	B
8	-	O
9	<UNK>	B
10	transactivation	O
11	domains	O
12	,	O
13	we	O
14	fused	O
15	C	O
16	-	O
17	terminal	O
18	test	O
19	fragments	O
20	to	O
21	the	O
22	heterologous	O
23	GAL4	B
24	DNA	O
25	-	O
26	binding	O
27	domain	O
28	and	O
29	tested	O
30	activation	O
31	of	O
32	a	O
33	reporter	O
34	gene	O
35	co	O
36	-	O
37	transfected	O
38	into	O
39	four	O
40	cell	O
41	types	O
42	.	O
1	All	O
2	subjects	O
3	were	O
4	<UNK>	O
5	to	O
6	ECG	O
7	and	O
8	arterial	O
9	blood	O
10	pressure	O
11	determination	O
12	and	O
13	were	O
14	assayed	O
15	for	O
16	TSH	B
17	,	O
18	thyroid	O
19	hormone	O
20	,	O
21	PRL	B
22	,	O
23	glucose	O
24	,	O
25	creatinine	O
26	,	O
27	nitrogen	O
28	,	O
29	<UNK>	O
30	<UNK>	O
31	,	O
32	cholesterol	O
33	and	O
34	<UNK>	O
35	plasma	O
36	levels	O
37	before	O
38	therapy	O
39	(	O
40	<UNK>	O
41	),	O
42	after	O
43	30	O
44	treatment	O
45	days	O
46	(	O
47	<UNK>	O
48	)	O
49	and	O
50	after	O
51	a	O
52	15	O
53	days	O
54	<UNK>	O
55	(	O
56	<UNK>	O
57	).	O
1	The	O
2	Drosophila	O
3	insulin	B
4	receptor	O
5	homolog	O
6	:	O
7	a	O
8	gene	O
9	essential	O
10	for	O
11	embryonic	O
12	development	O
13	encodes	O
14	two	O
15	receptor	O
16	isoforms	O
17	with	O
18	different	O
19	signaling	O
20	potential	O
21	.	O
1	We	O
2	have	O
3	found	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	GTPase	B
9	-	O
10	deficient	O
11	mutants	O
12	of	O
13	alpha	O
14	12	O
15	(	O
16	alpha	O
17	<UNK>	B
18	)	O
19	or	O
20	alpha	O
21	13	O
22	(	O
23	alpha	O
24	<UNK>	B
25	)	O
26	leads	O
27	to	O
28	<UNK>	O
29	activation	O
30	of	O
31	the	O
32	Jun	B
33	kinase	I
34	/	O
35	stress	O
36	-	O
37	activated	O
38	protein	O
39	kinase	B
40	(	O
41	JNK	B
42	/	O
43	SAPK	B
44	)	O
45	pathway	O
46	.	O
1	The	O
2	objective	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	age	O
11	,	O
12	sex	O
13	,	O
14	clinical	O
15	conditions	O
16	,	O
17	family	O
18	history	O
19	,	O
20	site	O
21	,	O
22	catheter	O
23	association	O
24	,	O
25	means	O
26	of	O
27	<UNK>	O
28	evaluation	O
29	,	O
30	development	O
31	of	O
32	pulmonary	O
33	involvement	O
34	,	O
35	prevalence	O
36	of	O
37	antithrombin	B
38	III	O
39	,	O
40	protein	O
41	C	O
42	and	O
43	protein	O
44	S	O
45	<UNK>	O
46	,	O
47	and	O
48	<UNK>	O
49	<UNK>	O
50	in	O
51	children	O
52	who	O
53	<UNK>	O
54	a	O
55	<UNK>	O
56	event	O
57	.	O
1	A	O
2	model	O
3	with	O
4	age	O
5	and	O
6	weight	O
7	described	O
8	the	O
9	best	O
10	<UNK>	O
11	for	O
12	<UNK>	O
13	,	O
14	whereas	O
15	age	O
16	,	O
17	weight	O
18	,	O
19	and	O
20	height	O
21	described	O
22	the	O
23	best	O
24	<UNK>	O
25	for	O
26	total	O
27	body	O
28	<UNK>	O
29	.	O
1	In	O
2	contrast	O
3	,	O
4	both	O
5	C	O
6	-	O
7	Lys	O
8	and	O
9	C	O
10	-	O
11	Thr	O
12	retained	O
13	high	O
14	levels	O
15	of	O
16	kinase	B
17	activity	O
18	and	O
19	were	O
20	capable	O
21	of	O
22	responding	O
23	to	O
24	stimulation	O
25	.	O
1	Here	O
2	we	O
3	describe	O
4	an	O
5	in	O
6	vitro	O
7	assay	O
8	where	O
9	the	O
10	<UNK>	O
11	-	O
12	<UNK>	B
13	<UNK>	O
14	,	O
15	<UNK>	O
16	,	O
17	the	O
18	serine	O
19	proteinase	O
20	domain	O
21	(	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	<UNK>	O
27	residues	O
28	of	O
29	<UNK>	O
30	),	O
31	and	O
32	the	O
33	<UNK>	B
34	cofactor	O
35	were	O
36	produced	O
37	by	O
38	cell	O
39	-	O
40	free	O
41	translation	O
42	and	O
43	tested	O
44	for	O
45	trans	O
46	-	O
47	processing	O
48	of	O
49	<UNK>	O
50	substrates	O
51	.	O
1	The	O
2	most	O
3	likely	O
4	<UNK>	O
5	for	O
6	this	O
7	is	O
8	that	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	O
12	in	O
13	the	O
14	<UNK>	O
15	cells	O
16	and	O
17	renal	O
18	cortex	O
19	and	O
20	these	O
21	cells	O
22	do	O
23	not	O
24	express	O
25	Type	O
26	I	O
27	<UNK>	B
28	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	different	O
6	models	O
7	of	O
8	intestinal	O
9	ischemia	O
10	have	O
11	different	O
12	cytokine	O
13	profiles	O
14	and	O
15	that	O
16	the	O
17	early	O
18	TNF	B
19	response	O
20	associated	O
21	with	O
22	<UNK>	O
23	occlusion	O
24	model	O
25	is	O
26	primarily	O
27	due	O
28	to	O
29	the	O
30	<UNK>	O
31	.	O
1	The	O
2	changes	O
3	after	O
4	treatment	O
5	were	O
6	observed	O
7	<UNK>	O
8	by	O
9	<UNK>	O
10	while	O
11	sensory	O
12	and	O
13	motor	O
14	improvement	O
15	were	O
16	also	O
17	recorded	O
18	as	O
19	<UNK>	O
20	indicators	O
21	.	O
1	However	O
2	,	O
3	the	O
4	relative	O
5	binding	O
6	affinity	O
7	for	O
8	the	O
9	motifs	O
10	is	O
11	different	O
12	.	O
1	Furthermore	O
2	,	O
3	<UNK>	O
4	of	O
5	dominant	O
6	negative	O
7	forms	O
8	of	O
9	<UNK>	B
10	and	O
11	Cdc42	B
12	or	O
13	of	O
14	the	O
15	Rho	B
16	inhibitor	O
17	C3	B
18	transferase	I
19	blocked	O
20	serum	O
21	-	O
22	induced	O
23	DNA	O
24	synthesis	O
25	.	O
1	<UNK>	O
2	areas	O
3	of	O
4	the	O
5	selection	O
6	process	O
7	including	O
8	medical	O
9	and	O
10	surgical	O
11	<UNK>	O
12	to	O
13	transplantation	O
14	,	O
15	the	O
16	composition	O
17	of	O
18	the	O
19	transplant	O
20	work	O
21	-	O
22	up	O
23	,	O
24	specific	O
25	<UNK>	O
26	criteria	O
27	as	O
28	well	O
29	as	O
30	specific	O
31	<UNK>	O
32	factors	O
33	and	O
34	specific	O
35	disease	O
36	<UNK>	O
37	and	O
38	co	O
39	-	O
40	<UNK>	O
41	that	O
42	might	O
43	represent	O
44	<UNK>	O
45	were	O
46	<UNK>	O
47	reviewed	O
48	.	O
1	The	O
2	transport	O
3	of	O
4	a	O
5	<UNK>	O
6	<UNK>	O
7	chimeric	O
8	transmembrane	O
9	protein	O
10	connected	O
11	to	O
12	this	O
13	ER	O
14	leader	O
15	sequence	O
16	was	O
17	as	O
18	efficient	O
19	as	O
20	that	O
21	of	O
22	the	O
23	original	O
24	protein	O
25	from	O
26	which	O
27	the	O
28	ER	O
29	sequence	O
30	has	O
31	been	O
32	derived	O
33	.	O
1	<UNK>	O
2	DNA	O
3	sequence	O
4	analysis	O
5	showed	O
6	the	O
7	<UNK>	O
8	<UNK>	O
9	<UNK>	B
10	lies	O
11	2	O
12	.	O
13	2	O
14	kb	O
15	downstream	O
16	of	O
17	the	O
18	coding	O
19	region	O
20	of	O
21	<UNK>	B
22	,	O
23	indicating	O
24	that	O
25	the	O
26	cluster	O
27	<UNK>	O
28	the	O
29	closely	O
30	linked	O
31	<UNK>	B
32	and	O
33	<UNK>	B
34	genes	O
35	is	O
36	located	O
37	4	O
38	<UNK>	O
39	distal	O
40	to	O
41	<UNK>	B
42	(	O
43	<UNK>	O
44	score	O
45	13	O
46	.	O
47	7	O
48	)	O
49	and	O
50	9	O
51	<UNK>	O
52	proximal	O
53	to	O
54	<UNK>	B
55	(	O
56	<UNK>	O
57	score	O
58	11	O
59	.	O
60	7	O
61	).	O
1	We	O
2	conclude	O
3	that	O
4	transcription	O
5	activation	O
6	by	O
7	<UNK>	B
8	-	O
9	1	O
10	in	O
11	vitro	O
12	is	O
13	a	O
14	chromatin	O
15	-	O
16	dependent	O
17	process	O
18	that	O
19	requires	O
20	a	O
21	functional	O
22	trans	O
23	-	O
24	activation	O
25	domain	O
26	in	O
27	addition	O
28	to	O
29	the	O
30	HMG	B
31	domain	O
32	.	O
1	The	O
2	ubiquitous	O
3	transcription	O
4	factor	O
5	Oct	B
6	-	O
7	1	O
8	forms	O
9	complexes	O
10	with	O
11	an	O
12	octamer	O
13	motif	O
14	present	O
15	within	O
16	<UNK>	O
17	by	O
18	gel	O
19	shift	O
20	analysis	O
21	with	O
22	liver	O
23	and	O
24	kidney	O
25	extracts	O
26	,	O
27	<UNK>	O
28	Oct	B
29	-	O
30	1	O
31	an	O
32	<UNK>	O
33	candidate	O
34	for	O
35	<UNK>	O
36	in	O
37	androgen	O
38	regulation	O
39	.	O
1	A	O
2	new	O
3	non	O
4	-	O
5	LTR	O
6	<UNK>	O
7	provides	O
8	evidence	O
9	for	O
10	multiple	O
11	distinct	O
12	site	O
13	-	O
14	specific	O
15	elements	O
16	in	O
17	<UNK>	O
18	<UNK>	O
19	<UNK>	O
20	<UNK>	O
21	.	O
1	<UNK>	O
2	extension	O
3	and	O
4	S1	B
5	nuclease	I
6	mapping	O
7	experiments	O
8	were	O
9	used	O
10	to	O
11	<UNK>	O
12	the	O
13	transcription	O
14	initiation	O
15	site	O
16	of	O
17	<UNK>	B
18	and	O
19	revealed	O
20	the	O
21	presence	O
22	of	O
23	one	O
24	major	O
25	and	O
26	several	O
27	minor	O
28	initiation	O
29	sites	O
30	.	O
1	<UNK>	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	<UNK>	B
8	-	O
9	1	O
10	gene	O
11	was	O
12	determined	O
13	by	O
14	<UNK>	O
15	of	O
16	a	O
17	promoter	O
18	/	O
19	lacZ	B
20	fusion	O
21	gene	O
22	and	O
23	with	O
24	<UNK>	O
25	by	O
26	using	O
27	affinity	O
28	-	O
29	purified	O
30	tissue	O
31	-	O
32	specific	O
33	anti	O
34	-	O
35	<UNK>	B
36	.	O
1	Mean	O
2	<UNK>	O
3	extension	O
4	of	O
5	the	O
6	<UNK>	O
7	lesion	O
8	was	O
9	2	O
10	.	O
11	6	O
12	<UNK>	O
13	segments	O
14	.	O
1	The	O
2	tyrosine	O
3	-	O
4	phosphorylated	O
5	state	O
6	of	O
7	<UNK>	B
8	beta	O
9	was	O
10	not	O
11	reduced	O
12	on	O
13	<UNK>	O
14	,	O
15	nor	O
16	enhanced	O
17	in	O
18	response	O
19	to	O
20	<UNK>	O
21	<UNK>	O
22	cells	O
23	<UNK>	O
24	fibronectin	B
25	.	O
1	Our	O
2	results	O
3	suggest	O
4	that	O
5	while	O
6	many	O
7	muscle	O
8	gene	O
9	E	O
10	-	O
11	boxes	O
12	are	O
13	capable	O
14	of	O
15	binding	O
16	the	O
17	previously	O
18	characterized	O
19	spectrum	O
20	of	O
21	<UNK>	B
22	/	O
23	<UNK>	B
24	-	O
25	L	O
26	-	O
27	H	O
28	heterodimers	O
29	in	O
30	vitro	O
31	,	O
32	<UNK>	B
33	-	O
34	L	O
35	type	O
36	E	O
37	-	O
38	boxes	O
39	probably	O
40	bind	O
41	<UNK>	O
42	different	O
43	factors	O
44	in	O
45	vivo	O
46	.	O
1	In	O
2	one	O
3	<UNK>	O
4	cell	O
5	line	O
6	,	O
7	a	O
8	Shc	B
9	-	O
10	associated	O
11	<UNK>	B
12	was	O
13	identified	O
14	as	O
15	the	O
16	activated	O
17	<UNK>	B
18	.	O
1	A	O
2	significant	O
3	correlation	O
4	between	O
5	a	O
6	number	O
7	of	O
8	functional	O
9	parameters	O
10	of	O
11	gastric	O
12	secretion	O
13	,	O
14	<UNK>	O
15	and	O
16	histological	O
17	changes	O
18	of	O
19	gastric	O
20	mucosa	O
21	was	O
22	found	O
23	in	O
24	patients	O
25	with	O
26	chronic	O
27	<UNK>	O
28	.	O
1	The	O
2	<UNK>	B
3	mutants	O
4	that	O
5	failed	O
6	to	O
7	associate	O
8	with	O
9	PLC	B
10	gamma	O
11	were	O
12	not	O
13	able	O
14	to	O
15	mediate	O
16	the	O
17	PDGF	B
18	-	O
19	dependent	O
20	production	O
21	of	O
22	<UNK>	O
23	<UNK>	O
24	.	O
1	We	O
2	found	O
3	a	O
4	direct	O
5	correlation	O
6	between	O
7	the	O
8	levels	O
9	of	O
10	transcription	O
11	of	O
12	the	O
13	<UNK>	B
14	genes	O
15	and	O
16	the	O
17	rate	O
18	of	O
19	cellular	O
20	growth	O
21	.	O
1	To	O
2	study	O
3	the	O
4	origin	O
5	of	O
6	different	O
7	<UNK>	B
8	-	O
9	R	O
10	transcripts	O
11	,	O
12	the	O
13	genetic	O
14	<UNK>	O
15	of	O
16	<UNK>	O
17	receptor	O
18	genes	O
19	,	O
20	and	O
21	the	O
22	regulation	O
23	of	O
24	<UNK>	B
25	-	O
26	R	O
27	gene	O
28	expression	O
29	,	O
30	we	O
31	determined	O
32	the	O
33	copy	O
34	number	O
35	,	O
36	chromosomal	O
37	location	O
38	,	O
39	structural	O
40	organization	O
41	,	O
42	and	O
43	5	O
44	'-	O
45	flanking	O
46	sequence	O
47	of	O
48	the	O
49	human	O
50	<UNK>	B
51	-	O
52	R	O
53	gene	O
54	.	O
1	Using	O
2	the	O
3	polymerase	O
4	chain	O
5	reaction	O
6	,	O
7	<UNK>	O
8	-	O
9	specific	O
10	DNA	O
11	fragments	O
12	of	O
13	<UNK>	O
14	base	O
15	pairs	O
16	from	O
17	the	O
18	genome	O
19	of	O
20	the	O
21	<UNK>	O
22	<UNK>	O
23	(	O
24	<UNK>	O
25	<UNK>	O
26	)	O
27	were	O
28	demonstrated	O
29	.	O
1	We	O
2	here	O
3	demonstrate	O
4	that	O
5	a	O
6	temperature	O
7	-	O
8	sensitive	O
9	fission	O
10	yeast	O
11	mutant	O
12	which	O
13	has	O
14	a	O
15	mutation	O
16	in	O
17	a	O
18	homologous	O
19	gene	O
20	,	O
21	and	O
22	two	O
23	of	O
24	three	O
25	additional	O
26	(	O
27	<UNK>	B
28	/	O
29	<UNK>	B
30	/	O
31	<UNK>	B
32	)	O
33	mutants	O
34	accumulate	O
35	nuclear	O
36	poly	O
37	(	O
38	A	O
39	<UNK>	O
40	RNA	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	.	O
1	<UNK>	B
2	specific	O
3	antigen	O
4	shows	O
5	the	O
6	metastatic	O
7	cases	O
8	better	O
9	[	O
10	correction	O
11	of	O
12	<UNK>	O
13	]	O
14	than	O
15	prostatic	O
16	acid	O
17	phosphatase	B
18	.	O
1	An	O
2	abundant	O
3	1	O
4	.	O
5	1	O
6	-	O
7	kb	O
8	<UNK>	O
9	-	O
10	sense	O
11	<UNK>	O
12	RNA	O
13	and	O
14	four	O
15	complementary	O
16	-	O
17	sense	O
18	<UNK>	O
19	RNAs	O
20	of	O
21	1	O
22	.	O
23	7	O
24	,	O
25	1	O
26	.	O
27	5	O
28	,	O
29	1	O
30	.	O
31	3	O
32	,	O
33	and	O
34	0	O
35	.	O
36	7	O
37	kb	O
38	have	O
39	been	O
40	identified	O
41	by	O
42	<UNK>	O
43	blot	O
44	hybridization	O
45	,	O
46	confirming	O
47	the	O
48	<UNK>	O
49	transcription	O
50	strategy	O
51	<UNK>	O
52	by	O
53	the	O
54	arrangement	O
55	of	O
56	ORFs	O
57	.	O
1	In	O
2	addition	O
3	,	O
4	an	O
5	<UNK>	B
6	<UNK>	I
7	<UNK>	I
8	triple	O
9	<UNK>	O
10	was	O
11	viable	O
12	.	O
1	<UNK>	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	O
9	6	O
10	beta	O
11	1	O
12	is	O
13	the	O
14	major	O
15	<UNK>	B
16	receptor	O
17	in	O
18	<UNK>	O
19	<UNK>	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	<UNK>	O
25	-	O
26	derived	O
27	<UNK>	O
28	cells	O
29	.	O
1	Our	O
2	data	O
3	complement	O
4	other	O
5	studies	O
6	of	O
7	<UNK>	O
8	populations	O
9	and	O
10	<UNK>	O
11	the	O
12	reported	O
13	high	O
14	<UNK>	O
15	of	O
16	<UNK>	O
17	and	O
18	HLA	B
19	-	O
20	<UNK>	B
21	among	O
22	those	O
23	populations	O
24	.	O
1	<UNK>	O
2	-	O
3	early	O
4	transcription	O
5	from	O
6	the	O
7	channel	O
8	<UNK>	O
9	virus	O
10	genome	O
11	:	O
12	characterization	O
13	of	O
14	two	O
15	immediate	O
16	-	O
17	early	O
18	transcripts	O
19	.	O
1	<UNK>	B
2	<UNK>	I
3	(	O
4	<UNK>	O
5	)	O
6	II	O
7	deficiency	O
8	is	O
9	the	O
10	most	O
11	common	O
12	<UNK>	O
13	disorder	O
14	of	O
15	lipid	O
16	metabolism	O
17	affecting	O
18	skeletal	O
19	muscle	O
20	.	O
1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	<UNK>	B
26	being	O
27	the	O
28	<UNK>	O
29	and	O
30	<UNK>	B
31	the	O
32	<UNK>	O
33	.	O
1	Binding	O
2	of	O
3	<UNK>	B
4	is	O
5	necessary	O
6	to	O
7	activate	O
8	transcription	O
9	of	O
10	the	O
11	<UNK>	O
12	response	O
13	genes	O
14	;	O
15	<UNK>	O
16	,	O
17	in	O
18	vitro	O
19	transcription	O
20	of	O
21	<UNK>	B
22	is	O
23	dependent	O
24	on	O
25	the	O
26	presence	O
27	of	O
28	<UNK>	B
29	.	O
1	We	O
2	suggest	O
3	that	O
4	this	O
5	gene	O
6	cluster	O
7	<UNK>	O
8	for	O
9	(	O
10	parts	O
11	of	O
12	)	O
13	a	O
14	<UNK>	O
15	cytochrome	B
16	c	I
17	<UNK>	O
18	<UNK>	B
19	.	O
1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	<UNK>	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	<UNK>	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	<UNK>	O
40	<UNK>	O
41	and	O
42	<UNK>	O
43	<UNK>	O
44	.	O
1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	<UNK>	O
9	<UNK>	O
10	of	O
11	five	O
12	<UNK>	O
13	per	O
14	<UNK>	O
15	for	O
16	21	O
17	d	O
18	.	O
1	The	O
2	<UNK>	B
3	/	O
4	<UNK>	B
5	and	O
6	PKC	B
7	-	O
8	gamma	O
9	genes	O
10	have	O
11	a	O
12	similar	O
13	expression	O
14	pattern	O
15	in	O
16	the	O
17	brain	O
18	during	O
19	development	O
20	.	O
1	No	O
2	homologs	O
3	of	O
4	other	O
5	members	O
6	of	O
7	the	O
8	<UNK>	B
9	gene	O
10	cluster	O
11	were	O
12	detected	O
13	in	O
14	close	O
15	<UNK>	O
16	to	O
17	the	O
18	D	O
19	.	O
20	melanogaster	O
21	<UNK>	B
22	-	O
23	3	O
24	/	O
25	<UNK>	B
26	gene	O
27	.	O
1	By	O
2	<UNK>	O
3	<UNK>	B
4	-	O
5	6	O
6	-	O
7	<UNK>	B
8	fusion	O
9	proteins	O
10	,	O
11	we	O
12	were	O
13	able	O
14	to	O
15	identify	O
16	a	O
17	short	O
18	amino	O
19	acid	O
20	stretch	O
21	in	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	the	O
29	paired	O
30	domain	O
31	which	O
32	is	O
33	responsible	O
34	for	O
35	these	O
36	differences	O
37	in	O
38	DNA	O
39	-	O
40	binding	O
41	specificity	O
42	.	O
1	The	O
2	cases	O
3	included	O
4	35	O
5	de	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	<UNK>	O
10	(	O
11	<UNK>	O
12	;	O
13	19	O
14	large	O
15	-	O
16	cell	O
17	,	O
18	4	O
19	mixed	O
20	-	O
21	cell	O
22	,	O
23	and	O
24	12	O
25	large	O
26	-	O
27	cell	O
28	<UNK>	O
29	),	O
30	52	O
31	transformed	O
32	<UNK>	O
33	<UNK>	O
34	derived	O
35	from	O
36	follicular	O
37	<UNK>	O
38	(	O
39	<UNK>	O
40	),	O
41	42	O
42	<UNK>	O
43	follicular	O
44	<UNK>	O
45	(	O
46	<UNK>	O
47	),	O
48	14	O
49	<UNK>	O
50	cell	O
51	<UNK>	O
52	(	O
53	<UNK>	O
54	),	O
55	and	O
56	27	O
57	small	O
58	<UNK>	O
59	cell	O
60	<UNK>	O
61	(	O
62	<UNK>	O
63	).	O
1	In	O
2	the	O
3	<UNK>	O
4	available	O
5	intravenous	O
6	<UNK>	O
7	of	O
8	<UNK>	O
9	A	O
10	(	O
11	<UNK>	O
12	),	O
13	<UNK>	O
14	<UNK>	O
15	oil	O
16	(	O
17	<UNK>	O
18	<UNK>	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	<UNK>	O
25	agent	O
26	.	O
1	<UNK>	O
2	function	O
3	tests	O
4	(	O
5	<UNK>	O
6	)	O
7	were	O
8	performed	O
9	on	O
10	these	O
11	patients	O
12	for	O
13	a	O
14	period	O
15	of	O
16	19	O
17	.	O
18	2	O
19	+/-	O
20	3	O
21	.	O
22	4	O
23	months	O
24	.	O
1	Sequence	O
2	<UNK>	O
3	of	O
4	<UNK>	O
5	<UNK>	B
6	<UNK>	I
7	has	O
8	revealed	O
9	a	O
10	set	O
11	of	O
12	three	O
13	common	O
14	motifs	O
15	,	O
16	two	O
17	of	O
18	which	O
19	,	O
20	a	O
21	putative	O
22	metal	O
23	<UNK>	O
24	site	O
25	and	O
26	a	O
27	downstream	O
28	active	O
29	-	O
30	site	O
31	tyrosine	O
32	motif	O
33	,	O
34	could	O
35	be	O
36	<UNK>	O
37	identified	O
38	in	O
39	<UNK>	B
40	<UNK>	I
41	proteins	O
42	.	O
1	The	O
2	characterized	O
3	<UNK>	B
4	<UNK>	I
5	is	O
6	a	O
7	candidate	O
8	PC	O
9	that	O
10	may	O
11	play	O
12	an	O
13	important	O
14	role	O
15	in	O
16	the	O
17	processing	O
18	of	O
19	<UNK>	O
20	-	O
21	<UNK>	B
22	hormone	O
23	(	O
24	<UNK>	B
25	)-	O
26	related	O
27	precursors	O
28	in	O
29	the	O
30	secretory	O
31	cells	O
32	of	O
33	the	O
34	atrial	O
35	gland	O
36	.	O
1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	<UNK>	B
6	alpha	O
7	subunit	O
8	promoter	O
9	by	O
10	the	O
11	transient	O
12	transfection	O
13	of	O
14	several	O
15	<UNK>	B
16	alpha	O
17	/	O
18	CAT	B
19	chimeric	O
20	plasmids	O
21	into	O
22	<UNK>	O
23	<UNK>	O
24	pituitary	O
25	cells	O
26	suggests	O
27	that	O
28	its	O
29	pituitary	O
30	-	O
31	specific	O
32	expression	O
33	is	O
34	<UNK>	B
35	-	O
36	dependent	O
37	.	O
1	<UNK>	O
2	-	O
3	111	O
4	<UNK>	O
5	<UNK>	O
6	/	O
7	<UNK>	O
8	and	O
9	F	O
10	-	O
11	18	O
12	<UNK>	O
13	in	O
14	<UNK>	O
15	and	O
16	ovarian	O
17	carcinoma	O
18	<UNK>	O
19	.	O
1	The	O
2	Myc	B
3	<UNK>	I
4	was	O
5	found	O
6	to	O
7	prevent	O
8	<UNK>	O
9	interactions	O
10	,	O
11	thus	O
12	<UNK>	O
13	Myc	B
14	<UNK>	O
15	to	O
16	<UNK>	O
17	efficiently	O
18	.	O
1	The	O
2	gene	O
3	pairs	O
4	<UNK>	B
5	-	O
6	<UNK>	B
7	and	O
8	<UNK>	B
9	-	O
10	<UNK>	B
11	are	O
12	<UNK>	O
13	from	O
14	opposite	O
15	<UNK>	O
16	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	of	O
5	the	O
6	5	O
7	'	O
8	regulatory	O
9	region	O
10	of	O
11	the	O
12	GH	B
13	receptor	O
14	gene	O
15	was	O
16	<UNK>	O
17	by	O
18	the	O
19	observation	O
20	that	O
21	probes	O
22	derived	O
23	from	O
24	exon	O
25	<UNK>	O
26	and	O
27	the	O
28	distal	O
29	3	O
30	'	O
31	intron	O
32	boundary	O
33	do	O
34	not	O
35	<UNK>	O
36	with	O
37	previously	O
38	cloned	O
39	genomic	O
40	sequences	O
41	that	O
42	<UNK>	O
43	the	O
44	liver	O
45	-	O
46	specific	O
47	P1	O
48	promoter	O
49	and	O
50	exon	O
51	2	O
52	.	O
1	We	O
2	used	O
3	two	O
4	<UNK>	O
5	to	O
6	<UNK>	O
7	whether	O
8	<UNK>	B
9	/	O
10	cut	O
11	serves	O
12	as	O
13	a	O
14	repressor	O
15	of	O
16	<UNK>	B
17	-	O
18	<UNK>	B
19	gene	O
20	expression	O
21	.	O
1	Serum	O
2	induction	O
3	of	O
4	a	O
5	<UNK>	B
6	reporter	O
7	gene	O
8	was	O
9	not	O
10	observed	O
11	in	O
12	a	O
13	line	O
14	of	O
15	NIH	O
16	3T3	O
17	cells	O
18	which	O
19	contain	O
20	low	O
21	<UNK>	B
22	site	O
23	binding	O
24	activity	O
25	.	O
1	Since	O
2	AP	B
3	-	O
4	1	O
5	is	O
6	an	O
7	important	O
8	<UNK>	O
9	of	O
10	tumor	O
11	promoter	O
12	action	O
13	,	O
14	these	O
15	findings	O
16	may	O
17	<UNK>	O
18	the	O
19	anti	O
20	-	O
21	tumor	O
22	-	O
23	<UNK>	O
24	activity	O
25	of	O
26	<UNK>	O
27	<UNK>	O
28	.	O
1	The	O
2	timing	O
3	of	O
4	<UNK>	B
5	gene	O
6	expression	O
7	in	O
8	the	O
9	cell	O
10	cycle	O
11	is	O
12	determined	O
13	by	O
14	<UNK>	O
15	forms	O
16	of	O
17	RNA	O
18	polymerase	O
19	and	O
20	the	O
21	appearance	O
22	and	O
23	/	O
24	or	O
25	activation	O
26	of	O
27	regulatory	O
28	proteins	O
29	.	O
1	<UNK>	O
2	of	O
3	the	O
4	same	O
5	apparent	O
6	sizes	O
7	are	O
8	detected	O
9	in	O
10	<UNK>	O
11	of	O
12	a	O
13	<UNK>	B
14	null	O
15	mutant	O
16	,	O
17	on	O
18	which	O
19	basis	O
20	we	O
21	<UNK>	O
22	that	O
23	the	O
24	products	O
25	of	O
26	the	O
27	<UNK>	B
28	operon	O
29	are	O
30	required	O
31	for	O
32	the	O
33	normal	O
34	formation	O
35	of	O
36	the	O
37	inner	O
38	<UNK>	O
39	of	O
40	the	O
41	coat	O
42	or	O
43	are	O
44	<UNK>	O
45	structural	O
46	components	O
47	of	O
48	the	O
49	coat	O
50	.	O
1	<UNK>	O
2	with	O
3	<UNK>	O
4	and	O
5	<UNK>	O
6	modified	O
7	carbon	O
8	electrodes	O
9	.	O
1	The	O
2	present	O
3	study	O
4	describes	O
5	the	O
6	cell	O
7	volume	O
8	dynamics	O
9	in	O
10	intact	O
11	rat	O
12	hearts	O
13	,	O
14	during	O
15	ischemia	O
16	and	O
17	after	O
18	reperfusion	O
19	.	O
1	We	O
2	found	O
3	that	O
4	<UNK>	O
5	was	O
6	expressed	O
7	at	O
8	a	O
9	lower	O
10	level	O
11	in	O
12	S	O
13	,	O
14	G2	O
15	,	O
16	and	O
17	M	O
18	phases	O
19	and	O
20	at	O
21	a	O
22	significantly	O
23	higher	O
24	level	O
25	in	O
26	G1	O
27	phase	O
28	.	O
1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	<UNK>	O
8	sequence	O
9	<UNK>	O
10	GDP	O
11	binding	O
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	O
29	binding	O
30	protein	O
31	,	O
32	<UNK>	B
33	/	O
34	<UNK>	B
35	.	O
1	<UNK>	O
2	extracts	O
3	from	O
4	a	O
5	variety	O
6	of	O
7	mammalian	O
8	cell	O
9	lines	O
10	(	O
11	monkey	O
12	<UNK>	O
13	,	O
14	several	O
15	mouse	O
16	<UNK>	O
17	and	O
18	human	O
19	HeLa	O
20	<UNK>	O
21	)	O
22	demonstrated	O
23	similar	O
24	TGF	B
25	-	O
26	beta	O
27	1	O
28	dependent	O
29	RNA	O
30	-	O
31	protein	O
32	band	O
33	shifts	O
34	as	O
35	cell	O
36	extract	O
37	from	O
38	BALB	O
39	/	O
40	c	B
41	3T3	O
42	mouse	O
43	fibroblasts	O
44	.	O
1	The	O
2	<UNK>	O
3	reports	O
4	are	O
5	based	O
6	mainly	O
7	upon	O
8	<UNK>	O
9	findings	O
10	,	O
11	whereas	O
12	the	O
13	final	O
14	reports	O
15	include	O
16	the	O
17	information	O
18	provided	O
19	by	O
20	<UNK>	O
21	investigations	O
22	such	O
23	as	O
24	microscopy	O
25	,	O
26	<UNK>	O
27	,	O
28	more	O
29	<UNK>	O
30	electron	O
31	microscopy	O
32	,	O
33	<UNK>	O
34	and	O
35	/	O
36	or	O
37	<UNK>	O
38	.	O
1	Moreover	O
2	,	O
3	Western	O
4	<UNK>	O
5	demonstrated	O
6	at	O
7	least	O
8	six	O
9	types	O
10	of	O
11	<UNK>	B
12	in	O
13	both	O
14	<UNK>	O
15	and	O
16	<UNK>	O
17	,	O
18	suggesting	O
19	that	O
20	these	O
21	<UNK>	B
22	are	O
23	used	O
24	for	O
25	<UNK>	O
26	functions	O
27	responsible	O
28	for	O
29	<UNK>	O
30	transport	O
31	rather	O
32	than	O
33	for	O
34	cellular	O
35	differentiation	O
36	.	O
1	The	O
2	absence	O
3	of	O
4	other	O
5	regions	O
6	of	O
7	hybridization	O
8	suggests	O
9	that	O
10	there	O
11	are	O
12	no	O
13	closely	O
14	related	O
15	sequences	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	reverse	O
22	transcribed	O
23	<UNK>	O
24	)	O
25	<UNK>	O
26	throughout	O
27	the	O
28	genome	O
29	and	O
30	that	O
31	if	O
32	there	O
33	are	O
34	closely	O
35	related	O
36	genes	O
37	,	O
38	they	O
39	must	O
40	be	O
41	<UNK>	O
42	near	O
43	<UNK>	B
44	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	an	O
5	<UNK>	B
6	insulin	I
7	receptor	O
8	substrate	O
9	1	O
10	-	O
11	like	O
12	cDNA	O
13	and	O
14	involvement	O
15	of	O
16	phosphatidylinositol	B
17	3	O
18	-	O
19	kinase	B
20	in	O
21	insulin	B
22	-	O
23	induced	O
24	Xenopus	O
25	oocyte	O
26	maturation	O
27	.	O
1	<UNK>	B
2	has	O
3	been	O
4	shown	O
5	to	O
6	form	O
7	<UNK>	O
8	complexes	O
9	<UNK>	O
10	with	O
11	the	O
12	TATA	O
13	box	O
14	-	O
15	binding	O
16	protein	O
17	and	O
18	<UNK>	B
19	on	O
20	DNA	O
21	containing	O
22	an	O
23	<UNK>	B
24	binding	O
25	site	O
26	and	O
27	a	O
28	TATA	O
29	box	O
30	(	O
31	C	O
32	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	.	O
1	<UNK>	B
2	-	O
3	related	O
4	cDNA	O
5	encoding	O
6	a	O
7	protein	O
8	with	O
9	a	O
10	high	O
11	-	O
12	mobility	O
13	-	O
14	group	O
15	(	O
16	HMG	B
17	)	O
18	box	O
19	and	O
20	a	O
21	leucine	O
22	zipper	O
23	motif	O
24	,	O
25	which	O
26	was	O
27	designated	O
28	<UNK>	B
29	-	O
30	<UNK>	B
31	,	O
32	was	O
33	isolated	O
34	from	O
35	a	O
36	<UNK>	O
37	<UNK>	O
38	testis	O
39	cDNA	O
40	library	O
41	.	O
1	Therefore	O
2	,	O
3	it	O
4	is	O
5	<UNK>	O
6	that	O
7	by	O
8	<UNK>	O
9	the	O
10	transcriptional	O
11	control	O
12	of	O
13	the	O
14	<UNK>	B
15	gene	O
16	<UNK>	O
17	into	O
18	the	O
19	mechanisms	O
20	that	O
21	control	O
22	functional	O
23	fate	O
24	and	O
25	organization	O
26	in	O
27	the	O
28	nervous	O
29	system	O
30	can	O
31	be	O
32	<UNK>	O
33	.	O
1	Characterization	O
2	of	O
3	the	O
4	promoter	O
5	for	O
6	the	O
7	human	O
8	85	O
9	kDa	O
10	cytosolic	O
11	<UNK>	B
12	A2	O
13	gene	O
14	.	O
1	Further	O
2	studies	O
3	established	O
4	that	O
5	the	O
6	<UNK>	O
7	-	O
8	induced	O
9	increase	O
10	in	O
11	beta	O
12	-	O
13	globin	B
14	mRNA	O
15	could	O
16	be	O
17	inhibited	O
18	by	O
19	the	O
20	tyrosine	O
21	kinase	B
22	inhibitor	O
23	<UNK>	O
24	and	O
25	the	O
26	protein	O
27	kinase	B
28	C	O
29	inhibitor	O
30	<UNK>	O
31	3	O
32	.(	O
33	ABSTRACT	O
34	TRUNCATED	O
35	AT	O
36	250	O
37	WORDS	O
38	)	O
1	This	O
2	structure	O
3	of	O
4	<UNK>	B
5	suggests	O
6	that	O
7	it	O
8	is	O
9	probably	O
10	synthesized	O
11	as	O
12	an	O
13	inactive	O
14	precursor	O
15	.	O
1	Molecular	O
2	<UNK>	O
3	of	O
4	the	O
5	<UNK>	O
6	CD3	B
7	-	O
8	TCR	B
9	complex	O
10	revealed	O
11	that	O
12	at	O
13	least	O
14	two	O
15	associated	O
16	polypeptides	O
17	,	O
18	CD3	B
19	zeta	I
20	and	O
21	CD3	B
22	epsilon	O
23	,	O
24	<UNK>	O
25	<UNK>	O
26	<UNK>	O
27	recognition	O
28	event	O
29	to	O
30	early	O
31	and	O
32	late	O
33	events	O
34	of	O
35	the	O
36	<UNK>	O
37	activation	O
38	cascade	O
39	.	O
1	<UNK>	O
2	capacity	O
3	of	O
4	the	O
5	<UNK>	B
6	gene	O
7	.	O
1	A	O
2	unique	O
3	leucine	O
4	-	O
5	proline	O
6	repeat	O
7	element	O
8	found	O
9	N	O
10	-	O
11	terminal	O
12	to	O
13	the	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	<UNK>	B
20	-	O
21	1	O
22	does	O
23	not	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	DNA	O
31	-	O
32	binding	O
33	or	O
34	dimerization	O
35	.	O
1	Another	O
2	full	O
3	ORF	O
4	was	O
5	found	O
6	on	O
7	the	O
8	opposite	O
9	strand	O
10	downstream	O
11	from	O
12	the	O
13	<UNK>	B
14	gene	O
15	.	O
1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	<UNK>	B
13	TATA	O
14	motif	O
15	.	O
1	<UNK>	O
2	in	O
3	this	O
4	family	O
5	of	O
6	proteins	O
7	suggests	O
8	that	O
9	<UNK>	B
10	and	O
11	<UNK>	B
12	may	O
13	participate	O
14	in	O
15	an	O
16	export	O
17	pathway	O
18	required	O
19	for	O
20	<UNK>	O
21	assembly	O
22	.	O
1	Furthermore	O
2	,	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	<UNK>	B
8	-	O
9	like	O
10	protein	O
11	in	O
12	A	O
13	.	O
14	thaliana	O
15	strongly	O
16	<UNK>	O
17	for	O
18	the	O
19	<UNK>	O
20	of	O
21	this	O
22	protein	O
23	among	O
24	eukaryotic	O
25	<UNK>	O
26	and	O
27	for	O
28	a	O
29	conserved	O
30	mechanism	O
31	to	O
32	regulate	O
33	transcription	O
34	initiation	O
35	that	O
36	involves	O
37	<UNK>	B
38	.	O
1	The	O
2	introduction	O
3	of	O
4	an	O
5	acidic	O
6	residue	O
7	at	O
8	the	O
9	second	O
10	site	O
11	was	O
12	essential	O
13	for	O
14	suppression	O
15	of	O
16	the	O
17	<UNK>	O
18	-	O
19	<UNK>	O
20	mutation	O
21	because	O
22	Lys	O
23	-	O
24	<UNK>	O
25	and	O
26	<UNK>	O
27	-	O
28	<UNK>	O
29	second	O
30	-	O
31	site	O
32	mutants	O
33	of	O
34	the	O
35	<UNK>	O
36	-	O
37	<UNK>	O
38	mutant	O
39	showed	O
40	very	O
41	low	O
42	<UNK>	O
43	resistance	O
44	.(	O
45	ABSTRACT	O
46	TRUNCATED	O
47	AT	O
48	250	O
49	WORDS	O
50	)	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	<UNK>	B
6	provides	O
7	a	O
8	crucial	O
9	transactivation	O
10	function	O
11	for	O
12	globin	B
13	expression	O
14	and	O
15	further	O
16	<UNK>	O
17	the	O
18	<UNK>	O
19	that	O
20	<UNK>	B
21	is	O
22	an	O
23	important	O
24	regulator	O
25	of	O
26	<UNK>	O
27	element	O
28	-	O
29	directed	O
30	transcription	O
31	in	O
32	erythroid	O
33	cells	O
34	.	O
1	<UNK>	O
2	of	O
3	<UNK>	B
4	enhances	O
5	the	O
6	ability	O
7	of	O
8	c	B
9	-	O
10	Fos	B
11	to	O
12	activate	O
13	an	O
14	AP1	B
15	bearing	O
16	promoter	O
17	.	O
1	This	O
2	failure	O
3	to	O
4	<UNK>	O
5	regulated	O
6	G1	O
7	/	O
8	S	O
9	arrest	O
10	is	O
11	correlated	O
12	with	O
13	enhanced	O
14	<UNK>	O
15	of	O
16	colony	O
17	-	O
18	forming	O
19	ability	O
20	.	O
1	Mutations	O
2	that	O
3	alter	O
4	<UNK>	O
5	cell	O
6	structure	O
7	and	O
8	development	O
9	were	O
10	isolated	O
11	that	O
12	fail	O
13	to	O
14	complement	O
15	these	O
16	deletions	O
17	.	O
1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	<UNK>	O
7	of	O
8	the	O
9	two	O
10	nuclei	O
11	have	O
12	different	O
13	functions	O
14	.	O
1	<UNK>	O
2	mapping	O
3	and	O
4	sequence	O
5	analysis	O
6	of	O
7	the	O
8	mouse	O
9	<UNK>	B
10	gene	O
11	<UNK>	O
12	susceptibility	O
13	to	O
14	infection	O
15	with	O
16	intracellular	O
17	<UNK>	O
18	.	O
1	To	O
2	further	O
3	our	O
4	knowledge	O
5	about	O
6	the	O
7	systemic	O
8	<UNK>	O
9	immune	O
10	system	O
11	response	O
12	to	O
13	weak	O
14	<UNK>	O
15	-	O
16	<UNK>	O
17	or	O
18	<UNK>	O
19	protein	O
20	<UNK>	O
21	(	O
22	<UNK>	O
23	and	O
24	<UNK>	O
25	products	O
26	of	O
27	<UNK>	O
28	<UNK>	O
29	<UNK>	O
30	),	O
31	a	O
32	sensitive	O
33	enzyme	O
34	-	O
35	linked	O
36	<UNK>	O
37	assay	O
38	(	O
39	ELISA	O
40	)	O
41	method	O
42	for	O
43	testing	O
44	for	O
45	antibody	O
46	(	O
47	<UNK>	O
48	immunity	O
49	)	O
50	to	O
51	<UNK>	O
52	was	O
53	developed	O
54	.	O
1	Therefore	O
2	the	O
3	<UNK>	O
4	of	O
5	total	O
6	diabetes	O
7	and	O
8	<UNK>	O
9	were	O
10	1	O
11	.	O
12	19	O
13	%	O
14	and	O
15	0	O
16	.	O
17	56	O
18	%,	O
19	respectively	O
20	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	of	O
5	the	O
6	<UNK>	O
7	<UNK>	O
8	--	O
9	an	O
10	<UNK>	O
11	.	O
1	These	O
2	studies	O
3	indicate	O
4	that	O
5	in	O
6	vitro	O
7	and	O
8	in	O
9	vivo	O
10	electrical	O
11	stimulation	O
12	generate	O
13	reactive	O
14	oxygen	O
15	species	O
16	and	O
17	affect	O
18	<UNK>	B
19	activity	O
20	,	O
21	which	O
22	in	O
23	part	O
24	are	O
25	responsible	O
26	for	O
27	decreased	O
28	sperm	O
29	motion	O
30	and	O
31	viability	O
32	.	O
1	Molecular	O
2	cloning	O
3	and	O
4	sequencing	O
5	of	O
6	a	O
7	cDNA	O
8	encoding	O
9	SR	O
10	beta	O
11	revealed	O
12	that	O
13	SR	O
14	beta	O
15	is	O
16	a	O
17	transmembrane	O
18	protein	O
19	and	O
20	,	O
21	like	O
22	SR	O
23	alpha	O
24	and	O
25	<UNK>	B
26	,	O
27	is	O
28	a	O
29	member	O
30	of	O
31	the	O
32	GTPase	B
33	superfamily	O
34	.	O
1	Comparison	O
2	of	O
3	human	O
4	and	O
5	murine	O
6	<UNK>	B
7	sequences	O
8	indicated	O
9	that	O
10	they	O
11	share	O
12	86	O
13	%	O
14	amino	O
15	acid	O
16	identity	O
17	,	O
18	the	O
19	most	O
20	conserved	O
21	region	O
22	being	O
23	the	O
24	catalytic	O
25	domain	O
26	(	O
27	93	O
28	%	O
29	identity	O
30	).	O
1	The	O
2	effect	O
3	of	O
4	ethanol	O
5	on	O
6	human	O
7	<UNK>	O
8	reactivity	O
9	was	O
10	assessed	O
11	by	O
12	<UNK>	O
13	the	O
14	<UNK>	O
15	<UNK>	O
16	response	O
17	.	O
1	VIII	O
2	in	O
3	doses	O
4	2	O
5	-	O
6	3	O
7	times	O
8	higher	O
9	than	O
10	usually	O
11	used	O
12	in	O
13	<UNK>	O
14	without	O
15	inhibitor	O
16	were	O
17	successful	O
18	.	O
1	<UNK>	O
2	analysis	O
3	maps	O
4	<UNK>	B
5	to	O
6	chromosome	O
7	<UNK>	O
8	between	O
9	<UNK>	B
10	and	O
11	<UNK>	B
12	.	O
1	A	O
2	major	O
3	task	O
4	for	O
5	<UNK>	O
6	<UNK>	O
7	may	O
8	be	O
9	to	O
10	<UNK>	O
11	<UNK>	O
12	the	O
13	nature	O
14	of	O
15	an	O
16	integrated	O
17	model	O
18	of	O
19	the	O
20	<UNK>	O
21	<UNK>	O
22	.	O
1	These	O
2	data	O
3	indicate	O
4	that	O
5	phosphorylation	O
6	of	O
7	M	O
8	protein	O
9	at	O
10	the	O
11	major	O
12	in	O
13	vivo	O
14	sites	O
15	is	O
16	not	O
17	essential	O
18	for	O
19	virus	O
20	assembly	O
21	.	O
1	The	O
2	mean	O
3	<UNK>	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	<UNK>	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	<UNK>	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O
1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	show	O
7	that	O
8	<UNK>	B
9	has	O
10	an	O
11	apparent	O
12	molecular	O
13	mass	O
14	of	O
15	approximately	O
16	65	O
17	kDa	O
18	.	O
1	In	O
2	the	O
3	presence	O
4	of	O
5	<UNK>	O
6	and	O
7	<UNK>	O
8	(	O
9	<UNK>	O
10	),	O
11	the	O
12	product	O
13	of	O
14	the	O
15	<UNK>	B
16	gene	O
17	represses	O
18	transcription	O
19	<UNK>	O
20	by	O
21	the	O
22	<UNK>	O
23	element	O
24	.	O
1	The	O
2	interleukin	B
3	2	O
4	receptor	O
5	alpha	O
6	-	O
7	chain	O
8	(	O
9	IL	B
10	-	O
11	<UNK>	B
12	alpha	O
13	)	O
14	gene	O
15	is	O
16	rapidly	O
17	and	O
18	<UNK>	O
19	induced	O
20	in	O
21	T	O
22	cells	O
23	in	O
24	response	O
25	to	O
26	mitogenic	O
27	stimuli	O
28	.	O
1	<UNK>	O
2	designed	O
3	and	O
4	expressed	O
5	were	O
6	<UNK>	O
7	(	O
8	1	O
9	-	O
10	98	O
11	),	O
12	<UNK>	O
13	.	O
14	H1	O
15	(	O
16	1	O
17	-	O
18	<UNK>	O
19	),	O
20	<UNK>	O
21	(	O
22	120	O
23	-	O
24	<UNK>	O
25	),	O
26	<UNK>	O
27	.	O
28	L2	O
29	(	O
30	98	O
31	-	O
32	<UNK>	O
33	),	O
34	and	O
35	<UNK>	O
36	.	O
37	H1	O
38	.	O
39	L2	O
40	(	O
41	1	O
42	-	O
43	<UNK>	O
44	),	O
45	where	O
46	numbers	O
47	in	O
48	<UNK>	O
49	give	O
50	the	O
51	amino	O
52	acid	O
53	sequence	O
54	for	O
55	the	O
56	portions	O
57	of	O
58	the	O
59	E2	O
60	component	O
61	incorporated	O
62	into	O
63	a	O
64	construct	O
65	.	O
1	Similarly	O
2	,	O
3	in	O
4	mammalian	O
5	cells	O
6	<UNK>	B
7	is	O
8	synthesized	O
9	as	O
10	a	O
11	pre	O
12	-	O
13	protein	O
14	that	O
15	requires	O
16	membrane	O
17	potential	O
18	-	O
19	dependent	O
20	import	O
21	into	O
22	mitochondria	O
23	for	O
24	its	O
25	maturation	O
26	.	O
1	When	O
2	expressed	O
3	per	O
4	<UNK>	O
5	body	O
6	weight	O
7	,	O
8	mean	O
9	<UNK>	O
10	increased	O
11	in	O
12	the	O
13	<UNK>	O
14	group	O
15	from	O
16	0	O
17	.	O
18	14	O
19	%	O
20	to	O
21	0	O
22	.	O
23	16	O
24	%	O
25	above	O
26	<UNK>	O
27	,	O
28	with	O
29	a	O
30	significant	O
31	decrease	O
32	from	O
33	0	O
34	.	O
35	15	O
36	%	O
37	to	O
38	0	O
39	.	O
40	13	O
41	%	O
42	in	O
43	the	O
44	P	O
45	group	O
46	.	O
1	However	O
2	,	O
3	<UNK>	O
4	of	O
5	the	O
6	<UNK>	O
7	<UNK>	O
8	motifs	O
9	from	O
10	the	O
11	<UNK>	B
12	promoter	O
13	,	O
14	which	O
15	bind	O
16	factors	O
17	<UNK>	B
18	alpha	O
19	and	O
20	beta	O
21	,	O
22	results	O
23	in	O
24	a	O
25	strong	O
26	synergistic	O
27	activation	O
28	.	O
1	<UNK>	O
2	pancreatic	O
3	involvement	O
4	of	O
5	<UNK>	O
6	<UNK>	O
7	detected	O
8	by	O
9	a	O
10	clinically	O
11	<UNK>	O
12	mass	O
13	.	O
1	In	O
2	ICE	B
3	gamma	O
4	,	O
5	most	O
6	of	O
7	the	O
8	<UNK>	O
9	(	O
10	amino	O
11	acids	O
12	20	O
13	-	O
14	112	O
15	)	O
16	is	O
17	deleted	O
18	,	O
19	which	O
20	suggests	O
21	that	O
22	it	O
23	may	O
24	function	O
25	as	O
26	a	O
27	<UNK>	O
28	for	O
29	ICE	B
30	<UNK>	O
31	in	O
32	vivo	O
33	.	O
1	Mutation	O
2	of	O
3	the	O
4	<UNK>	B
5	-	O
6	3	O
7	<UNK>	O
8	box	O
9	significantly	O
10	increased	O
11	the	O
12	expression	O
13	of	O
14	both	O
15	<UNK>	B
16	-	O
17	3	O
18	and	O
19	<UNK>	B
20	(	O
21	another	O
22	small	O
23	gene	O
24	located	O
25	upstream	O
26	of	O
27	the	O
28	<UNK>	B
29	-	O
30	3	O
31	gene	O
32	that	O
33	encodes	O
34	a	O
35	second	O
36	putative	O
37	regulatory	O
38	protein	O
39	)	O
40	in	O
41	response	O
42	to	O
43	<UNK>	O
44	induction	O
45	but	O
46	left	O
47	the	O
48	basal	O
49	levels	O
50	unaffected	O
51	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	found	O
6	that	O
7	cell	O
8	-	O
9	specific	O
10	suppression	O
11	of	O
12	RA	O
13	-	O
14	stimulated	O
15	<UNK>	B
16	gene	O
17	expression	O
18	can	O
19	be	O
20	<UNK>	O
21	to	O
22	a	O
23	29	O
24	base	O
25	pair	O
26	nucleotide	O
27	sequence	O
28	,	O
29	located	O
30	downstream	O
31	of	O
32	the	O
33	RA	O
34	-	O
35	responsive	O
36	region	O
37	in	O
38	the	O
39	<UNK>	B
40	gene	O
41	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	<UNK>	O
10	sequences	O
11	were	O
12	carried	O
13	out	O
14	in	O
15	29	O
16	patients	O
17	.	O
1	Several	O
2	nuclear	O
3	factors	O
4	that	O
5	interact	O
6	with	O
7	sequences	O
8	in	O
9	the	O
10	5	O
11	'	O
12	flanking	O
13	region	O
14	of	O
15	the	O
16	mouse	O
17	<UNK>	B
18	gene	O
19	were	O
20	identified	O
21	using	O
22	band	O
23	shift	O
24	and	O
25	methylation	O
26	interference	O
27	assays	O
28	.	O
1	<UNK>	B
2	displays	O
3	96	O
4	and	O
5	80	O
6	%	O
7	identity	O
8	respectively	O
9	with	O
10	the	O
11	tobacco	O
12	<UNK>	B
13	and	O
14	Arabidopsis	O
15	<UNK>	B
16	kinases	O
17	,	O
18	and	O
19	only	O
20	50	O
21	%	O
22	to	O
23	the	O
24	more	O
25	<UNK>	O
26	related	O
27	plant	O
28	MAP	B
29	kinase	I
30	<UNK>	I
31	from	O
32	<UNK>	O
33	.	O
1	<UNK>	O
2	of	O
3	the	O
4	coding	O
5	segment	O
6	,	O
7	which	O
8	was	O
9	designated	O
10	<UNK>	B
11	,	O
12	suggested	O
13	it	O
14	encodes	O
15	a	O
16	chimeric	O
17	40	O
18	,	O
19	<UNK>	O
20	<UNK>	O
21	cell	O
22	wall	O
23	protein	O
24	with	O
25	an	O
26	amino	O
27	-	O
28	terminal	O
29	signal	O
30	sequence	O
31	,	O
32	a	O
33	repetitive	O
34	proline	O
35	-	O
36	rich	O
37	sequence	O
38	,	O
39	and	O
40	a	O
41	cysteine	O
42	-	O
43	rich	O
44	carboxyl	O
45	-	O
46	terminal	O
47	sequence	O
48	homologous	O
49	to	O
50	<UNK>	O
51	lipid	O
52	transfer	O
53	proteins	O
54	.	O
1	The	O
2	presence	O
3	of	O
4	type	O
5	I	O
6	hypersensitivity	O
7	in	O
8	a	O
9	subgroup	O
10	of	O
11	<UNK>	O
12	suggests	O
13	an	O
14	<UNK>	O
15	component	O
16	to	O
17	this	O
18	disease	O
19	which	O
20	could	O
21	contribute	O
22	to	O
23	a	O
24	chronic	O
25	inflammatory	O
26	response	O
27	to	O
28	<UNK>	O
29	in	O
30	some	O
31	<UNK>	O
32	.	O
1	The	O
2	<UNK>	B
3	bind	O
4	to	O
5	<UNK>	O
6	and	O
7	E	O
8	-	O
9	<UNK>	B
10	in	O
11	a	O
12	similar	O
13	fashion	O
14	,	O
15	but	O
16	<UNK>	O
17	and	O
18	E	O
19	-	O
20	<UNK>	B
21	do	O
22	not	O
23	associate	O
24	with	O
25	each	O
26	other	O
27	either	O
28	in	O
29	the	O
30	presence	O
31	or	O
32	absence	O
33	of	O
34	<UNK>	B
35	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	<UNK>	O
6	genes	O
7	are	O
8	<UNK>	O
9	upon	O
10	binding	O
11	of	O
12	<UNK>	B
13	,	O
14	whose	O
15	synthesis	O
16	depends	O
17	on	O
18	the	O
19	release	O
20	of	O
21	<UNK>	B
22	(	O
23	<UNK>	B
24	)	O
25	from	O
26	the	O
27	<UNK>	B
28	promoter	O
29	.	O
1	Both	O
2	factors	O
3	demonstrated	O
4	significant	O
5	correlations	O
6	with	O
7	rCBF	O
8	in	O
9	the	O
10	medial	O
11	<UNK>	O
12	cortex	O
13	and	O
14	frontal	O
15	<UNK>	O
16	cortex	O
17	while	O
18	for	O
19	each	O
20	factor	O
21	there	O
22	were	O
23	also	O
24	unique	O
25	patterns	O
26	of	O
27	correlations	O
28	with	O
29	posterior	O
30	brain	O
31	regions	O
32	.	O
1	The	O
2	wild	O
3	-	O
4	type	O
5	and	O
6	altered	O
7	forms	O
8	of	O
9	the	O
10	F	O
11	protein	O
12	were	O
13	expressed	O
14	in	O
15	<UNK>	O
16	-	O
17	21	O
18	and	O
19	HeLa	O
20	T4	O
21	cells	O
22	by	O
23	use	O
24	of	O
25	the	O
26	recombinant	O
27	vaccinia	O
28	virus	O
29	-	O
30	encoding	O
31	T7	O
32	polymerase	O
33	system	O
34	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	<UNK>	O
9	DNA	O
10	enhances	O
11	transcription	O
12	from	O
13	the	O
14	thymidine	B
15	kinase	I
16	(	O
17	TK	B
18	)	O
19	promoter	O
20	in	O
21	various	O
22	EC	O
23	cells	O
24	.	O
1	Analysis	O
2	of	O
3	<UNK>	O
4	rates	O
5	indicates	O
6	that	O
7	the	O
8	<UNK>	B
9	-	O
10	<UNK>	B
11	-	O
12	DNA	O
13	complex	O
14	has	O
15	a	O
16	longer	O
17	half	O
18	-	O
19	life	O
20	than	O
21	protein	O
22	-	O
23	DNA	O
24	complexes	O
25	that	O
26	contain	O
27	only	O
28	<UNK>	B
29	or	O
30	<UNK>	B
31	.	O
1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	<UNK>	O
8	<UNK>	B
9	beta	O
10	1	O
11	at	O
12	the	O
13	5	O
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	<UNK>	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O
1	<UNK>	O
2	5	O
3	<UNK>	O
4	.	O
1	At	O
2	the	O
3	<UNK>	O
4	(	O
5	8	O
6	mg	O
7	/	O
8	m2	O
9	/	O
10	day	O
11	),	O
12	the	O
13	dose	O
14	-	O
15	limiting	O
16	toxicity	O
17	of	O
18	this	O
19	agent	O
20	is	O
21	<UNK>	O
22	.	O
1	Northern	O
2	analysis	O
3	of	O
4	RNA	O
5	samples	O
6	isolated	O
7	from	O
8	<UNK>	O
9	-	O
10	grown	O
11	cultures	O
12	of	O
13	the	O
14	<UNK>	B
15	mutant	O
16	showed	O
17	reduced	O
18	amounts	O
19	of	O
20	<UNK>	B
21	message	O
22	and	O
23	the	O
24	absence	O
25	of	O
26	a	O
27	1	O
28	.	O
29	7	O
30	-	O
31	kb	O
32	transcript	O
33	.	O
1	Comparison	O
2	of	O
3	cDNA	O
4	sequences	O
5	revealed	O
6	that	O
7	the	O
8	two	O
9	mRNA	O
10	species	O
11	<UNK>	O
12	as	O
13	a	O
14	result	O
15	of	O
16	<UNK>	O
17	use	O
18	of	O
19	poly	O
20	(	O
21	A	O
22	)-	O
23	addition	O
24	sites	O
25	.	O
1	The	O
2	gene	O
3	for	O
4	the	O
5	RNA	O
6	-	O
7	dependent	O
8	eIF	B
9	-	O
10	2	O
11	alpha	O
12	protein	O
13	kinase	B
14	(	O
15	PKR	B
16	)	O
17	was	O
18	isolated	O
19	from	O
20	mouse	O
21	genomic	O
22	DNA	O
23	and	O
24	characterized	O
25	.	O
1	In	O
2	order	O
3	to	O
4	define	O
5	potential	O
6	candidate	O
7	genes	O
8	for	O
9	<UNK>	O
10	disorders	O
11	characterized	O
12	by	O
13	aberrant	O
14	gene	O
15	expression	O
16	,	O
17	we	O
18	utilized	O
19	<UNK>	B
20	-	O
21	related	O
22	sequences	O
23	to	O
24	isolate	O
25	zinc	O
26	finger	O
27	-	O
28	containing	O
29	cDNAs	O
30	.	O
1	The	O
2	novel	O
3	<UNK>	B
4	homologue	O
5	mouse	O
6	<UNK>	B
7	3	O
8	lacks	O
9	specific	O
10	epidermal	B
11	growth	O
12	factor	O
13	-	O
14	repeats	O
15	and	O
16	is	O
17	expressed	O
18	in	O
19	<UNK>	O
20	<UNK>	O
21	.	O
1	Expression	O
2	is	O
3	exclusively	O
4	limited	O
5	to	O
6	the	O
7	CNS	O
8	at	O
9	this	O
10	and	O
11	later	O
12	stages	O
13	.	O
1	The	O
2	<UNK>	B
3	/	O
4	<UNK>	B
5	complex	O
6	binds	O
7	both	O
8	in	O
9	vitro	O
10	and	O
11	in	O
12	vivo	O
13	to	O
14	<UNK>	B
15	but	O
16	not	O
17	<UNK>	B
18	or	O
19	E2F	B
20	sites	O
21	.	O
1	(	O
2	1992	O
3	)	O
4	<UNK>	O
5	12	O
6	,	O
7	58	O
8	-	O
9	62	O
10	).	O
1	Identification	O
2	of	O
3	the	O
4	<UNK>	B
5	-	O
6	binding	O
7	domain	O
8	in	O
9	<UNK>	B
10	and	O
11	its	O
12	role	O
13	in	O
14	<UNK>	O
15	assembly	O
16	and	O
17	intermediate	O
18	<UNK>	O
19	<UNK>	O
20	.	O
1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	TATA	O
8	element	O
9	is	O
10	critical	O
11	for	O
12	basal	O
13	and	O
14	Tat	B
15	-	O
16	induced	O
17	HIV	O
18	-	O
19	1	O
20	gene	O
21	expression	O
22	.	O
1	Expression	O
2	of	O
3	a	O
4	dominant	O
5	-	O
6	negative	O
7	ras	B
8	gene	O
9	also	O
10	blocks	O
11	<UNK>	B
12	/	O
13	<UNK>	B
14	induction	O
15	by	O
16	v	O
17	-	O
18	src	B
19	.	O
1	The	O
2	protein	O
3	encoded	O
4	is	O
5	<UNK>	O
6	kDa	O
7	and	O
8	contains	O
9	eight	O
10	zinc	O
11	finger	O
12	motifs	O
13	,	O
14	seven	O
15	of	O
16	which	O
17	are	O
18	present	O
19	in	O
20	two	O
21	clusters	O
22	at	O
23	opposite	O
24	ends	O
25	of	O
26	the	O
27	molecule	O
28	.	O
1	The	O
2	predominant	O
3	binding	O
4	activity	O
5	was	O
6	not	O
7	Ets	B
8	-	O
9	1	O
10	but	O
11	rather	O
12	two	O
13	independent	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	that	O
19	<UNK>	O
20	in	O
21	mobility	O
22	shift	O
23	assays	O
24	.	O
1	Treatment	O
2	with	O
3	amphotericin	O
4	B	O
5	and	O
6	<UNK>	O
7	led	O
8	to	O
9	improvement	O
10	of	O
11	the	O
12	symptoms	O
13	but	O
14	did	O
15	not	O
16	<UNK>	O
17	the	O
18	<UNK>	O
19	-	O
20	organisms	O
21	from	O
22	the	O
23	cerebrospinal	O
24	fluid	O
25	(	O
26	CSF	B
27	).	O
1	The	O
2	parameters	O
3	of	O
4	<UNK>	O
5	<UNK>	O
6	immunity	O
7	--	O
8	serum	O
9	<UNK>	B
10	and	O
11	immune	O
12	complexes	O
13	--	O
14	were	O
15	evaluated	O
16	in	O
17	<UNK>	O
18	group	O
19	of	O
20	patients	O
21	with	O
22	uterine	O
23	<UNK>	O
24	carcinoma	O
25	(	O
26	<UNK>	O
27	<UNK>	O
28	and	O
29	<UNK>	O
30	),	O
31	during	O
32	one	O
33	year	O
34	follow	O
35	up	O
36	.	O
1	Mutation	O
2	of	O
3	<UNK>	O
4	to	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	B
8	in	O
9	the	O
10	cytoplasmic	O
11	<UNK>	O
12	,	O
13	<UNK>	O
14	the	O
15	wild	O
16	-	O
17	type	O
18	protein	O
19	is	O
20	detected	O
21	exclusively	O
22	in	O
23	the	O
24	nucleus	O
25	.	O
1	To	O
2	confirm	O
3	the	O
4	binding	O
5	of	O
6	protein	O
7	to	O
8	these	O
9	sites	O
10	in	O
11	cells	O
12	,	O
13	we	O
14	carried	O
15	out	O
16	an	O
17	in	O
18	vivo	O
19	genomic	O
20	footprinting	O
21	analysis	O
22	of	O
23	this	O
24	portion	O
25	of	O
26	the	O
27	TGF	B
28	alpha	O
29	promoter	O
30	in	O
31	normal	O
32	and	O
33	transformed	O
34	rat	O
35	liver	O
36	epithelial	O
37	cell	O
38	lines	O
39	that	O
40	express	O
41	the	O
42	endogenous	O
43	gene	O
44	at	O
45	varying	O
46	levels	O
47	.	O
1	<UNK>	O
2	,	O
3	this	O
4	<UNK>	O
5	is	O
6	also	O
7	present	O
8	in	O
9	the	O
10	otherwise	O
11	unrelated	O
12	N	O
13	-	O
14	terminal	O
15	activating	O
16	region	O
17	of	O
18	<UNK>	B
19	-	O
20	ets	B
21	-	O
22	2	O
23	and	O
24	was	O
25	thus	O
26	named	O
27	<UNK>	B
28	for	O
29	Ets	B
30	-	O
31	1	O
32	-	O
33	beta	O
34	/	O
35	Ets	B
36	-	O
37	2	O
38	-	O
39	<UNK>	O
40	sequence	O
41	.	O
1	<UNK>	O
2	,	O
3	<UNK>	B
4	contains	O
5	a	O
6	long	O
7	stretch	O
8	(	O
9	13	O
10	nt	O
11	.)	O
12	of	O
13	<UNK>	O
14	to	O
15	a	O
16	highly	O
17	conserved	O
18	sequence	O
19	in	O
20	<UNK>	B
21	rRNA	O
22	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	was	O
5	earlier	O
6	and	O
7	more	O
8	widely	O
9	used	O
10	than	O
11	<UNK>	O
12	in	O
13	<UNK>	O
14	advanced	O
15	breast	O
16	carcinoma	O
17	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	<UNK>	O
5	host	O
6	organism	O
7	increases	O
8	the	O
9	negative	O
10	effect	O
11	of	O
12	<UNK>	O
13	radiation	O
14	on	O
15	the	O
16	hamster	O
17	immune	O
18	system	O
19	.	O
1	During	O
2	heat	O
3	exposure	O
4	,	O
5	<UNK>	O
6	that	O
7	had	O
8	been	O
9	subjected	O
10	to	O
11	early	O
12	60	O
13	%	O
14	restriction	O
15	with	O
16	non	O
17	-	O
18	<UNK>	O
19	-	O
20	treated	O
21	food	O
22	had	O
23	lower	O
24	H	O
25	/	O
26	L	O
27	ratios	O
28	and	O
29	improved	O
30	resistance	O
31	to	O
32	<UNK>	O
33	spleen	O
34	disease	O
35	infection	O
36	.	O
1	<UNK>	B
2	contains	O
3	three	O
4	proteins	O
5	,	O
6	<UNK>	B
7	,	O
8	<UNK>	B
9	and	O
10	<UNK>	B
11	.	O
1	These	O
2	mutations	O
3	are	O
4	localized	O
5	in	O
6	the	O
7	same	O
8	region	O
9	where	O
10	the	O
11	HSV	O
12	transactivator	O
13	VP16	B
14	binds	O
15	,	O
16	but	O
17	did	O
18	not	O
19	<UNK>	O
20	with	O
21	the	O
22	VP16	B
23	<UNK>	O
24	.	O
1	In	O
2	general	O
3	,	O
4	the	O
5	filtration	O
6	rate	O
7	in	O
8	relevant	O
9	areas	O
10	appears	O
11	to	O
12	be	O
13	an	O
14	<UNK>	O
15	and	O
16	easily	O
17	determined	O
18	parameter	O
19	,	O
20	<UNK>	O
21	hormonal	O
22	and	O
23	<UNK>	O
24	vascular	O
25	as	O
26	well	O
27	as	O
28	local	O
29	<UNK>	O
30	control	O
31	of	O
32	the	O
33	<UNK>	O
34	<UNK>	O
35	.	O
1	However	O
2	,	O
3	<UNK>	O
4	inhibited	O
5	proliferation	O
6	of	O
7	<UNK>	O
8	/	O
9	<UNK>	O
10	-	O
11	<UNK>	O
12	but	O
13	not	O
14	of	O
15	<UNK>	O
16	cells	O
17	despite	O
18	inhibition	O
19	of	O
20	p70	B
21	<UNK>	I
22	kinase	I
23	activity	O
24	in	O
25	both	O
26	cells	O
27	.	O
1	A	O
2	strong	O
3	<UNK>	B
4	binding	O
5	site	O
6	was	O
7	found	O
8	at	O
9	the	O
10	<UNK>	O
11	location	O
12	of	O
13	the	O
14	<UNK>	B
15	head	O
16	gene	O
17	,	O
18	a	O
19	region	O
20	-	O
21	specific	O
22	<UNK>	B
23	gene	O
24	not	O
25	located	O
26	within	O
27	a	O
28	<UNK>	B
29	complex	O
30	.	O
1	C	O
2	/	O
3	EBP	B
4	alpha	O
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	O
12	class	O
13	-	O
14	I	O
15	<UNK>	B
16	gene	O
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	<UNK>	O
25	et	O
26	al	O
27	.,	O
28	<UNK>	O
29	.	O
1	C	O
2	/	O
3	EBP	B
4	alpha	O
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	O
12	class	O
13	-	O
14	I	O
15	<UNK>	B
16	gene	O
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	<UNK>	O
25	et	O
26	al	O
27	.,	O
28	<UNK>	O
29	.	O
1	<UNK>	O
2	was	O
3	also	O
4	detected	O
5	between	O
6	the	O
7	putative	O
8	transit	O
9	peptide	O
10	sequence	O
11	of	O
12	cysteine	O
13	synthase	B
14	C	O
15	and	O
16	other	O
17	<UNK>	O
18	-	O
19	targeting	O
20	leader	O
21	sequences	O
22	.	O
1	<UNK>	O
2	kidney	O
3	<UNK>	B
4	.	O
1	A	O
2	candidate	O
3	gene	O
4	for	O
5	<UNK>	B
6	,	O
7	designated	O
8	natural	O
9	resistance	O
10	-	O
11	associated	O
12	macrophage	O
13	protein	O
14	(	O
15	<UNK>	B
16	),	O
17	has	O
18	been	O
19	isolated	O
20	and	O
21	shown	O
22	to	O
23	encode	O
24	a	O
25	novel	O
26	macrophage	O
27	-	O
28	specific	O
29	membrane	O
30	protein	O
31	,	O
32	which	O
33	is	O
34	altered	O
35	in	O
36	susceptible	O
37	animals	O
38	.	O
1	The	O
2	defined	O
3	length	O
4	of	O
5	the	O
6	mRNA	O
7	,	O
8	1	O
9	,	O
10	<UNK>	O
11	nucleotides	O
12	,	O
13	was	O
14	in	O
15	agreement	O
16	with	O
17	that	O
18	of	O
19	a	O
20	1	O
21	.	O
22	9	O
23	-	O
24	kb	O
25	RNA	O
26	expressed	O
27	throughout	O
28	the	O
29	replication	O
30	cycle	O
31	,	O
32	<UNK>	O
33	at	O
34	the	O
35	early	O
36	stages	O
37	of	O
38	infection	O
39	.	O
1	<UNK>	O
2	.	O
1	The	O
2	present	O
3	data	O
4	also	O
5	indicate	O
6	that	O
7	patients	O
8	with	O
9	<UNK>	O
10	<UNK>	O
11	often	O
12	have	O
13	concomitant	O
14	IgA	B
15	<UNK>	O
16	and	O
17	<UNK>	O
18	<UNK>	O
19	<UNK>	O
20	.	O
1	<UNK>	O
2	responsible	O
3	for	O
4	the	O
5	<UNK>	O
6	,	O
7	<UNK>	O
8	-	O
9	specific	O
10	alternative	O
11	pre	O
12	-	O
13	mRNA	O
14	splicing	O
15	characteristic	O
16	of	O
17	<UNK>	O
18	are	O
19	almost	O
20	<UNK>	O
21	unknown	O
22	or	O
23	<UNK>	O
24	.	O
1	A	O
2	full	O
3	-	O
4	length	O
5	cDNA	O
6	clone	O
7	isolated	O
8	from	O
9	a	O
10	rat	O
11	lung	O
12	library	O
13	was	O
14	predicted	O
15	to	O
16	encode	O
17	a	O
18	55	O
19	-	O
20	kDa	O
21	protein	O
22	containing	O
23	at	O
24	its	O
25	amino	O
26	terminus	O
27	a	O
28	targeting	O
29	domain	O
30	that	O
31	binds	O
32	to	O
33	the	O
34	<UNK>	B
35	-	O
36	receptor	O
37	kinase	B
38	-	O
39	like	O
40	domain	O
41	and	O
42	containing	O
43	at	O
44	its	O
45	carboxyl	O
46	terminus	O
47	a	O
48	putative	O
49	protein	O
50	-	O
51	serine	O
52	phosphatase	B
53	domain	O
54	.	O
1	Human	O
2	adenovirus	O
3	type	O
4	41	O
5	contains	O
6	two	O
7	fibers	O
8	.	O
1	<UNK>	O
2	<UNK>	O
3	of	O
4	pancreatic	O
5	<UNK>	O
6	,	O
7	i	O
8	.	O
9	e	O
10	.,	O
11	""""	O
12	relative	O
13	stenosis	O
14	of	O
15	the	O
16	minor	O
17	<UNK>	O
18	<UNK>	O
19	was	O
20	considered	O
21	to	O
22	be	O
23	present	O
24	in	O
25	the	O
26	patients	O
27	with	O
28	type	O
29	II	O
30	<UNK>	O
31	,	O
32	and	O
33	,	O
34	therefore	O
35	,	O
36	the	O
37	patients	O
38	with	O
39	type	O
40	II	O
41	<UNK>	O
42	might	O
43	<UNK>	O
44	from	O
45	acute	O
46	pancreatitis	O
47	resulting	O
48	from	O
49	poor	O
50	<UNK>	O
51	of	O
52	pancreatic	O
53	<UNK>	O
54	and	O
55	<UNK>	O
56	pressure	O
57	in	O
58	the	O
59	dorsal	O
60	<UNK>	O
61	.	O
1	An	O
2	unusual	O
3	<UNK>	O
4	in	O
5	an	O
6	<UNK>	O
7	patient	O
8	.	O
1	In	O
2	the	O
3	<UNK>	O
4	group	O
5	,	O
6	at	O
7	pre	O
8	-	O
9	<UNK>	O
10	,	O
11	CBF	O
12	increased	O
13	from	O
14	86	O
15	+/-	O
16	8	O
17	to	O
18	<UNK>	O
19	+/-	O
20	19	O
21	mL	O
22	.	O
23	min	O
24	-	O
25	1	O
26	.	O
27	100	O
28	g	O
29	-	O
30	1	O
31	in	O
32	response	O
33	to	O
34	<UNK>	O
35	(	O
36	PCO2	O
37	approximately	O
38	90	O
39	mmHg	O
40	<UNK>	O
41	ABSTRACT	O
42	TRUNCATED	O
43	AT	O
44	250	O
45	WORDS	O
46	)	O
1	<UNK>	O
2	<UNK>	O
3	,	O
4	<UNK>	O
5	-	O
6	120	O
7	].	O
1	<UNK>	B
2	,	O
3	like	O
4	PC	O
5	-	O
6	1	O
7	,	O
8	was	O
9	found	O
10	to	O
11	<UNK>	O
12	the	O
13	type	O
14	I	O
15	phosphodiesterase	O
16	substrate	O
17	p	O
18	-	O
19	<UNK>	O
20	thymidine	B
21	-	O
22	5	O
23	'-	O
24	<UNK>	O
25	.	O
1	Recently	O
2	,	O
3	a	O
4	protein	O
5	designated	O
6	<UNK>	B
7	has	O
8	been	O
9	isolated	O
10	that	O
11	is	O
12	associated	O
13	with	O
14	the	O
15	<UNK>	B
16	protein	O
17	complex	O
18	.	O
1	This	O
2	technique	O
3	has	O
4	a	O
5	sensitivity	O
6	and	O
7	a	O
8	specificity	O
9	of	O
10	almost	O
11	100	O
12	%,	O
13	and	O
14	is	O
15	currently	O
16	the	O
17	best	O
18	way	O
19	to	O
20	<UNK>	O
21	nodal	O
22	involvement	O
23	,	O
24	<UNK>	O
25	from	O
26	<UNK>	O
27	.	O
1	A	O
2	sequence	O
3	<UNK>	O
4	about	O
5	50	O
6	%	O
7	of	O
8	the	O
9	expected	O
10	complete	O
11	sequence	O
12	was	O
13	obtained	O
14	by	O
15	translation	O
16	of	O
17	the	O
18	two	O
19	open	O
20	reading	O
21	frames	O
22	present	O
23	on	O
24	a	O
25	1	O
26	.	O
27	6	O
28	kb	O
29	DNA	O
30	genomic	O
31	fragment	O
32	.	O
1	A	O
2	cDNA	O
3	clone	O
4	<UNK>	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	<UNK>	O
19	-	O
20	<UNK>	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	<UNK>	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	<UNK>	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O
1	The	O
2	<UNK>	B
3	,	O
4	<UNK>	B
5	,	O
6	<UNK>	B
7	,	O
8	<UNK>	B
9	,	O
10	<UNK>	B
11	and	O
12	<UNK>	B
13	genes	O
14	act	O
15	upstream	O
16	of	O
17	<UNK>	B
18	cyclase	I
19	,	O
20	<UNK>	O
21	encoding	O
22	an	O
23	<UNK>	B
24	cyclase	I
25	activation	O
26	pathway	O
27	.	O
1	DNA	O
2	sequence	O
3	analysis	O
4	has	O
5	confirmed	O
6	that	O
7	this	O
8	mutation	O
9	affects	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	region	O
15	of	O
16	the	O
17	alpha	O
18	subunit	O
19	,	O
20	changing	O
21	a	O
22	leucine	O
23	residue	O
24	at	O
25	position	O
26	<UNK>	O
27	to	O
28	a	O
29	histidine	O
30	(	O
31	<UNK>	B
32	).	O
1	Using	O
2	this	O
3	reporter	O
4	gene	O
5	system	O
6	,	O
7	we	O
8	previously	O
9	showed	O
10	that	O
11	EPO	B
12	-	O
13	induced	O
14	activation	O
15	of	O
16	the	O
17	c	B
18	-	O
19	fos	B
20	promoter	O
21	can	O
22	be	O
23	detected	O
24	rapidly	O
25	and	O
26	<UNK>	O
27	as	O
28	an	O
29	elevation	O
30	of	O
31	cellular	O
32	luciferase	B
33	activity	O
34	.	O
1	I	O
2	<UNK>	O
3	that	O
4	white	O
5	gene	O
6	expression	O
7	from	O
8	P	O
9	[	O
10	<UNK>	O
11	]	O
12	is	O
13	repressed	O
14	by	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	protein	O
20	complex	O
21	which	O
22	is	O
23	initiated	O
24	at	O
25	the	O
26	<UNK>	B
27	<UNK>	O
28	sites	O
29	and	O
30	also	O
31	requires	O
32	interactions	O
33	with	O
34	flanking	O
35	genomic	O
36	DNA	O
37	.	O
1	<UNK>	O
2	curve	O
3	correlation	O
4	coefficients	O
5	of	O
6	0	O
7	.	O
8	<UNK>	O
9	or	O
10	greater	O
11	were	O
12	obtained	O
13	during	O
14	<UNK>	O
15	experiments	O
16	and	O
17	analysis	O
18	of	O
19	study	O
20	samples	O
21	.	O
1	2	O
2	.	O
1	<UNK>	B
2	,	O
3	a	O
4	regulatory	O
5	gene	O
6	in	O
7	yeast	O
8	<UNK>	O
9	biosynthesis	O
10	,	O
11	affects	O
12	nuclear	O
13	<UNK>	O
14	and	O
15	<UNK>	O
16	pattern	O
17	formation	O
18	.	O
1	In	O
2	an	O
3	in	O
4	vitro	O
5	study	O
6	,	O
7	10	O
8	/	O
9	0	O
10	<UNK>	O
11	was	O
12	found	O
13	to	O
14	require	O
15	a	O
16	significantly	O
17	lower	O
18	laser	O
19	energy	O
20	density	O
21	to	O
22	produce	O
23	<UNK>	O
24	<UNK>	O
25	following	O
26	a	O
27	single	O
28	<UNK>	O
29	than	O
30	either	O
31	10	O
32	/	O
33	0	O
34	<UNK>	O
35	or	O
36	10	O
37	/	O
38	0	O
39	<UNK>	O
40	.	O
1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	<UNK>	B
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	O
14	activity	O
15	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	<UNK>	O
6	of	O
7	an	O
8	anti	O
9	-	O
10	CBP	B
11	antiserum	O
12	into	O
13	fibroblasts	O
14	can	O
15	inhibit	O
16	transcription	O
17	from	O
18	a	O
19	cAMP	O
20	responsive	O
21	promoter	O
22	.	O
1	65	O
2	,	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	,	O
7	1991	O
8	),	O
9	a	O
10	truncated	O
11	form	O
12	of	O
13	the	O
14	<UNK>	B
15	polypeptide	O
16	lacking	O
17	<UNK>	B
18	amino	O
19	acid	O
20	residues	O
21	1	O
22	-	O
23	<UNK>	O
24	(	O
25	and	O
26	,	O
27	therefore	O
28	lacks	O
29	the	O
30	deduced	O
31	transcriptional	O
32	activation	O
33	domain	O
34	),	O
35	<UNK>	O
36	to	O
37	<UNK>	O
38	the	O
39	<UNK>	O
40	-	O
41	1	O
42	<UNK>	B
43	promoter	O
44	,	O
45	but	O
46	<UNK>	O
47	the	O
48	ability	O
49	to	O
50	down	O
51	-	O
52	regulate	O
53	the	O
54	<UNK>	O
55	-	O
56	1	O
57	<UNK>	B
58	promoter	O
59	.	O
1	At	O
2	least	O
3	some	O
4	of	O
5	the	O
6	difference	O
7	in	O
8	stability	O
9	of	O
10	the	O
11	two	O
12	<UNK>	O
13	of	O
14	complexes	O
15	was	O
16	due	O
17	to	O
18	the	O
19	fact	O
20	that	O
21	the	O
22	<UNK>	O
23	rate	O
24	of	O
25	the	O
26	A	O
27	stem	O
28	substrate	O
29	from	O
30	the	O
31	protein	O
32	-	O
33	DNA	O
34	complexes	O
35	was	O
36	approximately	O
37	<UNK>	O
38	<UNK>	O
39	than	O
40	that	O
41	of	O
42	the	O
43	complete	O
44	TR	B
45	.	O
1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	<UNK>	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	<UNK>	B
16	.	O
1	Thus	O
2	,	O
3	<UNK>	B
4	is	O
5	a	O
6	functional	O
7	homolog	O
8	of	O
9	<UNK>	B
10	and	O
11	represents	O
12	a	O
13	new	O
14	component	O
15	of	O
16	the	O
17	yeast	O
18	mitochondrial	O
19	import	O
20	machinery	O
21	.	O
1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	kinetics	O
7	of	O
8	erythropoietin	B
9	(	O
10	EPO	B
11	)	O
12	production	O
13	and	O
14	<UNK>	O
15	the	O
16	pathogenesis	O
17	of	O
18	<UNK>	O
19	of	O
20	<UNK>	O
21	,	O
22	we	O
23	measured	O
24	EPO	B
25	levels	O
26	in	O
27	infants	O
28	during	O
29	the	O
30	first	O
31	year	O
32	of	O
33	life	O
34	.	O
1	We	O
2	<UNK>	O
3	that	O
4	mast	O
5	cell	O
6	<UNK>	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	the	O
12	pathogenesis	O
13	of	O
14	<UNK>	O
15	by	O
16	<UNK>	O
17	fibroblast	O
18	enzyme	O
19	activity	O
20	and	O
21	/	O
22	or	O
23	producing	O
24	prolonged	O
25	inflammatory	O
26	reactions	O
27	.	O
1	<UNK>	B
2	showed	O
3	strong	O
4	identity	O
5	to	O
6	<UNK>	B
7	and	O
8	<UNK>	B
9	-	O
10	like	O
11	proteins	O
12	from	O
13	many	O
14	other	O
15	bacteria	O
16	.	O
1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	<UNK>	O
13	following	O
14	gastric	O
15	resection	O
16	.	O
1	<UNK>	O
2	was	O
3	combined	O
4	with	O
5	the	O
6	increase	O
7	of	O
8	glucocorticoid	O
9	activity	O
10	of	O
11	adrenal	O
12	cortex	O
13	,	O
14	while	O
15	no	O
16	significant	O
17	changes	O
18	in	O
19	thyroid	O
20	hormones	O
21	were	O
22	<UNK>	O
23	.	O
1	<UNK>	O
2	cleavage	O
3	and	O
4	peptide	O
5	sequence	O
6	analysis	O
7	demonstrated	O
8	that	O
9	the	O
10	98	O
11	-	O
12	kD	O
13	protein	O
14	is	O
15	identical	O
16	to	O
17	a	O
18	recently	O
19	cloned	O
20	protein	O
21	,	O
22	special	O
23	A	O
24	-	O
25	T	O
26	-	O
27	rich	O
28	binding	O
29	protein	O
30	1	O
31	(	O
32	<UNK>	B
33	),	O
34	that	O
35	binds	O
36	selectively	O
37	to	O
38	nuclear	O
39	matrix	O
40	/	O
41	<UNK>	O
42	-	O
43	associated	O
44	regions	O
45	of	O
46	DNA	O
47	(	O
48	<UNK>	O
49	/	O
50	<UNK>	O
51	).	O
1	A	O
2	single	O
3	<UNK>	O
4	was	O
5	present	O
6	in	O
7	69	O
8	.	O
9	4	O
10	%,	O
11	two	O
12	in	O
13	16	O
14	%,	O
15	three	O
16	in	O
17	6	O
18	.	O
19	4	O
20	%,	O
21	four	O
22	in	O
23	3	O
24	.	O
25	5	O
26	%,	O
27	five	O
28	to	O
29	nine	O
30	in	O
31	4	O
32	.	O
33	2	O
34	%,	O
35	and	O
36	0	O
37	.	O
38	5	O
39	%	O
40	had	O
41	ten	O
42	or	O
43	more	O
44	.	O
1	CONCLUSION	O
2	:	O
3	<UNK>	O
4	<UNK>	O
5	has	O
6	a	O
7	possible	O
8	role	O
9	in	O
10	the	O
11	detection	O
12	of	O
13	small	O
14	<UNK>	O
15	in	O
16	patients	O
17	with	O
18	<UNK>	O
19	.	O
1	We	O
2	find	O
3	that	O
4	beta	O
5	II	O
6	PKC	B
7	<UNK>	O
8	nuclear	O
9	envelope	O
10	<UNK>	B
11	B	O
12	at	O
13	10	O
14	-	O
15	20	O
16	times	O
17	the	O
18	rate	O
19	of	O
20	alpha	O
21	PKC	B
22	,	O
23	whereas	O
24	both	O
25	kinases	O
26	phosphorylate	O
27	soluble	O
28	<UNK>	B
29	B	O
30	at	O
31	similar	O
32	rates	O
33	.	O
1	Regulation	O
2	of	O
3	<UNK>	O
4	hormone	O
5	-	O
6	related	O
7	protein	O
8	(	O
9	<UNK>	B
10	)	O
11	gene	O
12	expression	O
13	.	O
1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	O
6	<UNK>	B
7	activates	O
8	c	B
9	-	O
10	myc	B
11	transcription	O
12	<UNK>	O
13	with	O
14	no	O
15	requirement	O
16	for	O
17	DNA	O
18	binding	O
19	by	O
20	c	B
21	-	O
22	<UNK>	B
23	.	O
1	The	O
2	Oct	B
3	-	O
4	2	O
5	<UNK>	O
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	<UNK>	O
16	with	O
17	each	O
18	other	O
19	or	O
20	<UNK>	O
21	of	O
22	<UNK>	O
23	to	O
24	activate	O
25	transcription	O
26	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	.	O
1	<UNK>	O
2	features	O
3	of	O
4	this	O
5	model	O
6	are	O
7	<UNK>	O
8	of	O
9	the	O
10	DNA	O
11	double	O
12	helix	O
13	and	O
14	contact	O
15	of	O
16	operator	O
17	sites	O
18	with	O
19	repressor	O
20	domains	O
21	bearing	O
22	sequence	O
23	<UNK>	O
24	with	O
25	the	O
26	helix	O
27	-	O
28	turn	O
29	-	O
30	helix	O
31	(	O
32	<UNK>	O
33	)	O
34	motifs	O
35	of	O
36	other	O
37	DNA	O
38	-	O
39	binding	O
40	proteins	O
41	.	O
1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	<UNK>	B
15	.	O
1	The	O
2	binding	O
3	of	O
4	transcription	O
5	factor	O
6	AP	B
7	-	O
8	1	O
9	and	O
10	vitamin	O
11	D	O
12	receptor	O
13	(	O
14	VDR	B
15	)	O
16	to	O
17	the	O
18	composite	O
19	AP	B
20	-	O
21	1	O
22	plus	O
23	vitamin	O
24	-	O
25	D	O
26	-	O
27	responsive	O
28	promoter	O
29	region	O
30	(	O
31	AP	B
32	-	O
33	1	O
34	+	O
35	<UNK>	O
36	)	O
37	of	O
38	the	O
39	human	O
40	<UNK>	B
41	gene	O
42	was	O
43	characterized	O
44	in	O
45	<UNK>	B
46	-	O
47	producing	O
48	(	O
49	<UNK>	O
50	-	O
51	63	O
52	)	O
53	and	O
54	non	O
55	-	O
56	producing	O
57	(	O
58	U2	B
59	-	O
60	<UNK>	O
61	,	O
62	<UNK>	O
63	-	O
64	2	O
65	)	O
66	human	O
67	<UNK>	O
68	cell	O
69	lines	O
70	.	O
1	Use	O
2	of	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	for	O
9	anesthesia	O
10	in	O
11	minor	O
12	surgery	O
1	<UNK>	O
2	history	O
3	and	O
4	<UNK>	O
5	oxygen	O
6	saturation	O
7	(	O
8	<UNK>	O
9	)	O
10	was	O
11	recorded	O
12	in	O
13	all	O
14	of	O
15	them	O
16	.	O
1	(	O
2	LH	B
3	P	O
4	<	O
5	0	O
6	.	O
7	05	O
8	,	O
9	LH	B
10	/	O
11	FSH	B
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	).	O
1	We	O
2	describe	O
3	49	O
4	cases	O
5	with	O
6	<UNK>	O
7	tumor	O
8	<	O
9	1	O
10	cm	O
11	.	O
1	The	O
2	consensus	O
3	gene	O
4	order	O
5	deduced	O
6	by	O
7	<UNK>	O
8	data	O
9	from	O
10	both	O
11	<UNK>	O
12	is	O
13	<UNK>	B
14	-(	O
15	<UNK>	B
16	,	O
17	<UNK>	B
18	<UNK>	O
19	<UNK>	B
20	,	O
21	<UNK>	B
22	)-	O
23	<UNK>	B
24	-	O
25	<UNK>	O
26	l	O
27	-(	O
28	<UNK>	B
29	,	O
30	<UNK>	B
31	)-	O
32	(	O
33	<UNK>	B
34	,	O
35	<UNK>	B
36	<UNK>	O
37	<UNK>	B
38	.	O
39	2	O
40	,	O
41	<UNK>	B
42	,	O
43	<UNK>	B
44	)-	O
45	<UNK>	B
46	.	O
1	The	O
2	high	O
3	level	O
4	of	O
5	transformation	O
6	-	O
7	associated	O
8	deletions	O
9	in	O
10	the	O
11	human	O
12	<UNK>	O
13	was	O
14	reduced	O
15	over	O
16	10	O
17	-	O
18	fold	O
19	when	O
20	the	O
21	host	O
22	was	O
23	a	O
24	recombination	O
25	-	O
26	deficient	O
27	strain	O
28	deleted	O
29	for	O
30	the	O
31	<UNK>	B
32	gene	O
33	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	<UNK>	O
6	region	O
7	surrounding	O
8	the	O
9	<UNK>	B
10	locus	O
11	was	O
12	mapped	O
13	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	--	O
5	<UNK>	O
6	-	O
7	blind	O
8	<UNK>	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O
1	We	O
2	present	O
3	evidence	O
4	that	O
5	DNA	O
6	polymerase	O
7	delta	O
8	of	O
9	Saccharomyces	O
10	cerevisiae	O
11	,	O
12	an	O
13	enzyme	O
14	that	O
15	is	O
16	essential	O
17	for	O
18	viability	O
19	and	O
20	chromosomal	O
21	replication	O
22	,	O
23	is	O
24	also	O
25	required	O
26	for	O
27	base	O
28	excision	O
29	repair	O
30	of	O
31	exogenous	O
32	DNA	O
33	methylation	O
34	damage	O
35	.	O
1	<UNK>	O
2	of	O
3	each	O
4	<UNK>	B
5	-	O
6	1	O
7	motif	O
8	in	O
9	the	O
10	<UNK>	B
11	promoter	O
12	gave	O
13	substantially	O
14	<UNK>	O
15	levels	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	expression	O
20	,	O
21	whereas	O
22	mutagenesis	O
23	of	O
24	both	O
25	<UNK>	B
26	-	O
27	1	O
28	motifs	O
29	resulted	O
30	in	O
31	the	O
32	almost	O
33	complete	O
34	loss	O
35	of	O
36	expression	O
37	.	O
1	DNase	B
2	I	O
3	footprinting	O
4	analysis	O
5	indicated	O
6	that	O
7	<UNK>	B
8	binds	O
9	to	O
10	the	O
11	24	O
12	-	O
13	bp	O
14	<UNK>	O
15	region	O
16	of	O
17	the	O
18	DNA	O
19	polymerase	O
20	alpha	O
21	gene	O
22	in	O
23	which	O
24	8	O
25	-	O
26	bp	O
27	palindromic	O
28	sequences	O
29	are	O
30	<UNK>	O
31	.	O
1	<UNK>	O
2	8	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	(	O
8	Drosophila	O
9	DNA	O
10	replication	O
11	-	O
12	related	O
13	element	O
14	)	O
15	and	O
16	specific	O
17	binding	O
18	factor	O
19	involved	O
20	in	O
21	the	O
22	expression	O
23	of	O
24	Drosophila	O
25	genes	O
26	for	O
27	DNA	O
28	polymerase	O
29	alpha	O
30	and	O
31	<UNK>	O
32	cell	O
33	nuclear	O
34	antigen	O
35	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	<UNK>	O
6	repeat	O
7	<UNK>	O
8	with	O
9	a	O
10	<UNK>	O
11	of	O
12	71	O
13	%	O
14	at	O
15	the	O
16	<UNK>	B
17	locus	O
18	and	O
19	a	O
20	restriction	O
21	fragment	O
22	length	O
23	<UNK>	O
24	with	O
25	a	O
26	<UNK>	O
27	of	O
28	42	O
29	%	O
30	detected	O
31	by	O
32	a	O
33	lambda	O
34	clone	O
35	from	O
36	the	O
37	<UNK>	B
38	locus	O
39	have	O
40	been	O
41	developed	O
42	for	O
43	high	O
44	-	O
45	resolution	O
46	genetic	O
47	<UNK>	O
48	mapping	O
49	and	O
50	predictive	O
51	diagnostic	O
52	testing	O
53	.	O
1	However	O
2	,	O
3	<UNK>	B
4	can	O
5	be	O
6	expressed	O
7	efficiently	O
8	from	O
9	an	O
10	internal	O
11	promoter	O
12	which	O
13	appears	O
14	to	O
15	<UNK>	O
16	within	O
17	the	O
18	3	O
19	'	O
20	portion	O
21	of	O
22	<UNK>	B
23	.	O
1	<UNK>	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	<UNK>	B
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	<UNK>	B
17	-	O
18	positive	O
19	<UNK>	O
20	.	O
1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	<UNK>	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O
1	Clinical	O
2	aspects	O
3	of	O
4	early	O
5	increase	O
6	in	O
7	serum	O
8	gamma	O
9	-	O
10	<UNK>	B
11	transferase	I
12	in	O
13	cerebral	O
14	infarction	O
15	.	O
1	<UNK>	B
2	-	O
3	B	O
4	.	O
5	<UNK>	O
6	,	O
7	anti	O
8	-	O
9	B	O
10	.	O
11	<UNK>	B
12	and	O
13	anti	O
14	-	O
15	B	O
16	.	O
17	<UNK>	B
18	antibodies	O
19	,	O
20	tested	O
21	by	O
22	the	O
23	indirect	O
24	<UNK>	O
25	assay	O
26	(	O
27	<UNK>	O
28	),	O
29	were	O
30	detected	O
31	in	O
32	10	O
33	.	O
34	8	O
35	,	O
36	16	O
37	.	O
38	1	O
39	and	O
40	8	O
41	.	O
42	2	O
43	%	O
44	of	O
45	the	O
46	serum	O
47	samples	O
48	tested	O
49	,	O
50	and	O
51	confirmed	O
52	by	O
53	<UNK>	O
54	-	O
55	<UNK>	O
56	in	O
57	1	O
58	.	O
59	3	O
60	,	O
61	1	O
62	.	O
63	3	O
64	and	O
65	1	O
66	.	O
67	0	O
68	%,	O
69	respectively	O
70	.	O
1	<UNK>	O
2	analysis	O
3	with	O
4	an	O
5	<UNK>	O
6	<UNK>	O
7	and	O
8	synthetic	O
9	GnRH	B
10	was	O
11	carried	O
12	out	O
13	in	O
14	22	O
15	normal	O
16	subjects	O
17	,	O
18	14	O
19	patients	O
20	with	O
21	primary	O
22	and	O
23	20	O
24	ones	O
25	with	O
26	secondary	O
27	<UNK>	O
28	,	O
29	and	O
30	in	O
31	5	O
32	patients	O
33	with	O
34	clinical	O
35	signs	O
36	of	O
37	<UNK>	O
38	<UNK>	O
39	and	O
40	<UNK>	O
41	diagnosis	O
42	in	O
43	order	O
44	to	O
45	elucidate	O
46	the	O
47	pituitary	O
48	<UNK>	B
49	<UNK>	O
50	.	O
1	This	O
2	indicates	O
3	that	O
4	the	O
5	mechanism	O
6	by	O
7	which	O
8	<UNK>	O
9	blocks	O
10	rapid	O
11	degradation	O
12	of	O
13	<UNK>	B
14	mRNA	O
15	in	O
16	vivo	O
17	is	O
18	not	O
19	<UNK>	O
20	by	O
21	preventing	O
22	its	O
23	translation	O
24	and	O
25	suggests	O
26	the	O
27	involvement	O
28	of	O
29	an	O
30	altered	O
31	trans	O
32	-	O
33	factor	O
34	.	O
1	The	O
2	sequence	O
3	has	O
4	a	O
5	<UNK>	O
6	-	O
7	bp	O
8	open	O
9	reading	O
10	frame	O
11	encoding	O
12	a	O
13	protein	O
14	of	O
15	<UNK>	O
16	amino	O
17	acids	O
18	.	O
1	Western	O
2	blotting	O
3	(	O
4	<UNK>	O
5	)	O
6	with	O
7	an	O
8	antiserum	O
9	to	O
10	a	O
11	partial	O
12	<UNK>	B
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	revealed	O
18	two	O
19	proteins	O
20	with	O
21	estimated	O
22	molecular	O
23	<UNK>	O
24	of	O
25	19	O
26	and	O
27	29	O
28	kDa	O
29	.	O
1	<UNK>	O
2	of	O
3	the	O
4	<UNK>	B
5	-	O
6	specific	O
7	enhancer	O
8	-	O
9	binding	O
10	factor	O
11	2	O
12	(	O
13	<UNK>	B
14	)	O
15	family	O
16	of	O
17	transcription	O
18	factors	O
19	bind	O
20	a	O
21	conserved	O
22	A	O
23	/	O
24	T	O
25	-	O
26	rich	O
27	sequence	O
28	in	O
29	the	O
30	control	O
31	regions	O
32	of	O
33	numerous	O
34	muscle	O
35	-	O
36	specific	O
37	genes	O
38	.	O
1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	<UNK>	B
7	-	O
8	1	O
9	represses	O
10	HIV	O
11	-	O
12	1	O
13	transcription	O
14	by	O
15	inhibiting	O
16	the	O
17	binding	O
18	of	O
19	TFIID	B
20	to	O
21	the	O
22	TATA	O
23	box	O
24	.	O
1	<UNK>	O
2	genomic	O
3	RNA	O
4	for	O
5	these	O
6	reactions	O
7	was	O
8	obtained	O
9	directly	O
10	from	O
11	<UNK>	O
12	specimens	O
13	of	O
14	infected	O
15	<UNK>	O
16	rats	O
17	.	O
1	<UNK>	O
2	necrosis	O
3	factor	O
4	-	O
5	alpha	O
6	(	O
7	TNF	B
8	alpha	O
9	)	O
10	is	O
11	one	O
12	of	O
13	several	O
14	<UNK>	O
15	/	O
16	<UNK>	O
17	factors	O
18	known	O
19	to	O
20	exert	O
21	potent	O
22	inhibitory	O
23	effects	O
24	on	O
25	bone	O
26	.	O
1	Furthermore	O
2	,	O
3	in	O
4	vitro	O
5	decay	O
6	reaction	O
7	<UNK>	O
8	<UNK>	O
9	with	O
10	the	O
11	20	O
12	-	O
13	nt	O
14	sense	O
15	RNA	O
16	transcript	O
17	resulted	O
18	in	O
19	<UNK>	O
20	of	O
21	R2	O
22	message	O
23	.	O
1	<UNK>	O
2	analysis	O
3	of	O
4	the	O
5	disrupted	O
6	mutant	O
7	demonstrated	O
8	the	O
9	accumulation	O
10	of	O
11	<UNK>	O
12	,	O
13	indicating	O
14	a	O
15	loss	O
16	of	O
17	<UNK>	B
18	activity	O
19	.	O
1	The	O
2	alpha	O
3	<UNK>	O
4	form	O
5	RNA	O
6	contains	O
7	an	O
8	additional	O
9	<UNK>	O
10	nucleotides	O
11	compared	O
12	to	O
13	the	O
14	B	O
15	form	O
16	,	O
17	and	O
18	a	O
19	common	O
20	coding	O
21	region	O
22	in	O
23	the	O
24	A	O
25	and	O
26	B	O
27	form	O
28	RNAs	O
29	is	O
30	used	O
31	in	O
32	<UNK>	O
33	reading	O
34	frames	O
35	.	O
1	<UNK>	O
2	levels	O
3	of	O
4	<UNK>	B
5	T	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	CK	B
11	-	O
12	MB	O
13	were	O
14	measured	O
15	6	O
16	,	O
17	12	O
18	,	O
19	24	O
20	and	O
21	48	O
22	h	O
23	after	O
24	aortic	O
25	<UNK>	O
26	.	O
1	The	O
2	c	B
3	-	O
4	myc	B
5	and	O
6	skeletal	O
7	alpha	O
8	-	O
9	actin	B
10	gene	O
11	promoters	O
12	contain	O
13	YY1	B
14	binding	O
15	sites	O
16	thought	O
17	to	O
18	act	O
19	either	O
20	as	O
21	positive	O
22	or	O
23	negative	O
24	cis	O
25	-	O
26	acting	O
27	elements	O
28	.	O
1	<UNK>	O
2	,	O
3	by	O
4	oligonucleotide	O
5	-	O
6	directed	O
7	site	O
8	-	O
9	specific	O
10	mutagenesis	O
11	,	O
12	we	O
13	demonstrate	O
14	that	O
15	of	O
16	10	O
17	cysteine	O
18	residues	O
19	in	O
20	the	O
21	<UNK>	O
22	polypeptide	O
23	,	O
24	only	O
25	C	O
26	-	O
27	<UNK>	O
28	and	O
29	C	O
30	-	O
31	<UNK>	O
32	are	O
33	essential	O
34	for	O
35	transactivator	O
36	function	O
37	and	O
38	suggest	O
39	that	O
40	these	O
41	cysteine	O
42	residues	O
43	may	O
44	participate	O
45	in	O
46	critical	O
47	protein	O
48	-	O
49	protein	O
50	interactions	O
51	rather	O
52	than	O
53	protein	O
54	-	O
55	nucleic	O
56	acid	O
57	interactions	O
58	to	O
59	mediate	O
60	<UNK>	O
61	inducibility	O
62	.	O
1	Genetic	O
2	and	O
3	<UNK>	O
4	analysis	O
5	indicates	O
6	that	O
7	<UNK>	B
8	and	O
9	<UNK>	B
10	function	O
11	downstream	O
12	of	O
13	<UNK>	B
14	.	O
1	To	O
2	achieve	O
3	complete	O
4	<UNK>	O
5	of	O
6	the	O
7	anterior	O
8	<UNK>	O
9	,	O
10	we	O
11	<UNK>	O
12	even	O
13	a	O
14	clear	O
15	<UNK>	O
16	during	O
17	the	O
18	first	O
19	surgical	O
20	<UNK>	O
21	in	O
22	selected	O
23	cases	O
24	.	O
1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	alternative	O
7	sigma	B
8	factor	O
9	,	O
10	<UNK>	B
11	,	O
12	in	O
13	<UNK>	O
14	<UNK>	O
15	;	O
16	physiological	O
17	<UNK>	O
18	of	O
19	an	O
20	<UNK>	O
21	<UNK>	B
22	-	O
23	<UNK>	B
24	<UNK>	O
25	.	O
1	The	O
2	colony	O
3	-	O
4	stimulating	O
5	factors	O
6	(	O
7	<UNK>	B
8	)	O
9	<UNK>	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	O
22	granulocyte	B
23	-	O
24	macrophage	O
25	CSF	B
26	,	O
27	macrophage	O
28	CSF	B
29	,	O
30	and	O
31	interleukin	B
32	3	O
33	(	O
34	<UNK>	O
35	called	O
36	<UNK>	O
37	-	O
38	CSF	B
39	).	O
1	With	O
2	a	O
3	<UNK>	O
4	level	O
5	for	O
6	<UNK>	B
7	-	O
8	1	O
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	<UNK>	B
27	-	O
28	1	O
29	.	O
1	<UNK>	O
2	of	O
3	intracellular	O
4	localization	O
5	domains	O
6	and	O
7	evidence	O
8	for	O
9	<UNK>	O
10	interactions	O
11	between	O
12	the	O
13	<UNK>	B
14	and	O
15	<UNK>	B
16	nuclear	O
17	transactivator	O
18	proteins	O
19	of	O
20	herpes	O
21	simplex	O
22	virus	O
23	.	O
1	<UNK>	B
2	<UNK>	I
3	signal	O
4	anchor	O
5	sequence	O
6	.	O
1	<UNK>	O
2	labelled	O
3	neurons	O
4	significantly	O
5	<UNK>	O
6	in	O
7	the	O
8	<UNK>	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	to	O
3	treatment	O
4	was	O
5	better	O
6	in	O
7	patients	O
8	with	O
9	less	O
10	pretreatment	O
11	(	O
12	one	O
13	-	O
14	two	O
15	prior	O
16	treatments	O
17	)	O
18	than	O
19	in	O
20	<UNK>	O
21	<UNK>	O
22	ones	O
23	(	O
24	more	O
25	than	O
26	three	O
27	)	O
28	and	O
29	this	O
30	relation	O
31	was	O
32	found	O
33	to	O
34	be	O
35	statistically	O
36	significant	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	05	O
43	).	O
1	Northern	O
2	-	O
3	blot	O
4	analysis	O
5	of	O
6	mRNA	O
7	from	O
8	<UNK>	O
9	-	O
10	grown	O
11	N	O
12	.	O
13	<UNK>	O
14	showed	O
15	that	O
16	<UNK>	B
17	<UNK>	O
18	to	O
19	a	O
20	3	O
21	.	O
22	4	O
23	kb	O
24	mRNA	O
25	species	O
26	.	O
1	The	O
2	high	O
3	degree	O
4	of	O
5	conservation	O
6	between	O
7	<UNK>	B
8	and	O
9	<UNK>	B
10	gene	O
11	organization	O
12	and	O
13	sequence	O
14	confirmed	O
15	that	O
16	<UNK>	B
17	gene	O
18	encodes	O
19	for	O
20	a	O
21	second	O
22	member	O
23	of	O
24	the	O
25	<UNK>	B
26	gene	O
27	family	O
28	in	O
29	human	O
30	.	O
1	The	O
2	efficacy	O
3	of	O
4	a	O
5	<UNK>	O
6	<UNK>	O
7	product	O
8	for	O
9	treatment	O
10	of	O
11	<UNK>	O
12	<UNK>	O
13	was	O
14	evaluated	O
15	following	O
16	<UNK>	O
17	infusion	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O
1	<UNK>	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	O
10	<UNK>	B
11	NF	I
12	-	O
13	kappa	B
14	B	O
15	gene	O
16	<UNK>	O
17	I	O
18	kappa	B
19	B	O
20	gamma	O
21	isoforms	O
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O
1	The	O
2	<UNK>	O
3	latency	O
4	(	O
5	from	O
6	the	O
7	ECG	O
8	R	O
9	-	O
10	wave	O
11	to	O
12	the	O
13	integrated	O
14	<UNK>	O
15	<UNK>	O
16	peak	O
17	)	O
18	was	O
19	constant	O
20	at	O
21	approximately	O
22	1	O
23	.	O
24	20	O
25	s	O
26	during	O
27	sleep	O
28	,	O
29	suggesting	O
30	that	O
31	pulse	O
32	-	O
33	<UNK>	O
34	was	O
35	maintained	O
36	.	O
1	We	O
2	have	O
3	used	O
4	a	O
5	full	O
6	-	O
7	length	O
8	cDNA	O
9	clone	O
10	of	O
11	a	O
12	mouse	O
13	hepatitis	O
14	virus	O
15	strain	O
16	<UNK>	O
17	defective	O
18	<UNK>	O
19	(	O
20	<UNK>	O
21	)	O
22	RNA	O
23	,	O
24	<UNK>	B
25	-	O
26	C	O
27	,	O
28	and	O
29	<UNK>	O
30	mutagenesis	O
31	to	O
32	study	O
33	the	O
34	mechanism	O
35	of	O
36	<UNK>	O
37	<UNK>	O
38	mRNA	O
39	synthesis	O
40	.	O
1	A	O
2	partial	O
3	cDNA	O
4	sequence	O
5	indicated	O
6	that	O
7	the	O
8	T	O
9	lymphocyte	O
10	early	O
11	-	O
12	activation	O
13	gene	O
14	(	O
15	<UNK>	B
16	)	O
17	encodes	O
18	a	O
19	protein	O
20	related	O
21	to	O
22	the	O
23	dual	O
24	-	O
25	function	O
26	<UNK>	B
27	retrovirus	O
28	receptor	O
29	/	O
30	<UNK>	O
31	amino	O
32	acid	O
33	transporter	O
34	(	O
35	<UNK>	B
36	/	O
37	<UNK>	B
38	),	O
39	and	O
40	RNA	O
41	<UNK>	O
42	suggested	O
43	highest	O
44	<UNK>	B
45	expression	O
46	in	O
47	T	O
48	lymphocytes	O
49	and	O
50	liver	O
51	(	O
52	<UNK>	O
53	,	O
54	C	O
55	.	O
56	L	O
57	.,	O
58	<UNK>	O
59	,	O
60	K	O
61	.,	O
62	<UNK>	O
63	,	O
64	D	O
65	.	O
1	Deletion	O
2	analysis	O
3	of	O
4	the	O
5	<UNK>	B
6	promoter	O
7	led	O
8	to	O
9	the	O
10	identification	O
11	of	O
12	an	O
13	upstream	O
14	activating	O
15	sequence	O
16	element	O
17	,	O
18	<UNK>	O
19	(	O
20	5	O
21	'	O
22	<UNK>	O
23	3	O
24	<UNK>	O
25	necessary	O
26	and	O
27	sufficient	O
28	for	O
29	<UNK>	O
30	carbon	O
31	source	O
32	-	O
33	dependent	O
34	regulation	O
35	on	O
36	a	O
37	heterologous	O
38	reporter	O
39	gene	O
40	.	O
1	PRL	B
2	-	O
3	1	O
4	is	O
5	able	O
6	to	O
7	<UNK>	O
8	<UNK>	O
9	substrates	O
10	,	O
11	and	O
12	mutation	O
13	of	O
14	the	O
15	active	O
16	-	O
17	site	O
18	cysteine	O
19	residue	O
20	<UNK>	O
21	this	O
22	activity	O
23	.	O
1	50	O
2	kDa	O
3	and	O
4	130	O
5	-	O
6	<UNK>	O
7	kDa	O
8	were	O
9	detected	O
10	.	O
1	H	O
2	-	O
3	7	O
4	,	O
5	which	O
6	specifically	O
7	,	O
8	although	O
9	weakly	O
10	,	O
11	inhibited	O
12	PKC	B
13	activation	O
14	,	O
15	had	O
16	no	O
17	effect	O
18	on	O
19	tyrosine	O
20	phosphorylation	O
21	and	O
22	<UNK>	O
23	(	O
24	3	O
25	,	O
26	4	O
27	)	O
28	P2	O
29	production	O
30	.	O
1	In	O
2	the	O
3	case	O
4	of	O
5	congenital	O
6	protein	O
7	C	O
8	deficiency	O
9	,	O
10	vitamin	O
11	K	O
12	antagonists	O
13	must	O
14	be	O
15	<UNK>	O
16	<UNK>	O
17	due	O
18	to	O
19	the	O
20	risk	O
21	of	O
22	skin	O
23	necrosis	O
24	.	O
1	On	O
2	physical	O
3	examination	O
4	a	O
5	mild	O
6	<UNK>	O
7	<UNK>	O
8	of	O
9	small	O
10	and	O
11	large	O
12	<UNK>	O
13	was	O
14	seen	O
15	.	O
1	We	O
2	conclude	O
3	that	O
4	the	O
5	<UNK>	O
6	is	O
7	useful	O
8	in	O
9	<UNK>	O
10	<UNK>	O
11	from	O
12	the	O
13	<UNK>	O
14	.	O
1	<UNK>	O
2	,	O
3	bilateral	O
4	and	O
5	<UNK>	O
6	ventilation	O
7	with	O
8	a	O
9	<UNK>	O
10	pacing	O
11	in	O
12	childhood	O
13	:	O
14	the	O
15	<UNK>	O
16	technique	O
17	and	O
18	<UNK>	O
1	<UNK>	O
2	composition	O
3	and	O
4	domain	O
5	structure	O
6	of	O
7	the	O
8	<UNK>	B
9	<UNK>	O
10	transcription	O
11	factor	O
12	of	O
13	Bacillus	O
14	subtilis	O
15	.	O
1	<UNK>	O
2	mobility	O
3	shift	O
4	analysis	O
5	indicates	O
6	that	O
7	NF	B
8	-	O
9	IL	B
10	-	O
11	6	O
12	,	O
13	as	O
14	well	O
15	as	O
16	other	O
17	related	O
18	members	O
19	of	O
20	this	O
21	family	O
22	,	O
23	bind	O
24	specifically	O
25	to	O
26	the	O
27	NF	B
28	-	O
29	IL	B
30	-	O
31	6	O
32	site	O
33	in	O
34	the	O
35	IL	B
36	-	O
37	8	O
38	promoter	O
39	.	O
1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	corresponding	O
7	cDNAs	O
8	indicates	O
9	that	O
10	,	O
11	via	O
12	alternative	O
13	splicing	O
14	,	O
15	the	O
16	<UNK>	O
17	gene	O
18	<UNK>	O
19	for	O
20	two	O
21	proteins	O
22	of	O
23	84	O
24	and	O
25	85	O
26	kD	O
27	(	O
28	<UNK>	B
29	/	O
30	85	O
31	)	O
32	which	O
33	<UNK>	O
34	the	O
35	DNA	O
36	-	O
37	binding	O
38	<UNK>	B
39	domain	O
40	and	O
41	the	O
42	first	O
43	five	O
44	<UNK>	B
45	repeats	O
46	,	O
47	but	O
48	have	O
49	lost	O
50	their	O
51	carboxy	O
52	-	O
53	terminus	O
54	including	O
55	the	O
56	<UNK>	O
57	<UNK>	B
58	repeat	O
59	.	O
1	<UNK>	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	<UNK>	O
7	nucleotide	O
8	sequence	O
9	within	O
10	<UNK>	O
11	-	O
12	1	O
13	BamHI	B
14	-	O
15	D	O
16	DNA	O
17	fragment	O
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O
1	<UNK>	O
2	-	O
3	1	O
4	had	O
5	no	O
6	influence	O
7	on	O
8	either	O
9	the	O
10	ischemic	O
11	parameters	O
12	in	O
13	the	O
14	surface	O
15	<UNK>	O
16	(	O
17	ECG	O
18	)	O
19	or	O
20	the	O
21	<UNK>	O
22	ECG	O
23	.	O
1	The	O
2	absence	O
3	of	O
4	<UNK>	O
5	bound	O
6	to	O
7	the	O
8	T	O
9	protein	O
10	in	O
11	our	O
12	experimental	O
13	conditions	O
14	demonstrates	O
15	that	O
16	<UNK>	O
17	is	O
18	not	O
19	<UNK>	O
20	linked	O
21	to	O
22	the	O
23	T	O
24	protein	O
25	.	O
1	<UNK>	B
2	is	O
3	the	O
4	same	O
5	gene	O
6	as	O
7	<UNK>	B
8	which	O
9	was	O
10	identified	O
11	as	O
12	encoding	O
13	a	O
14	subunit	O
15	of	O
16	the	O
17	<UNK>	B
18	-	O
19	6	O
20	-	O
21	phosphate	O
22	synthase	B
23	/	O
24	phosphatase	B
25	complex	O
26	and	O
27	it	O
28	is	O
29	<UNK>	O
30	to	O
31	the	O
32	<UNK>	B
33	,	O
34	<UNK>	B
35	,	O
36	<UNK>	B
37	and	O
38	<UNK>	O
39	mutations	O
40	.	O
1	<UNK>	O
2	interference	O
3	:	O
4	<UNK>	O
5	effects	O
6	assessed	O
7	with	O
8	the	O
9	<UNK>	O
10	<UNK>	O
11	-	O
12	<UNK>	O
13	<UNK>	O
14	.	O
1	Genomic	O
2	Southern	O
3	blot	O
4	analysis	O
5	of	O
6	rat	O
7	<UNK>	B
8	(	O
9	gene	O
10	encoding	O
11	enhancer	O
12	factor	O
13	I	O
14	subunit	O
15	A	O
16	)	O
17	reveals	O
18	a	O
19	complex	O
20	band	O
21	pattern	O
22	when	O
23	cDNA	O
24	<UNK>	O
25	probes	O
26	are	O
27	used	O
28	.	O
1	There	O
2	was	O
3	no	O
4	apparent	O
5	effect	O
6	of	O
7	growth	O
8	temperature	O
9	on	O
10	the	O
11	steady	O
12	-	O
13	state	O
14	levels	O
15	of	O
16	<UNK>	B
17	mRNA	O
18	in	O
19	wild	O
20	type	O
21	plants	O
22	.	O
1	The	O
2	major	O
3	myosin	B
4	-	O
5	binding	O
6	domain	O
7	of	O
8	skeletal	O
9	muscle	O
10	<UNK>	B
11	-	O
12	C	O
13	(	O
14	C	O
15	protein	O
16	)	O
17	<UNK>	O
18	in	O
19	the	O
20	COOH	O
21	-	O
22	terminal	O
23	,	O
24	immunoglobulin	B
25	C2	O
26	motif	O
27	.	O
1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	<UNK>	O
9	grown	O
10	under	O
11	<UNK>	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	<UNK>	O
32	and	O
33	-	O
34	<UNK>	O
35	(	O
36	relative	O
37	to	O
38	<UNK>	B
39	<UNK>	O
40	).	O
1	The	O
2	<UNK>	O
3	of	O
4	<UNK>	O
5	from	O
6	<UNK>	O
7	exposed	O
8	to	O
9	<UNK>	O
10	conditions	O
11	was	O
12	compared	O
13	in	O
14	both	O
15	dogs	O
16	and	O
17	humans	O
18	to	O
19	<UNK>	O
20	<UNK>	O
21	at	O
22	RT	O
23	conditions	O
24	.	O
1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	<UNK>	O
8	protein	O
9	and	O
10	known	O
11	structures	O
12	of	O
13	proteins	O
14	.	O
1	Four	O
2	forms	O
3	of	O
4	<UNK>	O
5	were	O
6	<UNK>	O
7	in	O
8	<UNK>	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	<UNK>	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	<UNK>	O
21	and	O
22	chronic	O
23	<UNK>	O
24	.	O
1	These	O
2	cells	O
3	produce	O
4	a	O
5	low	O
6	level	O
7	of	O
8	IL	B
9	-	O
10	5	O
11	when	O
12	stimulated	O
13	with	O
14	PMA	O
15	alone	O
16	;	O
17	however	O
18	,	O
19	<UNK>	O
20	,	O
21	O2	O
22	-	O
23	<UNK>	O
24	cAMP	O
25	(	O
26	<UNK>	O
27	),	O
28	in	O
29	combination	O
30	with	O
31	PMA	O
32	,	O
33	<UNK>	O
34	by	O
35	more	O
36	than	O
37	<UNK>	O
38	the	O
39	IL	B
40	-	O
41	5	O
42	production	O
43	at	O
44	the	O
45	mRNA	O
46	and	O
47	the	O
48	protein	O
49	levels	O
50	.	O
1	<UNK>	O
2	<UNK>	O
3	was	O
4	higher	O
5	in	O
6	the	O
7	treatments	O
8	.	O
1	<UNK>	O
2	bearing	O
3	the	O
4	<UNK>	B
5	mutation	O
6	process	O
7	the	O
8	<UNK>	B
9	precursor	O
10	of	O
11	the	O
12	mature	O
13	<UNK>	B
14	rRNA	O
15	<UNK>	O
16	and	O
17	are	O
18	deficient	O
19	in	O
20	<UNK>	B
21	ribosomal	O
22	subunits	O
23	.	O
1	One	O
2	complex	O
3	most	O
4	likely	O
5	contained	O
6	Sp1	B
7	,	O
8	and	O
9	another	O
10	complex	O
11	showed	O
12	S	O
13	-	O
14	phase	O
15	-	O
16	specific	O
17	binding	O
18	,	O
19	suggesting	O
20	a	O
21	direct	O
22	role	O
23	in	O
24	the	O
25	cell	O
26	-	O
27	cycle	O
28	-	O
29	dependent	O
30	R1	O
31	gene	O
32	expression	O
33	.	O
1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O
1	A	O
2	cAMP	O
3	response	O
4	element	O
5	(	O
6	CRE	O
7	)	O
8	consensus	O
9	signal	O
10	was	O
11	identified	O
12	in	O
13	the	O
14	5	O
15	'-	O
16	noncoding	O
17	region	O
18	.	O
19	cAMP	O
20	regulates	O
21	the	O
22	expression	O
23	of	O
24	<UNK>	B
25	.	O
26	5	O
27	gene	O
28	in	O
29	a	O
30	cell	O
31	-	O
32	specific	O
33	manner	O
34	.	O
1	A	O
2	number	O
3	of	O
4	<UNK>	O
5	tests	O
6	measuring	O
7	the	O
8	presence	O
9	of	O
10	<UNK>	O
11	pylori	O
12	-	O
13	specific	O
14	serum	O
15	immunoglobulin	B
16	G	O
17	(	O
18	IgG	B
19	)	O
20	are	O
21	now	O
22	<UNK>	O
23	available	O
24	.	O
1	CONCLUSIONS	O
2	:	O
3	In	O
4	our	O
5	patients	O
6	and	O
7	within	O
8	the	O
9	range	O
10	of	O
11	treatment	O
12	variables	O
13	studied	O
14	,	O
15	age	O
16	,	O
17	<UNK>	O
18	index	O
19	,	O
20	and	O
21	graft	O
22	-	O
23	versus	O
24	-	O
25	host	O
26	disease	O
27	are	O
28	the	O
29	most	O
30	important	O
31	factors	O
32	related	O
33	with	O
34	early	O
35	mortality	O
36	.	O
1	By	O
2	using	O
3	the	O
4	full	O
5	-	O
6	length	O
7	cytoplasmic	O
8	domain	O
9	and	O
10	mutants	O
11	with	O
12	progressive	O
13	carboxy	O
14	-	O
15	terminal	O
16	deletions	O
17	,	O
18	internal	O
19	deletions	O
20	,	O
21	or	O
22	point	O
23	mutations	O
24	,	O
25	we	O
26	identified	O
27	the	O
28	first	O
29	150	O
30	amino	O
31	acid	O
32	residues	O
33	of	O
34	<UNK>	B
35	as	O
36	the	O
37	minimal	O
38	region	O
39	necessary	O
40	for	O
41	signaling	O
42	.	O
1	Recombinant	O
2	expression	O
3	of	O
4	a	O
5	chimeric	O
6	<UNK>	B
7	/	O
8	ErbB	B
9	-	O
10	3	O
11	receptor	O
12	in	O
13	NIH	O
14	3T3	O
15	fibroblasts	O
16	allowed	O
17	us	O
18	to	O
19	investigate	O
20	cytoplasmic	O
21	events	O
22	associated	O
23	with	O
24	ErbB	B
25	-	O
26	3	O
27	signal	O
28	transduction	O
29	upon	O
30	ligand	O
31	activation	O
32	.	O
1	The	O
2	<UNK>	O
3	-	O
4	to	O
5	-	O
6	<UNK>	O
7	region	O
8	blocked	O
9	<UNK>	B
10	activity	O
11	independently	O
12	of	O
13	the	O
14	<UNK>	B
15	present	O
16	on	O
17	<UNK>	B
18	,	O
19	<UNK>	B
20	DNA	O
21	binding	O
22	,	O
23	and	O
24	specific	O
25	<UNK>	B
26	promoter	O
27	sequences	O
28	.	O
1	<UNK>	O
2	analgesia	O
3	:	O
4	is	O
5	there	O
6	a	O
7	<UNK>	O
8	for	O
9	<UNK>	O
10	<UNK>	O
11	?	O
12	<UNK>	O
13	can	O
14	be	O
15	a	O
16	useful	O
17	<UNK>	O
18	agent	O
19	for	O
20	the	O
21	management	O
22	of	O
23	acute	O
24	dental	O
25	pain	O
26	.	O
1	<UNK>	O
2	<UNK>	O
3	were	O
4	short	O
5	.	O
1	We	O
2	present	O
3	evidence	O
4	that	O
5	YY1	B
6	,	O
7	a	O
8	ubiquitously	O
9	expressed	O
10	DNA	O
11	-	O
12	binding	O
13	protein	O
14	,	O
15	regulates	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	c	B
21	-	O
22	fos	B
23	promoter	O
24	primarily	O
25	through	O
26	an	O
27	effect	O
28	on	O
29	DNA	O
30	structure	O
31	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	<UNK>	O
7	indicates	O
8	an	O
9	overall	O
10	identity	O
11	of	O
12	58	O
13	and	O
14	56	O
15	%,	O
16	respectively	O
17	,	O
18	with	O
19	a	O
20	91	O
21	and	O
22	92	O
23	%	O
24	identity	O
25	in	O
26	the	O
27	highly	O
28	conserved	O
29	transmembrane	O
30	and	O
31	cytoplasmic	O
32	domains	O
33	.	O
1	S	O
2	.,	O
3	K	O
4	.	O
1	The	O
2	<UNK>	B
3	,	O
4	<UNK>	B
5	,	O
6	<UNK>	B
7	,	O
8	and	O
9	<UNK>	B
10	products	O
11	have	O
12	two	O
13	isoforms	O
14	each	O
15	that	O
16	are	O
17	<UNK>	O
18	by	O
19	different	O
20	<UNK>	O
21	in	O
22	polyacrylamide	O
23	gel	O
24	electrophoresis	O
25	,	O
26	and	O
27	the	O
28	<UNK>	B
29	product	O
30	has	O
31	four	O
32	isoforms	O
33	.	O
1	Plasma	O
2	,	O
3	LDL	B
4	and	O
5	liver	O
6	cholesterol	O
7	concentrations	O
8	were	O
9	higher	O
10	in	O
11	the	O
12	<UNK>	O
13	control	O
14	than	O
15	the	O
16	<UNK>	O
17	control	O
18	and	O
19	lower	O
20	in	O
21	the	O
22	groups	O
23	fed	O
24	<UNK>	O
25	containing	O
26	<UNK>	B
27	or	O
28	<UNK>	O
29	fiber	O
30	than	O
31	in	O
32	the	O
33	<UNK>	O
34	control	O
35	group	O
36	.	O
1	<UNK>	O
2	this	O
3	sequence	O
4	information	O
5	from	O
6	<UNK>	O
7	/	O
8	1	O
9	,	O
10	the	O
11	<UNK>	O
12	/	O
13	1	O
14	-	O
15	specific	O
16	cDNA	O
17	was	O
18	generated	O
19	from	O
20	poly	O
21	(	O
22	A	O
23	<UNK>	O
24	RNA	O
25	of	O
26	bovine	O
27	<UNK>	O
28	by	O
29	reverse	O
30	transcription	O
31	and	O
32	a	O
33	combination	O
34	of	O
35	polymerase	O
36	chain	O
37	reaction	O
38	(	O
39	PCR	O
40	)	O
41	methods	O
42	.	O
1	The	O
2	sequence	O
3	similarity	O
4	has	O
5	suggested	O
6	that	O
7	<UNK>	B
8	and	O
9	<UNK>	B
10	have	O
11	been	O
12	derived	O
13	from	O
14	structurally	O
15	and	O
16	evolutionarily	O
17	related	O
18	genes	O
19	.	O
1	A	O
2	complementary	O
3	DNA	O
4	was	O
5	isolated	O
6	from	O
7	Caenorhabditis	O
8	elegans	O
9	that	O
10	encoded	O
11	a	O
12	polypeptide	O
13	of	O
14	<UNK>	O
15	amino	O
16	acid	O
17	residues	O
18	,	O
19	<UNK>	B
20	,	O
21	which	O
22	contains	O
23	a	O
24	domain	O
25	with	O
26	sequence	O
27	similarity	O
28	to	O
29	the	O
30	COOH	O
31	-	O
32	terminal	O
33	segment	O
34	(	O
35	GTPase	B
36	-	O
37	activating	O
38	protein	O
39	region	O
40	)	O
41	of	O
42	<UNK>	B
43	and	O
44	other	O
45	known	O
46	GTPase	B
47	-	O
48	activating	O
49	proteins	O
50	of	O
51	the	O
52	Rho	B
53	subfamily	O
54	.	O
1	<UNK>	O
2	is	O
3	<UNK>	O
4	when	O
5	the	O
6	two	O
7	(	O
8	for	O
9	E2	O
10	)	O
11	or	O
12	three	O
13	(	O
14	for	O
15	E2	O
16	-	O
17	C	O
18	)	O
19	promoter	O
20	-	O
21	proximal	O
22	copies	O
23	of	O
24	E2	O
25	-	O
26	<UNK>	O
27	are	O
28	mutated	O
29	.	O
1	A	O
2	mutant	O
3	in	O
4	the	O
5	<UNK>	O
6	terminal	O
7	resolution	O
8	site	O
9	(	O
10	<UNK>	O
11	)	O
12	was	O
13	defective	O
14	for	O
15	DNA	O
16	replication	O
17	in	O
18	the	O
19	in	O
20	vitro	O
21	assay	O
22	.	O
1	However	O
2	,	O
3	<UNK>	O
4	<UNK>	O
5	rats	O
6	,	O
7	<UNK>	O
8	with	O
9	<UNK>	O
10	-	O
11	<UNK>	O
12	,	O
13	were	O
14	more	O
15	sensitive	O
16	(	O
17	lethal	O
18	<UNK>	O
19	dose	O
20	,	O
21	76	O
22	.	O
23	6	O
24	+/-	O
25	8	O
26	.	O
27	0	O
28	mg	O
29	/	O
30	kg	O
31	,	O
32	n	O
33	=	O
34	5	O
35	)	O
36	than	O
37	<UNK>	O
38	<UNK>	O
39	rats	O
40	(	O
41	<UNK>	O
42	.	O
43	4	O
44	+/-	O
45	15	O
46	.	O
47	8	O
48	mg	O
49	/	O
50	kg	O
51	,	O
52	n	O
53	=	O
54	6	O
55	),	O
56	indicating	O
57	that	O
58	<UNK>	O
59	-	O
60	<UNK>	O
61	may	O
62	increase	O
63	both	O
64	the	O
65	respiratory	O
66	and	O
67	the	O
68	cardiac	O
69	toxicity	O
70	of	O
71	<UNK>	O
72	in	O
73	<UNK>	O
74	anesthetized	O
75	rats	O
76	.	O
1	Furthermore	O
2	,	O
3	the	O
4	negative	O
5	transcriptional	O
6	effect	O
7	of	O
8	COUP	B
9	-	O
10	<UNK>	B
11	is	O
12	dominant	O
13	over	O
14	the	O
15	activating	O
16	effect	O
17	of	O
18	the	O
19	<UNK>	B
20	embryonic	O
21	stem	O
22	cell	O
23	-	O
24	specific	O
25	enhancer	O
26	.	O
1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	<UNK>	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	<UNK>	O
17	.	O
1	These	O
2	data	O
3	indicate	O
4	that	O
5	activation	O
6	of	O
7	these	O
8	enzymes	O
9	is	O
10	not	O
11	sufficient	O
12	for	O
13	the	O
14	acute	O
15	stimulation	O
16	of	O
17	glucose	O
18	transport	O
19	.	O
1	The	O
2	inserted	O
3	region	O
4	,	O
5	which	O
6	represents	O
7	an	O
8	intron	O
9	in	O
10	brain	O
11	and	O
12	muscle	O
13	,	O
14	is	O
15	expressed	O
16	in	O
17	the	O
18	tumor	O
19	cell	O
20	lines	O
21	either	O
22	as	O
23	a	O
24	""""	O
25	<UNK>	O
26	""""	O
27	form	O
28	or	O
29	with	O
30	78	O
31	residues	O
32	deleted	O
33	from	O
34	its	O
35	5	O
36	'	O
37	end	O
38	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	scores	O
5	was	O
6	tested	O
7	in	O
8	<UNK>	O
9	stable	O
10	subjects	O
11	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	used	O
5	as	O
6	first	O
7	-	O
8	line	O
9	treatment	O
10	,	O
11	appears	O
12	to	O
13	be	O
14	the	O
15	most	O
16	effective	O
17	drug	O
18	.	O
1	The	O
2	<UNK>	O
3	of	O
4	<UNK>	O
5	'	O
6	s	O
7	theory	O
8	demonstrates	O
9	the	O
10	range	O
11	of	O
12	factors	O
13	,	O
14	other	O
15	than	O
16	the	O
17	<UNK>	O
18	<UNK>	O
19	,	O
20	which	O
21	can	O
22	be	O
23	important	O
24	in	O
25	determining	O
26	the	O
27	influence	O
28	or	O
29	otherwise	O
30	of	O
31	a	O
32	<UNK>	O
33	theory	O
34	.	O
1	The	O
2	5	O
3	'	O
4	ends	O
5	of	O
6	<UNK>	B
7	late	O
8	transcripts	O
9	were	O
10	located	O
11	to	O
12	an	O
13	A	O
14	within	O
15	the	O
16	sequence	O
17	5	O
18	'-	O
19	<UNK>	O
20	,	O
21	41	O
22	nt	O
23	downstream	O
24	from	O
25	the	O
26	early	O
27	promoter	O
28	and	O
29	17	O
30	nt	O
31	upstream	O
32	from	O
33	the	O
34	initiation	O
35	codon	O
36	.	O
1	The	O
2	first	O
3	group	O
4	of	O
5	<UNK>	O
6	<UNK>	O
7	showed	O
8	a	O
9	significant	O
10	<UNK>	O
11	to	O
12	<UNK>	O
13	in	O
14	so	O
15	-	O
16	called	O
17	""""	O
18	Chronic	O
19	<UNK>	O
20	-	O
21	<UNK>	O
22	<UNK>	O
23	<UNK>	O
24	<UNK>	O
25	-,	O
26	which	O
27	corresponds	O
28	to	O
29	<UNK>	O
30	<UNK>	O
31	<UNK>	O
32	-	O
33	<UNK>	O
34	-	O
35	in	O
36	72	O
37	.	O
38	4	O
39	%	O
40	(	O
41	21	O
42	/	O
43	29	O
44	patients	O
45	),	O
46	as	O
47	well	O
48	as	O
49	in	O
50	<UNK>	O
51	with	O
52	<UNK>	O
53	increase	O
54	-	O
55	<UNK>	O
56	.	O
57	<UNK>	O
58	-	O
59	in	O
60	39	O
61	.	O
62	2	O
63	%	O
64	(	O
65	20	O
66	/	O
67	51	O
68	).	O
1	<UNK>	O
2	sterol	O
3	carrier	O
4	protein	O
5	2	O
6	/	O
7	sterol	O
8	carrier	O
9	protein	O
10	x	O
11	:	O
12	cDNA	O
13	cloning	O
14	reveals	O
15	evolutionary	O
16	conservation	O
17	of	O
18	structure	O
19	and	O
20	regulated	O
21	expression	O
22	.	O
1	Previous	O
2	studies	O
3	indicated	O
4	that	O
5	the	O
6	<UNK>	B
7	proteasome	O
8	is	O
9	a	O
10	catalytic	O
11	core	O
12	of	O
13	the	O
14	<UNK>	B
15	proteolytic	O
16	complex	O
17	that	O
18	possesses	O
19	a	O
20	latent	O
21	<UNK>	O
22	proteinase	O
23	activity	O
24	and	O
25	<UNK>	O
26	an	O
27	ATP	O
28	-	O
29	dependent	O
30	,	O
31	selective	O
32	<UNK>	O
33	of	O
34	proteins	O
35	<UNK>	O
36	to	O
37	ubiquitin	B
38	.	O
1	The	O
2	O2	O
3	<UNK>	O
4	was	O
5	not	O
6	related	O
7	to	O
8	blood	O
9	lactate	O
10	during	O
11	<UNK>	O
12	exercise	O
13	,	O
14	muscle	O
15	enzyme	O
16	activity	O
17	(	O
18	<UNK>	O
19	synthase	B
20	,	O
21	3	O
22	-	O
23	<UNK>	B
24	-	O
25	CoA	B
26	-	O
27	dehydrogenase	B
28	,	O
29	lactate	O
30	dehydrogenase	B
31	),	O
32	number	O
33	of	O
34	muscle	O
35	<UNK>	O
36	,	O
37	%	O
38	ST	O
39	<UNK>	O
40	or	O
41	muscle	O
42	<UNK>	O
43	capacity	O
44	.	O
1	<UNK>	O
2	of	O
3	this	O
4	selective	O
5	pressure	O
6	,	O
7	however	O
8	,	O
9	gave	O
10	way	O
11	to	O
12	homologous	O
13	resolution	O
14	of	O
15	the	O
16	<UNK>	O
17	structures	O
18	.	O
1	Binding	O
2	of	O
3	U2	B
4	small	O
5	nuclear	O
6	ribonucleoprotein	O
7	was	O
8	partially	O
9	inhibited	O
10	.	O
1	<UNK>	O
2	,	O
3	significant	O
4	level	O
5	of	O
6	CAT	B
7	activity	O
8	was	O
9	observed	O
10	in	O
11	human	O
12	lung	O
13	adenocarcinoma	O
14	(	O
15	<UNK>	O
16	-	O
17	1	O
18	)	O
19	cells	O
20	which	O
21	had	O
22	been	O
23	<UNK>	O
24	with	O
25	a	O
26	complex	O
27	of	O
28	T7	O
29	RNA	O
30	polymerase	O
31	,	O
32	<UNK>	B
33	-	O
34	<UNK>	B
35	-	O
36	CAT	B
37	DNA	O
38	and	O
39	<UNK>	O
40	-	O
41	<UNK>	O
42	<UNK>	O
43	<UNK>	O
44	.	O
1	The	O
2	influence	O
3	of	O
4	a	O
5	high	O
6	<UNK>	O
7	strength	O
8	on	O
9	the	O
10	resolution	O
11	was	O
12	clearly	O
13	shown	O
14	.	O
1	Similar	O
2	results	O
3	were	O
4	seen	O
5	on	O
6	Western	O
7	<UNK>	O
8	of	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	O
12	(	O
13	<UNK>	O
14	)-	O
15	infected	O
16	<UNK>	O
17	<UNK>	O
18	cells	O
19	.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	<UNK>	O
14	<UNK>	O
15	(	O
16	<UNK>	O
17	)	O
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	O
27	in	O
28	seven	O
29	patients	O
30	with	O
31	cortical	O
32	visual	O
33	impairment	O
34	.	O
1	2	O
2	-	O
3	AP	B
4	induced	O
5	marked	O
6	,	O
7	steady	O
8	<UNK>	O
9	in	O
10	mRNA	O
11	accumulation	O
12	from	O
13	both	O
14	transfected	O
15	and	O
16	<UNK>	O
17	integrated	O
18	HIV	O
19	-	O
20	1	O
21	constructs	O
22	but	O
23	no	O
24	increases	O
25	from	O
26	an	O
27	endogenous	O
28	gene	O
29	encoding	O
30	gamma	O
31	-	O
32	actin	B
33	or	O
34	glucose	O
35	6	O
36	-	O
37	phosphate	O
38	dehydrogenase	B
39	.	O
1	Furthermore	O
2	,	O
3	a	O
4	<UNK>	B
5	protein	O
6	lacking	O
7	the	O
8	N	O
9	-	O
10	terminus	O
11	of	O
12	<UNK>	B
13	was	O
14	expressed	O
15	at	O
16	high	O
17	levels	O
18	;	O
19	our	O
20	data	O
21	indicate	O
22	that	O
23	<UNK>	B
24	is	O
25	translated	O
26	from	O
27	the	O
28	1	O
29	.	O
30	6	O
31	-	O
32	kb	O
33	mRNA	O
34	which	O
35	is	O
36	derived	O
37	primarily	O
38	from	O
39	deleted	O
40	<UNK>	O
41	.	O
1	<UNK>	O
2	.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	syndrome	O
7	(	O
8	<UNK>	O
9	-	O
10	<UNK>	O
11	syndrome	O
12	II	O
13	)	O
1	<UNK>	O
2	in	O
3	profiles	O
4	of	O
5	<UNK>	O
6	variables	O
7	between	O
8	<UNK>	O
9	of	O
10	<UNK>	O
11	in	O
12	RA	O
13	patients	O
14	were	O
15	observed	O
16	.	O
1	Deletion	O
2	of	O
3	a	O
4	53	O
5	-	O
6	bp	O
7	early	O
8	promoter	O
9	region	O
10	containing	O
11	the	O
12	transcription	O
13	start	O
14	site	O
15	and	O
16	a	O
17	putative	O
18	TATA	O
19	box	O
20	completely	O
21	<UNK>	O
22	the	O
23	ability	O
24	of	O
25	upstream	O
26	elements	O
27	to	O
28	<UNK>	O
29	transcription	O
30	of	O
31	the	O
32	luciferase	B
33	cDNA	O
34	.	O
1	To	O
2	analyze	O
3	the	O
4	<UNK>	O
5	regions	O
6	of	O
7	<UNK>	O
8	antibodies	O
9	,	O
10	with	O
11	particular	O
12	attention	O
13	at	O
14	their	O
15	<UNK>	O
16	mutated	O
17	status	O
18	,	O
19	we	O
20	generated	O
21	five	O
22	IgG	B
23	(	O
24	three	O
25	<UNK>	B
26	and	O
27	two	O
28	<UNK>	B
29	)	O
30	<UNK>	O
31	(	O
32	using	O
33	B	O
34	cells	O
35	from	O
36	a	O
37	healthy	O
38	subject	O
39	,	O
40	a	O
41	patient	O
42	with	O
43	insulin	B
44	-	O
45	dependent	O
46	diabetes	O
47	mellitus	O
48	and	O
49	a	O
50	patient	O
51	with	O
52	<UNK>	O
53	),	O
54	which	O
55	bound	O
56	with	O
57	various	O
58	<UNK>	O
59	a	O
60	number	O
61	of	O
62	different	O
63	self	O
64	and	O
65	<UNK>	O
66	Ag	O
67	.	O
1	These	O
2	findings	O
3	suggest	O
4	a	O
5	functional	O
6	cross	O
7	-	O
8	<UNK>	O
9	between	O
10	RB	B
11	protein	O
12	and	O
13	<UNK>	B
14	,	O
15	which	O
16	<UNK>	O
17	the	O
18	cell	O
19	phenotype	O
20	between	O
21	normal	O
22	and	O
23	transformed	O
24	states	O
25	.	O
1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	<UNK>	B
19	mutant	O
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	<UNK>	B
26	and	O
27	<UNK>	B
28	null	O
29	mutants	O
30	.	O
1	The	O
2	E1	O
3	nuclear	O
4	transport	O
5	motif	O
6	is	O
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	<UNK>	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	O
26	genes	O
27	.	O
1	A	O
2	sequence	O
3	comparison	O
4	reveals	O
5	two	O
6	CCAAT	O
7	/	O
8	enhancer	O
9	binding	O
10	protein	O
11	(	O
12	C	O
13	/	O
14	EBP	B
15	)	O
16	consensus	O
17	sequences	O
18	,	O
19	basic	O
20	DNA	O
21	binding	O
22	region	O
23	and	O
24	leucine	O
25	<UNK>	O
26	1	O
27	and	O
28	2	O
29	(	O
30	<UNK>	O
31	and	O
32	<UNK>	O
33	),	O
34	within	O
35	this	O
36	region	O
37	.	O
1	The	O
2	<UNK>	B
3	gene	O
4	product	O
5	,	O
6	when	O
7	expressed	O
8	from	O
9	an	O
10	exogenous	O
11	promoter	O
12	,	O
13	inhibited	O
14	<UNK>	B
15	-	O
16	mediated	O
17	integration	O
18	at	O
19	the	O
20	chromosomal	O
21	<UNK>	B
22	site	O
23	.	O
1	<UNK>	O
2	treatment	O
3	in	O
4	high	O
5	doses	O
6	is	O
7	effective	O
8	in	O
9	reducing	O
10	adult	O
11	<UNK>	O
12	in	O
13	<UNK>	O
14	<UNK>	O
15	<UNK>	O
16	.	O
1	<UNK>	B
2	DNA	O
3	<UNK>	B
4	<UNK>	O
5	the	O
6	initial	O
7	step	O
8	in	O
9	the	O
10	repair	O
11	pathway	O
12	that	O
13	<UNK>	O
14	potentially	O
15	<UNK>	O
16	<UNK>	O
17	from	O
18	duplex	O
19	DNA	O
20	.	O
1	A	O
2	<UNK>	O
3	<UNK>	O
4	cDNA	O
5	library	O
6	constructed	O
7	in	O
8	<UNK>	O
9	vector	O
10	was	O
11	screened	O
12	with	O
13	a	O
14	probe	O
15	generated	O
16	by	O
17	polymerase	O
18	chain	O
19	reaction	O
20	(	O
21	PCR	O
22	)	O
23	and	O
24	corresponding	O
25	to	O
26	a	O
27	1	O
28	.	O
29	6	O
30	kb	O
31	fragment	O
32	of	O
33	the	O
34	rat	O
35	<UNK>	B
36	hormone	O
37	receptor	O
38	cDNA	O
39	.	O
1	Three	O
2	group	O
3	1	O
4	patients	O
5	developed	O
6	CMV	O
7	disease	O
8	;	O
9	1	O
10	group	O
11	2	O
12	patient	O
13	developed	O
14	CMV	O
15	hepatitis	O
16	.	O
1	The	O
2	ability	O
3	of	O
4	<UNK>	B
5	mutations	O
6	to	O
7	suppress	O
8	the	O
9	transcriptional	O
10	interference	O
11	caused	O
12	by	O
13	the	O
14	delta	O
15	promoter	O
16	insertion	O
17	his	O
18	-	O
19	4	O
20	-	O
21	<UNK>	O
22	delta	O
23	correlates	O
24	with	O
25	an	O
26	increase	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	<UNK>	B
32	mRNA	O
33	levels	O
34	.	O
1	BCR	B
2	-	O
3	<UNK>	B
4	and	O
5	v	O
6	-	O
7	abl	B
8	oncogenes	O
9	induce	O
10	distinct	O
11	patterns	O
12	of	O
13	<UNK>	O
14	lymphoma	O
15	involving	O
16	different	O
17	lymphocyte	O
18	<UNK>	O
19	.	O
1	A	O
2	new	O
3	<UNK>	O
4	<UNK>	O
5	for	O
6	<UNK>	O
7	<UNK>	O
8	.	O
1	<UNK>	O
2	<UNK>	O
3	given	O
4	<UNK>	O
5	fever	O
6	vaccine	O
7	<UNK>	O
8	with	O
9	hepatitis	O
10	B	O
11	virus	O
12	in	O
13	<UNK>	O
14	and	O
15	controls	O
16	and	O
17	(	O
18	b	O
19	)	O
20	a	O
21	case	O
22	-	O
23	control	O
24	study	O
25	comparing	O
26	<UNK>	O
27	with	O
28	<UNK>	O
29	carcinoma	O
30	in	O
31	<UNK>	O
32	<UNK>	O
33	<UNK>	O
34	with	O
35	matched	O
36	controls	O
37	with	O
38	respect	O
39	to	O
40	<UNK>	O
41	of	O
42	<UNK>	O
43	vaccine	O
44	in	O
45	<UNK>	O
46	.	O
1	They	O
2	were	O
3	found	O
4	to	O
5	be	O
6	<UNK>	O
7	for	O
8	antibodies	O
9	to	O
10	hepatitis	O
11	C	O
12	virus	O
13	by	O
14	second	O
15	-	O
16	generation	O
17	testing	O
18	(	O
19	<UNK>	O
20	2	O
21	,	O
22	<UNK>	O
23	<UNK>	O
24	<UNK>	O
25	<UNK>	O
26	,	O
27	<UNK>	O
28	,	O
29	<UNK>	O
30	).	O
1	<UNK>	O
2	,	O
3	and	O
4	L	O
5	.	O
1	The	O
2	<UNK>	B
3	gene	O
4	is	O
5	present	O
6	as	O
7	a	O
8	unique	O
9	copy	O
10	in	O
11	the	O
12	<UNK>	O
13	N	O
14	.	O
15	<UNK>	O
16	species	O
17	.	O
1	<UNK>	O
2	mice	O
3	harboring	O
4	the	O
5	rat	O
6	<UNK>	B
7	-	O
8	CAT	B
9	fusion	O
10	gene	O
11	expressed	O
12	the	O
13	reporter	O
14	specifically	O
15	in	O
16	the	O
17	skeletal	O
18	muscle	O
19	.	O
1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	one	O
6	healthy	O
7	eyes	O
8	,	O
9	<UNK>	O
10	ocular	O
11	hypertensive	O
12	eyes	O
13	with	O
14	normal	O
15	visual	O
16	<UNK>	O
17	,	O
18	and	O
19	<UNK>	O
20	<UNK>	O
21	eyes	O
22	with	O
23	early	O
24	visual	O
25	field	O
26	defects	O
27	were	O
28	evaluated	O
29	with	O
30	<UNK>	O
31	and	O
32	quantitative	O
33	measures	O
34	of	O
35	structural	O
36	damage	O
37	to	O
38	the	O
39	<UNK>	O
40	nerve	O
41	and	O
42	nerve	O
43	fiber	O
44	layer	O
45	.	O
1	The	O
2	<UNK>	O
3	-	O
4	<UNK>	O
5	factor	O
6	(	O
7	ARF	B
8	)	O
9	family	O
10	is	O
11	one	O
12	of	O
13	four	O
14	<UNK>	O
15	of	O
16	the	O
17	<UNK>	B
18	superfamily	O
19	of	O
20	low	O
21	molecular	O
22	weight	O
23	GTP	O
24	-	O
25	binding	O
26	proteins	O
27	(	O
28	G	O
29	proteins	O
30	).	O
1	The	O
2	E1	O
3	gene	O
4	is	O
5	located	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	gene	O
13	for	O
14	<UNK>	B
15	,	O
16	a	O
17	protein	O
18	that	O
19	regulates	O
20	onset	O
21	of	O
22	mitosis	O
23	.	O
1	To	O
2	identify	O
3	factors	O
4	that	O
5	may	O
6	<UNK>	O
7	the	O
8	<UNK>	O
9	transmission	O
10	of	O
11	human	O
12	T	O
13	cell	O
14	leukemia	O
15	/	O
16	lymphoma	O
17	virus	O
18	type	O
19	I	O
20	(	O
21	HTLV	O
22	-	O
23	I	O
24	),	O
25	<UNK>	O
26	<UNK>	O
27	<UNK>	O
28	<UNK>	O
29	in	O
30	the	O
31	<UNK>	O
32	<UNK>	O
33	Study	O
34	between	O
35	<UNK>	O
36	<UNK>	O
37	and	O
38	<UNK>	O
39	<UNK>	O
40	were	O
41	studied	O
42	:	O
43	95	O
44	<UNK>	O
45	HTLV	O
46	-	O
47	I	O
48	-	O
49	<UNK>	O
50	(	O
51	H	O
52	<UNK>	O
53	<UNK>	O
54	<UNK>	O
55	(	O
56	W	O
57	<UNK>	O
58	33	O
59	H	O
60	+/	O
61	W	O
62	-,	O
63	64	O
64	H	O
65	<UNK>	O
66	W	O
67	+,	O
68	and	O
69	<UNK>	O
70	H	O
71	<UNK>	O
72	W	O
73	<UNK>	O
1	Biol	O
2	.	O
1	L	O
2	.,	O
3	<UNK>	O
4	,	O
5	G	O
6	.,	O
7	<UNK>	O
8	,	O
9	D	O
10	.,	O
11	<UNK>	O
12	,	O
13	J	O
14	.,	O
15	<UNK>	O
16	,	O
17	X	O
18	.,	O
19	<UNK>	O
20	,	O
21	A	O
22	.,	O
23	<UNK>	O
24	,	O
25	M	O
26	.,	O
27	and	O
28	<UNK>	O
29	,	O
30	H	O
31	.	O
1	The	O
2	use	O
3	of	O
4	this	O
5	model	O
6	for	O
7	<UNK>	O
8	<UNK>	O
9	significant	O
10	<UNK>	O
11	in	O
12	<UNK>	O
13	diseases	O
14	is	O
15	<UNK>	O
16	with	O
17	five	O
18	different	O
19	sets	O
20	of	O
21	parameters	O
22	.	O
1	<UNK>	O
2	of	O
3	the	O
4	<UNK>	O
5	gene	O
6	coding	O
7	for	O
8	calmodulin	B
9	-	O
10	like	O
11	protein	O
12	<UNK>	O
13	to	O
14	human	O
15	chromosome	O
16	<UNK>	O
17	-	O
18	<UNK>	O
19	.	O
1	This	O
2	study	O
3	compared	O
4	the	O
5	gross	O
6	and	O
7	<UNK>	O
8	motor	O
9	performance	O
10	of	O
11	14	O
12	<UNK>	O
13	brain	O
14	-	O
15	<UNK>	O
16	children	O
17	(	O
18	five	O
19	to	O
20	15	O
21	years	O
22	old	O
23	,	O
24	with	O
25	loss	O
26	of	O
27	<UNK>	O
28	for	O
29	at	O
30	least	O
31	24	O
32	hours	O
33	)	O
34	to	O
35	14	O
36	normal	O
37	children	O
38	group	O
39	matched	O
40	for	O
41	age	O
42	and	O
43	sex	O
44	.	O
1	We	O
2	compared	O
3	the	O
4	parameters	O
5	pleural	O
6	adenosine	O
7	<UNK>	B
8	(	O
9	<UNK>	B
10	,	O
11	determined	O
12	in	O
13	<UNK>	O
14	patients	O
15	),	O
16	the	O
17	<UNK>	B
18	/	O
19	serum	O
20	<UNK>	O
21	ratio	O
22	(	O
23	P	O
24	/	O
25	<UNK>	B
26	;	O
27	<UNK>	O
28	cases	O
29	),	O
30	pleural	O
31	<UNK>	B
32	(	O
33	<UNK>	B
34	,	O
35	<UNK>	O
36	cases	O
37	),	O
38	the	O
39	<UNK>	B
40	/	O
41	serum	O
42	<UNK>	B
43	ratio	O
44	(	O
45	P	O
46	/	O
47	<UNK>	B
48	;	O
49	<UNK>	O
50	cases	O
51	),	O
52	and	O
53	pleural	O
54	interferon	B
55	gamma	O
56	(	O
57	IFN	B
58	,	O
59	<UNK>	O
60	cases	O
61	)	O
62	<UNK>	O
63	their	O
64	ability	O
65	to	O
66	<UNK>	O
67	<UNK>	O
68	pleural	O
69	<UNK>	O
70	from	O
71	others	O
72	.	O
1	There	O
2	was	O
3	a	O
4	positive	O
5	correlation	O
6	between	O
7	<UNK>	O
8	cross	O
9	-	O
10	<UNK>	O
11	excretion	O
12	and	O
13	thyroid	O
14	hormone	O
15	concentrations	O
16	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	value	O
5	was	O
6	that	O
7	predicted	O
8	by	O
9	<UNK>	O
10	relation	O
11	.	O
1	While	O
2	the	O
3	latter	O
4	<UNK>	O
5	to	O
6	a	O
7	protein	O
8	of	O
9	<UNK>	O
10	amino	O
11	acids	O
12	,	O
13	an	O
14	upstream	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	<UNK>	O
20	)	O
21	within	O
22	the	O
23	5	O
24	'	O
25	leader	O
26	could	O
27	potentially	O
28	encode	O
29	a	O
30	54	O
31	amino	O
32	acid	O
33	peptide	O
34	.	O
1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	<UNK>	B
10	gene	O
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	O
18	)	O
19	and	O
20	is	O
21	not	O
22	affected	O
23	by	O
24	<UNK>	O
25	.	O
1	<UNK>	O
2	of	O
3	the	O
4	insertion	O
5	locus	O
6	in	O
7	the	O
8	yeast	O
9	genome	O
10	and	O
11	complementation	O
12	studies	O
13	with	O
14	the	O
15	temperature	O
16	-	O
17	sensitive	O
18	mutant	O
19	indicate	O
20	that	O
21	the	O
22	two	O
23	mutations	O
24	are	O
25	<UNK>	O
26	.	O
1	Type	O
2	II	O
3	could	O
4	be	O
5	divided	O
6	further	O
7	into	O
8	two	O
9	forms	O
10	(	O
11	<UNK>	O
12	and	O
13	<UNK>	O
14	)	O
15	that	O
16	may	O
17	represent	O
18	two	O
19	<UNK>	O
20	species	O
21	or	O
22	developmental	O
23	stages	O
24	of	O
25	the	O
26	same	O
27	species	O
28	.	O
1	Ig	B
2	-	O
3	alpha	O
4	and	O
5	Ig	B
6	-	O
7	beta	O
8	contain	O
9	extended	O
10	cytoplasmic	O
11	structure	O
12	(	O
13	61	O
14	and	O
15	48	O
16	amino	O
17	acids	O
18	,	O
19	respectively	O
20	)	O
21	and	O
22	associate	O
23	with	O
24	cytoplasmic	O
25	<UNK>	O
26	indicating	O
27	that	O
28	they	O
29	are	O
30	directly	O
31	involved	O
32	in	O
33	signal	O
34	transduction	O
35	.	O
1	OBJECTIVE	O
2	:	O
3	Our	O
4	purpose	O
5	was	O
6	to	O
7	determine	O
8	the	O
9	simultaneous	O
10	concentrations	O
11	of	O
12	serum	O
13	<UNK>	O
14	in	O
15	both	O
16	fetal	O
17	and	O
18	maternal	O
19	blood	O
20	.	O
1	<UNK>	O
2	amino	O
3	acid	O
4	sequence	O
5	has	O
6	now	O
7	been	O
8	obtained	O
9	from	O
10	this	O
11	protein	O
12	which	O
13	shares	O
14	50	O
15	-	O
16	100	O
17	%	O
18	sequence	O
19	identity	O
20	with	O
21	sequences	O
22	encoded	O
23	by	O
24	mammalian	O
25	G	O
26	alpha	O
27	11	O
28	and	O
29	G	O
30	alpha	O
31	q	O
32	cDNAs	O
33	.	O
1	<UNK>	O
2	lead	O
3	was	O
4	not	O
5	a	O
6	significant	O
7	<UNK>	O
8	variable	O
9	.	O
1	5	O
2	micrograms	O
3	/	O
4	l	O
5	was	O
6	detected	O
7	in	O
8	urine	O
9	from	O
10	some	O
11	non	O
12	-	O
13	<UNK>	O
14	exposed	O
15	persons	O
16	.	O
1	<UNK>	O
2	<UNK>	O
3	with	O
4	deficiency	O
5	of	O
6	the	O
7	<UNK>	O
8	.	O
1	Further	O
2	evidence	O
3	for	O
4	a	O
5	<UNK>	O
6	organization	O
7	of	O
8	<UNK>	B
9	-	O
10	<UNK>	B
11	transcription	O
12	units	O
13	is	O
14	provided	O
15	by	O
16	Southern	O
17	blot	O
18	analysis	O
19	of	O
20	large	O
21	genomic	O
22	restriction	O
23	fragments	O
24	separated	O
25	by	O
26	<UNK>	O
27	field	O
28	gel	O
29	electrophoresis	O
30	,	O
31	and	O
32	by	O
33	in	O
34	situ	O
35	hybridization	O
36	on	O
37	intact	O
38	chromosomes	O
39	.	O
1	In	O
2	<UNK>	O
3	-	O
4	stimulated	O
5	<UNK>	O
6	assays	O
7	on	O
8	<UNK>	O
9	-	O
10	induced	O
11	<UNK>	O
12	-	O
13	1	O
14	cells	O
15	,	O
16	the	O
17	IL	B
18	-	O
19	<UNK>	B
20	alpha	O
21	chain	O
22	is	O
23	<UNK>	O
24	<UNK>	O
25	together	O
26	with	O
27	the	O
28	IL	B
29	-	O
30	<UNK>	B
31	beta	O
32	subunit	O
33	indicating	O
34	that	O
35	IL	B
36	-	O
37	<UNK>	B
38	alpha	O
39	is	O
40	stably	O
41	associated	O
42	with	O
43	the	O
44	<UNK>	O
45	-	O
46	IL	B
47	-	O
48	<UNK>	B
49	beta	O
50	complex	O
51	even	O
52	though	O
53	the	O
54	alpha	O
55	-	O
56	subunit	O
57	contributes	O
58	little	O
59	if	O
60	any	O
61	affinity	O
62	to	O
63	the	O
64	<UNK>	O
65	binding	O
66	reaction	O
67	.	O
1	<UNK>	O
2	oxide	O
3	inhalation	O
4	selectively	O
5	reduces	O
6	pulmonary	O
7	hypertension	O
8	in	O
9	porcine	O
10	<UNK>	O
11	shock	O
12	and	O
13	<UNK>	O
14	arterial	O
15	<UNK>	O
16	and	O
17	pH	O
18	with	O
19	a	O
20	marked	O
21	attenuation	O
22	of	O
23	sympathetic	O
24	activation	O
25	.	O
1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	<UNK>	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	<UNK>	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	<UNK>	B
36	(	O
37	<UNK>	B
38	E	O
39	-	O
40	box	O
41	)	O
42	site	O
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	<UNK>	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	B
6	and	O
7	cAMP	O
8	can	O
9	repress	O
10	collagen	B
11	promoter	O
12	activity	O
13	in	O
14	<UNK>	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	alpha	O
23	1	O
24	(	O
25	I	O
26	)	O
27	collagen	B
28	promoter	O
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	<UNK>	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	B
45	and	O
46	cAMP	O
47	repression	O
48	of	O
49	collagen	B
50	gene	O
51	expression	O
52	in	O
53	bone	O
54	.	O
1	The	O
2	retention	O
3	of	O
4	<UNK>	O
5	was	O
6	low	O
7	.	O
1	<UNK>	O
2	of	O
3	the	O
4	C	O
5	/	O
6	EBP	B
7	family	O
8	of	O
9	basic	O
10	-	O
11	leucine	O
12	zipper	O
13	(	O
14	<UNK>	O
15	)	O
16	transcription	O
17	factors	O
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	O
30	related	O
31	enhancer	O
32	motifs	O
33	.	O
1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	O
19	cytoplasmic	O
20	<UNK>	B
21	activity	O
22	was	O
23	produced	O
24	.	O
1	Here	O
2	,	O
3	we	O
4	have	O
5	more	O
6	closely	O
7	investigated	O
8	transactivation	O
9	of	O
10	the	O
11	human	O
12	<UNK>	B
13	promoter	O
14	by	O
15	Myb	B
16	proteins	O
17	.	O
1	A	O
2	second	O
3	hydrophobic	O
4	domain	O
5	,	O
6	<UNK>	O
7	by	O
8	two	O
9	<UNK>	O
10	regions	O
11	strongly	O
12	suggests	O
13	a	O
14	transmembrane	O
15	region	O
16	.	O
1	This	O
2	gene	O
3	spans	O
4	23	O
5	kb	O
6	and	O
7	is	O
8	composed	O
9	of	O
10	five	O
11	exons	O
12	and	O
13	four	O
14	introns	O
15	.	O
1	The	O
2	remaining	O
3	<UNK>	B
4	+	O
5	cells	O
6	<UNK>	O
7	to	O
8	form	O
9	<UNK>	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	<UNK>	O
16	<UNK>	O
17	<UNK>	O
18	cells	O
19	.	O
1	<UNK>	O
2	<UNK>	O
3	system	O
4	may	O
5	contribute	O
6	to	O
7	understand	O
8	the	O
9	mechanisms	O
10	underlying	O
11	the	O
12	decrease	O
13	of	O
14	<UNK>	O
15	with	O
16	<UNK>	O
17	.	O
1	The	O
2	5	O
3	'	O
4	flanking	O
5	regions	O
6	of	O
7	both	O
8	<UNK>	B
9	and	O
10	<UNK>	B
11	were	O
12	<UNK>	O
13	fused	O
14	to	O
15	the	O
16	beta	O
17	-	O
18	<UNK>	B
19	gene	O
20	and	O
21	introduced	O
22	into	O
23	F	O
24	.	O
25	<UNK>	O
26	<UNK>	O
27	.	O
28	sp	O
29	.	O
30	<UNK>	O
31	,	O
32	and	O
33	beta	O
34	-	O
35	<UNK>	B
36	activities	O
37	of	O
38	the	O
39	<UNK>	O
40	were	O
41	measured	O
42	.	O
1	Similarly	O
2	,	O
3	expression	O
4	of	O
5	a	O
6	transiently	O
7	transfected	O
8	wild	O
9	-	O
10	type	O
11	<UNK>	B
12	alpha	O
13	gene	O
14	as	O
15	the	O
16	reporter	O
17	was	O
18	not	O
19	affected	O
20	by	O
21	a	O
22	<UNK>	O
23	of	O
24	myc	B
25	-	O
26	derived	O
27	genes	O
28	,	O
29	including	O
30	myc	B
31	itself	O
32	and	O
33	dominant	O
34	or	O
35	<UNK>	O
36	negative	O
37	myc	B
38	mutants	O
39	.	O
1	<UNK>	O
2	contain	O
3	<UNK>	O
4	less	O
5	P	O
6	protein	O
7	mRNA	O
8	and	O
9	the	O
10	relative	O
11	level	O
12	in	O
13	roots	O
14	is	O
15	very	O
16	low	O
17	but	O
18	still	O
19	clearly	O
20	detectable	O
21	.	O
1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	<UNK>	O
8	-	O
9	<UNK>	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	<UNK>	O
36	.	O
1	Consistent	O
2	with	O
3	the	O
4	hepatic	O
5	and	O
6	epidermal	B
7	expression	O
8	of	O
9	<UNK>	B
10	,	O
11	this	O
12	finding	O
13	suggests	O
14	that	O
15	<UNK>	B
16	transcription	O
17	may	O
18	be	O
19	regulated	O
20	by	O
21	these	O
22	factors	O
23	.	O
1	Transfection	O
2	analyses	O
3	indicate	O
4	that	O
5	mutation	O
6	of	O
7	any	O
8	one	O
9	of	O
10	these	O
11	<UNK>	O
12	motifs	O
13	or	O
14	<UNK>	O
15	of	O
16	the	O
17	entire	O
18	HD	O
19	<UNK>	O
20	into	O
21	a	O
22	separate	O
23	<UNK>	B
24	and	O
25	<UNK>	O
26	element	O
27	significantly	O
28	reduced	O
29	the	O
30	transcriptional	O
31	response	O
32	of	O
33	HD	O
34	<UNK>	O
35	to	O
36	<UNK>	O
37	<UNK>	O
38	.	O
1	<UNK>	B
2	-	O
3	<UNK>	O
4	differs	O
5	from	O
6	<UNK>	B
7	-	O
8	<UNK>	B
9	in	O
10	having	O
11	a	O
12	deletion	O
13	of	O
14	19	O
15	amino	O
16	acids	O
17	corresponding	O
18	to	O
19	exon	O
20	E1	O
21	.	O
1	The	O
2	protein	O
3	kinase	B
4	domains	O
5	of	O
6	<UNK>	B
7	and	O
8	<UNK>	B
9	are	O
10	unique	O
11	in	O
12	that	O
13	they	O
14	contain	O
15	an	O
16	unusual	O
17	sequence	O
18	motif	O
19	Asp	O
20	-	O
21	Leu	O
22	-	O
23	<UNK>	O
24	-	O
25	Ser	O
26	-	O
27	His	O
28	-	O
29	<UNK>	O
30	in	O
31	<UNK>	O
32	<UNK>	O
33	and	O
34	a	O
35	highly	O
36	basic	O
37	insert	O
38	between	O
39	<UNK>	O
40	VII	O
41	and	O
42	VIII	O
43	.	O
1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	<UNK>	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	O
15	-	O
16	finger	O
17	protein	O
18	(	O
19	<UNK>	B
20	-	O
21	1	O
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	<UNK>	O
34	leukemia	O
35	<UNK>	O
36	cells	O
37	with	O
38	synthetic	O
39	<UNK>	O
40	probes	O
41	that	O
42	<UNK>	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	<UNK>	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	B
62	-	O
63	hypersensitive	O
64	element	O
65	(	O
66	<UNK>	B
67	)	O
68	of	O
69	the	O
70	human	O
71	c	B
72	-	O
73	myc	B
74	gene	O
75	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	<UNK>	O
5	+	O
6	EPO	B
7	-	O
8	<UNK>	O
9	infants	O
10	remained	O
11	low	O
12	and	O
13	below	O
14	breast	O
15	-	O
16	and	O
17	placebo	O
18	<UNK>	O
19	-	O
20	fed	O
21	levels	O
22	.	O
1	<UNK>	O
2	into	O
3	<UNK>	O
4	weight	O
5	and	O
6	<UNK>	O
7	changes	O
8	in	O
9	bone	O
10	mass	O
11	,	O
12	total	O
13	(	O
14	<UNK>	O
15	)	O
16	and	O
17	regional	O
18	body	O
19	bone	O
20	mineral	O
21	content	O
22	were	O
23	measured	O
24	in	O
25	38	O
26	women	O
27	treated	O
28	with	O
29	GnRH	B
30	agonists	O
31	for	O
32	6	O
33	months	O
34	for	O
35	<UNK>	O
36	or	O
37	<UNK>	O
38	.	O
1	The	O
2	<UNK>	B
3	gene	O
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	<UNK>	O
11	expression	O
12	of	O
13	<UNK>	O
14	genes	O
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	<UNK>	B
22	.	O
1	According	O
2	to	O
3	the	O
4	investigation	O
5	,	O
6	the	O
7	recent	O
8	<UNK>	O
9	of	O
10	<UNK>	O
11	in	O
12	this	O
13	area	O
14	can	O
15	be	O
16	<UNK>	O
17	to	O
18	the	O
19	increased	O
20	presence	O
21	of	O
22	sea	O
23	<UNK>	O
24	,	O
25	which	O
26	<UNK>	O
27	in	O
28	the	O
29	<UNK>	O
30	region	O
31	,	O
32	then	O
33	<UNK>	O
34	to	O
35	the	O
36	<UNK>	O
37	<UNK>	O
38	<UNK>	O
39	and	O
40	<UNK>	O
41	the	O
42	intermediate	O
43	host	O
44	<UNK>	O
45	.	O
1	Thus	O
2	,	O
3	SPECT	O
4	was	O
5	not	O
6	as	O
7	sensitive	O
8	as	O
9	PET	O
10	in	O
11	this	O
12	activation	O
13	task	O
14	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	<UNK>	O
7	agents	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	do	O
12	not	O
13	exert	O
14	<UNK>	O
15	efficacy	O
16	against	O
17	<UNK>	O
18	induced	O
19	during	O
20	<UNK>	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O
1	The	O
2	gene	O
3	was	O
4	<UNK>	O
5	mapped	O
6	with	O
7	<UNK>	O
8	>	O
9	1	O
10	,	O
11	000	O
12	:	O
13	1	O
14	on	O
15	chromosome	O
16	<UNK>	O
17	in	O
18	<UNK>	O
19	d	O
20	'	O
21	<UNK>	O
22	<UNK>	O
23	<UNK>	O
24	<UNK>	O
25	<UNK>	O
26	.	O
1	The	O
2	promoter	O
3	of	O
4	the	O
5	first	O
6	gene	O
7	,	O
8	<UNK>	B
9	,	O
10	<UNK>	O
11	to	O
12	the	O
13	activator	O
14	protein	O
15	<UNK>	B
16	and	O
17	contained	O
18	a	O
19	palindromic	O
20	sequence	O
21	similar	O
22	to	O
23	the	O
24	<UNK>	B
25	binding	O
26	site	O
27	of	O
28	the	O
29	<UNK>	B
30	promoter	O
31	,	O
32	which	O
33	is	O
34	also	O
35	activated	O
36	by	O
37	<UNK>	B
38	.	O
1	<UNK>	O
2	<UNK>	O
3	bind	O
4	to	O
5	unique	O
6	sets	O
7	of	O
8	<UNK>	O
9	<UNK>	O
10	that	O
11	can	O
12	function	O
13	independently	O
14	and	O
15	are	O
16	<UNK>	O
17	distributed	O
18	on	O
19	multiple	O
20	domains	O
21	of	O
22	human	O
23	interleukin	B
24	-	O
25	8	O
26	receptor	O
27	B	O
28	.	O
1	Consistent	O
2	with	O
3	a	O
4	possible	O
5	role	O
6	in	O
7	transcription	O
8	,	O
9	<UNK>	B
10	is	O
11	localized	O
12	to	O
13	the	O
14	nucleus	O
15	.	O
1	By	O
2	comparing	O
3	the	O
4	<UNK>	O
5	of	O
6	many	O
7	yeast	O
8	transcripts	O
9	in	O
10	<UNK>	O
11	wild	O
12	-	O
13	type	O
14	and	O
15	<UNK>	B
16	mutant	O
17	strains	O
18	,	O
19	we	O
20	have	O
21	identified	O
22	genes	O
23	whose	O
24	expression	O
25	is	O
26	affected	O
27	by	O
28	<UNK>	B
29	.	O
1	<UNK>	O
2	that	O
3	expressed	O
4	<UNK>	O
5	exhibited	O
6	a	O
7	dominant	O
8	negative	O
9	phenotype	O
10	and	O
11	did	O
12	not	O
13	<UNK>	O
14	<UNK>	O
15	activity	O
16	against	O
17	<UNK>	O
18	<UNK>	O
19	virus	O
20	(	O
21	<UNK>	O
22	)	O
23	infection	O
24	upon	O
25	IFN	B
26	treatment	O
27	.	O
1	<UNK>	O
2	<UNK>	O
3	indicators	O
4	could	O
5	be	O
6	used	O
7	in	O
8	<UNK>	O
9	,	O
10	in	O
11	<UNK>	O
12	and	O
13	for	O
14	special	O
15	<UNK>	O
16	.	O
1	Human	O
2	<UNK>	B
3	-	O
4	4	O
5	readily	O
6	<UNK>	O
7	with	O
8	genes	O
9	in	O
10	mouse	O
11	and	O
12	chicken	O
13	,	O
14	thus	O
15	showing	O
16	that	O
17	this	O
18	gene	O
19	family	O
20	has	O
21	been	O
22	highly	O
23	conserved	O
24	during	O
25	vertebrate	O
26	evolution	O
27	.	O
1	Neither	O
2	class	O
3	II	O
4	nor	O
5	IV	O
6	infections	O
7	<UNK>	O
8	transplantation	O
9	.	O
1	<UNK>	O
2	of	O
3	-	O
4	37	O
5	,	O
6	the	O
7	5	O
8	'	O
9	untranslated	O
10	sequences	O
11	of	O
12	the	O
13	isolates	O
14	differ	O
15	in	O
16	both	O
17	length	O
18	and	O
19	sequence	O
20	.	O
1	In	O
2	these	O
3	cases	O
4	,	O
5	greatly	O
6	increased	O
7	human	O
8	<UNK>	B
9	<UNK>	I
10	(	O
11	hCG	B
12	)	O
13	levels	O
14	and	O
15	suppressed	O
16	TSH	B
17	levels	O
18	suggest	O
19	that	O
20	hCG	B
21	has	O
22	<UNK>	O
23	activity	O
24	.	O
1	This	O
2	study	O
3	determined	O
4	the	O
5	<UNK>	O
6	potential	O
7	of	O
8	<UNK>	O
9	gel	O
10	by	O
11	either	O
12	<UNK>	O
13	it	O
14	with	O
15	bovine	O
16	collagen	B
17	II	O
18	(	O
19	<UNK>	O
20	)	O
21	or	O
22	by	O
23	<UNK>	O
24	<UNK>	O
25	gel	O
26	alone	O
27	in	O
28	<UNK>	O
29	rats	O
30	.	O
1	<UNK>	O
2	binds	O
3	to	O
4	the	O
5	promoter	O
6	prior	O
7	to	O
8	the	O
9	activation	O
10	of	O
11	transcription	O
12	in	O
13	late	O
14	G1	O
15	,	O
16	suggesting	O
17	that	O
18	<UNK>	B
19	/	O
20	<UNK>	B
21	kinase	I
22	regulates	O
23	the	O
24	ability	O
25	of	O
26	previously	O
27	bound	O
28	<UNK>	O
29	to	O
30	activate	O
31	transcription	O
32	.	O
1	This	O
2	5	O
3	'	O
4	splice	O
5	site	O
6	sequence	O
7	was	O
8	required	O
9	for	O
10	enhanced	O
11	polyadenylation	O
12	and	O
13	was	O
14	recognized	O
15	by	O
16	both	O
17	U1	B
18	small	O
19	nuclear	O
20	<UNK>	O
21	(	O
22	<UNK>	O
23	)	O
24	and	O
25	alternative	O
26	splicing	O
27	factor	O
28	/	O
29	splicing	O
30	factor	O
31	2	O
32	(	O
33	<UNK>	B
34	/	O
35	<UNK>	O
36	).	O
1	Although	O
2	the	O
3	consumption	O
4	of	O
5	<UNK>	B
6	-	O
7	bound	O
8	O2	O
9	(	O
10	<UNK>	O
11	)	O
12	<UNK>	O
13	in	O
14	<UNK>	O
15	muscles	O
16	has	O
17	been	O
18	demonstrated	O
19	in	O
20	<UNK>	O
21	muscles	O
22	during	O
23	laboratory	O
24	<UNK>	O
25	of	O
26	<UNK>	O
27	,	O
28	this	O
29	may	O
30	not	O
31	be	O
32	a	O
33	feature	O
34	of	O
35	normal	O
36	field	O
37	<UNK>	O
38	in	O
39	which	O
40	measurements	O
41	of	O
42	heart	O
43	rate	O
44	and	O
45	lactate	O
46	production	O
47	show	O
48	marked	O
49	differences	O
50	from	O
51	the	O
52	<UNK>	O
53	<UNK>	O
54	response	O
55	induced	O
56	by	O
57	<UNK>	O
58	<UNK>	O
59	.	O
1	The	O
2	<UNK>	B
3	kinase	I
4	,	O
5	which	O
6	<UNK>	O
7	S	O
8	phase	O
9	,	O
10	remains	O
11	active	O
12	during	O
13	the	O
14	G2	O
15	-	O
16	phase	O
17	arrest	O
18	of	O
19	cells	O
20	of	O
21	the	O
22	parental	O
23	strain	O
24	,	O
25	but	O
26	its	O
27	activity	O
28	<UNK>	O
29	rapidly	O
30	in	O
31	<UNK>	B
32	mutants	O
33	.	O
1	<UNK>	B
2	mutants	O
3	display	O
4	a	O
5	<UNK>	O
6	<UNK>	O
7	phenotype	O
8	,	O
9	<UNK>	O
10	the	O
11	protein	O
12	in	O
13	DNA	O
14	damage	O
15	-	O
16	induced	O
17	mutagenesis	O
18	,	O
19	<UNK>	O
20	repair	O
21	,	O
22	repression	O
23	of	O
24	<UNK>	O
25	,	O
26	and	O
27	<UNK>	O
28	.	O
1	With	O
2	current	O
3	<UNK>	O
4	beta	O
5	-	O
6	2	O
7	transferrin	B
8	does	O
9	not	O
10	appear	O
11	to	O
12	be	O
13	a	O
14	reliable	O
15	clinical	O
16	marker	O
17	for	O
18	<UNK>	O
19	in	O
20	the	O
21	operative	O
22	<UNK>	O
23	.	O
1	Significant	O
2	correlations	O
3	<UNK>	O
4	between	O
5	FEV1	O
6	and	O
7	the	O
8	corresponding	O
9	values	O
10	of	O
11	<UNK>	O
12	,	O
13	<UNK>	O
14	and	O
15	<UNK>	O
16	,	O
17	although	O
18	there	O
19	were	O
20	considerable	O
21	individual	O
22	differences	O
23	between	O
24	test	O
25	results	O
26	.	O
1	<UNK>	O
2	exposure	O
3	to	O
4	hepatitis	O
5	B	O
6	virus	O
7	and	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	:	O
12	a	O
13	comparative	O
14	risk	O
15	analysis	O
16	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	<UNK>	O
12	<UNK>	O
13	.	O
1	One	O
2	hundred	O
3	units	O
4	/	O
5	kg	O
6	of	O
7	recombinant	O
8	human	O
9	erythropoietin	B
10	(	O
11	<UNK>	B
12	)	O
13	was	O
14	given	O
15	<UNK>	O
16	3	O
17	times	O
18	a	O
19	week	O
20	for	O
21	3	O
22	weeks	O
23	.	O
1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	<UNK>	O
6	patients	O
7	with	O
8	chronic	O
9	hepatitis	O
10	C	O
11	respond	O
12	well	O
13	to	O
14	interferon	B
15	treatment	O
16	and	O
17	that	O
18	a	O
19	long	O
20	-	O
21	term	O
22	response	O
23	is	O
24	achieved	O
25	in	O
26	a	O
27	high	O
28	proportion	O
29	of	O
30	patients	O
31	.	O
1	This	O
2	study	O
3	<UNK>	O
4	an	O
5	<UNK>	O
6	for	O
7	such	O
8	global	O
9	<UNK>	O
10	effects	O
11	upon	O
12	unit	O
13	-	O
14	pair	O
15	correlations	O
16	based	O
17	on	O
18	local	O
19	field	O
20	potentials	O
21	(	O
22	<UNK>	O
23	).	O
1	Effects	O
2	of	O
3	repeated	O
4	<UNK>	O
5	of	O
6	<UNK>	O
7	<UNK>	O
8	on	O
9	rat	O
10	<UNK>	O
11	EEG	O
12	.	O
1	The	O
2	gene	O
3	encodes	O
4	an	O
5	ATP	O
6	-	O
7	binding	O
8	<UNK>	O
9	,	O
10	<UNK>	O
11	transporter	O
12	.	O
1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O
1	<UNK>	O
2	<UNK>	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O
1	In	O
2	view	O
3	of	O
4	the	O
5	presence	O
6	of	O
7	<UNK>	O
8	elements	O
9	in	O
10	the	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	)	O
17	of	O
18	bacterial	O
19	<UNK>	B
20	,	O
21	we	O
22	examine	O
23	the	O
24	effects	O
25	in	O
26	the	O
27	type	O
28	1	O
29	<UNK>	B
30	of	O
31	<UNK>	O
32	the	O
33	ORF	O
34	into	O
35	the	O
36	<UNK>	O
37	element	O
38	,	O
39	and	O
40	find	O
41	that	O
42	this	O
43	dramatically	O
44	inhibits	O
45	<UNK>	O
46	function	O
47	.	O
1	This	O
2	spindle	O
3	defect	O
4	of	O
5	<UNK>	B
6	mutants	O
7	results	O
8	from	O
9	a	O
10	temperature	O
11	-	O
12	sensitive	O
13	step	O
14	that	O
15	occurs	O
16	around	O
17	the	O
18	G1	O
19	/	O
20	S	O
21	boundary	O
22	about	O
23	the	O
24	time	O
25	of	O
26	spindle	O
27	assembly	O
28	.	O
1	However	O
2	,	O
3	for	O
4	the	O
5	<UNK>	O
6	cases	O
7	,	O
8	the	O
9	<UNK>	O
10	of	O
11	the	O
12	<UNK>	O
13	and	O
14	the	O
15	<UNK>	O
16	were	O
17	<UNK>	O
18	similar	O
19	and	O
20	generally	O
21	correlated	O
22	well	O
23	with	O
24	the	O
25	<UNK>	O
26	reference	O
27	procedure	O
28	.	O
1	<UNK>	O
2	-	O
3	terminal	O
4	<UNK>	B
5	<UNK>	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	O
10	site	O
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O
1	In	O
2	conclusion	O
3	,	O
4	IgM	B
5	class	O
6	<UNK>	O
7	is	O
8	the	O
9	predominant	O
10	<UNK>	O
11	in	O
12	acute	O
13	hepatitis	O
14	A	O
15	and	O
16	correlated	O
17	with	O
18	disease	O
19	activity	O
20	.	O
1	The	O
2	membrane	O
3	-	O
4	distal	O
5	cytoplasmic	O
6	region	O
7	of	O
8	human	O
9	granulocyte	B
10	colony	O
11	-	O
12	stimulating	O
13	factor	O
14	receptor	O
15	is	O
16	required	O
17	for	O
18	<UNK>	B
19	but	O
20	not	O
21	STAT1	B
22	<UNK>	O
23	formation	O
24	.	O
1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	<UNK>	O
17	by	O
18	the	O
19	<UNK>	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	O
25	.	O
26	<UNK>	B
27	RNA	O
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	<UNK>	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O
1	<UNK>	O
2	-	O
3	five	O
4	patients	O
5	with	O
6	pleural	O
7	lesions	O
8	identified	O
9	on	O
10	CT	O
11	scans	O
12	were	O
13	subsequently	O
14	examined	O
15	by	O
16	MR	O
17	imaging	O
18	at	O
19	0	O
20	.	O
21	5	O
22	T	O
23	.	O
1	We	O
2	observed	O
3	abundant	O
4	levels	O
5	of	O
6	Rev	B
7	-	O
8	<UNK>	B
9	alpha	O
10	mRNA	O
11	in	O
12	<UNK>	O
13	<UNK>	O
14	<UNK>	O
15	,	O
16	which	O
17	were	O
18	suppressed	O
19	when	O
20	the	O
21	cells	O
22	differentiated	O
23	into	O
24	<UNK>	O
25	<UNK>	O
26	<UNK>	O
27	.	O
1	We	O
2	then	O
3	demonstrated	O
4	that	O
5	1	O
6	)	O
7	GAL4	B
8	-	O
9	<UNK>	O
10	-	O
11	<UNK>	B
12	alpha	O
13	<UNK>	O
14	that	O
15	contain	O
16	the	O
17	'	O
18	<UNK>	O
19	'	O
20	region	O
21	and	O
22	lack	O
23	the	O
24	'	O
25	E	O
26	'	O
27	region	O
28	activated	O
29	transcription	O
30	of	O
31	GAL4	B
32	response	O
33	elements	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	8	O
39	-	O
40	<UNK>	O
41	-	O
42	cAMP	O
43	and	O
44	2	O
45	)	O
46	the	O
47	ligand	O
48	-	O
49	binding	O
50	domain	O
51	(	O
52	<UNK>	O
53	)	O
54	contains	O
55	an	O
56	active	O
57	transcriptional	O
58	<UNK>	O
59	.	O
1	TNF	B
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	B
8	MAP	I
9	kinase	I
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	B
19	MAP	I
20	kinase	I
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	O
27	protein	O
28	<UNK>	B
29	kinase	I
30	-	O
31	2	O
32	,	O
33	and	O
34	<UNK>	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	O
41	shock	O
42	protein	O
43	27	O
44	(	O
45	<UNK>	B
46	).	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	protein	O
7	from	O
8	Drosophila	O
9	nuclear	O
10	extracts	O
11	which	O
12	binds	O
13	specifically	O
14	to	O
15	a	O
16	site	O
17	in	O
18	this	O
19	second	O
20	region	O
21	.	O
1	Further	O
2	analysis	O
3	of	O
4	this	O
5	domain	O
6	by	O
7	in	O
8	vitro	O
9	mutagenesis	O
10	<UNK>	O
11	to	O
12	a	O
13	core	O
14	of	O
15	hydrophobic	O
16	and	O
17	acidic	O
18	residues	O
19	as	O
20	critical	O
21	for	O
22	the	O
23	activity	O
24	.	O
1	Analysis	O
2	of	O
3	RAR	B
4	alpha	O
5	mutants	O
6	in	O
7	transfection	O
8	studies	O
9	reveals	O
10	that	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	is	O
16	sufficient	O
17	for	O
18	inhibition	O
19	of	O
20	<UNK>	B
21	activity	O
22	.	O
1	We	O
2	measured	O
3	serum	O
4	hepatocyte	O
5	growth	O
6	factor	O
7	(	O
8	<UNK>	B
9	)	O
10	in	O
11	patients	O
12	with	O
13	acute	O
14	myocardial	O
15	infarction	O
16	,	O
17	angina	O
18	<UNK>	O
19	,	O
20	and	O
21	other	O
22	heart	O
23	diseases	O
24	.	O
1	It	O
2	is	O
3	shown	O
4	that	O
5	the	O
6	(	O
7	G	O
8	+	O
9	C	O
10	)-	O
11	rich	O
12	element	O
13	of	O
14	the	O
15	<UNK>	B
16	C	O
17	promoter	O
18	<UNK>	O
19	transcription	O
20	in	O
21	neuronal	O
22	as	O
23	well	O
24	as	O
25	in	O
26	<UNK>	O
27	cells	O
28	.	O
1	We	O
2	isolated	O
3	a	O
4	complementary	O
5	DNA	O
6	(	O
7	cDNA	O
8	)	O
9	clone	O
10	from	O
11	an	O
12	<UNK>	O
13	-	O
14	2	O
15	expression	O
16	library	O
17	that	O
18	encodes	O
19	the	O
20	C1	O
21	site	O
22	-	O
23	binding	O
24	protein	O
25	.	O
1	Thus	O
2	,	O
3	<UNK>	B
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	<UNK>	B
13	activity	O
14	.	O
1	<UNK>	O
2	of	O
3	the	O
4	extended	O
5	N	O
6	terminus	O
7	into	O
8	the	O
9	<UNK>	O
10	reported	O
11	protein	O
12	resulted	O
13	in	O
14	a	O
15	striking	O
16	similarity	O
17	to	O
18	the	O
19	lymphoid	O
20	factor	O
21	<UNK>	B
22	-	O
23	1	O
24	.	O
1	The	O
2	large	O
3	subfamily	O
4	of	O
5	receptor	O
6	tyrosine	O
7	kinases	O
8	(	O
9	<UNK>	B
10	)	O
11	for	O
12	which	O
13	<UNK>	B
14	is	O
15	the	O
16	<UNK>	O
17	have	O
18	likely	O
19	roles	O
20	in	O
21	<UNK>	O
22	<UNK>	O
23	during	O
24	normal	O
25	mammalian	O
26	development	O
27	,	O
28	but	O
29	the	O
30	biochemical	O
31	signalling	O
32	pathways	O
33	<UNK>	O
34	by	O
35	this	O
36	family	O
37	are	O
38	poorly	O
39	<UNK>	O
40	.	O
1	In	O
2	agreement	O
3	with	O
4	previous	O
5	in	O
6	vitro	O
7	data	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	<UNK>	O
14	and	O
15	<UNK>	O
16	'	O
17	are	O
18	able	O
19	to	O
20	form	O
21	both	O
22	homodimers	O
23	(	O
24	<UNK>	O
25	-	O
26	<UNK>	O
27	and	O
28	<UNK>	O
29	'-	O
30	<UNK>	O
31	<UNK>	O
32	and	O
33	a	O
34	heterodimer	O
35	(	O
36	<UNK>	O
37	-	O
38	<UNK>	O
39	<UNK>	O
1	<UNK>	B
2	<UNK>	I
3	constitute	O
4	a	O
5	family	O
6	of	O
7	<UNK>	O
8	proteins	O
9	that	O
10	participate	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	<UNK>	O
16	release	O
17	.	O
1	This	O
2	result	O
3	suggested	O
4	that	O
5	mutant	O
6	<UNK>	O
7	has	O
8	diminished	O
9	cap	O
10	-	O
11	binding	O
12	activity	O
13	.	O
1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	O
20	-	O
21	kDa	O
22	component	O
23	of	O
24	cleavage	O
25	stimulation	O
26	factor	O
27	(	O
28	<UNK>	B
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	<UNK>	B
53	.	O
1	In	O
2	<UNK>	O
3	HeLa	O
4	cells	O
5	,	O
6	expression	O
7	of	O
8	luciferase	B
9	activity	O
10	was	O
11	induced	O
12	at	O
13	the	O
14	beginning	O
15	of	O
16	DNA	O
17	synthesis	O
18	and	O
19	was	O
20	dependent	O
21	on	O
22	the	O
23	presence	O
24	of	O
25	an	O
26	E2F	B
27	-	O
28	binding	O
29	site	O
30	in	O
31	the	O
32	<UNK>	B
33	.	O
34	1	O
35	promoter	O
36	.	O
1	A	O
2	<UNK>	O
3	regulated	O
4	4	O
5	.	O
6	6	O
7	kb	O
8	mRNA	O
9	is	O
10	recognized	O
11	on	O
12	Northern	O
13	<UNK>	O
14	of	O
15	oocyte	O
16	RNA	O
17	using	O
18	the	O
19	X	O
20	.	O
21	<UNK>	O
22	cDNA	O
23	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	increase	O
7	in	O
8	V	O
9	O2	O
10	may	O
11	have	O
12	been	O
13	a	O
14	consequence	O
15	of	O
16	the	O
17	increase	O
18	in	O
19	Q	O
20	O2	O
21	rather	O
22	than	O
23	a	O
24	response	O
25	to	O
26	the	O
27	procedure	O
28	itself	O
29	.	O
1	Several	O
2	cytokines	O
3	exhibit	O
4	a	O
5	high	O
6	degree	O
7	of	O
8	temporal	O
9	regulation	O
10	as	O
11	well	O
12	as	O
13	<UNK>	O
14	<UNK>	O
15	(	O
16	e	O
17	.	O
18	g	O
19	.,	O
20	interleukin	B
21	-	O
22	1	O
23	[	O
24	IL	B
25	-	O
26	1	O
27	<UNK>	O
28	tumor	O
29	necrosis	O
30	factor	O
31	-	O
32	alpha	O
33	[	O
34	TNF	B
35	-	O
36	alpha	O
37	<UNK>	O
1	The	O
2	members	O
3	of	O
4	the	O
5	Myb	B
6	family	O
7	of	O
8	transcription	O
9	factors	O
10	are	O
11	defined	O
12	by	O
13	homology	O
14	in	O
15	the	O
16	DNA	O
17	-	O
18	binding	O
19	domain	O
20	;	O
21	all	O
22	bind	O
23	the	O
24	Myb	B
25	-	O
26	binding	O
27	site	O
28	(	O
29	<UNK>	B
30	)	O
31	sequence	O
32	(	O
33	<UNK>	O
34	(	O
35	A	O
36	/	O
37	G	O
38	)	O
39	C	O
40	(	O
41	A	O
42	/	O
43	C	O
44	/	O
45	G	O
46	)	O
47	<UNK>	O
48	(	O
49	G	O
50	/	O
51	A	O
52	<UNK>	O
1	The	O
2	frequency	O
3	of	O
4	<UNK>	O
5	that	O
6	led	O
7	to	O
8	transcription	O
9	of	O
10	the	O
11	lacZ	B
12	gene	O
13	was	O
14	estimated	O
15	to	O
16	be	O
17	0	O
18	.	O
19	5	O
20	%	O
21	of	O
22	all	O
23	<UNK>	O
24	,	O
25	of	O
26	which	O
27	14	O
28	%	O
29	were	O
30	<UNK>	O
31	on	O
32	differentiation	O
33	of	O
34	<UNK>	O
35	cells	O
36	towards	O
37	neutrophils	O
38	.	O
1	Both	O
2	mutant	O
3	receptors	O
4	were	O
5	expressed	O
6	on	O
7	the	O
8	cell	O
9	surface	O
10	and	O
11	bound	O
12	insulin	B
13	normally	O
14	,	O
15	but	O
16	showed	O
17	markedly	O
18	impaired	O
19	<UNK>	O
20	in	O
21	response	O
22	to	O
23	insulin	B
24	.	O
1	<UNK>	O
2	8	O
3	mg	O
4	<UNK>	O
5	days	O
6	2	O
7	-	O
8	3	O
9	,	O
10	and	O
11	8	O
12	mg	O
13	<UNK>	O
14	<UNK>	O
15	days	O
16	4	O
17	-	O
18	5	O
19	and	O
20	<UNK>	O
21	75	O
22	-	O
23	100	O
24	mg	O
25	<UNK>	O
26	days	O
27	2	O
28	-	O
29	5	O
30	and	O
31	2	O
32	)	O
33	<UNK>	O
34	30	O
35	mg	O
36	/	O
37	<UNK>	O
38	80	O
39	mg	O
40	i	O
41	.	O
42	v	O
43	.	O
44	before	O
45	CT	O
46	and	O
47	<UNK>	O
48	20	O
49	mg	O
50	p	O
51	.	O
52	r	O
53	.	O
54	after	O
55	4	O
56	and	O
57	8	O
58	h	O
59	respectively	O
60	.	O
1	The	O
2	dynamic	O
3	properties	O
4	of	O
5	this	O
6	protein	O
7	fragment	O
8	were	O
9	measured	O
10	and	O
11	analyzed	O
12	using	O
13	both	O
14	<UNK>	O
15	and	O
16	<UNK>	O
17	models	O
18	of	O
19	molecular	O
20	motion	O
21	.	O
1	T	O
2	cell	O
3	leukemia	O
4	-	O
5	associated	O
6	human	O
7	<UNK>	B
8	/	O
9	translocation	O
10	-	O
11	associated	O
12	<UNK>	B
13	homologue	O
14	has	O
15	I	O
16	kappa	B
17	B	O
18	-	O
19	like	O
20	activity	O
21	and	O
22	physically	O
23	interacts	O
24	with	O
25	nuclear	O
26	factor	O
27	-	O
28	kappa	B
29	B	O
30	proteins	O
31	in	O
32	T	O
33	cells	O
34	.	O
1	An	O
2	apparent	O
3	N	O
4	-	O
5	terminal	O
6	transit	O
7	peptide	O
8	in	O
9	the	O
10	coding	O
11	region	O
12	and	O
13	a	O
14	3	O
15	'	O
16	poly	O
17	(	O
18	A	O
19	)	O
20	tail	O
21	exist	O
22	in	O
23	the	O
24	cDNA	O
25	clone	O
26	indicated	O
27	that	O
28	this	O
29	chloroplast	O
30	protein	O
31	as	O
32	nuclear	O
33	encoded	O
34	.	O
1	<UNK>	O
2	<UNK>	O
3	of	O
4	the	O
5	wild	O
6	-	O
7	type	O
8	<UNK>	B
9	and	O
10	the	O
11	<UNK>	B
12	-	O
13	<UNK>	B
14	fusion	O
15	protein	O
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	<UNK>	O
26	wild	O
27	-	O
28	type	O
29	or	O
30	fusion	O
31	protein	O
32	.	O
1	<UNK>	O
2	-	O
3	cycle	O
4	phase	O
5	did	O
6	not	O
7	significantly	O
8	affect	O
9	<UNK>	O
10	variables	O
11	in	O
12	either	O
13	group	O
14	.	O
1	The	O
2	Cdk2	B
3	-	O
4	cyclin	B
5	-	O
6	D1	B
7	complex	O
8	did	O
9	not	O
10	phosphorylate	O
11	any	O
12	tested	O
13	substrates	O
14	,	O
15	such	O
16	as	O
17	H1	O
18	histone	B
19	,	O
20	<UNK>	B
21	,	O
22	SV40	O
23	large	O
24	T	O
25	antigen	O
26	,	O
27	p53	B
28	,	O
29	E2F	B
30	-	O
31	1	O
32	or	O
33	a	O
34	preparation	O
35	of	O
36	nuclear	O
37	proteins	O
38	from	O
39	HeLa	O
40	cells	O
41	;	O
42	in	O
43	contrast	O
44	,	O
45	Cdk2	B
46	-	O
47	cyclin	B
48	-	O
49	E	O
50	and	O
51	Cdk2	B
52	-	O
53	cyclin	B
54	-	O
55	A	O
56	phosphorylated	O
57	these	O
58	proteins	O
59	.	O
1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	P2	O
6	-	O
7	proximal	O
8	<UNK>	B
9	binding	O
10	site	O
11	and	O
12	transient	O
13	-	O
14	cotransfection	O
15	experiments	O
16	demonstrate	O
17	that	O
18	<UNK>	B
19	is	O
20	a	O
21	transcriptional	O
22	repressor	O
23	of	O
24	the	O
25	human	O
26	c	B
27	-	O
28	myc	B
29	gene	O
30	.	O
1	The	O
2	<UNK>	O
3	of	O
4	bovine	O
5	<UNK>	B
6	--	O
7	VIII	O
8	.	O
1	<UNK>	O
2	temporal	O
3	<UNK>	O
4	was	O
5	characterized	O
6	by	O
7	severe	O
8	neuronal	O
9	loss	O
10	accompanied	O
11	by	O
12	<UNK>	O
13	occurring	O
14	in	O
15	the	O
16	<UNK>	O
17	/	O
18	<UNK>	O
19	(	O
20	27	O
21	patients	O
22	,	O
23	100	O
24	%),	O
25	<UNK>	O
26	in	O
27	the	O
28	<UNK>	O
29	<UNK>	O
30	(	O
31	12	O
32	patients	O
33	,	O
34	44	O
35	%),	O
36	and	O
37	in	O
38	the	O
39	<UNK>	O
40	region	O
41	(	O
42	11	O
43	patients	O
44	,	O
45	41	O
46	%).	O
1	Therefore	O
2	,	O
3	magnetic	O
4	resonance	O
5	imaging	O
6	was	O
7	used	O
8	to	O
9	determine	O
10	liver	O
11	volume	O
12	in	O
13	pediatric	O
14	and	O
15	<UNK>	O
16	patients	O
17	,	O
18	in	O
19	whom	O
20	systemic	O
21	clearance	O
22	of	O
23	three	O
24	model	O
25	substrates	O
26	[	O
27	<UNK>	O
28	(	O
29	0	O
30	.	O
31	03	O
32	mg	O
33	/	O
34	kg	O
35	),	O
36	<UNK>	O
37	(	O
38	10	O
39	mg	O
40	/	O
41	kg	O
42	),	O
43	and	O
44	<UNK>	O
45	<UNK>	O
46	(	O
47	<UNK>	O
48	;	O
49	0	O
50	.	O
51	5	O
52	mg	O
53	/	O
54	kg	O
55	<UNK>	O
56	was	O
57	also	O
58	determined	O
59	.	O
1	The	O
2	transcription	O
3	start	O
4	point	O
5	of	O
6	the	O
7	proximal	O
8	promoter	O
9	<UNK>	O
10	to	O
11	that	O
12	of	O
13	mouse	O
14	promoter	O
15	<UNK>	O
16	and	O
17	lies	O
18	within	O
19	a	O
20	conserved	O
21	region	O
22	of	O
23	sequence	O
24	.	O
1	<UNK>	O
2	AND	O
3	METHODS	O
4	:	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	imaging	O
9	was	O
10	used	O
11	to	O
12	study	O
13	the	O
14	<UNK>	O
15	,	O
16	middle	O
17	,	O
18	and	O
19	dorsal	O
20	portions	O
21	of	O
22	the	O
23	<UNK>	O
24	in	O
25	14	O
26	patients	O
27	with	O
28	an	O
29	<UNK>	O
30	normal	O
31	<UNK>	O
32	and	O
33	in	O
34	five	O
35	<UNK>	O
36	<UNK>	O
37	that	O
38	had	O
39	a	O
40	normal	O
41	<UNK>	O
42	proved	O
43	with	O
44	<UNK>	O
45	.	O
1	The	O
2	exon	O
3	-	O
4	intron	O
5	distribution	O
6	of	O
7	<UNK>	B
8	appears	O
9	<UNK>	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	the	O
15	<UNK>	B
16	gene	O
17	in	O
18	the	O
19	regions	O
20	encoding	O
21	the	O
22	conserved	O
23	domains	O
24	,	O
25	with	O
26	a	O
27	divergent	O
28	structure	O
29	in	O
30	the	O
31	other	O
32	parts	O
33	.	O
1	<UNK>	O
2	Raf	B
3	-	O
4	1	O
5	activates	O
6	p70	B
7	<UNK>	I
8	kinase	I
9	via	O
10	a	O
11	mitogen	B
12	-	O
13	activated	O
14	protein	O
15	kinase	B
16	-	O
17	independent	O
18	pathway	O
19	.	O
1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	<UNK>	B
7	-	O
8	2	O
9	gene	O
10	contains	O
11	a	O
12	CAAT	O
13	enhancer	O
14	-	O
15	binding	O
16	protein	O
17	consensus	O
18	site	O
19	(	O
20	CAAT	O
21	box	O
22	)	O
23	which	O
24	can	O
25	confer	O
26	hormone	O
27	inducibility	O
28	to	O
29	a	O
30	<UNK>	B
31	-	O
32	2	O
33	.	O
34	CAT	B
35	reporter	O
36	gene	O
37	,	O
38	as	O
39	well	O
40	as	O
41	a	O
42	putative	O
43	E	O
44	-	O
45	box	O
46	region	O
47	.	O
1	Clinical	O
2	evaluation	O
3	of	O
4	the	O
5	<UNK>	O
6	<UNK>	O
7	500	O
8	<UNK>	O
9	and	O
10	the	O
11	<UNK>	O
12	AR	O
13	-	O
14	<UNK>	O
15	<UNK>	O
16	.	O
1	These	O
2	changes	O
3	may	O
4	be	O
5	the	O
6	result	O
7	of	O
8	,	O
9	on	O
10	the	O
11	one	O
12	hand	O
13	,	O
14	an	O
15	increased	O
16	sensitivity	O
17	of	O
18	the	O
19	<UNK>	O
20	transmission	O
21	and	O
22	/	O
23	or	O
24	decreased	O
25	muscle	O
26	<UNK>	O
27	and	O
28	,	O
29	on	O
30	the	O
31	other	O
32	hand	O
33	,	O
34	the	O
35	result	O
36	of	O
37	a	O
38	reduced	O
39	plasma	O
40	clearance	O
41	during	O
42	<UNK>	O
43	.	O
1	YAC	O
2	and	O
3	cosmid	O
4	<UNK>	O
5	spanning	O
6	the	O
7	<UNK>	B
8	disease	O
9	(	O
10	<UNK>	B
11	)	O
12	region	O
13	at	O
14	<UNK>	O
15	.	O
16	1	O
17	-	O
18	<UNK>	O
19	.	O
20	2	O
21	.	O
1	The	O
2	introduction	O
3	of	O
4	<UNK>	B
5	to	O
6	the	O
7	cells	O
8	maintained	O
9	the	O
10	balance	O
11	between	O
12	cytosolic	O
13	and	O
14	membrane	O
15	-	O
16	associated	O
17	<UNK>	B
18	<UNK>	O
19	.	O
1	<UNK>	B
2	is	O
3	also	O
4	abundantly	O
5	expressed	O
6	in	O
7	the	O
8	pancreas	O
9	and	O
10	may	O
11	exert	O
12	differentiation	O
13	functions	O
14	in	O
15	<UNK>	O
16	<UNK>	O
17	,	O
18	similar	O
19	to	O
20	SF	O
21	-	O
22	1	O
23	in	O
24	<UNK>	O
25	tissues	O
26	.	O
1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	<UNK>	O
14	(	O
15	<UNK>	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	<UNK>	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	<UNK>	O
38	(	O
39	<UNK>	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	<UNK>	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O
1	Interestingly	O
2	,	O
3	however	O
4	,	O
5	it	O
6	is	O
7	homologous	O
8	to	O
9	several	O
10	expressed	O
11	sequence	O
12	<UNK>	O
13	(	O
14	<UNK>	O
15	)	O
16	of	O
17	unknown	O
18	function	O
19	from	O
20	Caenorhabditis	O
21	elegans	O
22	,	O
23	<UNK>	O
24	<UNK>	O
25	and	O
26	<UNK>	O
27	<UNK>	O
28	.	O
1	RESULTS	O
2	:	O
3	The	O
4	<UNK>	O
5	model	O
6	provided	O
7	a	O
8	significantly	O
9	better	O
10	<UNK>	O
11	to	O
12	the	O
13	<UNK>	O
14	outcome	O
15	data	O
16	.	O
1	The	O
2	mean	O
3	values	O
4	of	O
5	protease	O
6	activity	O
7	were	O
8	significantly	O
9	higher	O
10	in	O
11	the	O
12	test	O
13	groups	O
14	than	O
15	in	O
16	the	O
17	control	O
18	group	O
19	at	O
20	baseline	O
21	.	O
1	However	O
2	,	O
3	one	O
4	3	O
5	'	O
6	splice	O
7	site	O
8	,	O
9	located	O
10	at	O
11	nucleotide	O
12	(	O
13	nt	O
14	)	O
15	<UNK>	O
16	,	O
17	is	O
18	used	O
19	for	O
20	the	O
21	processing	O
22	of	O
23	most	O
24	<UNK>	O
25	-	O
26	1	O
27	pre	O
28	-	O
29	mRNAs	O
30	in	O
31	<UNK>	O
32	-	O
33	1	O
34	-	O
35	transformed	O
36	<UNK>	O
37	cells	O
38	and	O
39	at	O
40	early	O
41	to	O
42	intermediate	O
43	times	O
44	in	O
45	<UNK>	O
46	infected	O
47	<UNK>	O
48	.	O
1	A	O
2	<UNK>	O
3	<UNK>	O
4	of	O
5	members	O
6	of	O
7	the	O
8	T2	O
9	/	O
10	S	O
11	-	O
12	RNase	B
13	superfamily	O
14	in	O
15	plants	O
16	was	O
17	obtained	O
18	.	O
1	Although	O
2	the	O
3	<UNK>	B
4	-	O
5	1	O
6	mutation	O
7	<UNK>	O
8	a	O
9	conserved	O
10	residue	O
11	in	O
12	the	O
13	<UNK>	B
14	ubiquitin	I
15	-	O
16	like	O
17	domain	O
18	,	O
19	we	O
20	detect	O
21	no	O
22	differences	O
23	in	O
24	<UNK>	B
25	or	O
26	<UNK>	B
27	stability	O
28	.	O
1	Although	O
2	IL	B
3	-	O
4	2	O
5	and	O
6	IFN	B
7	-	O
8	alpha	O
9	activated	O
10	STAT1	B
11	alpha	O
12	and	O
13	<UNK>	B
14	,	O
15	IL	B
16	-	O
17	2	O
18	predominantly	O
19	activated	O
20	<UNK>	B
21	,	O
22	while	O
23	IFN	B
24	-	O
25	alpha	O
26	predominantly	O
27	activated	O
28	STAT1	B
29	alpha	O
30	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	compare	O
5	pregnancy	O
6	complications	O
7	in	O
8	women	O
9	having	O
10	genetic	O
11	<UNK>	O
12	at	O
13	11	O
14	-	O
15	14	O
16	weeks	O
17	versus	O
18	those	O
19	undergoing	O
20	<UNK>	O
21	at	O
22	16	O
23	-	O
24	19	O
25	weeks	O
26	'	O
27	gestation	O
28	.	O
1	<UNK>	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	<UNK>	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	<UNK>	O
17	cells	O
18	.	O
1	The	O
2	ability	O
3	of	O
4	<UNK>	O
5	to	O
6	block	O
7	NF	B
8	-	O
9	kappaB	B
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	O
15	C	O
16	-	O
17	terminal	O
18	zinc	O
19	finger	O
20	domain	O
21	.	O
1	The	O
2	Pro	O
3	-	O
4	<UNK>	O
5	-->	O
6	Leu	O
7	(	O
8	<UNK>	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	O
35	-	O
36	factor	O
37	.	O
1	The	O
2	mechanism	O
3	involves	O
4	<UNK>	B
5	subunit	O
6	-	O
7	mediated	O
8	increases	O
9	in	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	Shc	B
15	<UNK>	O
16	protein	O
17	,	O
18	Shc	B
19	*	O
20	Grb2	B
21	complex	O
22	formation	O
23	,	O
24	and	O
25	recruitment	O
26	of	O
27	Ras	B
28	guanine	O
29	nucleotide	O
30	exchange	O
31	factor	O
32	activity	O
33	.	O
1	<UNK>	O
2	estimates	O
3	indicate	O
4	that	O
5	27	O
6	,	O
7	<UNK>	O
8	<UNK>	O
9	are	O
10	either	O
11	in	O
12	<UNK>	O
13	of	O
14	or	O
15	in	O
16	need	O
17	of	O
18	mental	O
19	<UNK>	O
20	<UNK>	O
21	.	O
1	It	O
2	is	O
3	exclusively	O
4	observed	O
5	in	O
6	smooth	O
7	muscle	O
8	cells	O
9	by	O
10	Northern	O
11	blotting	O
12	and	O
13	<UNK>	O
14	analysis	O
15	and	O
16	therefore	O
17	designated	O
18	""""	O
19	<UNK>	B
20	<UNK>	O
21	A	O
22	human	O
23	smooth	O
24	muscle	O
25	cDNA	O
26	library	O
27	was	O
28	screened	O
29	with	O
30	the	O
31	monoclonal	O
32	antibody	O
33	<UNK>	B
34	,	O
35	and	O
36	a	O
37	full	O
38	-	O
39	size	O
40	cDNA	O
41	of	O
42	the	O
43	protein	O
44	was	O
45	selected	O
46	.	O
1	Our	O
2	studies	O
3	also	O
4	excluded	O
5	the	O
6	possibility	O
7	that	O
8	the	O
9	phosphorylation	O
10	of	O
11	Ser	O
12	-	O
13	2	O
14	,	O
15	Ser	O
16	-	O
17	<UNK>	O
18	,	O
19	or	O
20	Ser	O
21	-	O
22	<UNK>	O
23	,	O
24	had	O
25	roles	O
26	in	O
27	the	O
28	trans	O
29	-	O
30	suppression	O
31	activity	O
32	of	O
33	the	O
34	large	O
35	<UNK>	B
36	,	O
37	in	O
38	the	O
39	assembly	O
40	of	O
41	<UNK>	O
42	virus	O
43	-	O
44	like	O
45	<UNK>	B
46	particle	O
47	,	O
48	and	O
49	in	O
50	the	O
51	nuclear	O
52	transport	O
53	of	O
54	<UNK>	B
55	.	O
1	The	O
2	data	O
3	further	O
4	indicate	O
5	that	O
6	the	O
7	IL	B
8	-	O
9	<UNK>	B
10	alpha	O
11	chains	O
12	are	O
13	directly	O
14	involved	O
15	in	O
16	the	O
17	activation	O
18	of	O
19	<UNK>	B
20	and	O
21	<UNK>	B
22	and	O
23	have	O
24	a	O
25	major	O
26	role	O
27	in	O
28	<UNK>	O
29	signaling	O
30	in	O
31	precursor	O
32	B	O
33	cells	O
34	.	O
1	5	O
2	)	O
3	We	O
4	'	O
5	<UNK>	O
6	<UNK>	O
7	that	O
8	the	O
9	mean	O
10	value	O
11	of	O
12	the	O
13	cost	O
14	for	O
15	<UNK>	O
16	of	O
17	<UNK>	O
18	s	O
19	.	O
20	in	O
21	class	O
22	A	O
23	was	O
24	more	O
25	than	O
26	15	O
27	%	O
28	compared	O
29	to	O
30	class	O
31	B	O
32	and	O
33	the	O
34	cost	O
35	for	O
36	patient	O
37	in	O
38	class	O
39	A	O
40	was	O
41	nearly	O
42	double	O
43	than	O
44	in	O
45	class	O
46	B	O
47	.	O
1	<UNK>	O
2	evaluation	O
3	was	O
4	normal	O
5	,	O
6	and	O
7	<UNK>	O
8	failed	O
9	to	O
10	confirm	O
11	<UNK>	O
12	of	O
13	venous	O
14	or	O
15	<UNK>	O
16	<UNK>	O
17	.	O
1	METHODS	O
2	:	O
3	<UNK>	O
4	was	O
5	<UNK>	O
6	in	O
7	one	O
8	eye	O
9	<UNK>	O
10	at	O
11	random	O
12	and	O
13	<UNK>	O
14	in	O
15	the	O
16	<UNK>	O
17	eye	O
18	of	O
19	13	O
20	normal	O
21	subjects	O
22	and	O
23	in	O
24	13	O
25	patients	O
26	with	O
27	<UNK>	B
28	.	O
1	The	O
2	concentrations	O
3	of	O
4	vitamin	O
5	A	O
6	precursors	O
7	and	O
8	vitamin	O
9	E	O
10	in	O
11	the	O
12	<UNK>	O
13	were	O
14	below	O
15	currently	O
16	recommended	O
17	dietary	O
18	levels	O
19	for	O
20	<UNK>	O
21	,	O
22	and	O
23	<UNK>	O
24	<UNK>	O
25	appears	O
26	to	O
27	provide	O
28	an	O
29	<UNK>	O
30	source	O
31	of	O
32	<UNK>	O
33	A	O
34	and	O
35	E	O
36	in	O
37	this	O
38	species	O
39	.	O
1	Eight	O
2	cats	O
3	infected	O
4	with	O
5	H	O
6	.	O
7	pylori	O
8	were	O
9	used	O
10	in	O
11	the	O
12	study	O
13	.	O
1	Ten	O
2	weeks	O
3	after	O
4	<UNK>	O
5	,	O
6	the	O
7	<UNK>	O
8	nerves	O
9	already	O
10	<UNK>	O
11	normal	O
12	nerves	O
13	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	(	O
5	<UNK>	O
6	)	O
7	is	O
8	an	O
9	<UNK>	O
10	dominant	O
11	,	O
12	<UNK>	O
13	disorder	O
14	characterized	O
15	by	O
16	progressive	O
17	<UNK>	O
18	of	O
19	muscles	O
20	in	O
21	the	O
22	face	O
23	,	O
24	<UNK>	O
25	and	O
26	upper	O
27	arm	O
28	.	O
1	The	O
2	mature	O
3	chromosome	O
4	4	O
5	<UNK>	B
6	transcript	O
7	is	O
8	<UNK>	O
9	bp	O
10	in	O
11	length	O
12	and	O
13	contains	O
14	nine	O
15	exons	O
16	which	O
17	encode	O
18	a	O
19	putative	O
20	protein	O
21	of	O
22	<UNK>	O
23	amino	O
24	acid	O
25	residues	O
26	.	O
1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	<UNK>	O
7	<UNK>	O
8	between	O
9	<UNK>	O
10	<UNK>	O
11	was	O
12	investigated	O
13	,	O
14	and	O
15	it	O
16	was	O
17	found	O
18	that	O
19	the	O
20	more	O
21	<UNK>	O
22	<UNK>	O
23	carried	O
24	the	O
25	<UNK>	O
26	.	O
1	Protein	O
2	<UNK>	O
3	are	O
4	<UNK>	O
5	different	O
6	in	O
7	mechanical	O
8	profiles	O
9	from	O
10	those	O
11	<UNK>	O
12	made	O
13	of	O
14	other	O
15	materials	O
16	.	O
1	<UNK>	O
2	/	O
3	METHODS	O
4	:	O
5	<UNK>	O
6	system	O
7	function	O
8	,	O
9	as	O
10	assessed	O
11	by	O
12	clearance	O
13	of	O
14	<UNK>	O
15	bacteria	O
16	,	O
17	was	O
18	evaluated	O
19	in	O
20	acute	O
21	liver	O
22	injury	O
23	induced	O
24	by	O
25	D	O
26	-	O
27	<UNK>	O
28	in	O
29	rats	O
30	,	O
31	and	O
32	compared	O
33	with	O
34	that	O
35	after	O
36	70	O
37	%	O
38	liver	O
39	resection	O
40	model	O
41	.	O
1	The	O
2	<UNK>	O
3	binds	O
4	more	O
5	<UNK>	B
6	homodimers	O
7	and	O
8	less	O
9	<UNK>	B
10	-	O
11	RXR	B
12	heterodimers	O
13	than	O
14	the	O
15	<UNK>	O
16	,	O
17	and	O
18	T3	O
19	more	O
20	readily	O
21	<UNK>	O
22	heterodimer	O
23	binding	O
24	to	O
25	the	O
26	<UNK>	O
27	-	O
28	than	O
29	to	O
30	the	O
31	<UNK>	O
32	.	O
1	<UNK>	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	<UNK>	B
19	mRNA	O
20	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	was	O
7	highly	O
8	conserved	O
9	across	O
10	the	O
11	wide	O
12	range	O
13	of	O
14	<UNK>	O
15	(	O
16	<UNK>	O
17	,	O
18	<UNK>	O
19	,	O
20	<UNK>	O
21	,	O
22	plants	O
23	and	O
24	<UNK>	O
25	)	O
26	in	O
27	which	O
28	this	O
29	gene	O
30	has	O
31	now	O
32	been	O
33	identified	O
34	.	O
1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	the	O
7	<UNK>	O
8	amino	O
9	acid	O
10	,	O
11	70	O
12	-	O
13	kDa	O
14	subunit	O
15	of	O
16	<UNK>	B
17	(	O
18	<UNK>	B
19	70	O
20	)	O
21	is	O
22	composed	O
23	of	O
24	multiple	O
25	structural	O
26	/	O
27	functional	O
28	domains	O
29	.	O
1	It	O
2	is	O
3	the	O
4	oxidation	O
5	peak	O
6	of	O
7	this	O
8	product	O
9	,	O
10	<UNK>	O
11	in	O
12	acidic	O
13	media	O
14	at	O
15	0	O
16	.	O
17	42	O
18	V	O
19	,	O
20	which	O
21	was	O
22	analysed	O
23	using	O
24	<UNK>	O
25	,	O
26	again	O
27	following	O
28	the	O
29	accumulation	O
30	of	O
31	<UNK>	O
32	at	O
33	the	O
34	<UNK>	O
35	-	O
36	modified	O
37	<UNK>	O
38	.	O
1	In	O
2	an	O
3	<UNK>	O
4	to	O
5	isolate	O
6	genes	O
7	with	O
8	down	O
9	-	O
10	regulated	O
11	expression	O
12	at	O
13	the	O
14	mRNA	O
15	level	O
16	during	O
17	oncogenic	O
18	transformation	O
19	of	O
20	human	O
21	mammary	O
22	epithelial	O
23	cells	O
24	(	O
25	<UNK>	O
26	),	O
27	we	O
28	performed	O
29	<UNK>	O
30	hybridization	O
31	between	O
32	normal	O
33	<UNK>	O
34	strain	O
35	<UNK>	O
36	and	O
37	its	O
38	radiation	O
39	-	O
40	transformed	O
41	<UNK>	O
42	derivative	O
43	<UNK>	O
44	-	O
45	30	O
46	.	O
1	The	O
2	P	O
3	-	O
4	<UNK>	B
5	and	O
6	P	O
7	-	O
8	<UNK>	B
9	cDNA	O
10	sequences	O
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O
1	We	O
2	have	O
3	previously	O
4	isolated	O
5	a	O
6	cDNA	O
7	for	O
8	a	O
9	transcription	O
10	factor	O
11	referred	O
12	to	O
13	as	O
14	<UNK>	B
15	(	O
16	zinc	O
17	finger	O
18	homeodomain	B
19	enhancer	O
20	-	O
21	binding	O
22	protein	O
23	)	O
24	containing	O
25	two	O
26	separate	O
27	zinc	O
28	finger	O
29	domains	O
30	,	O
31	<UNK>	B
32	and	O
33	<UNK>	B
34	,	O
35	each	O
36	of	O
37	which	O
38	binds	O
39	DNA	O
40	,	O
41	and	O
42	a	O
43	homeodomain	B
44	.	O
1	<UNK>	O
2	to	O
3	their	O
4	secretion	O
5	,	O
6	the	O
7	IGF	B
8	-	O
9	II	O
10	in	O
11	<UNK>	O
12	and	O
13	<UNK>	O
14	cells	O
15	<UNK>	O
16	in	O
17	the	O
18	<UNK>	O
19	medium	O
20	<UNK>	O
21	as	O
22	two	O
23	partially	O
24	processed	O
25	species	O
26	with	O
27	<UNK>	O
28	,	O
29	of	O
30	<UNK>	O
31	and	O
32	<UNK>	O
33	,	O
34	respectively	O
35	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	of	O
5	the	O
6	transcriptionally	O
7	inactive	O
8	,	O
9	amino	O
10	-	O
11	terminally	O
12	deleted	O
13	<UNK>	B
14	-	O
15	1	O
16	mutant	O
17	proteins	O
18	,	O
19	either	O
20	with	O
21	the	O
22	wild	O
23	-	O
24	type	O
25	<UNK>	B
26	-	O
27	1	O
28	or	O
29	with	O
30	<UNK>	O
31	,	O
32	results	O
33	in	O
34	a	O
35	marked	O
36	enhancement	O
37	of	O
38	transactivation	O
39	of	O
40	the	O
41	transcriptional	O
42	<UNK>	B
43	-	O
44	1	O
45	element	O
46	reporter	O
47	.	O
1	<UNK>	O
2	methods	O
3	have	O
4	been	O
5	developed	O
6	for	O
7	maintaining	O
8	and	O
9	<UNK>	O
10	the	O
11	<UNK>	O
12	short	O
13	-	O
14	<UNK>	O
15	<UNK>	O
16	<UNK>	O
17	,	O
18	<UNK>	O
19	<UNK>	O
20	,	O
21	in	O
22	an	O
23	easily	O
24	-	O
25	<UNK>	O
26	,	O
27	laboratory	O
28	<UNK>	O
29	.	O
1	Using	O
2	<UNK>	O
3	in	O
4	situ	O
5	hybridization	O
6	,	O
7	we	O
8	mapped	O
9	the	O
10	chromosome	O
11	-	O
12	17	O
13	breakpoint	O
14	in	O
15	a	O
16	patient	O
17	with	O
18	<UNK>	O
19	<UNK>	O
20	and	O
21	sex	O
22	reversal	O
23	,	O
24	who	O
25	<UNK>	O
26	a	O
27	de	O
28	<UNK>	O
29	<UNK>	O
30	t	O
31	(	O
32	12	O
33	;	O
34	17	O
35	)	O
36	translocation	O
37	,	O
38	between	O
39	two	O
40	known	O
41	cosmid	O
42	markers	O
43	in	O
44	the	O
45	<UNK>	O
46	-	O
47	<UNK>	O
48	region	O
49	.	O
1	Control	O
2	intact	O
3	rats	O
4	were	O
5	age	O
6	-	O
7	matched	O
8	to	O
9	the	O
10	different	O
11	treated	O
12	groups	O
13	.	O
1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	<UNK>	O
7	study	O
8	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	<UNK>	O
7	structural	O
8	homology	O
9	,	O
10	<UNK>	B
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	O
20	fos	B
21	gene	O
22	family	O
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O
1	Plasma	O
2	<UNK>	B
3	:	O
4	a	O
5	marker	O
6	for	O
7	<UNK>	O
8	complications	O
9	in	O
10	diabetes	O
11	mellitus	O
12	.	O
1	The	O
2	characterization	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	indicated	O
8	that	O
9	three	O
10	distinct	O
11	regulatory	O
12	elements	O
13	corresponding	O
14	to	O
15	an	O
16	AP	B
17	-	O
18	1	O
19	binding	O
20	site	O
21	(	O
22	or	O
23	TRE	O
24	),	O
25	a	O
26	<UNK>	O
27	/	O
28	kappaB	B
29	domain	O
30	,	O
31	and	O
32	a	O
33	CAAT	O
34	box	O
35	are	O
36	involved	O
37	in	O
38	the	O
39	activation	O
40	by	O
41	<UNK>	B
42	(	O
43	v	O
44	<UNK>	O
45	src	B
46	.	O
1	Cys	O
2	-	O
3	<UNK>	O
4	within	O
5	the	O
6	(	O
7	<UNK>	O
8	)-	O
9	<UNK>	O
10	-	O
11	binding	O
12	domain	O
13	was	O
14	essential	O
15	for	O
16	native	O
17	enzyme	O
18	activity	O
19	.	O
1	<UNK>	O
2	,	O
3	our	O
4	results	O
5	indicate	O
6	that	O
7	the	O
8	transcriptional	O
9	activity	O
10	of	O
11	<UNK>	O
12	proteins	O
13	is	O
14	modulated	O
15	by	O
16	PKC	B
17	.	O
1	<UNK>	O
2	for	O
3	both	O
4	<UNK>	B
5	-	O
6	<UNK>	B
7	and	O
8	<UNK>	B
9	-	O
10	<UNK>	B
11	<UNK>	O
12	from	O
13	conserved	O
14	<UNK>	O
15	motifs	O
16	,	O
17	and	O
18	transcripts	O
19	are	O
20	detected	O
21	from	O
22	16	O
23	through	O
24	72	O
25	hr	O
26	p	O
27	.	O
28	i	O
29	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	isolated	O
6	genomic	O
7	clone	O
8	revealed	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	of	O
15	this	O
16	orphan	O
17	receptor	O
18	is	O
19	most	O
20	homologous	O
21	to	O
22	the	O
23	human	O
24	<UNK>	B
25	receptor	O
26	.	O
1	A	O
2	3	O
3	-	O
4	<UNK>	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	<UNK>	O
11	94	O
12	%	O
13	of	O
14	the	O
15	<UNK>	O
16	.	O
1	<UNK>	B
2	mRNA	O
3	has	O
4	a	O
5	3	O
6	'	O
7	UTR	O
8	antisense	O
9	to	O
10	<UNK>	O
11	<UNK>	O
12	RNA	O
13	and	O
14	is	O
15	localized	O
16	in	O
17	<UNK>	O
18	<UNK>	O
19	and	O
20	embryos	O
21	.	O
1	Two	O
2	closely	O
3	related	O
4	variants	O
5	of	O
6	<UNK>	B
7	,	O
8	<UNK>	B
9	and	O
10	<UNK>	B
11	,	O
12	are	O
13	encoded	O
14	by	O
15	distinct	O
16	genes	O
17	.	O
1	The	O
2	serine	O
3	/	O
4	threonine	O
5	kinase	B
6	Raf	I
7	-	O
8	1	O
9	functions	O
10	downstream	O
11	of	O
12	<UNK>	O
13	in	O
14	a	O
15	signal	O
16	transduction	O
17	cascade	O
18	which	O
19	<UNK>	O
20	mitogenic	O
21	stimuli	O
22	from	O
23	the	O
24	plasma	O
25	membrane	O
26	to	O
27	the	O
28	nucleus	O
29	.	O
1	The	O
2	retinoid	O
3	Z	O
4	receptor	O
5	beta	O
6	(	O
7	<UNK>	B
8	beta	O
9	),	O
10	an	O
11	orphan	O
12	receptor	O
13	,	O
14	is	O
15	a	O
16	member	O
17	of	O
18	the	O
19	retinoic	O
20	acid	O
21	receptor	O
22	(	O
23	RAR	B
24	)/	O
25	thyroid	O
26	hormone	O
27	receptor	O
28	(	O
29	TR	B
30	)	O
31	subfamily	O
32	of	O
33	nuclear	O
34	receptors	O
35	.	O
1	<UNK>	O
2	complete	O
3	sequence	O
4	identity	O
5	was	O
6	found	O
7	between	O
8	the	O
9	3	O
10	'	O
11	end	O
12	of	O
13	the	O
14	<UNK>	B
15	gene	O
16	and	O
17	two	O
18	expressed	O
19	sequence	O
20	<UNK>	O
21	(	O
22	<UNK>	O
23	)	O
24	and	O
25	between	O
26	the	O
27	5	O
28	'	O
29	end	O
30	of	O
31	the	O
32	<UNK>	B
33	gene	O
34	and	O
35	a	O
36	third	O
37	<UNK>	O
38	.	O
1	The	O
2	fragments	O
3	are	O
4	separated	O
5	and	O
6	directly	O
7	<UNK>	O
8	by	O
9	<UNK>	O
10	gel	O
11	electrophoresis	O
12	.	O
1	Several	O
2	of	O
3	the	O
4	exon	O
5	boundaries	O
6	<UNK>	O
7	to	O
8	the	O
9	boundaries	O
10	of	O
11	functional	O
12	domains	O
13	in	O
14	the	O
15	<UNK>	B
16	protein	O
17	.	O
1	The	O
2	<UNK>	O
3	expression	O
4	of	O
5	the	O
6	folate	O
7	sensitive	O
8	<UNK>	O
9	site	O
10	,	O
11	<UNK>	B
12	,	O
13	is	O
14	due	O
15	to	O
16	the	O
17	<UNK>	O
18	of	O
19	a	O
20	<UNK>	O
21	repeat	O
22	in	O
23	proximal	O
24	<UNK>	O
25	of	O
26	the	O
27	human	O
28	X	O
29	chromosome	O
30	and	O
31	is	O
32	associated	O
33	with	O
34	a	O
35	mild	O
36	form	O
37	of	O
38	mental	O
39	<UNK>	O
40	.	O
1	DNA	O
2	sequence	O
3	analysis	O
4	of	O
5	a	O
6	<UNK>	O
7	bp	O
8	BamHI	B
9	-	O
10	<UNK>	B
11	fragment	O
12	revealed	O
13	that	O
14	three	O
15	open	O
16	reading	O
17	frames	O
18	(	O
19	ORFs	O
20	)	O
21	were	O
22	encoded	O
23	in	O
24	the	O
25	same	O
26	orientation	O
27	.	O
1	Analysis	O
2	of	O
3	human	O
4	genomic	O
5	DNA	O
6	reveals	O
7	an	O
8	<UNK>	O
9	sequence	O
10	with	O
11	strong	O
12	homology	O
13	to	O
14	human	O
15	G	O
16	alpha	O
17	q	O
18	cDNA	O
19	.	O
1	The	O
2	use	O
3	of	O
4	primary	O
5	<UNK>	O
6	cells	O
7	thus	O
8	provides	O
9	a	O
10	<UNK>	O
11	in	O
12	vitro	O
13	system	O
14	for	O
15	further	O
16	study	O
17	of	O
18	the	O
19	<UNK>	O
20	,	O
21	<UNK>	O
22	,	O
23	and	O
24	<UNK>	O
25	factors	O
26	regulating	O
27	endometrial	O
28	gene	O
29	expression	O
30	during	O
31	pregnancy	O
32	.	O
1	Both	O
2	<UNK>	O
3	and	O
4	propranolol	O
5	can	O
6	exhibit	O
7	<UNK>	O
8	effects	O
9	with	O
10	adenosine	O
11	in	O
12	<UNK>	O
13	<UNK>	O
14	nodal	O
15	<UNK>	O
16	time	O
17	;	O
18	however	O
19	,	O
20	only	O
21	<UNK>	O
22	can	O
23	reduce	O
24	the	O
25	dose	O
26	of	O
27	adenosine	O
28	required	O
29	to	O
30	produce	O
31	<UNK>	O
32	nodal	O
33	block	O
34	.	O
1	<UNK>	B
2	'	O
3	loss	O
4	of	O
5	function	O
6	'	O
7	studies	O
8	by	O
9	constitutive	O
10	over	O
11	-	O
12	expression	O
13	of	O
14	a	O
15	dominant	O
16	negative	O
17	<UNK>	B
18	delta	O
19	E	O
20	resulted	O
21	in	O
22	increased	O
23	levels	O
24	of	O
25	<UNK>	B
26	/	O
27	<UNK>	B
28	and	O
29	<UNK>	B
30	mRNAs	O
31	after	O
32	serum	O
33	withdrawal	O
34	.	O
1	Neither	O
2	<UNK>	B
3	nor	O
4	<UNK>	B
5	is	O
6	essential	O
7	for	O
8	cell	O
9	growth	O
10	,	O
11	and	O
12	a	O
13	double	O
14	deletion	O
15	mutant	O
16	is	O
17	viable	O
18	.	O
1	A	O
2	stable	O
3	heterologous	O
4	cell	O
5	line	O
6	containing	O
7	the	O
8	mouse	O
9	<UNK>	B
10	receptor	O
11	was	O
12	constructed	O
13	by	O
14	transfection	O
15	of	O
16	<UNK>	O
17	293	O
18	cells	O
19	,	O
20	which	O
21	lack	O
22	L	O
23	channel	O
24	activity	O
25	.	O
1	<UNK>	O
2	phosphorylation	O
3	of	O
4	the	O
5	<UNK>	B
6	protein	O
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O
1	We	O
2	report	O
3	here	O
4	the	O
5	<UNK>	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	O
11	related	O
12	gene	O
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	<UNK>	B
22	.	O
1	<UNK>	O
2	:	O
3	<UNK>	O
4	the	O
5	small	O
6	size	O
7	of	O
8	this	O
9	study	O
10	and	O
11	the	O
12	<UNK>	O
13	of	O
14	results	O
15	among	O
16	the	O
17	few	O
18	prospective	O
19	studies	O
20	of	O
21	ovarian	O
22	cancer	O
23	conducted	O
24	to	O
25	test	O
26	these	O
27	<UNK>	O
28	,	O
29	<UNK>	O
30	of	O
31	these	O
32	findings	O
33	are	O
34	highly	O
35	<UNK>	O
36	.	O
1	Previous	O
2	work	O
3	showed	O
4	that	O
5	<UNK>	B
6	(	O
7	initiator	O
8	protein	O
9	)	O
10	expression	O
11	requires	O
12	<UNK>	O
13	(	O
14	leader	O
15	peptide	O
16	)	O
17	translation	O
18	.	O
1	A	O
2	system	O
3	is	O
4	described	O
5	in	O
6	which	O
7	the	O
8	volume	O
9	flow	O
10	rate	O
11	of	O
12	blood	O
13	in	O
14	a	O
15	<UNK>	O
16	is	O
17	determined	O
18	using	O
19	<UNK>	O
20	<UNK>	O
21	Doppler	O
22	ultrasound	O
23	imaging	O
24	.	O
1	In	O
2	<UNK>	O
3	mice	O
4	,	O
5	the	O
6	fat	O
7	/	O
8	water	O
9	intensity	O
10	ratio	O
11	was	O
12	about	O
13	1	O
14	:	O
15	4	O
16	,	O
17	about	O
18	half	O
19	that	O
20	in	O
21	normal	O
22	mice	O
23	.	O
1	This	O
2	GAP	B
3	activity	O
4	was	O
5	observed	O
6	in	O
7	3T3	O
8	-	O
9	L1	O
10	<UNK>	O
11	<UNK>	O
12	,	O
13	and	O
14	was	O
15	able	O
16	to	O
17	<UNK>	O
18	the	O
19	hydrolysis	O
20	of	O
21	the	O
22	[	O
23	alpha	O
24	-	O
25	32P	O
26	]	O
27	GTP	O
28	bound	O
29	to	O
30	GST	B
31	-	O
32	<UNK>	B
33	into	O
34	[	O
35	alpha	O
36	-	O
37	32P	O
38	]	O
39	GDP	O
40	.	O
1	The	O
2	<UNK>	O
3	RNA	O
4	polymerases	B
5	containing	O
6	the	O
7	mutant	O
8	alpha	O
9	subunits	O
10	were	O
11	examined	O
12	for	O
13	their	O
14	response	O
15	to	O
16	transcription	O
17	activation	O
18	by	O
19	cAMP	O
20	-	O
21	CRP	B
22	and	O
23	the	O
24	<UNK>	B
25	<UNK>	O
26	element	O
27	.	O
1	Consistent	O
2	with	O
3	this	O
4	similarity	O
5	,	O
6	the	O
7	<UNK>	B
8	-	O
9	<UNK>	O
10	mutant	O
11	<UNK>	O
12	<UNK>	O
13	precursors	O
14	at	O
15	the	O
16	<UNK>	O
17	temperature	O
18	.	O
1	The	O
2	<UNK>	O
3	achieved	O
4	by	O
5	<UNK>	O
6	given	O
7	s	O
8	.	O
9	c	B
10	.	O
11	were	O
12	higher	O
13	than	O
14	those	O
15	achieved	O
16	after	O
17	i	O
18	.	O
19	p	O
20	.	O
21	administration	O
22	and	O
23	<UNK>	O
24	for	O
25	longer	O
26	periods	O
27	.	O
1	<UNK>	O
2	human	O
3	viruses	O
4	are	O
5	able	O
6	to	O
7	develop	O
8	suitable	O
9	<UNK>	O
10	for	O
11	<UNK>	O
12	apoptosis	O
13	in	O
14	virus	O
15	-	O
16	infected	O
17	cells	O
18	and	O
19	in	O
20	virus	O
21	-	O
22	<UNK>	O
23	T	O
24	cells	O
25	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	observed	O
7	clinical	O
8	phenomena	O
9	in	O
10	response	O
11	to	O
12	morphine	O
13	can	O
14	be	O
15	<UNK>	O
16	by	O
17	differences	O
18	in	O
19	expression	O
20	and	O
21	sensitivity	O
22	of	O
23	some	O
24	opioid	O
25	receptor	O
26	<UNK>	O
27	in	O
28	<UNK>	O
29	.	O
1	B	O
2	cell	O
3	antigen	O
4	receptor	O
5	(	O
6	BCR	B
7	)-	O
8	induced	O
9	apoptosis	O
10	in	O
11	the	O
12	<UNK>	O
13	-	O
14	<UNK>	O
15	B	O
16	lymphoma	O
17	cell	O
18	line	O
19	can	O
20	be	O
21	prevented	O
22	by	O
23	<UNK>	O
24	<UNK>	B
25	.	O
1	The	O
2	model	O
3	also	O
4	<UNK>	O
5	that	O
6	blood	O
7	flow	O
8	<UNK>	O
9	fraction	O
10	(	O
11	<UNK>	O
12	/	O
13	<UNK>	O
14	)	O
15	is	O
16	directly	O
17	related	O
18	to	O
19	the	O
20	oxygen	O
21	<UNK>	O
22	-	O
23	wave	O
24	amplitude	O
25	<UNK>	O
26	transmitted	O
27	to	O
28	end	O
29	-	O
30	<UNK>	O
31	air	O
32	and	O
33	arterial	O
34	and	O
35	mixed	O
36	-	O
37	venous	O
38	blood	O
39	through	O
40	two	O
41	simple	O
42	<UNK>	O
43	.	O
1	<UNK>	O
2	between	O
3	HIV	O
4	-	O
5	1	O
6	and	O
7	HIV	O
8	-	O
9	2	O
10	showed	O
11	evidence	O
12	for	O
13	the	O
14	presence	O
15	of	O
16	HIV	O
17	-	O
18	1	O
19	only	O
20	.	O
1	The	O
2	mammalian	O
3	homeodomain	B
4	proteins	O
5	encoded	O
6	by	O
7	<UNK>	B
8	genes	O
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	embryonic	O
15	development	O
16	by	O
17	<UNK>	O
18	<UNK>	O
19	<UNK>	O
20	which	O
21	define	O
22	developmental	O
23	<UNK>	O
24	along	O
25	the	O
26	<UNK>	O
27	<UNK>	O
28	of	O
29	developing	O
30	organisms	O
31	.	O
1	As	O
2	<UNK>	O
3	examined	O
4	with	O
5	the	O
6	<UNK>	B
7	promoter	O
8	,	O
9	presence	O
10	of	O
11	one	O
12	or	O
13	multiple	O
14	copies	O
15	of	O
16	<UNK>	O
17	in	O
18	the	O
19	vectors	O
20	elevated	O
21	the	O
22	expression	O
23	activity	O
24	in	O
25	<UNK>	O
26	by	O
27	4	O
28	.	O
29	5	O
30	-	O
31	to	O
32	19	O
33	-	O
34	fold	O
35	over	O
36	those	O
37	without	O
38	<UNK>	O
39	,	O
40	but	O
41	not	O
42	significantly	O
43	in	O
44	<UNK>	O
45	.	O
1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	<UNK>	O
11	of	O
12	the	O
13	5	O
14	'	O
15	<UNK>	B
16	sequences	O
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	<UNK>	O
25	to	O
26	-	O
27	<UNK>	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O
1	In	O
2	addition	O
3	,	O
4	<UNK>	O
5	<UNK>	B
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	O
12	<UNK>	B
13	in	O
14	both	O
15	the	O
16	kinase	B
17	-	O
18	like	O
19	(	O
20	<UNK>	B
21	)	O
22	and	O
23	kinase	B
24	(	O
25	<UNK>	B
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O
1	<UNK>	O
2	alone	O
3	resulted	O
4	in	O
5	elevated	O
6	bone	O
7	turnover	O
8	.	O
1	<UNK>	O
2	.	O
1	<UNK>	O
2	<UNK>	O
3	protein	O
4	has	O
5	been	O
6	purified	O
7	from	O
8	a	O
9	<UNK>	O
10	cell	O
11	line	O
12	and	O
13	shown	O
14	to	O
15	be	O
16	a	O
17	65	O
18	kD	O
19	<UNK>	O
20	-	O
21	linked	O
22	<UNK>	O
23	glycoprotein	O
24	<UNK>	O
25	of	O
26	30	O
27	kD	O
28	subunits	O
29	,	O
30	each	O
31	containing	O
32	12	O
33	kD	O
34	of	O
35	N	O
36	-	O
37	and	O
38	O	O
39	-	O
40	linked	O
41	<UNK>	O
42	.	O
1	<UNK>	O
2	factors	O
3	induce	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	immediate	O
9	early	O
10	gene	O
11	products	O
12	MAP	B
13	kinase	I
14	phosphatase	I
15	-	O
16	1	O
17	(	O
18	<UNK>	B
19	-	O
20	1	O
21	),	O
22	c	B
23	-	O
24	Fos	B
25	and	O
26	c	B
27	-	O
28	Jun	B
29	.	O
1	The	O
2	evidence	O
3	in	O
4	support	O
5	of	O
6	this	O
7	was	O
8	derived	O
9	from	O
10	the	O
11	fact	O
12	that	O
13	the	O
14	affinity	O
15	or	O
16	interaction	O
17	between	O
18	the	O
19	two	O
20	subunits	O
21	was	O
22	impaired	O
23	as	O
24	indicated	O
25	by	O
26	the	O
27	first	O
28	order	O
29	rate	O
30	constant	O
31	of	O
32	hCG	B
33	alpha	O
34	1	O
35	beta	O
36	(	O
37	<UNK>	O
38	=	O
39	4	O
40	.	O
41	1	O
42	x	O
43	10	O
44	(-	O
45	2	O
46	)	O
47	min	O
48	-	O
49	1	O
50	)	O
51	at	O
52	pH	O
53	3	O
54	.	O
55	0	O
56	at	O
57	23	O
58	degrees	O
59	C	O
60	which	O
61	is	O
62	one	O
63	order	O
64	of	O
65	magnitude	O
66	greater	O
67	relative	O
68	to	O
69	<UNK>	B
70	(	O
71	<UNK>	O
72	=	O
73	4	O
74	.	O
75	6	O
76	x	O
77	10	O
78	(-	O
79	3	O
80	)	O
81	min	O
82	-	O
83	1	O
84	).	O
1	However	O
2	,	O
3	the	O
4	truncated	O
5	<UNK>	O
6	receptor	O
7	lacks	O
8	the	O
9	most	O
10	C	O
11	-	O
12	terminal	O
13	tyrosine	O
14	residue	O
15	in	O
16	the	O
17	intracellular	O
18	domain	O
19	which	O
20	is	O
21	believed	O
22	to	O
23	be	O
24	essential	O
25	for	O
26	activation	O
27	of	O
28	the	O
29	beta	O
30	-	O
31	casein	B
32	promoter	O
33	.	O
1	<UNK>	O
2	has	O
3	substantial	O
4	efficacy	O
5	when	O
6	combined	O
7	with	O
8	other	O
9	agents	O
10	.	O
1	This	O
2	enzyme	O
3	is	O
4	designated	O
5	(	O
6	1	O
7	-->	O
8	4	O
9	)-	O
10	beta	O
11	-	O
12	<UNK>	O
13	<UNK>	B
14	<UNK>	O
15	X	O
16	-	O
17	I	O
18	.	O
1	To	O
2	analyze	O
3	the	O
4	mechanism	O
5	of	O
6	fos	B
7	/	O
8	jun	B
9	activation	O
10	by	O
11	<UNK>	O
12	we	O
13	have	O
14	used	O
15	electrophoretic	O
16	mobility	O
17	shift	O
18	and	O
19	transient	O
20	expression	O
21	assays	O
22	of	O
23	reporter	O
24	gene	O
25	constructs	O
26	containing	O
27	response	O
28	elements	O
29	for	O
30	12	O
31	-	O
32	O	O
33	-	O
34	<UNK>	O
35	-	O
36	phorbol	O
37	-	O
38	13	O
39	-	O
40	acetate	O
41	(	O
42	TRE	O
43	),	O
44	serum	O
45	(	O
46	SRE	O
47	),	O
48	cAMP	O
49	(	O
50	CRE	O
51	),	O
52	and	O
53	<UNK>	O
54	<UNK>	O
55	(	O
56	<UNK>	O
57	)	O
58	from	O
59	the	O
60	fos	B
61	and	O
62	jun	B
63	genes	O
64	fused	O
65	to	O
66	the	O
67	<UNK>	B
68	luciferase	I
69	gene	O
70	under	O
71	the	O
72	control	O
73	of	O
74	the	O
75	SV40	O
76	minimal	O
77	promoter	O
78	.	O
1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	the	O
7	<UNK>	O
8	repeat	O
9	regions	O
10	of	O
11	<UNK>	B
12	and	O
13	<UNK>	B
14	indicated	O
15	that	O
16	<UNK>	B
17	was	O
18	probably	O
19	interacting	O
20	with	O
21	the	O
22	<UNK>	O
23	-	O
24	containing	O
25	core	O
26	of	O
27	these	O
28	repeats	O
29	and	O
30	not	O
31	the	O
32	<UNK>	O
33	<UNK>	O
34	<UNK>	O
35	.	O
1	A	O
2	given	O
3	standard	O
4	input	O
5	function	O
6	and	O
7	a	O
8	given	O
9	value	O
10	of	O
11	distribution	O
12	volume	O
13	(	O
14	<UNK>	O
15	)	O
16	used	O
17	for	O
18	the	O
19	rCBF	O
20	measurement	O
21	of	O
22	this	O
23	method	O
24	were	O
25	calculated	O
26	from	O
27	the	O
28	dynamic	O
29	study	O
30	by	O
31	six	O
32	normal	O
33	volunteers	O
34	.	O
1	It	O
2	can	O
3	be	O
4	concluded	O
5	that	O
6	in	O
7	<UNK>	O
8	subjects	O
9	,	O
10	<UNK>	O
11	acid	O
12	and	O
13	<UNK>	B
14	oxidase	I
15	have	O
16	significant	O
17	association	O
18	with	O
19	blood	O
20	pressure	O
21	and	O
22	thus	O
23	are	O
24	one	O
25	of	O
26	the	O
27	many	O
28	factors	O
29	which	O
30	are	O
31	involved	O
32	in	O
33	the	O
34	cause	O
35	or	O
36	effect	O
37	of	O
38	hypertension	O
39	.	O
1	We	O
2	<UNK>	O
3	that	O
4	the	O
5	dominant	O
6	negative	O
7	inhibition	O
8	results	O
9	from	O
10	both	O
11	direct	O
12	proteolysis	O
13	of	O
14	the	O
15	beta	O
16	-	O
17	galactosidase	B
18	<UNK>	O
19	by	O
20	the	O
21	fusion	O
22	subunit	O
23	and	O
24	<UNK>	O
25	of	O
26	the	O
27	<UNK>	O
28	to	O
29	the	O
30	<UNK>	O
31	.	O
1	Several	O
2	agents	O
3	have	O
4	been	O
5	<UNK>	O
6	for	O
7	treatment	O
8	,	O
9	often	O
10	limited	O
11	by	O
12	toxic	O
13	side	O
14	effects	O
15	.	O
1	<UNK>	B
2	gamma	O
3	mRNA	O
4	levels	O
5	were	O
6	reduced	O
7	by	O
8	95	O
9	%	O
10	with	O
11	3	O
12	nM	O
13	TNF	B
14	alpha	O
15	treatment	O
16	for	O
17	24	O
18	h	O
19	.	O
1	Recombinant	O
2	erythropoietin	B
3	(	O
4	r	O
5	-	O
6	<UNK>	B
7	)	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	<UNK>	O
13	in	O
14	multiple	O
15	<UNK>	O
1	<UNK>	O
2	data	O
3	are	O
4	<UNK>	O
5	<UNK>	O
6	but	O
7	<UNK>	O
8	death	O
9	occurring	O
10	during	O
11	<UNK>	O
12	activity	O
13	is	O
14	probably	O
15	not	O
16	a	O
17	rare	O
18	occurrence	O
19	.	O
1	Moreover	O
2	,	O
3	the	O
4	same	O
5	mutations	O
6	alter	O
7	the	O
8	structure	O
9	of	O
10	<UNK>	B
11	5	O
12	'	O
13	flanking	O
14	DNA	O
15	within	O
16	chromatin	O
17	.	O
1	RESULTS	O
2	:	O
3	The	O
4	age	O
5	distribution	O
6	was	O
7	28	O
8	to	O
9	83	O
10	years	O
11	old	O
12	(	O
13	mean	O
14	was	O
15	54	O
16	.	O
17	1	O
18	years	O
19	).	O
1	In	O
2	<UNK>	O
3	and	O
4	<UNK>	O
5	v	O
6	-	O
7	<UNK>	B
8	-	O
9	transformed	O
10	fibroblasts	O
11	,	O
12	almost	O
13	all	O
14	of	O
15	the	O
16	total	O
17	<UNK>	B
18	and	O
19	about	O
20	40	O
21	%	O
22	of	O
23	total	O
24	p130	B
25	(	O
26	<UNK>	B
27	)	O
28	co	O
29	-	O
30	<UNK>	O
31	with	O
32	membranes	O
33	composed	O
34	primarily	O
35	of	O
36	endoplasmic	O
37	reticulum	O
38	.	O
1	<UNK>	O
2	residues	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	on	O
7	<UNK>	O
8	with	O
9	the	O
10	conserved	O
11	AF	O
12	-	O
13	2	O
14	domain	O
15	from	O
16	the	O
17	vitamin	O
18	D3	O
19	receptor	O
20	or	O
21	the	O
22	estrogen	O
23	receptor	O
24	results	O
25	in	O
26	a	O
27	receptor	O
28	with	O
29	wild	O
30	-	O
31	type	O
32	or	O
33	low	O
34	transcriptional	O
35	activity	O
36	,	O
37	respectively	O
38	.	O
1	<UNK>	O
2	,	O
3	as	O
4	<UNK>	O
5	<UNK>	O
6	,	O
7	<UNK>	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O
1	The	O
2	0	O
3	.	O
4	22	O
5	-	O
6	kb	O
7	<UNK>	B
8	/	O
9	<UNK>	B
10	promoter	O
11	exhibited	O
12	PMA	O
13	inducibility	O
14	in	O
15	myeloid	O
16	cells	O
17	and	O
18	contained	O
19	a	O
20	PMA	O
21	-	O
22	responsive	O
23	element	O
24	recognized	O
25	by	O
26	Sp1	B
27	and	O
28	<UNK>	B
29	-	O
30	1	O
31	transcription	O
32	factors	O
33	.	O
1	<UNK>	O
2	to	O
3	the	O
4	<UNK>	O
5	was	O
6	<UNK>	O
7	by	O
8	<UNK>	O
9	of	O
10	<UNK>	O
11	<UNK>	O
12	(	O
13	<UNK>	O
14	)	O
15	dye	O
16	,	O
17	which	O
18	was	O
19	administered	O
20	either	O
21	2	O
22	,	O
23	3	O
24	,	O
25	24	O
26	or	O
27	48	O
28	h	O
29	after	O
30	onset	O
31	of	O
32	<UNK>	O
33	.	O
1	When	O
2	the	O
3	degree	O
4	of	O
5	exercise	O
6	was	O
7	maximal	O
8	,	O
9	<UNK>	O
10	was	O
11	maintained	O
12	,	O
13	<UNK>	O
14	decreased	O
15	,	O
16	HR	O
17	was	O
18	unchanged	O
19	,	O
20	and	O
21	<UNK>	O
22	and	O
23	VO2	O
24	decreased	O
25	.	O
1	In	O
2	Group	O
3	IV	O
4	dogs	O
5	that	O
6	received	O
7	alpha	O
8	-	O
9	<UNK>	B
10	only	O
11	during	O
12	reperfusion	O
13	,	O
14	<UNK>	O
15	were	O
16	increased	O
17	approximately	O
18	10	O
19	to	O
20	14	O
21	%	O
22	more	O
23	than	O
24	in	O
25	Group	O
26	II	O
27	during	O
28	the	O
29	late	O
30	reperfusion	O
31	period	O
32	.	O
1	The	O
2	<UNK>	O
3	expression	O
4	of	O
5	the	O
6	endogenous	O
7	gene	O
8	can	O
9	be	O
10	<UNK>	O
11	in	O
12	mice	O
13	by	O
14	using	O
15	a	O
16	14	O
17	-	O
18	kb	O
19	<UNK>	O
20	encompassing	O
21	4	O
22	kb	O
23	of	O
24	5	O
25	'-	O
26	flanking	O
27	sequence	O
28	,	O
29	8	O
30	kb	O
31	of	O
32	3	O
33	'-	O
34	flanking	O
35	sequence	O
36	,	O
37	which	O
38	includes	O
39	the	O
40	two	O
41	<UNK>	O
42	-	O
43	specific	O
44	<UNK>	O
45	,	O
46	and	O
47	an	O
48	<UNK>	O
49	deleted	O
50	structural	O
51	gene	O
52	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	<UNK>	B
9	is	O
10	also	O
11	an	O
12	<UNK>	O
13	and	O
14	has	O
15	the	O
16	same	O
17	substrate	O
18	specificity	O
19	as	O
20	<UNK>	B
21	.	O
1	By	O
2	screening	O
3	a	O
4	cDNA	O
5	library	O
6	with	O
7	a	O
8	probe	O
9	derived	O
10	from	O
11	sequences	O
12	downstream	O
13	of	O
14	the	O
15	<UNK>	B
16	start	O
17	site	O
18	,	O
19	we	O
20	have	O
21	cloned	O
22	and	O
23	characterized	O
24	a	O
25	cDNA	O
26	that	O
27	represents	O
28	a	O
29	mRNA	O
30	that	O
31	appears	O
32	to	O
33	have	O
34	been	O
35	initiated	O
36	from	O
37	the	O
38	<UNK>	B
39	promoter	O
40	.	O
1	The	O
2	<UNK>	B
3	alpha	O
4	gene	O
5	is	O
6	composed	O
7	of	O
8	nine	O
9	coding	O
10	exons	O
11	of	O
12	varying	O
13	<UNK>	O
14	,	O
15	separated	O
16	by	O
17	introns	O
18	,	O
19	giving	O
20	the	O
21	gene	O
22	a	O
23	total	O
24	length	O
25	of	O
26	at	O
27	least	O
28	21	O
29	kb	O
30	.	O
31	our	O
32	recent	O
33	cloning	O
34	of	O
35	a	O
36	processed	O
37	<UNK>	B
38	alpha	O
39	pseudogene	O
40	with	O
41	a	O
42	5	O
43	'-	O
44	noncoding	O
45	region	O
46	different	O
47	from	O
48	the	O
49	previously	O
50	reported	O
51	<UNK>	B
52	alpha	O
53	complementary	O
54	RNA	O
55	indicated	O
56	that	O
57	the	O
58	<UNK>	B
59	alpha	O
60	gene	O
61	may	O
62	have	O
63	multiple	O
64	leader	O
65	exons	O
66	giving	O
67	rise	O
68	to	O
69	<UNK>	O
70	spliced	O
71	messenger	O
72	RNAs	O
73	(	O
74	mRNAs	O
75	).	O
1	Further	O
2	,	O
3	the	O
4	<UNK>	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	O
19	1	O
20	treatment	O
21	.	O
1	<UNK>	O
2	caused	O
3	a	O
4	transient	O
5	reduction	O
6	in	O
7	lactate	O
8	production	O
9	and	O
10	a	O
11	significant	O
12	increase	O
13	in	O
14	<UNK>	B
15	release	O
16	.	O
1	To	O
2	evaluate	O
3	the	O
4	hepatic	O
5	<UNK>	O
6	response	O
7	in	O
8	patients	O
9	with	O
10	<UNK>	O
11	liver	O
12	disease	O
13	,	O
14	sera	O
15	from	O
16	<UNK>	O
17	patients	O
18	with	O
19	severe	O
20	<UNK>	O
21	hepatitis	O
22	and	O
23	/	O
24	or	O
25	cirrhosis	O
26	were	O
27	analyzed	O
28	for	O
29	hepatocyte	O
30	growth	O
31	factor	O
32	(	O
33	<UNK>	B
34	)	O
35	and	O
36	alpha	O
37	-	O
38	<UNK>	B
39	(	O
40	<UNK>	O
41	).	O
1	Finally	O
2	,	O
3	<UNK>	O
4	mutants	O
5	,	O
6	including	O
7	the	O
8	<UNK>	B
9	-	O
10	lacking	O
11	<UNK>	B
12	I	O
13	mutant	O
14	,	O
15	<UNK>	O
16	,	O
17	did	O
18	not	O
19	show	O
20	evidence	O
21	of	O
22	light	O
23	-	O
24	stimulated	O
25	RNA	O
26	processing	O
27	.	O
1	<UNK>	O
2	expression	O
3	of	O
4	<UNK>	B
5	-	O
6	3	O
7	in	O
8	<UNK>	O
9	or	O
10	HeLa	O
11	cells	O
12	induced	O
13	marked	O
14	apoptosis	O
15	.	O
1	D	O
2	.	O
3	melanogaster	O
4	<UNK>	B
5	-	O
6	A	O
7	coding	O
8	sequences	O
9	have	O
10	a	O
11	polymorphic	O
12	region	O
13	with	O
14	insertions	O
15	/	O
16	deletions	O
17	of	O
18	1	O
19	-	O
20	31	O
21	codons	O
22	and	O
23	many	O
24	nucleotide	O
25	changes	O
26	.	O
1	<UNK>	O
2	of	O
3	sufficient	O
4	data	O
5	on	O
6	<UNK>	O
7	measurements	O
8	and	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	O
12	to	O
13	the	O
14	<UNK>	O
15	,	O
16	as	O
17	do	O
18	variations	O
19	in	O
20	<UNK>	O
21	conditions	O
22	(	O
23	<UNK>	O
24	<UNK>	O
25	,	O
26	<UNK>	O
27	)	O
28	and	O
29	<UNK>	O
30	<UNK>	O
31	in	O
32	measurement	O
33	.	O
1	The	O
2	differences	O
3	among	O
4	<UNK>	O
5	of	O
6	the	O
7	<UNK>	O
8	<UNK>	O
9	are	O
10	more	O
11	significant	O
12	.	O
1	<UNK>	O
2	the	O
3	E	O
4	-	O
5	box	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	3	O
12	'-	O
13	flanking	O
14	region	O
15	confirmed	O
16	that	O
17	it	O
18	contributes	O
19	to	O
20	the	O
21	enhancement	O
22	of	O
23	transcriptional	O
24	activity	O
25	of	O
26	the	O
27	alpha1	O
28	(	O
29	I	O
30	)	O
31	collagen	B
32	gene	O
33	promoter	O
34	.	O
1	Expression	O
2	of	O
3	neuronal	O
4	<UNK>	O
5	in	O
6	pancreatic	O
7	beta	O
8	cells	O
9	.	O
1	In	O
2	the	O
3	<UNK>	B
4	subunit	O
5	,	O
6	the	O
7	<UNK>	O
8	side	O
9	-	O
10	chain	O
11	is	O
12	<UNK>	O
13	in	O
14	a	O
15	similar	O
16	direction	O
17	to	O
18	the	O
19	<UNK>	O
20	side	O
21	-	O
22	chain	O
23	in	O
24	the	O
25	wild	O
26	-	O
27	type	O
28	complex	O
29	.	O
1	A	O
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	<UNK>	B
16	gene	O
17	(	O
18	named	O
19	<UNK>	B
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O
1	The	O
2	primary	O
3	structure	O
4	of	O
5	a	O
6	<UNK>	O
7	bp	O
8	DNA	O
9	fragment	O
10	between	O
11	the	O
12	<UNK>	B
13	gene	O
14	(	O
15	encoding	O
16	plasminogen	B
17	activator	O
18	)	O
19	and	O
20	the	O
21	origin	O
22	of	O
23	replication	O
24	of	O
25	the	O
26	wild	O
27	-	O
28	type	O
29	<UNK>	O
30	<UNK>	O
31	plasmid	O
32	<UNK>	O
33	was	O
34	determined	O
35	.	O
1	CONCLUSION	O
2	:	O
3	Some	O
4	<UNK>	O
5	<UNK>	O
6	<UNK>	O
7	may	O
8	have	O
9	delayed	O
10	,	O
11	chronic	O
12	<UNK>	O
13	<UNK>	O
14	from	O
15	<UNK>	O
16	exposure	O
17	to	O
18	<UNK>	O
19	of	O
20	<UNK>	O
21	that	O
22	inhibit	O
23	<UNK>	B
24	and	O
25	<UNK>	O
26	target	O
27	esterase	B
28	.	O
1	JNK	B
2	and	O
3	p38	B
4	are	O
5	constitutively	O
6	present	O
7	in	O
8	the	O
9	nucleus	O
10	,	O
11	and	O
12	DNA	O
13	-	O
14	bound	O
15	c	B
16	-	O
17	<UNK>	B
18	and	O
19	ATF	B
20	-	O
21	2	O
22	are	O
23	stably	O
24	<UNK>	O
25	by	O
26	JNK	B
27	and	O
28	p38	B
29	,	O
30	respectively	O
31	.	O
1	<UNK>	O
2	enzyme	O
3	forms	O
4	were	O
5	prepared	O
6	to	O
7	<UNK>	O
8	the	O
9	initial	O
10	<UNK>	O
11	site	O
12	and	O
13	thus	O
14	form	O
15	an	O
16	active	O
17	single	O
18	-	O
19	chain	O
20	protein	O
21	for	O
22	structure	O
23	-	O
24	function	O
25	studies	O
26	.	O
1	The	O
2	primer	O
3	is	O
4	generated	O
5	by	O
6	a	O
7	cleavage	O
8	that	O
9	occurs	O
10	between	O
11	bases	O
12	11	O
13	and	O
14	12	O
15	of	O
16	the	O
17	<UNK>	B
18	mRNA	O
19	.	O
1	<UNK>	O
2	,	O
3	both	O
4	<UNK>	O
5	-	O
6	A	O
7	and	O
8	<UNK>	O
9	-	O
10	D	O
11	defects	O
12	are	O
13	associated	O
14	with	O
15	subunits	O
16	of	O
17	<UNK>	B
18	,	O
19	a	O
20	basal	O
21	transcription	O
22	factor	O
23	with	O
24	a	O
25	second	O
26	function	O
27	in	O
28	DNA	O
29	repair	O
30	.	O
1	In	O
2	<UNK>	O
3	1	O
4	,	O
5	<UNK>	O
6	that	O
7	had	O
8	received	O
9	an	O
10	injection	O
11	of	O
12	the	O
13	<UNK>	O
14	N	O
15	-	O
16	methyl	O
17	-	O
18	D	O
19	-	O
20	aspartate	O
21	receptor	O
22	antagonist	O
23	<UNK>	O
24	-	O
25	<UNK>	O
26	(	O
27	0	O
28	.	O
29	1	O
30	mg	O
31	/	O
32	kg	O
33	,	O
34	i	O
35	.	O
36	p	O
37	.)	O
38	either	O
39	30	O
40	min	O
41	before	O
42	or	O
43	immediately	O
44	after	O
45	conditioning	O
46	<UNK>	O
47	less	O
48	time	O
49	over	O
50	the	O
51	<UNK>	O
52	<UNK>	O
53	than	O
54	saline	O
55	-	O
56	treated	O
57	controls	O
58	.	O
1	<UNK>	B
2	and	O
3	<UNK>	B
4	do	O
5	not	O
6	form	O
7	homodimers	O
8	,	O
9	and	O
10	they	O
11	do	O
12	not	O
13	interact	O
14	with	O
15	<UNK>	O
16	.	O
1	Moreover	O
2	,	O
3	the	O
4	effect	O
5	<UNK>	O
6	by	O
7	<UNK>	B
8	appeared	O
9	to	O
10	be	O
11	selective	O
12	for	O
13	the	O
14	<UNK>	B
15	promoter	O
16	.	O
1	Because	O
2	L	O
3	-	O
4	<UNK>	B
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	<UNK>	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	O
25	-	O
26	<UNK>	B
27	gene	O
28	expression	O
29	in	O
30	human	O
31	and	O
32	<UNK>	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	O
52	L	O
53	-	O
54	<UNK>	B
55	gene	O
56	promoters	O
57	.	O
1	The	O
2	<UNK>	B
3	operon	O
4	of	O
5	Bacillus	O
6	subtilis	O
7	is	O
8	<UNK>	O
9	.	O
1	Finally	O
2	,	O
3	antibody	O
4	binding	O
5	to	O
6	site	O
7	<UNK>	O
8	on	O
9	the	O
10	hCG	B
11	-	O
12	<UNK>	O
13	complex	O
14	was	O
15	also	O
16	<UNK>	O
17	by	O
18	an	O
19	anti	O
20	-	O
21	peptide	O
22	<UNK>	O
23	directed	O
24	against	O
25	a	O
26	peptide	O
27	encoded	O
28	by	O
29	the	O
30	<UNK>	O
31	exon	O
32	(	O
33	<UNK>	O
34	x	O
35	8	O
36	)	O
37	of	O
38	the	O
39	<UNK>	B
40	.	O
1	cDNA	O
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	<UNK>	O
18	eIF	B
19	-(	O
20	<UNK>	B
21	)	O
22	<UNK>	B
23	and	O
24	mammalian	O
25	eIF	B
26	-	O
27	<UNK>	B
28	.	O
1	The	O
2	interferon	B
3	(	O
4	IFN	B
5	)-	O
6	induced	O
7	double	O
8	-	O
9	stranded	O
10	RNA	O
11	(	O
12	<UNK>	O
13	)-	O
14	activated	O
15	Ser	O
16	/	O
17	Thr	O
18	protein	O
19	kinase	B
20	(	O
21	PKR	B
22	)	O
23	plays	O
24	a	O
25	role	O
26	in	O
27	the	O
28	<UNK>	O
29	and	O
30	<UNK>	O
31	effects	O
32	of	O
33	IFN	B
34	.	O
1	Most	O
2	kinases	O
3	are	O
4	not	O
5	significantly	O
6	inhibited	O
7	by	O
8	<UNK>	O
9	.	O
10	<UNK>	B
11	/	O
12	cyclin	B
13	B	O
14	,	O
15	<UNK>	B
16	/	O
17	cyclin	B
18	A	O
19	,	O
20	<UNK>	B
21	/	O
22	cyclin	B
23	E	O
24	and	O
25	<UNK>	B
26	/	O
27	<UNK>	B
28	only	O
29	are	O
30	substantially	O
31	inhibited	O
32	(	O
33	<UNK>	O
34	values	O
35	of	O
36	0	O
37	.	O
38	65	O
39	,	O
40	0	O
41	.	O
42	7	O
43	,	O
44	0	O
45	.	O
46	7	O
47	and	O
48	0	O
49	.	O
50	2	O
51	<UNK>	O
52	,	O
53	respectively	O
54	).	O
55	<UNK>	B
56	/	O
57	cyclin	B
58	D1	I
59	and	O
60	<UNK>	B
61	/	O
62	cyclin	B
63	D2	I
64	are	O
65	very	O
66	poorly	O
67	inhibited	O
68	by	O
69	<UNK>	O
70	(	O
71	<UNK>	O
72	>	O
73	100	O
74	<UNK>	O
75	).	O
1	<UNK>	O
2	of	O
3	Ets	B
4	-	O
5	1	O
6	and	O
7	the	O
8	POU	B
9	-	O
10	homeodomain	B
11	protein	O
12	<UNK>	B
13	-	O
14	1	O
15	/	O
16	Pit	B
17	-	O
18	1	O
19	<UNK>	O
20	pituitary	O
21	-	O
22	specific	O
23	gene	O
24	expression	O
25	.	O
1	Furthermore	O
2	,	O
3	<UNK>	B
4	activation	O
5	of	O
6	JNK	B
7	or	O
8	SRF	B
9	,	O
10	or	O
11	induction	O
12	of	O
13	<UNK>	O
14	,	O
15	was	O
16	neither	O
17	necessary	O
18	nor	O
19	sufficient	O
20	for	O
21	<UNK>	B
22	transforming	O
23	activity	O
24	.	O
1	These	O
2	data	O
3	support	O
4	the	O
5	<UNK>	O
6	that	O
7	the	O
8	repression	O
9	activity	O
10	of	O
11	<UNK>	B
12	/	O
13	<UNK>	B
14	depends	O
15	upon	O
16	the	O
17	species	O
18	of	O
19	promoter	O
20	to	O
21	which	O
22	it	O
23	is	O
24	linked	O
25	and	O
26	upon	O
27	the	O
28	proteins	O
29	that	O
30	bind	O
31	to	O
32	those	O
33	promoters	O
34	.	O
1	METHODS	O
2	:	O
3	Fifty	O
4	-	O
5	eight	O
6	patients	O
7	who	O
8	underwent	O
9	a	O
10	<UNK>	O
11	hepatic	O
12	resection	O
13	for	O
14	<UNK>	O
15	and	O
16	whose	O
17	<UNK>	O
18	<UNK>	O
19	levels	O
20	were	O
21	>	O
22	100	O
23	ng	O
24	/	O
25	ml	O
26	,	O
27	were	O
28	selected	O
29	for	O
30	this	O
31	study	O
32	.	O
1	<UNK>	B
2	-	O
3	binding	O
4	peptide	O
5	(	O
6	CBP	B
7	),	O
8	a	O
9	peptide	O
10	of	O
11	26	O
12	amino	O
13	acids	O
14	derived	O
15	from	O
16	muscle	O
17	myosin	B
18	light	O
19	chain	O
20	kinase	B
21	(	O
22	<UNK>	B
23	),	O
24	binds	O
25	to	O
26	calmodulin	B
27	with	O
28	<UNK>	O
29	affinity	O
30	.	O
1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	<UNK>	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	<UNK>	B
27	-	O
28	<UNK>	O
29	/	O
30	<UNK>	B
31	exhibits	O
32	a	O
33	pronounced	O
34	<UNK>	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O
1	In	O
2	this	O
3	regard	O
4	,	O
5	it	O
6	differs	O
7	from	O
8	a	O
9	recently	O
10	reported	O
11	<UNK>	O
12	-	O
13	sensitive	O
14	ARF	B
15	-	O
16	<UNK>	B
17	that	O
18	contains	O
19	a	O
20	<UNK>	B
21	domain	O
22	.	O
1	These	O
2	elements	O
3	<UNK>	O
4	a	O
5	binding	O
6	site	O
7	for	O
8	<UNK>	B
9	proteins	O
10	,	O
11	one	O
12	for	O
13	nuclear	O
14	factor	O
15	1	O
16	,	O
17	an	O
18	octamer	O
19	motif	O
20	that	O
21	binds	O
22	POU	B
23	-	O
24	homeodomain	B
25	proteins	O
26	,	O
27	and	O
28	a	O
29	novel	O
30	<UNK>	B
31	control	O
32	element	O
33	.	O
1	RESULTS	O
2	:	O
3	The	O
4	<UNK>	O
5	of	O
6	average	O
7	daily	O
8	<UNK>	B
9	+	O
10	cell	O
11	<UNK>	O
12	for	O
13	patients	O
14	who	O
15	received	O
16	<UNK>	O
17	plus	O
18	<UNK>	O
19	,	O
20	<UNK>	O
21	,	O
22	and	O
23	<UNK>	O
24	with	O
25	G	O
26	-	O
27	CSF	B
28	were	O
29	12	O
30	.	O
31	9	O
32	,	O
33	11	O
34	.	O
35	03	O
36	,	O
37	and	O
38	5	O
39	.	O
40	37	O
41	x	O
42	10	O
43	(	O
44	6	O
45	)/	O
46	kg	O
47	,	O
48	respectively	O
49	,	O
50	compared	O
51	with	O
52	2	O
53	.	O
54	02	O
55	x	O
56	10	O
57	(	O
58	6	O
59	)/	O
60	kg	O
61	in	O
62	the	O
63	reference	O
64	group	O
65	that	O
66	received	O
67	<UNK>	O
68	with	O
69	G	O
70	-	O
71	CSF	B
72	(	O
73	P	O
74	=	O
75	<	O
76	.	O
77	0001	O
78	,	O
79	.	O
80	<UNK>	O
81	,	O
82	and	O
83	.	O
84	<UNK>	O
85	,	O
86	respectively	O
87	).	O
1	The	O
2	intensity	O
3	of	O
4	the	O
5	<UNK>	O
6	is	O
7	an	O
8	order	O
9	of	O
10	magnitude	O
11	larger	O
12	than	O
13	that	O
14	of	O
15	the	O
16	<UNK>	O
17	and	O
18	<UNK>	O
19	the	O
20	signal	O
21	contrast	O
22	if	O
23	both	O
24	effects	O
25	are	O
26	selected	O
27	simultaneously	O
28	.	O
1	In	O
2	eukaryotic	O
3	cells	O
4	,	O
5	premature	O
6	termination	O
7	of	O
8	translation	O
9	at	O
10	nonsense	O
11	codons	O
12	has	O
13	been	O
14	implicated	O
15	as	O
16	the	O
17	cause	O
18	of	O
19	a	O
20	variety	O
21	of	O
22	<UNK>	O
23	events	O
24	,	O
25	including	O
26	rapid	O
27	mRNA	O
28	decay	O
29	in	O
30	the	O
31	cytoplasm	O
32	or	O
33	the	O
34	nucleus	O
35	,	O
36	altered	O
37	splice	O
38	site	O
39	selection	O
40	,	O
41	and	O
42	exon	O
43	<UNK>	O
44	.	O
1	The	O
2	region	O
3	of	O
4	plasmid	O
5	<UNK>	O
6	encoding	O
7	the	O
8	<UNK>	O
9	locus	O
10	<UNK>	B
11	-	O
12	1	O
13	was	O
14	mapped	O
15	by	O
16	deletion	O
17	analysis	O
18	and	O
19	complementation	O
20	studies	O
21	to	O
22	a	O
23	1	O
24	.	O
25	5	O
26	-	O
27	kb	O
28	<UNK>	B
29	/	O
30	II	O
31	/	O
32	<UNK>	B
33	DNA	O
34	fragment	O
35	.	O
1	RNase	B
2	protection	O
3	experiments	O
4	confirmed	O
5	the	O
6	presence	O
7	of	O
8	the	O
9	<UNK>	B
10	-	O
11	<UNK>	O
12	variant	O
13	in	O
14	<UNK>	O
15	-	O
16	9	O
17	cells	O
18	and	O
19	human	O
20	liver	O
21	.	O
1	<UNK>	O
2	,	O
3	activated	O
4	glucocorticoid	O
5	receptors	O
6	suppressed	O
7	the	O
8	transactivation	O
9	function	O
10	of	O
11	p53	B
12	,	O
13	while	O
14	<UNK>	O
15	by	O
16	p53	B
17	was	O
18	largely	O
19	unaffected	O
20	.	O
1	The	O
2	addition	O
3	of	O
4	<UNK>	O
5	did	O
6	not	O
7	influence	O
8	this	O
9	transfer	O
10	.	O
1	The	O
2	second	O
3	class	O
4	of	O
5	cDNA	O
6	<UNK>	O
7	to	O
8	a	O
9	13	O
10	kb	O
11	transcript	O
12	,	O
13	which	O
14	was	O
15	approximately	O
16	twice	O
17	as	O
18	large	O
19	as	O
20	the	O
21	mammalian	O
22	<UNK>	B
23	mRNA	O
24	.	O
1	<UNK>	O
2	transcription	O
3	of	O
4	a	O
5	murine	O
6	<UNK>	B
7	-	O
8	3	O
9	<UNK>	B
10	during	O
11	fetal	O
12	<UNK>	O
13	.	O
1	A	O
2	previous	O
3	report	O
4	described	O
5	that	O
6	a	O
7	<UNK>	O
8	-	O
9	bp	O
10	<UNK>	B
11	-	O
12	<UNK>	B
13	fragment	O
14	has	O
15	an	O
16	<UNK>	O
17	activity	O
18	(	O
19	<UNK>	O
20	;	O
21	<UNK>	O
22	et	O
23	al	O
24	.,	O
25	<UNK>	O
26	.	O
1	During	O
2	the	O
3	<UNK>	O
4	period	O
5	,	O
6	<UNK>	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	O
17	6	O
18	,	O
19	TNF	B
20	-	O
21	alpha	O
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O
1	<UNK>	B
2	-	O
3	4	O
4	is	O
5	a	O
6	focal	O
7	adhesion	O
8	component	O
9	,	O
10	and	O
11	this	O
12	interaction	O
13	may	O
14	both	O
15	<UNK>	O
16	PKC	B
17	and	O
18	<UNK>	O
19	its	O
20	activity	O
21	at	O
22	sites	O
23	of	O
24	forming	O
25	<UNK>	O
26	.	O
1	The	O
2	reduced	O
3	NO	O
4	production	O
5	in	O
6	these	O
7	cells	O
8	was	O
9	associated	O
10	with	O
11	low	O
12	levels	O
13	of	O
14	mRNA	O
15	of	O
16	inducible	O
17	NO	O
18	synthetase	B
19	.	O
1	Molecular	O
2	characterization	O
3	of	O
4	a	O
5	large	O
6	<UNK>	O
7	<UNK>	O
8	motility	O
9	operon	O
10	which	O
11	is	O
12	initiated	O
13	by	O
14	a	O
15	consensus	O
16	<UNK>	B
17	promoter	O
18	.	O
1	Therefore	O
2	more	O
3	active	O
4	and	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	are	O
9	needed	O
10	.	O
1	However	O
2	,	O
3	the	O
4	range	O
5	of	O
6	values	O
7	observed	O
8	is	O
9	<UNK>	O
10	of	O
11	the	O
12	need	O
13	to	O
14	investigate	O
15	<UNK>	O
16	with	O
17	<UNK>	O
18	values	O
19	of	O
20	<UNK>	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	<UNK>	O
26	-	O
27	relationships	O
28	between	O
29	<UNK>	O
30	characteristics	O
31	,	O
32	duration	O
33	of	O
34	symptoms	O
35	,	O
36	clinical	O
37	presentation	O
38	and	O
39	treatment	O
40	efficacy	O
41	.	O
1	The	O
2	<UNK>	O
3	lesions	O
4	were	O
5	<UNK>	O
6	to	O
7	the	O
8	cerebral	O
9	surface	O
10	layer	O
11	and	O
12	<UNK>	O
13	tissue	O
14	including	O
15	the	O
16	<UNK>	O
17	vessels	O
18	,	O
19	which	O
20	were	O
21	all	O
22	<UNK>	O
23	in	O
24	the	O
25	cerebrospinal	O
26	fluid	O
27	,	O
28	suggesting	O
29	that	O
30	some	O
31	<UNK>	O
32	<UNK>	O
33	had	O
34	been	O
35	secreted	O
36	into	O
37	the	O
38	fluid	O
39	by	O
40	the	O
41	B	O
42	.	O
43	<UNK>	O
44	.	O
1	Analysis	O
2	for	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	by	O
8	in	O
9	vitro	O
10	DNase	B
11	-	O
12	I	O
13	footprinting	O
14	identified	O
15	a	O
16	broad	O
17	region	O
18	of	O
19	protection	O
20	<UNK>	O
21	from	O
22	nt	O
23	-	O
24	12	O
25	to	O
26	+	O
27	38	O
28	.	O
1	Analysis	O
2	of	O
3	homologous	O
4	DNA	O
5	sequences	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	mouse	O
13	and	O
14	human	O
15	<UNK>	B
16	genes	O
17	:	O
18	<UNK>	B
19	-	O
20	like	O
21	site	O
22	and	O
23	<UNK>	O
24	DNA	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	examined	O
8	the	O
9	regulation	O
10	of	O
11	B	O
12	-	O
13	Myb	B
14	activity	O
15	by	O
16	cyclin	B
17	-	O
18	<UNK>	B
19	.	O
1	Based	O
2	on	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	<UNK>	B
8	,	O
9	we	O
10	located	O
11	a	O
12	putative	O
13	<UNK>	B
14	,	O
15	referred	O
16	to	O
17	as	O
18	P2	O
19	-	O
20	<UNK>	O
21	,	O
22	in	O
23	the	O
24	5	O
25	'	O
26	promoter	O
27	-	O
28	flanking	O
29	region	O
30	of	O
31	the	O
32	mouse	O
33	<UNK>	O
34	2	O
35	gene	O
36	,	O
37	which	O
38	is	O
39	induced	O
40	during	O
41	the	O
42	same	O
43	stage	O
44	of	O
45	<UNK>	O
46	as	O
47	<UNK>	B
48	.	O
1	The	O
2	new	O
3	<UNK>	O
4	<UNK>	O
5	of	O
6	cervical	O
7	cancer	O
8	stage	O
9	<UNK>	O
10	:	O
11	a	O
12	<UNK>	O
13	.	O
1	A	O
2	method	O
3	for	O
4	the	O
5	simultaneous	O
6	determination	O
7	of	O
8	de	O
9	(	O
10	N	O
11	-	O
12	methyl	O
13	)-	O
14	N	O
15	-	O
16	<UNK>	O
17	-	O
18	8	O
19	,	O
20	9	O
21	-	O
22	<UNK>	O
23	A	O
24	6	O
25	,	O
26	9	O
27	-	O
28	<UNK>	O
29	(	O
30	<UNK>	O
31	,	O
32	I	O
33	)	O
34	and	O
35	its	O
36	three	O
37	metabolites	O
38	in	O
39	human	O
40	plasma	O
41	and	O
42	urine	O
43	has	O
44	been	O
45	developed	O
46	using	O
47	high	O
48	-	O
49	performance	O
50	liquid	O
51	chromatography	O
52	(	O
53	<UNK>	O
54	)	O
55	with	O
56	<UNK>	O
57	(	O
58	<UNK>	O
59	)	O
60	detection	O
61	.	O
1	However	O
2	,	O
3	its	O
4	<UNK>	O
5	in	O
6	<UNK>	O
7	induced	O
8	by	O
9	<UNK>	O
10	<UNK>	O
11	is	O
12	<UNK>	O
13	.	O
1	<UNK>	B
2	D1	I
3	could	O
4	not	O
5	be	O
6	<UNK>	O
7	from	O
8	<UNK>	B
9	in	O
10	the	O
11	resistant	O
12	<UNK>	O
13	cell	O
14	<UNK>	O
15	.	O
1	The	O
2	importance	O
3	of	O
4	<UNK>	O
5	regulation	O
6	of	O
7	<UNK>	B
8	by	O
9	TGF	B
10	-	O
11	beta	O
12	is	O
13	<UNK>	O
14	by	O
15	the	O
16	observation	O
17	that	O
18	in	O
19	TGF	B
20	-	O
21	beta	O
22	-	O
23	resistant	O
24	<UNK>	O
25	,	O
26	although	O
27	the	O
28	<UNK>	O
29	transcript	O
30	increased	O
31	,	O
32	<UNK>	B
33	protein	O
34	was	O
35	not	O
36	<UNK>	O
37	and	O
38	did	O
39	not	O
40	accumulate	O
41	,	O
42	and	O
43	cyclin	B
44	D1	I
45	-	O
46	<UNK>	B
47	association	O
48	and	O
49	kinase	B
50	activation	O
51	were	O
52	not	O
53	inhibited	O
54	.	O
1	Furthermore	O
2	,	O
3	experiments	O
4	with	O
5	<UNK>	O
6	temperature	O
7	-	O
8	sensitive	O
9	p53	B
10	cells	O
11	indicate	O
12	that	O
13	aberrant	O
14	tal	B
15	-	O
16	1	O
17	expression	O
18	at	O
19	the	O
20	<UNK>	O
21	temperature	O
22	does	O
23	not	O
24	exert	O
25	a	O
26	<UNK>	O
27	effect	O
28	but	O
29	causes	O
30	p53	B
31	-	O
32	mediated	O
33	apoptosis	O
34	,	O
35	i	O
36	.	O
37	e	O
38	.,	O
39	the	O
40	tal	B
41	-	O
42	1	O
43	<UNK>	O
44	effect	O
45	depends	O
46	on	O
47	the	O
48	integrity	O
49	of	O
50	the	O
51	cell	O
52	cycle	O
53	<UNK>	O
54	of	O
55	the	O
56	host	O
57	cell	O
58	,	O
59	as	O
60	observed	O
61	for	O
62	c	B
63	-	O
64	myc	B
65	and	O
66	other	O
67	oncogenes	O
68	.	O
69	tal	B
70	-	O
71	1	O
72	mutant	O
73	experiments	O
74	indicate	O
75	that	O
76	ectopic	O
77	tal	B
78	-	O
79	1	O
80	effects	O
81	are	O
82	mediated	O
83	by	O
84	both	O
85	the	O
86	DNA	O
87	-	O
88	binding	O
89	and	O
90	the	O
91	<UNK>	O
92	domains	O
93	,	O
94	while	O
95	the	O
96	N	O
97	-	O
98	terminally	O
99	truncated	O
100	tal	B
101	-	O
102	1	O
103	variant	O
104	(	O
105	<UNK>	O
106	)	O
107	expressed	O
108	in	O
109	T	O
110	-	O
111	<UNK>	O
112	malignant	O
113	cells	O
114	<UNK>	O
115	the	O
116	effects	O
117	of	O
118	the	O
119	wild	O
120	-	O
121	type	O
122	protein	O
123	.	O
1	However	O
2	,	O
3	in	O
4	some	O
5	of	O
6	them	O
7	either	O
8	pattern	O
9	may	O
10	<UNK>	O
11	or	O
12	be	O
13	exclusively	O
14	present	O
15	.	O
1	<UNK>	O
2	is	O
3	known	O
4	about	O
5	the	O
6	mechanism	O
7	,	O
8	but	O
9	the	O
10	availability	O
11	of	O
12	rapid	O
13	<UNK>	O
14	assays	O
15	for	O
16	monitoring	O
17	immunoglobulin	B
18	<UNK>	O
19	would	O
20	greatly	O
21	aid	O
22	the	O
23	development	O
24	of	O
25	culture	O
26	systems	O
27	for	O
28	<UNK>	O
29	B	O
30	cells	O
31	as	O
32	well	O
33	as	O
34	the	O
35	screening	O
36	for	O
37	individuals	O
38	deficient	O
39	in	O
40	the	O
41	process	O
42	.	O
1	L	O
2	-	O
3	<UNK>	O
4	,	O
5	a	O
6	selective	O
7	inhibitor	O
8	of	O
9	the	O
10	inducible	O
11	<UNK>	O
12	oxide	O
13	synthase	B
14	,	O
15	increases	O
16	the	O
17	mean	O
18	systemic	O
19	filling	O
20	pressure	O
21	,	O
22	thereby	O
23	<UNK>	O
24	venous	O
25	<UNK>	O
26	,	O
27	under	O
28	these	O
29	conditions	O
30	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	<UNK>	O
5	<UNK>	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	<UNK>	B
11	-	O
12	S	O
13	<UNK>	O
14	<UNK>	O
15	-	O
16	carrier	O
17	protein	O
18	]	O
19	from	O
20	<UNK>	B
21	-	O
22	S	O
23	<UNK>	O
24	<UNK>	O
25	-	O
26	carrier	O
27	protein	O
28	]	O
29	and	O
30	<UNK>	O
31	,	O
32	<UNK>	O
33	to	O
34	a	O
35	<UNK>	O
36	protein	O
37	and	O
38	its	O
39	<UNK>	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	O
45	mu	O
46	Na	O
47	+	O
48	generation	O
49	.	O
1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	protein	O
9	that	O
10	binds	O
11	to	O
12	enhancer	O
13	site	O
14	III	O
15	.	O
1	A	O
2	genetic	O
3	screen	O
4	applied	O
5	to	O
6	mutants	O
7	in	O
8	the	O
9	branch	O
10	site	O
11	region	O
12	shows	O
13	that	O
14	all	O
15	positions	O
16	in	O
17	the	O
18	conserved	O
19	<UNK>	O
20	sequence	O
21	are	O
22	important	O
23	for	O
24	intron	O
25	recognition	O
26	.	O
1	RESULTS	O
2	:	O
3	Surprisingly	O
4	,	O
5	<UNK>	B
6	blockade	O
7	increased	O
8	mortality	O
9	after	O
10	trauma	O
11	(	O
12	5	O
13	of	O
14	11	O
15	<UNK>	O
16	-	O
17	<UNK>	O
18	animals	O
19	versus	O
20	1	O
21	of	O
22	9	O
23	<UNK>	O
24	animals	O
25	;	O
26	p	O
27	=	O
28	0	O
29	.	O
30	15	O
31	)	O
32	and	O
33	depressed	O
34	cardiac	O
35	index	O
36	and	O
37	O2	O
38	delivery	O
39	at	O
40	72	O
41	hours	O
42	(	O
43	p	O
44	<	O
45	0	O
46	.	O
47	05	O
48	).	O
1	In	O
2	a	O
3	model	O
4	of	O
5	the	O
6	ternary	O
7	complex	O
8	,	O
9	the	O
10	segment	O
11	of	O
12	<UNK>	B
13	<UNK>	O
14	AP	B
15	-	O
16	1	O
17	is	O
18	the	O
19	Rel	B
20	insert	O
21	region	O
22	(	O
23	<UNK>	O
24	),	O
25	a	O
26	feature	O
27	that	O
28	is	O
29	<UNK>	O
30	for	O
31	its	O
32	<UNK>	O
33	in	O
34	size	O
35	and	O
36	in	O
37	sequence	O
38	<UNK>	O
39	members	O
40	of	O
41	the	O
42	Rel	B
43	transcription	O
44	factor	O
45	family	O
46	.	O
1	<UNK>	O
2	chain	O
3	enzyme	O
4	activity	O
5	was	O
6	normal	O
7	.	O
1	<UNK>	O
2	'	O
3	s	O
4	<UNK>	O
5	and	O
6	maternal	O
7	<UNK>	O
8	at	O
9	<UNK>	O
10	1	O
11	(	O
12	n	O
13	=	O
14	<UNK>	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	<UNK>	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	<UNK>	O
33	and	O
34	<UNK>	O
35	measures	O
36	.	O
1	One	O
2	P1	O
3	genomic	O
4	clone	O
5	and	O
6	six	O
7	subsequent	O
8	plasmid	O
9	<UNK>	O
10	were	O
11	isolated	O
12	and	O
13	analyzed	O
14	for	O
15	the	O
16	exon	O
17	-	O
18	intron	O
19	organization	O
20	of	O
21	the	O
22	<UNK>	B
23	gene	O
24	.	O
1	We	O
2	also	O
3	review	O
4	the	O
5	role	O
6	of	O
7	<UNK>	O
8	in	O
9	the	O
10	formation	O
11	of	O
12	complex	O
13	molecules	O
14	in	O
15	<UNK>	O
16	molecular	O
17	<UNK>	O
18	.	O
1	The	O
2	mRNA	O
3	from	O
4	this	O
5	gene	O
6	,	O
7	termed	O
8	<UNK>	B
9	,	O
10	is	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	but	O
15	strongly	O
16	so	O
17	in	O
18	heart	O
19	and	O
20	skeletal	O
21	muscle	O
22	.	O
1	They	O
2	observed	O
3	depressed	O
4	protein	O
5	C	O
6	activity	O
7	that	O
8	significantly	O
9	(	O
10	p	O
11	<	O
12	0	O
13	.	O
14	<UNK>	O
15	)	O
16	increased	O
17	and	O
18	became	O
19	normal	O
20	immediately	O
21	after	O
22	hemodialysis	O
23	while	O
24	factor	O
25	X	O
26	and	O
27	factor	O
28	VII	O
29	increased	O
30	(	O
31	p	O
32	<	O
33	0	O
34	.	O
35	01	O
36	;	O
37	p	O
38	<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	despite	O
44	<UNK>	O
45	together	O
46	with	O
47	amount	O
48	of	O
49	serum	O
50	lipoprotein	O
51	(	O
52	a	O
53	).	O
1	<UNK>	O
2	patients	O
3	with	O
4	New	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	class	O
9	II	O
10	<UNK>	O
11	heart	O
12	failure	O
13	were	O
14	<UNK>	O
15	in	O
16	a	O
17	double	O
18	-	O
19	blind	O
20	,	O
21	cross	O
22	-	O
23	over	O
24	study	O
25	.	O
1	Using	O
2	various	O
3	techniques	O
4	,	O
5	we	O
6	have	O
7	undertaken	O
8	a	O
9	systematic	O
10	analysis	O
11	of	O
12	the	O
13	natural	O
14	TATA	O
15	-	O
16	less	O
17	human	O
18	DNA	O
19	polymerase	O
20	beta	O
21	(	O
22	beta	O
23	-	O
24	pol	B
25	)	O
26	gene	O
27	promoter	O
28	.	O
1	This	O
2	association	O
3	appears	O
4	to	O
5	be	O
6	mediated	O
7	by	O
8	Src	B
9	-	O
10	SH2	B
11	domain	O
12	,	O
13	because	O
14	<UNK>	B
15	-	O
16	1	O
17	can	O
18	be	O
19	<UNK>	O
20	by	O
21	a	O
22	GST	B
23	-	O
24	Src	B
25	-	O
26	SH2	B
27	affinity	O
28	matrix	O
29	.	O
1	We	O
2	have	O
3	used	O
4	a	O
5	site	O
6	-	O
7	directed	O
8	mutagenesis	O
9	approach	O
10	to	O
11	examine	O
12	how	O
13	the	O
14	<UNK>	O
15	and	O
16	hydroxy	O
17	(	O
18	Ser	O
19	/	O
20	Thr	O
21	)	O
22	amino	O
23	acid	O
24	residues	O
25	in	O
26	<UNK>	O
27	influence	O
28	core	O
29	-	O
30	glycosylation	O
31	efficiency	O
32	.	O
1	<UNK>	O
2	AND	O
3	METHODS	O
4	:	O
5	The	O
6	authors	O
7	analyzed	O
8	41	O
9	persons	O
10	<UNK>	O
11	<UNK>	O
12	to	O
13	surgery	O
14	(	O
15	after	O
16	8	O
17	years	O
18	and	O
19	4	O
20	months	O
21	,	O
22	as	O
23	a	O
24	mean	O
25	),	O
26	31	O
27	to	O
28	highly	O
29	selective	O
30	<UNK>	O
31	,	O
32	and	O
33	10	O
34	to	O
35	<UNK>	O
36	or	O
37	selective	O
38	<UNK>	O
39	plus	O
40	<UNK>	O
41	<UNK>	O
42	.	O
1	This	O
2	region	O
3	does	O
4	not	O
5	contain	O
6	an	O
7	<UNK>	O
8	TATA	O
9	element	O
10	,	O
11	indicating	O
12	that	O
13	transcription	O
14	of	O
15	the	O
16	<UNK>	B
17	gene	O
18	is	O
19	driven	O
20	by	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	.	O
1	In	O
2	<UNK>	B
3	-	O
4	4	O
5	mutants	O
6	,	O
7	<UNK>	O
8	motor	O
9	neurons	O
10	<UNK>	O
11	the	O
12	pattern	O
13	of	O
14	<UNK>	O
15	input	O
16	normally	O
17	<UNK>	O
18	for	O
19	their	O
20	<UNK>	O
21	<UNK>	O
22	cells	O
23	,	O
24	the	O
25	<UNK>	O
26	motor	O
27	neurons	O
28	;	O
29	the	O
30	loss	O
31	of	O
32	normal	O
33	input	O
34	to	O
35	the	O
36	<UNK>	O
37	produces	O
38	a	O
39	<UNK>	O
40	<UNK>	O
41	movement	O
42	defect	O
43	.	O
1	No	O
2	patient	O
3	in	O
4	group	O
5	2	O
6	developed	O
7	<UNK>	O
8	(	O
9	P	O
10	=	O
11	0	O
12	.	O
13	<UNK>	O
14	versus	O
15	group	O
16	1	O
17	).	O
1	The	O
2	mammalian	O
3	<UNK>	B
4	3	O
5	-	O
6	kinases	O
7	(	O
8	<UNK>	B
9	)	O
10	<UNK>	B
11	,	O
12	beta	O
13	,	O
14	and	O
15	delta	O
16	form	O
17	heterodimers	O
18	with	O
19	Src	B
20	homology	O
21	2	O
22	(	O
23	SH2	B
24	)	O
25	domain	O
26	-	O
27	containing	O
28	<UNK>	O
29	such	O
30	as	O
31	<UNK>	B
32	or	O
33	<UNK>	B
34	(	O
35	<UNK>	B
36	).	O
1	Surprisingly	O
2	,	O
3	the	O
4	RXR	B
5	-	O
6	specific	O
7	ligand	O
8	9	O
9	-	O
10	cis	O
11	-	O
12	retinoic	O
13	acid	O
14	induced	O
15	binding	O
16	of	O
17	SRC	B
18	-	O
19	1	O
20	to	O
21	the	O
22	RXR	B
23	component	O
24	of	O
25	the	O
26	TRE	O
27	-	O
28	bound	O
29	heterodimer	O
30	.	O
1	In	O
2	<UNK>	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O
1	The	O
2	most	O
3	important	O
4	one	O
5	among	O
6	them	O
7	is	O
8	<UNK>	O
9	A	O
10	,	O
11	which	O
12	is	O
13	a	O
14	selective	O
15	<UNK>	O
16	drug	O
17	.	O
1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	B
7	<UNK>	O
8	,	O
9	<UNK>	B
10	-	O
11	AP	B
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	<UNK>	O
20	,	O
21	while	O
22	<UNK>	B
23	-	O
24	4	O
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	<UNK>	O
31	.	O
1	Also	O
2	,	O
3	transient	O
4	overexpression	O
5	of	O
6	this	O
7	protein	O
8	in	O
9	<UNK>	O
10	cells	O
11	reduced	O
12	the	O
13	transcription	O
14	of	O
15	a	O
16	CAT	B
17	-	O
18	reporter	O
19	regulated	O
20	by	O
21	an	O
22	E12	B
23	/	O
24	MyoD	B
25	driven	O
26	enhancer	O
27	.	O
1	<UNK>	O
2	deficiency	O
3	significantly	O
4	depressed	O
5	the	O
6	amplitude	O
7	of	O
8	<UNK>	O
9	and	O
10	<UNK>	O
11	.	O
1	The	O
2	findings	O
3	suggest	O
4	that	O
5	<UNK>	O
6	effects	O
7	of	O
8	distinct	O
9	memory	O
10	processes	O
11	are	O
12	differentially	O
13	influenced	O
14	by	O
15	the	O
16	encoding	O
17	<UNK>	O
18	.	O
1	Using	O
2	mouse	O
3	-	O
4	human	O
5	somatic	O
6	<UNK>	O
7	and	O
8	<UNK>	O
9	analysis	O
10	,	O
11	the	O
12	<UNK>	O
13	-	O
14	2	O
15	gene	O
16	is	O
17	localized	O
18	to	O
19	human	O
20	chromosome	O
21	<UNK>	O
22	.	O
23	2	O
24	,	O
25	a	O
26	region	O
27	involved	O
28	in	O
29	<UNK>	O
30	and	O
31	deletions	O
32	in	O
33	<UNK>	O
34	and	O
35	several	O
36	solid	O
37	tumors	O
38	,	O
39	suggesting	O
40	that	O
41	this	O
42	novel	O
43	ETS	B
44	factor	O
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	<UNK>	O
51	.	O
1	The	O
2	<UNK>	B
3	,	O
4	which	O
5	can	O
6	be	O
7	of	O
8	the	O
9	<UNK>	O
10	-	O
11	or	O
12	cyclosporin	O
13	A	O
14	-	O
15	binding	O
16	class	O
17	,	O
18	binds	O
19	to	O
20	<UNK>	B
21	via	O
22	its	O
23	<UNK>	O
24	repeat	O
25	(	O
26	<UNK>	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	different	O
32	receptor	O
33	<UNK>	O
34	exist	O
35	depending	O
36	upon	O
37	which	O
38	<UNK>	B
39	<UNK>	O
40	the	O
41	<UNK>	O
42	-	O
43	binding	O
44	region	O
45	of	O
46	<UNK>	B
47	.	O
1	In	O
2	<UNK>	O
3	macrophages	O
4	,	O
5	absence	O
6	of	O
7	<UNK>	B
8	led	O
9	to	O
10	the	O
11	<UNK>	O
12	and	O
13	<UNK>	O
14	of	O
15	<UNK>	B
16	/	O
17	59	O
18	(	O
19	<UNK>	B
20	)	O
21	and	O
22	p53	B
23	/	O
24	56	O
25	(	O
26	<UNK>	B
27	),	O
28	but	O
29	not	O
30	of	O
31	<UNK>	B
32	(	O
33	c	B
34	-	O
35	<UNK>	B
36	).	O
1	With	O
2	a	O
3	view	O
4	to	O
5	<UNK>	O
6	other	O
7	important	O
8	<UNK>	B
9	interactions	O
10	,	O
11	a	O
12	stem	O
13	-	O
14	loop	O
15	domain	O
16	required	O
17	for	O
18	activity	O
19	of	O
20	Saccharomyces	O
21	cerevisiae	O
22	<UNK>	B
23	RNAs	O
24	(	O
25	the	O
26	Y	O
27	domain	O
28	)	O
29	was	O
30	first	O
31	subjected	O
32	to	O
33	detailed	O
34	mutational	O
35	analysis	O
36	.	O
1	The	O
2	linear	O
3	plasmid	O
4	<UNK>	O
5	from	O
6	<UNK>	O
7	<UNK>	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	<UNK>	B
16	-	O
17	plasmid	O
18	DNA	O
19	polymerase	O
20	.	O
1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	<UNK>	O
7	<UNK>	O
8	reflex	O
9	evoked	O
10	by	O
11	bladder	O
12	filling	O
13	and	O
14	L	O
15	-	O
16	<UNK>	O
17	involves	O
18	a	O
19	<UNK>	O
20	pathway	O
21	where	O
22	transmission	O
23	is	O
24	partly	O
25	mediated	O
26	by	O
27	spinal	O
28	alpha	O
29	1	O
30	-	O
31	<UNK>	B
32	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	in	O
5	the	O
6	above	O
7	pathological	O
8	condition	O
9	results	O
10	from	O
11	the	O
12	damage	O
13	to	O
14	<UNK>	O
15	<UNK>	O
16	and	O
17	loss	O
18	of	O
19	its	O
20	function	O
21	for	O
22	the	O
23	support	O
24	of	O
25	structural	O
26	<UNK>	O
27	.	O
1	<UNK>	O
2	,	O
3	neck	O
4	or	O
5	<UNK>	O
6	muscles	O
7	<UNK>	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O
1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	O
11	guanine	O
12	nucleotide	O
13	exchange	O
14	factors	O
15	or	O
16	GTPase	B
17	-	O
18	activating	O
19	proteins	O
20	in	O
21	the	O
22	c	B
23	-	O
24	<UNK>	B
25	gene	O
26	.	O
1	The	O
2	ubiquitously	O
3	expressed	O
4	hypoxia	O
5	-	O
6	inducible	O
7	factor	O
8	-	O
9	1	O
10	(	O
11	<UNK>	B
12	-	O
13	1	O
14	)	O
15	is	O
16	involved	O
17	in	O
18	expression	O
19	of	O
20	a	O
21	large	O
22	number	O
23	of	O
24	oxygen	O
25	-	O
26	regulated	O
27	genes	O
28	.	O
1	<UNK>	O
2	for	O
3	<UNK>	O
4	was	O
5	conducted	O
6	by	O
7	<UNK>	O
8	<UNK>	O
9	of	O
10	treatment	O
11	-	O
12	group	O
13	<UNK>	O
14	,	O
15	using	O
16	<UNK>	O
17	measurements	O
18	of	O
19	blood	O
20	pressure	O
21	and	O
22	urinary	O
23	protein	O
24	excretion	O
25	at	O
26	<UNK>	O
27	<UNK>	O
28	<UNK>	O
29	<UNK>	O
30	,	O
31	<UNK>	O
32	for	O
33	monitoring	O
34	these	O
35	measurements	O
36	during	O
37	the	O
38	<UNK>	O
39	for	O
40	delivery	O
41	,	O
42	and	O
43	<UNK>	O
44	of	O
45	medical	O
46	<UNK>	O
47	of	O
48	<UNK>	O
49	<UNK>	O
50	<UNK>	O
51	and	O
52	all	O
53	<UNK>	O
54	.	O
1	We	O
2	have	O
3	initiated	O
4	studies	O
5	to	O
6	identify	O
7	candidate	O
8	signal	O
9	<UNK>	O
10	that	O
11	associate	O
12	with	O
13	the	O
14	cytosolic	O
15	domain	O
16	(	O
17	<UNK>	O
18	)	O
19	of	O
20	the	O
21	IL	B
22	-	O
23	<UNK>	O
24	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	<UNK>	O
7	to	O
8	identify	O
9	mechanisms	O
10	that	O
11	could	O
12	account	O
13	for	O
14	the	O
15	<UNK>	O
16	effects	O
17	of	O
18	IL	B
19	-	O
20	4	O
21	.	O
1	Pseudomonas	O
2	<UNK>	O
3	strains	O
4	<UNK>	O
5	patients	O
6	with	O
7	cystic	O
8	<UNK>	O
9	(	O
10	<UNK>	O
11	)	O
12	<UNK>	O
13	a	O
14	<UNK>	O
15	phenotype	O
16	due	O
17	to	O
18	<UNK>	O
19	of	O
20	<UNK>	O
21	.	O
1	<UNK>	B
2	acetyltransferase	I
3	assays	O
4	<UNK>	O
5	the	O
6	ability	O
7	of	O
8	<UNK>	B
9	to	O
10	repress	O
11	activity	O
12	from	O
13	the	O
14	<UNK>	O
15	major	O
16	<UNK>	B
17	promoter	O
18	or	O
19	activate	O
20	the	O
21	<UNK>	O
22	early	O
23	promoter	O
24	for	O
25	the	O
26	2	O
27	.	O
28	2	O
29	-	O
30	kb	O
31	class	O
32	of	O
33	RNAs	O
34	demonstrated	O
35	the	O
36	functional	O
37	integrity	O
38	of	O
39	the	O
40	<UNK>	B
41	protein	O
42	.	O
1	ORF	O
2	<UNK>	O
3	has	O
4	striking	O
5	homology	O
6	to	O
7	<UNK>	O
8	<UNK>	B
9	,	O
10	while	O
11	ORF	O
12	<UNK>	O
13	encodes	O
14	a	O
15	potential	O
16	homolog	O
17	of	O
18	Bcl	B
19	-	O
20	2	O
21	-	O
22	like	O
23	molecules	O
24	encoded	O
25	by	O
26	other	O
27	<UNK>	O
28	(	O
29	gene	O
30	16	O
31	of	O
32	<UNK>	O
33	and	O
34	<UNK>	O
35	and	O
36	the	O
37	<UNK>	B
38	gene	O
39	of	O
40	EBV	O
41	).	O
1	The	O
2	behavior	O
3	of	O
4	different	O
5	types	O
6	of	O
7	<UNK>	O
8	(	O
9	<UNK>	O
10	)	O
11	<UNK>	O
12	in	O
13	the	O
14	<UNK>	O
15	<UNK>	O
16	process	O
17	of	O
18	abdominal	O
19	wall	O
20	defects	O
21	.	O
1	The	O
2	control	O
3	group	O
4	revealed	O
5	significantly	O
6	higher	O
7	levels	O
8	of	O
9	coagulation	O
10	factors	O
11	II	O
12	,	O
13	V	O
14	and	O
15	VIII	O
16	,	O
17	compared	O
18	to	O
19	the	O
20	index	O
21	group	O
22	.	O
1	If	O
2	E	O
3	.	O
4	coli	O
5	is	O
6	present	O
7	in	O
8	any	O
9	source	O
10	water	O
11	sample	O
12	,	O
13	the	O
14	<UNK>	O
15	and	O
16	any	O
17	directly	O
18	connected	O
19	<UNK>	O
20	should	O
21	be	O
22	<UNK>	O
23	.	O
1	In	O
2	summary	O
3	,	O
4	<UNK>	O
5	express	O
6	receptors	O
7	for	O
8	a	O
9	broad	O
10	panel	O
11	of	O
12	cytokines	O
13	,	O
14	even	O
15	receptors	O
16	for	O
17	cytokines	O
18	whose	O
19	effects	O
20	on	O
21	<UNK>	O
22	are	O
23	still	O
24	unknown	O
25	(	O
26	i	O
27	.	O
28	e	O
29	.	O
1	<UNK>	O
2	-	O
3	evaluation	O
4	of	O
5	the	O
6	biopsy	O
7	<UNK>	O
8	from	O
9	the	O
10	right	O
11	hip	O
12	taken	O
13	at	O
14	the	O
15	time	O
16	of	O
17	the	O
18	initial	O
19	operation	O
20	showed	O
21	areas	O
22	of	O
23	<UNK>	O
24	<UNK>	O
25	in	O
26	the	O
27	background	O
28	of	O
29	<UNK>	O
30	<UNK>	O
31	.	O
1	<UNK>	O
2	analysis	O
3	of	O
4	long	O
5	-	O
6	term	O
7	outcome	O
8	measures	O
9	of	O
10	performance	O
11	with	O
12	the	O
13	implant	O
14	will	O
15	confirm	O
16	or	O
17	<UNK>	O
18	the	O
19	<UNK>	O
20	of	O
21	ear	O
22	selection	O
23	using	O
24	the	O
25	<UNK>	O
26	-	O
27	<UNK>	O
28	.	O
1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	Cbl	B
7	,	O
8	the	O
9	120	O
10	-	O
11	kDa	O
12	protein	O
13	product	O
14	of	O
15	the	O
16	c	B
17	-	O
18	<UNK>	B
19	proto	O
20	-	O
21	oncogene	B
22	,	O
23	serves	O
24	as	O
25	a	O
26	substrate	O
27	of	O
28	a	O
29	number	O
30	of	O
31	receptor	O
32	-	O
33	coupled	O
34	tyrosine	O
35	kinases	O
36	and	O
37	forms	O
38	complexes	O
39	with	O
40	SH3	B
41	and	O
42	SH2	B
43	domain	O
44	-	O
45	containing	O
46	proteins	O
47	,	O
48	<UNK>	O
49	to	O
50	its	O
51	role	O
52	in	O
53	signal	O
54	transduction	O
55	.	O
1	Although	O
2	neither	O
3	constitutively	O
4	activated	O
5	MEK	B
6	(	O
7	MEK	B
8	-	O
9	<UNK>	B
10	)	O
11	nor	O
12	v	O
13	-	O
14	Src	B
15	was	O
16	sufficient	O
17	<UNK>	O
18	to	O
19	<UNK>	O
20	the	O
21	<UNK>	B
22	-	O
23	7	O
24	cells	O
25	,	O
26	<UNK>	O
27	of	O
28	constitutively	O
29	activated	O
30	MEK	B
31	and	O
32	v	O
33	-	O
34	Src	B
35	induced	O
36	<UNK>	O
37	<UNK>	O
38	.	O
1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	<UNK>	O
18	of	O
19	AP	B
20	-	O
21	1	O
22	activity	O
23	.	O
1	In	O
2	a	O
3	series	O
4	of	O
5	patients	O
6	with	O
7	<UNK>	O
8	,	O
9	<UNK>	O
10	disease	O
11	,	O
12	<UNK>	O
13	<UNK>	O
14	syndrome	O
15	,	O
16	<UNK>	O
17	,	O
18	partial	O
19	or	O
20	generalized	O
21	,	O
22	epilepsy	O
23	,	O
24	we	O
25	have	O
26	investigated	O
27	<UNK>	O
28	antibodies	O
29	of	O
30	IgG	B
31	and	O
32	IgM	B
33	<UNK>	O
34	,	O
35	together	O
36	with	O
37	<UNK>	O
38	factors	O
39	,	O
40	member	O
41	of	O
42	<UNK>	O
43	,	O
44	<UNK>	O
45	rate	O
46	of	O
47	<UNK>	O
48	.	O
1	(	O
2	<UNK>	O
3	)	O
4	<UNK>	O
5	35	O
6	,	O
7	<UNK>	O
8	-	O
9	<UNK>	O
10	].	O
1	<UNK>	O
2	,	O
3	the	O
4	membrane	O
5	expression	O
6	of	O
7	alpha	O
8	and	O
9	beta	O
10	subunits	O
11	was	O
12	<UNK>	O
13	by	O
14	cholesterol	O
15	and	O
16	17	O
17	-	O
18	<UNK>	O
19	,	O
20	both	O
21	of	O
22	which	O
23	inhibit	O
24	HMG	B
25	-	O
26	CoA	B
27	reductase	I
28	.	O
1	In	O
2	all	O
3	experimental	O
4	eyes	O
5	,	O
6	there	O
7	was	O
8	a	O
9	marked	O
10	reduction	O
11	,	O
12	but	O
13	<UNK>	O
14	a	O
15	complete	O
16	absence	O
17	of	O
18	adrenergic	O
19	nerves	O
20	in	O
21	the	O
22	<UNK>	O
23	.	O
1	Therefore	O
2	,	O
3	use	O
4	of	O
5	<UNK>	O
6	is	O
7	recommended	O
8	for	O
9	myocardial	O
10	motion	O
11	studies	O
12	using	O
13	<UNK>	O
14	PC	O
15	velocity	O
16	data	O
17	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	DNA	O
6	-	O
7	binding	O
8	experiments	O
9	show	O
10	that	O
11	either	O
12	one	O
13	of	O
14	the	O
15	two	O
16	<UNK>	B
17	domains	O
18	of	O
19	a	O
20	dimer	O
21	can	O
22	be	O
23	sufficient	O
24	to	O
25	confer	O
26	a	O
27	particular	O
28	DNA	O
29	-	O
30	binding	O
31	specificity	O
32	to	O
33	the	O
34	complex	O
35	and	O
36	that	O
37	sequences	O
38	outside	O
39	the	O
40	amino	O
41	-	O
42	terminal	O
43	basic	O
44	region	O
45	of	O
46	the	O
47	<UNK>	B
48	domain	O
49	can	O
50	,	O
51	in	O
52	some	O
53	cases	O
54	,	O
55	contribute	O
56	to	O
57	the	O
58	DNA	O
59	-	O
60	binding	O
61	specificity	O
62	of	O
63	the	O
64	proteins	O
65	.	O
1	Two	O
2	related	O
3	studies	O
4	conducted	O
5	over	O
6	a	O
7	five	O
8	week	O
9	period	O
10	measured	O
11	and	O
12	<UNK>	O
13	HLA	B
14	-	O
15	<UNK>	B
16	from	O
17	<UNK>	O
18	DNA	O
19	on	O
20	<UNK>	O
21	<UNK>	O
22	and	O
23	<UNK>	O
24	DNA	O
25	<UNK>	O
26	structures	O
27	.	O
1	Thirty	O
2	-	O
3	two	O
4	rats	O
5	were	O
6	divided	O
7	into	O
8	four	O
9	groups	O
10	.	O
1	<UNK>	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O
1	<UNK>	O
2	lymphoid	O
3	hyperplasia	O
4	was	O
5	found	O
6	in	O
7	15	O
8	cases	O
9	,	O
10	2	O
11	cases	O
12	had	O
13	<UNK>	O
14	lymphoid	O
15	hyperplasia	O
16	or	O
17	<UNK>	O
18	'	O
19	s	O
20	disease	O
21	,	O
22	atypical	O
23	lymphoid	O
24	hyperplasia	O
25	<UNK>	O
26	of	O
27	malignant	O
28	lymphoma	O
29	was	O
30	observed	O
31	in	O
32	3	O
33	cases	O
34	,	O
35	and	O
36	malignant	O
37	lymphoma	O
38	was	O
39	diagnosed	O
40	in	O
41	the	O
42	remaining	O
43	4	O
44	cases	O
45	.	O
1	For	O
2	E2	O
3	,	O
4	each	O
5	cat	O
6	was	O
7	given	O
8	either	O
9	5	O
10	(	O
11	group	O
12	[	O
13	G	O
14	]	O
15	1	O
16	)	O
17	or	O
18	10	O
19	(	O
20	G2	O
21	)	O
22	mg	O
23	of	O
24	<UNK>	O
25	/	O
26	kg	O
27	(	O
28	<UNK>	O
29	)	O
30	twice	O
31	daily	O
32	for	O
33	6	O
34	weeks	O
35	.	O
1	G	O
2	-	O
3	CSF	B
4	was	O
5	<UNK>	O
6	on	O
7	day	O
8	3	O
9	of	O
10	each	O
11	cycle	O
12	(	O
13	5	O
14	microg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	was	O
22	<UNK>	O
23	the	O
24	day	O
25	before	O
26	the	O
27	last	O
28	<UNK>	O
29	or	O
30	when	O
31	absolute	O
32	neutrophil	O
33	count	O
34	was	O
35	above	O
36	0	O
37	.	O
38	5	O
39	x	O
40	10	O
41	(	O
42	9	O
43	)/	O
44	l	O
45	.	O
1	<UNK>	O
2	assays	O
3	,	O
4	using	O
5	Jun	B
6	and	O
7	Fos	B
8	family	O
9	member	O
10	-	O
11	specific	O
12	antibodies	O
13	,	O
14	showed	O
15	that	O
16	protein	O
17	complexes	O
18	formed	O
19	by	O
20	<UNK>	O
21	-	O
22	20	O
23	cell	O
24	nuclear	O
25	extracts	O
26	bound	O
27	to	O
28	the	O
29	c	B
30	-	O
31	jun	B
32	AP	I
33	-	O
34	1	O
35	site	O
36	were	O
37	<UNK>	O
38	of	O
39	Jun	B
40	family	O
41	members	O
42	,	O
43	<UNK>	B
44	,	O
45	<UNK>	B
46	,	O
47	and	O
48	<UNK>	B
49	.	O
1	Using	O
2	<UNK>	B
3	-	O
4	affinity	O
5	chromatography	O
6	,	O
7	<UNK>	O
8	between	O
9	the	O
10	pattern	O
11	of	O
12	O	O
13	-	O
14	glycosylation	O
15	of	O
16	<UNK>	B
17	and	O
18	<UNK>	B
19	was	O
20	demonstrated	O
21	.	O
1	The	O
2	dose	O
3	was	O
4	50	O
5	Gy	O
6	/	O
7	20	O
8	fractions	O
9	/	O
10	5	O
11	weeks	O
12	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	identify	O
7	and	O
8	characterize	O
9	two	O
10	overlapping	O
11	<UNK>	B
12	functional	O
13	domains	O
14	that	O
15	<UNK>	O
16	its	O
17	interaction	O
18	with	O
19	RNA	O
20	polymerase	O
21	II	O
22	and	O
23	the	O
24	ternary	O
25	elongation	O
26	complex	O
27	.	O
1	Here	O
2	,	O
3	we	O
4	describe	O
5	<UNK>	O
6	chromosome	O
7	<UNK>	O
8	studies	O
9	<UNK>	O
10	from	O
11	<UNK>	B
12	as	O
13	well	O
14	as	O
15	<UNK>	B
16	.	O
1	We	O
2	describe	O
3	a	O
4	novel	O
5	zinc	O
6	finger	O
7	protein	O
8	,	O
9	<UNK>	B
10	-	O
11	<UNK>	B
12	,	O
13	isolated	O
14	by	O
15	screening	O
16	an	O
17	expression	O
18	library	O
19	with	O
20	<UNK>	O
21	.	O
1	<UNK>	O
2	absorption	O
3	was	O
4	rapid	O
5	,	O
6	nasal	O
7	<UNK>	O
8	was	O
9	43	O
10	%,	O
11	and	O
12	the	O
13	iv	O
14	and	O
15	nasal	O
16	elimination	O
17	profiles	O
18	were	O
19	similar	O
20	.	O
1	<UNK>	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	EGF	B
8	/	O
9	Ras	B
10	/	O
11	Raf	B
12	induces	O
13	transcription	O
14	via	O
15	combined	O
16	activation	O
17	of	O
18	<UNK>	B
19	/	O
20	c	B
21	-	O
22	Jun	B
23	and	O
24	a	O
25	52	O
26	-	O
27	kDa	O
28	nuclear	O
29	factor	O
30	,	O
31	whereas	O
32	<UNK>	B
33	acts	O
34	as	O
35	a	O
36	repressor	O
37	of	O
38	this	O
39	response	O
40	.	O
1	<UNK>	O
2	assays	O
3	demonstrate	O
4	promoter	O
5	activity	O
6	in	O
7	this	O
8	sequence	O
9	that	O
10	<UNK>	O
11	the	O
12	normal	O
13	control	O
14	of	O
15	<UNK>	B
16	expression	O
17	during	O
18	a	O
19	growth	O
20	stimulation	O
21	.	O
1	The	O
2	<UNK>	B
3	nuclear	O
4	receptor	O
5	response	O
6	element	O
7	1	O
8	(	O
9	<UNK>	B
10	-	O
11	1	O
12	)	O
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	<UNK>	B
18	alpha	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O
1	The	O
2	complete	O
3	response	O
4	(	O
5	<UNK>	O
6	)	O
7	rate	O
8	was	O
9	34	O
10	%	O
11	in	O
12	the	O
13	<UNK>	O
14	with	O
15	<UNK>	B
16	-	O
17	CSF	B
18	group	O
19	and	O
20	23	O
21	%	O
22	in	O
23	the	O
24	<UNK>	O
25	alone	O
26	group	O
27	;	O
28	the	O
29	median	O
30	survival	O
31	was	O
32	59	O
33	and	O
34	32	O
35	weeks	O
36	,	O
37	respectively	O
38	,	O
39	in	O
40	these	O
41	groups	O
42	(	O
43	P	O
44	=	O
45	0	O
46	.	O
47	<UNK>	O
48	).	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	<UNK>	O
15	<UNK>	O
16	.	O
1	Overexpression	O
2	of	O
3	<UNK>	B
4	in	O
5	<UNK>	O
6	suppresses	O
7	cardiac	O
8	<UNK>	B
9	C	O
10	and	O
11	atrial	O
12	<UNK>	O
13	factor	O
14	transcription	O
15	.	O
1	<UNK>	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	competition	O
7	experiments	O
8	showed	O
9	that	O
10	site	O
11	A	O
12	is	O
13	recognized	O
14	by	O
15	an	O
16	NF1	B
17	protein	O
18	.	O
1	<UNK>	B
2	was	O
3	shown	O
4	to	O
5	be	O
6	a	O
7	dimer	O
8	of	O
9	two	O
10	equal	O
11	subunits	O
12	,	O
13	each	O
14	with	O
15	a	O
16	molecular	O
17	mass	O
18	of	O
19	37	O
20	,	O
21	000	O
22	<UNK>	O
23	.	O
1	Neither	O
2	mutant	O
3	exhibited	O
4	<UNK>	O
5	of	O
6	the	O
7	<UNK>	O
8	mating	O
9	type	O
10	loci	O
11	.	O
1	These	O
2	repressor	O
3	sites	O
4	are	O
5	<UNK>	O
6	rich	O
7	and	O
8	bind	O
9	<UNK>	O
10	to	O
11	the	O
12	<UNK>	O
13	tract	O
14	binding	O
15	protein	O
16	(	O
17	PTB	O
18	)	O
19	in	O
20	HeLa	O
21	nuclear	O
22	extracts	O
23	as	O
24	determined	O
25	by	O
26	UV	O
27	<UNK>	O
28	/	O
29	competition	O
30	assays	O
31	.	O
1	Within	O
2	a	O
3	<UNK>	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	O
12	<UNK>	B
13	<UNK>	O
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	O
22	homolog	O
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	O
37	enhancer	O
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	<UNK>	O
51	functional	O
52	motifs	O
53	.	O
1	The	O
2	<UNK>	O
3	mutant	O
4	produced	O
5	reduced	O
6	levels	O
7	of	O
8	<UNK>	B
9	,	O
10	indicating	O
11	that	O
12	<UNK>	O
13	may	O
14	have	O
15	a	O
16	role	O
17	in	O
18	T	O
19	beta	O
20	L	O
21	biosynthesis	O
22	.	O
1	These	O
2	transcripts	O
3	contain	O
4	the	O
5	5	O
6	'	O
7	ends	O
8	of	O
9	mature	O
10	<UNK>	B
11	mRNAs	O
12	;	O
13	extend	O
14	through	O
15	<UNK>	B
16	,	O
17	across	O
18	the	O
19	<UNK>	O
20	region	O
21	,	O
22	and	O
23	a	O
24	significant	O
25	distance	O
26	3	O
27	'	O
28	into	O
29	the	O
30	<UNK>	B
31	gene	O
32	.	O
1	For	O
2	<UNK>	O
3	interleukin	B
4	-	O
5	8	O
6	there	O
7	was	O
8	an	O
9	estimated	O
10	true	O
11	treatment	O
12	median	O
13	difference	O
14	of	O
15	<UNK>	O
16	pg	O
17	/	O
18	ml	O
19	(	O
20	95	O
21	%	O
22	<UNK>	O
23	interval	O
24	(	O
25	CI	O
26	)	O
27	8	O
28	to	O
29	<UNK>	O
30	pg	O
31	/	O
32	ml	O
33	)	O
34	in	O
35	<UNK>	O
36	of	O
37	placebo	O
38	;	O
39	while	O
40	for	O
41	maximal	O
42	<UNK>	O
43	flow	O
44	at	O
45	25	O
46	%	O
47	(	O
48	<UNK>	O
49	%)	O
50	remaining	O
51	<UNK>	O
52	<UNK>	O
53	capacity	O
54	predicted	O
55	for	O
56	sex	O
57	and	O
58	height	O
59	there	O
60	was	O
61	a	O
62	15	O
63	percentage	O
64	points	O
65	(	O
66	<UNK>	O
67	)	O
68	(	O
69	95	O
70	%	O
71	CI	O
72	4	O
73	to	O
74	26	O
75	<UNK>	O
76	)	O
77	mean	O
78	treatment	O
79	difference	O
80	in	O
81	<UNK>	O
82	of	O
83	placebo	O
84	.	O
1	Six	O
2	tandem	O
3	repeats	O
4	of	O
5	the	O
6	P	O
7	element	O
8	linked	O
9	to	O
10	the	O
11	SV40	O
12	promoter	O
13	<UNK>	O
14	to	O
15	phorbol	O
16	12	O
17	-	O
18	myristate	O
19	13	O
20	-	O
21	acetate	O
22	,	O
23	while	O
24	that	O
25	of	O
26	other	O
27	elements	O
28	did	O
29	not	O
30	.	O
1	The	O
2	cleavage	O
3	<UNK>	O
4	of	O
5	<UNK>	B
6	<UNK>	I
7	protease	O
8	are	O
9	Q	O
10	(	O
11	E	O
12	)/	O
13	S	O
14	(	O
15	A	O
16	,	O
17	G	O
18	).	O
1	These	O
2	effects	O
3	were	O
4	<UNK>	O
5	by	O
6	co	O
7	-	O
8	expression	O
9	of	O
10	kinase	B
11	-	O
12	deficient	O
13	PKC	B
14	zeta	I
15	and	O
16	inhibition	O
17	of	O
18	phosphatidylinositol	B
19	3	O
20	-	O
21	kinase	B
22	<UNK>	I
23	-	O
24	<UNK>	B
25	by	O
26	<UNK>	O
27	,	O
28	<UNK>	O
29	and	O
30	a	O
31	dominant	O
32	-	O
33	negative	O
34	mutant	O
35	of	O
36	<UNK>	B
37	.	O
1	<UNK>	O
2	the	O
3	<UNK>	O
4	of	O
5	these	O
6	risk	O
7	variables	O
8	were	O
9	three	O
10	factors	O
11	.	O
1	Deletion	O
2	of	O
3	the	O
4	<UNK>	B
5	gene	O
6	alone	O
7	had	O
8	no	O
9	detectable	O
10	phenotype	O
11	,	O
12	while	O
13	<UNK>	O
14	with	O
15	deletions	O
16	of	O
17	both	O
18	the	O
19	<UNK>	B
20	and	O
21	<UNK>	B
22	genes	O
23	were	O
24	viable	O
25	and	O
26	able	O
27	to	O
28	<UNK>	O
29	on	O
30	<UNK>	O
31	at	O
32	30	O
33	degrees	O
34	C	O
35	,	O
36	<UNK>	O
37	more	O
38	<UNK>	O
39	than	O
40	delta	O
41	<UNK>	B
42	single	O
43	mutants	O
44	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
1	In	O
2	this	O
3	study	O
4	we	O
5	have	O
6	introduced	O
7	mutations	O
8	into	O
9	the	O
10	corresponding	O
11	elements	O
12	of	O
13	two	O
14	<UNK>	B
15	promoters	O
16	and	O
17	show	O
18	that	O
19	while	O
20	the	O
21	core	O
22	element	O
23	is	O
24	essential	O
25	for	O
26	<UNK>	B
27	promoter	O
28	activity	O
29	,	O
30	upstream	O
31	element	O
32	mutations	O
33	have	O
34	little	O
35	or	O
36	no	O
37	effect	O
38	.	O
1	We	O
2	found	O
3	that	O
4	multiple	O
5	tumor	O
6	suppressor	O
7	genes	O
8	(	O
9	e	O
10	.	O
11	g	O
12	.,	O
13	p53	B
14	,	O
15	<UNK>	B
16	,	O
17	<UNK>	O
18	,	O
19	<UNK>	B
20	,	O
21	<UNK>	B
22	,	O
23	and	O
24	<UNK>	B
25	/	O
26	<UNK>	B
27	)	O
28	were	O
29	<UNK>	O
30	at	O
31	different	O
32	<UNK>	O
33	via	O
34	various	O
35	mechanisms	O
36	[	O
37	e	O
38	.	O
39	g	O
40	.,	O
41	loss	O
42	of	O
43	<UNK>	O
44	(	O
45	<UNK>	O
46	),	O
47	loss	O
48	of	O
49	expression	O
50	(	O
51	<UNK>	O
52	),	O
53	mutation	O
54	,	O
55	and	O
56	inactivation	O
57	by	O
58	cellular	O
59	binding	O
60	protein	O
61	].	O
1	<UNK>	O
2	include	O
3	the	O
4	p21	B
5	(	O
6	ras	B
7	)	O
8	proteins	O
9	,	O
10	nuclear	O
11	<UNK>	B
12	,	O
13	and	O
14	a	O
15	series	O
16	of	O
17	retinal	O
18	proteins	O
19	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	<UNK>	B
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	<UNK>	O
14	of	O
15	ubiquitin	B
16	by	O
17	hydrolysis	O
18	of	O
19	<UNK>	O
20	poly	O
21	-	O
22	ubiquitin	B
23	chains	O
24	generated	O
25	by	O
26	the	O
27	action	O
28	of	O
29	26	O
30	S	O
31	proteasome	O
32	on	O
33	poly	O
34	-	O
35	<UNK>	O
36	protein	O
37	substrates	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	production	O
45	of	O
46	free	O
47	ubiquitin	B
48	from	O
49	linear	O
50	poly	O
51	-	O
52	ubiquitin	B
53	chains	O
54	and	O
55	of	O
56	certain	O
57	ribosomal	O
58	proteins	O
59	from	O
60	ubiquitin	B
61	fusion	O
62	proteins	O
63	.	O
1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	<UNK>	B
17	and	O
18	<UNK>	B
19	genes	O
20	prior	O
21	to	O
22	any	O
23	<UNK>	O
24	analysis	O
25	.	O
1	<UNK>	O
2	emission	O
3	tomography	O
4	<UNK>	O
5	for	O
6	dopamine	O
7	<UNK>	B
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	<UNK>	O
14	<UNK>	O
15	.	O
1	<UNK>	O
2	from	O
3	the	O
4	<UNK>	B
5	A2	O
6	consensus	O
7	<UNK>	O
8	is	O
9	not	O
10	<UNK>	O
11	dependent	O
12	on	O
13	DNA	O
14	binding	O
15	as	O
16	the	O
17	TR	B
18	alpha	O
19	DNA	O
20	binding	O
21	mutant	O
22	was	O
23	still	O
24	able	O
25	to	O
26	inhibit	O
27	E	O
28	-	O
29	dependent	O
30	transactivation	O
31	.	O
1	Expression	O
2	from	O
3	this	O
4	element	O
5	is	O
6	regulated	O
7	by	O
8	a	O
9	<UNK>	O
10	protein	O
11	complex	O
12	containing	O
13	ubiquitous	O
14	(	O
15	i	O
16	.	O
17	e	O
18	.	O
19	the	O
20	<UNK>	B
21	-	O
22	and	O
23	<UNK>	B
24	-	O
25	encoded	O
26	proteins	O
27	)	O
28	and	O
29	<UNK>	O
30	-	O
31	enriched	O
32	members	O
33	of	O
34	the	O
35	bHLH	O
36	family	O
37	.	O
1	Thus	O
2	,	O
3	the	O
4	CCAAT	O
5	box	O
6	also	O
7	has	O
8	tissue	O
9	-	O
10	specific	O
11	characteristics	O
12	that	O
13	<UNK>	O
14	in	O
15	targeting	O
16	expression	O
17	of	O
18	the	O
19	alpha	O
20	-	O
21	subunit	O
22	gene	O
23	to	O
24	<UNK>	O
25	.	O
1	The	O
2	growth	O
3	-	O
4	<UNK>	O
5	properties	O
6	of	O
7	the	O
8	retroviral	O
9	v	O
10	-	O
11	<UNK>	B
12	oncogene	I
13	,	O
14	a	O
15	highly	O
16	mutated	O
17	<UNK>	O
18	of	O
19	the	O
20	chicken	O
21	thyroid	O
22	hormone	O
23	receptor	O
24	(	O
25	TR	B
26	)	O
27	alpha	O
28	,	O
29	have	O
30	so	O
31	far	O
32	exclusively	O
33	been	O
34	linked	O
35	to	O
36	dominant	O
37	repression	O
38	of	O
39	the	O
40	<UNK>	O
41	roles	O
42	of	O
43	TR	B
44	and	O
45	retinoic	O
46	acid	O
47	receptors	O
48	.	O
1	Serum	O
2	concentrations	O
3	of	O
4	E2	O
5	and	O
6	<UNK>	O
7	were	O
8	measured	O
9	on	O
10	d	O
11	0	O
12	,	O
13	1	O
14	,	O
15	3	O
16	,	O
17	5	O
18	,	O
19	7	O
20	,	O
21	13	O
22	,	O
23	21	O
24	,	O
25	28	O
26	,	O
27	42	O
28	,	O
29	56	O
30	,	O
31	84	O
32	,	O
33	112	O
34	,	O
35	and	O
36	<UNK>	O
37	in	O
38	<UNK>	O
39	<UNK>	O
40	administered	O
41	the	O
42	following	O
43	treatments	O
44	:	O
45	1	O
46	)	O
47	control	O
48	;	O
49	2	O
50	)	O
51	<UNK>	O
52	,	O
53	.	O
54	5	O
55	mg	O
56	per	O
57	<UNK>	O
58	daily	O
59	;	O
60	3	O
61	)	O
62	<UNK>	O
63	-	O
64	H	O
65	(	O
66	<UNK>	O
67	mg	O
68	<UNK>	O
69	+	O
70	14	O
71	mg	O
72	E2	O
73	);	O
74	4	O
75	)	O
76	<UNK>	O
77	-	O
78	H	O
79	+	O
80	<UNK>	O
81	;	O
82	5	O
83	)	O
84	<UNK>	O
85	-	O
86	H	O
87	(	O
88	200	O
89	mg	O
90	<UNK>	O
91	);	O
92	and	O
93	6	O
94	)	O
95	<UNK>	O
96	-	O
97	H	O
98	+	O
99	<UNK>	O
100	.	O
1	Because	O
2	of	O
3	the	O
4	operon	O
5	structure	O
6	of	O
7	this	O
8	organism	O
9	,	O
10	<UNK>	O
11	methods	O
12	such	O
13	as	O
14	<UNK>	O
15	mutagenesis	O
16	<UNK>	O
17	the	O
18	risk	O
19	of	O
20	<UNK>	O
21	<UNK>	O
22	effects	O
23	on	O
24	downstream	O
25	genes	O
26	or	O
27	<UNK>	O
28	secondary	O
29	mutations	O
30	<UNK>	O
31	in	O
32	the	O
33	genome	O
34	.	O
1	We	O
2	have	O
3	measured	O
4	the	O
5	kinetics	O
6	of	O
7	the	O
8	recovery	O
9	of	O
10	mRNA	O
11	synthesis	O
12	in	O
13	the	O
14	inducible	O
15	<UNK>	B
16	and	O
17	<UNK>	B
18	genes	O
19	after	O
20	exposure	O
21	of	O
22	yeast	O
23	cells	O
24	to	O
25	<UNK>	O
26	(	O
27	UV	O
28	)	O
29	radiation	O
30	.	O
1	The	O
2	medium	O
3	chains	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	<UNK>	B
9	and	O
10	<UNK>	B
11	,	O
12	have	O
13	been	O
14	implicated	O
15	in	O
16	two	O
17	types	O
18	of	O
19	interaction	O
20	:	O
21	assembly	O
22	with	O
23	the	O
24	beta1	B
25	and	O
26	<UNK>	B
27	chains	O
28	of	O
29	the	O
30	corresponding	O
31	complexes	O
32	and	O
33	recognition	O
34	of	O
35	tyrosine	O
36	-	O
37	based	O
38	sorting	O
39	signals	O
40	.	O
1	<UNK>	O
2	shock	O
3	stimulates	O
4	<UNK>	B
5	translocation	O
6	in	O
7	<UNK>	O
8	adipocytes	O
9	by	O
10	a	O
11	novel	O
12	tyrosine	O
13	kinase	B
14	pathway	O
15	.	O
1	<UNK>	O
2	,	O
3	<UNK>	B
4	-	O
5	delta	O
6	reduces	O
7	silencing	O
8	of	O
9	the	O
10	telomere	O
11	-	O
12	located	O
13	<UNK>	B
14	II	O
15	-	O
16	transcribed	O
17	genes	O
18	<UNK>	B
19	and	O
20	<UNK>	B
21	.	O
1	PET	O
2	activation	O
3	studies	O
4	are	O
5	performed	O
6	widely	O
7	to	O
8	study	O
9	human	O
10	brain	O
11	function	O
12	.	O
1	Interestingly	O
2	,	O
3	EGF	B
4	,	O
5	but	O
6	not	O
7	insulin	B
8	,	O
9	stimulated	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	c	B
14	-	O
15	<UNK>	B
16	and	O
17	its	O
18	association	O
19	with	O
20	Crk	B
21	-	O
22	II	O
23	.	O
1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	N	O
7	-	O
8	terminal	O
9	portion	O
10	common	O
11	to	O
12	various	O
13	chimeric	O
14	<UNK>	B
15	products	O
16	,	O
17	as	O
18	well	O
19	as	O
20	to	O
21	<UNK>	B
22	-	O
23	<UNK>	B
24	and	O
25	<UNK>	B
26	-	O
27	<UNK>	B
28	,	O
29	<UNK>	O
30	in	O
31	the	O
32	nuclei	O
33	,	O
34	and	O
35	therefore	O
36	suggested	O
37	that	O
38	it	O
39	might	O
40	play	O
41	an	O
42	important	O
43	role	O
44	in	O
45	<UNK>	O
46	.	O
1	Induction	O
2	of	O
3	<UNK>	B
4	mRNA	O
5	accumulation	O
6	in	O
7	salt	O
8	-	O
9	treated	O
10	<UNK>	O
11	involves	O
12	an	O
13	immediate	O
14	early	O
15	transcriptional	O
16	response	O
17	regulated	O
18	by	O
19	<UNK>	O
20	signalling	O
21	that	O
22	is	O
23	not	O
24	inhibited	O
25	by	O
26	<UNK>	O
27	,	O
28	but	O
29	abolished	O
30	by	O
31	the	O
32	deficiency	O
33	of	O
34	<UNK>	O
35	biosynthesis	O
36	in	O
37	the	O
38	<UNK>	B
39	Arabidopsis	O
40	mutant	O
41	.	O
1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	B
6	functions	O
7	in	O
8	<UNK>	O
9	maturation	O
10	by	O
11	preventing	O
12	<UNK>	O
13	<UNK>	O
14	from	O
15	<UNK>	O
16	into	O
17	<UNK>	O
18	development	O
19	.	O
1	Their	O
2	biosynthesis	O
3	<UNK>	O
4	via	O
5	linear	O
6	precursors	O
7	that	O
8	become	O
9	<UNK>	O
10	by	O
11	beta1	B
12	,	O
13	6	O
14	-	O
15	<UNK>	O
16	<UNK>	O
17	(	O
18	<UNK>	O
19	,	O
20	<UNK>	O
21	to	O
22	<UNK>	B
23	).	O
1	In	O
2	addition	O
3	,	O
4	mutation	O
5	of	O
6	the	O
7	Sp1	B
8	site	O
9	also	O
10	significantly	O
11	reduced	O
12	promoter	O
13	activity	O
14	.	O
1	Moreover	O
2	,	O
3	in	O
4	one	O
5	patient	O
6	with	O
7	a	O
8	sarcoma	O
9	who	O
10	underwent	O
11	a	O
12	<UNK>	O
13	-	O
14	<UNK>	O
15	procedure	O
16	,	O
17	no	O
18	<UNK>	O
19	nerve	O
20	<UNK>	O
21	was	O
22	seen	O
23	<UNK>	O
24	.	O
1	20	O
2	%	O
3	of	O
4	total	O
5	<UNK>	B
6	transcripts	O
7	in	O
8	human	O
9	subcutaneous	O
10	adipocytes	O
11	.	O
1	A	O
2	DNase	B
3	I	O
4	-	O
5	hypersensitive	O
6	site	O
7	has	O
8	also	O
9	been	O
10	mapped	O
11	in	O
12	the	O
13	<UNK>	O
14	-	O
15	base	O
16	pair	O
17	enhancer	O
18	region	O
19	.	O
1	An	O
2	unusual	O
3	cysteine	O
4	<UNK>	O
5	conserved	O
6	in	O
7	the	O
8	sequences	O
9	of	O
10	<UNK>	O
11	domains	O
12	is	O
13	localized	O
14	to	O
15	the	O
16	hydrophobic	O
17	core	O
18	,	O
19	at	O
20	the	O
21	C	O
22	-	O
23	terminus	O
24	of	O
25	an	O
26	alpha	O
27	-	O
28	helix	O
29	.	O
1	Protein	O
2	phosphatases	B
3	play	O
4	a	O
5	critical	O
6	role	O
7	in	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	eukaryotic	O
13	cell	O
14	cycle	O
15	and	O
16	signal	O
17	transduction	O
18	.	O
1	The	O
2	cell	O
3	cycle	O
4	-	O
5	regulated	O
6	transcription	O
7	factor	O
8	E2F	B
9	is	O
10	also	O
11	known	O
12	to	O
13	<UNK>	O
14	DNA	O
15	upon	O
16	binding	O
17	.	O
1	Our	O
2	study	O
3	reveals	O
4	that	O
5	the	O
6	<UNK>	O
7	structure	O
8	of	O
9	the	O
10	FSH	B
11	receptor	O
12	gene	O
13	<UNK>	O
14	motifs	O
15	that	O
16	allows	O
17	coupling	O
18	to	O
19	different	O
20	<UNK>	O
21	.	O
1	PKA	B
2	phosphorylated	O
3	<UNK>	B
4	at	O
5	Ser	O
6	-	O
7	<UNK>	O
8	and	O
9	Ser	O
10	-	O
11	<UNK>	O
12	in	O
13	vitro	O
14	,	O
15	as	O
16	well	O
17	as	O
18	at	O
19	additional	O
20	sites	O
21	,	O
22	and	O
23	this	O
24	phosphorylation	O
25	abolished	O
26	the	O
27	DNA	O
28	-	O
29	binding	O
30	activity	O
31	of	O
32	<UNK>	B
33	in	O
34	vitro	O
35	.	O
1	<UNK>	O
2	:	O
3	""""	O
4	<UNK>	O
5	the	O
6	direction	O
7	of	O
8	<UNK>	O
9	in	O
10	cross	O
11	-	O
12	<UNK>	O
13	studies	O
14	<UNK>	O
1	The	O
2	presence	O
3	of	O
4	an	O
5	additional	O
6	sequence	O
7	of	O
8	nucleotides	O
9	<UNK>	O
10	-	O
11	<UNK>	O
12	from	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	<UNK>	B
19	enhanced	O
20	template	O
21	recognition	O
22	by	O
23	<UNK>	B
24	in	O
25	vitro	O
26	and	O
27	accumulation	O
28	of	O
29	<UNK>	B
30	in	O
31	vivo	O
32	to	O
33	wild	O
34	-	O
35	type	O
36	levels	O
37	.	O
1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	O
10	kappaB	B
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	B
26	-	O
27	1	O
28	.	O
1	The	O
2	<UNK>	B
3	<UNK>	I
4	site	O
5	is	O
6	immediately	O
7	5	O
8	'	O
9	to	O
10	a	O
11	PU	B
12	.	O
1	However	O
2	,	O
3	one	O
4	<UNK>	B
5	-	O
6	phosphorylated	O
7	<UNK>	O
8	<UNK>	O
9	with	O
10	a	O
11	Cdc2	B
12	-	O
13	phosphorylated	O
14	<UNK>	O
15	previously	O
16	shown	O
17	to	O
18	be	O
19	mitosis	O
20	-	O
21	specific	O
22	,	O
23	suggesting	O
24	that	O
25	,	O
26	in	O
27	vitro	O
28	,	O
29	<UNK>	B
30	is	O
31	able	O
32	to	O
33	phosphorylate	O
34	at	O
35	least	O
36	one	O
37	site	O
38	that	O
39	is	O
40	also	O
41	phosphorylated	O
42	in	O
43	vivo	O
44	.	O
1	One	O
2	of	O
3	these	O
4	,	O
5	an	O
6	<UNK>	O
7	motif	O
8	,	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	be	O
14	a	O
15	negative	O
16	regulator	O
17	in	O
18	non	O
19	-	O
20	<UNK>	O
21	tissues	O
22	and	O
23	has	O
24	a	O
25	similarity	O
26	to	O
27	the	O
28	<UNK>	O
29	<UNK>	O
30	responsive	O
31	element	O
32	recognized	O
33	by	O
34	<UNK>	B
35	-	O
36	like	O
37	DNA	O
38	binding	O
39	proteins	O
40	.	O
1	Expression	O
2	of	O
3	<UNK>	O
4	biosynthetic	O
5	genes	O
6	(	O
7	<UNK>	B
8	)	O
9	and	O
10	production	O
11	of	O
12	<UNK>	B
13	terminal	O
14	oxidase	B
15	<UNK>	I
16	in	O
17	<UNK>	O
18	<UNK>	O
19	.	O
1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	region	O
8	encoding	O
9	a	O
10	lipase	B
11	operon	O
12	and	O
13	a	O
14	putative	O
15	,	O
16	previously	O
17	<UNK>	O
18	<UNK>	B
19	of	O
20	<UNK>	O
21	<UNK>	O
22	<UNK>	O
23	.	O
1	Furthermore	O
2	,	O
3	the	O
4	amount	O
5	of	O
6	tRNA	O
7	(	O
8	<UNK>	B
9	)	O
10	that	O
11	was	O
12	placed	O
13	<UNK>	O
14	viral	O
15	RNA	O
16	in	O
17	mutated	O
18	viruses	O
19	was	O
20	significantly	O
21	less	O
22	than	O
23	that	O
24	placed	O
25	in	O
26	the	O
27	wild	O
28	-	O
29	type	O
30	virus	O
31	.	O
1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	pre	O
6	-	O
7	C	O
8	and	O
9	<UNK>	O
10	promoters	O
11	of	O
12	human	O
13	hepatitis	O
14	B	O
15	virus	O
16	by	O
17	members	O
18	of	O
19	the	O
20	nuclear	O
21	receptor	O
22	superfamily	O
23	.	O
1	Both	O
2	<UNK>	O
3	are	O
4	larger	O
5	than	O
6	their	O
7	homologues	O
8	in	O
9	eIF	B
10	-	O
11	<UNK>	B
12	kinases	O
13	.	O
1	<UNK>	O
2	of	O
3	adhesion	O
4	-	O
5	<UNK>	O
6	monoclonal	O
7	antibodies	O
8	map	O
9	within	O
10	a	O
11	predicted	O
12	alpha	O
13	-	O
14	helical	O
15	domain	O
16	of	O
17	the	O
18	integrin	B
19	beta	O
20	1	O
21	subunit	O
22	.	O
1	Furthermore	O
2	,	O
3	both	O
4	<UNK>	B
5	proteins	O
6	function	O
7	in	O
8	a	O
9	defined	O
10	<UNK>	O
11	system	O
12	<UNK>	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	<UNK>	B
22	proteins	O
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	O
30	with	O
31	<UNK>	B
32	.	O
1	The	O
2	yeast	O
3	<UNK>	O
4	information	O
5	regulator	O
6	<UNK>	B
7	<UNK>	O
8	and	O
9	<UNK>	O
10	plasmids	O
11	.	O
1	Two	O
2	sterol	O
3	regulatory	O
4	element	O
5	-	O
6	like	O
7	sequences	O
8	mediate	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	<UNK>	B
14	gene	O
15	transcription	O
16	in	O
17	response	O
18	to	O
19	low	O
20	density	O
21	lipoprotein	O
22	free	O
23	cholesterol	O
24	.	O
1	<UNK>	O
2	,	O
3	two	O
4	<UNK>	O
5	using	O
6	a	O
7	long	O
8	<UNK>	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	<UNK>	O
28	by	O
29	a	O
30	short	O
31	<UNK>	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	<UNK>	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O
1	<UNK>	O
2	evidence	O
3	indicates	O
4	that	O
5	,	O
6	upon	O
7	stimulation	O
8	with	O
9	interferon	B
10	-	O
11	gamma	O
12	(	O
13	IFN	B
14	-	O
15	gamma	O
16	),	O
17	three	O
18	beta	O
19	-	O
20	type	O
21	subunits	O
22	,	O
23	designated	O
24	<UNK>	B
25	,	O
26	<UNK>	B
27	,	O
28	and	O
29	<UNK>	B
30	,	O
31	are	O
32	incorporated	O
33	into	O
34	the	O
35	<UNK>	B
36	proteasome	O
37	by	O
38	<UNK>	O
39	the	O
40	<UNK>	O
41	beta	O
42	-	O
43	type	O
44	subunits	O
45	designated	O
46	<UNK>	B
47	,	O
48	<UNK>	B
49	,	O
50	and	O
51	<UNK>	B
52	,	O
53	respectively	O
54	.	O
1	This	O
2	difference	O
3	may	O
4	result	O
5	from	O
6	the	O
7	lower	O
8	<UNK>	O
9	to	O
10	the	O
11	<UNK>	O
12	box	O
13	consensus	O
14	of	O
15	the	O
16	O	O
17	(	O
18	<UNK>	B
19	)	O
20	site	O
21	.	O
1	The	O
2	<UNK>	O
3	of	O
4	morphological	O
5	research	O
6	on	O
7	the	O
8	<UNK>	O
9	nucleus	O
1	Inhibition	O
2	appears	O
3	to	O
4	result	O
5	from	O
6	<UNK>	O
7	of	O
8	general	O
9	transcription	O
10	factors	O
11	because	O
12	<UNK>	B
13	overexpression	O
14	inhibits	O
15	c	B
16	-	O
17	fos	B
18	as	O
19	well	O
20	as	O
21	other	O
22	promoters	O
23	in	O
24	vivo	O
25	and	O
26	basal	O
27	transcription	O
28	in	O
29	vitro	O
30	.	O
1	RESULTS	O
2	:	O
3	The	O
4	overall	O
5	<UNK>	O
6	for	O
7	1992	O
8	was	O
9	12	O
10	.	O
11	3	O
12	%	O
13	and	O
14	was	O
15	19	O
16	.	O
17	1	O
18	%,	O
19	22	O
20	.	O
21	2	O
22	%,	O
23	3	O
24	.	O
25	8	O
26	%	O
27	and	O
28	6	O
29	.	O
30	1	O
31	%	O
32	per	O
33	<UNK>	O
34	<UNK>	O
35	in	O
36	1992	O
37	.	O
1	Western	O
2	blot	O
3	analysis	O
4	of	O
5	various	O
6	bovine	O
7	tissues	O
8	with	O
9	human	O
10	<UNK>	B
11	peptide	O
12	antibody	O
13	indicated	O
14	a	O
15	common	O
16	<UNK>	O
17	<UNK>	O
18	band	O
19	with	O
20	an	O
21	apparent	O
22	molecular	O
23	mass	O
24	of	O
25	48	O
26	.	O
27	5	O
28	-	O
29	50	O
30	kDa	O
31	in	O
32	all	O
33	tissues	O
34	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	find	O
9	out	O
10	whether	O
11	it	O
12	was	O
13	possible	O
14	to	O
15	detect	O
16	normal	O
17	lymph	O
18	nodes	O
19	by	O
20	high	O
21	-	O
22	resolution	O
23	<UNK>	O
24	<UNK>	O
25	.	O
1	<UNK>	B
2	-	O
3	II	O
4	is	O
5	predicted	O
6	to	O
7	encode	O
8	a	O
9	type	O
10	II	O
11	transmembrane	O
12	glycoprotein	O
13	of	O
14	43	O
15	kDa	O
16	with	O
17	five	O
18	potential	O
19	N	O
20	-	O
21	linked	O
22	glycosylation	O
23	sites	O
24	.	O
1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	a	O
7	transfected	O
8	Chinese	O
9	hamster	O
10	ovary	O
11	(	O
12	<UNK>	O
13	)	O
14	cell	O
15	line	O
16	expressing	O
17	a	O
18	murine	O
19	CD4	B
20	fragment	O
21	containing	O
22	the	O
23	first	O
24	two	O
25	N	O
26	-	O
27	terminal	O
28	domains	O
29	<UNK>	O
30	both	O
31	<UNK>	O
32	molecules	O
33	and	O
34	<UNK>	O
35	-	O
36	linked	O
37	<UNK>	O
38	.	O
1	<UNK>	O
2	of	O
3	mouse	O
4	PKR	B
5	(	O
6	1	O
7	-	O
8	<UNK>	B
9	)	O
10	<UNK>	O
11	as	O
12	a	O
13	<UNK>	B
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	fusion	O
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	O
28	1	O
29	-	O
30	<UNK>	O
31	)	O
32	<UNK>	O
33	mutant	O
34	,	O
35	the	O
36	RNA	O
37	-	O
38	binding	O
39	-	O
40	deficient	O
41	human	O
42	PKR	B
43	(	O
44	1	O
45	-	O
46	<UNK>	O
47	)	O
48	<UNK>	B
49	/	O
50	<UNK>	O
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	O
56	-	O
57	type	O
58	mouse	O
59	PKR	B
60	(	O
61	1	O
62	-	O
63	<UNK>	B
64	)	O
65	<UNK>	O
66	as	O
67	full	O
68	-	O
69	length	O
70	PKR	B
71	-	O
72	<UNK>	B
73	activation	O
74	domain	O
75	fusions	O
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	<UNK>	B
82	and	O
83	lacZ	B
84	<UNK>	O
85	.	O
1	Interestingly	O
2	,	O
3	the	O
4	<UNK>	O
5	strain	O
6	<UNK>	O
7	showed	O
8	weak	O
9	hybridization	O
10	with	O
11	these	O
12	two	O
13	probes	O
14	,	O
15	suggesting	O
16	that	O
17	these	O
18	genes	O
19	might	O
20	have	O
21	been	O
22	deleted	O
23	in	O
24	the	O
25	<UNK>	O
26	strain	O
27	or	O
28	are	O
29	present	O
30	in	O
31	limited	O
32	copy	O
33	numbers	O
34	as	O
35	<UNK>	O
36	to	O
37	those	O
38	in	O
39	the	O
40	<UNK>	O
41	strain	O
42	<UNK>	O
43	.	O
1	<UNK>	O
2	between	O
3	the	O
4	<UNK>	B
5	-	O
6	1	O
7	and	O
8	<UNK>	B
9	kinase	I
10	(	O
11	<UNK>	B
12	)	O
13	promoters	O
14	,	O
15	including	O
16	regions	O
17	<UNK>	O
18	insulin	B
19	,	O
20	glucocorticoid	O
21	,	O
22	and	O
23	cyclic	O
24	adenosine	O
25	-	O
26	<UNK>	O
27	responses	O
28	,	O
29	are	O
30	consistent	O
31	with	O
32	our	O
33	previous	O
34	hypothesis	O
35	that	O
36	<UNK>	B
37	-	O
38	1	O
39	is	O
40	involved	O
41	in	O
42	regulation	O
43	of	O
44	glucose	O
45	metabolism	O
46	.	O
1	Moreover	O
2	,	O
3	moderate	O
4	overexpression	O
5	of	O
6	<UNK>	B
7	suppresses	O
8	the	O
9	phenotypes	O
10	of	O
11	<UNK>	B
12	and	O
13	<UNK>	B
14	mutants	O
15	.	O
1	<UNK>	O
2	basal	O
3	arteries	O
4	were	O
5	measured	O
6	by	O
7	the	O
8	<UNK>	O
9	approach	O
10	with	O
11	a	O
12	2	O
13	<UNK>	O
14	<UNK>	O
15	Doppler	O
16	<UNK>	O
17	(	O
18	<UNK>	O
19	-	O
20	2	O
21	<UNK>	O
22	<UNK>	O
23	).	O
1	Gel	O
2	mobility	O
3	shift	O
4	and	O
5	<UNK>	O
6	-	O
7	shift	O
8	assays	O
9	using	O
10	liver	O
11	nuclear	O
12	extracts	O
13	from	O
14	either	O
15	rat	O
16	liver	O
17	or	O
18	<UNK>	O
19	-	O
20	2	O
21	cells	O
22	demonstrated	O
23	that	O
24	the	O
25	CRE	O
26	in	O
27	the	O
28	alpha	O
29	<UNK>	O
30	-	O
31	AR	O
32	gene	O
33	bound	O
34	CRE	O
35	binding	O
36	protein	O
37	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	in	O
7	this	O
8	experimental	O
9	model	O
10	,	O
11	ACE	B
12	inhibitors	O
13	limit	O
14	the	O
15	arrhythmias	O
16	following	O
17	ischemia	O
18	-	O
19	reperfusion	O
20	and	O
21	free	O
22	<UNK>	O
23	<UNK>	O
24	action	O
25	of	O
26	these	O
27	drugs	O
28	does	O
29	not	O
30	have	O
31	a	O
32	major	O
33	<UNK>	O
34	role	O
35	in	O
36	their	O
37	protective	O
38	effect	O
39	.	O
1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	first	O
7	three	O
8	components	O
9	were	O
10	not	O
11	significantly	O
12	different	O
13	in	O
14	<UNK>	O
15	patients	O
16	and	O
17	control	O
18	subjects	O
19	.	O
1	One	O
2	R	O
3	-	O
4	<UNK>	O
5	and	O
6	one	O
7	<UNK>	B
8	-	O
9	like	O
10	sequence	O
11	each	O
12	mapped	O
13	to	O
14	two	O
15	<UNK>	O
16	.	O
1	<UNK>	B
2	<UNK>	I
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	O
12	coli	O
13	<UNK>	B
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	<UNK>	B
20	-	O
21	60	O
22	family	O
23	.	O
1	<UNK>	O
2	was	O
3	named	O
4	as	O
5	an	O
6	<UNK>	O
7	for	O
8	<UNK>	O
9	<UNK>	O
10	.	O
1	<UNK>	O
2	mechanisms	O
3	underlying	O
4	stimulus	O
5	-	O
6	response	O
7	(	O
8	S	O
9	-	O
10	R	O
11	)	O
12	<UNK>	O
13	in	O
14	S	O
15	-	O
16	R	O
17	<UNK>	O
18	<UNK>	O
19	were	O
20	identified	O
21	in	O
22	2	O
23	experiments	O
24	with	O
25	monkeys	O
26	.	O
1	The	O
2	<UNK>	B
3	gene	O
4	is	O
5	<UNK>	O
6	in	O
7	an	O
8	unusual	O
9	operon	O
10	which	O
11	contains	O
12	,	O
13	in	O
14	addition	O
15	,	O
16	two	O
17	genes	O
18	encoding	O
19	stress	O
20	-	O
21	sensitive	O
22	restriction	O
23	enzymes	O
24	.	O
1	The	O
2	gene	O
3	contains	O
4	six	O
5	exons	O
6	separated	O
7	by	O
8	1	O
9	.	O
10	1	O
11	-	O
12	5	O
13	.	O
14	8	O
15	kb	O
16	introns	O
17	and	O
18	has	O
19	been	O
20	localized	O
21	to	O
22	the	O
23	murine	O
24	chromosome	O
25	2	O
26	by	O
27	<UNK>	O
28	analysis	O
29	.	O
1	In	O
2	Xenopus	O
3	embryos	O
4	,	O
5	the	O
6	<UNK>	O
7	PDGF	B
8	receptor	O
9	protein	O
10	induced	O
11	the	O
12	formation	O
13	of	O
14	<UNK>	O
15	from	O
16	animal	O
17	-	O
18	<UNK>	O
19	<UNK>	O
20	in	O
21	an	O
22	<UNK>	O
23	-	O
24	dependent	O
25	manner	O
26	.	O
1	CONCLUSIONS	O
2	:	O
3	A	O
4	50	O
5	-	O
6	mg	O
7	daily	O
8	dose	O
9	of	O
10	<UNK>	O
11	is	O
12	sufficient	O
13	when	O
14	given	O
15	in	O
16	combination	O
17	with	O
18	an	O
19	agent	O
20	,	O
21	such	O
22	as	O
23	a	O
24	<UNK>	B
25	-	O
26	A	O
27	,	O
28	that	O
29	<UNK>	O
30	serum	O
31	testosterone	O
32	,	O
33	but	O
34	higher	O
35	doses	O
36	of	O
37	<UNK>	O
38	may	O
39	be	O
40	needed	O
41	when	O
42	the	O
43	drug	O
44	is	O
45	given	O
46	as	O
47	<UNK>	O
48	.	O
1	Although	O
2	the	O
3	gene	O
4	is	O
5	substantially	O
6	smaller	O
7	than	O
8	the	O
9	human	O
10	genes	O
11	for	O
12	other	O
13	mitochondrial	O
14	enzymes	O
15	,	O
16	its	O
17	intron	O
18	/	O
19	exon	O
20	organization	O
21	is	O
22	very	O
23	similar	O
24	,	O
25	especially	O
26	to	O
27	that	O
28	of	O
29	<UNK>	B
30	.	O
1	The	O
2	patient	O
3	underwent	O
4	two	O
5	<UNK>	O
6	sperm	O
7	injection	O
8	cycles	O
9	with	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	,	O
14	in	O
15	which	O
16	,	O
17	due	O
18	to	O
19	a	O
20	<UNK>	O
21	'	O
22	s	O
23	<UNK>	O
24	,	O
25	ovarian	O
26	stimulation	O
27	was	O
28	carried	O
29	out	O
30	by	O
31	a	O
32	combination	O
33	of	O
34	long	O
35	-	O
36	acting	O
37	<UNK>	B
38	-	O
39	releasing	B
40	hormone	O
41	agonist	O
42	(	O
43	<UNK>	O
44	<UNK>	O
45	)	O
46	and	O
47	<UNK>	B
48	.	O
1	To	O
2	examine	O
3	the	O
4	role	O
5	of	O
6	this	O
7	<UNK>	O
8	element	O
9	in	O
10	regulating	O
11	<UNK>	B
12	expression	O
13	in	O
14	vivo	O
15	,	O
16	transgenic	O
17	mice	O
18	were	O
19	generated	O
20	which	O
21	express	O
22	a	O
23	<UNK>	B
24	beta	O
25	-	O
26	galactosidase	B
27	reporter	O
28	gene	O
29	that	O
30	contains	O
31	a	O
32	mutation	O
33	in	O
34	the	O
35	<UNK>	O
36	element	O
37	.	O
1	<UNK>	O
2	46	O
3	phase	O
4	III	O
5	activities	O
6	were	O
7	recorded	O
8	.	O
1	In	O
2	vitro	O
3	DNase	B
4	I	O
5	footprinting	O
6	of	O
7	the	O
8	200	O
9	-	O
10	bp	O
11	proximal	O
12	region	O
13	of	O
14	the	O
15	promoter	O
16	with	O
17	a	O
18	murine	O
19	<UNK>	O
20	1	O
21	-	O
22	6	O
23	cell	O
24	nuclear	O
25	extract	O
26	revealed	O
27	a	O
28	clear	O
29	<UNK>	O
30	of	O
31	a	O
32	region	O
33	corresponding	O
34	to	O
35	-	O
36	80	O
37	to	O
38	-	O
39	28	O
40	bp	O
41	of	O
42	the	O
43	murine	O
44	<UNK>	B
45	gene	O
46	,	O
47	suggesting	O
48	that	O
49	liver	O
50	factors	O
51	interact	O
52	with	O
53	this	O
54	region	O
55	of	O
56	the	O
57	DNA	O
58	.	O
1	Both	O
2	increasing	O
3	basal	O
4	FSH	B
5	and	O
6	age	O
7	were	O
8	associated	O
9	significantly	O
10	with	O
11	increased	O
12	total	O
13	<UNK>	B
14	dose	O
15	,	O
16	and	O
17	reduced	O
18	number	O
19	of	O
20	<UNK>	O
21	collected	O
22	and	O
23	pregnancy	O
24	rate	O
25	.	O
1	Our	O
2	results	O
3	establish	O
4	<UNK>	B
5	as	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcription	O
11	factor	O
12	likely	O
13	involved	O
14	in	O
15	regulation	O
16	of	O
17	expression	O
18	of	O
19	endogenous	O
20	genes	O
21	.	O
1	In	O
2	addition	O
3	,	O
4	negatively	O
5	regulatory	O
6	region	O
7	may	O
8	exist	O
9	from	O
10	-	O
11	<UNK>	O
12	to	O
13	-	O
14	<UNK>	O
15	bp	O
16	.	O
1	We	O
2	have	O
3	cloned	O
4	a	O
5	kinase	B
6	,	O
7	<UNK>	B
8	,	O
9	that	O
10	is	O
11	a	O
12	murine	O
13	homolog	O
14	of	O
15	the	O
16	Drosophila	O
17	<UNK>	B
18	(	O
19	<UNK>	B
20	)	O
21	gene	O
22	.	O
1	This	O
2	region	O
3	,	O
4	however	O
5	,	O
6	contains	O
7	a	O
8	<UNK>	O
9	box	O
10	in	O
11	the	O
12	reverse	O
13	complement	O
14	and	O
15	several	O
16	GC	O
17	boxes	O
18	that	O
19	are	O
20	recognition	O
21	sites	O
22	for	O
23	<UNK>	B
24	.	O
1	Surprisingly	O
2	,	O
3	the	O
4	COOH	O
5	-	O
6	terminal	O
7	domain	O
8	of	O
9	<UNK>	B
10	was	O
11	also	O
12	found	O
13	to	O
14	<UNK>	O
15	a	O
16	nuclear	O
17	localization	O
18	signal	O
19	.	O
1	<UNK>	O
2	to	O
3	thyroid	O
4	hormone	O
5	:	O
6	implications	O
7	for	O
8	<UNK>	O
9	research	O
10	on	O
11	the	O
12	effects	O
13	of	O
14	thyroid	O
15	hormone	O
16	<UNK>	O
17	.	O
1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	that	O
7	exposure	O
8	of	O
9	<UNK>	O
10	lymphoma	O
11	B	O
12	cells	O
13	to	O
14	low	O
15	energy	O
16	<UNK>	O
17	field	O
18	(	O
19	<UNK>	O
20	)	O
21	results	O
22	in	O
23	a	O
24	tyrosine	O
25	kinase	B
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	<UNK>	B
31	<UNK>	I
32	(	O
33	PLC	B
34	-	O
35	<UNK>	B
36	)	O
37	leading	O
38	to	O
39	increased	O
40	<UNK>	O
41	<UNK>	O
42	turnover	O
43	.	O
1	<UNK>	O
2	AND	O
3	<UNK>	O
4	:	O
5	Since	O
6	<UNK>	O
7	,	O
8	62	O
9	patients	O
10	were	O
11	<UNK>	O
12	<UNK>	O
13	.	O
1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	O
6	single	O
7	-	O
8	chain	O
9	<UNK>	B
10	and	O
11	<UNK>	B
12	fragments	O
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O
1	A	O
2	putative	O
3	inhibitor	O
4	(	O
5	s	O
6	)	O
7	appears	O
8	to	O
9	co	O
10	-	O
11	<UNK>	O
12	in	O
13	the	O
14	inactive	O
15	fraction	O
16	that	O
17	blocked	O
18	the	O
19	L	O
20	(	O
21	alpha	O
22	)	O
23	activity	O
24	.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	among	O
5	Drosophila	O
6	nuclear	O
7	receptors	O
8	at	O
9	the	O
10	<UNK>	O
11	response	O
12	element	O
13	of	O
14	the	O
15	ng	O
16	-	O
17	1	O
18	and	O
19	ng	O
20	-	O
21	2	O
22	<UNK>	B
23	genes	O
24	.	O
1	<UNK>	O
2	aggregation	O
3	of	O
4	low	O
5	-	O
6	and	O
7	high	O
8	-	O
9	density	O
10	lipoprotein	O
11	cholesterol	O
12	and	O
13	<UNK>	B
14	B	O
15	and	O
16	A	O
17	-	O
18	I	O
19	levels	O
20	in	O
21	<UNK>	O
22	and	O
23	white	O
24	children	O
25	:	O
26	the	O
27	<UNK>	O
28	<UNK>	O
29	Study	O
30	.	O
1	Northern	O
2	analysis	O
3	indicated	O
4	differential	O
5	expression	O
6	by	O
7	tissue	O
8	with	O
9	highest	O
10	expression	O
11	in	O
12	the	O
13	heart	O
14	.	O
1	It	O
2	may	O
3	also	O
4	be	O
5	suggested	O
6	that	O
7	particular	O
8	care	O
9	should	O
10	be	O
11	taken	O
12	when	O
13	such	O
14	a	O
15	trans	O
16	-	O
17	dominant	O
18	Rev	B
19	mutant	O
20	is	O
21	considered	O
22	to	O
23	be	O
24	used	O
25	as	O
26	a	O
27	genetic	O
28	therapy	O
29	against	O
30	HIV	O
31	-	O
32	I	O
33	infection	O
34	,	O
35	in	O
36	individuals	O
37	infected	O
38	with	O
39	both	O
40	HIV	O
41	-	O
42	I	O
43	and	O
44	HTLV	O
45	-	O
46	1	O
47	.	O
1	<UNK>	O
2	reverse	O
3	transcription	O
4	-	O
5	polymerase	O
6	chain	O
7	reaction	O
8	and	O
9	<UNK>	O
10	analysis	O
11	showed	O
12	that	O
13	<UNK>	B
14	-	O
15	<UNK>	B
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O
1	Transfection	O
2	studies	O
3	also	O
4	showed	O
5	that	O
6	3	O
7	'-	O
8	deletion	O
9	of	O
10	sequences	O
11	downstream	O
12	of	O
13	the	O
14	transcriptional	O
15	start	O
16	site	O
17	(+	O
18	1	O
19	<UNK>	O
20	47	O
21	)	O
22	markedly	O
23	reduced	O
24	<UNK>	B
25	-	O
26	fold	O
27	induction	O
28	.	O
1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	O
8	<UNK>	O
9	gene	O
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	<UNK>	O
21	gene	O
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	<UNK>	O
31	).	O
1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	<UNK>	O
9	/	O
10	2	O
11	)	O
12	<UNK>	B
13	,	O
14	both	O
15	<UNK>	O
16	and	O
17	<UNK>	O
18	BALB	O
19	/	O
20	c	B
21	-	O
22	specific	O
23	variants	O
24	of	O
25	<UNK>	B
26	were	O
27	<UNK>	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	O
39	<UNK>	B
40	in	O
41	kinase	B
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	O
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	<UNK>	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	B
65	mice	O
66	for	O
67	<UNK>	O
68	induction	O
69	and	O
70	that	O
71	<UNK>	B
72	(	O
73	<UNK>	B
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	<UNK>	B
82	locus	O
83	.	O
1	METHODS	O
2	:	O
3	A	O
4	population	O
5	survey	O
6	was	O
7	undertaken	O
8	in	O
9	10	O
10	,	O
11	<UNK>	O
12	individuals	O
13	to	O
14	measure	O
15	the	O
16	prevalence	O
17	and	O
18	identify	O
19	the	O
20	causes	O
21	of	O
22	<UNK>	O
23	in	O
24	<UNK>	O
25	.	O
1	The	O
2	TATA	O
3	box	O
4	-	O
5	binding	O
6	protein	O
7	(	O
8	TBP	B
9	)	O
10	plays	O
11	an	O
12	essential	O
13	role	O
14	in	O
15	transcription	O
16	by	O
17	all	O
18	three	O
19	eukaryotic	O
20	nuclear	O
21	RNA	O
22	polymerases	B
23	,	O
24	polymerases	B
25	(	O
26	Pol	B
27	)	O
28	I	O
29	,	O
30	II	O
31	,	O
32	and	O
33	III	O
34	.	O
1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	<UNK>	B
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O
1	Molecular	O
2	characterization	O
3	of	O
4	the	O
5	50	O
6	-	O
7	and	O
8	57	O
9	-	O
10	kDa	O
11	subunits	O
12	of	O
13	the	O
14	bovine	O
15	vacuolar	O
16	<UNK>	O
17	<UNK>	O
18	.	O
1	CONCLUSIONS	O
2	:	O
3	<UNK>	B
4	may	O
5	play	O
6	a	O
7	<UNK>	O
8	role	O
9	in	O
10	the	O
11	transcriptional	O
12	cascade	O
13	that	O
14	<UNK>	O
15	primary	O
16	neurons	O
17	in	O
18	Xenopus	O
19	embryos	O
20	:	O
21	by	O
22	maintaining	O
23	<UNK>	O
24	-	O
25	<UNK>	B
26	signalling	O
27	,	O
28	<UNK>	B
29	<UNK>	O
30	the	O
31	higher	O
32	neural	O
33	potential	O
34	of	O
35	selected	O
36	progenitor	O
37	cells	O
38	that	O
39	express	O
40	X	O
41	-	O
42	<UNK>	B
43	-	O
44	1	O
45	,	O
46	<UNK>	O
47	the	O
48	transition	O
49	between	O
50	neural	O
51	<UNK>	O
52	and	O
53	<UNK>	O
54	<UNK>	O
55	to	O
56	a	O
57	neural	O
58	fate	O
59	;	O
60	and	O
61	it	O
62	<UNK>	O
63	neuronal	O
64	differentiation	O
65	by	O
66	activating	O
67	<UNK>	B
68	expression	O
69	,	O
70	directly	O
71	or	O
72	<UNK>	O
73	.	O
1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	<UNK>	B
7	-	O
8	<UNK>	B
9	gene	O
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	<UNK>	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	<UNK>	O
26	(	O
27	<UNK>	O
28	<UNK>	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	O
37	S	O
38	-	O
39	transferase	B
40	(	O
41	GST	B
42	)	O
43	gene	O
44	using	O
45	a	O
46	<UNK>	O
47	gene	O
48	fusion	O
49	vector	O
50	(	O
51	<UNK>	O
52	-	O
53	<UNK>	O
54	-	O
55	2	O
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	O
72	-	O
73	thrombin	B
74	.	O
1	<UNK>	O
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	<UNK>	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	<UNK>	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	<UNK>	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	<UNK>	O
25	<UNK>	O
26	10	O
27	trial	O
28	.	O
1	<UNK>	O
2	-	O
3	independent	O
4	expression	O
5	of	O
6	a	O
7	human	O
8	nerve	O
9	growth	O
10	factor	O
11	-	O
12	luciferase	B
13	reporter	O
14	gene	O
15	cloned	O
16	on	O
17	a	O
18	yeast	O
19	artificial	O
20	chromosome	O
21	vector	O
22	.	O
1	<UNK>	O
2	in	O
3	DNase	B
4	I	O
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	O
16	receptor	O
17	-	O
18	GC	O
19	complexes	O
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	<UNK>	O
34	<UNK>	O
35	control	O
36	state	O
37	.	O
1	Most	O
2	pituitary	O
3	hormone	O
4	-	O
5	coding	O
6	gene	O
7	promoters	O
8	are	O
9	activated	O
10	by	O
11	<UNK>	B
12	.	O
1	One	O
2	of	O
3	these	O
4	small	O
5	<UNK>	B
6	might	O
7	be	O
8	inactive	O
9	or	O
10	a	O
11	""""	O
12	<UNK>	O
13	<UNK>	B
14	<UNK>	O
15	The	O
16	results	O
17	suggest	O
18	a	O
19	<UNK>	O
20	<UNK>	O
21	for	O
22	<UNK>	B
23	,	O
24	<UNK>	O
25	their	O
26	origin	O
27	and	O
28	relationship	O
29	to	O
30	other	O
31	protein	O
32	families	O
33	,	O
34	and	O
35	extend	O
36	recent	O
37	experimental	O
38	findings	O
39	on	O
40	the	O
41	functional	O
42	roles	O
43	of	O
44	<UNK>	B
45	N	O
46	,	O
47	C	O
48	,	O
49	and	O
50	<UNK>	B
51	motifs	O
52	.	O
1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	O
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	efficacy	O
5	in	O
6	AIDS	O
7	-	O
8	related	O
9	CMV	O
10	<UNK>	O
11	.	O
1	The	O
2	<UNK>	B
3	complex	O
4	-	O
5	encoding	O
6	genes	O
7	were	O
8	identified	O
9	by	O
10	hybridization	O
11	experiments	O
12	and	O
13	sequence	O
14	analysis	O
15	in	O
16	two	O
17	separate	O
18	gene	O
19	regions	O
20	in	O
21	the	O
22	genome	O
23	of	O
24	Z	O
25	.	O
26	<UNK>	O
27	.	O
1	The	O
2	study	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	co	O
7	-	O
8	infected	O
9	with	O
10	CMV	O
11	and	O
12	HIV	O
13	,	O
14	with	O
15	at	O
16	least	O
17	one	O
18	CD4	B
19	count	O
20	recorded	O
21	<	O
22	100	O
23	x	O
24	10	O
25	(	O
26	6	O
27	)	O
28	cells	O
29	/	O
30	l	O
31	.	O
1	We	O
2	also	O
3	recovered	O
4	mutations	O
5	in	O
6	the	O
7	<UNK>	B
8	gene	O
9	which	O
10	encodes	O
11	another	O
12	TGF	B
13	-	O
14	beta	O
15	-	O
16	related	O
17	factor	O
18	in	O
19	Drosophila	O
20	.	O
1	<UNK>	O
2	<UNK>	O
3	fibronectin	B
4	in	O
5	the	O
6	<UNK>	O
7	of	O
8	<UNK>	O
9	<UNK>	O
10	in	O
11	a	O
12	low	O
13	-	O
14	risk	O
15	population	O
16	.	O
1	A	O
2	constitutive	O
3	allele	O
4	of	O
5	<UNK>	B
6	could	O
7	stimulate	O
8	growth	O
9	of	O
10	a	O
11	strain	O
12	lacking	O
13	both	O
14	<UNK>	B
15	genes	O
16	.	O
1	PCR	O
2	analysis	O
3	indicates	O
4	that	O
5	this	O
6	new	O
7	beta	O
8	-	O
9	<UNK>	B
10	isoform	O
11	is	O
12	expressed	O
13	in	O
14	fetal	O
15	brain	O
16	and	O
17	liver	O
18	,	O
19	bone	O
20	marrow	O
21	,	O
22	and	O
23	<UNK>	O
24	-	O
25	2	O
26	(	O
27	<UNK>	O
28	)	O
29	cells	O
30	,	O
31	but	O
32	is	O
33	not	O
34	detected	O
35	in	O
36	several	O
37	other	O
38	tissues	O
39	.	O
1	<UNK>	O
2	-	O
3	length	O
4	<UNK>	B
5	clones	O
6	were	O
7	isolated	O
8	from	O
9	a	O
10	mouse	O
11	skeletal	O
12	muscle	O
13	cDNA	O
14	library	O
15	.	O
1	<UNK>	B
2	-	O
3	1	O
4	,	O
5	a	O
6	gene	O
7	encoding	O
8	a	O
9	transcription	O
10	factor	O
11	expressed	O
12	in	O
13	the	O
14	early	O
15	embryo	O
16	,	O
17	is	O
18	regulated	O
19	via	O
20	Oct	B
21	-	O
22	3	O
23	/	O
24	4	O
25	and	O
26	Oct	B
27	-	O
28	6	O
29	binding	O
30	to	O
31	an	O
32	octamer	O
33	site	O
34	and	O
35	a	O
36	novel	O
37	protein	O
38	,	O
39	<UNK>	B
40	-	O
41	1	O
42	,	O
43	binding	O
44	to	O
45	an	O
46	adjacent	O
47	site	O
48	.	O
1	Deletion	O
2	of	O
3	the	O
4	last	O
5	two	O
6	Ser	O
7	residues	O
8	,	O
9	including	O
10	one	O
11	PKC	B
12	consensus	O
13	site	O
14	in	O
15	the	O
16	receptor	O
17	tail	O
18	,	O
19	prevented	O
20	only	O
21	phorbol	O
22	12	O
23	-	O
24	myristate	O
25	13	O
26	-	O
27	acetate	O
28	-	O
29	induced	O
30	<UNK>	O
31	by	O
32	30	O
33	%.	O
1	<UNK>	O
2	or	O
3	<UNK>	O
4	was	O
5	<UNK>	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	<UNK>	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O
1	In	O
2	vitro	O
3	binding	O
4	studies	O
5	using	O
6	GST	B
7	fusion	O
8	proteins	O
9	and	O
10	yeast	O
11	extracts	O
12	defined	O
13	distinct	O
14	binding	O
15	sites	O
16	on	O
17	<UNK>	B
18	for	O
19	<UNK>	B
20	and	O
21	clathrin	B
22	.	O
23	<UNK>	B
24	proteins	O
25	and	O
26	<UNK>	B
27	,	O
28	like	O
29	actin	B
30	,	O
31	<UNK>	O
32	to	O
33	peripheral	O
34	<UNK>	O
35	along	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O
1	A	O
2	possible	O
3	decrease	O
4	in	O
5	theophylline	O
6	'	O
7	s	O
8	volume	O
9	of	O
10	distribution	O
11	at	O
12	4	O
13	days	O
14	,	O
15	but	O
16	not	O
17	immediately	O
18	,	O
19	after	O
20	administration	O
21	of	O
22	<UNK>	O
23	was	O
24	suggested	O
25	,	O
26	although	O
27	this	O
28	<UNK>	O
29	failed	O
30	to	O
31	achieve	O
32	statistical	O
33	significance	O
34	(	O
35	p	O
36	=	O
37	0	O
38	.	O
39	<UNK>	O
40	).	O
1	The	O
2	addition	O
3	of	O
4	a	O
5	<UNK>	O
6	-	O
7	containing	O
8	extract	O
9	does	O
10	not	O
11	lead	O
12	to	O
13	significant	O
14	protein	O
15	binding	O
16	to	O
17	these	O
18	two	O
19	<UNK>	B
20	target	O
21	sequences	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	<UNK>	B
27	but	O
28	<UNK>	O
29	the	O
30	complex	O
31	(	O
32	<UNK>	O
33	)	O
34	consisting	O
35	of	O
36	<UNK>	B
37	and	O
38	the	O
39	<UNK>	O
40	bp	O
41	<UNK>	B
42	DNA	O
43	fragment	O
44	to	O
45	a	O
46	<UNK>	O
47	<UNK>	O
48	<UNK>	B
49	-	O
50	<UNK>	O
51	-	O
52	DNA	O
53	complex	O
54	(	O
55	CI	O
56	).	O
1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	m	O
8	-	O
9	<UNK>	B
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	that	O
15	of	O
16	<UNK>	B
17	,	O
18	another	O
19	<UNK>	O
20	tRNA	O
21	gene	O
22	transcription	O
23	activating	O
24	factor	O
25	of	O
26	Xenopus	O
27	<UNK>	O
28	.	O
1	Among	O
2	three	O
3	isoforms	O
4	,	O
5	the	O
6	beta	O
7	isoform	O
8	has	O
9	the	O
10	<UNK>	O
11	<UNK>	O
12	value	O
13	for	O
14	the	O
15	<UNK>	O
16	(	O
17	4	O
18	)	O
19	P	O
20	kinase	B
21	activity	O
22	and	O
23	the	O
24	gamma	O
25	isoform	O
26	is	O
27	most	O
28	markedly	O
29	stimulated	O
30	by	O
31	<UNK>	O
32	acid	O
33	.	O
1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	<UNK>	B
7	G	O
8	proteins	O
9	that	O
10	<UNK>	O
11	signals	O
12	across	O
13	the	O
14	plasma	O
15	membrane	O
16	is	O
17	made	O
18	up	O
19	of	O
20	an	O
21	amino	O
22	-	O
23	terminal	O
24	alpha	O
25	-	O
26	helical	O
27	segment	O
28	followed	O
29	by	O
30	seven	O
31	<UNK>	O
32	units	O
33	called	O
34	<UNK>	O
35	(	O
36	<UNK>	O
37	-	O
38	Asp	O
39	)	O
40	repeats	O
41	that	O
42	occur	O
43	in	O
44	about	O
45	<UNK>	O
46	different	O
47	proteins	O
48	.	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	<UNK>	O
6	action	O
7	of	O
8	<UNK>	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	<UNK>	O
14	<UNK>	B
15	product	O
16	that	O
17	mediated	O
18	the	O
19	<UNK>	O
20	caused	O
21	by	O
22	both	O
23	TF	B
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O
1	Recent	O
2	studies	O
3	have	O
4	revealed	O
5	<UNK>	O
6	myosin	B
7	V	O
8	to	O
9	be	O
10	an	O
11	important	O
12	actin	B
13	-	O
14	based	O
15	molecular	O
16	motor	O
17	involved	O
18	in	O
19	<UNK>	O
20	movement	O
21	.	O
1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	O
7	sequences	O
8	required	O
9	for	O
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	O
15	androgen	O
16	-	O
17	binding	O
18	protein	O
19	gene	O
20	.	O
1	The	O
2	mitochondrial	O
3	regulatory	O
4	region	O
5	(	O
6	<UNK>	B
7	)	O
8	located	O
9	between	O
10	the	O
11	<UNK>	B
12	and	O
13	<UNK>	B
14	genes	O
15	of	O
16	mitochondrial	O
17	DNA	O
18	(	O
19	<UNK>	O
20	)	O
21	is	O
22	essential	O
23	for	O
24	regulation	O
25	of	O
26	replication	O
27	and	O
28	transcription	O
29	of	O
30	the	O
31	mitochondrial	O
32	genome	O
33	.	O
1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	<UNK>	O
6	-	O
7	PR	O
8	-	O
9	B	O
10	interacts	O
11	physically	O
12	with	O
13	<UNK>	B
14	in	O
15	vitro	O
16	.	O
1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	<UNK>	O
14	and	O
15	the	O
16	yeast	O
17	<UNK>	B
18	-	O
19	<UNK>	B
20	and	O
21	<UNK>	B
22	-	O
23	<UNK>	B
24	protein	O
25	complexes	O
26	.	O
1	Recombinant	O
2	<UNK>	B
3	protein	O
4	encoded	O
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	<UNK>	O
14	activity	O
15	in	O
16	vitro	O
17	.	O
1	Interestingly	O
2	,	O
3	the	O
4	activated	O
5	PDGF	B
6	beta	O
7	-	O
8	receptor	O
9	was	O
10	found	O
11	not	O
12	to	O
13	bind	O
14	Crk	B
15	proteins	O
16	.	O
1	Furthermore	O
2	,	O
3	interactions	O
4	were	O
5	identified	O
6	between	O
7	endogenous	O
8	E	O
9	-	O
10	<UNK>	B
11	and	O
12	the	O
13	<UNK>	O
14	containing	O
15	the	O
16	E	O
17	-	O
18	<UNK>	B
19	extracellular	O
20	domain	O
21	and	O
22	the	O
23	<UNK>	B
24	1	O
25	intracellular	O
26	domain	O
27	<UNK>	O
28	in	O
29	vivo	O
30	evidence	O
31	for	O
32	previously	O
33	predicted	O
34	lateral	O
35	interactions	O
36	of	O
37	E	O
38	-	O
39	<UNK>	B
40	extracellular	O
41	domains	O
42	.	O
1	Their	O
2	use	O
3	resulted	O
4	in	O
5	a	O
6	sensitivity	O
7	of	O
8	73	O
9	%	O
10	and	O
11	a	O
12	specificity	O
13	of	O
14	74	O
15	%	O
16	with	O
17	regard	O
18	to	O
19	<UNK>	O
20	of	O
21	<UNK>	B
22	levels	O
23	increasing	O
24	during	O
25	the	O
26	trial	O
27	.	O
1	<UNK>	O
2	accuracy	O
3	of	O
4	primary	O
5	and	O
6	secondary	O
7	memory	O
8	-	O
9	<UNK>	O
10	<UNK>	O
11	in	O
12	<UNK>	O
13	patients	O
14	.	O
1	When	O
2	data	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	<UNK>	O
8	manner	O
9	,	O
10	the	O
11	response	O
12	to	O
13	intravenous	O
14	adenosine	O
15	3	O
16	mg	O
17	,	O
18	6	O
19	mg	O
20	,	O
21	9	O
22	mg	O
23	and	O
24	12	O
25	mg	O
26	in	O
27	the	O
28	24	O
29	episodes	O
30	of	O
31	<UNK>	O
32	were	O
33	5	O
34	episodes	O
35	(	O
36	21	O
37	%),	O
38	16	O
39	episodes	O
40	(	O
41	67	O
42	%),	O
43	20	O
44	episodes	O
45	(	O
46	83	O
47	%)	O
48	and	O
49	20	O
50	episodes	O
51	(	O
52	83	O
53	%)	O
54	respectively	O
55	.	O
1	To	O
2	study	O
3	retinoid	O
4	signalling	O
5	in	O
6	<UNK>	O
7	embryos	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	novel	O
13	method	O
14	to	O
15	detect	O
16	endogenous	O
17	<UNK>	O
18	in	O
19	situ	O
20	in	O
21	embryos	O
22	,	O
23	using	O
24	a	O
25	fusion	O
26	protein	O
27	of	O
28	the	O
29	ligand	O
30	inducible	O
31	transactivation	O
32	domain	O
33	of	O
34	a	O
35	retinoic	O
36	acid	O
37	receptor	O
38	and	O
39	a	O
40	heterologous	O
41	DNA	O
42	binding	O
43	domain	O
44	.	O
1	To	O
2	identify	O
3	nuclear	O
4	regulatory	O
5	factors	O
6	,	O
7	we	O
8	have	O
9	located	O
10	and	O
11	functionally	O
12	characterized	O
13	the	O
14	<UNK>	B
15	gene	O
16	promoter	O
17	.	O
1	<UNK>	O
2	in	O
3	situ	O
4	hybridization	O
5	of	O
6	<UNK>	O
7	<UNK>	O
8	of	O
9	chromosome	O
10	8	O
11	,	O
12	containing	O
13	hybrid	O
14	cell	O
15	line	O
16	<UNK>	O
17	-	O
18	<UNK>	O
19	clone	O
20	17	O
21	(	O
22	<UNK>	O
23	-	O
24	17	O
25	)	O
26	with	O
27	cosmid	O
28	<UNK>	O
29	,	O
30	placed	O
31	the	O
32	<UNK>	B
33	gene	O
34	close	O
35	to	O
36	the	O
37	telomere	O
38	at	O
39	<UNK>	O
40	.	O
41	3	O
42	.	O
1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	<UNK>	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	<UNK>	O
17	(	O
18	<UNK>	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	<UNK>	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	<UNK>	O
43	<UNK>	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	<UNK>	O
51	designed	O
52	for	O
53	<UNK>	O
54	<UNK>	O
55	of	O
56	7	O
57	days	O
58	(	O
59	<UNK>	O
60	called	O
61	""""	O
62	<UNK>	O
63	<UNK>	O
64	<UNK>	O
1	We	O
2	previously	O
3	demonstrated	O
4	that	O
5	acute	O
6	expression	O
7	of	O
8	the	O
9	bovine	O
10	papillomavirus	O
11	type	O
12	1	O
13	(	O
14	<UNK>	O
15	)	O
16	E2	O
17	protein	O
18	in	O
19	HeLa	O
20	and	O
21	HT	O
22	-	O
23	3	O
24	cervical	O
25	carcinoma	O
26	cell	O
27	lines	O
28	greatly	O
29	reduced	O
30	cellular	O
31	proliferation	O
32	by	O
33	<UNK>	O
34	a	O
35	specific	O
36	G1	O
37	/	O
38	S	O
39	phase	O
40	growth	O
41	arrest	O
42	.	O
1	<UNK>	O
2	actin	B
3	<UNK>	O
4	that	O
5	<UNK>	O
6	<UNK>	O
7	particles	O
8	to	O
9	the	O
10	<UNK>	O
11	and	O
12	virus	O
13	-	O
14	<UNK>	O
15	<UNK>	O
16	(	O
17	both	O
18	common	O
19	in	O
20	wild	O
21	-	O
22	type	O
23	-	O
24	infected	O
25	cells	O
26	)	O
27	were	O
28	absent	O
29	in	O
30	cells	O
31	infected	O
32	with	O
33	<UNK>	O
34	.	O
1	<UNK>	O
2	-	O
3	translational	O
4	<UNK>	O
5	such	O
6	as	O
7	glycosylation	O
8	and	O
9	phosphorylation	O
10	could	O
11	be	O
12	excluded	O
13	as	O
14	potential	O
15	<UNK>	O
16	for	O
17	the	O
18	protein	O
19	<UNK>	O
20	.	O
1	In	O
2	addition	O
3	to	O
4	<UNK>	O
5	<UNK>	O
6	control	O
7	,	O
8	overexpression	O
9	of	O
10	<UNK>	B
11	+	O
12	inhibits	O
13	the	O
14	normal	O
15	cell	O
16	cycle	O
17	response	O
18	to	O
19	<UNK>	O
20	stress	O
21	.	O
1	All	O
2	three	O
3	genes	O
4	have	O
5	been	O
6	mapped	O
7	<UNK>	O
8	to	O
9	a	O
10	small	O
11	region	O
12	on	O
13	human	O
14	chromosome	O
15	<UNK>	O
16	.	O
17	1	O
18	-	O
19	<UNK>	O
20	.	O
21	2	O
22	(	O
23	homologous	O
24	to	O
25	mouse	O
26	chromosome	O
27	7	O
28	),	O
29	using	O
30	somatic	O
31	cell	O
32	<UNK>	O
33	and	O
34	cosmid	O
35	clones	O
36	.	O
1	Their	O
2	function	O
3	is	O
4	not	O
5	only	O
6	to	O
7	<UNK>	O
8	<UNK>	B
9	to	O
10	the	O
11	promoter	O
12	but	O
13	to	O
14	allow	O
15	<UNK>	O
16	binding	O
17	of	O
18	<UNK>	B
19	together	O
20	with	O
21	<UNK>	B
22	.	O
1	<UNK>	O
2	growth	O
3	retardation	O
4	as	O
5	a	O
6	cause	O
7	of	O
8	impaired	O
9	ovarian	O
10	development	O
11	.	O
1	The	O
2	complete	O
3	exon	O
4	-	O
5	intron	O
6	organization	O
7	of	O
8	the	O
9	murine	O
10	gene	O
11	encoding	O
12	M	O
13	-	O
14	protein	O
15	,	O
16	a	O
17	structural	O
18	protein	O
19	of	O
20	<UNK>	O
21	<UNK>	O
22	,	O
23	was	O
24	determined	O
25	.	O
1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O
1	The	O
2	localization	O
3	of	O
4	ZAP	B
5	-	O
6	70	O
7	to	O
8	the	O
9	cell	O
10	cortex	O
11	is	O
12	,	O
13	therefore	O
14	,	O
15	regulated	O
16	by	O
17	the	O
18	activity	O
19	of	O
20	SRC	B
21	-	O
22	family	O
23	kinases	O
24	,	O
25	independently	O
26	of	O
27	their	O
28	ability	O
29	to	O
30	phosphorylate	O
31	<UNK>	O
32	tyrosine	O
33	-	O
34	based	O
35	activation	O
36	motifs	O
37	of	O
38	the	O
39	TCR	B
40	.	O
1	In	O
2	<UNK>	O
3	,	O
4	<UNK>	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	O
15	IV	O
16	than	O
17	<UNK>	O
18	<UNK>	O
19	vessels	O
20	in	O
21	the	O
22	<UNK>	O
23	,	O
24	and	O
25	<UNK>	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	<UNK>	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	<UNK>	O
40	<UNK>	O
41	.	O
1	The	O
2	DNA	O
3	binding	O
4	activities	O
5	of	O
6	the	O
7	three	O
8	repressor	O
9	preparations	O
10	were	O
11	studied	O
12	using	O
13	fragments	O
14	containing	O
15	<UNK>	O
16	(	O
17	<UNK>	O
18	-	O
19	<UNK>	O
20	)	O
21	from	O
22	the	O
23	essential	O
24	early	O
25	region	O
26	as	O
27	templates	O
28	for	O
29	DNase	B
30	I	O
31	footprinting	O
32	.	O
1	N	O
2	.,	O
3	and	O
4	<UNK>	O
5	,	O
6	E	O
7	.	O
1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	<UNK>	O
7	cells	O
8	transfected	O
9	with	O
10	the	O
11	rat	O
12	GnRH	B
13	receptor	O
14	cDNA	O
15	(	O
16	<UNK>	O
17	-	O
18	1	O
19	'	O
20	cells	O
21	)	O
22	support	O
23	the	O
24	expression	O
25	of	O
26	a	O
27	<UNK>	O
28	fusion	O
29	gene	O
30	composed	O
31	of	O
32	<UNK>	O
33	base	O
34	pairs	O
35	of	O
36	rat	O
37	<UNK>	B
38	gene	O
39	5	O
40	'-	O
41	flanking	O
42	sequence	O
43	and	O
44	the	O
45	first	O
46	5	O
47	base	O
48	pairs	O
49	of	O
50	the	O
51	5	O
52	'-	O
53	untranslated	O
54	region	O
55	fused	O
56	to	O
57	a	O
58	luciferase	B
59	reporter	O
60	(-	O
61	<UNK>	O
62	<UNK>	O
63	<UNK>	B
64	)	O
65	and	O
66	respond	O
67	to	O
68	a	O
69	GnRH	B
70	agonist	O
71	with	O
72	a	O
73	10	O
74	-	O
75	fold	O
76	stimulation	O
77	of	O
78	activity	O
79	.	O
1	In	O
2	patients	O
3	with	O
4	type	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	urine	O
9	disease	O
10	,	O
11	the	O
12	<UNK>	B
13	subunit	O
14	is	O
15	affected	O
16	,	O
17	resulting	O
18	in	O
19	the	O
20	loss	O
21	of	O
22	E1	O
23	and	O
24	<UNK>	O
25	-	O
26	chain	O
27	<UNK>	B
28	dehydrogenase	I
29	catalytic	O
30	activities	O
31	.	O
1	<UNK>	O
2	:	O
3	To	O
4	measure	O
5	coagulation	O
6	factor	O
7	VIII	O
8	:	O
9	<UNK>	B
10	(	O
11	F	O
12	.	O
13	VIII	O
14	:	O
15	C	O
16	)	O
17	and	O
18	C1	O
19	-	O
20	esterase	B
21	inhibitor	O
22	(	O
23	C1	O
24	-	O
25	<UNK>	B
26	),	O
27	<UNK>	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	<UNK>	O
34	proteins	O
35	and	O
36	coagulation	O
37	factors	O
38	VII	O
39	(	O
40	F	O
41	.	O
42	VII	O
43	),	O
44	IX	O
45	(	O
46	F	O
47	.	O
48	IX	O
49	),	O
50	and	O
51	X	O
52	(	O
53	F	O
54	.	O
55	X	O
56	),	O
57	<UNK>	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	<UNK>	O
71	population	O
72	of	O
73	<UNK>	O
74	with	O
75	<UNK>	O
76	and	O
77	<UNK>	O
78	abnormalities	O
79	,	O
80	and	O
81	<UNK>	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O
1	<UNK>	O
2	sequences	O
3	of	O
4	the	O
5	zinc	O
6	finger	O
7	protein	O
8	<UNK>	B
9	and	O
10	the	O
11	transcription	O
12	factor	O
13	<UNK>	B
14	-	O
15	1	O
16	were	O
17	obtained	O
18	.	O
1	<UNK>	O
2	,	O
3	<UNK>	B
4	19	O
5	antibody	O
6	revealed	O
7	strong	O
8	staining	O
9	in	O
10	both	O
11	epithelial	O
12	and	O
13	<UNK>	O
14	<UNK>	O
15	tissues	O
16	.	O
1	Structural	O
2	features	O
3	of	O
4	the	O
5	minimal	O
6	DNA	O
7	binding	O
8	domain	O
9	(	O
10	<UNK>	O
11	-	O
12	<UNK>	O
13	)	O
14	of	O
15	human	O
16	nucleotide	O
17	excision	O
18	repair	O
19	protein	O
20	<UNK>	B
21	.	O
1	Recently	O
2	,	O
3	extremely	O
4	high	O
5	levels	O
6	of	O
7	<UNK>	B
8	-	O
9	1	O
10	(	O
11	<UNK>	O
12	-	O
13	1	O
14	)	O
15	were	O
16	detected	O
17	in	O
18	the	O
19	<UNK>	O
20	fluid	O
21	of	O
22	patients	O
23	undergoing	O
24	cardiac	O
25	surgery	O
26	.	O
1	<UNK>	O
2	mapping	O
3	of	O
4	the	O
5	<UNK>	O
6	S	O
7	locus	O
8	region	O
9	and	O
10	its	O
11	<UNK>	O
12	in	O
13	Arabidopsis	O
14	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	hydrophobic	O
5	residues	O
6	with	O
7	<UNK>	O
8	residues	O
9	within	O
10	<UNK>	B
11	affects	O
12	the	O
13	fusion	O
14	activity	O
15	of	O
16	the	O
17	S	O
18	protein	O
19	without	O
20	affecting	O
21	processing	O
22	and	O
23	surface	O
24	expression	O
25	.	O
1	<UNK>	O
2	and	O
3	its	O
4	<UNK>	O
5	products	O
6	,	O
7	<UNK>	O
8	-	O
9	and	O
10	<UNK>	O
11	-	O
12	<UNK>	O
13	,	O
14	were	O
15	determined	O
16	in	O
17	water	O
18	<UNK>	O
19	collected	O
20	from	O
21	<UNK>	O
22	<UNK>	O
23	(	O
24	the	O
25	<UNK>	O
26	<UNK>	O
27	),	O
28	<UNK>	O
29	<UNK>	O
30	<UNK>	O
31	<UNK>	O
32	,	O
33	and	O
34	the	O
35	<UNK>	O
36	<UNK>	O
37	of	O
38	<UNK>	O
39	<UNK>	O
40	,	O
41	<UNK>	O
42	.	O
1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	<UNK>	B
9	gene	O
10	contained	O
11	the	O
12	binding	O
13	motifs	O
14	for	O
15	two	O
16	cytokine	O
17	-	O
18	inducible	O
19	transcription	O
20	factors	O
21	,	O
22	NF	B
23	-	O
24	<UNK>	B
25	-	O
26	A	O
27	and	O
28	NF	B
29	-	O
30	IL6	B
31	.	O
1	<UNK>	O
2	expression	O
3	of	O
4	c	B
5	-	O
6	Jun	B
7	and	O
8	p65	B
9	induced	O
10	<UNK>	O
11	transcription	O
12	of	O
13	IL	B
14	-	O
15	2	O
16	promoter	O
17	-	O
18	and	O
19	<UNK>	B
20	-	O
21	driven	O
22	reporter	O
23	constructs	O
24	in	O
25	both	O
26	<UNK>	B
27	-	O
28	3	O
29	-	O
30	and	O
31	<UNK>	B
32	-	O
33	1	O
34	-	O
35	<UNK>	O
36	Jurkat	O
37	cells	O
38	.	O
1	<UNK>	O
2	chromatographic	O
3	method	O
4	for	O
5	analysis	O
6	of	O
7	all	O
8	-	O
9	<UNK>	O
10	-	O
11	alpha	O
12	-	O
13	<UNK>	O
14	acetate	O
15	and	O
16	<UNK>	O
17	<UNK>	O
18	in	O
19	milk	O
20	-	O
21	based	O
22	<UNK>	O
23	<UNK>	O
24	using	O
25	matrix	O
26	solid	O
27	-	O
28	phase	O
29	<UNK>	O
30	.	O
1	Two	O
2	protease	O
3	-	O
4	resistant	O
5	fragments	O
6	spanning	O
7	the	O
8	N	O
9	-	O
10	and	O
11	C	O
12	-	O
13	terminal	O
14	<UNK>	O
15	of	O
16	the	O
17	nuclease	B
18	were	O
19	identified	O
20	using	O
21	different	O
22	<UNK>	O
23	which	O
24	<UNK>	O
25	the	O
26	protein	O
27	in	O
28	the	O
29	same	O
30	region	O
31	.	O
1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	<UNK>	B
8	in	O
9	<UNK>	B
10	-	O
11	<UNK>	B
12	<UNK>	O
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	<UNK>	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	O
37	protein	O
38	N	O
39	-	O
40	<UNK>	O
41	-	O
42	<UNK>	O
43	.	O
1	Rev	B
2	-	O
3	<UNK>	B
4	/	O
5	beta	O
6	),	O
7	<UNK>	B
8	-	O
9	1	O
10	and	O
11	<UNK>	B
12	bHLH	O
13	-	O
14	<UNK>	O
15	proteins	O
16	and	O
17	the	O
18	<UNK>	O
19	<UNK>	B
20	and	O
21	<UNK>	B
22	/	O
23	<UNK>	B
24	is	O
25	mediated	O
26	by	O
27	the	O
28	<UNK>	O
29	N	O
30	-	O
31	<UNK>	B
32	and	O
33	<UNK>	B
34	.	O
1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	<UNK>	O
7	-	O
8	binding	O
9	motif	O
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	<UNK>	B
23	.	O
1	In	O
2	mammals	O
3	,	O
4	the	O
5	Rb	B
6	protein	O
7	interacts	O
8	specifically	O
9	with	O
10	D	O
11	-	O
12	type	O
13	<UNK>	B
14	and	O
15	regulates	O
16	cell	O
17	proliferation	O
18	by	O
19	binding	O
20	and	O
21	inhibiting	O
22	E2F	B
23	transcription	O
24	factors	O
25	.	O
1	The	O
2	importance	O
3	of	O
4	these	O
5	sites	O
6	for	O
7	transcriptional	O
8	activation	O
9	was	O
10	studied	O
11	by	O
12	site	O
13	-	O
14	directed	O
15	mutagenesis	O
16	followed	O
17	by	O
18	promoter	O
19	function	O
20	analysis	O
21	of	O
22	the	O
23	mutants	O
24	with	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	O
29	system	O
30	.	O
1	<UNK>	O
2	blood	O
3	examination	O
4	showed	O
5	<UNK>	O
6	,	O
7	<UNK>	O
8	,	O
9	positive	O
10	CRP	B
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O
1	<UNK>	O
2	:	O
3	<UNK>	O
4	hospital	O
5	-	O
6	based	O
7	,	O
8	<UNK>	O
9	care	O
10	<UNK>	O
11	<UNK>	O
12	.	O
1	After	O
2	the	O
3	first	O
4	cycle	O
5	,	O
6	18	O
7	cases	O
8	were	O
9	treated	O
10	at	O
11	dose	O
12	level	O
13	1	O
14	,	O
15	after	O
16	a	O
17	second	O
18	cycle	O
19	,	O
20	13	O
21	cases	O
22	were	O
23	treated	O
24	at	O
25	dose	O
26	level	O
27	2	O
28	.	O
1	Despite	O
2	continuous	O
3	<UNK>	O
4	,	O
5	<UNK>	O
6	<UNK>	O
7	of	O
8	serum	O
9	ferritin	B
10	levels	O
11	occurred	O
12	in	O
13	4	O
14	/	O
15	7	O
16	patients	O
17	of	O
18	the	O
19	'	O
20	<UNK>	O
21	'	O
22	group	O
23	after	O
24	4	O
25	-	O
26	5	O
27	years	O
28	on	O
29	L1	O
30	.	O
1	After	O
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	(	O
6	<UNK>	O
7	9	O
8	%)	O
9	<UNK>	O
10	of	O
11	LV	O
12	<UNK>	O
13	and	O
14	LV	O
15	diastolic	O
16	properties	O
17	was	O
18	found	O
19	,	O
20	when	O
21	myocardial	O
22	<UNK>	O
23	was	O
24	supported	O
25	by	O
26	i	O
27	.	O
28	v	O
29	.	O
30	<UNK>	O
31	<UNK>	O
32	,	O
33	a	O
34	<UNK>	O
35	O2	O
36	carrier	O
37	.	O
1	In	O
2	this	O
3	report	O
4	we	O
5	studied	O
6	the	O
7	role	O
8	of	O
9	protein	O
10	-	O
11	tyrosine	O
12	phosphatase	B
13	SHP	I
14	-	O
15	2	O
16	in	O
17	ErbB	B
18	-	O
19	mediated	O
20	activation	O
21	of	O
22	mitogen	B
23	-	O
24	activated	O
25	protein	O
26	kinase	B
27	(	O
28	MAPK	B
29	)	O
30	by	O
31	<UNK>	O
32	SHP	B
33	-	O
34	2	O
35	mutants	O
36	in	O
37	COS	O
38	-	O
39	7	O
40	cells	O
41	.	O
1	The	O
2	intron	O
3	8	O
4	enhancer	O
5	region	O
6	was	O
7	not	O
8	activated	O
9	by	O
10	GATA	B
11	-	O
12	1	O
13	together	O
14	with	O
15	Sp1	B
16	in	O
17	transactivation	O
18	experiments	O
19	in	O
20	COS	O
21	-	O
22	1	O
23	cells	O
24	indicating	O
25	the	O
26	involvement	O
27	of	O
28	a	O
29	related	O
30	Sp1	B
31	protein	O
32	or	O
33	of	O
34	another	O
35	<UNK>	O
36	erythroid	O
37	factor	O
38	.	O
1	Transcription	O
2	initiation	O
3	occurred	O
4	predominantly	O
5	at	O
6	the	O
7	putative	O
8	<UNK>	B
9	-	O
10	dependent	O
11	promoter	O
12	in	O
13	<UNK>	O
14	growing	O
15	cells	O
16	and	O
17	was	O
18	induced	O
19	under	O
20	stress	O
21	conditions	O
22	.	O
1	A	O
2	major	O
3	<UNK>	O
4	of	O
5	<UNK>	B
6	-	O
7	<UNK>	B
8	complexes	O
9	<UNK>	O
10	at	O
11	<UNK>	O
12	and	O
13	exhibited	O
14	a	O
15	1	O
16	:	O
17	1	O
18	<UNK>	O
19	.	O
1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	<UNK>	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	O
15	-	O
16	terminally	O
17	truncated	O
18	<UNK>	B
19	-	O
20	1	O
21	beta	O
22	variants	O
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	<UNK>	O
34	.	O
1	Recently	O
2	,	O
3	a	O
4	human	O
5	transcription	O
6	elongation	O
7	factor	O
8	P	O
9	-	O
10	<UNK>	B
11	,	O
12	consisting	O
13	of	O
14	<UNK>	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	O
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	<UNK>	O
33	Tat	B
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	O
42	-	O
43	<UNK>	B
44	.	O
1	<UNK>	B
2	A	O
3	,	O
4	a	O
5	cysteine	O
6	proteinase	O
7	inhibitor	O
8	,	O
9	is	O
10	one	O
11	of	O
12	the	O
13	precursor	O
14	proteins	O
15	of	O
16	<UNK>	B
17	cell	O
18	envelope	O
19	of	O
20	<UNK>	O
21	and	O
22	is	O
23	expressed	O
24	during	O
25	the	O
26	late	O
27	stage	O
28	of	O
29	<UNK>	O
30	differentiation	O
31	.	O
1	<UNK>	O
2	shift	O
3	/	O
4	<UNK>	O
5	analysis	O
6	indicates	O
7	that	O
8	Fos	B
9	family	O
10	member	O
11	proteins	O
12	especially	O
13	<UNK>	B
14	-	O
15	1	O
16	and	O
17	<UNK>	B
18	-	O
19	2	O
20	are	O
21	related	O
22	to	O
23	progression	O
24	and	O
25	no	O
26	changes	O
27	found	O
28	in	O
29	the	O
30	Jun	B
31	family	O
32	member	O
33	proteins	O
34	although	O
35	they	O
36	are	O
37	present	O
38	in	O
39	the	O
40	AP	B
41	-	O
42	1	O
43	/	O
44	DNA	O
45	binding	O
46	complex	O
47	.	O
1	<UNK>	O
2	was	O
3	administered	O
4	recombinant	O
5	IFN	B
6	alpha	O
7	-	O
8	2b	O
9	under	O
10	the	O
11	diagnosis	O
12	of	O
13	chronic	O
14	hepatitis	O
15	C	O
16	.	O
1	Regulation	O
2	at	O
3	37	O
4	degrees	O
5	C	O
6	,	O
7	therefore	O
8	,	O
9	involves	O
10	the	O
11	action	O
12	of	O
13	three	O
14	protein	O
15	kinase	B
16	<UNK>	O
17	that	O
18	repress	O
19	<UNK>	B
20	through	O
21	phosphorylation	O
22	of	O
23	serine	O
24	residues	O
25	<UNK>	O
26	,	O
27	<UNK>	O
28	,	O
29	and	O
30	<UNK>	O
31	and	O
32	may	O
33	promote	O
34	growth	O
35	by	O
36	<UNK>	O
37	the	O
38	heat	O
39	shock	O
40	response	O
41	.	O
1	<UNK>	O
2	bond	O
3	<UNK>	O
4	between	O
5	resin	O
6	composite	O
7	and	O
8	bovine	O
9	<UNK>	O
10	using	O
11	<UNK>	O
12	<UNK>	O
13	systems	O
14	(	O
15	<UNK>	O
16	<UNK>	O
17	<UNK>	O
18	II	O
19	:	O
20	<UNK>	O
21	II	O
22	;	O
23	<UNK>	O
24	<UNK>	O
25	-	O
26	<UNK>	O
27	:	O
28	MP	O
29	)	O
30	<UNK>	O
31	systems	O
32	showed	O
33	a	O
34	large	O
35	<UNK>	O
36	among	O
37	<UNK>	O
38	and	O
39	<UNK>	O
40	.	O
1	<UNK>	O
2	healthy	O
3	male	O
4	volunteers	O
5	completed	O
6	the	O
7	study	O
8	.	O
1	<UNK>	O
2	of	O
3	the	O
4	<UNK>	O
5	regulators	O
6	involved	O
7	in	O
8	cell	O
9	cycle	O
10	arrest	O
11	and	O
12	apoptosis	O
13	may	O
14	thus	O
15	provide	O
16	a	O
17	novel	O
18	strategy	O
19	to	O
20	cancer	O
21	therapy	O
22	.	O
1	""""	O
2	<UNK>	O
3	partial	O
4	""""	O
5	<UNK>	O
6	.	O
1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	<UNK>	O
13	with	O
14	<UNK>	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	<UNK>	O
20	<UNK>	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	<UNK>	O
27	<UNK>	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	<UNK>	O
35	.	O
1	These	O
2	results	O
3	provide	O
4	the	O
5	first	O
6	<UNK>	O
7	that	O
8	an	O
9	SR	O
10	protein	O
11	can	O
12	influence	O
13	splicing	O
14	of	O
15	specific	O
16	pre	O
17	-	O
18	mRNAs	O
19	in	O
20	vivo	O
21	.	O
1	METHODS	O
2	:	O
3	<UNK>	O
4	<UNK>	O
5	membranes	O
6	of	O
7	three	O
8	different	O
9	pore	O
10	sizes	O
11	were	O
12	used	O
13	as	O
14	model	O
15	<UNK>	O
16	materials	O
17	.	O
18	The	O
19	<UNK>	O
20	membrane	O
21	pore	O
22	sizes	O
23	were	O
24	0	O
25	.	O
26	1	O
27	microm	O
28	,	O
29	0	O
30	.	O
31	45	O
32	microm	O
33	,	O
34	and	O
35	3	O
36	microm	O
37	;	O
38	the	O
39	surface	O
40	<UNK>	O
41	increased	O
42	in	O
43	the	O
44	same	O
45	order	O
46	The	O
47	membranes	O
48	were	O
49	<UNK>	O
50	with	O
51	a	O
52	thin	O
53	layer	O
54	of	O
55	collagen	B
56	I	O
57	and	O
58	<UNK>	O
59	in	O
60	a	O
61	<UNK>	O
62	<UNK>	O
63	of	O
64	the	O
65	anterior	O
66	<UNK>	O
67	of	O
68	adult	O
69	cats	O
70	,	O
71	and	O
72	were	O
73	clinically	O
74	evaluated	O
75	for	O
76	the	O
77	extent	O
78	of	O
79	<UNK>	O
80	and	O
81	the	O
82	<UNK>	O
83	of	O
84	epithelial	O
85	attachment	O
86	.	O
1	The	O
2	biochemical	O
3	and	O
4	molecular	O
5	spectrum	O
6	of	O
7	<UNK>	B
8	<UNK>	I
9	deficiency	O
10	.	O
1	To	O
2	further	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	cis	O
8	-	O
9	acting	O
10	elements	O
11	in	O
12	these	O
13	regulatory	O
14	mechanisms	O
15	,	O
16	we	O
17	have	O
18	characterized	O
19	a	O
20	transcriptional	O
21	promoter	O
22	that	O
23	<UNK>	O
24	<UNK>	O
25	expression	O
26	of	O
27	TCR	B
28	beta	O
29	gene	O
30	segments	O
31	in	O
32	vivo	O
33	.	O
1	A	O
2	<UNK>	O
3	for	O
4	the	O
5	synthesis	O
6	of	O
7	<UNK>	O
8	<UNK>	O
9	is	O
10	the	O
11	activated	O
12	<UNK>	O
13	-	O
14	nucleotide	O
15	<UNK>	O
16	5	O
17	'-	O
18	<UNK>	O
19	N	O
20	-	O
21	<UNK>	O
22	acid	O
23	(	O
24	<UNK>	O
25	-	O
26	<UNK>	O
27	),	O
28	which	O
29	provides	O
30	a	O
31	substrate	O
32	for	O
33	Golgi	O
34	<UNK>	B
35	.	O
1	<UNK>	O
2	,	O
3	I	O
4	use	O
5	molecular	O
6	markers	O
7	that	O
8	identify	O
9	particular	O
10	<UNK>	O
11	domains	O
12	,	O
13	all	O
14	<UNK>	O
15	or	O
16	individual	O
17	<UNK>	O
18	,	O
19	to	O
20	show	O
21	that	O
22	in	O
23	<UNK>	B
24	mutant	O
25	embryos	O
26	(	O
27	1	O
28	)	O
29	intermediate	O
30	column	O
31	<UNK>	O
32	do	O
33	not	O
34	form	O
35	,	O
36	(	O
37	2	O
38	)	O
39	medial	O
40	column	O
41	<UNK>	O
42	often	O
43	<UNK>	O
44	<UNK>	O
45	<UNK>	O
46	for	O
47	their	O
48	position	O
49	,	O
50	while	O
51	(	O
52	3	O
53	)	O
54	lateral	O
55	<UNK>	O
56	develop	O
57	normally	O
58	.	O
1	<UNK>	B
2	mRNA	O
3	was	O
4	expressed	O
5	in	O
6	brain	O
7	,	O
8	skeletal	O
9	muscle	O
10	,	O
11	13	O
12	.	O
13	5	O
14	-	O
15	day	O
16	embryos	O
17	,	O
18	and	O
19	<UNK>	O
20	cells	O
21	treated	O
22	with	O
23	retinoic	O
24	acid	O
25	.	O
1	The	O
2	genomic	O
3	structure	O
4	and	O
5	chromosomal	O
6	location	O
7	of	O
8	the	O
9	human	O
10	<UNK>	B
11	orphan	O
12	receptor	O
13	,	O
14	a	O
15	member	O
16	of	O
17	the	O
18	steroid	O
19	receptor	O
20	superfamily	O
21	.	O
1	The	O
2	effect	O
3	of	O
4	Rho	B
5	on	O
6	AP	B
7	-	O
8	1	O
9	is	O
10	independent	O
11	of	O
12	the	O
13	mitogen	B
14	-	O
15	activated	O
16	protein	O
17	kinase	B
18	pathway	O
19	,	O
20	as	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	MEK	B
26	and	O
27	a	O
28	MEK	B
29	inhibitor	O
30	(	O
31	<UNK>	O
32	)	O
33	did	O
34	not	O
35	affect	O
36	Rho	B
37	-	O
38	induced	O
39	AP	B
40	-	O
41	1	O
42	activity	O
43	.	O
1	Mutations	O
2	within	O
3	the	O
4	C	O
5	terminus	O
6	of	O
7	c	B
8	-	O
9	fos	B
10	at	O
11	serine	O
12	residues	O
13	that	O
14	are	O
15	phosphorylation	O
16	targets	O
17	for	O
18	growth	O
19	factors	O
20	and	O
21	MAP	B
22	kinase	I
23	completely	O
24	<UNK>	O
25	transactivation	O
26	and	O
27	block	O
28	<UNK>	O
29	by	O
30	MAP	B
31	kinase	I
32	.	O
1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	<UNK>	B
6	gene	O
7	:	O
8	neural	O
9	-	O
10	specific	O
11	expression	O
12	,	O
13	multiple	O
14	promoters	O
15	,	O
16	and	O
17	regulatory	O
18	elements	O
19	.	O
1	The	O
2	binding	O
3	of	O
4	NF	B
5	-	O
6	<UNK>	B
7	,	O
8	although	O
9	not	O
10	NF	B
11	-	O
12	<UNK>	B
13	,	O
14	to	O
15	this	O
16	enhancer	O
17	also	O
18	occurs	O
19	along	O
20	with	O
21	HTLV	O
22	-	O
23	I	O
24	-	O
25	mediated	O
26	infection	O
27	of	O
28	human	O
29	peripheral	O
30	blood	O
31	T	O
32	-	O
33	cells	O
34	.	O
1	The	O
2	activity	O
3	of	O
4	the	O
5	minimal	O
6	promoter	O
7	was	O
8	found	O
9	to	O
10	be	O
11	controlled	O
12	by	O
13	a	O
14	combination	O
15	of	O
16	the	O
17	activities	O
18	of	O
19	the	O
20	transcription	O
21	factors	O
22	Sp1	B
23	,	O
24	<UNK>	B
25	,	O
26	and	O
27	NF	B
28	-	O
29	Y	O
30	.	O
1	The	O
2	present	O
3	study	O
4	<UNK>	O
5	to	O
6	develop	O
7	an	O
8	<UNK>	O
9	to	O
10	<UNK>	O
11	<UNK>	O
12	in	O
13	peripheral	O
14	arterial	O
15	<UNK>	O
16	disease	O
17	(	O
18	<UNK>	O
19	)	O
20	patients	O
21	with	O
22	<UNK>	O
23	<UNK>	O
24	and	O
25	to	O
26	determine	O
27	independent	O
28	predictors	O
29	of	O
30	<UNK>	O
31	in	O
32	this	O
33	population	O
34	.	O
1	The	O
2	<UNK>	O
3	<UNK>	O
4	Scale	O
5	(	O
6	<UNK>	O
7	),	O
8	<UNK>	O
9	<UNK>	O
10	Scale	O
11	and	O
12	<UNK>	O
13	<UNK>	O
14	<UNK>	O
15	a	O
16	<UNK>	O
17	<UNK>	O
18	system	O
19	for	O
20	the	O
21	analysis	O
22	of	O
23	injuries	O
24	and	O
25	<UNK>	O
26	patients	O
27	.	O
1	<UNK>	O
2	-	O
3	five	O
4	percent	O
5	of	O
6	children	O
7	who	O
8	received	O
9	a	O
10	second	O
11	transplant	O
12	for	O
13	HCV	O
14	hepatitis	O
15	had	O
16	early	O
17	<UNK>	O
18	<UNK>	O
19	that	O
20	led	O
21	to	O
22	liver	O
23	failure	O
24	and	O
25	death	O
26	.	O
1	However	O
2	,	O
3	both	O
4	<UNK>	O
5	groups	O
6	showed	O
7	a	O
8	marked	O
9	increase	O
10	in	O
11	activities	O
12	of	O
13	liver	O
14	<UNK>	O
15	enzymes	O
16	.	O
1	Furthermore	O
2	,	O
3	we	O
4	demonstrated	O
5	that	O
6	<UNK>	B
7	<UNK>	I
8	stimulated	O
9	Src	B
10	family	O
11	kinase	B
12	activity	O
13	and	O
14	induced	O
15	tyrosine	O
16	phosphorylation	O
17	of	O
18	several	O
19	proteins	O
20	in	O
21	<UNK>	O
22	-	O
23	293	O
24	cells	O
25	.	O
1	The	O
2	<UNK>	B
3	site	O
4	within	O
5	<UNK>	O
6	<UNK>	O
7	near	O
8	sites	O
9	for	O
10	hematopoietic	O
11	regulators	O
12	such	O
13	as	O
14	GATA	B
15	-	O
16	1	O
17	,	O
18	NF	B
19	-	O
20	E2	O
21	,	O
22	and	O
23	<UNK>	B
24	.	O
1	The	O
2	rat	O
3	<UNK>	O
4	-	O
5	chain	O
6	-	O
7	2	O
8	-	O
9	<UNK>	B
10	-	O
11	acid	O
12	dehydrogenase	B
13	(	O
14	<UNK>	B
15	)	O
16	kinase	B
17	mRNA	O
18	is	O
19	transcribed	O
20	from	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	that	O
27	has	O
28	GC	O
29	-	O
30	rich	O
31	sequences	O
32	and	O
33	two	O
34	putative	O
35	Sp1	B
36	binding	O
37	sites	O
38	near	O
39	the	O
40	transcription	O
41	start	O
42	site	O
43	.	O
1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	<UNK>	O
10	of	O
11	transcription	O
12	factors	O
13	NF	B
14	-	O
15	kappaB	B
16	and	O
17	AP	B
18	-	O
19	1	O
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	O
25	IL	B
26	-	O
27	8	O
28	gene	O
29	by	O
30	HTLV	O
31	-	O
32	I	O
33	Tax	B
34	.	O
1	Using	O
2	homology	O
3	cloning	O
4	techniques	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	mouse	O
10	homologue	O
11	of	O
12	E	O
13	(	O
14	<UNK>	O
15	),	O
16	termed	O
17	<UNK>	B
18	,	O
19	a	O
20	yeast	O
21	protein	O
22	that	O
23	we	O
24	<UNK>	O
25	<UNK>	B
26	,	O
27	and	O
28	as	O
29	well	O
30	as	O
31	additional	O
32	<UNK>	O
33	from	O
34	Caenorhabditis	O
35	elegans	O
36	,	O
37	mice	O
38	and	O
39	humans	O
40	.	O
1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	<UNK>	B
7	-	O
8	1	O
9	is	O
10	a	O
11	new	O
12	temperature	O
13	-	O
14	sensitive	O
15	allele	O
16	of	O
17	the	O
18	clathrin	B
19	heavy	O
20	chain	O
21	gene	O
22	(	O
23	<UNK>	B
24	-	O
25	5	O
26	),	O
27	which	O
28	<UNK>	O
29	a	O
30	<UNK>	O
31	mutation	O
32	near	O
33	the	O
34	3	O
35	'	O
36	end	O
37	of	O
38	the	O
39	<UNK>	B
40	open	O
41	reading	O
42	frame	O
43	.	O
1	We	O
2	have	O
3	determined	O
4	the	O
5	molecular	O
6	lesions	O
7	of	O
8	nine	O
9	<UNK>	B
10	mutant	O
11	alleles	O
12	,	O
13	which	O
14	identify	O
15	functional	O
16	requirements	O
17	for	O
18	specific	O
19	domains	O
20	.	O
1	BACKGROUND	O
2	:	O
3	<UNK>	O
4	(	O
5	<UNK>	O
6	)	O
7	are	O
8	<UNK>	O
9	in	O
10	children	O
11	because	O
12	of	O
13	the	O
14	risk	O
15	of	O
16	cartilage	O
17	damage	O
18	.	O
1	<UNK>	O
2	with	O
3	ATF	B
4	-	O
5	2	O
6	and	O
7	HNF	B
8	-	O
9	4	O
10	expression	O
11	plasmids	O
12	resulted	O
13	in	O
14	<UNK>	O
15	transactivation	O
16	of	O
17	the	O
18	<UNK>	B
19	promoter	O
20	.	O
1	<UNK>	O
2	hydrolysis	O
3	during	O
4	<UNK>	O
5	exercise	O
6	:	O
7	the	O
8	effect	O
9	of	O
10	<UNK>	O
11	.	O
1	The	O
2	human	O
3	T	O
4	cell	O
5	<UNK>	O
6	retrovirus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	trans	O
15	-	O
16	activator	O
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	O
25	-	O
26	domain	O
27	/	O
28	leucine	O
29	-	O
30	zipper	O
31	(	O
32	<UNK>	O
33	)	O
34	protein	O
35	,	O
36	cAMP	O
37	response	O
38	element	O
39	binding	O
40	protein	O
41	(	O
42	CREB	B
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	O
48	Tax	B
49	-	O
50	responsive	O
51	element	O
52	consisting	O
53	of	O
54	three	O
55	<UNK>	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	<UNK>	O
70	by	O
71	G	O
72	/	O
73	C	O
74	-	O
75	rich	O
76	sequences	O
77	.	O
1	The	O
2	murine	O
3	<UNK>	B
4	glucose	O
5	transporter	O
6	isoform	O
7	3	O
8	(	O
9	<UNK>	B
10	3	O
11	)	O
12	is	O
13	<UNK>	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	<UNK>	O
23	.	O
1	The	O
2	levels	O
3	of	O
4	transactivation	O
5	are	O
6	correlated	O
7	with	O
8	the	O
9	<UNK>	O
10	binding	O
11	affinities	O
12	of	O
13	the	O
14	response	O
15	elements	O
16	(	O
17	<UNK>	O
18	-	O
19	1	O
20	>	O
21	DR	O
22	-	O
23	4	O
24	>	O
25	<UNK>	O
26	-	O
27	1	O
28	).	O
1	Previous	O
2	genetic	O
3	studies	O
4	led	O
5	to	O
6	the	O
7	conclusion	O
8	that	O
9	nitrate	O
10	and	O
11	<UNK>	O
12	induction	O
13	of	O
14	<UNK>	B
15	operon	O
16	expression	O
17	is	O
18	determined	O
19	by	O
20	a	O
21	transcriptional	O
22	<UNK>	O
23	mechanism	O
24	.	O
1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	<UNK>	B
6	<UNK>	O
7	contains	O
8	a	O
9	motif	O
10	(	O
11	<UNK>	O
12	)	O
13	at	O
14	amino	O
15	acid	O
16	positions	O
17	<UNK>	O
18	-	O
19	<UNK>	O
20	that	O
21	represents	O
22	a	O
23	classical	O
24	<UNK>	O
25	nuclear	O
26	localization	O
27	signal	O
28	(	O
29	<UNK>	O
30	).	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	<UNK>	O
6	<UNK>	O
7	B	O
8	and	O
9	<UNK>	O
10	are	O
11	weakly	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	codon	O
3	position	O
4	affects	O
5	the	O
6	efficiency	O
7	of	O
8	<UNK>	O
9	<UNK>	O
10	into	O
11	glutathione	B
12	peroxidase	I
13	-	O
14	1	O
15	.	O
1	RESULTS	O
2	:	O
3	The	O
4	binding	O
5	of	O
6	99mTc	O
7	d	O
8	,	O
9	1	O
10	-	O
11	<UNK>	O
12	to	O
13	human	O
14	placenta	O
15	ranged	O
16	from	O
17	2	O
18	.	O
19	95	O
20	%	O
21	+/-	O
22	1	O
23	.	O
24	5	O
25	%	O
26	to	O
27	5	O
28	.	O
29	82	O
30	%	O
31	+/-	O
32	0	O
33	.	O
34	3	O
35	%	O
36	per	O
37	1	O
38	ml	O
39	standard	O
40	solution	O
41	.	O
1	<UNK>	O
2	reduced	O
3	the	O
4	nuclear	O
5	binding	O
6	activity	O
7	of	O
8	transcription	O
9	factor	O
10	AP	B
11	-	O
12	1	O
13	.	O
1	A	O
2	simple	O
3	<UNK>	O
4	method	O
5	for	O
6	l	O
7	-	O
8	<UNK>	O
9	by	O
10	high	O
11	-	O
12	performance	O
13	liquid	O
14	chromatography	O
15	with	O
16	a	O
17	<UNK>	O
18	<UNK>	O
19	detector	O
20	was	O
21	established	O
22	.	O
1	The	O
2	predicted	O
3	domain	O
4	structures	O
5	of	O
6	<UNK>	B
7	and	O
8	<UNK>	B
9	are	O
10	<UNK>	O
11	to	O
12	that	O
13	of	O
14	<UNK>	B
15	and	O
16	<UNK>	O
17	30	O
18	fatty	O
19	-	O
20	acid	O
21	-	O
22	synthase	B
23	(	O
24	<UNK>	B
25	)-	O
26	like	O
27	domains	O
28	<UNK>	O
29	in	O
30	6	O
31	<UNK>	O
32	.	O
1	Analysis	O
2	of	O
3	<UNK>	B
4	mRNA	O
5	expression	O
6	in	O
7	<UNK>	O
8	and	O
9	adult	O
10	mouse	O
11	<UNK>	O
12	,	O
13	and	O
14	in	O
15	isolated	O
16	populations	O
17	of	O
18	germ	O
19	cells	O
20	,	O
21	reveals	O
22	maximal	O
23	expression	O
24	in	O
25	<UNK>	O
26	<UNK>	O
27	<UNK>	O
28	,	O
29	a	O
30	cell	O
31	type	O
32	with	O
33	abundant	O
34	amounts	O
35	of	O
36	<UNK>	O
37	messenger	O
38	<UNK>	O
39	.	O
1	The	O
2	<UNK>	B
3	-	O
4	1	O
5	mutation	O
6	was	O
7	identified	O
8	as	O
9	a	O
10	guanine	O
11	to	O
12	adenine	O
13	substitution	O
14	at	O
15	nucleotide	O
16	<UNK>	O
17	of	O
18	the	O
19	coding	O
20	region	O
21	,	O
22	<UNK>	O
23	the	O
24	change	O
25	<UNK>	O
26	in	O
27	the	O
28	<UNK>	B
29	.	O
1	Analysis	O
2	of	O
3	chromosomal	O
4	DNA	O
5	sequence	O
6	immediately	O
7	downstream	O
8	of	O
9	the	O
10	transposon	O
11	insertion	O
12	identified	O
13	two	O
14	open	O
15	reading	O
16	frames	O
17	,	O
18	designated	O
19	<UNK>	B
20	and	O
21	<UNK>	B
22	,	O
23	which	O
24	exhibited	O
25	sequence	O
26	similarity	O
27	to	O
28	bacterial	O
29	two	O
30	-	O
31	component	O
32	regulatory	O
33	systems	O
34	.	O
1	<UNK>	O
2	+/-	O
3	<UNK>	O
4	<UNK>	O
5	/	O
6	ml	O
7	at	O
8	0	O
9	<UNK>	O
10	;	O
11	P	O
12	<	O
13	0	O
14	.	O
15	001	O
16	).	O
1	Additionally	O
2	in	O
3	seven	O
4	subjects	O
5	<UNK>	O
6	(	O
7	A	O
8	)	O
9	and	O
10	noradrenaline	O
11	(	O
12	<UNK>	O
13	)	O
14	concentrations	O
15	were	O
16	determined	O
17	.	O
1	Inhibition	O
2	of	O
3	the	O
4	<UNK>	B
5	B	O
6	mRNA	O
7	<UNK>	O
8	enzyme	O
9	-	O
10	complex	O
11	by	O
12	hnRNP	B
13	C1	O
14	protein	O
15	and	O
16	<UNK>	B
17	hnRNP	I
18	complexes	O
19	.	O
1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	<UNK>	O
10	(+	O
11	1	O
12	)	O
13	<UNK>	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	<UNK>	O
20	(+	O
21	1	O
22	)	O
23	<UNK>	O
24	(	O
25	N	O
26	is	O
27	any	O
28	<UNK>	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	O
37	<UNK>	B
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O
1	<UNK>	O
2	binding	O
3	to	O
4	the	O
5	receptor	O
6	complex	O
7	leads	O
8	to	O
9	tyrosine	O
10	phosphorylation	O
11	and	O
12	activation	O
13	of	O
14	<UNK>	B
15	kinases	O
16	(	O
17	<UNK>	B
18	),	O
19	phosphorylation	O
20	of	O
21	the	O
22	signal	O
23	<UNK>	O
24	subunit	O
25	<UNK>	B
26	,	O
27	followed	O
28	by	O
29	recruitment	O
30	and	O
31	phosphorylation	O
32	of	O
33	the	O
34	signal	O
35	<UNK>	O
36	and	O
37	activator	O
38	of	O
39	transcription	O
40	factors	O
41	<UNK>	B
42	and	O
43	STAT1	B
44	and	O
45	the	O
46	src	B
47	homology	O
48	domain	O
49	(	O
50	SH2	B
51	)-	O
52	containing	O
53	protein	O
54	tyrosine	O
55	phosphatase	B
56	(	O
57	<UNK>	B
58	).	O
1	SRF	B
2	-	O
3	deficient	O
4	embryos	O
5	(	O
6	<UNK>	B
7	<UNK>	O
8	have	O
9	a	O
10	severe	O
11	<UNK>	O
12	defect	O
13	and	O
14	do	O
15	not	O
16	develop	O
17	to	O
18	term	O
19	.	O
1	We	O
2	have	O
3	generated	O
4	a	O
5	computer	O
6	model	O
7	of	O
8	the	O
9	C	O
10	-	O
11	terminal	O
12	domain	O
13	of	O
14	the	O
15	<UNK>	O
16	repressor	O
17	based	O
18	on	O
19	the	O
20	crystal	O
21	structure	O
22	of	O
23	the	O
24	homologous	O
25	<UNK>	O
26	'	O
27	protein	O
28	.	O
1	<UNK>	O
2	-	O
3	scale	O
4	sequencing	O
5	of	O
6	two	O
7	regions	O
8	in	O
9	human	O
10	chromosome	O
11	<UNK>	O
12	:	O
13	analysis	O
14	of	O
15	<UNK>	O
16	kb	O
17	of	O
18	genomic	O
19	sequence	O
20	around	O
21	the	O
22	EPO	B
23	and	O
24	<UNK>	B
25	loci	O
26	reveals	O
27	17	O
28	genes	O
29	.	O
1	Based	O
2	on	O
3	sequence	O
4	homology	O
5	,	O
6	the	O
7	genes	O
8	were	O
9	identified	O
10	as	O
11	<UNK>	B
12	,	O
13	encoding	O
14	translation	O
15	elongation	O
16	factor	O
17	-	O
18	1	O
19	alpha	O
20	and	O
21	<UNK>	B
22	,	O
23	encoding	O
24	ribosomal	O
25	protein	O
26	<UNK>	B
27	.	O
1	Transcription	O
2	factors	O
3	of	O
4	the	O
5	<UNK>	B
6	family	O
7	are	O
8	controlled	O
9	by	O
10	protein	O
11	kinases	O
12	.	O
1	We	O
2	propose	O
3	that	O
4	two	O
5	pathways	O
6	regulate	O
7	<UNK>	B
8	serine	O
9	phosphorylation	O
10	,	O
11	one	O
12	that	O
13	is	O
14	prolactin	B
15	-	O
16	activated	O
17	and	O
18	<UNK>	O
19	-	O
20	resistant	O
21	and	O
22	one	O
23	that	O
24	is	O
25	constitutively	O
26	active	O
27	and	O
28	<UNK>	O
29	-	O
30	sensitive	O
31	and	O
32	preferentially	O
33	targets	O
34	<UNK>	B
35	.	O
1	This	O
2	association	O
3	was	O
4	independently	O
5	significant	O
6	for	O
7	patients	O
8	treated	O
9	primarily	O
10	(	O
11	not	O
12	for	O
13	<UNK>	O
14	).	O
1	An	O
2	open	O
3	reading	O
4	frame	O
5	encoding	O
6	a	O
7	protein	O
8	which	O
9	shows	O
10	significant	O
11	similarity	O
12	to	O
13	<UNK>	B
14	and	O
15	<UNK>	B
16	was	O
17	located	O
18	immediately	O
19	upstream	O
20	of	O
21	the	O
22	<UNK>	B
23	R	O
24	-	O
25	M	O
26	operon	O
27	.	O
1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	<UNK>	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	<UNK>	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	<UNK>	O
20	)	O
21	during	O
22	<UNK>	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O
1	A	O
2	comparative	O
3	analysis	O
4	of	O
5	the	O
6	reported	O
7	<UNK>	O
8	-	O
9	associated	O
10	malignant	O
11	<UNK>	O
12	<UNK>	O
13	the	O
14	<UNK>	O
15	of	O
16	our	O
17	case	O
18	in	O
19	the	O
20	<UNK>	O
21	<UNK>	O
22	of	O
23	the	O
24	melanoma	O
25	,	O
26	its	O
27	<UNK>	O
28	and	O
29	the	O
30	<UNK>	O
31	of	O
32	invasive	O
33	<UNK>	O
34	cell	O
35	carcinoma	O
36	.	O
1	RESULTS	O
2	:	O
3	An	O
4	<UNK>	O
5	<UNK>	O
6	is	O
7	observed	O
8	with	O
9	presence	O
10	of	O
11	type	O
12	I	O
13	herpes	O
14	simplex	O
15	virus	O
16	(	O
17	HSV	O
18	I	O
19	)	O
20	nucleic	O
21	acids	O
22	in	O
23	the	O
24	<UNK>	O
25	'	O
26	s	O
27	<UNK>	O
28	<UNK>	O
29	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	HIV	O
6	-	O
7	1	O
8	<UNK>	B
9	sequences	O
10	can	O
11	influence	O
12	the	O
13	viral	O
14	PR	O
15	-	O
16	mediated	O
17	processing	O
18	of	O
19	the	O
20	MuLV	O
21	<UNK>	O
22	<UNK>	B
23	protein	O
24	<UNK>	O
25	(	O
26	E	O
27	).	O
1	These	O
2	results	O
3	demonstrate	O
4	a	O
5	specific	O
6	association	O
7	of	O
8	<UNK>	O
9	and	O
10	HIV	O
11	-	O
12	2	O
13	<UNK>	B
14	,	O
15	but	O
16	not	O
17	HIV	O
18	-	O
19	1	O
20	<UNK>	B
21	,	O
22	with	O
23	<UNK>	B
24	.	O
1	GH	B
2	failed	O
3	to	O
4	stimulate	O
5	phosphorylation	O
6	or	O
7	activation	O
8	of	O
9	Jun	B
10	N	O
11	-	O
12	terminal	O
13	kinase	B
14	under	O
15	the	O
16	conditions	O
17	used	O
18	.	O
1	Expression	O
2	of	O
3	a	O
4	novel	O
5	murine	O
6	<UNK>	B
7	D	O
8	homolog	O
9	<UNK>	O
10	with	O
11	late	O
12	neuronal	O
13	development	O
14	in	O
15	the	O
16	<UNK>	O
17	.	O
1	The	O
2	pharmacokinetic	O
3	parameters	O
4	which	O
5	<UNK>	O
6	<UNK>	O
7	these	O
8	<UNK>	O
9	included	O
10	area	O
11	under	O
12	the	O
13	curve	O
14	and	O
15	peak	O
16	plasma	O
17	level	O
18	.	O
1	(	O
2	1992	O
3	)	O
4	<UNK>	O
5	31	O
6	,	O
7	<UNK>	O
8	-	O
9	<UNK>	O
10	].	O
1	<UNK>	O
2	of	O
3	serum	O
4	IgE	B
5	were	O
6	measured	O
7	<UNK>	O
8	,	O
9	and	O
10	nasal	O
11	IgE	B
12	was	O
13	measured	O
14	at	O
15	the	O
16	height	O
17	and	O
18	end	O
19	of	O
20	the	O
21	<UNK>	O
22	.	O
1	<UNK>	B
2	are	O
3	cis	O
4	-	O
5	trans	O
6	-	O
7	<UNK>	B
8	-	O
9	<UNK>	B
10	<UNK>	I
11	that	O
12	bind	O
13	to	O
14	and	O
15	are	O
16	inhibited	O
17	by	O
18	the	O
19	<UNK>	O
20	cyclosporin	O
21	A	O
22	(	O
23	<UNK>	O
24	).	O
1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	mechanism	O
7	of	O
8	activation	O
9	of	O
10	<UNK>	B
11	-	O
12	<UNK>	B
13	is	O
14	a	O
15	<UNK>	O
16	-	O
17	step	O
18	process	O
19	which	O
20	includes	O
21	hypoxia	O
22	-	O
23	dependent	O
24	nuclear	O
25	import	O
26	and	O
27	activation	O
28	(	O
29	<UNK>	O
30	)	O
31	of	O
32	the	O
33	transactivation	O
34	domain	O
35	,	O
36	resulting	O
37	in	O
38	recruitment	O
39	of	O
40	the	O
41	CREB	B
42	-	O
43	binding	O
44	protein	O
45	(	O
46	CBP	B
47	)/	O
48	p300	B
49	coactivator	O
50	.	O
1	A	O
2	synergistic	O
3	effect	O
4	on	O
5	<UNK>	B
6	promoter	O
7	activity	O
8	was	O
9	observed	O
10	at	O
11	high	O
12	concentrations	O
13	of	O
14	Sp1	B
15	.	O
1	<UNK>	O
2	-	O
3	binding	O
4	domain	O
5	and	O
6	amino	O
7	acid	O
8	residues	O
9	involved	O
10	in	O
11	<UNK>	O
12	binding	O
13	.	O
1	Western	O
2	analyses	O
3	with	O
4	<UNK>	O
5	raised	O
6	against	O
7	<UNK>	O
8	-	O
9	<UNK>	B
10	-	O
11	1	O
12	peptides	O
13	show	O
14	that	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	predicted	O
23	open	O
24	reading	O
25	frame	O
26	is	O
27	present	O
28	only	O
29	in	O
30	the	O
31	larger	O
32	size	O
33	proteins	O
34	(	O
35	i	O
36	.	O
37	e	O
38	.	O
1	<UNK>	O
2	sperm	O
3	motility	O
4	is	O
5	regulated	O
6	by	O
7	a	O
8	cascade	O
9	of	O
10	cAMP	O
11	-	O
12	dependent	O
13	protein	O
14	phosphorylation	O
15	events	O
16	mediated	O
17	by	O
18	protein	O
19	kinase	B
20	A	O
21	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	show	O
7	that	O
8	,	O
9	like	O
10	<UNK>	B
11	,	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	<UNK>	B
17	gene	O
18	in	O
19	S	O
20	.	O
21	cerevisiae	O
22	is	O
23	induced	O
24	by	O
25	the	O
26	addition	O
27	of	O
28	<UNK>	O
29	-	O
30	chain	O
31	amino	O
32	acids	O
33	to	O
34	the	O
35	medium	O
36	.	O
1	<UNK>	O
2	characterization	O
3	of	O
4	the	O
5	active	O
6	site	O
7	human	O
8	platelet	O
9	cAMP	O
10	phosphodiesterase	O
11	,	O
12	<UNK>	B
13	,	O
14	by	O
15	site	O
16	-	O
17	directed	O
18	mutagenesis	O
19	.	O
1	<UNK>	O
2	-	O
3	expression	O
4	of	O
5	the	O
6	cofactor	O
7	p300	B
8	,	O
9	which	O
10	functions	O
11	as	O
12	a	O
13	coactivator	O
14	of	O
15	<UNK>	B
16	-	O
17	mediated	O
18	transcription	O
19	,	O
20	<UNK>	O
21	repression	O
22	by	O
23	COUP	B
24	-	O
25	TF	B
26	II	O
27	.	O
1	Expression	O
2	of	O
3	lacZ	B
4	from	O
5	the	O
6	promoter	O
7	of	O
8	the	O
9	Escherichia	O
10	coli	O
11	<UNK>	B
12	operon	O
13	cloned	O
14	into	O
15	vectors	O
16	carrying	O
17	the	O
18	<UNK>	O
19	<UNK>	B
20	-	O
21	<UNK>	B
22	fusion	O
23	.	O
1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	rat	O
12	placental	O
13	prolactin	B
14	(	O
15	PRL	B
16	)	O
17	family	O
18	,	O
19	PRL	B
20	-	O
21	like	O
22	protein	O
23	H	O
24	.	O
1	Interestingly	O
2	,	O
3	we	O
4	find	O
5	that	O
6	the	O
7	interaction	O
8	between	O
9	Tat	B
10	and	O
11	<UNK>	B
12	requires	O
13	zinc	O
14	as	O
15	well	O
16	as	O
17	essential	O
18	cysteine	O
19	residues	O
20	in	O
21	both	O
22	proteins	O
23	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	,	O
6	for	O
7	a	O
8	constant	O
9	amount	O
10	of	O
11	transfected	O
12	DNA	O
13	,	O
14	the	O
15	level	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	(	O
20	CAT	B
21	)	O
22	mRNA	O
23	is	O
24	increased	O
25	in	O
26	<UNK>	B
27	-	O
28	expressing	O
29	cells	O
30	using	O
31	either	O
32	HIV	O
33	-	O
34	1	O
35	or	O
36	a	O
37	murine	O
38	leukemia	O
39	virus	O
40	(	O
41	<UNK>	O
42	)	O
43	<UNK>	B
44	-	O
45	3	O
46	LTR	O
47	-	O
48	CAT	B
49	reporter	O
50	construct	O
51	.	O
1	We	O
2	identified	O
3	<UNK>	B
4	mutations	O
5	in	O
6	11	O
7	of	O
8	these	O
9	unrelated	O
10	<UNK>	O
11	-	O
12	like	O
13	individuals	O
14	who	O
15	<UNK>	O
16	a	O
17	single	O
18	copy	O
19	of	O
20	<UNK>	B
21	:	O
22	these	O
23	include	O
24	two	O
25	<UNK>	O
26	mutations	O
27	(	O
28	<UNK>	O
29	and	O
30	<UNK>	O
31	)	O
32	and	O
33	three	O
34	missense	O
35	mutations	O
36	(	O
37	<UNK>	O
38	,	O
39	<UNK>	O
40	,	O
41	and	O
42	<UNK>	O
43	).	O
1	Here	O
2	we	O
3	have	O
4	investigated	O
5	the	O
6	structural	O
7	requirements	O
8	and	O
9	consequences	O
10	of	O
11	regulatory	O
12	phosphorylation	O
13	for	O
14	the	O
15	interaction	O
16	between	O
17	c	B
18	-	O
19	Jun	B
20	and	O
21	JNK	B
22	in	O
23	vivo	O
24	.	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	O
7	cyclin	B
8	,	O
9	cyclin	B
10	E2	O
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	O
19	.	O
1	The	O
2	dopamine	O
3	<UNK>	O
4	receptor	O
5	as	O
6	well	O
7	as	O
8	many	O
9	other	O
10	<UNK>	B
11	receptors	O
12	contain	O
13	several	O
14	putative	O
15	SH3	B
16	binding	O
17	domains	O
18	.	O
1	The	O
2	<UNK>	O
3	National	O
4	<UNK>	O
5	on	O
6	<UNK>	O
7	<UNK>	O
8	and	O
9	<UNK>	O
10	(	O
11	<UNK>	O
12	)	O
13	<UNK>	O
14	two	O
15	forms	O
16	of	O
17	<UNK>	O
18	drinking	O
19	:	O
20	'	O
21	<UNK>	O
22	alcohol	O
23	<UNK>	O
24	',	O
25	a	O
26	<UNK>	O
27	problem	O
28	,	O
29	and	O
30	'	O
31	alcohol	O
32	dependence	O
33	',	O
34	a	O
35	true	O
36	medical	O
37	disorder	O
38	,	O
39	which	O
40	includes	O
41	a	O
42	genetic	O
43	component	O
44	,	O
45	that	O
46	can	O
47	be	O
48	<UNK>	O
49	<UNK>	O
50	and	O
51	<UNK>	O
52	treated	O
53	.	O
1	<UNK>	O
2	disease	O
3	virus	O
4	(	O
5	<UNK>	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	<UNK>	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	O
20	immunodeficiency	O
21	virus	O
22	(	O
23	<UNK>	O
24	).	O
1	<UNK>	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O
1	<UNK>	O
2	-	O
3	regulation	O
4	of	O
5	<UNK>	B
6	-	O
7	1	O
8	is	O
9	linked	O
10	to	O
11	its	O
12	serine	O
13	phosphorylation	O
14	dependent	O
15	on	O
16	PI	O
17	3	O
18	-	O
19	kinase	B
20	activity	O
21	and	O
22	appears	O
23	required	O
24	for	O
25	differentiation	O
26	to	O
27	occur	O
28	,	O
29	as	O
30	<UNK>	B
31	-	O
32	1	O
33	is	O
34	not	O
35	modified	O
36	and	O
37	<UNK>	O
38	to	O
39	accumulate	O
40	in	O
41	a	O
42	<UNK>	O
43	<UNK>	O
44	cell	O
45	line	O
46	.	O
1	However	O
2	,	O
3	no	O
4	studies	O
5	have	O
6	been	O
7	conducted	O
8	to	O
9	further	O
10	investigate	O
11	this	O
12	potentially	O
13	<UNK>	O
14	effect	O
15	of	O
16	<UNK>	O
17	.	O
1	Both	O
2	<UNK>	B
3	-	O
4	<UNK>	B
5	<UNK>	O
6	transformed	O
7	NIH	O
8	3T3	O
9	fibroblasts	O
10	,	O
11	and	O
12	this	O
13	transformation	O
14	required	O
15	the	O
16	<UNK>	B
17	domains	O
18	for	O
19	DNA	O
20	binding	O
21	and	O
22	<UNK>	B
23	interaction	O
24	.	O
1	<UNK>	O
2	analysis	O
3	gave	O
4	a	O
5	<UNK>	O
6	of	O
7	4	O
8	.	O
9	4	O
10	x	O
11	10	O
12	(	O
13	10	O
14	)	O
15	M	O
16	-	O
17	1	O
18	for	O
19	the	O
20	binding	O
21	of	O
22	N	O
23	-	O
24	<UNK>	O
25	to	O
26	<UNK>	O
27	.	O
28	1	O
29	and	O
30	2	O
31	.	O
32	2	O
33	x	O
34	10	O
35	(	O
36	10	O
37	)	O
38	M	O
39	-	O
40	1	O
41	for	O
42	the	O
43	binding	O
44	of	O
45	N	O
46	-	O
47	<UNK>	O
48	to	O
49	<UNK>	O
50	.	O
51	66	O
52	.	O
1	The	O
2	<UNK>	B
3	enzyme	O
4	-	O
5	linked	O
6	<UNK>	O
7	assay	O
8	(	O
9	ELISA	O
10	)	O
11	to	O
12	detect	O
13	circulating	O
14	<UNK>	B
15	<UNK>	I
16	antigen	O
17	<UNK>	O
18	50	O
19	<UNK>	O
20	of	O
21	serum	O
22	.	O
1	We	O
2	now	O
3	show	O
4	that	O
5	<UNK>	B
6	-	O
7	<UNK>	B
8	ligation	O
9	can	O
10	also	O
11	<UNK>	O
12	IL	B
13	-	O
14	4	O
15	and	O
16	have	O
17	an	O
18	anti	O
19	-	O
20	<UNK>	O
21	pro	O
22	-	O
23	<UNK>	O
24	influence	O
25	within	O
26	the	O
27	immune	O
28	system	O
29	,	O
30	causing	O
31	up	O
32	-	O
33	regulation	O
34	of	O
35	co	O
36	-	O
37	stimulatory	O
38	molecules	O
39	on	O
40	B	O
41	lymphocytes	O
42	.	O
1	The	O
2	<UNK>	B
3	repressor	O
4	is	O
5	a	O
6	zinc	O
7	finger	O
8	protein	O
9	that	O
10	mediates	O
11	glucose	O
12	repression	O
13	in	O
14	yeast	O
15	.	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	the	O
9	<UNK>	B
10	gene	O
11	<UNK>	O
12	as	O
13	a	O
14	negative	O
15	regulator	O
16	of	O
17	drug	O
18	resistance	O
19	in	O
20	C	O
21	.	O
22	<UNK>	O
23	and	O
24	constitute	O
25	the	O
26	first	O
27	evidence	O
28	that	O
29	<UNK>	O
30	resistance	O
31	can	O
32	result	O
33	from	O
34	the	O
35	inactivation	O
36	of	O
37	a	O
38	regulatory	O
39	factor	O
40	such	O
41	as	O
42	<UNK>	B
43	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	study	O
5	shows	O
6	that	O
7	(	O
8	1	O
9	)	O
10	total	O
11	body	O
12	<UNK>	O
13	and	O
14	<UNK>	O
15	neck	O
16	<UNK>	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	study	O
23	group	O
24	that	O
25	performed	O
26	weight	O
27	-	O
28	bearing	O
29	<UNK>	O
30	than	O
31	in	O
32	control	O
33	subjects	O
34	,	O
35	(	O
36	2	O
37	)	O
38	<UNK>	O
39	exercise	O
40	had	O
41	no	O
42	effect	O
43	on	O
44	<UNK>	O
45	,	O
46	and	O
47	(	O
48	3	O
49	)	O
50	although	O
51	<UNK>	O
52	is	O
53	not	O
54	a	O
55	bone	O
56	-	O
57	<UNK>	O
58	exercise	O
59	,	O
60	it	O
61	can	O
62	significantly	O
63	improve	O
64	<UNK>	O
65	,	O
66	back	O
67	,	O
68	and	O
69	<UNK>	O
70	muscle	O
71	strength	O
72	.	O
1	This	O
2	suggests	O
3	roles	O
4	for	O
5	both	O
6	the	O
7	<UNK>	O
8	and	O
9	<UNK>	O
10	elements	O
11	in	O
12	regulating	O
13	<UNK>	B
14	gene	O
15	expression	O
16	during	O
17	development	O
18	.	O
1	<UNK>	O
2	gain	O
3	<UNK>	O
4	to	O
5	4	O
6	.	O
7	2	O
8	+/-	O
9	1	O
10	.	O
11	3	O
12	mm	O
13	,	O
14	60	O
15	%	O
16	of	O
17	the	O
18	defects	O
19	showing	O
20	<UNK>	O
21	gain	O
22	>	O
23	or	O
24	=	O
25	4	O
26	mm	O
27	.	O
1	<UNK>	O
2	<UNK>	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	<UNK>	O
8	energy	O
9	.	O
1	However	O
2	,	O
3	there	O
4	has	O
5	not	O
6	been	O
7	any	O
8	evidence	O
9	of	O
10	A	O
11	.	O
12	<UNK>	O
13	infections	O
14	,	O
15	specifically	O
16	<UNK>	O
17	,	O
18	associated	O
19	with	O
20	the	O
21	<UNK>	O
22	in	O
23	this	O
24	<UNK>	O
25	.	O
1	<UNK>	O
2	analyses	O
3	indicated	O
4	that	O
5	inhibition	O
6	of	O
7	ERK	B
8	-	O
9	1	O
10	/	O
11	2	O
12	decreased	O
13	<UNK>	O
14	acid	O
15	-	O
16	elevated	O
17	phosphorylation	O
18	of	O
19	<UNK>	B
20	and	O
21	<UNK>	B
22	.	O
1	The	O
2	<UNK>	O
3	biogenesis	O
4	disorders	O
5	(	O
6	<UNK>	O
7	)	O
8	are	O
9	a	O
10	set	O
11	of	O
12	lethal	O
13	genetic	O
14	diseases	O
15	characterized	O
16	by	O
17	<UNK>	O
18	metabolic	O
19	<UNK>	O
20	,	O
21	<UNK>	O
22	abnormalities	O
23	,	O
24	mental	O
25	retardation	O
26	,	O
27	and	O
28	premature	O
29	death	O
30	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	<UNK>	B
6	is	O
7	directly	O
8	regulated	O
9	by	O
10	retinoic	O
11	acid	O
12	-	O
13	bound	O
14	receptors	O
15	and	O
16	Sp1	B
17	.	O
1	A	O
2	motif	O
3	(	O
4	<UNK>	O
5	)	O
6	which	O
7	<UNK>	O
8	a	O
9	CREB	B
10	site	O
11	and	O
12	is	O
13	similar	O
14	to	O
15	an	O
16	AP	B
17	-	O
18	1	O
19	site	O
20	is	O
21	<UNK>	O
22	within	O
23	<UNK>	B
24	.	O
1	Epstein	O
2	-	O
3	Barr	O
4	virus	O
5	-	O
6	encoded	O
7	latent	O
8	membrane	O
9	protein	O
10	1	O
11	activates	O
12	the	O
13	JNK	B
14	pathway	O
15	through	O
16	its	O
17	<UNK>	O
18	C	O
19	terminus	O
20	via	O
21	a	O
22	mechanism	O
23	involving	O
24	<UNK>	B
25	and	O
26	<UNK>	B
27	.	O
1	However	O
2	,	O
3	serial	O
4	<UNK>	O
5	of	O
6	fetal	O
7	<UNK>	O
8	kidney	O
9	(	O
10	<UNK>	O
11	)	O
12	cells	O
13	,	O
14	which	O
15	are	O
16	sensitive	O
17	to	O
18	infection	O
19	with	O
20	<UNK>	O
21	,	O
22	after	O
23	transient	O
24	transfection	O
25	revealed	O
26	that	O
27	mutation	O
28	of	O
29	a	O
30	second	O
31	tyrosine	O
32	residue	O
33	in	O
34	the	O
35	N	O
36	-	O
37	terminal	O
38	motif	O
39	completely	O
40	prevented	O
41	the	O
42	<UNK>	O
43	of	O
44	the	O
45	virus	O
46	.	O
1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	O
13	endogenous	O
14	<UNK>	B
15	gene	O
16	(	O
17	<UNK>	B
18	)	O
19	had	O
20	been	O
21	deleted	O
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	O
28	<UNK>	O
29	were	O
30	characterized	O
31	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	specific	O
13	<UNK>	B
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	<UNK>	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	<UNK>	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O
1	<UNK>	O
2	tissue	O
3	and	O
4	<UNK>	O
5	collagen	B
6	fibers	O
7	in	O
8	the	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	O
12	its	O
13	<UNK>	O
14	during	O
15	<UNK>	O
16	.	O
1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	<UNK>	B
7	,	O
8	<UNK>	B
9	and	O
10	bacteria	O
11	-	O
12	<UNK>	O
13	<UNK>	O
14	<UNK>	B
15	and	O
16	<UNK>	B
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	<UNK>	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	<UNK>	B
38	gene	O
39	.	O
1	BACKGROUND	O
2	:	O
3	<UNK>	O
4	,	O
5	one	O
6	of	O
7	the	O
8	<UNK>	O
9	group	O
10	of	O
11	<UNK>	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	<UNK>	O
18	drug	O
19	for	O
20	<UNK>	O
21	and	O
22	for	O
23	<UNK>	O
24	of	O
25	<UNK>	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	mouse	O
5	<UNK>	B
6	oxidase	I
7	.	O
1	In	O
2	such	O
3	a	O
4	manner	O
5	,	O
6	activated	O
7	PKR	B
8	inhibits	O
9	cell	O
10	growth	O
11	and	O
12	induces	O
13	apoptosis	O
14	,	O
15	whereas	O
16	disruption	O
17	of	O
18	normal	O
19	PKR	B
20	signaling	O
21	results	O
22	in	O
23	<UNK>	O
24	cell	O
25	growth	O
26	.	O
1	Five	O
2	different	O
3	<UNK>	O
4	of	O
5	<UNK>	O
6	(	O
7	<UNK>	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O
1	The	O
2	<UNK>	O
3	connective	O
4	tissue	O
5	<UNK>	O
6	is	O
7	important	O
8	in	O
9	<UNK>	O
10	the	O
11	<UNK>	O
12	of	O
13	the	O
14	myocardium	O
15	by	O
16	preventing	O
17	lateral	O
18	spread	O
19	of	O
20	<UNK>	O
21	and	O
22	by	O
23	<UNK>	O
24	transmission	O
25	of	O
26	the	O
27	<UNK>	O
28	only	O
29	at	O
30	the	O
31	termination	O
32	of	O
33	the	O
34	<UNK>	O
35	<UNK>	O
36	.	O
1	Here	O
2	we	O
3	describe	O
4	a	O
5	mutant	O
6	alpha	O
7	subunit	O
8	designed	O
9	to	O
10	inhibit	O
11	receptor	O
12	-	O
13	mediated	O
14	hormonal	O
15	activation	O
16	of	O
17	<UNK>	B
18	,	O
19	the	O
20	stimulatory	O
21	regulator	O
22	of	O
23	<UNK>	B
24	cyclase	I
25	.	O
1	<UNK>	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	<UNK>	O
7	at	O
8	32	O
9	.	O
10	6	O
11	<UNK>	O
12	in	O
13	<UNK>	O
14	-	O
15	like	O
16	<UNK>	O
17	<UNK>	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	<UNK>	O
27	-	O
28	<UNK>	O
29	laser	O
30	<UNK>	O
31	.	O
1	This	O
2	region	O
3	of	O
4	<UNK>	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	<UNK>	O
10	activity	O
11	,	O
12	<UNK>	O
13	the	O
14	<UNK>	B
15	dimerization	O
16	domain	O
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	O
25	receptor	O
26	interaction	O
27	.	O
1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	<UNK>	B
7	/	O
8	<UNK>	B
9	gene	O
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	<UNK>	B
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	<UNK>	B
25	genes	O
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	O
32	.	O
1	Transcription	O
2	<UNK>	O
3	into	O
4	the	O
5	inverted	O
6	repeats	O
7	has	O
8	little	O
9	effect	O
10	on	O
11	this	O
12	event	O
13	.	O
1	All	O
2	<UNK>	O
3	were	O
4	down	O
5	-	O
6	regulated	O
7	with	O
8	GnRH	B
9	-	O
10	a	O
11	<UNK>	O
12	on	O
13	day	O
14	21	O
15	in	O
16	a	O
17	long	O
18	protocol	O
19	before	O
20	<UNK>	B
21	stimulation	O
22	.	O
1	<UNK>	O
2	.	O
1	We	O
2	used	O
3	expression	O
4	cloning	O
5	to	O
6	identify	O
7	interleukin	B
8	-	O
9	6	O
10	(	O
11	IL	B
12	-	O
13	6	O
14	)	O
15	as	O
16	one	O
17	factor	O
18	that	O
19	suppressed	O
20	growth	O
21	of	O
22	a	O
23	pre	O
24	-	O
25	B	O
26	-	O
27	cell	O
28	variant	O
29	line	O
30	,	O
31	<UNK>	O
32	-	O
33	M	O
34	.	O
1	The	O
2	<UNK>	O
3	ratio	O
4	for	O
5	<UNK>	O
6	was	O
7	1	O
8	.	O
9	21	O
10	(	O
11	95	O
12	%	O
13	<UNK>	O
14	interval	O
15	,	O
16	0	O
17	.	O
18	84	O
19	-	O
20	1	O
21	.	O
22	75	O
23	)	O
24	given	O
25	a	O
26	positive	O
27	<UNK>	O
28	of	O
29	specific	O
30	IgG	B
31	antibodies	O
32	after	O
33	<UNK>	O
34	for	O
35	<UNK>	O
36	.	O
1	Another	O
2	group	O
3	of	O
4	<UNK>	O
5	-	O
6	and	O
7	<UNK>	O
8	-	O
9	<UNK>	O
10	animals	O
11	<UNK>	O
12	on	O
13	the	O
14	<UNK>	O
15	after	O
16	the	O
17	lesion	O
18	showed	O
19	reduced	O
20	<UNK>	O
21	of	O
22	the	O
23	type	O
24	described	O
25	above	O
26	,	O
27	suggesting	O
28	that	O
29	<UNK>	O
30	structures	O
31	<UNK>	O
32	after	O
33	the	O
34	lesion	O
35	can	O
36	<UNK>	O
37	the	O
38	role	O
39	of	O
40	the	O
41	<UNK>	O
42	to	O
43	some	O
44	degree	O
45	.	O
1	Mutations	O
2	affecting	O
3	only	O
4	CD4	B
5	regulation	O
6	mapped	O
7	to	O
8	residues	O
9	previously	O
10	shown	O
11	to	O
12	mediate	O
13	the	O
14	binding	O
15	of	O
16	<UNK>	B
17	to	O
18	this	O
19	receptor	O
20	,	O
21	such	O
22	as	O
23	<UNK>	O
24	and	O
25	<UNK>	O
26	,	O
27	as	O
28	well	O
29	as	O
30	to	O
31	an	O
32	AP	B
33	-	O
34	<UNK>	O
35	<UNK>	B
36	motif	O
37	and	O
38	to	O
39	an	O
40	acidic	O
41	<UNK>	O
42	in	O
43	the	O
44	C	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	the	O
50	protein	O
51	.	O
1	Several	O
2	mutations	O
3	disrupted	O
4	the	O
5	endonuclease	O
6	and	O
7	helicase	B
8	activities	O
9	;	O
10	however	O
11	,	O
12	only	O
13	one	O
14	amino	O
15	-	O
16	terminal	O
17	-	O
18	<UNK>	O
19	cluster	O
20	mutant	O
21	protein	O
22	(	O
23	<UNK>	O
24	-	O
25	<UNK>	O
26	-	O
27	<UNK>	O
28	)	O
29	completely	O
30	lost	O
31	<UNK>	O
32	<UNK>	O
33	DNA	O
34	binding	O
35	activity	O
36	.	O
1	<UNK>	O
2	in	O
3	the	O
4	specific	O
5	heat	O
6	of	O
7	<UNK>	O
8	<UNK>	O
9	induced	O
10	by	O
11	critical	O
12	<UNK>	O
13	-	O
14	wave	O
15	dynamics	O
16	.	O
1	<UNK>	O
2	coupling	O
3	in	O
4	the	O
5	<UNK>	O
6	<UNK>	O
7	as	O
8	revealed	O
9	by	O
10	<UNK>	O
11	<UNK>	O
12	-	O
13	<UNK>	O
14	double	O
15	resonance	O
16	.	O
1	<UNK>	O
2	structure	O
3	of	O
4	a	O
5	<UNK>	O
6	<UNK>	O
7	or	O
8	<UNK>	O
9	layer	O
10	in	O
11	<UNK>	O
12	<UNK>	O
13	.	O
1	However	O
2	,	O
3	deletions	O
4	of	O
5	the	O
6	C	O
7	terminal	O
8	11	O
9	or	O
10	14	O
11	amino	O
12	acids	O
13	had	O
14	more	O
15	substantial	O
16	effects	O
17	.	O
1	<UNK>	O
2	-	O
3	statistical	O
4	theory	O
5	of	O
6	high	O
7	-	O
8	field	O
9	transport	O
10	phenomena	O
11	.	O
1	<UNK>	O
2	<UNK>	O
3	to	O
4	second	O
5	post	O
6	-	O
7	<UNK>	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O
1	Genetic	O
2	experiments	O
3	using	O
4	mutants	O
5	defective	O
6	in	O
7	<UNK>	B
8	and	O
9	<UNK>	B
10	reveal	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	these	O
16	genes	O
17	.	O
1	<UNK>	O
2	of	O
3	<UNK>	B
4	in	O
5	<UNK>	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	<UNK>	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	<UNK>	O
32	,	O
33	respectively	O
34	.	O
1	The	O
2	<UNK>	B
3	protein	O
4	sequence	O
5	does	O
6	not	O
7	contain	O
8	readily	O
9	<UNK>	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O
1	<UNK>	B
2	simultaneously	O
3	regulates	O
4	both	O
5	<UNK>	O
6	<UNK>	O
7	and	O
8	<UNK>	O
9	<UNK>	O
10	in	O
11	the	O
12	spinal	O
13	<UNK>	O
14	mouse	O
15	(	O
16	<UNK>	B
17	/	O
18	<UNK>	B
19	)	O
20	in	O
21	vivo	O
22	.	O
1	<UNK>	O
2	mobility	O
3	-	O
4	shift	O
5	assays	O
6	performed	O
7	with	O
8	the	O
9	HNF	B
10	-	O
11	3	O
12	X	O
13	and	O
14	Y	O
15	sites	O
16	demonstrated	O
17	that	O
18	both	O
19	sites	O
20	are	O
21	capable	O
22	of	O
23	binding	O
24	HNF	B
25	-	O
26	<UNK>	B
27	and	O
28	HNF	B
29	-	O
30	<UNK>	B
31	.	O
1	<UNK>	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	<UNK>	B
7	CRE	O
8	include	O
9	the	O
10	CRE	O
11	-	O
12	binding	O
13	protein	O
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	O
22	/	O
23	enhancer	O
24	-	O
25	binding	O
26	protein	O
27	(	O
28	C	O
29	/	O
30	EBP	B
31	)	O
32	family	O
33	.	O
1	In	O
2	addition	O
3	,	O
4	in	O
5	vitro	O
6	mutagenesis	O
7	of	O
8	both	O
9	<UNK>	B
10	and	O
11	<UNK>	B
12	sites	O
13	indicated	O
14	that	O
15	other	O
16	<UNK>	O
17	sites	O
18	are	O
19	responsible	O
20	for	O
21	the	O
22	transcriptional	O
23	enhancement	O
24	observed	O
25	with	O
26	the	O
27	<UNK>	O
28	fragment	O
29	.	O
1	<UNK>	O
2	functional	O
3	analysis	O
4	of	O
5	<UNK>	B
6	/	O
7	<UNK>	B
8	hybrid	O
9	receptors	O
10	showed	O
11	that	O
12	the	O
13	second	O
14	intracellular	O
15	loop	O
16	of	O
17	the	O
18	<UNK>	B
19	receptor	O
20	is	O
21	required	O
22	and	O
23	sufficient	O
24	for	O
25	efficient	O
26	coupling	O
27	to	O
28	<UNK>	B
29	/	O
30	11	O
31	,	O
32	whereas	O
33	the	O
34	third	O
35	intracellular	O
36	loop	O
37	of	O
38	the	O
39	<UNK>	B
40	receptor	O
41	is	O
42	required	O
43	and	O
44	sufficient	O
45	for	O
46	coupling	O
47	to	O
48	<UNK>	B
49	.	O
1	<UNK>	O
2	<UNK>	O
3	of	O
4	<UNK>	O
5	-	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	.	O
1	In	O
2	the	O
3	brain	O
4	,	O
5	<UNK>	B
6	receptors	O
7	mediate	O
8	motor	O
9	and	O
10	memory	O
11	function	O
12	by	O
13	interaction	O
14	with	O
15	their	O
16	ligand	O
17	<UNK>	O
18	.	O
1	<UNK>	O
2	-	O
3	onset	O
4	<UNK>	O
5	necrosis	O
6	after	O
7	<UNK>	O
8	I	O
9	125	O
10	<UNK>	O
11	radiotherapy	O
12	for	O
13	<UNK>	O
14	melanoma	O
15	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	as	O
5	a	O
6	feature	O
7	of	O
8	linear	O
9	-	O
10	<UNK>	O
11	theory	O
12	:	O
13	Analysis	O
14	and	O
15	experimental	O
16	observations	O
17	.	O
1	High	O
2	-	O
3	pressure	O
4	effects	O
5	on	O
6	<UNK>	O
7	-	O
8	<UNK>	O
9	kinetics	O
10	of	O
11	<UNK>	O
12	in	O
13	<UNK>	O
14	<UNK>	O
15	.	O
1	Recombinant	O
2	<UNK>	B
3	acts	O
4	synergistically	O
5	with	O
6	recombinant	O
7	PTB	O
8	to	O
9	stimulate	O
10	translation	O
11	dependent	O
12	on	O
13	the	O
14	<UNK>	O
15	<UNK>	O
16	.	O
1	Identification	O
2	of	O
3	RNase	B
4	T	O
5	as	O
6	a	O
7	high	O
8	-	O
9	copy	O
10	suppressor	O
11	of	O
12	the	O
13	UV	O
14	sensitivity	O
15	associated	O
16	with	O
17	single	O
18	-	O
19	strand	O
20	DNA	O
21	<UNK>	O
22	deficiency	O
23	in	O
24	Escherichia	O
25	coli	O
26	.	O
1	<UNK>	O
2	at	O
3	these	O
4	three	O
5	sites	O
6	may	O
7	partially	O
8	<UNK>	O
9	<UNK>	B
10	,	O
11	thereby	O
12	<UNK>	O
13	rapid	O
14	repair	O
15	.	O
1	<UNK>	B
2	D1	I
3	-	O
4	associated	O
5	kinase	B
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	<UNK>	B
22	(	O
23	c	B
24	-	O
25	<UNK>	B
26	)	O
27	transgenic	O
28	mice	O
29	.	O
1	<UNK>	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	<UNK>	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O
1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	<UNK>	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	<UNK>	B
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	<UNK>	O
32	of	O
33	the	O
34	above	O
35	<UNK>	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O
1	The	O
2	rate	O
3	of	O
4	<UNK>	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O
1	In	O
2	order	O
3	to	O
4	better	O
5	characterize	O
6	the	O
7	distribution	O
8	of	O
9	<UNK>	O
10	and	O
11	MAP	B
12	estimates	O
13	under	O
14	these	O
15	conditions	O
16	,	O
17	we	O
18	<UNK>	O
19	a	O
20	point	O
21	<UNK>	O
22	to	O
23	density	O
24	values	O
25	of	O
26	the	O
27	conditional	O
28	distribution	O
29	of	O
30	such	O
31	estimates	O
32	.	O
1	<UNK>	O
2	,	O
3	inactivation	O
4	of	O
5	the	O
6	cyclin	B
7	E	O
8	-	O
9	Cdk2	B
10	complex	O
11	in	O
12	response	O
13	to	O
14	mitogen	B
15	starvation	O
16	occurs	O
17	normally	O
18	in	O
19	<UNK>	O
20	that	O
21	have	O
22	a	O
23	<UNK>	O
24	deletion	O
25	of	O
26	the	O
27	<UNK>	B
28	gene	O
29	.	O
1	Functional	O
2	domains	O
3	of	O
4	c	B
5	-	O
6	myc	B
7	promoter	O
8	binding	O
9	protein	O
10	1	O
11	involved	O
12	in	O
13	transcriptional	O
14	repression	O
15	and	O
16	cell	O
17	growth	O
18	regulation	O
19	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	ATF	B
6	-	O
7	2	O
8	plays	O
9	a	O
10	central	O
11	role	O
12	in	O
13	TGF	B
14	-	O
15	beta	O
16	signaling	O
17	by	O
18	acting	O
19	as	O
20	a	O
21	common	O
22	nuclear	O
23	target	O
24	of	O
25	both	O
26	<UNK>	B
27	and	O
28	<UNK>	B
29	pathways	O
30	.	O
1	The	O
2	following	O
3	data	O
4	were	O
5	recorded	O
6	at	O
7	<UNK>	O
8	in	O
9	the	O
10	<UNK>	O
11	care	O
12	unit	O
13	6	O
14	,	O
15	12	O
16	,	O
17	24	O
18	,	O
19	and	O
20	48	O
21	hours	O
22	after	O
23	termination	O
24	of	O
25	<UNK>	O
26	:	O
27	heart	O
28	rate	O
29	,	O
30	blood	O
31	pressure	O
32	,	O
33	left	O
34	atrial	O
35	pressure	O
36	,	O
37	central	O
38	-	O
39	peripheral	O
40	temperature	O
41	difference	O
42	,	O
43	arterial	O
44	-	O
45	central	O
46	venous	O
47	oxygen	O
48	saturation	O
49	difference	O
50	,	O
51	urine	O
52	output	O
53	,	O
54	serum	O
55	creatinine	O
56	,	O
57	lactate	O
58	and	O
59	neutrophil	O
60	<UNK>	B
61	levels	O
62	,	O
63	the	O
64	Doppler	O
65	<UNK>	O
66	factors	O
67	<UNK>	O
68	fraction	O
69	and	O
70	<UNK>	O
71	period	O
72	/	O
73	left	O
74	-	O
75	ventricular	O
76	ejection	O
77	time	O
78	,	O
79	and	O
80	<UNK>	O
81	doses	O
82	of	O
83	<UNK>	O
84	(	O
85	<UNK>	O
86	),	O
87	<UNK>	O
88	,	O
89	and	O
90	<UNK>	O
91	.	O
1	The	O
2	<UNK>	O
3	delta	O
4	among	O
5	the	O
6	three	O
7	groups	O
8	did	O
9	not	O
10	differ	O
11	as	O
12	well	O
13	:	O
14	<UNK>	O
15	delta	O
16	of	O
17	the	O
18	VT	O
19	group	O
20	was	O
21	70	O
22	ms	O
23	+/-	O
24	30	O
25	ms	O
26	,	O
27	the	O
28	<UNK>	O
29	delta	O
30	of	O
31	the	O
32	<UNK>	O
33	group	O
34	was	O
35	60	O
36	<UNK>	O
37	+/-	O
38	25	O
39	<UNK>	O
40	,	O
41	and	O
42	the	O
43	<UNK>	O
44	delta	O
45	of	O
46	the	O
47	control	O
48	group	O
49	was	O
50	70	O
51	ms	O
52	+/-	O
53	30	O
54	ms	O
55	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	<UNK>	O
5	scores	O
6	in	O
7	the	O
8	""""	O
9	off	O
10	""""	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	""""	O
21	on	O
22	""""	O
23	state	O
24	the	O
25	scores	O
26	<UNK>	O
27	by	O
28	2	O
29	%.	O
1	<UNK>	B
2	II	O
3	is	O
4	a	O
5	major	O
6	target	O
7	of	O
8	the	O
9	protein	O
10	kinase	B
11	casein	I
12	kinase	I
13	2	O
14	(	O
15	<UNK>	O
16	<UNK>	B
17	)	O
18	in	O
19	vivo	O
20	.	O
1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	<UNK>	B
7	protein	O
8	is	O
9	identical	O
10	with	O
11	a	O
12	<UNK>	O
13	kDa	O
14	nuclear	O
15	'	O
16	domain	O
17	rich	O
18	in	O
19	<UNK>	O
20	'	O
21	(	O
22	<UNK>	B
23	)	O
24	protein	O
25	occurring	O
26	free	O
27	in	O
28	the	O
29	<UNK>	O
30	and	O
31	in	O
32	U2	B
33	-	O
34	ribonucleoprotein	O
35	structures	O
36	.	O
1	Four	O
2	<UNK>	O
3	-	O
4	treated	O
5	patients	O
6	developed	O
7	<UNK>	O
8	elevated	O
9	<UNK>	O
10	>	O
11	30	O
12	mg	O
13	/	O
14	24	O
15	h	O
16	(	O
17	n	O
18	=	O
19	3	O
20	with	O
21	<UNK>	O
22	),	O
23	whereas	O
24	all	O
25	the	O
26	17	O
27	placebo	O
28	-	O
29	treated	O
30	patients	O
31	had	O
32	normal	O
33	<UNK>	O
34	(<	O
35	30	O
36	mg	O
37	/	O
38	24	O
39	h	O
40	)	O
41	after	O
42	7	O
43	years	O
44	of	O
45	follow	O
46	-	O
47	up	O
48	.	O
1	In	O
2	all	O
3	trials	O
4	,	O
5	antigen	O
6	challenge	O
7	followed	O
8	1	O
9	h	O
10	after	O
11	the	O
12	last	O
13	treatment	O
14	.	O
1	31	O
2	,	O
3	<UNK>	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	<UNK>	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	<UNK>	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O
1	<UNK>	O
2	v	O
3	.	O
1	We	O
2	have	O
3	screened	O
4	the	O
5	<UNK>	B
6	gene	O
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	<UNK>	O
12	aortic	O
13	stenosis	O
14	(	O
15	<UNK>	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	<UNK>	O
28	)	O
29	<UNK>	O
30	.	O
1	<UNK>	O
2	<UNK>	O
3	(	O
4	<UNK>	O
5	):	O
6	a	O
7	double	O
8	-	O
9	blind	O
10	,	O
11	placebo	O
12	-	O
13	controlled	O
14	study	O
15	of	O
16	safety	O
17	and	O
18	efficacy	O
19	in	O
20	the	O
21	treatment	O
22	of	O
23	<UNK>	O
24	<UNK>	O
25	of	O
26	the	O
27	<UNK>	O
28	type	O
29	.	O
1	Characterization	O
2	of	O
3	the	O
4	transcription	O
5	factor	O
6	<UNK>	O
7	-	O
8	1	O
9	from	O
10	the	O
11	Japanese	O
12	<UNK>	O
13	(	O
14	<UNK>	O
15	<UNK>	O
16	)	O
17	reveals	O
18	evolutionary	O
19	conservation	O
20	of	O
21	heavy	O
22	metal	O
23	stress	O
24	response	O
25	.	O
1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	O
10	-	O
11	<UNK>	B
12	rapidly	O
13	<UNK>	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	<UNK>	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O
1	Plasma	O
2	glucose	O
3	,	O
4	<UNK>	O
5	insulin	B
6	(	O
7	<UNK>	B
8	),	O
9	C	O
10	-	O
11	peptide	O
12	,	O
13	<UNK>	B
14	,	O
15	and	O
16	<UNK>	B
17	-	O
18	1	O
19	levels	O
20	at	O
21	each	O
22	time	O
23	point	O
24	during	O
25	<UNK>	O
26	were	O
27	measured	O
28	.	O
1	<UNK>	O
2	-	O
3	99m	O
4	<UNK>	O
5	<UNK>	O
6	<UNK>	O
7	for	O
8	evaluation	O
9	of	O
10	<UNK>	O
11	breast	O
12	<UNK>	O
13	.	O
1	<UNK>	O
2	can	O
3	also	O
4	cause	O
5	a	O
6	<UNK>	O
7	acting	O
8	directly	O
9	on	O
10	the	O
11	inner	O
12	ear	O
13	:	O
14	among	O
15	these	O
16	,	O
17	<UNK>	O
18	<UNK>	O
19	,	O
20	a	O
21	<UNK>	O
22	which	O
23	causes	O
24	<UNK>	O
25	and	O
26	<UNK>	O
27	<UNK>	O
28	,	O
29	a	O
30	<UNK>	O
31	that	O
32	causes	O
33	<UNK>	O
34	<UNK>	O
35	,	O
36	must	O
37	be	O
38	<UNK>	O
39	.	O
1	<UNK>	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	<UNK>	O
11	via	O
12	a	O
13	<UNK>	O
14	mechanism	O
15	.	O
1	The	O
2	Fyn	B
3	NH2	O
4	terminus	O
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	B
14	and	O
15	both	O
16	Fyn	B
17	kinase	I
18	and	O
19	SH2	B
20	domains	O
21	were	O
22	required	O
23	,	O
24	<UNK>	O
25	phosphorylation	O
26	of	O
27	zeta	B
28	<UNK>	I
29	<UNK>	O
30	and	O
31	binding	O
32	to	O
33	zeta	B
34	<UNK>	I
35	<UNK>	O
36	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	<UNK>	B
15	and	O
16	<UNK>	B
17	genes	O
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	<UNK>	O
32	non	O
33	-	O
34	<UNK>	O
35	,	O
36	but	O
37	potentially	O
38	<UNK>	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O
1	In	O
2	<UNK>	O
3	,	O
4	the	O
5	<UNK>	O
6	were	O
7	<UNK>	O
8	<UNK>	O
9	<UNK>	O
10	criteria	O
11	.	O
1	<UNK>	B
2	growth	O
3	factor	O
4	(	O
5	TGF	B
6	)-	O
7	beta1	B
8	induces	O
9	extracellular	O
10	matrix	O
11	<UNK>	O
12	and	O
13	proliferation	O
14	of	O
15	<UNK>	O
16	cells	O
17	.	O
1	RESULTS	O
2	AND	O
3	CONCLUSIONS	O
4	:	O
5	<UNK>	O
6	'	O
7	s	O
8	double	O
9	<UNK>	O
10	-	O
11	<UNK>	O
12	(	O
13	G2	O
14	)	O
15	<UNK>	O
16	in	O
17	<UNK>	O
18	<UNK>	O
19	increase	O
20	of	O
21	<UNK>	O
22	-	O
23	pressure	O
24	during	O
25	<UNK>	O
26	with	O
27	<UNK>	O
28	.	O
1	The	O
2	binding	O
3	of	O
4	<UNK>	B
5	domains	O
6	to	O
7	<UNK>	B
8	was	O
9	inhibited	O
10	by	O
11	<UNK>	O
12	of	O
13	<UNK>	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	<UNK>	B
28	.	O
1	<UNK>	O
2	<UNK>	O
3	and	O
4	<UNK>	O
5	disease	O
6	linked	O
7	to	O
8	<UNK>	O
9	dopamine	O
10	agonist	O
11	therapy	O
12	(	O
13	<UNK>	O
14	)	O
15	for	O
16	<UNK>	O
17	'	O
18	s	O
19	disease	O
20	.	O
1	An	O
2	<UNK>	O
3	type	O
4	of	O
5	<UNK>	O
6	is	O
7	frequently	O
8	associated	O
9	with	O
10	<UNK>	O
11	and	O
12	we	O
13	<UNK>	O
14	,	O
15	therefore	O
16	,	O
17	that	O
18	<UNK>	O
19	should	O
20	be	O
21	<UNK>	O
22	of	O
23	a	O
24	possible	O
25	<UNK>	O
26	of	O
27	<UNK>	O
28	and	O
29	<UNK>	O
30	.	O
1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	<UNK>	B
16	-	O
17	kappa	B
18	function	O
19	.	O
1	The	O
2	control	O
3	group	O
4	included	O
5	8	O
6	<UNK>	O
7	samples	O
8	from	O
9	physiological	O
10	full	O
11	-	O
12	term	O
13	<UNK>	O
14	.	O
1	However	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	gene	O
7	between	O
8	the	O
9	<UNK>	B
10	<UNK>	I
11	and	O
12	<UNK>	B
13	genes	O
14	with	O
15	homology	O
16	to	O
17	the	O
18	first	O
19	ORF	O
20	(	O
21	ORF	O
22	-	O
23	1	O
24	)	O
25	of	O
26	<UNK>	O
27	herpesvirus	O
28	type	O
29	1	O
30	and	O
31	corresponding	O
32	gene	O
33	identified	O
34	in	O
35	<UNK>	O
36	virus	O
37	.	O
1	The	O
2	5	O
3	'	O
4	untranslated	O
5	and	O
6	coding	O
7	regions	O
8	are	O
9	contained	O
10	within	O
11	12	O
12	exons	O
13	,	O
14	with	O
15	the	O
16	translation	O
17	start	O
18	site	O
19	located	O
20	within	O
21	the	O
22	first	O
23	exon	O
24	.	O
1	A	O
2	<UNK>	B
3	-	O
4	dependent	O
5	spindle	O
6	<UNK>	O
7	pathway	O
8	regulates	O
9	the	O
10	<UNK>	B
11	kinase	I
12	in	O
13	budding	O
14	yeast	O
15	.	O
1	We	O
2	show	O
3	that	O
4	other	O
5	<UNK>	B
6	mutants	O
7	also	O
8	arrest	O
9	in	O
10	G1	O
11	.	O
1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	<UNK>	B
6	contains	O
7	a	O
8	<UNK>	O
9	guanine	O
10	<UNK>	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	<UNK>	O
16	-	O
17	<UNK>	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	<UNK>	B
23	binds	O
24	four	O
25	[	O
26	<UNK>	O
27	-	O
28	<UNK>	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	<UNK>	B
35	is	O
36	an	O
37	<UNK>	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	<UNK>	O
43	oxidation	O
44	site	O
45	.	O
1	<UNK>	O
2	<UNK>	O
3	demonstrates	O
4	a	O
5	shift	O
6	in	O
7	identification	O
8	of	O
9	the	O
10	library	O
11	as	O
12	an	O
13	isolated	O
14	unit	O
15	to	O
16	an	O
17	<UNK>	O
18	<UNK>	O
19	<UNK>	O
20	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	<UNK>	B
6	inhibits	O
7	tyrosine	O
8	phosphatases	B
9	,	O
10	<UNK>	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	<UNK>	B
16	.	O
1	We	O
2	suggest	O
3	that	O
4	<UNK>	B
5	and	O
6	<UNK>	B
7	are	O
8	substrate	O
9	-	O
10	specific	O
11	<UNK>	O
12	<UNK>	O
13	that	O
14	prevent	O
15	<UNK>	O
16	of	O
17	the	O
18	<UNK>	B
19	by	O
20	binding	O
21	to	O
22	their	O
23	helical	O
24	domains	O
25	before	O
26	export	O
27	.	O
1	As	O
2	determined	O
3	in	O
4	a	O
5	modified	O
6	yeast	O
7	two	O
8	-	O
9	hybrid	O
10	system	O
11	,	O
12	<UNK>	B
13	bound	O
14	strongly	O
15	to	O
16	the	O
17	<UNK>	B
18	subunit	O
19	of	O
20	phosphatidylinositol	B
21	3	O
22	-	O
23	kinase	B
24	.	O
1	Insulin	B
2	stimulation	O
3	<UNK>	O
4	the	O
5	association	O
6	of	O
7	<UNK>	B
8	with	O
9	<UNK>	B
10	,	O
11	<UNK>	B
12	,	O
13	<UNK>	B
14	,	O
15	and	O
16	Shc	B
17	.	O
1	In	O
2	the	O
3	case	O
4	of	O
5	the	O
6	<UNK>	O
7	intron	O
8	,	O
9	repression	O
10	of	O
11	luciferase	B
12	expression	O
13	likely	O
14	involved	O
15	two	O
16	<UNK>	B
17	-	O
18	binding	O
19	sequences	O
20	,	O
21	since	O
22	luciferase	B
23	expression	O
24	was	O
25	increased	O
26	by	O
27	deletion	O
28	of	O
29	these	O
30	sites	O
31	.	O
1	Additionally	O
2	,	O
3	deletion	O
4	analysis	O
5	of	O
6	the	O
7	<UNK>	B
8	promoter	O
9	-	O
10	<UNK>	B
11	constructs	O
12	indicated	O
13	that	O
14	the	O
15	minimal	O
16	region	O
17	<UNK>	O
18	the	O
19	promoter	O
20	activity	O
21	was	O
22	located	O
23	between	O
24	nt	O
25	-	O
26	33	O
27	and	O
28	+	O
29	100	O
30	,	O
31	and	O
32	that	O
33	a	O
34	strong	O
35	enhancer	O
36	was	O
37	present	O
38	within	O
39	<UNK>	O
40	bp	O
41	of	O
42	the	O
43	5	O
44	'-	O
45	promoter	O
46	region	O
47	.	O
1	<UNK>	B
2	also	O
3	was	O
4	identified	O
5	as	O
6	a	O
7	component	O
8	of	O
9	a	O
10	cytoplasmic	O
11	<UNK>	O
12	<UNK>	O
13	containing	O
14	<UNK>	B
15	/	O
16	<UNK>	B
17	,	O
18	<UNK>	B
19	,	O
20	and	O
21	<UNK>	B
22	.	O
1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	<UNK>	O
10	and	O
11	0	O
12	.	O
13	<UNK>	O
14	for	O
15	the	O
16	<UNK>	O
17	and	O
18	the	O
19	<UNK>	O
20	system	O
21	,	O
22	respectively	O
23	.	O
1	The	O
2	5	O
3	-	O
4	year	O
5	<UNK>	O
6	for	O
7	stage	O
8	<UNK>	O
9	was	O
10	30	O
11	.	O
12	9	O
13	%,	O
14	compared	O
15	to	O
16	7	O
17	.	O
18	8	O
19	%	O
20	for	O
21	stage	O
22	IV	O
23	.	O
1	Furthermore	O
2	,	O
3	heparin	O
4	<UNK>	B
5	treatment	O
6	of	O
7	extracts	O
8	of	O
9	cells	O
10	expressing	O
11	recombinant	O
12	<UNK>	B
13	-	O
14	repeat	O
15	protein	O
16	<UNK>	O
17	this	O
18	protein	O
19	from	O
20	high	O
21	molecular	O
22	mass	O
23	<UNK>	O
24	.	O
1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	<UNK>	O
10	gave	O
11	no	O
12	<UNK>	O
13	information	O
14	,	O
15	<UNK>	O
16	/	O
17	<UNK>	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	<UNK>	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	<UNK>	O
32	<UNK>	O
33	<UNK>	O
34	,	O
35	partially	O
36	<UNK>	O
37	<UNK>	O
38	/	O
39	casein	B
40	<UNK>	O
41	,	O
42	<UNK>	O
43	/	O
44	<UNK>	B
45	collagen	I
46	<UNK>	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	<UNK>	O
53	.	O
1	Although	O
2	it	O
3	has	O
4	two	O
5	potential	O
6	binding	O
7	sites	O
8	,	O
9	the	O
10	purified	O
11	<UNK>	B
12	<UNK>	O
13	binds	O
14	only	O
15	one	O
16	Hg	O
17	(	O
18	II	O
19	)	O
20	ion	O
21	,	O
22	employing	O
23	<UNK>	O
24	from	O
25	one	O
26	<UNK>	O
27	and	O
28	<UNK>	O
29	and	O
30	<UNK>	O
31	from	O
32	the	O
33	other	O
34	.	O
1	<UNK>	B
2	,	O
3	a	O
4	<UNK>	B
5	A	O
6	inhibitor	O
7	,	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	cell	O
13	type	O
14	-	O
15	specific	O
16	manner	O
17	in	O
18	both	O
19	central	O
20	and	O
21	peripheral	O
22	nervous	O
23	systems	O
24	in	O
25	the	O
26	rat	O
27	.	O
1	<UNK>	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O
1	<UNK>	O
2	follow	O
3	-	O
4	up	O
5	at	O
6	age	O
7	2	O
8	years	O
9	was	O
10	performed	O
11	.	O
1	<UNK>	O
2	of	O
3	human	O
4	heat	O
5	shock	O
6	factor	O
7	<UNK>	O
8	by	O
9	the	O
10	linker	O
11	domain	O
12	.	O
1	Three	O
2	<UNK>	O
3	also	O
4	<UNK>	O
5	15	O
6	to	O
7	75	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'	O
14	part	O
15	of	O
16	the	O
17	<UNK>	B
18	gene	O
19	.	O
1	Of	O
2	those	O
3	injuries	O
4	,	O
5	<UNK>	O
6	cases	O
7	were	O
8	<UNK>	O
9	related	O
10	and	O
11	<UNK>	O
12	cases	O
13	were	O
14	<UNK>	O
15	related	O
16	.	O
1	<UNK>	O
2	fluorescent	O
3	protein	O
4	-	O
5	tagged	O
6	<UNK>	B
7	-	O
8	<UNK>	B
9	and	O
10	<UNK>	B
11	-	O
12	<UNK>	B
13	subunits	O
14	are	O
15	<UNK>	O
16	in	O
17	muscle	O
18	cells	O
19	and	O
20	are	O
21	<UNK>	O
22	to	O
23	<UNK>	O
24	regions	O
25	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	<UNK>	O
31	(	O
32	<UNK>	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	<UNK>	O
40	<UNK>	O
41	to	O
42	31	O
43	<UNK>	O
44	<UNK>	O
45	.	O
1	Identification	O
2	and	O
3	structure	O
4	of	O
5	the	O
6	<UNK>	O
7	'	O
8	s	O
9	disease	O
10	virus	O
11	<UNK>	O
12	2	O
13	glycoprotein	O
14	M	O
15	gene	O
16	:	O
17	comparison	O
18	with	O
19	glycoprotein	O
20	M	O
21	genes	O
22	of	O
23	<UNK>	O
24	family	O
25	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	<UNK>	O
5	a	O
6	cost	O
7	-	O
8	effectiveness	O
9	analysis	O
10	(	O
11	<UNK>	B
12	)	O
13	between	O
14	a	O
15	standard	O
16	<UNK>	O
17	regimen	O
18	-	O
19	<UNK>	O
20	+	O
21	<UNK>	O
22	(	O
23	<UNK>	O
24	-	O
25	<UNK>	O
26	)-	O
27	and	O
28	a	O
29	5	O
30	-	O
31	<UNK>	B
32	receptor	O
33	antagonist	O
34	-	O
35	<UNK>	O
36	(	O
37	<UNK>	O
38	<UNK>	O
39	in	O
40	the	O
41	control	O
42	of	O
43	acute	O
44	<UNK>	O
45	induced	O
46	by	O
47	highly	O
48	<UNK>	O
49	chemotherapy	O
50	in	O
51	children	O
52	,	O
53	<UNK>	O
54	two	O
55	<UNK>	O
56	<UNK>	O
57	:	O
58	hospital	O
59	and	O
60	patients	O
61	.	O
1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	and	O
7	deduced	O
8	amino	O
9	acid	O
10	sequences	O
11	of	O
12	the	O
13	core	O
14	regions	O
15	of	O
16	the	O
17	RNA	O
18	-	O
19	dependent	O
20	RNA	O
21	polymerase	O
22	domains	O
23	found	O
24	in	O
25	these	O
26	three	O
27	<UNK>	O
28	suggested	O
29	that	O
30	these	O
31	<UNK>	O
32	probably	O
33	evolved	O
34	independently	O
35	within	O
36	each	O
37	host	O
38	plant	O
39	from	O
40	a	O
41	common	O
42	<UNK>	O
43	.	O
1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	<UNK>	B
7	1	O
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	<UNK>	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	<UNK>	O
26	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	rat	O
5	SH2	B
6	-	O
7	containing	O
8	<UNK>	O
9	phosphatase	B
10	2	O
11	(	O
12	<UNK>	B
13	)	O
14	and	O
15	its	O
16	role	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	insulin	B
22	signaling	O
23	.	O
1	<UNK>	B
2	represses	O
3	transcription	O
4	via	O
5	this	O
6	binding	O
7	site	O
8	in	O
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	O
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	<UNK>	B
22	<UNK>	O
23	in	O
24	<UNK>	O
25	regions	O
26	during	O
27	late	O
28	stages	O
29	of	O
30	<UNK>	O
31	.	O
1	<UNK>	B
2	is	O
3	physically	O
4	located	O
5	at	O
6	or	O
7	near	O
8	the	O
9	<UNK>	B
10	locus	O
11	,	O
12	while	O
13	<UNK>	B
14	and	O
15	<UNK>	B
16	are	O
17	flanking	O
18	the	O
19	locus	O
20	at	O
21	about	O
22	17	O
23	.	O
24	5	O
25	<UNK>	O
26	genetic	O
27	distance	O
28	each	O
29	side	O
30	.	O
1	This	O
2	<UNK>	O
3	was	O
4	therefore	O
5	used	O
6	as	O
7	control	O
8	in	O
9	experiments	O
10	where	O
11	another	O
12	anti	O
13	-	O
14	Ras	B
15	<UNK>	O
16	(	O
17	<UNK>	B
18	<UNK>	O
19	,	O
20	derived	O
21	from	O
22	the	O
23	<UNK>	O
24	anti	O
25	-	O
26	Ras	B
27	<UNK>	O
28	<UNK>	B
29	-	O
30	<UNK>	O
31	)	O
32	blocked	O
33	the	O
34	Ras	B
35	pathway	O
36	in	O
37	vitro	O
38	and	O
39	led	O
40	to	O
41	tumor	O
42	regression	O
43	in	O
44	a	O
45	<UNK>	O
46	mouse	O
47	model	O
48	[	O
49	<UNK>	O
50	,	O
51	O	O
52	.,	O
53	<UNK>	O
54	,	O
55	M	O
56	.,	O
57	<UNK>	O
58	,	O
59	I	O
60	.,	O
61	<UNK>	O
62	-	O
63	<UNK>	O
64	,	O
65	A	O
66	.,	O
67	<UNK>	O
68	,	O
69	M	O
70	.	O
71	C	O
72	.,	O
73	<UNK>	O
74	,	O
75	W	O
76	.	O
77	H	O
78	.,	O
79	<UNK>	O
80	,	O
81	F	O
82	.,	O
83	<UNK>	O
84	,	O
85	J	O
86	.	O
87	L	O
88	.,	O
89	<UNK>	O
90	,	O
91	B	O
92	.,	O
93	1998	O
94	.	O
1	Moreover	O
2	,	O
3	a	O
4	high	O
5	proportion	O
6	of	O
7	blood	O
8	samples	O
9	from	O
10	a	O
11	random	O
12	sample	O
13	of	O
14	the	O
15	rest	O
16	of	O
17	the	O
18	<UNK>	O
19	tested	O
20	positive	O
21	for	O
22	<UNK>	O
23	-	O
24	specific	O
25	DNA	O
26	by	O
27	PCR	O
28	(	O
29	79	O
30	.	O
31	9	O
32	%	O
33	for	O
34	T	O
35	.	O
36	b	O
37	.	O
38	<UNK>	O
39	and	O
40	13	O
41	.	O
42	9	O
43	%	O
44	for	O
45	T	O
46	.	O
47	b	O
48	.	O
49	<UNK>	O
50	).	O
1	<UNK>	O
2	<UNK>	O
3	virus	O
4	5	O
5	(	O
6	<UNK>	O
7	)	O
8	is	O
9	a	O
10	<UNK>	O
11	of	O
12	the	O
13	<UNK>	O
14	family	O
15	of	O
16	<UNK>	O
17	negative	O
18	-	O
19	sense	O
20	RNA	O
21	viruses	O
22	.	O
1	The	O
2	results	O
3	of	O
4	these	O
5	analyses	O
6	indicate	O
7	that	O
8	the	O
9	proteinase	O
10	<UNK>	O
11	at	O
12	amino	O
13	acid	O
14	residues	O
15	<UNK>	O
16	-	O
17	<UNK>	O
18	,	O
19	<UNK>	O
20	-	O
21	<UNK>	O
22	,	O
23	<UNK>	O
24	-	O
25	<UNK>	O
26	,	O
27	and	O
28	<UNK>	O
29	-	O
30	<UNK>	O
31	;	O
32	however	O
33	,	O
34	the	O
35	cleavage	O
36	efficiency	O
37	is	O
38	varied	O
39	.	O
1	In	O
2	a	O
3	prospective	O
4	randomized	O
5	study	O
6	,	O
7	<UNK>	O
8	patients	O
9	with	O
10	advanced	O
11	non	O
12	-	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	(	O
18	<UNK>	O
19	)	O
20	stage	O
21	<UNK>	O
22	or	O
23	IV	O
24	with	O
25	<UNK>	O
26	performance	O
27	status	O
28	(	O
29	<UNK>	O
30	)	O
31	0	O
32	-	O
33	1	O
34	or	O
35	2	O
36	were	O
37	randomly	O
38	assigned	O
39	to	O
40	receive	O
41	either	O
42	best	O
43	<UNK>	O
44	care	O
45	(	O
46	<UNK>	O
47	)	O
48	or	O
49	<UNK>	O
50	care	O
51	plus	O
52	combination	O
53	chemotherapy	O
54	(	O
55	<UNK>	O
56	regimen	O
57	:	O
58	<UNK>	O
59	3	O
60	<UNK>	O
61	/	O
62	m2	O
63	IV	O
64	with	O
65	<UNK>	O
66	<UNK>	O
67	,	O
68	<UNK>	O
69	60	O
70	mg	O
71	/	O
72	m2	O
73	IV	O
74	on	O
75	day	O
76	1	O
77	and	O
78	cisplatin	O
79	60	O
80	mg	O
81	/	O
82	m2	O
83	IV	O
84	on	O
85	day	O
86	2	O
87	;	O
88	or	O
89	<UNK>	O
90	regimen	O
91	:	O
92	<UNK>	O
93	-	O
94	C	O
95	8	O
96	mg	O
97	/	O
98	m2	O
99	,	O
100	cisplatin	O
101	100	O
102	mg	O
103	/	O
104	m2	O
105	IV	O
106	on	O
107	day	O
108	1	O
109	,	O
110	<UNK>	O
111	4	O
112	mg	O
113	/	O
114	m2	O
115	IV	O
116	on	O
117	days	O
118	1	O
119	and	O
120	15	O
121	).	O
1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	<UNK>	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	<UNK>	O
23	,	O
24	-	O
25	<UNK>	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O
1	<UNK>	O
2	stability	O
3	tests	O
4	and	O
5	site	O
6	-	O
7	specific	O
8	mutagenesis	O
9	identified	O
10	amino	O
11	acids	O
12	<UNK>	O
13	and	O
14	<UNK>	O
15	of	O
16	<UNK>	B
17	and	O
18	<UNK>	B
19	,	O
20	respectively	O
21	,	O
22	as	O
23	the	O
24	phosphorylated	O
25	residues	O
26	.	O
1	An	O
2	overexpression	O
3	of	O
4	the	O
5	<UNK>	B
6	gene	O
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	<UNK>	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	<UNK>	O
25	of	O
26	<UNK>	O
27	.	O
1	Role	O
2	of	O
3	secondary	O
4	structure	O
5	in	O
6	discrimination	O
7	between	O
8	constitutive	O
9	and	O
10	inducible	O
11	activators	O
12	.	O
1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	<UNK>	O
10	via	O
11	RNase	B
12	E	O
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	<UNK>	O
26	.	O
1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	O
6	-	O
7	dependent	O
8	kinases	O
9	(	O
10	<UNK>	B
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	<UNK>	O
23	the	O
24	<UNK>	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O
1	Fifty	O
2	six	O
3	young	O
4	patients	O
5	(	O
6	age	O
7	<	O
8	45	O
9	<UNK>	O
10	)	O
11	with	O
12	<UNK>	O
13	-	O
14	proven	O
15	<UNK>	O
16	were	O
17	investigated	O
18	for	O
19	the	O
20	presence	O
21	of	O
22	resistance	O
23	to	O
24	activated	O
25	protein	O
26	C	O
27	(	O
28	<UNK>	O
29	-	O
30	R	O
31	),	O
32	<UNK>	O
33	<UNK>	O
34	(	O
35	<UNK>	O
36	),	O
37	<UNK>	B
38	antibodies	O
39	and	O
40	<UNK>	O
41	of	O
42	protein	O
43	C	O
44	,	O
45	protein	O
46	S	O
47	,	O
48	<UNK>	B
49	activities	O
50	.	O
1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	<UNK>	O
13	(	O
14	<UNK>	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	<UNK>	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O
1	<UNK>	O
2	recovery	O
3	of	O
4	<UNK>	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	<UNK>	O
13	<UNK>	O
14	in	O
15	contact	O
16	<UNK>	O
17	and	O
18	<UNK>	O
19	from	O
20	contact	O
21	<UNK>	O
22	treated	O
23	with	O
24	<UNK>	B
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	<UNK>	O
36	and	O
37	<UNK>	O
38	.	O
1	<UNK>	O
2	of	O
3	double	O
4	-	O
5	strand	O
6	<UNK>	O
7	(	O
8	<UNK>	O
9	)	O
10	in	O
11	chromosomal	O
12	DNA	O
13	by	O
14	<UNK>	O
15	end	O
16	-	O
17	joining	O
18	(	O
19	<UNK>	O
20	)	O
21	is	O
22	not	O
23	well	O
24	characterized	O
25	in	O
26	the	O
27	yeast	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O
1	A	O
2	new	O
3	DNA	O
4	repair	O
5	gene	O
6	from	O
7	Schizosaccharomyces	O
8	pombe	O
9	with	O
10	homology	O
11	to	O
12	<UNK>	B
13	was	O
14	identified	O
15	and	O
16	characterized	O
17	.	O
1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	<UNK>	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	<UNK>	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O
1	There	O
2	were	O
3	27	O
4	men	O
5	and	O
6	<UNK>	O
7	women	O
8	.	O
1	A	O
2	.,	O
3	<UNK>	O
4	,	O
5	K	O
6	.	O
7	E	O
8	,	O
9	and	O
10	<UNK>	O
11	,	O
12	C	O
13	.	O
1	METHODS	O
2	:	O
3	<UNK>	O
4	suspected	O
5	cases	O
6	with	O
7	<UNK>	O
8	underwent	O
9	the	O
10	<UNK>	O
11	.	O
1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	<UNK>	O
27	.	O
1	<UNK>	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	<UNK>	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	<UNK>	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O
1	<UNK>	O
2	differentiation	O
3	of	O
4	<UNK>	O
5	cells	O
6	also	O
7	markedly	O
8	represses	O
9	the	O
10	ability	O
11	of	O
12	SRF	B
13	to	O
14	bind	O
15	to	O
16	the	O
17	<UNK>	B
18	SRE	O
19	,	O
20	the	O
21	c	B
22	-	O
23	fos	B
24	SRE	O
25	,	O
26	and	O
27	other	O
28	<UNK>	O
29	,	O
30	as	O
31	determined	O
32	by	O
33	mobility	O
34	shift	O
35	and	O
36	gel	O
37	<UNK>	O
38	assays	O
39	,	O
40	without	O
41	affecting	O
42	the	O
43	DNA	O
44	binding	O
45	characteristics	O
46	of	O
47	the	O
48	nuclear	O
49	protein	O
50	SP	O
51	-	O
52	1	O
53	.	O
1	The	O
2	STAT	B
3	protein	O
4	accumulation	O
5	resulting	O
6	from	O
7	C	O
8	/	O
9	EBP	B
10	expression	O
11	was	O
12	<UNK>	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O
1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	<UNK>	O
33	<UNK>	O
34	,	O
35	<UNK>	O
36	into	O
37	account	O
38	possible	O
39	<UNK>	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	<UNK>	O
46	,	O
47	oral	O
48	<UNK>	O
49	and	O
50	<UNK>	O
51	<UNK>	O
52	.	O
1	Patients	O
2	were	O
3	assessed	O
4	for	O
5	cardiac	O
6	<UNK>	O
7	uptake	O
8	,	O
9	circulating	O
10	norepinephrine	O
11	concentration	O
12	,	O
13	<UNK>	O
14	,	O
15	peak	O
16	<UNK>	O
17	,	O
18	x	O
19	-	O
20	ray	O
21	<UNK>	O
22	ratio	O
23	,	O
24	M	O
25	-	O
26	mode	O
27	<UNK>	O
28	end	O
29	-	O
30	diastolic	O
31	diameter	O
32	and	O
33	right	O
34	-	O
35	<UNK>	O
36	heart	O
37	<UNK>	O
38	parameters	O
39	.	O
1	Nuclear	O
2	hormone	O
3	receptors	O
4	(	O
5	<UNK>	O
6	)	O
7	are	O
8	ligand	O
9	-	O
10	inducible	O
11	transcription	O
12	factors	O
13	that	O
14	mediate	O
15	critical	O
16	functions	O
17	in	O
18	many	O
19	species	O
20	.	O
1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	O
13	<UNK>	B
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O
1	It	O
2	<UNK>	O
3	<UNK>	O
4	'	O
5	s	O
6	<UNK>	O
7	<UNK>	O
8	,	O
9	which	O
10	<UNK>	O
11	to	O
12	<UNK>	O
13	the	O
14	biological	O
15	and	O
16	<UNK>	O
17	models	O
18	of	O
19	<UNK>	O
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O
1	<UNK>	O
2	of	O
3	<UNK>	B
4	with	O
5	<UNK>	B
6	was	O
7	required	O
8	for	O
9	the	O
10	transformation	O
11	of	O
12	<UNK>	B
13	,	O
14	as	O
15	the	O
16	<UNK>	B
17	antagonist	O
18	<UNK>	O
19	acid	O
20	inhibited	O
21	the	O
22	<UNK>	O
23	of	O
24	<UNK>	B
25	into	O
26	a	O
27	mature	O
28	-	O
29	competent	O
30	conformation	O
31	.	O
1	In	O
2	the	O
3	budding	O
4	yeast	O
5	,	O
6	Saccharomyces	O
7	cerevisiae	O
8	,	O
9	<UNK>	O
10	can	O
11	function	O
12	outside	O
13	the	O
14	chromosome	O
15	as	O
16	<UNK>	O
17	<UNK>	O
18	sequence	O
19	(	O
20	<UNK>	O
21	)	O
22	elements	O
23	;	O
24	however	O
25	,	O
26	within	O
27	chromosome	O
28	III	O
29	,	O
30	certain	O
31	<UNK>	O
32	near	O
33	the	O
34	transcriptionally	O
35	<UNK>	O
36	<UNK>	B
37	locus	O
38	show	O
39	no	O
40	replication	O
41	origin	O
42	activity	O
43	.	O
1	<UNK>	O
2	experiments	O
3	on	O
4	the	O
5	catalytic	O
6	fragment	O
7	kinase	B
8	reaction	O
9	demonstrated	O
10	that	O
11	the	O
12	chemical	O
13	(	O
14	<UNK>	O
15	transfer	O
16	)	O
17	step	O
18	had	O
19	a	O
20	reduced	O
21	rate	O
22	.	O
1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	<UNK>	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	<UNK>	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	<UNK>	O
26	introns	O
27	(	O
28	<UNK>	O
29	et	O
30	al	O
31	.	O
1	Like	O
2	DNA	O
3	binding	O
4	,	O
5	transcriptional	O
6	enhancement	O
7	required	O
8	amino	O
9	-	O
10	terminally	O
11	located	O
12	basic	O
13	amino	O
14	acid	O
15	residues	O
16	but	O
17	not	O
18	the	O
19	carboxyl	O
20	-	O
21	terminal	O
22	portion	O
23	of	O
24	<UNK>	B
25	known	O
26	to	O
27	participate	O
28	in	O
29	hsp70	B
30	interaction	O
31	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	a	O
6	novel	O
7	isoform	O
8	of	O
9	<UNK>	B
10	GTPase	I
11	-	O
12	activating	O
13	protein	O
14	,	O
15	called	O
16	<UNK>	B
17	,	O
18	binds	O
19	specifically	O
20	to	O
21	the	O
22	alpha	O
23	-	O
24	subunits	O
25	of	O
26	the	O
27	G	O
28	(	O
29	i	O
30	)	O
31	family	O
32	of	O
33	<UNK>	B
34	G	O
35	-	O
36	proteins	O
37	.	O
1	The	O
2	B	O
3	-	O
4	<UNK>	O
5	of	O
6	<UNK>	O
7	toxin	B
8	<UNK>	O
9	CC	O
10	<UNK>	O
11	receptor	O
12	5	O
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	O
18	-	O
19	<UNK>	O
20	HIV	O
21	-	O
22	1	O
23	strains	O
24	.	O
1	<UNK>	O
2	-	O
3	linking	O
4	the	O
5	B	O
6	cell	O
7	Ag	O
8	receptor	O
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	O
14	Fc	B
15	receptors	O
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	O
21	R	O
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O
1	<UNK>	O
2	-	O
3	linking	O
4	the	O
5	B	O
6	cell	O
7	Ag	O
8	receptor	O
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	O
14	Fc	B
15	receptors	O
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	O
21	R	O
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O
1	<UNK>	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	O
9	-	O
10	kDa	O
11	serine	O
12	/	O
13	threonine	O
14	kinase	B
15	termed	O
16	<UNK>	O
17	<UNK>	O
18	kinase	B
19	related	O
20	(	O
21	<UNK>	B
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	<UNK>	B
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O
1	Furthermore	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	transcription	O
7	from	O
8	the	O
9	<UNK>	O
10	5	O
11	'	O
12	LTR	O
13	is	O
14	highly	O
15	active	O
16	in	O
17	the	O
18	absence	O
19	of	O
20	<UNK>	B
21	,	O
22	a	O
23	transcription	O
24	factor	O
25	that	O
26	had	O
27	been	O
28	shown	O
29	previously	O
30	to	O
31	be	O
32	required	O
33	for	O
34	transcription	O
35	from	O
36	the	O
37	<UNK>	O
38	LTR	O
39	.	O
1	<UNK>	O
2	staining	O
3	with	O
4	<UNK>	O
5	-	O
6	1	O
7	and	O
8	p53	B
9	antibodies	O
10	showed	O
11	low	O
12	(<	O
13	1	O
14	%)	O
15	and	O
16	negative	O
17	reaction	O
18	.	O
1	<UNK>	O
2	before	O
3	surgery	O
4	patients	O
5	received	O
6	either	O
7	intravenous	O
8	<UNK>	O
9	100	O
10	mg	O
11	or	O
12	placebo	O
13	in	O
14	random	O
15	,	O
16	double	O
17	-	O
18	blind	O
19	order	O
20	.	O
1	A	O
2	tyrosine	O
3	-	O
4	based	O
5	sorting	O
6	signal	O
7	in	O
8	the	O
9	<UNK>	B
10	integrin	I
11	cytoplasmic	O
12	domain	O
13	mediates	O
14	its	O
15	<UNK>	O
16	to	O
17	the	O
18	plasma	O
19	membrane	O
20	and	O
21	is	O
22	required	O
23	for	O
24	ligand	O
25	-	O
26	supported	O
27	migration	O
28	.	O
1	The	O
2	injection	O
3	of	O
4	<UNK>	B
5	protein	O
6	into	O
7	<UNK>	O
8	Xenopus	O
9	<UNK>	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O
1	NF	B
2	-	O
3	kappaB	B
4	plays	O
5	a	O
6	critical	O
7	role	O
8	in	O
9	activation	O
10	of	O
11	HIV	O
12	-	O
13	1	O
14	gene	O
15	expression	O
16	by	O
17	cytokines	O
18	and	O
19	other	O
20	stimuli	O
21	,	O
22	but	O
23	the	O
24	signal	O
25	transduction	O
26	pathways	O
27	that	O
28	regulate	O
29	the	O
30	<UNK>	O
31	from	O
32	latent	O
33	to	O
34	<UNK>	O
35	infection	O
36	have	O
37	not	O
38	been	O
39	defined	O
40	.	O
1	These	O
2	studies	O
3	suggest	O
4	that	O
5	MAPK	B
6	acts	O
7	by	O
8	stimulating	O
9	AP	B
10	-	O
11	1	O
12	and	O
13	a	O
14	subsequent	O
15	physical	O
16	and	O
17	functional	O
18	interaction	O
19	of	O
20	AP	B
21	-	O
22	1	O
23	with	O
24	NF	B
25	-	O
26	kappaB	B
27	,	O
28	resulting	O
29	in	O
30	a	O
31	complex	O
32	that	O
33	synergistically	O
34	<UNK>	O
35	the	O
36	HIV	O
37	-	O
38	1	O
39	LTR	O
40	.	O
1	A	O
2	human	O
3	nuclear	O
4	-	O
5	localized	O
6	<UNK>	O
7	that	O
8	regulates	O
9	dimerization	O
10	,	O
11	DNA	O
12	binding	O
13	,	O
14	and	O
15	transcriptional	O
16	activity	O
17	of	O
18	<UNK>	O
19	proteins	O
20	.	O
1	<UNK>	O
2	reduces	O
3	airway	O
4	<UNK>	O
5	<UNK>	O
6	in	O
7	asthma	O
8	:	O
9	a	O
10	randomized	O
11	,	O
12	controlled	O
13	trial	O
14	.	O
1	Treatment	O
2	of	O
3	<UNK>	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	<UNK>	O
9	therapy	O
10	.	O
1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	,	O
5	<UNK>	B
6	encodes	O
7	a	O
8	cyclin	B
9	-	O
10	dependent	O
11	protein	O
12	kinase	B
13	(	O
14	<UNK>	B
15	)	O
16	catalytic	O
17	subunit	O
18	with	O
19	multiple	O
20	regulatory	O
21	roles	O
22	thought	O
23	to	O
24	be	O
25	<UNK>	O
26	by	O
27	association	O
28	with	O
29	different	O
30	cyclin	B
31	<UNK>	O
32	(	O
33	<UNK>	B
34	).	O
1	<UNK>	B
2	encodes	O
3	a	O
4	<UNK>	O
5	/	O
6	Zn	O
7	finger	O
8	protein	O
9	,	O
10	a	O
11	structure	O
12	similar	O
13	to	O
14	that	O
15	of	O
16	many	O
17	Drosophila	O
18	developmental	O
19	regulators	O
20	and	O
21	to	O
22	another	O
23	protein	O
24	involved	O
25	in	O
26	a	O
27	human	O
28	hematopoietic	O
29	malignancy	O
30	,	O
31	<UNK>	B
32	.	O
1	<UNK>	O
2	CD	O
3	,	O
4	and	O
5	<UNK>	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	<UNK>	B
16	<UNK>	O
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O
1	Serum	O
2	antibodies	O
3	were	O
4	detected	O
5	in	O
6	at	O
7	least	O
8	95	O
9	%	O
10	of	O
11	the	O
12	infected	O
13	guinea	O
14	pigs	O
15	between	O
16	4	O
17	-	O
18	30	O
19	<UNK>	O
20	and	O
21	rats	O
22	between	O
23	3	O
24	-	O
25	16	O
26	<UNK>	O
27	.	O
1	A	O
2	genetic	O
3	screen	O
4	in	O
5	yeast	O
6	has	O
7	allowed	O
8	us	O
9	to	O
10	identify	O
11	a	O
12	novel	O
13	transcriptional	O
14	factor	O
15	binding	O
16	to	O
17	the	O
18	<UNK>	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	chicken	O
26	<UNK>	B
27	upstream	O
28	promoter	O
29	-	O
30	transcription	O
31	factor	O
32	II	O
33	(	O
34	COUP	B
35	-	O
36	<UNK>	B
37	).	O
1	We	O
2	have	O
3	cloned	O
4	the	O
5	single	O
6	-	O
7	copy	O
8	gene	O
9	for	O
10	the	O
11	trans	O
12	-	O
13	<UNK>	B
14	U5	I
15	snRNA	I
16	from	O
17	the	O
18	<UNK>	O
19	species	O
20	<UNK>	O
21	<UNK>	O
22	,	O
23	using	O
24	U5	B
25	RNA	O
26	affinity	O
27	selection	O
28	and	O
29	cDNA	O
30	cloning	O
31	.	O
1	All	O
2	were	O
3	<UNK>	O
4	<UNK>	O
5	aid	O
6	<UNK>	O
7	who	O
8	<UNK>	O
9	linear	O
10	Class	O
11	D	O
12	<UNK>	O
13	with	O
14	input	O
15	<UNK>	O
16	limiting	O
17	at	O
18	the	O
19	time	O
20	of	O
21	their	O
22	<UNK>	O
23	in	O
24	this	O
25	study	O
26	.	O
1	<UNK>	O
2	protection	O
3	assays	O
4	revealed	O
5	that	O
6	<UNK>	B
7	and	O
8	<UNK>	B
9	are	O
10	differentially	O
11	expressed	O
12	in	O
13	a	O
14	<UNK>	O
15	-	O
16	and	O
17	<UNK>	O
18	-	O
19	modulated	O
20	manner	O
21	during	O
22	<UNK>	O
23	of	O
24	<UNK>	O
25	<UNK>	O
26	-	O
27	containing	O
28	<UNK>	O
29	<UNK>	O
30	in	O
31	embryos	O
32	.	O
1	<UNK>	O
2	of	O
3	the	O
4	Neurospora	O
5	crassa	O
6	mitochondrial	O
7	outer	O
8	membrane	O
9	protein	O
10	<UNK>	B
11	by	O
12	repeat	O
13	-	O
14	induced	O
15	point	O
16	mutation	O
17	(	O
18	<UNK>	O
19	)	O
20	causes	O
21	defects	O
22	in	O
23	mitochondrial	O
24	protein	O
25	import	O
26	and	O
27	morphology	O
28	.	O
1	A	O
2	panel	O
3	of	O
4	<UNK>	O
5	inhibitors	O
6	was	O
7	used	O
8	to	O
9	investigate	O
10	the	O
11	signal	O
12	transduction	O
13	pathways	O
14	involved	O
15	in	O
16	<UNK>	B
17	gene	O
18	induction	O
19	following	O
20	T	O
21	lymphocyte	O
22	activation	O
23	.	O
1	A	O
2	total	O
3	of	O
4	<UNK>	O
5	primer	O
6	pairs	O
7	gave	O
8	<UNK>	O
9	<UNK>	O
10	patterns	O
11	,	O
12	<UNK>	O
13	(	O
14	79	O
15	%)	O
16	of	O
17	which	O
18	revealed	O
19	at	O
20	least	O
21	two	O
22	alleles	O
23	on	O
24	native	O
25	polyacrylamide	O
26	<UNK>	O
27	.	O
1	IL	B
2	-	O
3	12	O
4	production	O
5	was	O
6	correlated	O
7	with	O
8	<UNK>	O
9	concentration	O
10	measured	O
11	at	O
12	the	O
13	<UNK>	O
14	of	O
15	<UNK>	O
16	after	O
17	15	O
18	min	O
19	of	O
20	dialysis	O
21	(	O
22	r	O
23	=	O
24	0	O
25	.	O
26	69	O
27	,	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	).	O
1	J	O
2	.	O
1	Our	O
2	results	O
3	<UNK>	O
4	TGF	B
5	-	O
6	beta	O
7	<UNK>	B
8	as	O
9	a	O
10	direct	O
11	target	O
12	of	O
13	<UNK>	B
14	-	O
15	<UNK>	B
16	.	O
1	A	O
2	local	O
3	,	O
4	high	O
5	-	O
6	density	O
7	,	O
8	single	O
9	-	O
10	nucleotide	O
11	<UNK>	O
12	map	O
13	used	O
14	to	O
15	clone	O
16	Caenorhabditis	O
17	elegans	O
18	<UNK>	B
19	-	O
20	1	O
21	.	O
1	High	O
2	-	O
3	level	O
4	expression	O
5	in	O
6	Escherichia	O
7	coli	O
8	of	O
9	<UNK>	O
10	-	O
11	containing	O
12	rat	O
13	<UNK>	B
14	reductase	I
15	<UNK>	O
16	gene	O
17	fusions	O
18	with	O
19	<UNK>	O
20	bacterial	O
21	-	O
22	type	O
23	<UNK>	O
24	elements	O
25	and	O
26	co	O
27	-	O
28	expression	O
29	with	O
30	the	O
31	<UNK>	B
32	,	O
33	<UNK>	B
34	and	O
35	<UNK>	B
36	genes	O
37	.	O
1	In	O
2	<UNK>	B
3	signaling	O
4	,	O
5	beta	O
6	-	O
7	<UNK>	B
8	and	O
9	<UNK>	B
10	<UNK>	O
11	signals	O
12	to	O
13	the	O
14	nucleus	O
15	through	O
16	interactions	O
17	with	O
18	<UNK>	B
19	-	O
20	type	O
21	transcription	O
22	factors	O
23	.	O
1	For	O
2	<UNK>	O
3	3	O
4	,	O
5	10	O
6	,	O
7	or	O
8	40	O
9	,	O
10	the	O
11	<UNK>	O
12	<UNK>	O
13	25	O
14	%	O
15	for	O
16	7	O
17	,	O
18	3	O
19	,	O
20	and	O
21	1	O
22	in	O
23	the	O
24	8	O
25	-	O
26	<UNK>	O
27	model	O
28	respectively	O
29	,	O
30	when	O
31	a	O
32	conventional	O
33	selection	O
34	<UNK>	O
35	was	O
36	used	O
37	(	O
38	alpha	O
39	=	O
40	0	O
41	.	O
42	05	O
43	).	O
1	At	O
2	all	O
3	time	O
4	-	O
5	points	O
6	,	O
7	most	O
8	patients	O
9	<UNK>	O
10	87	O
11	%)	O
12	were	O
13	receiving	O
14	<UNK>	O
15	/	O
16	<UNK>	O
17	alone	O
18	.	O
1	Although	O
2	upstream	O
3	regulators	O
4	of	O
5	<UNK>	B
6	family	O
7	kinases	O
8	are	O
9	relatively	O
10	well	O
11	characterized	O
12	,	O
13	little	O
14	is	O
15	known	O
16	of	O
17	the	O
18	downstream	O
19	<UNK>	O
20	of	O
21	these	O
22	enzymes	O
23	.	O
1	<UNK>	O
2	phosphorylation	O
3	of	O
4	<UNK>	B
5	by	O
6	<UNK>	B
7	required	O
8	the	O
9	<UNK>	B
10	and	O
11	SH2	B
12	domains	O
13	as	O
14	well	O
15	as	O
16	the	O
17	kinase	B
18	domain	O
19	of	O
20	the	O
21	latter	O
22	.	O
1	<UNK>	O
2	type	O
3	1	O
4	,	O
5	with	O
6	<UNK>	O
7	low	O
8	and	O
9	<UNK>	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O
1	The	O
2	factor	O
3	designated	O
4	B	O
5	formed	O
6	a	O
7	complex	O
8	<UNK>	O
9	on	O
10	the	O
11	sequence	O
12	<UNK>	O
13	,	O
14	a	O
15	core	O
16	motif	O
17	recognized	O
18	by	O
19	members	O
20	of	O
21	the	O
22	<UNK>	O
23	/	O
24	<UNK>	B
25	transcription	O
26	factor	O
27	family	O
28	.	O
1	RNase	B
2	<UNK>	I
3	is	O
4	a	O
5	ribonucleoprotein	O
6	<UNK>	O
7	that	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	have	O
13	roles	O
14	in	O
15	both	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	and	O
20	nuclear	O
21	5	O
22	.	O
23	<UNK>	O
24	rRNA	O
25	processing	O
26	.	O
1	<UNK>	B
2	causes	O
3	<UNK>	O
4	of	O
5	actin	B
6	<UNK>	O
7	(	O
8	F	O
9	-	O
10	actin	B
11	)	O
12	at	O
13	the	O
14	plus	O
15	-	O
16	ends	O
17	,	O
18	through	O
19	phosphatidylinositol	B
20	4	O
21	,	O
22	5	O
23	<UNK>	O
24	(	O
25	<UNK>	O
26	),	O
27	and	O
28	<UNK>	O
29	induces	O
30	membrane	O
31	<UNK>	O
32	.	O
1	RESULTS	O
2	:	O
3	Factors	O
4	associated	O
5	with	O
6	significantly	O
7	(	O
8	P	O
9	<UNK>	O
10	05	O
11	)	O
12	increased	O
13	risk	O
14	of	O
15	treatment	O
16	failure	O
17	in	O
18	a	O
19	<UNK>	O
20	<UNK>	O
21	analysis	O
22	included	O
23	age	O
24	older	O
25	than	O
26	45	O
27	years	O
28	(	O
29	relative	O
30	<UNK>	O
31	,	O
32	1	O
33	.	O
34	17	O
35	;	O
36	95	O
37	%	O
38	<UNK>	O
39	interval	O
40	[	O
41	CI	O
42	<UNK>	O
43	1	O
44	.	O
45	02	O
46	-	O
47	1	O
48	.	O
49	33	O
50	),	O
51	<UNK>	O
52	performance	O
53	score	O
54	less	O
55	than	O
56	90	O
57	%	O
58	(	O
59	1	O
60	.	O
61	27	O
62	;	O
63	95	O
64	%	O
65	CI	O
66	,	O
67	1	O
68	.	O
69	07	O
70	-	O
71	1	O
72	.	O
73	51	O
74	),	O
75	absence	O
76	of	O
77	hormone	O
78	receptors	O
79	(	O
80	1	O
81	.	O
82	31	O
83	;	O
84	95	O
85	%	O
86	CI	O
87	,	O
88	1	O
89	.	O
90	15	O
91	-	O
92	1	O
93	.	O
94	51	O
95	),	O
96	prior	O
97	use	O
98	of	O
99	<UNK>	O
100	chemotherapy	O
101	(	O
102	1	O
103	.	O
104	31	O
105	;	O
106	95	O
107	%	O
108	CI	O
109	,	O
110	1	O
111	.	O
112	10	O
113	-	O
114	1	O
115	.	O
116	56	O
117	),	O
118	initial	O
119	disease	O
120	-	O
121	free	O
122	survival	O
123	interval	O
124	after	O
125	<UNK>	O
126	treatment	O
127	of	O
128	no	O
129	more	O
130	than	O
131	18	O
132	months	O
133	(	O
134	1	O
135	.	O
136	99	O
137	;	O
138	95	O
139	%	O
140	CI	O
141	,	O
142	1	O
143	.	O
144	62	O
145	-	O
146	2	O
147	.	O
148	43	O
149	),	O
150	<UNK>	O
151	in	O
152	the	O
153	liver	O
154	(	O
155	1	O
156	.	O
157	47	O
158	;	O
159	95	O
160	%	O
161	CI	O
162	,	O
163	1	O
164	.	O
165	20	O
166	-	O
167	1	O
168	.	O
169	80	O
170	)	O
171	or	O
172	central	O
173	nervous	O
174	system	O
175	(	O
176	1	O
177	.	O
178	56	O
179	;	O
180	95	O
181	%	O
182	CI	O
183	,	O
184	0	O
185	.	O
186	99	O
187	-	O
188	2	O
189	.	O
190	46	O
191	[	O
192	<UNK>	O
193	significance	O
194	<UNK>	O
195	vs	O
196	<UNK>	O
197	tissue	O
198	,	O
199	bone	O
200	,	O
201	or	O
202	lung	O
203	,	O
204	3	O
205	or	O
206	more	O
207	sites	O
208	of	O
209	metastatic	O
210	disease	O
211	(	O
212	1	O
213	.	O
214	32	O
215	;	O
216	95	O
217	%	O
218	CI	O
219	,	O
220	1	O
221	.	O
222	13	O
223	-	O
224	1	O
225	.	O
226	54	O
227	),	O
228	and	O
229	<UNK>	O
230	response	O
231	vs	O
232	complete	O
233	response	O
234	to	O
235	standard	O
236	-	O
237	dose	O
238	chemotherapy	O
239	(	O
240	1	O
241	.	O
242	65	O
243	;	O
244	95	O
245	%	O
246	CI	O
247	,	O
248	1	O
249	.	O
250	36	O
251	-	O
252	1	O
253	.	O
254	99	O
255	).	O
1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	<UNK>	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	<UNK>	O
22	surface	O
23	<UNK>	O
24	of	O
25	the	O
26	<UNK>	B
27	/	O
28	<UNK>	B
29	complex	O
30	.	O
1	<UNK>	O
2	were	O
3	<UNK>	O
4	to	O
5	death	O
6	8	O
7	weeks	O
8	later	O
9	and	O
10	the	O
11	grafts	O
12	were	O
13	<UNK>	O
14	<UNK>	O
15	and	O
16	analyzed	O
17	via	O
18	<UNK>	O
19	culture	O
20	and	O
21	standard	O
22	<UNK>	O
23	procedures	O
24	for	O
25	evidence	O
26	of	O
27	infection	O
28	.	O
1	C	O
2	-	O
3	SP	O
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	<UNK>	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	<UNK>	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	<UNK>	B
7	virulence	O
8	genes	O
9	<UNK>	O
10	simultaneously	O
11	to	O
12	several	O
13	<UNK>	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	<UNK>	O
19	the	O
20	possibility	O
21	that	O
22	<UNK>	B
23	expression	O
24	can	O
25	be	O
26	<UNK>	O
27	-	O
28	<UNK>	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	<UNK>	O
35	.	O
1	<UNK>	O
2	synthesis	O
3	of	O
4	<UNK>	B
5	in	O
6	the	O
7	cells	O
8	of	O
9	<UNK>	O
10	wall	O
11	<UNK>	O
12	of	O
13	their	O
14	high	O
15	functional	O
16	activity	O
17	,	O
18	and	O
19	the	O
20	synthesis	O
21	of	O
22	DNA	O
23	in	O
24	them	O
25	showed	O
26	their	O
27	ability	O
28	for	O
29	proliferation	O
30	,	O
31	i	O
32	.	O
33	g	O
34	<UNK>	O
35	for	O
36	growth	O
37	.	O
1	<UNK>	O
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	O
19	CAAT	O
20	enhancer	O
21	-	O
22	binding	O
23	protein	O
24	(	O
25	C	O
26	/	O
27	EBP	B
28	)	O
29	alpha	O
30	and	O
31	C	O
32	/	O
33	<UNK>	B
34	.	O
1	We	O
2	also	O
3	show	O
4	that	O
5	activation	O
6	of	O
7	protein	O
8	kinase	B
9	A	O
10	(	O
11	PKA	B
12	)	O
13	signaling	O
14	is	O
15	sufficient	O
16	to	O
17	down	O
18	-	O
19	regulate	O
20	<UNK>	B
21	-	O
22	1	O
23	protein	O
24	expression	O
25	and	O
26	promoter	O
27	activity	O
28	.	O
1	Despite	O
2	i	O
3	.	O
4	v	O
5	.	O
6	steroid	O
7	therapy	O
8	,	O
9	[	O
10	<UNK>	O
11	]	O
12	remained	O
13	elevated	O
14	throughout	O
15	recovery	O
16	(	O
17	37	O
18	.	O
19	9	O
20	+/-	O
21	4	O
22	.	O
23	8	O
24	<UNK>	O
25	,	O
26	p	O
27	<	O
28	0	O
29	.	O
30	001	O
31	)	O
32	until	O
33	<UNK>	O
34	(	O
35	40	O
36	.	O
37	9	O
38	+/-	O
39	4	O
40	.	O
41	3	O
42	<UNK>	O
43	,	O
44	p	O
45	<	O
46	0	O
47	.	O
48	001	O
49	).	O
1	It	O
2	contains	O
3	binding	O
4	sites	O
5	for	O
6	several	O
7	transcription	O
8	factors	O
9	,	O
10	for	O
11	example	O
12	:	O
13	(	O
14	i	O
15	)	O
16	a	O
17	well	O
18	-	O
19	characterized	O
20	binding	O
21	site	O
22	for	O
23	<UNK>	B
24	/	O
25	NF	B
26	-	O
27	kappaB	B
28	transcription	O
29	factors	O
30	in	O
31	its	O
32	3	O
33	'-	O
34	end	O
35	(	O
36	the	O
37	<UNK>	B
38	or	O
39	<UNK>	B
40	element	O
41	),	O
42	(	O
43	ii	O
44	)	O
45	a	O
46	second	O
47	kappaB	B
48	site	O
49	(	O
50	the	O
51	<UNK>	B
52	element	O
53	),	O
54	which	O
55	is	O
56	located	O
57	immediately	O
58	adjacent	O
59	5	O
60	'	O
61	to	O
62	the	O
63	<UNK>	B
64	element	O
65	and	O
66	which	O
67	is	O
68	recognized	O
69	by	O
70	p65	B
71	/	O
72	<UNK>	B
73	in	O
74	the	O
75	human	O
76	HLA	B
77	system	O
78	,	O
79	and	O
80	(	O
81	iii	O
82	)	O
83	an	O
84	AP	B
85	-	O
86	1	O
87	/	O
88	ATF	B
89	recognition	O
90	sequence	O
91	in	O
92	the	O
93	5	O
94	'	O
95	end	O
96	(	O
97	<UNK>	B
98	-	O
99	TRE	O
100	).	O
1	<UNK>	B
2	is	O
3	homologous	O
4	to	O
5	<UNK>	B
6	and	O
7	<UNK>	B
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	<UNK>	B
19	vs	O
20	<UNK>	B
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	<UNK>	B
27	vs	O
28	<UNK>	B
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	<UNK>	B
35	vs	O
36	<UNK>	B
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O
1	<UNK>	O
2	LTR	O
3	sequence	O
4	variability	O
5	is	O
6	<UNK>	O
7	<UNK>	O
8	to	O
9	a	O
10	small	O
11	portion	O
12	of	O
13	the	O
14	enhancer	O
15	within	O
16	the	O
17	<UNK>	O
18	segment	O
19	of	O
20	the	O
21	LTR	O
22	.	O
1	A	O
2	proportion	O
3	of	O
4	<UNK>	O
5	wild	O
6	-	O
7	type	O
8	colon	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	<UNK>	B
17	-	O
18	4	O
19	/	O
20	beta	O
21	-	O
22	<UNK>	B
23	complexes	O
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	O
29	mutations	O
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	O
36	-	O
37	<UNK>	B
38	that	O
39	<UNK>	O
40	it	O
41	<UNK>	O
42	to	O
43	<UNK>	O
44	by	O
45	<UNK>	O
46	,	O
47	<UNK>	B
48	beta	O
49	,	O
50	and	O
51	<UNK>	B
52	/	O
53	<UNK>	B
54	.	O
1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	<UNK>	O
7	,	O
8	Y	O
9	.,	O
10	<UNK>	O
11	,	O
12	K	O
13	.,	O
14	<UNK>	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	<UNK>	O
20	,	O
21	D	O
22	.	O
1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	O
8	is	O
9	a	O
10	<UNK>	O
11	homolog	O
12	of	O
13	<UNK>	O
14	<UNK>	O
15	protein	O
16	<UNK>	B
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	<UNK>	O
24	viral	O
25	RNAs	O
26	.	O
1	CONCLUSION	O
2	(	O
3	S	O
4	):	O
5	<UNK>	O
6	urinary	O
7	LH	B
8	levels	O
9	is	O
10	an	O
11	excellent	O
12	method	O
13	for	O
14	determining	O
15	<UNK>	O
16	.	O
1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	carcinoma	O
7	of	O
8	the	O
9	breast	O
10	presenting	O
11	<UNK>	O
12	with	O
13	<UNK>	O
14	that	O
15	subsequently	O
16	<UNK>	O
17	to	O
18	dialysis	O
19	-	O
20	dependent	O
21	renal	O
22	failure	O
23	in	O
24	<UNK>	O
25	1	O
26	month	O
27	.	O
1	In	O
2	contrast	O
3	,	O
4	AP	B
5	-	O
6	2	O
7	binding	O
8	activity	O
9	was	O
10	significantly	O
11	greater	O
12	in	O
13	<UNK>	O
14	cells	O
15	,	O
16	and	O
17	Western	O
18	<UNK>	O
19	confirmed	O
20	increased	O
21	AP	B
22	-	O
23	2	O
24	protein	O
25	levels	O
26	in	O
27	these	O
28	cells	O
29	.	O
1	In	O
2	addition	O
3	,	O
4	all	O
5	three	O
6	<UNK>	B
7	proteins	O
8	of	O
9	<UNK>	O
10	bind	O
11	<UNK>	O
12	well	O
13	to	O
14	HeLa	O
15	cells	O
16	transfected	O
17	with	O
18	cDNA	O
19	encoding	O
20	the	O
21	<UNK>	B
22	antigen	O
23	[	O
24	<UNK>	B
25	(	O
26	<UNK>	B
27	<UNK>	O
28	subgroup	O
29	of	O
30	the	O
31	<UNK>	B
32	family	O
33	,	O
34	but	O
35	show	O
36	distinct	O
37	<UNK>	O
38	for	O
39	<UNK>	B
40	-	O
41	(	O
42	<UNK>	B
43	)	O
44	and	O
45	<UNK>	O
46	(	O
47	<UNK>	B
48	)-	O
49	expressing	O
50	cells	O
51	.	O
1	<UNK>	O
2	studies	O
3	revealed	O
4	that	O
5	bovine	O
6	brain	O
7	<UNK>	O
8	(	O
9	q	O
10	/	O
11	11	O
12	)	O
13	could	O
14	also	O
15	bind	O
16	to	O
17	an	O
18	N	O
19	-	O
20	terminal	O
21	construct	O
22	of	O
23	<UNK>	B
24	,	O
25	while	O
26	no	O
27	binding	O
28	of	O
29	<UNK>	O
30	(	O
31	q	O
32	/	O
33	11	O
34	),	O
35	<UNK>	O
36	(	O
37	s	O
38	),	O
39	<UNK>	O
40	(	O
41	i	O
42	),	O
43	or	O
44	<UNK>	O
45	(	O
46	12	O
47	/	O
48	13	O
49	)	O
50	to	O
51	comparable	O
52	constructs	O
53	of	O
54	<UNK>	B
55	or	O
56	<UNK>	B
57	was	O
58	observed	O
59	.	O
1	The	O
2	level	O
3	of	O
4	serum	O
5	creatine	B
6	kinase	I
7	was	O
8	significantly	O
9	high	O
10	2	O
11	days	O
12	after	O
13	<UNK>	O
14	,	O
15	but	O
16	it	O
17	recovered	O
18	in	O
19	a	O
20	week	O
21	.	O
1	A	O
2	<UNK>	O
3	analysis	O
4	with	O
5	the	O
6	TK	B
7	domains	O
8	from	O
9	these	O
10	sequences	O
11	and	O
12	a	O
13	fourth	O
14	,	O
15	from	O
16	a	O
17	novel	O
18	<UNK>	O
19	<UNK>	B
20	(	O
21	all	O
22	domains	O
23	<UNK>	O
24	the	O
25	<UNK>	O
26	for	O
27	the	O
28	TK	B
29	class	O
30	II	O
31	receptors	O
32	),	O
33	showed	O
34	that	O
35	they	O
36	are	O
37	<UNK>	O
38	related	O
39	to	O
40	the	O
41	insulin	B
42	and	O
43	insulin	B
44	-	O
45	like	O
46	receptors	O
47	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	both	O
6	transcription	O
7	activators	O
8	<UNK>	O
9	on	O
10	or	O
11	interact	O
12	with	O
13	different	O
14	subunits	O
15	of	O
16	RNA	O
17	polymerase	O
18	,	O
19	although	O
20	their	O
21	role	O
22	in	O
23	formation	O
24	of	O
25	proper	O
26	DNA	O
27	<UNK>	O
28	may	O
29	also	O
30	be	O
31	crucial	O
32	.	O
1	Klebsiella	O
2	<UNK>	O
3	can	O
4	<UNK>	O
5	nitrate	O
6	and	O
7	<UNK>	O
8	by	O
9	using	O
10	enzymes	O
11	encoded	O
12	by	O
13	the	O
14	<UNK>	B
15	operon	O
16	.	O
1	<UNK>	O
2	<UNK>	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	<UNK>	O
11	,	O
12	total	O
13	protein	O
14	,	O
15	and	O
16	aspartate	O
17	aminotransferase	B
18	.	O
1	Based	O
2	on	O
3	<UNK>	O
4	<UNK>	O
5	,	O
6	the	O
7	47	O
8	-	O
9	kDa	O
10	P	O
11	-	O
12	<UNK>	B
13	protein	O
14	is	O
15	<UNK>	O
16	cytosolic	O
17	.	O
1	<UNK>	O
2	,	O
3	E1A	B
4	binding	O
5	to	O
6	only	O
7	p300	B
8	/	O
9	CBP	B
10	results	O
11	in	O
12	an	O
13	increase	O
14	in	O
15	<UNK>	B
16	enzyme	O
17	activity	O
18	and	O
19	<UNK>	O
20	in	O
21	cell	O
22	death	O
23	susceptibility	O
24	to	O
25	irradiation	O
26	,	O
27	which	O
28	is	O
29	<UNK>	O
30	<UNK>	O
31	by	O
32	the	O
33	<UNK>	B
34	chemical	O
35	inhibitor	O
36	3	O
37	-	O
38	<UNK>	O
39	.	O
1	This	O
2	<UNK>	O
3	was	O
4	based	O
5	upon	O
6	whether	O
7	the	O
8	diagnosis	O
9	provided	O
10	a	O
11	<UNK>	O
12	range	O
13	of	O
14	<UNK>	O
15	or	O
16	an	O
17	<UNK>	O
18	clinical	O
19	<UNK>	O
20	.	O
1	The	O
2	availability	O
3	of	O
4	potent	O
5	regulatory	O
6	DNA	O
7	<UNK>	O
8	harboring	O
9	the	O
10	murine	O
11	<UNK>	B
12	gene	O
13	promoter	O
14	could	O
15	aid	O
16	testing	O
17	the	O
18	neuronal	O
19	-	O
20	specific	O
21	expression	O
22	of	O
23	<UNK>	O
24	in	O
25	vivo	O
26	.	O
1	Recombinant	O
2	<UNK>	B
3	<UNK>	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	<UNK>	O
11	expression	O
12	system	O
13	.	O
1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	low	O
8	binding	O
9	activity	O
10	of	O
11	CBF	O
12	to	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	<UNK>	B
18	promoter	O
19	sequence	O
20	was	O
21	observed	O
22	with	O
23	nuclear	O
24	extracts	O
25	from	O
26	tissue	O
27	with	O
28	low	O
29	<UNK>	B
30	expression	O
31	levels	O
32	,	O
33	i	O
34	.	O
35	e	O
36	.	O
37	extracts	O
38	from	O
39	<UNK>	O
40	and	O
41	<UNK>	O
42	<UNK>	O
43	,	O
44	whereas	O
45	high	O
46	binding	O
47	activity	O
48	was	O
49	detectable	O
50	with	O
51	extracts	O
52	from	O
53	tissues	O
54	with	O
55	high	O
56	<UNK>	B
57	expression	O
58	levels	O
59	,	O
60	i	O
61	.	O
62	e	O
63	.	O
64	extracts	O
65	from	O
66	light	O
67	-	O
68	grown	O
69	<UNK>	O
70	and	O
71	<UNK>	O
72	<UNK>	O
73	treated	O
74	with	O
75	<UNK>	B
76	.	O
1	They	O
2	are	O
3	<UNK>	O
4	into	O
5	two	O
6	types	O
7	that	O
8	activate	O
9	transduction	O
10	pathways	O
11	via	O
12	different	O
13	cell	O
14	surface	O
15	receptors	O
16	.	O
1	<UNK>	O
2	diseases	O
3	involving	O
4	the	O
5	<UNK>	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	O
13	must	O
14	<UNK>	O
15	the	O
16	presence	O
17	of	O
18	<UNK>	O
19	<UNK>	O
20	involvement	O
21	in	O
22	patients	O
23	with	O
24	<UNK>	O
25	.	O
1	To	O
2	define	O
3	the	O
4	minimal	O
5	<UNK>	O
6	binding	O
7	domain	O
8	for	O
9	human	O
10	VDR	B
11	(	O
12	<UNK>	B
13	),	O
14	a	O
15	series	O
16	of	O
17	C	O
18	-	O
19	terminally	O
20	truncated	O
21	<UNK>	B
22	mutants	O
23	(	O
24	<UNK>	O
25	,	O
26	<UNK>	O
27	,	O
28	<UNK>	O
29	,	O
30	<UNK>	O
31	,	O
32	<UNK>	O
33	,	O
34	<UNK>	O
35	,	O
36	and	O
37	<UNK>	O
38	)	O
39	was	O
40	generated	O
41	and	O
42	expressed	O
43	in	O
44	bacteria	O
45	.	O
1	By	O
2	an	O
3	induced	O
4	-	O
5	<UNK>	O
6	mechanism	O
7	,	O
8	<UNK>	O
9	with	O
10	the	O
11	<UNK>	O
12	can	O
13	activate	O
14	formation	O
15	of	O
16	a	O
17	<UNK>	O
18	transition	O
19	state	O
20	at	O
21	a	O
22	site	O
23	over	O
24	70	O
25	A	O
26	<UNK>	O
27	.	O
1	<UNK>	O
2	in	O
3	the	O
4	<UNK>	O
5	p	O
6	.	O
7	a	O
8	.	O
9	,	O
10	<UNK>	O
11	<UNK>	O
12	.	O
13	and	O
14	at	O
15	<UNK>	O
16	'	O
17	s	O
18	<UNK>	O
19	were	O
20	made	O
21	in	O
22	a	O
23	total	O
24	of	O
25	100	O
26	patients	O
27	.	O
1	In	O
2	summary	O
3	,	O
4	<UNK>	B
5	is	O
6	enriched	O
7	by	O
8	<UNK>	O
9	(	O
10	dT	O
11	)	O
12	chromatography	O
13	,	O
14	as	O
15	are	O
16	<UNK>	B
17	,	O
18	the	O
19	U5	B
20	small	O
21	nuclear	O
22	<UNK>	O
23	-	O
24	associated	O
25	protein	O
26	<UNK>	B
27	and	O
28	hnRNP	B
29	A1	I
30	.	O
1	Six	O
2	out	O
3	of	O
4	ten	O
5	hearts	O
6	from	O
7	<UNK>	O
8	<UNK>	O
9	infants	O
10	showed	O
11	varying	O
12	degrees	O
13	of	O
14	positive	O
15	staining	O
16	.	O
1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	<UNK>	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	<UNK>	O
18	.	O
1	<UNK>	O
2	out	O
3	of	O
4	43	O
5	renal	O
6	failure	O
7	patients	O
8	had	O
9	<UNK>	B
10	I	O
11	0	O
12	.	O
13	13	O
14	-	O
15	0	O
16	.	O
17	9	O
18	microg	O
19	/	O
20	l	O
21	using	O
22	<UNK>	O
23	method	O
24	and	O
25	4	O
26	had	O
27	levels	O
28	of	O
29	0	O
30	.	O
31	07	O
32	-	O
33	0	O
34	.	O
35	13	O
36	microg	O
37	/	O
38	l	O
39	using	O
40	<UNK>	O
41	1	O
42	.	O
1	<UNK>	O
2	,	O
3	2	O
4	<UNK>	O
5	,	O
6	<UNK>	O
7	,	O
8	are	O
9	some	O
10	of	O
11	these	O
12	recent	O
13	<UNK>	O
14	.	O
1	In	O
2	addition	O
3	,	O
4	<UNK>	B
5	displays	O
6	high	O
7	homology	O
8	to	O
9	microtubule	O
10	and	O
11	nuclear	O
12	associated	O
13	protein	O
14	(	O
15	M	O
16	-	O
17	<UNK>	B
18	)	O
19	and	O
20	<UNK>	B
21	-	O
22	46	O
23	,	O
24	both	O
25	of	O
26	unknown	O
27	function	O
28	.	O
1	<UNK>	O
2	DESIGN	O
3	AND	O
4	METHODS	O
5	:	O
6	A	O
7	study	O
8	was	O
9	initiated	O
10	to	O
11	compare	O
12	the	O
13	<UNK>	O
14	of	O
15	<UNK>	O
16	with	O
17	the	O
18	new	O
19	<UNK>	O
20	,	O
21	the	O
22	<UNK>	O
23	(	O
24	<UNK>	O
25	[	O
26	V	O
27	]	O
28	6	O
29	.	O
30	0	O
31	with	O
32	<UNK>	O
33	<UNK>	O
34	set	O
35	),	O
36	and	O
37	that	O
38	with	O
39	the	O
40	<UNK>	O
41	(	O
42	<UNK>	O
43	cell	O
44	)	O
45	procedure	O
46	(	O
47	<UNK>	O
48	.	O
49	7	O
50	with	O
51	white	O
52	cell	O
53	<UNK>	O
54	set	O
55	),	O
56	for	O
57	patients	O
58	and	O
59	healthy	O
60	donors	O
61	.	O
1	<UNK>	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O
1	<UNK>	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	<UNK>	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	<UNK>	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	<UNK>	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	<UNK>	O
43	;	O
44	<UNK>	O
45	baseline	O
46	and	O
47	p	O
48	<UNK>	O
49	between	O
50	the	O
51	groups	O
52	).	O
1	Similar	O
2	to	O
3	<UNK>	B
4	,	O
5	isolated	O
6	<UNK>	B
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O
1	Northern	O
2	blot	O
3	and	O
4	reverse	O
5	transcription	O
6	-	O
7	PCR	O
8	analyses	O
9	of	O
10	human	O
11	mRNA	O
12	samples	O
13	demonstrate	O
14	that	O
15	<UNK>	B
16	is	O
17	expressed	O
18	exclusively	O
19	in	O
20	the	O
21	<UNK>	O
22	,	O
23	with	O
24	transcripts	O
25	of	O
26	approximately	O
27	7	O
28	.	O
29	5	O
30	kb	O
31	,	O
32	approximately	O
33	3	O
34	.	O
35	0	O
36	kb	O
37	,	O
38	and	O
39	approximately	O
40	2	O
41	.	O
42	3	O
43	kb	O
44	by	O
45	Northern	O
46	blot	O
47	analysis	O
48	.	O
1	<UNK>	B
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	<UNK>	O
8	?	O
9	Although	O
10	<UNK>	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	<UNK>	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	<UNK>	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	<UNK>	O
1	The	O
2	<UNK>	O
3	products	O
4	of	O
5	<UNK>	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	<UNK>	O
25	.	O
1	In	O
2	the	O
3	<UNK>	O
4	<UNK>	O
5	group	O
6	the	O
7	-	O
8	age	O
9	based	O
10	dose	O
11	would	O
12	have	O
13	been	O
14	<UNK>	O
15	dependent	O
16	on	O
17	the	O
18	initial	O
19	seizure	O
20	threshold	O
21	level	O
22	.	O
1	<UNK>	O
2	studies	O
3	showed	O
4	that	O
5	<UNK>	O
6	<UNK>	O
7	significantly	O
8	improved	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	image	O
13	quality	O
14	.	O
1	<UNK>	O
2	to	O
3	those	O
4	with	O
5	normal	O
6	renal	O
7	functions	O
8	,	O
9	these	O
10	patients	O
11	were	O
12	older	O
13	(	O
14	P	O
15	<	O
16	or	O
17	=	O
18	0	O
19	.	O
20	01	O
21	),	O
22	had	O
23	significantly	O
24	elevated	O
25	blood	O
26	pressures	O
27	(	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	or	O
34	P	O
35	=	O
36	0	O
37	.	O
38	0001	O
39	),	O
40	and	O
41	in	O
42	the	O
43	case	O
44	of	O
45	Type	O
46	1	O
47	<UNK>	O
48	,	O
49	with	O
50	a	O
51	higher	O
52	body	O
53	mass	O
54	index	O
55	(	O
56	P	O
57	=	O
58	0	O
59	.	O
60	0001	O
61	)	O
62	and	O
63	<UNK>	O
64	-	O
65	hip	O
66	ratio	O
67	(	O
68	P	O
69	<	O
70	0	O
71	.	O
72	01	O
73	).	O
1	However	O
2	,	O
3	activation	O
4	of	O
5	the	O
6	cAMP	O
7	pathway	O
8	,	O
9	which	O
10	is	O
11	known	O
12	to	O
13	regulate	O
14	<UNK>	B
15	alpha	O
16	expression	O
17	,	O
18	greatly	O
19	enhanced	O
20	the	O
21	<UNK>	O
22	of	O
23	SF	O
24	-	O
25	1	O
26	.	O
1	Deletion	O
2	and	O
3	site	O
4	-	O
5	directed	O
6	mutagenesis	O
7	localized	O
8	a	O
9	novel	O
10	SF	O
11	-	O
12	1	O
13	regulatory	O
14	element	O
15	(	O
16	<UNK>	O
17	<UNK>	O
18	;	O
19	-	O
20	<UNK>	O
21	to	O
22	-	O
23	<UNK>	O
24	)	O
25	adjacent	O
26	to	O
27	a	O
28	variant	O
29	cAMP	O
30	-	O
31	response	O
32	element	O
33	(	O
34	CRE	O
35	;	O
36	-	O
37	120	O
38	to	O
39	-	O
40	<UNK>	O
41	).	O
1	<UNK>	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	<UNK>	O
8	is	O
9	a	O
10	cytokine	O
11	[	O
12	tumor	O
13	necrosis	O
14	factor	O
15	-	O
16	alpha	O
17	(	O
18	<UNK>	B
19	<UNK>	O
20	inducible	O
21	enhancer	O
22	by	O
23	binding	O
24	the	O
25	heterodimeric	O
26	nuclear	O
27	factor	O
28	-	O
29	kappaB	B
30	(	O
31	NF	B
32	-	O
33	kappaB	B
34	)	O
35	complex	O
36	Rel	B
37	A	O
38	x	O
39	NF	B
40	-	O
41	<UNK>	B
42	.	O
1	In	O
2	addition	O
3	,	O
4	<UNK>	B
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	<UNK>	O
11	region	O
12	of	O
13	the	O
14	S	O
15	.	O
16	cerevisiae	O
17	<UNK>	B
18	gene	O
19	.	O
1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	<UNK>	O
7	<UNK>	O
8	that	O
9	was	O
10	treated	O
11	with	O
12	both	O
13	hemodialysis	O
14	(	O
15	HD	O
16	)	O
17	and	O
18	<UNK>	O
19	due	O
20	to	O
21	severe	O
22	<UNK>	O
23	and	O
24	slow	O
25	drug	O
26	clearance	O
27	.	O
1	<UNK>	O
2	expression	O
3	of	O
4	c	B
5	-	O
6	myc	B
7	is	O
8	likely	O
9	to	O
10	contribute	O
11	to	O
12	the	O
13	proliferation	O
14	of	O
15	<UNK>	B
16	-	O
17	null	O
18	cells	O
19	in	O
20	response	O
21	to	O
22	<UNK>	B
23	.	O
1	<UNK>	O
2	<UNK>	O
3	<UNK>	O
4	Group	O
5	trial	O
6	<UNK>	O
7	was	O
8	initiated	O
9	to	O
10	<UNK>	O
11	this	O
12	question	O
13	.	O
1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	O
7	-	O
8	<UNK>	B
9	antibody	O
10	affinity	O
11	column	O
12	<UNK>	O
13	sulfate	O
14	to	O
15	<UNK>	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	<UNK>	O
24	.	O
1	Overexpression	O
2	of	O
3	<UNK>	B
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	O
17	<UNK>	B
18	<UNK>	I
19	.	O
1	The	O
2	RNA	O
3	<UNK>	O
4	contains	O
5	three	O
6	<UNK>	O
7	separated	O
8	by	O
9	a	O
10	pair	O
11	of	O
12	two	O
13	-	O
14	base	O
15	<UNK>	O
16	,	O
17	and	O
18	<UNK>	O
19	an	O
20	<UNK>	O
21	fold	O
22	in	O
23	which	O
24	both	O
25	<UNK>	O
26	sites	O
27	are	O
28	<UNK>	O
29	through	O
30	base	O
31	triple	O
32	formation	O
33	.	O
1	To	O
2	<UNK>	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	<UNK>	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	<UNK>	O
15	)	O
16	on	O
17	<UNK>	O
18	activity	O
19	of	O
20	the	O
21	<UNK>	O
22	we	O
23	<UNK>	O
24	five	O
25	conscious	O
26	<UNK>	O
27	subjects	O
28	on	O
29	two	O
30	<UNK>	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	<UNK>	O
37	breathing	O
38	(	O
39	<UNK>	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	<UNK>	O
50	<UNK>	O
51	6	O
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	<UNK>	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	<UNK>	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	<UNK>	O
77	gas	O
78	).	O
1	<UNK>	O
2	signaling	O
3	properties	O
4	are	O
5	largely	O
6	determined	O
7	by	O
8	the	O
9	<UNK>	O
10	and	O
11	combination	O
12	of	O
13	ion	O
14	<UNK>	O
15	expressed	O
16	.	O
1	All	O
2	clones	O
3	and	O
4	strains	O
5	produced	O
6	have	O
7	been	O
8	<UNK>	O
9	in	O
10	the	O
11	<UNK>	O
12	genetic	O
13	<UNK>	O
14	<UNK>	O
15	(	O
16	<UNK>	O
17	,	O
18	<UNK>	O
19	).	O
1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	O
8	-	O
9	type	O
10	<UNK>	B
11	<UNK>	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	<UNK>	B
17	<UNK>	O
18	and	O
19	invasive	O
20	growth	O
21	.	O
1	The	O
2	insulin	B
3	therapy	O
4	regimen	O
5	did	O
6	not	O
7	affect	O
8	the	O
9	evolution	O
10	of	O
11	the	O
12	patients	O
13	and	O
14	no	O
15	significant	O
16	relationship	O
17	<UNK>	O
18	between	O
19	the	O
20	age	O
21	at	O
22	diagnosis	O
23	,	O
24	duration	O
25	of	O
26	diabetes	O
27	,	O
28	daily	O
29	insulin	B
30	dosage	O
31	or	O
32	metabolic	O
33	control	O
34	and	O
35	height	O
36	or	O
37	<UNK>	O
38	.	O
1	The	O
2	<UNK>	O
3	finger	O
4	,	O
5	<UNK>	O
6	box	O
7	,	O
8	and	O
9	coiled	O
10	-	O
11	coil	O
12	region	O
13	are	O
14	required	O
15	for	O
16	<UNK>	O
17	of	O
18	<UNK>	B
19	-	O
20	1	O
21	-	O
22	<UNK>	B
23	and	O
24	<UNK>	B
25	binding	O
26	,	O
27	as	O
28	mutations	O
29	in	O
30	these	O
31	domains	O
32	<UNK>	O
33	abolished	O
34	these	O
35	functions	O
36	.	O
1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O
1	We	O
2	<UNK>	O
3	assess	O
4	current	O
5	systematic	O
6	<UNK>	O
7	and	O
8	determine	O
9	the	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	within	O
14	new	O
15	,	O
16	much	O
17	<UNK>	O
18	limits	O
19	:	O
20	&	O
21	<UNK>	O
22	;	O
23	<UNK>	O
24	;	O
25	<UNK>	O
26	&	O
27	<UNK>	O
28	;	O
29	<UNK>	O
30	;	O
31	H	O
32	&	O
33	<UNK>	O
34	;	O
35	<UNK>	O
36	;	O
37	p	O
38	=	O
39	1	O
40	.	O
41	23	O
42	+	O
43	0	O
44	.	O
45	68	O
46	-	O
47	0	O
48	.	O
49	<UNK>	O
50	-	O
51	10	O
52	.	O
1	Thus	O
2	,	O
3	<UNK>	B
4	is	O
5	a	O
6	good	O
7	candidate	O
8	gene	O
9	<UNK>	O
10	to	O
11	the	O
12	mental	O
13	retardation	O
14	phenotype	O
15	seen	O
16	in	O
17	<UNK>	O
18	-	O
19	16	O
20	patients	O
21	.	O
1	<UNK>	O
2	endogenous	O
3	light	O
4	chains	O
5	contribute	O
6	to	O
7	<UNK>	O
8	membrane	O
9	reactivity	O
10	in	O
11	<UNK>	O
12	mice	O
13	transgenic	O
14	for	O
15	an	O
16	anti	O
17	-	O
18	<UNK>	B
19	Ig	I
20	heavy	O
21	chain	O
22	.	O
1	<UNK>	B
2	and	O
3	<UNK>	B
4	genes	O
5	appear	O
6	to	O
7	be	O
8	the	O
9	splice	O
10	variants	O
11	transcribed	O
12	from	O
13	the	O
14	same	O
15	gene	O
16	.	O
1	Two	O
2	distinct	O
3	<UNK>	O
4	<UNK>	B
5	,	O
6	<UNK>	B
7	and	O
8	<UNK>	B
9	,	O
10	<UNK>	O
11	thin	O
12	<UNK>	O
13	<UNK>	O
14	<UNK>	B
15	and	O
16	<UNK>	B
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	<UNK>	O
23	<UNK>	O
24	to	O
25	<UNK>	O
26	<UNK>	B
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	<UNK>	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	<UNK>	B
45	<UNK>	I
46	.	O
1	<UNK>	O
2	mitogen	B
3	-	O
4	activated	O
5	protein	O
6	kinase	B
7	signaling	O
8	pathways	O
9	<UNK>	O
10	the	O
11	<UNK>	B
12	<UNK>	O
13	to	O
14	the	O
15	c	B
16	-	O
17	jun	B
18	promoter	O
19	and	O
20	to	O
21	cellular	O
22	transformation	O
23	.	O
1	Copyright	O
2	2000	O
3	Academic	O
4	<UNK>	O
5	.	O
1	For	O
2	wild	O
3	type	O
4	<UNK>	B
5	and	O
6	its	O
7	<UNK>	B
8	and	O
9	<UNK>	O
10	mutants	O
11	,	O
12	<UNK>	O
13	of	O
14	log	O
15	(	O
16	<UNK>	O
17	(	O
18	cat	O
19	<UNK>	O
20	versus	O
21	pH	O
22	exhibited	O
23	a	O
24	limiting	O
25	<UNK>	O
26	of	O
27	1	O
28	on	O
29	the	O
30	<UNK>	O
31	limb	O
32	and	O
33	then	O
34	a	O
35	<UNK>	O
36	,	O
37	i	O
38	.	O
39	e	O
40	.,	O
41	a	O
42	<UNK>	O
43	defined	O
44	maximum	O
45	near	O
46	pH	O
47	8	O
48	followed	O
49	by	O
50	a	O
51	<UNK>	O
52	,	O
53	<UNK>	O
54	apparent	O
55	<UNK>	O
56	(	O
57	a	O
58	)	O
59	values	O
60	of	O
61	7	O
62	.	O
63	6	O
64	+/-	O
65	0	O
66	.	O
67	3	O
68	and	O
69	8	O
70	.	O
71	4	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	for	O
77	an	O
78	essential	O
79	base	O
80	and	O
81	a	O
82	<UNK>	O
83	acid	O
84	<UNK>	O
85	,	O
86	respectively	O
87	,	O
88	in	O
89	the	O
90	active	O
91	<UNK>	O
92	<UNK>	B
93	-	O
94	<UNK>	O
95	(	O
96	2	O
97	<UNK>	O
98	<UNK>	O
99	-	O
100	<UNK>	O
101	(	O
102	2	O
103	+)	O
104	complex	O
105	.	O
1	A	O
2	<UNK>	O
3	bp	O
4	<UNK>	O
5	<UNK>	O
6	<UNK>	O
7	(	O
8	<UNK>	O
9	)	O
10	was	O
11	identified	O
12	whose	O
13	glucocorticoid	O
14	induction	O
15	was	O
16	enhanced	O
17	by	O
18	<UNK>	O
19	-	O
20	cAMP	O
21	and	O
22	reduced	O
23	by	O
24	phorbol	O
25	esters	O
26	.	O
1	<UNK>	O
2	<UNK>	O
3	with	O
4	<UNK>	O
5	,	O
6	monitored	O
7	by	O
8	<UNK>	O
9	the	O
10	residual	O
11	<UNK>	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	<UNK>	O
17	derivative	O
18	of	O
19	<UNK>	O
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	<UNK>	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	<UNK>	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	<UNK>	O
41	.	O
1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	<UNK>	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	<UNK>	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	<UNK>	O
31	.	O
1	<UNK>	B
2	.	O
3	1	O
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	<UNK>	B
10	family	O
11	of	O
12	homeodomain	B
13	-	O
14	containing	O
15	transcription	O
16	factors	O
17	whose	O
18	targeted	O
19	disruption	O
20	in	O
21	mouse	O
22	results	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	thyroid	O
28	tissue	O
29	and	O
30	a	O
31	severely	O
32	abnormal	O
33	lung	O
34	phenotype	O
35	.	O
1	This	O
2	repression	O
3	does	O
4	not	O
5	require	O
6	the	O
7	PU	B
8	.	O
9	1	O
10	transactivation	O
11	or	O
12	<UNK>	O
13	domains	O
14	and	O
15	cannot	O
16	be	O
17	reversed	O
18	by	O
19	p300	B
20	expression	O
21	.	O
1	<UNK>	O
2	,	O
3	human	O
4	erythroid	O
5	<UNK>	O
6	cells	O
7	stably	O
8	integrated	O
9	with	O
10	various	O
11	<UNK>	O
12	-	O
13	40	O
14	mutants	O
15	cis	O
16	linked	O
17	to	O
18	a	O
19	human	O
20	alpha	O
21	-	O
22	globin	B
23	promoter	O
24	-	O
25	growth	O
26	hormone	O
27	hybrid	O
28	gene	O
29	were	O
30	analyzed	O
31	by	O
32	genomic	O
33	footprinting	O
34	and	O
35	expression	O
36	analysis	O
37	.	O
1	Its	O
2	cognate	O
3	binding	O
4	protein	O
5	,	O
6	<UNK>	B
7	/	O
8	<UNK>	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	transcription	O
14	factor	O
15	;	O
16	its	O
17	null	O
18	mutations	O
19	result	O
20	in	O
21	embryonic	O
22	<UNK>	O
23	,	O
24	and	O
25	its	O
26	dominant	O
27	negative	O
28	mutants	O
29	produce	O
30	aberrant	O
31	expression	O
32	of	O
33	neuron	O
34	-	O
35	specific	O
36	genes	O
37	.	O
1	<UNK>	O
2	of	O
3	all	O
4	core	O
5	histone	B
6	tail	O
7	domains	O
8	by	O
9	limited	O
10	<UNK>	B
11	proteolysis	O
12	or	O
13	<UNK>	O
14	of	O
15	the	O
16	core	O
17	histone	B
18	<UNK>	O
19	significantly	O
20	<UNK>	O
21	this	O
22	inhibition	O
23	and	O
24	allows	O
25	<UNK>	B
26	to	O
27	exhibit	O
28	high	O
29	-	O
30	affinity	O
31	binding	O
32	to	O
33	<UNK>	O
34	DNA	O
35	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	M	O
7	.	O
8	<UNK>	O
9	as	O
10	well	O
11	as	O
12	related	O
13	<UNK>	B
14	<UNK>	I
15	<UNK>	O
16	require	O
17	a	O
18	<UNK>	O
19	complex	O
20	such	O
21	as	O
22	<UNK>	B
23	to	O
24	mediate	O
25	the	O
26	energy	O
27	-	O
28	dependent	O
29	hydrolysis	O
30	of	O
31	<UNK>	O
32	-	O
33	substrate	O
34	proteins	O
35	and	O
36	that	O
37	the	O
38	N	O
39	-	O
40	terminal	O
41	73	O
42	amino	O
43	acid	O
44	residues	O
45	of	O
46	<UNK>	B
47	are	O
48	not	O
49	<UNK>	O
50	required	O
51	for	O
52	this	O
53	reaction	O
54	.	O
1	In	O
2	experiment	O
3	2	O
4	the	O
5	rats	O
6	had	O
7	free	O
8	<UNK>	O
9	to	O
10	two	O
11	<UNK>	O
12	,	O
13	one	O
14	of	O
15	which	O
16	contained	O
17	<UNK>	O
18	water	O
19	,	O
20	and	O
21	the	O
22	other	O
23	contained	O
24	either	O
25	an	O
26	ethanol	O
27	(	O
28	6	O
29	%)	O
30	or	O
31	a	O
32	<UNK>	O
33	(	O
34	5	O
35	%)	O
36	solution	O
37	.	O
1	The	O
2	patient	O
3	had	O
4	developed	O
5	left	O
6	-	O
7	<UNK>	O
8	low	O
9	-	O
10	frequency	O
11	<UNK>	O
12	and	O
13	<UNK>	O
14	after	O
15	a	O
16	severe	O
17	head	O
18	trauma	O
19	sustained	O
20	at	O
21	15	O
22	years	O
23	of	O
24	age	O
25	.	O
1	<UNK>	O
2	nitrate	O
3	mixed	O
4	with	O
5	<UNK>	O
6	acid	O
7	,	O
8	in	O
9	comparison	O
10	with	O
11	<UNK>	O
12	acid	O
13	alone	O
14	,	O
15	markedly	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	<UNK>	O
24	the	O
25	duration	O
26	of	O
27	the	O
28	<UNK>	O
29	<UNK>	O
30	from	O
31	24	O
32	.	O
33	4	O
34	+/-	O
35	4	O
36	.	O
37	1	O
38	(	O
39	mean	O
40	+/-	O
41	<UNK>	O
42	)	O
43	min	O
44	to	O
45	8	O
46	.	O
47	9	O
48	+/-	O
49	3	O
50	.	O
51	7	O
52	(	O
53	mean	O
54	+/-	O
55	<UNK>	O
56	)	O
57	min	O
58	,	O
59	and	O
60	significantly	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	05	O
67	)	O
68	reduced	O
69	the	O
70	mean	O
71	magnitude	O
72	of	O
73	the	O
74	<UNK>	O
75	<UNK>	O
76	at	O
77	all	O
78	time	O
79	points	O
80	(	O
81	overall	O
82	).	O
1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	<UNK>	B
10	is	O
11	<UNK>	O
12	into	O
13	<UNK>	O
14	and	O
15	<UNK>	B
16	is	O
17	not	O
18	clear	O
19	.	O
1	Thus	O
2	,	O
3	patients	O
4	with	O
5	metastatic	O
6	melanoma	O
7	are	O
8	not	O
9	<UNK>	O
10	to	O
11	<UNK>	B
12	Ag	O
13	based	O
14	on	O
15	the	O
16	detection	O
17	of	O
18	<UNK>	B
19	+	O
20	T	O
21	cells	O
22	specific	O
23	for	O
24	multiple	O
25	HLA	B
26	-	O
27	A	O
28	*	O
29	<UNK>	B
30	-	O
31	restricted	O
32	,	O
33	<UNK>	B
34	-	O
35	derived	O
36	<UNK>	O
37	.	O
1	<UNK>	O
2	20	O
3	%	O
4	of	O
5	<UNK>	O
6	that	O
7	express	O
8	<UNK>	O
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	<UNK>	O
29	expression	O
30	.	O
1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	<UNK>	B
8	enzymatic	O
9	function	O
10	in	O
11	<UNK>	B
12	-	O
13	<UNK>	O
14	-	O
15	containing	O
16	<UNK>	O
17	may	O
18	<UNK>	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	<UNK>	O
25	drugs	O
26	such	O
27	as	O
28	<UNK>	O
29	.	O
1	<UNK>	O
2	is	O
3	a	O
4	serotonin	O
5	antagonist	O
6	and	O
7	has	O
8	been	O
9	demonstrated	O
10	to	O
11	reduce	O
12	wound	O
13	blood	O
14	flow	O
15	and	O
16	<UNK>	O
17	formation	O
18	.	O
1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	IRF	B
7	-	O
8	1	O
9	is	O
10	<UNK>	O
11	via	O
12	the	O
13	ubiquitin	B
14	-	O
15	proteasome	O
16	pathway	O
17	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	<UNK>	O
6	pre	O
7	-	O
8	mRNA	O
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	<UNK>	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	<UNK>	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O
1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	<UNK>	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	<UNK>	B
27	-	O
28	<UNK>	B
29	leader	O
30	RNA	O
31	association	O
32	.	O
1	<UNK>	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	<UNK>	O
14	,	O
15	including	O
16	plants	O
17	.	O
1	We	O
2	show	O
3	,	O
4	by	O
5	injection	O
6	of	O
7	synthetic	O
8	mRNAs	O
9	,	O
10	that	O
11	the	O
12	cis	O
13	-	O
14	acting	O
15	sequences	O
16	responsible	O
17	for	O
18	repression	O
19	of	O
20	cyclin	B
21	B1	O
22	mRNA	O
23	<UNK>	O
24	within	O
25	its	O
26	3	O
27	'	O
28	UTR	O
29	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	mouse	O
5	<UNK>	B
6	<UNK>	I
7	.	O
1	Here	O
2	we	O
3	review	O
4	<UNK>	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O
1	Most	O
2	likely	O
3	they	O
4	might	O
5	represent	O
6	regulatory	O
7	RNAs	O
8	or	O
9	transcribed	O
10	<UNK>	O
11	elements	O
12	.	O
1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	<UNK>	B
20	-	O
21	1	O
22	isoforms	O
23	,	O
24	<UNK>	B
25	-	O
26	1beta	B
27	and	O
28	<UNK>	B
29	-	O
30	<UNK>	B
31	.	O
1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	O
6	<UNK>	O
7	expression	O
8	plasmid	O
9	<UNK>	O
10	CSF	B
11	-	O
12	1	O
13	-	O
14	dependent	O
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	O
24	AP1	B
25	(	O
26	activator	O
27	protein	O
28	1	O
29	)	O
30	element	O
31	in	O
32	the	O
33	<UNK>	B
34	promoter	O
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	O
46	ras	B
47	and	O
48	protein	O
49	kinase	B
50	C	O
51	pathways	O
52	.	O
1	<UNK>	O
2	use	O
3	of	O
4	the	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	<UNK>	O
9	would	O
10	support	O
11	further	O
12	development	O
13	as	O
14	a	O
15	research	O
16	<UNK>	O
17	for	O
18	a	O
19	simple	O
20	assessment	O
21	of	O
22	disease	O
23	severity	O
24	that	O
25	could	O
26	be	O
27	used	O
28	in	O
29	epidemiological	O
30	studies	O
31	.	O
1	<UNK>	O
2	<UNK>	O
3	was	O
4	defined	O
5	as	O
6	an	O
7	<UNK>	O
8	larger	O
9	than	O
10	10	O
11	mm	O
12	or	O
13	an	O
14	<UNK>	O
15	of	O
16	any	O
17	size	O
18	with	O
19	<UNK>	O
20	component	O
21	,	O
22	high	O
23	-	O
24	grade	O
25	<UNK>	O
26	or	O
27	invasive	O
28	carcinoma	O
29	.	O
1	Results	O
2	of	O
3	two	O
4	-	O
5	hybrid	O
6	assays	O
7	and	O
8	electrophoretic	O
9	mobility	O
10	shift	O
11	assays	O
12	strongly	O
13	suggest	O
14	that	O
15	all	O
16	HD	O
17	-	O
18	<UNK>	O
19	proteins	O
20	of	O
21	families	O
22	I	O
23	and	O
24	II	O
25	can	O
26	form	O
27	homodimers	O
28	and	O
29	also	O
30	heterodimers	O
31	with	O
32	all	O
33	HD	O
34	-	O
35	<UNK>	O
36	proteins	O
37	of	O
38	the	O
39	same	O
40	family	O
41	.	O
1	Southern	O
2	blotting	O
3	and	O
4	single	O
5	strand	O
6	conformation	O
7	<UNK>	O
8	analyses	O
9	did	O
10	not	O
11	show	O
12	tumor	O
13	-	O
14	specific	O
15	alterations	O
16	of	O
17	this	O
18	gene	O
19	in	O
20	<UNK>	O
21	and	O
22	RT	O
23	-	O
24	PCR	O
25	studies	O
26	showed	O
27	expression	O
28	in	O
29	<UNK>	O
30	cell	O
31	lines	O
32	,	O
33	suggesting	O
34	that	O
35	<UNK>	B
36	is	O
37	not	O
38	the	O
39	chromosome	O
40	<UNK>	O
41	<UNK>	O
42	tumor	O
43	suppressor	O
44	gene	O
45	.	O
1	It	O
2	was	O
3	established	O
4	that	O
5	<UNK>	O
6	or	O
7	<UNK>	O
8	<UNK>	O
9	,	O
10	elevated	O
11	the	O
12	<UNK>	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	<UNK>	O
20	test	O
21	in	O
22	rats	O
23	.	O
1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	O
16	c	B
17	-	O
18	myb	B
19	intron	O
20	1	O
21	transcription	O
22	<UNK>	O
23	region	O
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	<UNK>	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	<UNK>	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	B
62	regulatory	O
63	factors	O
64	(	O
65	<UNK>	B
66	)	O
67	nuclear	O
68	proteins	O
69	.	O
1	<UNK>	B
2	are	O
3	responsible	O
4	for	O
5	the	O
6	<UNK>	O
7	of	O
8	<UNK>	O
9	to	O
10	<UNK>	O
11	and	O
12	glucose	O
13	.	O
1	Thus	O
2	,	O
3	both	O
4	the	O
5	hyperplasia	O
6	and	O
7	<UNK>	O
8	complications	O
9	which	O
10	often	O
11	follow	O
12	<UNK>	O
13	might	O
14	be	O
15	<UNK>	O
16	by	O
17	employing	O
18	<UNK>	O
19	<UNK>	O
20	,	O
21	which	O
22	have	O
23	a	O
24	greater	O
25	capacity	O
26	than	O
27	<UNK>	O
28	in	O
29	<UNK>	O
30	a	O
31	functional	O
32	<UNK>	O
33	-	O
34	<UNK>	O
35	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	<UNK>	O
7	serves	O
8	as	O
9	a	O
10	""""	O
11	protein	O
12	<UNK>	O
13	""""	O
14	of	O
15	altered	O
16	minor	O
17	<UNK>	O
18	interactions	O
19	and	O
20	<UNK>	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O
1	The	O
2	recombinant	O
3	enzymes	O
4	exist	O
5	as	O
6	<UNK>	O
7	.	O
1	<UNK>	O
2	mutations	O
3	throughout	O
4	the	O
5	AC	O
6	element	O
7	<UNK>	O
8	with	O
9	induction	O
10	but	O
11	allowed	O
12	us	O
13	to	O
14	define	O
15	five	O
16	overlapping	O
17	sites	O
18	for	O
19	regulatory	O
20	factors	O
21	in	O
22	AC	O
23	and	O
24	to	O
25	<UNK>	O
26	probes	O
27	binding	O
28	<UNK>	O
29	one	O
30	or	O
31	two	O
32	factors	O
33	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	virulence	O
6	-	O
7	associated	O
8	genes	O
9	and	O
10	their	O
11	overall	O
12	chromosomal	O
13	arrangement	O
14	are	O
15	relatively	O
16	well	O
17	conserved	O
18	between	O
19	B	O
20	.	O
21	<UNK>	O
22	and	O
23	other	O
24	gram	O
25	-	O
26	negative	O
27	bacteria	O
28	such	O
29	as	O
30	A	O
31	.	O
32	<UNK>	O
33	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	O
9	<UNK>	B
10	promoter	O
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	<UNK>	B
18	or	O
19	Epstein	O
20	-	O
21	Barr	O
22	virus	O
23	latent	O
24	membrane	O
25	protein	O
26	1	O
27	was	O
28	overexpressed	O
29	.	O
1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	O
9	-	O
10	activating	O
11	factor	O
12	antagonist	O
13	<UNK>	O
14	-	O
15	<UNK>	O
16	<UNK>	O
17	no	O
18	<UNK>	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	<UNK>	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O
1	The	O
2	protein	O
3	was	O
4	associated	O
5	with	O
6	purified	O
7	vaccinia	O
8	virus	O
9	particles	O
10	and	O
11	with	O
12	membranes	O
13	of	O
14	<UNK>	O
15	and	O
16	mature	O
17	<UNK>	O
18	that	O
19	were	O
20	<UNK>	O
21	by	O
22	electron	O
23	microscopy	O
24	of	O
25	infected	O
26	cells	O
27	.	O
1	Our	O
2	data	O
3	suggest	O
4	that	O
5	,	O
6	at	O
7	least	O
8	at	O
9	high	O
10	temperature	O
11	,	O
12	a	O
13	critical	O
14	minimal	O
15	level	O
16	of	O
17	<UNK>	B
18	protein	O
19	<UNK>	O
20	is	O
21	required	O
22	for	O
23	maintaining	O
24	<UNK>	O
25	<UNK>	O
26	.	O
1	The	O
2	<UNK>	O
3	,	O
4	<UNK>	O
5	,	O
6	and	O
7	<UNK>	B
8	<UNK>	I
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	<UNK>	O
18	<UNK>	O
19	gene	O
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	<UNK>	O
26	and	O
27	<UNK>	B
28	<UNK>	I
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	<UNK>	O
37	codon	O
38	.	O
1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	O
6	are	O
7	<UNK>	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O
1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	O
7	<UNK>	B
8	<UNK>	I
9	is	O
10	available	O
11	from	O
12	<UNK>	O
13	(	O
14	<UNK>	O
15	)	O
16	as	O
17	<UNK>	O
18	number	O
19	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	alpha	O
7	-	O
8	helix	O
9	domain	O
10	of	O
11	<UNK>	B
12	(	O
13	<UNK>	B
14	),	O
15	which	O
16	is	O
17	conserved	O
18	in	O
19	the	O
20	<UNK>	B
21	/	O
22	<UNK>	B
23	proteins	O
24	,	O
25	is	O
26	implicated	O
27	in	O
28	protein	O
29	-	O
30	protein	O
31	interaction	O
32	and	O
33	<UNK>	O
34	a	O
35	specific	O
36	regulatory	O
37	mechanism	O
38	,	O
39	outside	O
40	of	O
41	their	O
42	<UNK>	B
43	-	O
44	inhibitory	O
45	activity	O
46	,	O
47	by	O
48	which	O
49	the	O
50	<UNK>	B
51	(	O
52	<UNK>	B
53	)	O
54	family	O
55	members	O
56	positively	O
57	act	O
58	on	O
59	myogenic	O
60	differentiation	O
61	.	O
1	<UNK>	O
2	-	O
3	operative	O
4	ultrasound	O
5	(	O
6	<UNK>	O
7	)	O
8	has	O
9	been	O
10	widely	O
11	used	O
12	in	O
13	an	O
14	<UNK>	O
15	to	O
16	<UNK>	O
17	these	O
18	<UNK>	O
19	,	O
20	but	O
21	is	O
22	limited	O
23	by	O
24	its	O
25	two	O
26	-	O
27	dimensional	O
28	nature	O
29	,	O
30	<UNK>	O
31	-	O
32	<UNK>	O
33	variability	O
34	,	O
35	and	O
36	image	O
37	<UNK>	O
38	with	O
39	<UNK>	O
40	or	O
41	<UNK>	O
42	techniques	O
43	.	O
1	<UNK>	O
2	-	O
3	<UNK>	O
4	disease	O
5	is	O
6	caused	O
7	by	O
8	mutations	O
9	in	O
10	<UNK>	B
11	encoding	O
12	a	O
13	novel	O
14	Ca	O
15	(	O
16	2	O
17	+)	O
18	<UNK>	O
19	.	O
1	<UNK>	O
2	cell	O
3	-	O
4	to	O
5	-	O
6	cell	O
7	movement	O
8	of	O
9	<UNK>	B
10	CP	O
11	mutant	O
12	was	O
13	<UNK>	O
14	in	O
15	<UNK>	O
16	<UNK>	O
17	<UNK>	O
18	.	O
1	We	O
2	conclude	O
3	that	O
4	,	O
5	both	O
6	in	O
7	atrial	O
8	<UNK>	O
9	and	O
10	in	O
11	Xenopus	O
12	<UNK>	O
13	,	O
14	beta	O
15	-	O
16	adrenergic	O
17	stimulation	O
18	<UNK>	O
19	the	O
20	<UNK>	O
21	-	O
22	evoked	O
23	<UNK>	B
24	<UNK>	O
25	via	O
26	a	O
27	pathway	O
28	that	O
29	involves	O
30	PKA	B
31	-	O
32	catalyzed	O
33	phosphorylation	O
34	downstream	O
35	from	O
36	beta	O
37	(	O
38	2	O
39	)	O
40	AR	O
41	.	O
1	<UNK>	O
2	receptor	O
3	-	O
4	related	O
5	receptor	O
6	alpha	O
7	1	O
8	interacts	O
9	with	O
10	coactivator	O
11	and	O
12	constitutively	O
13	activates	O
14	the	O
15	estrogen	O
16	response	O
17	elements	O
18	of	O
19	the	O
20	human	O
21	<UNK>	B
22	gene	O
23	.	O
1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O
1	Specific	O
2	and	O
3	<UNK>	O
4	genetic	O
5	interference	O
6	by	O
7	double	O
8	-	O
9	stranded	O
10	RNA	O
11	in	O
12	Arabidopsis	O
13	thaliana	O
14	.	O
1	The	O
2	interaction	O
3	does	O
4	not	O
5	<UNK>	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O
1	The	O
2	rate	O
3	-	O
4	limiting	O
5	step	O
6	for	O
7	<UNK>	B
8	activity	O
9	seems	O
10	to	O
11	be	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	catalytic	O
17	subunit	O
18	of	O
19	the	O
20	enzyme	O
21	,	O
22	encoded	O
23	by	O
24	the	O
25	human	O
26	<UNK>	B
27	reverse	O
28	transcriptase	B
29	(	O
30	<UNK>	B
31	)	O
32	gene	O
33	.	O
1	Regulation	O
2	of	O
3	mitochondrial	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	-	O
9	binding	O
10	protein	O
11	gene	O
12	expression	O
13	<UNK>	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	<UNK>	O
21	.	O
1	Genetic	O
2	and	O
3	molecular	O
4	<UNK>	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	<UNK>	O
10	<UNK>	O
11	<UNK>	B
12	(	O
13	<UNK>	B
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	<UNK>	B
19	(	O
20	<UNK>	B
21	),	O
22	also	O
23	known	O
24	as	O
25	E	O
26	(	O
27	<UNK>	O
28	)	O
29	3	O
30	-	O
31	<UNK>	B
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	<UNK>	O
49	(	O
50	<UNK>	O
51	),	O
52	the	O
53	control	O
54	of	O
55	<UNK>	B
56	<UNK>	I
57	sequences	O
58	,	O
59	regulation	O
60	of	O
61	<UNK>	B
62	gene	O
63	expression	O
64	,	O
65	and	O
66	<UNK>	O
67	cell	O
68	death	O
69	.	O
1	This	O
2	<UNK>	O
3	is	O
4	likely	O
5	due	O
6	to	O
7	the	O
8	<UNK>	O
9	nucleotide	O
10	composition	O
11	of	O
12	the	O
13	<UNK>	O
14	genome	O
15	,	O
16	rather	O
17	than	O
18	to	O
19	the	O
20	translational	O
21	selection	O
22	for	O
23	specific	O
24	codons	O
25	.	O
1	Regulation	O
2	of	O
3	pituitary	O
4	<UNK>	B
5	<UNK>	I
6	receptors	O
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	O
13	pituitary	O
14	<UNK>	B
15	hormone	O
16	(	O
17	ACTH	B
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O
1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	<UNK>	O
7	their	O
8	response	O
9	to	O
10	<UNK>	O
11	of	O
12	the	O
13	<UNK>	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O
1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	<UNK>	O
7	<UNK>	O
8	of	O
9	<UNK>	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	<UNK>	O
19	levels	O
20	for	O
21	<UNK>	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	<UNK>	O
27	-	O
28	deficient	O
29	patients	O
30	.	O
1	M	O
2	.	O
1	Our	O
2	data	O
3	provide	O
4	a	O
5	biochemical	O
6	<UNK>	O
7	for	O
8	the	O
9	similarity	O
10	in	O
11	phenotype	O
12	between	O
13	A	O
14	-	O
15	T	O
16	and	O
17	<UNK>	O
18	.	O
1	In	O
2	the	O
3	study	O
4	on	O
5	<UNK>	B
6	mRNA	O
7	expression	O
8	in	O
9	the	O
10	reproductive	O
11	organs	O
12	,	O
13	we	O
14	first	O
15	cloned	O
16	rat	O
17	<UNK>	B
18	cDNA	O
19	and	O
20	then	O
21	evaluated	O
22	the	O
23	effect	O
24	of	O
25	androgen	O
26	on	O
27	the	O
28	<UNK>	B
29	mRNA	O
30	expression	O
31	.	O
1	To	O
2	<UNK>	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	<UNK>	O
9	in	O
10	<UNK>	O
11	/	O
12	<UNK>	O
13	<UNK>	O
14	are	O
15	presented	O
16	.	O
1	<UNK>	O
2	evidence	O
3	indicates	O
4	that	O
5	p38	B
6	is	O
7	an	O
8	activator	O
9	of	O
10	MyoD	B
11	:	O
12	(	O
13	i	O
14	)	O
15	p38	B
16	kinase	I
17	activity	O
18	is	O
19	required	O
20	for	O
21	the	O
22	expression	O
23	of	O
24	MyoD	B
25	-	O
26	responsive	O
27	genes	O
28	,	O
29	(	O
30	ii	O
31	)	O
32	<UNK>	O
33	induction	O
34	of	O
35	p38	B
36	stimulates	O
37	the	O
38	transcriptional	O
39	activity	O
40	of	O
41	a	O
42	<UNK>	B
43	-	O
44	MyoD	B
45	fusion	O
46	protein	O
47	and	O
48	allows	O
49	efficient	O
50	activation	O
51	of	O
52	chromatin	O
53	-	O
54	integrated	O
55	<UNK>	O
56	by	O
57	MyoD	B
58	,	O
59	and	O
60	(	O
61	iii	O
62	)	O
63	MyoD	B
64	-	O
65	dependent	O
66	myogenic	O
67	conversion	O
68	is	O
69	reduced	O
70	in	O
71	mouse	O
72	embryonic	O
73	fibroblasts	O
74	derived	O
75	from	O
76	<UNK>	B
77	<UNK>	O
78	embryos	O
79	.	O
1	The	O
2	serine	O
3	-	O
4	threonine	O
5	kinase	B
6	gene	O
7	is	O
8	likely	O
9	functional	O
10	,	O
11	whereas	O
12	the	O
13	zinc	O
14	finger	O
15	motif	O
16	is	O
17	likely	O
18	<UNK>	O
19	.	O
1	RESULTS	O
2	:	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	<UNK>	O
18	<UNK>	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	<UNK>	O
29	<UNK>	O
30	.	O
1	Consistent	O
2	with	O
3	this	O
4	,	O
5	we	O
6	show	O
7	that	O
8	peptides	O
9	<UNK>	O
10	<UNK>	O
11	sites	O
12	within	O
13	the	O
14	target	O
15	substrates	O
16	<UNK>	B
17	-	O
18	1	O
19	and	O
20	<UNK>	B
21	(	O
22	<UNK>	B
23	)	O
24	inhibit	O
25	ERK	B
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	<UNK>	B
31	-	O
32	3	O
33	.	O
1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	<UNK>	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	<UNK>	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	<UNK>	O
20	in	O
21	that	O
22	<UNK>	O
23	.	O
1	<UNK>	O
2	of	O
3	protein	O
4	tyrosine	O
5	kinases	O
6	in	O
7	interleukin	B
8	-	O
9	2	O
10	(	O
11	IL	B
12	-	O
13	2	O
14	)	O
15	signaling	O
16	:	O
17	activation	O
18	of	O
19	<UNK>	B
20	depends	O
21	on	O
22	<UNK>	B
23	;	O
24	however	O
25	,	O
26	neither	O
27	<UNK>	B
28	nor	O
29	<UNK>	B
30	is	O
31	required	O
32	for	O
33	IL	B
34	-	O
35	2	O
36	-	O
37	mediated	O
38	STAT	B
39	activation	O
40	.	O
1	The	O
2	so	O
3	-	O
4	called	O
5	""""	O
6	SH3	B
7	""""	O
8	segment	O
9	of	O
10	the	O
11	linker	O
12	domain	O
13	,	O
14	in	O
15	contrast	O
16	,	O
17	shows	O
18	species	O
19	-	O
20	specific	O
21	sequence	O
22	identity	O
23	in	O
24	all	O
25	but	O
26	one	O
27	amino	O
28	acid	O
29	residues	O
30	in	O
31	both	O
32	factors	O
33	,	O
34	in	O
35	cattle	O
36	,	O
37	human	O
38	,	O
39	and	O
40	mouse	O
41	.	O
1	The	O
2	model	O
3	indicates	O
4	that	O
5	a	O
6	0	O
7	.	O
8	<UNK>	O
9	%	O
10	reduction	O
11	in	O
12	<UNK>	O
13	consumption	O
14	is	O
15	associated	O
16	with	O
17	the	O
18	availability	O
19	of	O
20	<UNK>	O
21	<UNK>	O
22	after	O
23	1992	O
24	.	O
1	<UNK>	O
2	<UNK>	O
3	.	O
1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	O
18	tyrosine	O
19	phosphatase	B
20	1	O
21	gene	O
22	,	O
23	although	O
24	<UNK>	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O
1	RESULTS	O
2	:	O
3	<UNK>	O
4	'	O
5	s	O
6	<UNK>	O
7	occurs	O
8	<UNK>	O
9	.	O
1	<UNK>	O
2	using	O
3	<UNK>	O
4	<UNK>	O
5	maintained	O
6	in	O
7	vitro	O
8	have	O
9	demonstrated	O
10	that	O
11	<UNK>	O
12	of	O
13	<UNK>	O
14	field	O
15	potentials	O
16	in	O
17	the	O
18	gamma	O
19	frequency	O
20	range	O
21	(	O
22	30	O
23	-	O
24	80	O
25	Hz	O
26	)	O
27	are	O
28	followed	O
29	by	O
30	a	O
31	<UNK>	O
32	<UNK>	O
33	in	O
34	the	O
35	beta	O
36	1	O
37	range	O
38	(	O
39	12	O
40	-	O
41	20	O
42	Hz	O
43	).	O
1	<UNK>	O
2	<UNK>	O
3	,	O
4	<UNK>	O
1	<UNK>	O
2	<UNK>	O
3	was	O
4	reduced	O
5	by	O
6	approximately	O
7	18	O
8	%	O
9	by	O
10	<UNK>	O
11	and	O
12	<UNK>	O
13	,	O
14	but	O
15	<UNK>	O
16	responses	O
17	to	O
18	noradrenaline	O
19	,	O
20	angiotensin	B
21	II	O
22	,	O
23	<UNK>	O
24	and	O
25	<UNK>	O
26	were	O
27	unaffected	O
28	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	<UNK>	O
7	(	O
8	<UNK>	B
9	/	O
10	<UNK>	B
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	<UNK>	O
20	(	O
21	<UNK>	B
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	<UNK>	O
28	database	O
29	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	were	O
5	evaluated	O
6	against	O
7	<UNK>	O
8	<UNK>	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	<UNK>	O
13	<UNK>	O
14	,	O
15	respectively	O
16	.	O
1	The	O
2	delta	O
3	<UNK>	B
4	mutation	O
5	also	O
6	influenced	O
7	on	O
8	the	O
9	transcript	O
10	levels	O
11	of	O
12	meiosis	O
13	-	O
14	<UNK>	O
15	genes	O
16	called	O
17	<UNK>	B
18	and	O
19	<UNK>	B
20	:	O
21	the	O
22	mutation	O
23	elevated	O
24	the	O
25	transcript	O
26	level	O
27	of	O
28	<UNK>	B
29	but	O
30	reduced	O
31	that	O
32	of	O
33	<UNK>	B
34	,	O
35	resulting	O
36	in	O
37	partial	O
38	defects	O
39	in	O
40	<UNK>	O
41	DNA	O
42	synthesis	O
43	and	O
44	meiosis	O
45	.	O
1	The	O
2	<UNK>	O
3	vectors	O
4	differ	O
5	among	O
6	them	O
7	in	O
8	:	O
9	(	O
10	a	O
11	)	O
12	the	O
13	<UNK>	O
14	marker	O
15	(	O
16	Saccharomyces	O
17	cerevisiae	O
18	<UNK>	B
19	2	O
20	gene	O
21	,	O
22	which	O
23	<UNK>	O
24	S	O
25	.	O
26	pombe	O
27	<UNK>	B
28	-	O
29	gene	O
30	and	O
31	S	O
32	.	O
33	pombe	O
34	<UNK>	B
35	+	O
36	and	O
37	<UNK>	B
38	+	O
39	genes	O
40	);	O
41	(	O
42	b	O
43	)	O
44	the	O
45	<UNK>	O
46	-	O
47	<UNK>	O
48	<UNK>	B
49	promoter	O
50	(	O
51	<UNK>	O
52	,	O
53	<UNK>	O
54	and	O
55	<UNK>	O
56	with	O
57	extremely	O
58	high	O
59	,	O
60	moderate	O
61	or	O
62	low	O
63	transcription	O
64	efficiency	O
65	,	O
66	respectively	O
67	);	O
68	and	O
69	(	O
70	c	B
71	)	O
72	the	O
73	multiple	O
74	cloning	O
75	site	O
76	(	O
77	two	O
78	multiple	O
79	cloning	O
80	sites	O
81	,	O
82	with	O
83	12	O
84	restriction	O
85	sites	O
86	each	O
87	).	O
1	(	O
2	<UNK>	O
3	)	O
4	<UNK>	O
5	of	O
6	30	O
7	<UNK>	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	B
24	anti	O
25	bodies	O
26	to	O
27	<UNK>	B
28	antigen	O
29	.	O
1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	<UNK>	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	<UNK>	O
22	<UNK>	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	<UNK>	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O
1	The	O
2	<UNK>	O
3	agent	O
4	<UNK>	O
5	<UNK>	O
6	(	O
7	<UNK>	O
8	)	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	<UNK>	O
14	endothelial	O
15	cells	O
16	(	O
17	EC	O
18	)	O
19	from	O
20	pro	O
21	-	O
22	inflammatory	O
23	-	O
24	induced	O
25	and	O
26	pro	O
27	-	O
28	<UNK>	O
29	-	O
30	induced	O
31	NF	B
32	-	O
33	kappaB	B
34	activation	O
35	.	O
1	<UNK>	O
2	of	O
3	the	O
4	breast	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	<UNK>	O
10	<UNK>	B
11	<UNK>	O
1	In	O
2	situ	O
3	hybridization	O
4	with	O
5	the	O
6	antisense	O
7	RNA	O
8	probes	O
9	further	O
10	supported	O
11	the	O
12	expression	O
13	changes	O
14	of	O
15	these	O
16	six	O
17	clones	O
18	and	O
19	localized	O
20	the	O
21	changes	O
22	in	O
23	multiple	O
24	germ	O
25	cell	O
26	stages	O
27	as	O
28	well	O
29	as	O
30	other	O
31	cell	O
32	types	O
33	(	O
34	<UNK>	O
35	,	O
36	<UNK>	O
37	and	O
38	<UNK>	O
39	cells	O
40	).	O
1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	<UNK>	O
8	is	O
9	critical	O
10	for	O
11	<UNK>	B
12	interaction	O
13	.	O
1	As	O
2	with	O
3	VP16	B
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	<UNK>	B
10	is	O
11	also	O
12	regulated	O
13	by	O
14	<UNK>	B
15	.	O
1	G	O
2	.,	O
3	and	O
4	<UNK>	O
5	,	O
6	C	O
7	.	O
1	Activation	O
2	of	O
3	nuclear	O
4	factor	O
5	(	O
6	NF	B
7	)-	O
8	kappaB	B
9	and	O
10	subsequent	O
11	<UNK>	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O
1	GAP	B
2	<UNK>	O
3	<UNK>	O
4	<UNK>	O
5	<UNK>	O
6	:	O
7	<UNK>	O
8	.	O
1	<UNK>	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	<UNK>	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	<UNK>	O
17	with	O
18	zipper	O
19	(	O
20	<UNK>	B
21	),	O
22	<UNK>	O
23	the	O
24	<UNK>	B
25	locus	O
26	.	O
1	The	O
2	outer	O
3	diameter	O
4	and	O
5	the	O
6	thickness	O
7	of	O
8	the	O
9	<UNK>	O
10	are	O
11	60	O
12	mm	O
13	and	O
14	8	O
15	mm	O
16	,	O
17	respectively	O
18	.	O
1	<UNK>	O
2	,	O
3	<UNK>	O
4	,	O
5	and	O
6	treatment	O
7	for	O
8	alcohol	O
9	and	O
10	<UNK>	O
11	drug	O
12	use	O
13	should	O
14	be	O
15	essential	O
16	components	O
17	in	O
18	<UNK>	O
19	<UNK>	O
20	care	O
21	.	O
1	Following	O
2	<UNK>	O
3	-	O
4	<UNK>	O
5	,	O
6	but	O
7	not	O
8	saline	O
9	or	O
10	<UNK>	O
11	<UNK>	O
12	,	O
13	there	O
14	were	O
15	transient	O
16	(<	O
17	72	O
18	hr	O
19	)	O
20	decreases	O
21	in	O
22	food	O
23	consumption	O
24	,	O
25	<UNK>	O
26	,	O
27	<UNK>	O
28	muscle	O
29	tone	O
30	,	O
31	and	O
32	body	O
33	temperature	O
34	.	O
1	<UNK>	O
2	was	O
3	the	O
4	most	O
5	cost	O
6	-	O
7	effective	O
8	HMG	B
9	-	O
10	CoA	B
11	reductase	I
12	inhibitor	O
13	.	O
1	The	O
2	effectiveness	O
3	of	O
4	<UNK>	O
5	appears	O
6	to	O
7	be	O
8	largely	O
9	independent	O
10	of	O
11	the	O
12	intensity	O
13	of	O
14	additional	O
15	support	O
16	provided	O
17	to	O
18	the	O
19	<UNK>	O
20	.	O
1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	<UNK>	B
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	B
19	-	O
20	<UNK>	B
21	SH3	I
22	domain	O
23	.	O
1	From	O
2	transient	O
3	expression	O
4	studies	O
5	,	O
6	we	O
7	could	O
8	demonstrate	O
9	that	O
10	the	O
11	SH3	B
12	domain	O
13	of	O
14	PLC	B
15	-	O
16	<UNK>	B
17	is	O
18	necessary	O
19	for	O
20	the	O
21	association	O
22	with	O
23	<UNK>	B
24	in	O
25	vivo	O
26	.	O
1	Twenty	O
2	<UNK>	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	<UNK>	O
18	units	O
19	of	O
20	natural	O
21	IFN	B
22	-	O
23	beta	O
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	B
35	therapy	O
36	.	O
1	Deletion	O
2	of	O
3	the	O
4	<UNK>	B
5	domain	O
6	resulted	O
7	in	O
8	loss	O
9	of	O
10	Ca	O
11	(	O
12	2	O
13	<UNK>	O
14	dependent	O
15	activation	O
16	.	O
1	<UNK>	O
2	and	O
3	<UNK>	O
4	co	O
5	-	O
6	<UNK>	O
7	with	O
8	<UNK>	B
9	,	O
10	but	O
11	not	O
12	with	O
13	<UNK>	B
14	,	O
15	<UNK>	B
16	,	O
17	or	O
18	<UNK>	B
19	.	O
1	Activation	O
2	was	O
3	<UNK>	O
4	;	O
5	<UNK>	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O
1	<UNK>	O
2	<UNK>	B
3	is	O
4	clearly	O
5	detectable	O
6	in	O
7	crude	O
8	<UNK>	O
9	,	O
10	cytosolic	O
11	and	O
12	ribosomal	O
13	salt	O
14	-	O
15	<UNK>	O
16	fractions	O
17	,	O
18	and	O
19	in	O
20	nuclear	O
21	extracts	O
22	,	O
23	<UNK>	B
24	is	O
25	preferentially	O
26	found	O
27	in	O
28	the	O
29	ribosomal	O
30	salt	O
31	-	O
32	<UNK>	O
33	preparation	O
34	.	O
1	The	O
2	<UNK>	O
3	technique	O
4	for	O
5	the	O
6	pathological	O
7	examination	O
8	of	O
9	<UNK>	O
10	lymph	O
11	nodes	O
12	(	O
13	<UNK>	O
14	)	O
15	is	O
16	still	O
17	under	O
18	<UNK>	O
19	.	O
1	This	O
2	study	O
3	demonstrated	O
4	that	O
5	the	O
6	<UNK>	O
7	-	O
8	100	O
9	<UNK>	O
10	can	O
11	<UNK>	O
12	assess	O
13	<UNK>	B
14	-	O
15	dependent	O
16	platelet	O
17	function	O
18	and	O
19	detect	O
20	other	O
21	platelet	O
22	defects	O
23	under	O
24	high	O
25	<UNK>	O
26	stress	O
27	in	O
28	complex	O
29	patient	O
30	populations	O
31	.	O
1	The	O
2	loss	O
3	of	O
4	<UNK>	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	O
26	simplex	O
27	viral	O
28	protein	O
29	VP16	B
30	.	O
1	Mutations	O
2	in	O
3	the	O
4	<UNK>	B
5	locus	O
6	at	O
7	<UNK>	O
8	.	O
9	3	O
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	<UNK>	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	<UNK>	O
27	studies	O
28	.	O
1	<UNK>	O
2	,	O
3	HD	O
4	inhibited	O
5	healing	O
6	because	O
7	it	O
8	significantly	O
9	delayed	O
10	<UNK>	O
11	and	O
12	caused	O
13	<UNK>	O
14	<UNK>	O
15	.	O
1	The	O
2	genome	O
3	of	O
4	the	O
5	human	O
6	herpesvirus	O
7	8	O
8	(	O
9	<UNK>	O
10	-	O
11	8	O
12	)	O
13	contains	O
14	a	O
15	cluster	O
16	of	O
17	open	O
18	reading	O
19	frames	O
20	(	O
21	ORFs	O
22	)	O
23	encoding	O
24	proteins	O
25	with	O
26	homology	O
27	to	O
28	the	O
29	cellular	O
30	transcription	O
31	factors	O
32	of	O
33	the	O
34	interferon	B
35	regulatory	O
36	factor	O
37	(	O
38	IRF	B
39	)	O
40	family	O
41	.	O
1	<UNK>	O
2	bone	O
3	area	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	001	O
10	),	O
11	height	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	01	O
18	),	O
19	years	O
20	in	O
21	present	O
22	colony	O
23	(	O
24	p	O
25	=	O
26	0	O
27	.	O
28	03	O
29	),	O
30	and	O
31	<UNK>	O
32	(	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	)	O
39	predicted	O
40	<UNK>	O
41	<UNK>	O
42	.	O
1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	<UNK>	B
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O
1	These	O
2	regions	O
3	may	O
4	be	O
5	differentially	O
6	involved	O
7	in	O
8	tissue	O
9	-	O
10	specificity	O
11	,	O
12	and	O
13	/	O
14	or	O
15	circadian	O
16	regulation	O
17	,	O
18	of	O
19	the	O
20	human	O
21	<UNK>	B
22	gene	O
23	transcription	O
24	.	O
1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	<UNK>	B
9	gene	O
10	represents	O
11	a	O
12	pseudogene	O
13	that	O
14	is	O
15	still	O
16	transcribed	O
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O
1	Two	O
2	distinct	O
3	<UNK>	O
4	susceptibility	O
5	loci	O
6	for	O
7	<UNK>	O
8	were	O
9	mapped	O
10	on	O
11	chromosome	O
12	(	O
13	<UNK>	O
14	)	O
15	4	O
16	at	O
17	<UNK>	B
18	and	O
19	<UNK>	B
20	in	O
21	both	O
22	<UNK>	O
23	.	O
1	The	O
2	ability	O
3	of	O
4	U6	B
5	-	O
6	<UNK>	B
7	mutants	O
8	to	O
9	influence	O
10	the	O
11	<UNK>	O
12	of	O
13	both	O
14	branch	O
15	site	O
16	and	O
17	3	O
18	'	O
19	splice	O
20	site	O
21	recognition	O
22	suggests	O
23	that	O
24	this	O
25	nucleotide	O
26	may	O
27	participate	O
28	in	O
29	the	O
30	formation	O
31	of	O
32	the	O
33	active	O
34	site	O
35	(	O
36	s	O
37	)	O
38	of	O
39	the	O
40	<UNK>	O
41	.	O
1	Five	O
2	of	O
3	the	O
4	<UNK>	O
5	strains	O
6	and	O
7	one	O
8	of	O
9	V	O
10	<UNK>	O
11	non	O
12	-	O
13	<UNK>	O
14	were	O
15	positive	O
16	for	O
17	<UNK>	O
18	activity	O
19	.	O
1	TNF	B
2	-	O
3	alpha	O
4	induced	O
5	a	O
6	dose	O
7	-	O
8	and	O
9	time	O
10	-	O
11	dependent	O
12	increase	O
13	in	O
14	<UNK>	B
15	-	O
16	2	O
17	(	O
18	<UNK>	B
19	-	O
20	2	O
21	)	O
22	expression	O
23	and	O
24	PGE2	O
25	formation	O
26	in	O
27	human	O
28	<UNK>	O
29	-	O
30	<UNK>	O
31	epithelial	O
32	cells	O
33	.	O
1	The	O
2	therapy	O
3	time	O
4	to	O
5	<UNK>	O
6	the	O
7	<UNK>	O
8	therapeutic	O
9	dose	O
10	of	O
11	<UNK>	O
12	<UNK>	O
13	-	O
14	<UNK>	O
15	,	O
16	is	O
17	27	O
18	times	O
19	longer	O
20	when	O
21	<UNK>	O
22	is	O
23	used	O
24	instead	O
25	of	O
26	<UNK>	O
27	.	O
1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	<UNK>	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	<UNK>	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	<UNK>	O
31	<UNK>	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O
1	We	O
2	have	O
3	also	O
4	identified	O
5	a	O
6	functional	O
7	domain	O
8	in	O
9	the	O
10	ORF	O
11	50	O
12	protein	O
13	,	O
14	an	O
15	immediate	O
16	-	O
17	early	O
18	gene	O
19	product	O
20	that	O
21	is	O
22	mainly	O
23	encoded	O
24	by	O
25	ORF	O
26	50	O
27	.	O
1	<UNK>	O
2	<UNK>	O
3	II	O
4	is	O
5	suspected	O
6	,	O
7	heparin	O
8	(	O
9	and	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	<UNK>	O
16	)	O
17	should	O
18	be	O
19	<UNK>	O
20	immediately	O
21	.	O
1	A	O
2	Y	O
3	.	O
4	<UNK>	O
5	<UNK>	B
6	mutant	O
7	was	O
8	isolated	O
9	that	O
10	restored	O
11	interaction	O
12	with	O
13	an	O
14	<UNK>	B
15	mutant	O
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	interaction	O
21	with	O
22	<UNK>	B
23	could	O
24	be	O
25	nucleotide	O
26	and	O
27	/	O
28	or	O
29	conformation	O
30	dependent	O
31	.	O
1	The	O
2	bases	O
3	of	O
4	this	O
5	comparison	O
6	are	O
7	reviewed	O
8	and	O
9	discussed	O
10	.	O
1	<UNK>	O
2	activity	O
3	was	O
4	dose	O
5	-	O
6	<UNK>	O
7	inhibited	O
8	by	O
9	cotransfection	O
10	with	O
11	either	O
12	ras	B
13	or	O
14	<UNK>	B
15	oncogenes	O
16	,	O
17	but	O
18	oncogene	B
19	inhibition	O
20	was	O
21	reversed	O
22	and	O
23	the	O
24	overall	O
25	activity	O
26	increased	O
27	when	O
28	cells	O
29	were	O
30	treated	O
31	with	O
32	the	O
33	MAP	B
34	kinase	I
35	kinase	I
36	(	O
37	<UNK>	B
38	)	O
39	inhibitor	O
40	<UNK>	O
41	.	O
1	Because	O
2	GH	B
3	-	O
4	induced	O
5	<UNK>	B
6	activation	O
7	was	O
8	completely	O
9	inhibited	O
10	in	O
11	both	O
12	cells	O
13	by	O
14	the	O
15	same	O
16	concentration	O
17	of	O
18	<UNK>	O
19	,	O
20	these	O
21	findings	O
22	indicate	O
23	that	O
24	the	O
25	<UNK>	O
26	sensitivity	O
27	of	O
28	both	O
29	the	O
30	<UNK>	B
31	-	O
32	1	O
33	-	O
34	independent	O
35	and	O
36	-	O
37	dependent	O
38	GH	B
39	-	O
40	induced	O
41	MAP	B
42	kinase	I
43	activation	O
44	may	O
45	reflect	O
46	the	O
47	activity	O
48	of	O
49	another	O
50	<UNK>	O
51	-	O
52	sensitive	O
53	target	O
54	(	O
55	s	O
56	)	O
57	in	O
58	addition	O
59	to	O
60	<UNK>	B
61	in	O
62	<UNK>	O
63	of	O
64	GH	B
65	-	O
66	induced	O
67	MAP	B
68	kinase	I
69	activation	O
70	in	O
71	these	O
72	cells	O
73	.	O
1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	O
9	level	O
10	<UNK>	O
11	the	O
12	current	O
13	values	O
14	by	O
15	2	O
16	-	O
17	3	O
18	<UNK>	O
19	of	O
20	magnitude	O
21	;	O
22	<UNK>	O
23	,	O
24	the	O
25	voltage	O
26	values	O
27	rise	O
28	by	O
29	about	O
30	three	O
31	times	O
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O
1	In	O
2	several	O
3	cell	O
4	lines	O
5	,	O
6	<UNK>	B
7	or	O
8	its	O
9	downstream	O
10	targets	O
11	can	O
12	be	O
13	regulated	O
14	by	O
15	phosphatidylinositol	B
16	(	O
17	PI	O
18	)	O
19	3	O
20	-	O
21	kinase	B
22	;	O
23	protein	O
24	kinases	O
25	A	O
26	,	O
27	B	O
28	,	O
29	and	O
30	C	O
31	;	O
32	<UNK>	B
33	G	O
34	-	O
35	proteins	O
36	;	O
37	a	O
38	<UNK>	O
39	-	O
40	sensitive	O
41	kinase	B
42	or	O
43	calcium	O
44	;	O
45	as	O
46	well	O
47	as	O
48	by	O
49	amino	O
50	acids	O
51	.	O
1	The	O
2	importance	O
3	of	O
4	this	O
5	new	O
6	epidemiological	O
7	profile	O
8	of	O
9	<UNK>	O
10	in	O
11	the	O
12	<UNK>	O
13	of	O
14	<UNK>	O
15	<UNK>	O
16	on	O
17	the	O
18	fact	O
19	that	O
20	it	O
21	can	O
22	be	O
23	related	O
24	with	O
25	the	O
26	<UNK>	O
27	human	O
28	interference	O
29	on	O
30	the	O
31	environment	O
32	.	O
1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	<UNK>	O
6	in	O
7	<UNK>	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	<UNK>	O
15	-	O
16	<UNK>	O
17	<UNK>	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	<UNK>	O
23	range	O
24	of	O
25	cervical	O
26	<UNK>	O
27	.	O
1	We	O
2	screened	O
3	a	O
4	<UNK>	O
5	cDNA	O
6	library	O
7	and	O
8	identified	O
9	novel	O
10	transcripts	O
11	,	O
12	<UNK>	B
13	and	O
14	<UNK>	B
15	.	O
1	RESULTS	O
2	:	O
3	Neither	O
4	basal	O
5	FSH	B
6	level	O
7	nor	O
8	stimulated	O
9	FSH	B
10	level	O
11	alone	O
12	were	O
13	statistically	O
14	significant	O
15	predictors	O
16	of	O
17	<UNK>	O
18	<UNK>	O
19	;	O
20	however	O
21	,	O
22	no	O
23	patient	O
24	with	O
25	a	O
26	day	O
27	3	O
28	FSH	B
29	level	O
30	>	O
31	11	O
32	.	O
33	1	O
34	<UNK>	O
35	/	O
36	ml	O
37	or	O
38	a	O
39	stimulated	O
40	day	O
41	10	O
42	FSH	B
43	level	O
44	>	O
45	13	O
46	.	O
47	5	O
48	<UNK>	O
49	/	O
50	ml	O
51	<UNK>	O
52	and	O
53	carried	O
54	a	O
55	pregnancy	O
56	.	O
1	These	O
2	include	O
3	<UNK>	O
4	repeats	O
5	,	O
6	a	O
7	leucine	O
8	<UNK>	O
9	repeat	O
10	enriched	O
11	in	O
12	<UNK>	O
13	residues	O
14	,	O
15	and	O
16	a	O
17	proline	O
18	-	O
19	rich	O
20	SH3	B
21	-	O
22	like	O
23	and	O
24	/	O
25	or	O
26	<UNK>	O
27	domain	O
28	-	O
29	binding	O
30	site	O
31	in	O
32	the	O
33	N	O
34	-	O
35	terminal	O
36	domain	O
37	,	O
38	which	O
39	is	O
40	followed	O
41	by	O
42	a	O
43	membrane	O
44	core	O
45	containing	O
46	four	O
47	putative	O
48	transmembrane	O
49	spans	O
50	and	O
51	three	O
52	<UNK>	O
53	segments	O
54	that	O
55	are	O
56	the	O
57	most	O
58	highly	O
59	conserved	O
60	structural	O
61	elements	O
62	.	O
1	<UNK>	O
2	application	O
3	of	O
4	<UNK>	O
5	-	O
6	<UNK>	O
7	,	O
8	however	O
9	,	O
10	did	O
11	not	O
12	cause	O
13	<UNK>	O
14	reduction	O
15	and	O
16	<UNK>	O
17	H	O
18	+	O
19	loss	O
20	,	O
21	but	O
22	produced	O
23	a	O
24	marked	O
25	<UNK>	O
26	,	O
27	resulting	O
28	in	O
29	no	O
30	damage	O
31	in	O
32	the	O
33	stomach	O
34	of	O
35	both	O
36	normal	O
37	and	O
38	<UNK>	O
39	-	O
40	diabetic	O
41	rats	O
42	.	O
1	<UNK>	O
2	both	O
3	MAP	B
4	and	O
5	<UNK>	O
6	increase	O
7	during	O
8	<UNK>	O
9	,	O
10	the	O
11	transition	O
12	from	O
13	<UNK>	O
14	to	O
15	<UNK>	O
16	is	O
17	characterized	O
18	by	O
19	a	O
20	transient	O
21	reduction	O
22	in	O
23	MAP	B
24	but	O
25	sustained	O
26	elevation	O
27	in	O
28	<UNK>	O
29	,	O
30	<UNK>	O
31	separation	O
32	of	O
33	these	O
34	factors	O
35	in	O
36	vivo	O
37	.	O
1	METHODS	O
2	:	O
3	In	O
4	the	O
5	current	O
6	study	O
7	the	O
8	authors	O
9	reported	O
10	on	O
11	<UNK>	O
12	cases	O
13	from	O
14	a	O
15	<UNK>	O
16	retrospective	O
17	search	O
18	performed	O
19	in	O
20	18	O
21	<UNK>	O
22	<UNK>	O
23	for	O
24	<UNK>	O
25	<UNK>	O
26	and	O
27	<UNK>	O
28	<UNK>	O
29	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	<UNK>	B
6	is	O
7	in	O
8	fact	O
9	required	O
10	for	O
11	<UNK>	O
12	response	O
13	and	O
14	that	O
15	interaction	O
16	with	O
17	the	O
18	<UNK>	B
19	<UNK>	I
20	is	O
21	critical	O
22	for	O
23	that	O
24	role	O
25	.	O
1	Deletion	O
2	of	O
3	an	O
4	<UNK>	O
5	DNA	O
6	-	O
7	binding	O
8	site	O
9	for	O
10	this	O
11	complex	O
12	from	O
13	a	O
14	human	O
15	beta	O
16	-	O
17	globin	B
18	locus	O
19	construct	O
20	results	O
21	in	O
22	delayed	O
23	human	O
24	gamma	O
25	-	O
26	to	O
27	beta	O
28	-	O
29	globin	B
30	<UNK>	O
31	in	O
32	transgenic	O
33	mice	O
34	,	O
35	suggesting	O
36	that	O
37	the	O
38	<UNK>	B
39	complex	O
40	acts	O
41	to	O
42	facilitate	O
43	the	O
44	<UNK>	O
45	.	O
1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	<UNK>	O
7	could	O
8	not	O
9	be	O
10	<UNK>	O
11	by	O
12	<UNK>	O
13	abnormalities	O
14	.	O
1	<UNK>	O
2	adrenal	O
3	hypersensitivity	O
4	to	O
5	ACTH	B
6	<UNK>	O
7	in	O
8	<UNK>	O
9	has	O
10	also	O
11	been	O
12	suggested	O
13	.	O
1	<UNK>	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	investigate	O
11	the	O
12	oxidative	O
13	susceptibility	O
14	of	O
15	<UNK>	B
16	B	O
17	-	O
18	containing	O
19	<UNK>	O
20	and	O
21	<UNK>	O
22	status	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	coronary	O
28	<UNK>	O
29	and	O
30	chronic	O
31	stable	O
32	angina	O
33	<UNK>	O
34	.	O
1	<UNK>	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	<UNK>	B
7	-	O
8	3	O
9	/	O
10	<UNK>	B
11	fusion	O
12	protein	O
13	,	O
14	cell	O
15	<UNK>	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	<UNK>	B
22	-	O
23	3	O
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O
1	<UNK>	O
2	<UNK>	O
3	,	O
4	<UNK>	O
5	-	O
6	<UNK>	O
7	)	O
8	that	O
9	the	O
10	amino	O
11	acid	O
12	sequences	O
13	of	O
14	peptide	O
15	fragments	O
16	obtained	O
17	from	O
18	a	O
19	polypeptide	O
20	found	O
21	in	O
22	a	O
23	complex	O
24	of	O
25	proteins	O
26	that	O
27	<UNK>	O
28	chromatin	O
29	structure	O
30	(	O
31	<UNK>	O
32	)	O
33	are	O
34	identical	O
35	to	O
36	portions	O
37	of	O
38	the	O
39	deduced	O
40	open	O
41	reading	O
42	frame	O
43	of	O
44	<UNK>	B
45	-	O
46	1	O
47	mRNA	O
48	.	O
1	<UNK>	O
2	of	O
3	plasma	O
4	<UNK>	B
5	were	O
6	observed	O
7	only	O
8	in	O
9	patients	O
10	with	O
11	delayed	O
12	gastric	O
13	emptying	O
14	.	O
1	As	O
2	a	O
3	result	O
4	,	O
5	we	O
6	have	O
7	defined	O
8	two	O
9	arginine	O
10	-	O
11	rich	O
12	motifs	O
13	(	O
14	<UNK>	O
15	and	O
16	<UNK>	O
17	)	O
18	that	O
19	mediate	O
20	the	O
21	RNA	O
22	binding	O
23	activity	O
24	of	O
25	<UNK>	O
26	(	O
27	S	O
28	).	O
1	Further	O
2	research	O
3	is	O
4	required	O
5	to	O
6	better	O
7	measure	O
8	treatment	O
9	effects	O
10	,	O
11	modification	O
12	of	O
13	MS	O
14	natural	O
15	history	O
16	,	O
17	and	O
18	<UNK>	O
19	<UNK>	O
20	costs	O
21	of	O
22	IFN	B
23	beta	O
24	-	O
25	<UNK>	B
26	in	O
27	<UNK>	O
28	.	O
1	<UNK>	B
2	intestinal	O
3	peptide	O
4	and	O
5	pituitary	O
6	<UNK>	B
7	cyclase	I
8	-	O
9	activating	O
10	polypeptide	O
11	inhibit	O
12	nuclear	O
13	factor	O
14	-	O
15	kappa	B
16	B	O
17	-	O
18	dependent	O
19	gene	O
20	activation	O
21	at	O
22	multiple	O
23	levels	O
24	in	O
25	the	O
26	human	O
27	<UNK>	O
28	cell	O
29	line	O
30	<UNK>	O
31	-	O
32	1	O
33	.	O
1	<UNK>	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	<UNK>	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O
1	<UNK>	O
2	from	O
3	<UNK>	O
4	<UNK>	O
5	were	O
6	<UNK>	O
7	in	O
8	<UNK>	O
9	water	O
10	(	O
11	1	O
12	x	O
13	10	O
14	(	O
15	6	O
16	)	O
17	<UNK>	O
18	/	O
19	mL	O
20	)	O
21	and	O
22	used	O
23	as	O
24	<UNK>	O
25	.	O
1	For	O
2	this	O
3	purpose	O
4	,	O
5	the	O
6	<UNK>	O
7	test	O
8	,	O
9	<UNK>	O
10	and	O
11	<UNK>	O
12	induced	O
13	-	O
14	pain	O
15	in	O
16	mice	O
17	were	O
18	used	O
19	.	O
1	2000	O
2	<UNK>	O
3	of	O
4	<UNK>	O
5	for	O
6	the	O
7	use	O
8	of	O
9	hematopoietic	O
10	colony	O
11	-	O
12	stimulating	O
13	factors	O
14	:	O
15	evidence	O
16	-	O
17	based	O
18	,	O
19	clinical	O
20	practice	O
21	<UNK>	O
22	.	O
1	<UNK>	B
2	is	O
3	required	O
4	for	O
5	two	O
6	different	O
7	pathways	O
8	,	O
9	the	O
10	<UNK>	B
11	pathway	O
12	and	O
13	<UNK>	O
14	polarity	O
15	pathway	O
16	in	O
17	Drosophila	O
18	.	O
1	The	O
2	small	O
3	<UNK>	O
4	GTP	O
5	-	O
6	binding	O
7	proteins	O
8	of	O
9	the	O
10	<UNK>	B
11	subfamily	O
12	are	O
13	key	O
14	regulatory	O
15	elements	O
16	of	O
17	the	O
18	machinery	O
19	that	O
20	controls	O
21	membrane	O
22	<UNK>	O
23	in	O
24	eukaryotic	O
25	cells	O
26	.	O
1	<UNK>	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	O
9	1	O
10	beta	O
11	induces	O
12	VEGF	B
13	gene	O
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	O
27	1	O
28	beta	O
29	<UNK>	O
30	p38	B
31	MAPK	I
32	and	O
33	JNK	B
34	<UNK>	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	O
46	through	O
47	Sp1	B
48	-	O
49	binding	O
50	sites	O
51	.	O
1	<UNK>	B
2	enhances	O
3	<UNK>	B
4	and	O
5	<UNK>	B
6	<UNK>	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	<UNK>	B
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	O
24	<UNK>	O
25	of	O
26	the	O
27	<UNK>	B
28	tyrosine	O
29	kinase	B
30	.	O
1	High	O
2	expression	O
3	of	O
4	the	O
5	<UNK>	O
6	<UNK>	B
7	-	O
8	activated	O
9	receptor	O
10	alpha	O
11	(	O
12	<UNK>	B
13	)	O
14	<UNK>	O
15	<UNK>	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O
1	<UNK>	O
2	causes	O
3	<UNK>	O
4	ulcers	O
5	<UNK>	O
6	by	O
7	reducing	O
8	gastric	O
9	mucosal	O
10	<UNK>	B
11	(	O
12	<UNK>	B
13	)	O
14	activity	O
15	and	O
16	prostaglandin	O
17	synthesis	O
18	.	O
1	A	O
2	total	O
3	of	O
4	<UNK>	O
5	clones	O
6	were	O
7	randomly	O
8	selected	O
9	for	O
10	sequencing	O
11	of	O
12	one	O
13	end	O
14	.	O
1	CONCLUSIONS	O
2	:	O
3	The	O
4	surgical	O
5	or	O
6	<UNK>	O
7	treatment	O
8	of	O
9	<UNK>	O
10	has	O
11	provided	O
12	a	O
13	good	O
14	<UNK>	O
15	control	O
16	(	O
17	78	O
18	%)	O
19	and	O
20	68	O
21	%	O
22	10	O
23	-	O
24	year	O
25	survival	O
26	in	O
27	a	O
28	series	O
29	of	O
30	patients	O
31	treated	O
32	at	O
33	the	O
34	<UNK>	O
35	<UNK>	O
36	of	O
37	a	O
38	general	O
39	hospital	O
40	in	O
41	<UNK>	O
42	,	O
43	<UNK>	O
44	.	O
1	Among	O
2	the	O
3	total	O
4	<UNK>	O
5	,	O
6	8	O
7	.	O
8	8	O
9	%	O
10	<UNK>	O
11	sequences	O
12	of	O
13	proteins	O
14	found	O
15	only	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	and	O
20	66	O
21	.	O
22	7	O
23	%	O
24	are	O
25	widely	O
26	conserved	O
27	in	O
28	comparison	O
29	with	O
30	the	O
31	proteins	O
32	of	O
33	various	O
34	organisms	O
35	,	O
36	including	O
37	B	O
38	.	O
39	subtilis	O
40	.	O
1	Thus	O
2	,	O
3	<UNK>	O
4	is	O
5	closely	O
6	related	O
7	to	O
8	<UNK>	O
9	of	O
10	the	O
11	<UNK>	O
12	<UNK>	O
13	in	O
14	the	O
15	family	O
16	<UNK>	O
17	,	O
18	and	O
19	we	O
20	therefore	O
21	propose	O
22	to	O
23	<UNK>	O
24	this	O
25	virus	O
26	<UNK>	O
27	<UNK>	O
28	<UNK>	O
29	(	O
30	<UNK>	O
31	).	O
1	<UNK>	O
2	-	O
3	activated	O
4	protein	O
5	kinase	B
6	1	O
7	(	O
8	<UNK>	B
9	),	O
10	also	O
11	called	O
12	c	B
13	-	O
14	Jun	B
15	N	O
16	-	O
17	terminal	O
18	kinase	B
19	(	O
20	JNK	B
21	),	O
22	<UNK>	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	<UNK>	O
36	.	O
1	<UNK>	O
2	transduction	O
3	via	O
4	modulation	O
5	of	O
6	phosphorylation	O
7	after	O
8	selective	O
9	inhibition	O
10	of	O
11	protein	O
12	phosphatase	B
13	(	O
14	<UNK>	O
15	)	O
16	1	O
17	and	O
18	/	O
19	or	O
20	<UNK>	B
21	appears	O
22	to	O
23	play	O
24	a	O
25	role	O
26	in	O
27	<UNK>	O
28	acid	O
29	(	O
30	<UNK>	O
31	)-	O
32	mediated	O
33	effects	O
34	.	O
1	<UNK>	O
2	A	O
3	is	O
4	located	O
5	approximately	O
6	7	O
7	kb	O
8	5	O
9	'	O
10	to	O
11	the	O
12	<UNK>	B
13	translation	O
14	start	O
15	site	O
16	.	O
1	NF	B
2	-	O
3	kappaB	B
4	is	O
5	a	O
6	<UNK>	O
7	-	O
8	sensitive	O
9	transcription	O
10	factor	O
11	known	O
12	to	O
13	be	O
14	activated	O
15	by	O
16	oxidative	O
17	stress	O
18	as	O
19	well	O
20	as	O
21	chemical	O
22	and	O
23	biological	O
24	<UNK>	O
25	.	O
1	Characterization	O
2	of	O
3	a	O
4	Xenopus	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	O
8	receptor	O
9	4	O
10	:	O
11	implications	O
12	for	O
13	hematopoietic	O
14	cell	O
15	development	O
16	in	O
17	the	O
18	vertebrate	O
19	embryo	O
20	.	O
1	Patients	O
2	had	O
3	to	O
4	have	O
5	adequate	O
6	liver	O
7	,	O
8	renal	O
9	,	O
10	and	O
11	marrow	O
12	functions	O
13	.	O
1	In	O
2	15	O
3	<UNK>	O
4	-	O
5	dependent	O
6	,	O
7	<UNK>	O
8	,	O
9	and	O
10	<UNK>	O
11	<UNK>	O
12	patients	O
13	,	O
14	we	O
15	found	O
16	that	O
17	the	O
18	difference	O
19	<UNK>	O
20	(	O
21	i	O
22	),	O
23	<UNK>	O
24	-	O
25	<UNK>	O
26	,	O
27	total	O
28	decay	O
29	(	O
30	mean	O
31	+/-	O
32	SD	O
33	,	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	1	O
39	.	O
40	9	O
41	cm	O
42	H	O
43	(	O
44	2	O
45	)	O
46	O	O
47	)	O
48	was	O
49	<UNK>	O
50	similar	O
51	to	O
52	<UNK>	O
53	(	O
54	i	O
55	),	O
56	<UNK>	O
57	<UNK>	O
58	(	O
59	5	O
60	.	O
61	3	O
62	+/-	O
63	1	O
64	.	O
65	9	O
66	cm	O
67	H	O
68	(	O
69	2	O
70	)	O
71	O	O
72	).	O
1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	O
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	<UNK>	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	<UNK>	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	<UNK>	B
27	and	O
28	<UNK>	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O
1	This	O
2	dynamic	O
3	response	O
4	strongly	O
5	suggests	O
6	that	O
7	the	O
8	p53	B
9	and	O
10	Rb	B
11	tumor	O
12	suppressor	O
13	pathways	O
14	are	O
15	intact	O
16	in	O
17	HeLa	O
18	cells	O
19	and	O
20	that	O
21	repression	O
22	of	O
23	HPV	O
24	E6	B
25	and	O
26	E7	B
27	<UNK>	O
28	these	O
29	pathways	O
30	in	O
31	an	O
32	<UNK>	O
33	fashion	O
34	to	O
35	<UNK>	O
36	growth	O
37	inhibitory	O
38	signals	O
39	to	O
40	the	O
41	cells	O
42	.	O
1	To	O
2	test	O
3	whether	O
4	or	O
5	not	O
6	<UNK>	B
7	-	O
8	3	O
9	also	O
10	binds	O
11	to	O
12	the	O
13	<UNK>	B
14	,	O
15	we	O
16	cloned	O
17	human	O
18	<UNK>	B
19	-	O
20	3	O
21	by	O
22	reverse	O
23	transcription	O
24	-	O
25	polymerase	O
26	chain	O
27	reaction	O
28	from	O
29	human	O
30	skeletal	O
31	muscle	O
32	mRNA	O
33	.	O
1	A	O
2	protein	O
3	lacking	O
4	the	O
5	SH2	B
6	and	O
7	<UNK>	O
8	finger	O
9	domains	O
10	has	O
11	no	O
12	activity	O
13	,	O
14	but	O
15	a	O
16	chimeric	O
17	protein	O
18	with	O
19	the	O
20	SH2	B
21	and	O
22	<UNK>	O
23	finger	O
24	domains	O
25	of	O
26	<UNK>	B
27	-	O
28	1	O
29	replaced	O
30	by	O
31	the	O
32	equivalent	O
33	domains	O
34	of	O
35	c	B
36	-	O
37	Cbl	B
38	has	O
39	activity	O
40	.	O
1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	O
6	<UNK>	B
7	in	O
8	<UNK>	O
9	(	O
10	<UNK>	B
11	<UNK>	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	<UNK>	O
18	<UNK>	O
19	of	O
20	<UNK>	B
21	positive	O
22	material	O
23	<UNK>	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O
1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	<UNK>	O
7	but	O
8	<UNK>	O
9	the	O
10	<UNK>	O
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	<UNK>	O
19	and	O
20	<UNK>	O
21	,	O
22	performed	O
23	an	O
24	<UNK>	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	<UNK>	O
30	varied	O
31	memory	O
32	<UNK>	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O
1	The	O
2	<UNK>	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O
1	The	O
2	<UNK>	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	<UNK>	O
8	of	O
9	<UNK>	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	<UNK>	O
15	(	O
16	<UNK>	O
17	/	O
18	6	O
19	-	O
20	<UNK>	O
21	<UNK>	O
22	<UNK>	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	<UNK>	O
33	of	O
34	the	O
35	associated	O
36	<UNK>	O
37	field	O
38	.	O
1	In	O
2	addition	O
3	,	O
4	<UNK>	B
5	,	O
6	which	O
7	is	O
8	usually	O
9	<UNK>	O
10	with	O
11	<UNK>	B
12	by	O
13	<UNK>	O
14	insertion	O
15	,	O
16	was	O
17	not	O
18	up	O
19	-	O
20	regulated	O
21	by	O
22	<UNK>	O
23	in	O
24	SC	O
25	-	O
26	3	O
27	cells	O
28	.	O
1	<UNK>	O
2	phosphorylation	O
3	of	O
4	human	O
5	p53	B
6	at	O
7	<UNK>	O
8	stimulates	O
9	p53	B
10	-	O
11	dependent	O
12	transcription	O
13	.	O
14	p53	B
15	protein	O
16	activity	O
17	as	O
18	a	O
19	transcription	O
20	factor	O
21	can	O
22	be	O
23	activated	O
24	in	O
25	vivo	O
26	by	O
27	antibodies	O
28	that	O
29	target	O
30	its	O
31	C	O
32	-	O
33	terminal	O
34	negative	O
35	regulatory	O
36	domain	O
37	suggesting	O
38	that	O
39	cellular	O
40	enzymes	O
41	that	O
42	target	O
43	this	O
44	domain	O
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	stimulating	O
51	p53	B
52	-	O
53	dependent	O
54	gene	O
55	expression	O
56	.	O
1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	<UNK>	B
12	regulatory	O
13	protein	O
14	,	O
15	<UNK>	B
16	.	O
1	The	O
2	Tax	B
3	/	O
4	<UNK>	B
5	interaction	O
6	serves	O
7	to	O
8	<UNK>	O
9	Tax	B
10	to	O
11	the	O
12	<UNK>	B
13	catalytic	O
14	subunits	O
15	,	O
16	<UNK>	B
17	and	O
18	<UNK>	B
19	,	O
20	and	O
21	this	O
22	recruitment	O
23	appears	O
24	to	O
25	be	O
26	an	O
27	essential	O
28	mechanism	O
29	by	O
30	which	O
31	Tax	B
32	stimulates	O
33	the	O
34	activity	O
35	of	O
36	<UNK>	B
37	.	O
1	The	O
2	<UNK>	B
3	-	O
4	1	O
5	allele	O
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	<UNK>	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	<UNK>	O
18	repeat	O
19	(	O
20	<UNK>	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	<UNK>	B
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	O
40	-	O
41	shock	O
42	proteins	O
43	.	O
1	A	O
2	thermal	O
3	<UNK>	O
4	-	O
5	<UNK>	O
6	-	O
7	<UNK>	O
8	condition	O
9	<UNK>	O
10	due	O
11	to	O
12	the	O
13	coupling	O
14	of	O
15	a	O
16	computer	O
17	to	O
18	a	O
19	strong	O
20	<UNK>	O
21	source	O
22	,	O
23	<UNK>	O
24	,	O
25	the	O
26	daily	O
27	and	O
28	weekly	O
29	usage	O
30	patterns	O
31	of	O
32	the	O
33	system	O
34	.	O
1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	O
8	<UNK>	B
9	and	O
10	<UNK>	B
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O
1	<UNK>	O
2	,	O
3	protein	O
4	kinase	B
5	A	O
6	stimulation	O
7	induces	O
8	<UNK>	B
9	to	O
10	activate	O
11	the	O
12	complex	O
13	native	O
14	promoter	O
15	in	O
16	the	O
17	<UNK>	B
18	<UNK>	I
19	(	O
20	<UNK>	B
21	)	O
22	gene	O
23	.	O
1	Another	O
2	putative	O
3	<UNK>	B
4	site	O
5	in	O
6	close	O
7	<UNK>	O
8	to	O
9	a	O
10	NF1	B
11	/	O
12	<UNK>	B
13	site	O
14	was	O
15	localized	O
16	upstream	O
17	of	O
18	the	O
19	<UNK>	O
20	-	O
21	like	O
22	element	O
23	.	O
1	The	O
2	<UNK>	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	<UNK>	O
14	<UNK>	O
15	to	O
16	a	O
17	<UNK>	O
18	-	O
19	<UNK>	O
20	,	O
21	<UNK>	O
22	the	O
23	<UNK>	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	<UNK>	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	<UNK>	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	<UNK>	O
53	survival	O
54	of	O
55	dog	O
56	<UNK>	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O
1	<UNK>	O
2	<UNK>	O
3	of	O
4	Klebsiella	O
5	<UNK>	O
6	<UNK>	O
7	<UNK>	B
8	-	O
9	<UNK>	B
10	beta	O
11	-	O
12	<UNK>	B
13	(	O
14	<UNK>	B
15	)	O
16	<UNK>	O
17	in	O
18	<UNK>	O
19	in	O
20	<UNK>	O
21	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	<UNK>	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	<UNK>	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	<UNK>	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O
1	<UNK>	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	<UNK>	O
16	-	O
17	1	O
18	(	O
19	C	O
20	-	O
21	terminal	O
22	<UNK>	B
23	amino	O
24	acids	O
25	)	O
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	<UNK>	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	O
39	S	O
40	-	O
41	transferase	B
42	(	O
43	GST	B
44	).	O
1	<UNK>	O
2	.	O
1	<UNK>	O
2	<UNK>	O
3	(	O
4	<UNK>	O
5	<UNK>	O
6	)	O
7	were	O
8	exposed	O
9	to	O
10	<UNK>	O
11	(	O
12	<UNK>	O
13	g	O
14	)	O
15	for	O
16	9	O
17	to	O
18	10	O
19	days	O
20	during	O
21	space	O
22	<UNK>	O
23	<UNK>	O
24	-	O
25	55	O
26	and	O
27	<UNK>	O
28	-	O
29	84	O
30	,	O
31	or	O
32	to	O
33	<UNK>	O
34	(	O
35	<UNK>	O
36	)	O
37	for	O
38	9	O
39	days	O
40	.	O
1	<UNK>	B
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	<UNK>	B
7	in	O
8	the	O
9	core	O
10	kinase	B
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	<UNK>	B
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	<UNK>	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	<UNK>	B
48	.	O
1	<UNK>	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	O
8	activated	O
9	protein	O
10	-	O
11	extracellular	O
12	signal	O
13	-	O
14	regulated	O
15	kinase	B
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	<UNK>	O
22	inhibited	O
23	<UNK>	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	<UNK>	B
31	.	O
1	<UNK>	O
2	,	O
3	a	O
4	<UNK>	O
5	drug	O
6	with	O
7	5	O
8	-	O
9	<UNK>	B
10	receptor	O
11	<UNK>	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	<UNK>	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	<UNK>	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	<UNK>	O
30	and	O
31	<UNK>	O
32	<UNK>	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	<UNK>	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	<UNK>	O
48	,	O
49	<UNK>	O
50	.	O
1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	<UNK>	B
7	transcripts	O
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	<UNK>	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	<UNK>	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O
1	Copyright	O
2	2000	O
3	Academic	O
4	<UNK>	O
5	.	O
1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	O
9	actin	B
10	<UNK>	O
11	factor	O
12	(	O
13	<UNK>	B
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	O
22	associated	O
23	proteins	O
24	.	O
1	These	O
2	results	O
3	also	O
4	suggest	O
5	the	O
6	involvement	O
7	of	O
8	additional	O
9	elements	O
10	in	O
11	the	O
12	<UNK>	O
13	.	O
1	Since	O
2	MEK	B
3	acts	O
4	as	O
5	a	O
6	cytoplasmic	O
7	anchor	O
8	for	O
9	the	O
10	<UNK>	B
11	,	O
12	the	O
13	lack	O
14	of	O
15	a	O
16	MEK	B
17	interaction	O
18	resulted	O
19	in	O
20	the	O
21	aberrant	O
22	nuclear	O
23	localization	O
24	of	O
25	ERK2	B
26	-	O
27	<UNK>	B
28	-	O
29	25	O
30	mutants	O
31	in	O
32	serum	O
33	-	O
34	<UNK>	O
35	cells	O
36	.	O
1	Regulation	O
2	of	O
3	<UNK>	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	<UNK>	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	<UNK>	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O
1	These	O
2	cells	O
3	produced	O
4	<UNK>	B
5	(	O
6	11	O
7	)	O
8	mRNA	O
9	during	O
10	culture	O
11	.	O
1	This	O
2	sensitivity	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	<UNK>	O
8	limits	O
9	of	O
10	the	O
11	accuracy	O
12	of	O
13	the	O
14	used	O
15	screening	O
16	test	O
17	<UNK>	O
18	the	O
19	estimation	O
20	of	O
21	the	O
22	true	O
23	<UNK>	O
24	prevalence	O
25	within	O
26	<UNK>	O
27	<UNK>	O
28	limits	O
29	,	O
30	because	O
31	the	O
32	within	O
33	-	O
34	<UNK>	O
35	PTB	O
36	true	O
37	prevalence	O
38	was	O
39	low	O
40	.	O
41	For	O
42	this	O
43	<UNK>	O
44	we	O
45	<UNK>	O
46	the	O
47	<UNK>	O
48	specificity	O
49	for	O
50	<UNK>	O
51	with	O
52	larger	O
53	adult	O
54	<UNK>	O
55	size	O
56	<UNK>	O
57	5	O
58	).	O
1	The	O
2	transcription	O
3	factor	O
4	<UNK>	B
5	/	O
6	<UNK>	B
7	gene	O
8	is	O
9	induced	O
10	by	O
11	cellular	O
12	stress	O
13	and	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	apoptosis	O
19	.	O
1	<UNK>	B
2	kinase	I
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	B
11	3	O
12	-	O
13	kinase	B
14	and	O
15	the	O
16	<UNK>	B
17	<UNK>	I
18	homology	O
19	domain	O
20	.	O
1	The	O
2	structure	O
3	of	O
4	the	O
5	free	O
6	SH2	B
7	domain	O
8	has	O
9	been	O
10	compared	O
11	to	O
12	that	O
13	of	O
14	the	O
15	SH2	B
16	<UNK>	O
17	with	O
18	a	O
19	<UNK>	O
20	phosphorylated	O
21	peptide	O
22	derived	O
23	from	O
24	<UNK>	O
25	middle	O
26	T	O
27	antigen	O
28	(	O
29	<UNK>	O
30	).	O
1	Nucleotide	O
2	sequence	O
3	,	O
4	genome	O
5	organization	O
6	and	O
7	<UNK>	O
8	analysis	O
9	of	O
10	<UNK>	O
11	<UNK>	O
12	<UNK>	O
13	-	O
14	associated	O
15	virus	O
16	-	O
17	2	O
18	.	O
1	All	O
2	9	O
3	untreated	O
4	patients	O
5	underwent	O
6	<UNK>	O
7	,	O
8	which	O
9	identified	O
10	3	O
11	intra	O
12	-	O
13	abdominal	O
14	,	O
15	3	O
16	<UNK>	O
17	and	O
18	2	O
19	<UNK>	O
20	<UNK>	O
21	,	O
22	and	O
23	1	O
24	<UNK>	O
25	testis	O
26	in	O
27	the	O
28	<UNK>	O
29	<UNK>	O
30	.	O
1	<UNK>	O
2	to	O
3	aid	O
4	smoking	O
5	<UNK>	O
6	.	O
1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	O
15	6	O
16	(	O
17	IL	B
18	-	O
19	6	O
20	)	O
21	levels	O
22	in	O
23	<UNK>	O
24	<UNK>	O
25	fluid	O
26	(	O
27	<UNK>	O
28	)	O
29	and	O
30	clinical	O
31	<UNK>	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	<UNK>	O
44	(	O
45	AP	B
46	).	O
1	In	O
2	a	O
3	prospective	O
4	,	O
5	<UNK>	O
6	trial	O
7	the	O
8	efficacy	O
9	of	O
10	an	O
11	<UNK>	O
12	<UNK>	O
13	<UNK>	O
14	L	O
15	extract	O
16	<UNK>	O
17	<UNK>	O
18	was	O
19	investigated	O
20	in	O
21	50	O
22	patients	O
23	with	O
24	pre	O
25	-	O
26	<UNK>	O
27	syndrome	O
28	(	O
29	<UNK>	O
30	).	O
1	The	O
2	standard	O
3	method	O
4	for	O
5	<UNK>	O
6	the	O
7	composite	O
8	score	O
9	on	O
10	the	O
11	S	O
12	-	O
13	B	O
14	IV	O
15	<UNK>	O
16	<UNK>	O
17	with	O
18	a	O
19	<UNK>	O
20	score	O
21	of	O
22	0	O
23	,	O
24	which	O
25	<UNK>	O
26	cognitive	O
27	<UNK>	O
28	in	O
29	young	O
30	<UNK>	O
31	high	O
32	risk	O
33	children	O
34	.	O
1	<UNK>	O
2	of	O
3	<UNK>	O
4	spectroscopy	O
5	for	O
6	<UNK>	O
7	measuring	O
8	muscle	O
9	oxidative	O
10	metabolic	O
11	rate	O
12	in	O
13	exercise	O
14	.	O
1	The	O
2	murine	O
3	<UNK>	B
4	-	O
5	6	O
6	locus	O
7	,	O
8	identified	O
9	as	O
10	a	O
11	frequent	O
12	integration	O
13	site	O
14	of	O
15	mouse	O
16	mammary	O
17	tumor	O
18	viruses	O
19	,	O
20	encodes	O
21	the	O
22	48	O
23	-	O
24	kDa	O
25	<UNK>	B
26	subunit	O
27	of	O
28	translation	O
29	initiation	O
30	factor	O
31	<UNK>	B
32	.	O
1	We	O
2	have	O
3	therefore	O
4	studied	O
5	the	O
6	molecular	O
7	mechanisms	O
8	of	O
9	TGF	B
10	-	O
11	beta1	B
12	action	O
13	on	O
14	<UNK>	B
15	(	O
16	TG	O
17	)	O
18	gene	O
19	expression	O
20	by	O
21	<UNK>	O
22	our	O
23	attention	O
24	on	O
25	TGF	B
26	-	O
27	beta1	B
28	regulation	O
29	of	O
30	thyroid	O
31	-	O
32	specific	O
33	transcription	O
34	factors	O
35	.	O
1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	O
14	-	O
15	aa	O
16	<UNK>	B
17	fragment	O
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	<UNK>	O
31	.	O
